Date;Close;JNJ_Summary;Close;PFE_Summary;Close;LLY_Summary;Close;NVO_Summary;Close;ABBV_Summary;Close;NVS_Summary;Close;MRK_Summary;Close;AZN_Summary;Close;BMY_Summary;Close;SNY_Summary;Close;GSK_Summary;Close;TAK_Summary;Close;RPRX_Summary;Close;VTRS_Summary;Close;RGEN_Summary;Close;GRFS_Summary;Close;BHVN_Summary;Close;ASND_Summary;Close;EVO_Summary;Close;OGN_Summary;Close;LEGN_Summary;Close;CVAC_Summary;Close;HCM_Summary;Close;CERE_Summary;Close;APLS_Summary;Close;KRTX_Summary;Close;IMAB_Summary;Close;SWTX_Summary;Close;OPK_Summary;Close;EQRX_Summary;Close;DRNA_Summary;Close;NKTR_Summary;Close;IBRX_Summary;Close;HRMY_Summary;Close;TPTX_Summary;Close;EBS_Summary;Close;ERAS_Summary;Close;ADCT_Summary;Close;QTRX_Summary;Close;AMRX_Summary;Close;KROS_Summary;Close;NRIX_Summary;Close;CRNX_Summary;Close;ATAI_Summary;Close;GHRS_Summary;Close;CNTA_Summary;Close;PROC_Summary;Close;ARCT_Summary;Close;RETA_Summary;Close;ARQT_Summary;Close;DAWN_Summary;Close;IGMS_Summary;Close;ZEAL_Summary;Close;PRAX_Summary;Close;RPTX_Summary
2021-11-09;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-10;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-12;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-17;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-19;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-20;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-22;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-23;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-25;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-11-26;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-03;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-04;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-05;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-08;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-09;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-10;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-13;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-15;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-23;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-25;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2021-12-28;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;"LEXINGTON, Mass., December 28, 2021--Novo Nordisk today announced that the acquisition of Dicerna, announced on 18 November 2021, has been completed.,LEXINGTON, Mass., December 25, 2021--Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna,Investment company MainStay VP Wellington Small Cap Portfolio (Current Portfolio) buys iShares Russell 2000 Growth ETF, United Natural Foods Inc, Mimecast, Insperity Inc, Chesapeake Energy Corp, sells Ollie's Bargain Outlet Holdings Inc, Apellis Pharmaceuticals Inc, Children's Place Inc, Hostess Brands Inc, Boston Beer Co Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, MainStay VP Wellington Small Cap Portfolio.,Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (""KSF"") are investigating the proposed sale of Dicerna Pharmaceuticals, Inc. (NasdaqGS: DRNA) to Novo Nordisk A/S (NYSE: NVO). Under the terms of the proposed transaction, shareholders of Dicerna will receive $38.25 in cash for each share of Dicerna that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration,Is Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […],Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:,Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology.,If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:,Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:,BALA CYNWYD, PA / ACCESSWIRE / December 3, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Dicerna Pharmaceuticals, Inc. (""Dicerna"" or the ""Company"") (Nasdaq:DRNA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Novo Nordisk, in an all-cash transaction with a total value of approximately $3.,If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Alpha Capital Acquisition Company (NASDAQ: ASPC) Alpha Capital has agreed to merge with Semantix,Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:,If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:,The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.NEW YORK, NY / ACCESSWIRE / November 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:CoreSite Realty Corporation (NYSE:COR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to American Tower Corporation for $170.If you are a CoreSite shareholder, click here to learn more about your rights and options.NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) relating to its proposed acquisition by Novo Nordisk.BALA CYNWYD, PA / ACCESSWIRE / November 22, 2021 / Brodsky & Smith reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions.If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who willJuan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Dicerna Pharmaceuticals, Inc. (""DRNA"" or the ""Company"") (DRNA) relating to its proposed acquisition by Novo Nordisk. Under the terms of the agreement, DRNA shareholders will receive $38.25 in cash per share they own.NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Novo Nordisk for $38.,NEW YORK, NY / ACCESSWIRE / November 22, 2021 /BM Technologies, Inc. (NYSE:BMTX)Lifshitz Law Firm, P.,Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:,Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dicerna Pharmaceuticals, Inc. (""Dicerna"" or the ""Company"") (NASDAQ: DRNA) in connection with the proposed acquisition of the Company by Novo Nordisk. Under the terms of the merger agreement, the Company's shareholders will receive $38.25 per share in cash for each share of Dicerna common stock that they hold. The all-cash transaction is valued at $3.3 billion.Novo Nordisk announced its $3.3 billion plan to acquire Dicerna Pharmaceuticals on Thursday, sending DRNA stock into the stratosphere.WILMINGTON, Del., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Dicerna Pharmaceuticals, Inc. (“Dicerna”) (NASDAQ GS: DRNA) regarding possible breaches of fiduciary duties and other violations of law related to Dicerna’s agreement to be acquired by Novo Nordisk A/S. Under the terms of the agreement, Dicerna’s shareholders will receive $38.25 in cash for each share of Dicerna common stock they own. To learn more about this investigation and your rights,New York, New York--(Newsfile Corp. - November 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Dicerna Pharmaceuticals, Inc. (""Dicerna"" or the ""Company"") (NASDAQ: DRNA) stock prior to November 18, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Dicerna to Novo Nordisk (""Novo). Under the terms of the merger Novo ...Toward the end of trading Thursday, the Dow traded down 0.21% to 35,855.96 while the NASDAQ rose 0.16% to 15,946.49. The S&P also rose, gaining 0.19% to 4,697.80. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 48,287,920 cases with around 787,980 deaths. India confirmed a total of at least 34,478,510 cases and 464,620 deaths, while Brazil reported over 21,977,660 COVID-19 cases with 611,890 deaths. In total, there were at least 255,882,770 caseNEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Novo Nordisk A/S (NYSE: NVO). Click here to learn more and participate in the action. On November 18, 2021, Dicerna announced that it hadThe stock market has seen mixed performance for much of the past two years, and more often than not, the Nasdaq Composite (NASDAQINDEX: ^IXIC) has fared better than its fellow major market benchmarks.  Rivian Automotive (NASDAQ: RIVN) has made headlines for posting strong gains since it went public last week, but its stock moved into the second day of a decline that has lopped off about a third of its value.  Shares of Rivian Automotive were down 17% in early afternoon trading Thursday.NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Novo Nordisk for $38.25 per share in cash. If you are a Dicerna shareholder, click here to learn more about your rights and options. Ready Capital Corporation (NYSE: RC) concerningDicerna Pharmaceuticals Inc., the Lexington-based firm focused on ribonucleic acid interference (RNAi) drugs, has agreed to be acquired by Denmark's Novo Nordisk A/S for $3.3 billion in cash.Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA), a clinical-stage biopharmaceutical company, are exploding higher today in response to a buyout offer from Novo Nordisk (NYSE: NVO).  Today, Novo Nordisk agreed to acquire all of Dicerna's outstanding shares for $38.25 each.  At the moment, Dicerna's pipeline has a handful of midstage candidates and one in late-stage trials called nedosiran.,Ademi LLP is investigating Dicerna (Nasdaq: DRNA), for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.NEW YORK, November 18, 2021--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders.Dicerna Pharmaceuticals (NASDAQ:DRNA) stock is surging higher on Thursday following news of a massive deal with Novo Nordisk. Source: Shutterstock The deal will have Novo Nordisk acquiring Dicerna Pharmaceuticals for $38.25 per share. That’s an 80% premium over the stock’s closing price on Wednesday and the purchase will be made with cash. That’s quite the offer for DRNA stock and it represents a total equity value of $3.3 billion. The deal will have a Novo Nordisk subsidiary initiating a tenderNovo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021. ""The acquisition of Dicerna accelerates Novo Nordisk's research within RNAi and expands the usage of the RNAi technology,"" said Marcus Schindler, the CSO of Novo Nordisk. Novo Nordisk and Dicerna have been parties to a research collaboration since 2019 toDanish drugmaker Novo Nordisk has agreed a $3.3 billion cash deal to buy Dicerna Pharmaceuticals which specializes in therapeutics that counteract disease-causing genes, it said on Thursday.  With the deal, Novo is following rivals including Novartis by betting on RNA interference technology, or RNAi, where genes that contribute to disease are silenced or rendered ineffective.  Novo started a research collaboration with Dicerna in 2019, pursuing several clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.Novo Nordisk said it's buying Dicerna Pharmaceuticals for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28. Novo Nordisk already had a research collaboration with Dicerna, and said the deal is part of a strategy of using a broad range of technology platforms applicable across all Novo Nordisk's therapeutic focus areas. The existing collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets. Novo Nordisk said the dealWith the deal, Novo is following rivals including Novartis by betting on RNA interference technology, or RNAi, where genes that contribute to disease are silenced or rendered ineffective.  Novo started a research collaboration with Dicerna in 2019, pursuing several clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases.LEXINGTON, Mass., November 18, 2021--DRNA announces definitive agreement with Novo Nordisk to be acquired for $38.25 per share in cash, which represents total equity value of $3.3 billionBy Sam BougheddaDiscerna Pharma shares jump after Novo Nordisk agrees to buy the company, with the deal expected to close in the fourth quarter of 2021.,The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.,LEXINGTON, Mass., November 12, 2021--Dicerna announces Lilly has declared proof of principle for first two targets in the companies’ exclusive relationship in neurodegeneration and pain.LEXINGTON, Mass., November 12, 2021--Dicerna presented results from its Phase 1 trial of belcesiran, in development for the treatment of AATLD, at AASLD.,Joining me for today's call is Doug Fambrough, our President and Chief Executive Officer; Doug Pagan, our Chief Financial Officer; and Dr. Shreeram Aradhye, our Chief Medical Officer.  Before we begin, I'd like to remind everyone that management will be making forward-looking statements on today's call pertaining to the company's finances, business, and operations including the discovery, development and commercialization of our product candidates and technology platform and the therapeutic potential thereof and our collaborations and any future collaborations.Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. Small-cap stocks experienced a bit of a disappointing quarter as both growth and value indexes saw negative quarterly returns for the first time since the pandemic-led […],Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of 46.34% and 7.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?LEXINGTON, Mass., November 09, 2021--Dicerna announces Q3FY21 financial results and provides business update.";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
2022-01-05;172.22000122070312;;55.630001068115234;;260.6499938964844;;102.54000091552734;;135.8699951171875;;88.02999877929688;;78.87999725341797;;56.880001068115234;;62.15999984741211;;49.720001220703125;PARIS (Reuters) -A French court ruled on Wednesday that families of victims of Depakine, an epilepsy drug that caused birth defects and learning difficulties when taken during pregnancy, could join a class action lawsuit against drugmaker Sanofi.  Sanofi said it would appeal against the decision.  APESAC, which represents 7,500 families, launched the class action in September 2021 against Sanofi, which was placed under formal investigation in 2020 on charges of manslaughter over Depakine https://www.reuters.com/article/us-sanofi-depakine-idUSKBN24Z14C.;43.599998474121094;;13.539999961853027;;38.09000015258789;;14.4399995803833;;216.02999877929688;With its stock down 14% over the past three months, it is easy to disregard Repligen (NASDAQ:RGEN). However, the...;11.229999542236328;Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country.;123.86000061035156;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two companies. The transaction agreements, including Pfizer's commercialization of rimegepant and zavegepant outside of the U.S., have become effective following the receipt of required regulatory approvals and the satisfaction of other customary conditions, and BHVN shares have been issued to Pfizer. Biohaven will contin;123.37000274658203;;22.190000534057617;;31.100000381469727;INCHEON, Korea & JERSEY CITY, N.J., January 05, 2022--FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate;44.66999816894531;;30.729999542236328;;31.59000015258789;;32.38999938964844;;45.20000076293945;;125.61000061035156;;39.20000076293945;;58.93000030517578;;4.5;;6.650000095367432;;;;12.770000457763672;Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 3:00 p.m. Eastern Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until Februar;6.409999847412109;;40.29999923706055;"Harmony Biosciences Holdings, Inc. (""Harmony"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs will present a company update and host investor meetings at the upcoming 40th Annual J.P. Morgan Healthcare Conference.";45.31999969482422;;46.2599983215332;;13.149999618530273;;19.59000015258789;;36.22999954223633;;4.760000228881836;"BRIDGEWATER, N.J. & ROSWELL, Ga., January 05, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"") and Saol Therapeutics, a private specialty pharmaceutical company (""Saol""), today announced a definitive agreement under which Amneal will acquire Saol’s Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development. The acquisition expands Amneal’s commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in";56.34000015258789;;27.75;;27.34000015258789;;6.440000057220459;;20.6200008392334;;9.760000228881836;;9.569999694824219;;34.779998779296875;;28.31999969482422;;20.290000915527344;;16.479999542236328;SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. ET. A live audio webcast of the presentation will b;25.670000076293945;MOUNTAIN VIEW, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 10:30 a.m. EST. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of t;21.5;;18.3700008392334;;19.1200008392334;"CAMBRIDGE, Mass. & MONTREAL, January 05, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development."
2022-01-06;171.6300048828125;;54.84000015258789;;259.3299865722656;;102.86000061035156;New York, NY, based Investment company Neville Rodie & Shaw Inc (Current Portfolio) buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk A/S, United Rentals Inc, CAE Inc, sells , Verizon Communications Inc, Trane Technologies PLC, Lululemon Athletica Inc, Organon during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Neville Rodie & Shaw Inc.;135.22999572753906;;88.29000091552734;;78.83000183105469;;56.66999816894531;;61.47999954223633;;49.599998474121094;;43.369998931884766;;13.739999771118164;;38.79999923706055;NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A share, reflecting a 12% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 15, 2022, to shareholders of record at the close of business on February 18, 2022. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of bNEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceu;14.5;Viatris Inc. (NASDAQ: VTRS) today announced that on Tuesday, January 4, its Board of Directors approved a 9% increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of 12 cents ($0.12) per share on outstanding common stock. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2022 is 48 cents ($0.48) per share.;216.8000030517578;;11.300000190734863;;131.10000610351562;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the fourth quarter of 2021.;121.69999694824219;;22.06999969482422;;31.510000228881836;New York, NY, based Investment company Neville Rodie & Shaw Inc (Current Portfolio) buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk A/S, United Rentals Inc, CAE Inc, sells , Verizon Communications Inc, Trane Technologies PLC, Lululemon Athletica Inc, Organon during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Neville Rodie & Shaw Inc.;44.33000183105469;;30.56999969482422;;33.70000076293945;;32.36000061035156;Investment company Tarbox Family Office, Inc. (Current Portfolio) buys iShares Core Total USD Bond Market ETF, iShares Core MSCI Total International Stock ETF, BTC iShares International Aggregate Bond Fund, IGM Biosciences Inc, Fisker Inc, sells Alphabet Inc, AT&T Inc, Meta Platforms Inc, Trex Co Inc, JPMorgan Chase during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Tarbox Family Office, Inc..;45.619998931884766;;126.69000244140625;;40.060001373291016;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the senior management team of the Company, including Founder, Chairman and Acting CEO Dr. Jingwu Zang, President Dr. Andrew Zhu, Chief Financial Officer John Long, Chief Strategy Officer Jielun Zhu and Chief Business Officer Dr. Weimin Tang, have informed the Company of their intention to use their personal funds";59.459999084472656;;4.630000114440918;MIAMI, January 05, 2022--OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022. Management will be hosting one-on-one meetings with investors and will be participating in a virtual fireside chat on Wednesday, January 12th at 3:00 p.m. Eastern time.Grosse Pointe Farms, MI, based Investment company RK Asset Management, LLC (Current Portfolio) buys FutureFuel Corp, OPKO Health Inc, Marten Transport, Fastenal Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, RK Asset Management, LLC.;6.550000190734863;;;;12.699999809265137;;6.239999771118164;;40.47999954223633;;45.13999938964844;;48.349998474121094;;13.350000381469727;;19.989999771118164;;36.0099983215332;;4.599999904632568;;54.68000030517578;;27.56999969482422;;26.829999923706055;;6.599999904632568;;21.739999771118164;;8.989999771118164;;9.229999542236328;;34.86000061035156;;29.459999084472656;"Every investor knows that the path toward profits lies in buying low and selling high. That’s a basic precept of any economic trading system. The trick, however, is recognizing when the stock is low enough to buy in. The prime moment to buy is when the stock hits bottom; that will maximize returns when the share price starts to rise again. There are a multitude of possible clues investors can use to find the price bottom; today, we’ll be looking at insider buying trends. Insiders – the corporate";19.700000762939453;;16.459999084472656;;25.780000686645508;;21.75;;18.989999771118164;;18.850000381469727;
2022-01-07;173.9499969482422;;55.720001220703125;;259.5;;101.48999786376953;"Not only do these companies offer the potential for new jobs and investment; in many cases they would bring a valuable diversity to the communities where they locate.";134.8800048828125;;89.30999755859375;;80.30000305175781;;57.47999954223633;;62.83000183105469;;50.189998626708984;(Bloomberg) -- Sanofi formed a deal to develop 15 experimental oncology and immunology drugs with Exscientia Plc with possible total payouts of as much as $5.2 billion, allying with a company that uses artificial intelligence to make new medicines.Most Read from BloombergOmicron Study in South Africa Points to End of Acute Pandemic PhaseU.S. Is Open as Canada Shuts Down. The Difference? Their Health Care SystemsCiti Confronts Vaccine Holdouts in No Jab, No Job MandateGhislaine Maxwell Juror WhoShares of Exscientia jumped 14.3% in premarket trading on Friday after it announced a deal with Sanofi to develop up to 15 new oncology and immunology drug candidates using Exscientia's artificial intelligence platform. Sanofi's stock was up 0.8%. As part of the agreement, Sanofi will pay Exscientia an upfront payment of $100 million. Additional milestone payments are worth up to $5.2 billion. So far this year, Exscientia's stock is down 7.9%, while Sanofi shares are down 1.0%. The broader S&P 5French drugmaker Sanofi SA will partner with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone payments, the two companies said on Friday.  Exscientia will get an upfront cash payment of $100 million, leading discovery and design of small molecule drugs up to nomination of the candidate most likely to be viable.  After that, Sanofi will take charge of clinical development.Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines Collaborative efforts aim to accelerate drug discovery and improve clinical successAgreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selectionResearch will be focused on up to 15 novel small molecule candidates across oncology and immunologyExscientia will receive an upfront cash paymen;43.849998474121094;;13.90999984741211;;40.2599983215332;Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of AficamtenRoyalty Pharma Purchases Royalties on Future Sales of AficamtenCytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET NEW YORK and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Cytokinetics has secured long-term capital fromRoyalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif. and NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Cytokinetics has secured long-term ca;14.739999771118164;Viatris Inc. said Thursday that its Board of Directors earlier this week approved a 9% increase in the pharmaceutical company's quarterly dividend.;206.7899932861328;;11.390000343322754;"Not only do these companies offer the potential for new jobs and investment; in many cases they would bring a valuable diversity to the communities where they locate.";128.8699951171875;;116.86000061035156;;21.049999237060547;;32.40999984741211;;44.65999984741211;;30.68000030517578;;33.02000045776367;;30.940000534057617;;44.04999923706055;WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 3, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 0 Inducement Stock Incentive Plan) and material to the employee’s acceptance of employment with the company.;125.12000274658203;Here's why you'll want to keep both eyes open for upcoming announcements from Alnylam Pharmaceuticals (NASDAQ: ALNY), Intercept Pharmaceuticals (NASDAQ: ICPT), and Karuna Therapeutics (NASDAQ: KRTX).  Shares of Alnylam recently slipped around 15% overnight in response to a surprising clinical-trial flop for a drug it isn't even developing.  Recently, BridgeBio Pharma told investors that people with heart damage caused by transthyretin amyloidosis (ATTR) who received acoramidis failed to outperform the placebo group on the six-minute walking test.;40.689998626708984;;56.060001373291016;;4.449999809265137;;6.460000038146973;Provides roadmap to commercial agreement between EQRx and Geisinger, a U.S.-based integrated delivery networkPotential to provide access to affordable treatments in areas of high-cost burden for more than 1 million people within Geisinger health systems CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced it has signe;;;12.680000305175781;;6.260000228881836;;37.959999084472656;;42.95000076293945;;48.779998779296875;;12.890000343322754;;19.799999237060547;;34.22999954223633;BILLERICA, Mass., January 06, 2022--Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference;4.630000114440918;;52.79999923706055;;27.65999984741211;;25.329999923706055;;6.420000076293945;;18.68000030517578;;8.859999656677246;;9.300000190734863;;34.150001525878906;;28.709999084472656;;18.65999984741211;;15.970000267028809;;24.600000381469727;;21.68000030517578;;18.110000610351562;;16.65999984741211;"CAMBRIDGE, Mass. & MONTREAL, January 07, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022."
2022-01-10;173.08999633789062;;56.2400016784668;;260.1099853515625;;101.79000091552734;;136.38999938964844;;90.08000183105469;"Novartis says it will license antiviral Covid-19 treatment ensovibep from Molecular Partners following positive trial results.Swiss drugmaker Novartis and partner Molecular Partners could have experimental drug Ensovibep on the market within weeks to treat COVID-19 patients, officials from the two companies said on Monday.  ""The emergency marketing authorisation application can be filed now,"" Molecular Chief Executive Patrick Amstutz told Reuters.  The antibody therapy developed by Molecular has met its main target in a phase II trial.It comes after its global clinical trials, which tested 407 patients during a Phase Two study, showed a 78% reduction in hospitalisations or emergency visits related to coronavirus versus a placebo.After getting positive trial data, Novartis AG (NYSE: NVS) said it would in-license a new drug developing with Molecular Partners AG (NASDAQ: MOLN) to treat COVID-19. Novartis will pay CHF 150 million to in-license ensovibep from Molecular Partners. The decision comes after the two companies said they had received positive topline data from a phase 2 study for ensovibep (mp0420), an antiviral therapeutic for COVID-19. Related Link: Molecular Partners' Ensovibep Shows Early Safety Profile In COVI";82.37000274658203;;57.880001068115234;;65.0999984741211;;51.5;Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.;44.84000015258789;;14.239999771118164;OSAKA, Japan & LONDON, January 10, 2022--Takeda exercised its option to acquire Adaptate Biotherapeutics, adding a gamma delta T-cell engager platform to Takeda's immuno-oncology portfolio.;42.439998626708984;"2021 Net cash provided by operating activities (GAAP) expected to be in the range of $2,010 to $2,030 million; 2021 Adjusted Cash Receipts (non-GAAP) expected to be at high end of guidance range of $2,110 to $2,130 million20 therapies added to portfolio in 2020-2021; 9 are currently or projected to be blockbustersAnnounced transactions of $5.5 billion from 2020-2021 expected to add >$750 million to Adjusted Cash Receipts (non-GAAP) in 2025 NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Royalty Phar";15.010000228881836;;210.52999877929688;Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.;12.039999961853027;;130.58999633789062;Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven, announced today that they have entered into an exclusive global license and research agreement to develop and commercialize first-in-class TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery (CD3) and the Laborator;116.18000030517578;COPENHAGEN, Denmark, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key milestones at the 40th Annual J.P. Morgan Healthcare Conference. Details of the update are outlined below, and CEO Jan Mikkelsen will give a virtual presentation to attendees from 3:00-3:40 p.m. Eastern Time.“We took major steps in 2021 to becoming a viable, sustainable, and profitable biopharmaceutical comp;20.81999969482422;;32.209999084472656;;42.849998474121094;;29.860000610351562;Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs. CureVac's preclinical second-generation mRNA vaccine candidate, CV2CoV, against SARS-CoV-2 is under development in collaboration with GlaxoSmithKline Plc (NYSE: GSK). The company expects to start a Phase 1 trial assessing CV2CoV in Q1 2022. Related: CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study. Additionally, the company expects;32.599998474121094;"— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 that also target the B-cell receptor (“BCR”) signaling pathway, and tazemetostat and HMPL-306 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) has initiated a Phase";28.6299991607666;"Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for emraclidine in schizophrenia by the middle of 2022, with data expected in the first half of 2024 Phase 1 trial for darigabat in acute anxiety completed; data is expected in the next several weeks Phase 2a data for CVL-871 in dementia-related apathy now expected 1H 2023; delayed from 2H 2022, due in";44.4900016784668;;124.93000030517578;;39.88999938964844;;58.630001068115234;;4.619999885559082;;6.429999828338623;The two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterpriseIncludes CVS Caremark, the leading pharmacy benefit manager in the U.S., covering 1 in 3 Americans – nearly 110 million livesInitial focus will be on EQRx’s two lead oncology programs with future therapies expected to follow CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering im;;;12.539999961853027;;6.139999866485596;;37.369998931884766;;41.849998474121094;;50.20000076293945;Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpointReports preliminary 2021 total revenues of $1.78 billion at the midpoint and Adjusted EBITDA of $513 million, or 29%, at the midpoint, both in line with prior guidance given in November 2021 GAITHERSBURG, Md., Jan. 09, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.;12.069999694824219;;19.8799991607666;;35.0;;4.699999809265137;;51.7599983215332;;23.270000457763672;Nurix leads protein modulation field with four active clinical stage programs Anticipates data-rich 2022 with clinical-stage programs and a pipeline fueled by proprietary DELigase platform SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today outlined key objectives and anticipated milestones for 2022 and provided an overview of recent progress. “2021 was a significant and highly p;24.8799991607666;;6.380000114440918;;19.079999923706055;;9.0;;9.180000305175781;;34.209999084472656;;28.3799991607666;;18.84000015258789;In this article, we discuss the 10 small-cap stocks to buy according to billionaire Steve Cohen. You can skip our detailed analysis of Steve Cohen’s hedge fund, and go directly to read 5 Small-Cap Stocks to Buy According to Billionaire Steve Cohen. Billionaire investor Steve Cohen is the brain behind Point72 Asset Management, a hedge fund […];14.479999542236328;;24.8700008392334;IGM Biosciences, Inc. (IGMS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.;21.68000030517578;;16.889999389648438;;15.880000114440918;
2022-01-11;171.25;;56.689998626708984;;262.32000732421875;;101.22000122070312;Jefferies Managing Director Michael Yee joins Yahoo Finance Live’s Julie Hyman and Brian Sozzi to discuss the biotech sector, outlook for M&A activity, and the outlook for COVID-19 stocks.;136.97000122070312;;89.87000274658203;The world is anxiously waiting for more-effective weapons against the coronavirus, so it was little wonder that the stock of Molecular Partners (NASDAQ: MOLN) shot more than 30% higher on Monday.  The German biotech, along with its partner Novartis (NYSE: NVS), had some potentially excellent news to report about their pipeline drug targeting the still-raging disease.  Molecular Partners and Novartis announced that the initial part of a phase 2 clinical trial evaluating intravenous dosing of that drug, ensovibep, met its primary endpoint of viral load reduction.;81.66999816894531;;58.099998474121094;;65.4800033569336;;51.40999984741211;Today's Research Daily features new research reports on 16 major stocks, including Sanofi (SNY), International Business Machines Corporation (IBM), and Deere & Company (DE).Pfizer is doubling down on mRNA investments as well as newer technology, including gene editing, to boost its pipeline.Comcast (NASDAQ: CMCSA) and Sanofi (NASDAQ: SNY) are value stocks on the Nasdaq exchange that are underpriced -- for now -- but offer great growth potential along with an above-average dividends.  Both companies' share prices have trailed the growth seen in the Nasdaq, where the average stock rose 35% over the last year.  In the same period, Comcast's shares are down around 2% while Sanofi's grew only 4%.;45.040000915527344;;14.3100004196167;"OSAKA, Japan & CAMBRIDGE, Mass., January 10, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (""Takeda"") today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through FY2030. Presenting at the 40th Annual J.P. Morgan Healthcare Conference, Christophe Weber, Takeda’s President and Chief Executive Officer, reinforced the mid-term revenue growth potential of its 14 global";41.599998474121094;;15.319999694824219;;210.58999633789062;;12.300000190734863;;128.7899932861328;;118.87999725341797;;21.559999465942383;Evotec receives payments totalling US$ 15 m from Bristol Myers Squibb.Under the expansion, Bristol Myers Squibb increases its access to a novel targeted protein degradation approach.;32.75;Organon Canada — Organon (NYSE: OGN) — is pleased to share that public listings in Ontario (Ontario Drug Benefit program), British Columbia (BC PharmaCare) and Nova Scotia (Nova Scotia PharmaCare) for NEXPLANON® (etonogestrel extended-release subdermal implant) are now currently effective. NEXPLANON® is a progestin-only hormonal implant used to prevent pregnancy for up to three years.1 With these additional listings, there are now eleven jurisdictions providing coverage for NEXPLANON on their puInvestment company Poehling Capital Management, LLC (Current Portfolio) buys ViacomCBS Inc, Fidelity National Information Services Inc, Organon, Amgen Inc, Occidental Petroleum Corp, sells Apollo Global Management Inc, Pfizer Inc, Discovery Inc, Vanguard Intermediate-Term Corporate Bond ETF, Starbucks Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Poehling Capital Management, LLC.Canton, OH, based Investment company Beese Fulmer Investment Management, Inc. (Current Portfolio) buys PIMCO Enhanced Short Maturity Active Exchange-Trad, Vanguard Ultra-Short Bond ETF, American Electric Power Co Inc, General Electric Co, iShares MSCI Emerging Markets ETF, sells Unilever PLC, Vanguard Total Stock Market ETF, Vanguard Short-Term Bond ETF, Eastern Bankshares Inc, Vanguard Short-Term Inflation-Protected Securities during the 3-months ended 2021Q4, according to the most recent filin;45.650001525878906;;29.860000610351562;;33.5099983215332;;28.469999313354492;;41.150001525878906;;124.97000122070312;;39.02000045776367;;55.400001525878906;;4.590000152587891;;7.389999866485596;;;;12.369999885559082;;6.480000019073486;;37.540000915527344;;42.40999984741211;;50.88999938964844;;12.550000190734863;;19.989999771118164;;35.08000183105469;;4.760000228881836;;54.599998474121094;;24.56999969482422;;25.510000228881836;;6.739999771118164;NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today: H.C. Wainwright BioConnect Conference (Virtual)Format: Fireside ChatDate and Time: Monday, January 10th, 2022, 2:00 p.m. ETWebcast Link: URL The presentations and archived webcasts will also be accessible in the Events section of at;19.18000030517578;;9.319999694824219;;9.199999809265137;;33.5099983215332;;29.479999542236328;;18.860000610351562;;15.09000015258789;;24.93000030517578;;21.739999771118164;;17.969999313354492;;16.25;
2022-01-12;169.7899932861328;;56.650001525878906;;255.9199981689453;;100.75;Investment company First American Trust, Fsb (Current Portfolio) buys Nike Inc, Tesla Inc, Teradyne Inc, Union Pacific Corp, Uber Technologies Inc, sells Starbucks Corp, Newmont Corp, Walmart Inc, Activision Blizzard Inc, Stericycle Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First American Trust, Fsb.;137.2899932861328;;89.79000091552734;"Rating Action: Moody's assigns B2 ratings to Covis Pharma; outlook stableGlobal Credit Research - 12 Jan 2022Assigns B2 ratings to backed senior secured term loan B and backed senior secured revolving credit facilityLondon, 12 January 2022 -- Moody's Investors Service (Moody's) has today assigned a B2 corporate family rating (CFR) and B2-PD probability of default rating (PDR) to patent-protected and mature drugs provider Covis Midco 2 S.a r.l.  Moody's has also assigned B2 ratings to the proposed $350 million backed senior secured first-lien term loan B and pari passu ranking $100 million backed senior secured multicurrency revolving credit facility (RCF), maturing in 2027 and for which Covis Finco S.a r.l.Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.";81.19999694824219;;58.400001525878906;;64.81999969482422;;51.5099983215332;Sanofi, International Business Machines Corp. and Deere & Company are included in this analyst blog.;45.2400016784668;;14.649999618530273;;40.84000015258789;;15.170000076293945;The company, formed by the merger of Mylan and the Upjohn division of Pfizer, has underwhelmed investors.;210.9499969482422;The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.;11.979999542236328;;123.61000061035156;;121.8499984741211;;21.780000686645508;;32.61000061035156;;46.95000076293945;;28.56999969482422;Investment company Green Alpha Advisors, LLC (Current Portfolio) buys Wolfspeed Inc, sells SK Telecom Co, PayPal Holdings Inc, Invitae Corp, Twilio Inc, Proto Labs Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Green Alpha Advisors, LLC.;33.95000076293945;"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, for the treatment of chronic adult primary immune thrombocytopenia (“ITP”) patients who have received at le";27.030000686645508;;41.70000076293945;;120.83000183105469;;40.5;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient had been dosed in its China phase 2 study (NCT05145907) of efineptakin alfa (also known as TJ107) in combination with pembrolizumab (Keytruda®) in patients with advanced solid tumors. The study will follow a ""basket"" trial design to include selected tumor types, including triple-negative breast c";60.22999954223633;;4.440000057220459;;7.199999809265137;;;;12.279999732971191;;6.320000171661377;"CULVER CITY, Calif., January 12, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (""ImmunityBio""), today announced that it has entered into a definitive agreement to acquire a leasehold interest in 409,000 square feet of ISO Class 5 pharmaceutical manufacturing space in western New York (the ""Dunkirk Facility""), and certain related assets, from global pharmaceutical company Athenex, Inc. (NASDAQ: ATNX) (""Athenex""). The agreement will provide ImmunityBio with a stateBUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a definitive agreement for ImmunityBio, Inc. (NASDAQ: IBRX) to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38 million, subject t";36.27000045776367;;36.970001220703125;;48.540000915527344;;13.369999885559082;;18.8799991607666;;33.22999954223633;;4.730000019073486;;53.060001373291016;;23.969999313354492;;24.649999618530273;- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with neuroendocrine tumors expected in 2022 - - Initiation of IND-enabling studies for parathyroid receptor type-1 antagonist expected in 2022 - SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development;6.659999847412109;• Enables expansion of PCN-101 clinical development to the U.S. • atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs • DDI trial will complement existing Phase 2a trial in treatment-resistant depression (TRD) recently initiated in Europe NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform;18.739999771118164;;9.050000190734863;;9.470000267028809;BARRANQUILLA, Colombia, January 12, 2022--Procaps Group Acquires 1st U.S.-Based Softgel Production Facility and Pharmaceutical R&D Center to Expand Global Growth of its iCDMO Business Unit;32.06999969482422;;28.510000228881836;All 327,400 square feet of a Class AA building along Plano's Legacy Drive has hit the sublease market, according to sources.;17.899999618530273;;15.359999656677246;;22.540000915527344;;23.020000457763672;;17.3799991607666;;15.180000305175781;
2022-01-13;168.75999450683594;;55.540000915527344;;249.6699981689453;;99.55999755859375;;133.52000427246094;;90.62000274658203;Investment company Kmg Fiduciary Partners, Llc (Current Portfolio) buys NVIDIA Corp, PayPal Holdings Inc, Delta Air Lines Inc, Block Inc, Caterpillar Inc, sells Archer-Daniels Midland Co, Bank of New York Mellon Corp, PepsiCo Inc, Deere, Biogen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Kmg Fiduciary Partners, Llc.;81.31999969482422;;58.099998474121094;;64.5999984741211;;50.72999954223633;;45.060001373291016;;14.5600004196167;These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2022.;40.18000030517578;;15.020000457763672;;191.55999755859375;If you've got the time and intestinal fortitude to deal with a stock's big ups and downs, a big potential payoff awaits.  If you think Advanced Micro Devices (NASDAQ: AMD) is always behind Nvidia in the graphics card market while at the same time perpetually playing second fiddle to Intel within the computer processor arena, you're right.  Namely, Advanced Micro Devices' hardware is a favorite among hardcore video gamers because it's affordable without sacrificing performance.;12.079999923706055;;122.73999786376953;;119.05000305175781;TransCon hGH (approved by the European Commission as Lonapegsomatropin Ascendis Pharma) is a once-weekly prodrug of somatropin for pediatric patients diagnosed with growth hormone deficiencyCOPENHAGEN, Denmark, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name TransCon hGH) as a once-weekly subcutaneous injection for the treatmen;20.75;;32.900001525878906;These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2022.;43.2400016784668;;27.030000686645508;;31.5;;27.040000915527344;;40.79999923706055;;122.20999908447266;;35.41999816894531;;61.04999923706055;Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […];4.28000020980835;;6.900000095367432;;;;12.0;;6.239999771118164;A relationship that began at American Pharmaceutical Partners, which had a longtime plant on Grand Island, led the immunotherapy and cell therapy company to Dunkirk.;36.040000915527344;;35.02000045776367;In this article we are going to use hedge fund sentiment as a tool and determine whether Turning Point Therapeutics, Inc. (NASDAQ:TPTX) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League […];49.47999954223633;;13.25;;18.989999771118164;;33.09000015258789;BILLERICA, Mass., January 13, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.;4.610000133514404;;49.95000076293945;;22.15999984741211;;24.049999237060547;;6.21999979019165;;18.90999984741211;;8.930000305175781;;9.479999542236328;;31.209999084472656;;28.1299991607666;;16.940000534057617;;14.1899995803833;;21.260000228881836;;22.690000534057617;;17.100000381469727;;14.649999618530273;
2022-01-14;167.83999633789062;;54.95000076293945;;244.1199951171875;;96.31999969482422;"Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, ""allegedly"" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) obesity drug Wegovy, reported BioProcess International reported. An FDA inspection of the CDMO's filling site in Brussels yielded a Form 483, the publication said, calling it a ""recent"" inspection. ""We are treating the FDA's 483 observations at the Brussels, Belgium, site very seriously and are working closelyBy Sam Boughedda";135.8699951171875;;90.55000305175781;Investment company 17 Capital Partners, Llc (Current Portfolio) buys Crown Castle International Corp, Constellation Brands Inc, SPDR Portfolio S&P 500 Growth ETF, The Trade Desk Inc, Tyler Technologies Inc, sells Novartis AG, Zendesk Inc, Chegg Inc, Wells Fargo, Twitter Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 17 Capital Partners, Llc.One of the best ways to generate wealth from the stock market is to invest over in long-term stocks. As the saying goes, it’s not timing the market, it’s time in the market. This saying holds just as true today as it did 10 years ago. For those looking to invest over the next 10 years, now’s certainly an interesting time. Those looking to put fresh capital to work have a number of considerations to think about. First of all, will the pandemic even be relevant in a few years’ time? How many compa;81.37999725341797;;58.849998474121094;;64.93000030517578;;51.93000030517578;Investment company McGuire Investment Group, LLC (Current Portfolio) buys SPDR Bloomberg 1-3 Month T-Bill ETF, WisdomTree Floating Rate Treasury Fund, BTC iShares Floating Rate Bond ETF, SPDR Bloomberg Investment Grade Floating Rate ETF, Global X Genomics & Biotechnology ETF, sells Sangamo Therapeutics Inc, ARK Genomic Revolution ETF, Editas Medicine Inc, Boston Scientific Corp, United Rentals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, M;45.470001220703125;;14.75;;39.65999984741211;Royalty Pharma plc ( NASDAQ:RPRX ) will increase its dividend on the 15th of March to US$0.19. This takes the annual...;15.220000267028809;Investment company Nexus Investment Management ULC (Current Portfolio) buys American Electric Power Co Inc, Fortis Inc, Union Pacific Corp, iShares MSCI EAFE ETF, Edison International, sells Open Text Corp, Viatris Inc, Bank of America Corp, Fortive Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Nexus Investment Management ULC.Washington, DC, based Investment company Bonness Enterprises Inc (Current Portfolio) buys Organon, Verizon Communications Inc, Viatris Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bonness Enterprises Inc.JUST Capital, a firm that works to help companies improve how they serve their stakeholders, released its annual rankings of the most “just” public companies in the country—and several Pittsburgh names made the list.;193.25999450683594;;12.630000114440918;;122.16999816894531;;122.95999908447266;The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH). The approval for TransCon covers a once-weekly subcutaneous injection for children and adolescents ages 3 to 18 years with growth failure due to growth hormone deficiency (GHD). TransCon hGH is a prodrug of somatropin that provides sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body. The EC a;20.06999969482422;;32.86000061035156;Washington, DC, based Investment company Bonness Enterprises Inc (Current Portfolio) buys Organon, Verizon Communications Inc, Viatris Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bonness Enterprises Inc.;41.5;;24.479999542236328;BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.;31.06999969482422;;27.56999969482422;;40.36000061035156;;124.47000122070312;;35.060001373291016;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the senior management team of the Company, including Founder, Chairman and Acting CEO Dr. Jingwu Zang, President Dr. Andrew Zhu, Chief Financial Officer John Long, Chief Strategy Officer Jielun Zhu and Chief Business Officer Dr. Weimin Tang, have executed the share purchase plan with the open market purchase of ov";62.47999954223633;;4.53000020980835;;6.449999809265137;;;;12.100000381469727;;6.670000076293945;;36.68000030517578;;38.34000015258789;;52.220001220703125;Fuad El-Hibri, the founder and executive chairman of Emergent BioSolutions (NYSE: EBS) is retiring 23 years after he founded the Gaithersburg biotech.  Emergent, which made its name selling anthrax vaccines to the U.S. government, has been in the news much more during the coronavirus pandemic for its Covid-19 vaccine efforts, which floundered due to manufacturing issues at its Baltimore facility.  El-Hibri founded the company, then called BioPort, in 1998, and served as its CEO until 2012, when he stepped into the executive chairman role.Fuad El-Hibri to Retire After More Than 20 YearsGAITHERSBURG, Md., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1, 2022. “Creating and leading Emergent has been the honor of my life, and it would not have been possible without the help of our incredible team,” said El-Hibri. “I want to thank everyone at Emergent, past and present, for helping advance our inspiring;12.9399995803833;;17.219999313354492;;32.650001525878906;;4.639999866485596;;51.779998779296875;;23.239999771118164;;24.010000228881836;;5.960000038146973;;19.209999084472656;;8.90999984741211;;9.149999618530273;;33.47999954223633;;28.739999771118164;;17.40999984741211;;14.09000015258789;;21.8799991607666;;21.3799991607666;;17.530000686645508;;15.229999542236328;
2022-01-18;167.10000610351562;;54.11000061035156;;247.07000732421875;;96.38999938964844;;136.77999877929688;;89.54000091552734;Investment company Norway Savings Bank (Current Portfolio) buys FedEx Corp, Vanguard Dividend Appreciation FTF, ConocoPhillips, SPDR Bloomberg Convertible Securities ETF, Visa Inc, sells Novartis AG, PIMCO Enhanced Short Maturity Active Exchange-Trad, iShares iBonds Dec 2021 Term Corporate ETF, Fortive Corp, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Norway Savings Bank.Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.;81.54000091552734;;59.84000015258789;;64.88999938964844;;52.16999816894531;Investment company T Rowe Price Equity Income Fund (Current Portfolio) buys The Walt Disney Co, Citigroup Inc, State Street Corporation, Dominion Energy Inc, Xcel Energy Inc, sells CF Industries Holdings Inc, Raymond James Financial Inc, Snap-on Inc, Citizens Financial Group Inc, Bank of New York Mellon Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, T Rowe Price Equity Income Fund.Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,526,866,030 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n;46.81999969482422;;14.550000190734863;;40.31999969482422;;15.0600004196167;;186.61000061035156;;12.529999732971191;;118.0;;117.51000213623047;;19.770000457763672;German biotech company Evotec said on Tuesday that it had entered into a drug discovery collaboration in metabolic diseases with U.S. drugmaker Eli Lilly.  The total potential value of the collaboration, which will run for three years, is up to $1 billion.  As part of the collaboration, Evotec will explore potential drug candidates for the treatment of diabetes and chronic liver disease, the Hamburg-based company said.The collaboration leverages Evotec's extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec.;32.06999969482422;Investment company Abacus Planning Group, Inc. (Current Portfolio) buys Distillate U.S. Fundamental Stability & Value ETF, Aramark, Vanguard Total Stock Market ETF, Vanguard FTSE Developed Markets ETF, VANGUARD BD IDX FD, sells Devon Energy Corp, Quanta Services Inc, Biogen Inc, PayPal Holdings Inc, Foot Locker Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Abacus Planning Group, Inc..;41.099998474121094;;22.469999313354492;;30.540000915527344;;25.780000686645508;;38.40999984741211;;112.3499984741211;;34.209999084472656;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab (TUOYI®) in patients with advanced solid tumors. The phase 2 study is designed as a basket trial and could potentially lead to a registrational trial in China.";57.9900016784668;;4.71999979019165;Investment company Aries Wealth Management (Current Portfolio) buys SPDR Portfolio Short Term Treasury ETF, Microsoft Corp, Vanguard Small Cap ETF, Vanguard Mid-Cap ETF, Vanguard Growth ETF, sells Invesco S&P 500 Low Volatility ETF, OPKO Health Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Aries Wealth Management.Investment company 360 Financial, Inc. (Current Portfolio) buys Global X U.S. Infrastructure Development ETF, AMMO Inc, Vanguard S&P Mid-Cap 400 Value ETF, Intuit Inc, Consumer Discretionary Select Sector SPDR, sells Invesco S&P 500 Equal Weight Materials ETF, ISHARES TRUST, Stem Inc, Clorox Co, FIGS Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 360 Financial, Inc..Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and former CCO of Invitae, to join Sema4 as Co-CEO, alongside Eric Schadt, PhD, and become a member of Sema4’s Board of Directors Director Jason Ryan, former CFO of Foundation Medicine, to assume role of Executive Chair of Sema4’s Board o;6.28000020980835;Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after sequential or concurrent chemoradiotherapy Concurrently published results from the pivotal Phase 3 GEMSTONE-302 study demonstrated PFS benefit with sugemalimab plus chemotherapy in first-line systemic treatment of patients with Stage IV NSCLC, regardless of tumor pathologic subtype o;;;11.720000267028809;;6.190000057220459;;35.029998779296875;;36.209999084472656;"Strong enrollment within multi-cohort TRIDENT-1 Phase 2 registration enabling study of repotrectinib; completion of targeted 60 patients within EXP-4 ROS1+ TKI-pretreated NSCLC cohort TRIDENT-1 topline BICR ORR and DOR data from ROS1+ NSCLC cohorts and pre-NDA discussion anticipated in 2Q 2022 Phase 1 TRIDENT-1 data in ROS1+ TKI-naïve NSCLC patients continue to show best-in-class potential with DOR range of 5.6-42.2+ months with 3 of 6 responding patients with DOR of greater than 30 months ElzovMORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors. “We are excited to welcome Barbara and Alfonso to the Syneos Health Board,” said John Dineen, Chair of the Syneos Health Board of Directors. “Barbara’s deep financial expertise combined with Alfonso’s expansive indust";47.22999954223633;;12.170000076293945;Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice Presi;16.940000534057617;ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize Zynlonta (loncastuximab tesirine-lpyl) for all hematologic and solid tumor indications in Japan. Under the agreement terms, ADC Therapeutics will receive an upfront payment of $30 million and up to an additional $205 million in milestones payments. ADC Therapeutics will also receive sales-based royalties ranging in percentage from the high teens to thLAUSANNE, Switzerland, January 18, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of ZYNLONTA® (loncastuximab tesirine-lpyl) for all hema;30.18000030517578;;4.5;;48.29999923706055;;19.889999389648438;;21.559999465942383;;5.389999866485596;;17.5;;8.710000038146973;;9.0;;27.209999084472656;PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, includin;27.600000381469727;;16.09000015258789;;14.260000228881836;;19.8799991607666;;21.940000534057617;;14.460000038146973;PRAX-562 demonstrated robust preclinical antiseizure activity and exhibited an improved preclinical tolerability profile compared to standard-of-care Praxis expects to initiate a Phase 2 trial in the first half of 2022 to explore the potential for PRAX-562 to treat rare DEEs BOSTON, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system;14.529999732971191;
2022-01-19;166.5800018310547;;53.540000915527344;;245.0500030517578;;97.29000091552734;Investment company Lowe Wealth Advisors, LLC (Current Portfolio) buys KraneShares Global Carbon Strategy ETF, Horizon Kinetics Inflation Beneficiaries ETF, JPMorgan Equity Premium Income ETF, iShares Russell 2000 ETF, Ford Motor Co, sells Industrial Select Sector SPDR, AT&T Inc, FMC Corp, First Trust Chindia ETF, VanEck Oil Services ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lowe Wealth Advisors, LLC.;135.2100067138672;;88.8499984741211;;81.29000091552734;;59.47999954223633;WILMINGTON, Del., January 18, 2022--Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.;64.72000122070312;;52.08000183105469;Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesionsData confirm results from first Phase 3 trial, with 60% of Dupixent patients meeting the primary endpoint of itch reduction compared to 18% ofInvestment company Pendal Group Ltd (Current Portfolio) buys NXP Semiconductors NV, Ferguson PLC, Unilever PLC, Taiwan Semiconductor Manufacturing Co, BioNTech SE, sells Philip Morris International Inc, Progressive Corp, Exelon Corp, Atmos Energy Corp, Sempra Energy during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Pendal Group Ltd.;45.689998626708984;;14.369999885559082;New York, NY, based Investment company Beech Hill Advisors, Inc. (Current Portfolio) buys Block Inc, The Walt Disney Co, Activision Blizzard Inc, Crown Castle International Corp, Gilead Sciences Inc, sells Delta Air Lines Inc, Broadcom Inc, L3Harris Technologies Inc, Exact Sciences Corp, Chewy Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Beech Hill Advisors, Inc..Investment company Veriti Management LLC (Current Portfolio) buys Aluminum Corporation of China, EPAM Systems Inc, United Microelectronics Corp, Clarivate PLC, Kite Realty Group Trust, sells Capital One Financial Corp, Hawaiian Electric Industries Inc, , Public Storage, Power Integrations Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Veriti Management LLC.Investment company Ridgewood Investments LLC (Current Portfolio) buys Vale SA, Activision Blizzard Inc, Calavo Growers Inc, FedEx Corp, Takeda Pharmaceutical Co, sells General Dynamics Corp, Merck Inc, Comcast Corp, U.S.;39.970001220703125;;14.720000267028809;;189.5800018310547;Investment company Accel Wealth Management (Current Portfolio) buys Vanguard Total Stock Market ETF, iShares Core Dividend Growth ETF, FIRST TR EXCHANGE, Vanguard Growth ETF, Recon Capital NASDAQ-100 Covered Call ETF, sells First Trust NASDAQ Clean Edge Green Energy Idx Fd, , Meta Platforms Inc, Vanguard Mortgage-Backed Securities ETF, BTC iShares U.S.;12.460000038146973;Investment company Ridgewood Investments LLC (Current Portfolio) buys Vale SA, Activision Blizzard Inc, Calavo Growers Inc, FedEx Corp, Takeda Pharmaceutical Co, sells General Dynamics Corp, Merck Inc, Comcast Corp, U.S.;115.04000091552734;;118.29000091552734;;20.530000686645508;;32.2400016784668;Boston, MA, based Investment company Welch & Forbes Llc (Current Portfolio) buys Vanguard Ultra-Short Bond ETF, First Trust Enhanced Short Maturity ETF, Verisk Analytics Inc, ConocoPhillips, HP Inc, sells Service Properties Trust, iShares Russell Top 200 Growth ETF, iShares Russell Top 200 Value ETF, Rio Tinto PLC, iShares Russell 1000 Value ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Welch & Forbes Llc.Investment company Courier Capital Llc (Current Portfolio) buys SPDR Bloomberg Investment Grade Floating Rate ETF, SPDR Blackstone Senior Loan ETF, ViacomCBS Inc, BTC BlackRock Short Maturity Bond ETF, iShares Russell 1000 ETF, sells iShares MSCI EAFE ETF, Vanguard Value ETF, Invesco BulletShares 2021 Corporate Bond ETF, JPMorgan Ultra-Short Income ETF, Invesco BulletShares 2021 High Yield Corporate Bon during the 3-months ended 2021Q4, according to the most recent filings of the investment comp;40.349998474121094;;22.469999313354492;;29.729999542236328;"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the upcoming 2022 ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022. The meeting will be held virtually and in person at the Moscone Center in San Francisco, California, US. Further details of the presenta";25.889999389648438;;37.75;;112.68000030517578;;32.75;;54.18000030517578;;4.429999828338623;;5.429999828338623;Pivotal Phase 3 GEMSTONE-302 trial met key secondary endpoint of prolongation of overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapyOverall survival benefit demonstrated regardless of tumor pathologic subtype or PD-L1 expression levels CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, along with it;;;12.140000343322754;;5.96999979019165;(Bloomberg) -- Most Read from BloombergMicrosoft Buys Scandal-Tainted Activision in Bet on MetaverseFourth Pfizer Dose Is Insufficient to Ward Off Omicron, Israeli Trial SuggestsCovid-19 Infected Lions Prompt Variant Warning in South AfricaMicrosoft Deal Wipes $20 Billion Off Sony's Market Value in a DayStocks Rise as Dip-Buyers Return, Nasdaq Rebounds: Markets WrapU.S. biotech billionaire Patrick Soon-Shiong launched a plant that will produce a billion Covid-19 vaccine doses a year in Cape TownCULVER CITY, Calif., January 18, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88) showing that the overall survival rate for patients doubled compared to historical survival rate of three months after two prior lines of therapy (Manax ASCO GI 2019). The data of the Phase 2 trial studying a combination immunotherapy (Nant Cancer Vaccine) also show treatment-related serious ad;35.189998626708984;;36.540000915527344;;45.59000015258789;Biotech investors still like BioCryst, Protagonist, Prometheus Biosciences, Rani, and Emergent BioSolutions. All sported recent double-digit gains despite the sector slump.;11.300000190734863;;16.780000686645508;;28.489999771118164;;4.460000038146973;;47.91999816894531;;19.489999771118164;;20.360000610351562;;5.579999923706055;;16.440000534057617;;8.930000305175781;;9.5;;26.65999984741211;;27.799999237060547;;15.619999885559082;;14.710000038146973;;20.010000228881836;;21.219999313354492;;14.850000381469727;;14.130000114440918;
2022-01-20;165.25;;54.04999923706055;;243.1300048828125;;95.45999908447266;Investment company Paces Ferry Wealth Advisors, Llc (Current Portfolio) buys Sprinklr Inc, Schwab U.S.Westport, CT, based Investment company Eagle Ridge Investment Management (Current Portfolio) buys Vanguard Short-Term Inflation-Protected Securities, Sempra Energy, Huntington Ingalls Industries Inc, iShares MSCI EAFE ETF, iShares Core S&P 500 ETF, sells Intel Corp, Lowe's Inc, Vanguard Mortgage-Backed Securities ETF, Enterprise Products Partners LP, PepsiCo Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Eagle Ridge Investment Management.;133.02999877929688;;88.19000244140625;Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.Investment company Aevitas Wealth Management, Inc. (Current Portfolio) buys Enbridge Inc, Mastercard Inc, Exxon Mobil Corp, Truist Financial Corp, NVIDIA Corp, sells ARK Innovation ETF, ARK Genomic Revolution ETF, ARK Fintech Innovation ETF, Invesco BulletShares 2021 Corporate Bond ETF, CRISPR Therapeutics AG during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Aevitas Wealth Management, Inc..Still earning peanuts in your savings account? These 3 income stocks might help.;80.75;;60.16999816894531;Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.A look at the shareholders of AstraZeneca PLC ( LON:AZN ) can tell us which group is most powerful. Generally speaking...Dr. Taison Bell, Assistant Professor of Medicine at the University of Virginia, joins Yahoo Finance Live to discuss Virginia getting rid of its mask mandate for schools, the Omicron variant, and coronavirus vaccinations.Birmingham, AL, based Investment company Cadence Bank Na (Current Portfolio) buys BTC BlackRock Short Maturity Bond ETF, Diageo PLC, Hasbro Inc, Vanguard Dividend Appreciation FTF, Goldman Sachs Group Inc, sells Novartis AG, AstraZeneca PLC, Whirlpool Corp, Vanguard Mid-Cap ETF, Comcast Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cadence Bank Na.A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable hepatocellular carcinoma compared with sorafenib. The risk of death was 22% lower for the Imfinzi + tremelimumab combo versus over sorafenib, a standard-of-care multi-kinase inhibitor. For the Phase 3 HIMALAYA trial in front-line liver cancer, the Company used a single dose of tremelimumab 300mg added to Imfinzi 1500mg followed by Imfinzi every f;64.58000183105469;;52.09000015258789;Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.;44.880001068115234;"One of Unilever's biggest shareholders has raised the prospect of replacing chief executive Alan Jope and accused management of putting the company through a ""near-death experience"" with an aborted £50bn bid for part of GlaxosmithKline.Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.Investment company Minot Wealth Management LLC (Current Portfolio) buys Schwab US Dividend Equity ETF, Goldman Sachs Group Inc, Luminar Technologies Inc, JPMorgan Chase, Invesco S&P MidCap Low Volatility ETF, sells Amgen Inc, Comcast Corp, 3M Co, Bristol-Myers Squibb Co, Meta Platforms Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Minot Wealth Management LLC.Glaxo says it will stick to its plan to separately list the consumer healthcare business in mid-2022.The consumer goods company had already made three separate bids to acquire the business, but GSK said earlier this week that the latest offer was still “fundamentally undervalued”.";14.399999618530273;"OSAKA, Japan & CAMBRIDGE, Mass., January 20, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (""Takeda"") today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide. In addition to the global certification, Takeda is also recognized as a Top Employer across four regions and 39 countries, reinforcing its steadfast coInvestment company Sippican Capital Advisors (Current Portfolio) buys Coterra Energy Inc, DaVita Inc, Physicians Realty Trust, Ncino Inc, Triumph Bancorp Inc, sells TriState Capital Holdings Inc, Central Securities Corp, Adobe Inc, Vulcan Materials Co, Berkshire Hathaway Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sippican Capital Advisors.";39.310001373291016;NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253 or for international callers by;14.640000343322754;Increasing real rates can hurt stocks in several ways, but so-called quality value stocks can thrive.Investment company First PREMIER Bank (Current Portfolio) buys SAB Biotherapeutics Inc, Amplify Transformational Data Sharing ETF, 3M Co, Global X Lithium & Battery Tech ETF, BHP Group, sells , iShares 0-5 Year TIPS Bond ETF, iShares Core 1-5 Year USD Bond ETF, Vanguard Short-Term Bond ETF, General Electric Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First PREMIER Bank.Lutz, FL, based Investment company Edmp, Inc. (Current Portfolio) buys Viatris Inc, The Western Union Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Edmp, Inc..Investment company Sippican Capital Advisors (Current Portfolio) buys Coterra Energy Inc, DaVita Inc, Physicians Realty Trust, Ncino Inc, Triumph Bancorp Inc, sells TriState Capital Holdings Inc, Central Securities Corp, Adobe Inc, Vulcan Materials Co, Berkshire Hathaway Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sippican Capital Advisors.;188.4600067138672;The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.;12.529999732971191;;116.0;;111.13999938964844;;20.8799991607666;;31.81999969482422;Investment company Sippican Capital Advisors (Current Portfolio) buys Coterra Energy Inc, DaVita Inc, Physicians Realty Trust, Ncino Inc, Triumph Bancorp Inc, sells TriState Capital Holdings Inc, Central Securities Corp, Adobe Inc, Vulcan Materials Co, Berkshire Hathaway Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sippican Capital Advisors.;39.189998626708984;;21.850000381469727;;29.940000534057617;"HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor (“CSF-1R”) inhibitor. The first patient received their first dose on January 18, 2022. The Phase I trial is a multicenter, open-label, single-arm study to evaluate the safety, tolerability,";25.6200008392334;;37.630001068115234;Investment company Sippican Capital Advisors (Current Portfolio) buys Coterra Energy Inc, DaVita Inc, Physicians Realty Trust, Ncino Inc, Triumph Bancorp Inc, sells TriState Capital Holdings Inc, Central Securities Corp, Adobe Inc, Vulcan Materials Co, Berkshire Hathaway Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sippican Capital Advisors.;111.75;;32.650001525878906;;54.619998931884766;;4.360000133514404;NGENLA® offers a new once-weekly treatment option for children living with growth hormone deficiencyTOKYO and MIAMI, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA® (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan. NGENLA® is a once-weekly long-acting recombinant human growth hormone, for the ind;4.550000190734863;;;;11.779999732971191;Santa Fe, NM, based Investment company New Mexico Educational Retirement Board (Current Portfolio) buys Alcoa Corp, EPAM Systems Inc, Bruker Corp, Macy's Inc, Power Integrations Inc, sells FactSet Research Systems Inc, Signature Bank, , SolarEdge Technologies Inc, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, New Mexico Educational Retirement Board.;5.630000114440918;;35.02000045776367;;35.93000030517578;SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the company has received clearance from the FDA for the company’s Investigational New Drug (IND) application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer (NSCLC). The company expects to initiate the Phase 1b;46.52000045776367;Santa Fe, NM, based Investment company New Mexico Educational Retirement Board (Current Portfolio) buys Alcoa Corp, EPAM Systems Inc, Bruker Corp, Macy's Inc, Power Integrations Inc, sells FactSet Research Systems Inc, Signature Bank, , SolarEdge Technologies Inc, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, New Mexico Educational Retirement Board.;11.40999984741211;;15.6899995803833;LAUSANNE, Switzerland, January 20, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it will host a webcast highlighting its ADC platform and solid tumor pipeline on Tuesday, February 8, from 9:00 to 11:00 a.m. ET.;28.889999389648438;;4.400000095367432;;47.22999954223633;;18.889999389648438;Investment company Mass General Brigham, Inc (Current Portfolio) buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Airbnb Inc, sells iShares Core S&P 500 ETF, iShares Core U.S.;20.93000030517578;;5.550000190734863;;16.989999771118164;;8.869999885559082;;9.609999656677246;;25.309999465942383;;27.260000228881836;;15.149999618530273;;14.779999732971191;;19.940000534057617;;20.65999984741211;Company announcement – No. 3 / 2022 Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. January 20, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on theCompany announcement – No. 2 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022 Copenhagen, DK and Boston, MA, January 19, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareho;14.479999542236328;;13.649999618530273;
2022-01-21;164.8699951171875;;52.790000915527344;;243.05999755859375;;95.36000061035156;;131.97999572753906;;87.02999877929688;;79.9800033569336;;59.099998474121094;"Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.Rating Action: Moody's assigns B2 ratings to Covis' proposed notes issuanceGlobal Credit Research - 21 Jan 2022  London, 21 January 2022 -- Moody's Investors Service (Moody's) has today assigned a B2 rating to the proposed notes issuance of Covis Finco S.a r.l.  The proposed notes issuance is part of pharmaceutical company Covis' refinancing of its entire capital structure and follows the recent acquisition of two respiratory assets from AstraZeneca PLC (A3 negative) for $270 million.Dr. Patrice Harris, former American Medical Association President, joins Yahoo Finance Live for ""The Biden Presidency: Year One"" special to discuss this administration's handling of COVID-19, the scarcity of testing resources and masks, being more proactive in the ongoing pandemic, and working to end it.Dr. Adrian Burrowes, Family Medicine Physician & CFP Physicians Group CEO, joins Yahoo Finance Live to discuss how Omicron is still surging in regions such as Florida, Governor Ron DeSantis' stance on COVID-19 vaccines, and historical references for pandemic lengths.With the markets in the early stage of 2022, the stage seems set for some degree of uncertainty. The good news is that the pandemic might soon become endemic. This is likely to help in accelerating global economic recovery. The worrying news is that there is a case for at least four interest rate hikes in 2022. In these market conditions, it’s a good idea to hold some bear market stocks. I would define bear market stocks as low-beta stocks that are relatively immune to economic or liquidity tigh";63.540000915527344;;51.2400016784668;Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.;45.099998474121094;PHILADELPHIA, January 21, 2022--Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis ShowsGlaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.Omaha, NE, based Investment company America First Investment Advisors, LLC (Current Portfolio) buys iShares TIPS Bond ETF, The Walt Disney Co, ConocoPhillips, GlaxoSmithKline PLC, Williams Inc, sells Unilever PLC, Werner Enterprises Inc, McDonald's Corp, Charles Schwab Corp, Union Pacific Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, America First Investment Advisors, LLC.GlaxoSmithKline (GSK) closed the most recent trading day at $44.88, moving -1.77% from the previous trading session.Company refuses to go higher in bid for health care business;14.65999984741211;;39.13999938964844;;14.529999732971191;Yes, the stock market is going to crash.  One of the best things you can do during a significant downturn is to buy strong dividend stocks.  Here are three dividend stocks to buy if the market crashes.22V Research, an investment research firm, has compiled a list of stocks that do well in times of rising interest rates.  The list includes pharmacy chain Walgreens Boots Alliance WBA, medical device maker Medtronic MDT, and drug companies Vertex Pharmaceuticals VRTX and Viatris VTRS, Barron's reports.  22V created the list by combing through the S&P 500 to find the stocks with the highest historical correlation to changes in both the real federal funds rate and the real 10-year Treasury yield — combining a short-term and a long-term rate.Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection. The Company cited the risk of the label is missing on some prefilled pens contained inside labeled cartons of the drug. The recall doesn't cover Viatris' recently launched interchangeable Semglee biosimilars, which come in branded and unbranded formats. The lot in question was produced by Biocon and distributed by Mylan in the U.S. between May 11, 2021, and Nov. 11, 20;183.80999755859375;Repligen (NASDAQ: RGEN) and ResMed (NYSE: RMD) are two stocks which could fit that bill with their proven track records and growing opportunities.  Repligen offers a unique way to invest in the healthcare space.  Operating in both the downstream and upstream processes of drug development, Repligen sells products in the areas of filtration, chromatography, process analytics, and proteins.;12.329999923706055;;110.08000183105469;;107.97000122070312;;19.950000762939453;;30.969999313354492;;39.209999084472656;;18.729999542236328;;28.90999984741211;;25.290000915527344;;35.459999084472656;;110.41999816894531;;28.81999969482422;;54.2400016784668;;4.239999771118164;Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.;4.429999828338623;;;;10.949999809265137;Montgomery, AL, based Investment company Retirement Systems of Alabama (Current Portfolio) buys Applied Materials Inc, Broadcom Inc, Johnson & Johnson, NXP Semiconductors NV, Ford Motor Co, sells Intel Corp, Skyworks Solutions Inc, The Mosaic Co, Signature Bank, Qualcomm Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Retirement Systems of Alabama.;5.420000076293945;;33.7400016784668;;35.90999984741211;;46.970001220703125;Investment company Bridge City Capital, LLC (Current Portfolio) buys IPG Photonics Corp, Performance Food Group Co, Getty Realty Corp, Amedisys Inc, Sleep Number Corp, sells , Perficient Inc, WD-40 Co, Monmouth Real Estate Investment Corp, Tandem Diabetes Care Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bridge City Capital, LLC.Montgomery, AL, based Investment company Retirement Systems of Alabama (Current Portfolio) buys Applied Materials Inc, Broadcom Inc, Johnson & Johnson, NXP Semiconductors NV, Ford Motor Co, sells Intel Corp, Skyworks Solutions Inc, The Mosaic Co, Signature Bank, Qualcomm Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Retirement Systems of Alabama.;11.050000190734863;;15.670000076293945;;27.3799991607666;;4.460000038146973;;46.29999923706055;;19.110000610351562;;18.969999313354492;;5.260000228881836;;17.190000534057617;;8.989999771118164;;9.130000114440918;;24.59000015258789;;26.18000030517578;Dallas, TX, based Investment company Penn Davis Mcfarland Inc (Current Portfolio) buys Lockheed Martin Corp, Activision Blizzard Inc, Despegar.com Corp, Independent Bank Group Inc, sells Inovalon Holdings Inc, Las Vegas Sands Corp, Matador Resources Co, Reata Pharmaceuticals Inc, Dorchester Minerals LP during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Penn Davis Mcfarland Inc.;15.399999618530273;;14.630000114440918;;18.770000457763672;;20.0;;15.0;;13.329999923706055;
2022-01-24;162.97000122070312;;51.540000915527344;;240.4199981689453;;95.44000244140625;;132.16000366210938;;85.12999725341797;;78.83000183105469;;56.970001220703125;A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac's CoronaVac shot, a study has found.  The study found that CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants, researchers from Brazil and Oxford University said https://www.ox.ac.uk/news/2022-01-24-mixed-vaccine-schedules-offer-strong-booster-responses-after-two-doses-coronavac on Monday.  China-based Sinovac's vaccine uses an inactivated version of a coronavirus strain that was isolated from a patient in China.The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for transthyretin-mediated amyloidosis. Eplontersen is currently in Phase 3 trials for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN). It is designed to reduce the production of transthyretin (TTR protein) to treat both hereditary and non-hereditary forms of TTR amyloidosis (ATTR). Related content: BenzingaWILMINGTON, Del., January 24, 2022--Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition.Patients will receive new cancer drugs more quickly following post-Brexit changes to the regulatory oversight of pharmaceuticals.;62.61000061035156;;50.84000015258789;Investment company Bond & Devick Financial Network, Inc. (Current Portfolio) buys Natixis Loomis Sayles Short Duration Income ETF, Vanguard Ultra-Short Bond ETF, Starbucks Corp, Sanofi SA, Abbott Laboratories, sells Schwab U.S.;44.380001068115234;"(Bloomberg) -- Activist investors are chasing ever-bigger prey in the U.K., with blue-chip consumer goods company Unilever Plc becoming the latest to come under fire. Most Read from BloombergStocks Storm Back From 4% Rout to Close Higher: Markets WrapUAE Says New Attack Repelled as Yemen’s Houthis Vow MoreChina’s ‘Little Giants’ Are Its Latest Weapon in the U.S. Tech WarCrypto Crash Erases More Than $1 Trillion in Market ValueMacron Plans Putin Call; Pentagon Readies Troops: Ukraine UpdateLondonThis blue chip stock at a 3-year low is a fantastic value(Bloomberg) -- Unilever Plc rose after Nelson Peltz built a stake in the maker of Dove soap, putting pressure on Chief Executive Officer Alan Jope to accelerate a revamp.Most Read from BloombergS&P 500 Extends Slide From Peak to 10%; Bonds Gain: Markets WrapCrypto Crash Erases More Than $1 Trillion in Market ValueUAE Says New Attack Repelled as Yemen’s Houthis Vow MoreChina’s ‘Little Giants’ Are Its Latest Weapon in the U.S. Tech WarMorgan Stanley’s Slimmon Warns Against Buying Growth-Stock DipPShares in Unilever rose 6% on Monday on reports that activist investor Nelson Peltz has built a stake in the consumer goods giant whose strategy is under scrutiny after a short-lived pursuit of GSK's consumer healthcare arm.  Peltz's hedge fund, Trian Partners, has built an unspecified stake in Unilever, a person familiar with the matter told Reuters on Sunday.  Unilever declined to comment on the investment.(Bloomberg) -- Private equity firms can look forward to a rich hunting ground for deals in 2022 as Europe’s corporate titans seek ways to shed businesses, according to one of Carlyle Group Inc.’s top dealmakers in the region.Most Read from BloombergStocks Tumble Amid Wild Swings While Bonds Rally: Markets WrapCrypto Crash Erases More Than $1 Trillion in Market ValueUAE Repels New Attack as Yemen’s Houthis Vow More to ComeMorgan Stanley’s Slimmon Warns Against Buying Growth-Stock DipSolana SufferBy Dhirendra TripathiUnilever's management risks coming under further pressure after an aggressive activist investor was reported to have built a stake in the Marmite maker.";14.479999542236328;;39.470001220703125;;14.359999656677246;;189.7899932861328;;12.0;;118.7699966430664;;115.0199966430664;;19.8700008392334;;30.450000762939453;;37.90999984741211;;18.219999313354492;;27.780000686645508;;26.15999984741211;;38.779998779296875;;114.58000183105469;;28.899999618530273;;55.66999816894531;;3.2300000190734863;The FDA has issued a Complete Response Letter (CRL) to Pfizer Inc (NYSE: PFE) and OPKO Health Inc's (NASDAQ: OPK) somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for pediatric growth hormone deficiency (GHD). Pfizer is evaluating the FDA's comments. Earlier this week, Japan's Ministry of Health, Labour, and Welfare approved Ngenla (somatrogon) Injection 24 mg Pens and 60mg Pens for the long-term treatment of GHD pediatric patients. In 2021, H;4.610000133514404;;;;11.180000305175781;;5.710000038146973;;35.11000061035156;;39.439998626708984;;46.20000076293945;;11.300000190734863;;15.449999809265137;;28.450000762939453;;4.449999809265137;;47.9900016784668;;19.6200008392334;;19.579999923706055;A look at the shareholders of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) can tell us which group is most powerful...;5.139999866485596;;16.780000686645508;;8.880000114440918;;9.140000343322754;;24.899999618530273;Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern. Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) Comirnaty immunization, demonstrated robust antibody responsesSAN DIEGO, January 24, 2022--Arcturus Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2;26.469999313354492;;15.890000343322754;;14.529999732971191;Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Day One...;19.889999389648438;;19.1299991607666;;14.630000114440918;;14.069999694824219;
2022-01-25;167.6300048828125;;52.540000915527344;;239.4600067138672;;95.16000366210938;San Rafael, CA, based Investment company Private Ocean, LLC (Current Portfolio) buys Regal Rexnord Corp, T-Mobile US Inc, Vanguard Total Bond Market ETF, WisdomTree U.S.Investment company DDD Partners, LLC (Current Portfolio) buys Intel Corp, Novo Nordisk A/S, Broadcom Inc, DocuSign Inc, Atlas Corp, sells Adaptive Biotechnologies Corp, Editas Medicine Inc, Magna International Inc, Activision Blizzard Inc, Gentex Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, DDD Partners, LLC.;133.08999633789062;;84.54000091552734;;79.45999908447266;;57.849998474121094;"APPN, AZN, and GRWG have been added to the Zacks Rank #5 (Strong Sell) List on January 25, 2022A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or Johnson & Johnson (NYSE: JNJ) increases antibody levels significantly in those who have previously received two doses of Sinovac Biotech Ltd (NASDAQ: SVA) CoronaVac. According to the study, CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants. ""This study provides important opt";62.459999084472656;;51.400001525878906;Investment company Bard Financial Services, Inc. (Current Portfolio) buys Edison International, Ionis Pharmaceuticals Inc, Omnicom Group Inc, Vanguard International High Dividend Yield ETF, Uber Technologies Inc, sells Templeton Global Income Fund, Welltower Inc, Sprott Physical Gold Trust, Truist Financial Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bard Financial Services, Inc..;44.369998931884766;"Unilever has shaken up management, set layoffs and simplified its organizational model following its failed bid for GlaxoSmithKline's Consumer Healthcare division.Unilever plans to cut 1,500 management jobs as part of a major overhaul following its failed £50bn bid for GlaxoSmithKline's healthcare division.Here are key developments around Unilever in the past two months.  Unilever agreed to sell its global tea business to CVC Capital Partners for 4.5 billion euros ($5.1 billion), concluding a process of reviewing and spinning off the division that took more than two years.  Unilever confirmed it had approached GlaxoSmithKline about buying its consumer goods business following media reports.Unilever will reduce staff numbers in more than 100 countries in a bid to shore up its finances and take on a more competitive operating model.Unilever will cut about 1,500 management jobs and reshape its business to focus on five main product areas as it tries to boost growth after a failed acquisition and with an activist investor to appease.  The move, which Unilever said had been in the works for a year, echoes the reshaping by rival Procter & Gamble (P&G) three years ago https://www.reuters.com/article/us-procter-gamble-strategy-idUKKCN1ND37M - which at the time also had activist investor Nelson Peltz's Trian Partners as a shareholder.  ""Moving to five category-focused business groups will enable us to be more responsive to consumer and channel trends, with crystal-clear accountability for delivery,"" Unilever CEO Alan Jope said.Investment company Hotaling Investment Management, LLC (Current Portfolio) buys Johnson & Johnson, Pfizer Inc, ON Semiconductor Corp, Merck Inc, Stanley Black & Decker Inc, sells Citigroup Inc, Activision Blizzard Inc, Texas Roadhouse Inc, FedEx Corp, Delta Air Lines Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hotaling Investment Management, LLC.Rishi Sunak resists pressure for tax raid U-turn despite borrowing boost Time to buy 'exceptionally cheap' London-listed shares, says JP Morgan FTSE 100 rebounds 1pc after Ukraine war fears rout Ambrose Evans-Pritchard: The EU's 'unforgivable failure' over Ukraine Sign up here for our daily business briefing newsletterThe U.S. Food and Drug Administration (FDA) is likely to restrict the use of COVID-19 antibody treatments from Regeneron and Eli Lilly as they are ineffective against the Omicron variant, the Washington Post reported on Monday.  The FDA action will involve revising the emergency use authorizations for the monoclonal antibodies, the report said https://wapo.st/3KDk1YI, citing two senior administration health officials.Investment company Rothschild Investment Corp (Current Portfolio) buys American Tower Corp, Grayscale Bitcoin Trust, Diamondback Energy Inc, BorgWarner Inc, Wolfspeed Inc, sells AMETEK Inc, Peloton Interactive Inc, Covanta Holding Corp, Danaher Corp, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Rothschild Investment Corp .The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors. LYL132 is an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1). LYL132 incorporates Epi-R, Lyell's epigenetic reprogramming technology, and is under investigation as a potential next-generation enhancement to letetresgene autoleucel (lete-cel), a";14.520000457763672;;39.130001068115234;;14.680000305175781;In the latest trading session, Viatris (VTRS) closed at $14.36, marking a -1.17% move from the previous day.;185.39999389648438;;11.920000076293945;;116.33999633789062;Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) extends its sponsorship for the second year as the primary partner for the No. 51 Rick Ware Racing entry during the entire 2022 NASCAR Cup Series Season and the NTT INDYCAR series, after a successful first season. Nurtec ODT is the first and only FDA-approved medication that's proven to both treat and prevent migraine attacks.;113.58000183105469;Ascendis Pharma AS (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.;19.459999084472656;Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions. Through phenotypic screening of human iPSC-derived cells, supported by Evotec's PanOmics platform, Evotec will identify small molecules able to modulate disease phenotypes, and then validate the underlying promising targets for potential therapeutic interventions.;30.709999084472656;;38.119998931884766;Miami, FL, based Investment company EFG Asset Management (Americas) Corp. (Current Portfolio) buys Tesla Inc, Microsoft Corp, Dick's Sporting Goods Inc, iShares MSCI All Country Asia ex Japan Index Fund, UnitedHealth Group Inc, sells TJX Inc, S&P Global Inc, Norfolk Southern Corp, Booking Holdings Inc, Heico Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, EFG Asset Management (Americas) Corp..;18.3799991607666;Investment company Newton One Investments LLC (Current Portfolio) buys Zillow Group Inc, Splunk Inc, Pinterest Inc, Mandiant Inc, Peloton Interactive Inc, sells Automatic Data Processing Inc, JPMorgan BetaBuilders Canada ETF, AllianceBernstein Holding LP, Bank of America Corp, Consumer Portfolio Services Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Newton One Investments LLC.;27.959999084472656;;25.56999969482422;;39.66999816894531;Ipswich, MA, based Investment company Ipswich Investment Management Co., Inc. (Current Portfolio) buys GXO Logistics Inc, Stag Industrial Inc, Moderna Inc, Ares Capital Corp, Coca-Cola Europacific Partners PLC, sells Church & Dwight Co Inc, Apellis Pharmaceuticals Inc, International Business Machines Corp, Sanofi SA, ISHARES TRUST during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Ipswich Investment Management Co., Inc..;112.0;;27.18000030517578;;55.150001525878906;;3.009999990463257;Pfizer stock skidded Monday after the Food and Drug Administration rejected its rare-disease drug — leading a smaller decline for similarly jilted Merck.A rough day for the broad market is a downright terrible one for Opko Health (NASDAQ: OPK).  Shares of the drug and diagnostics outfit were down by 23% as of 1:22 p.m. ET on Monday following Friday's post-close announcement that a growth-hormone deficiency treatment co-developed with Pfizer (NYSE: PFE) won't be approved by the Food and Drug Administration (FDA), at least not as requested in the initial New Drug Application.  The drug in question, somatrogon, aims to treat growth hormone deficiency in children.The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.;4.150000095367432;;;;10.899999618530273;;5.550000190734863;;34.08000183105469;On Jan. 5, Harmony shares triggered an important sell rule upon entering the 7%-8% sell zone.;38.08000183105469;;46.41999816894531;;11.859999656677246;;16.110000610351562;;27.09000015258789;;4.489999771118164;;47.29999923706055;;19.5;;19.0;;5.059999942779541;;16.170000076293945;;9.399999618530273;;9.399999618530273;;25.31999969482422;SAN DIEGO, January 25, 2022--Arcturus Reports Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Trial;26.719999313354492;;15.420000076293945;;14.75;;18.559999465942383;;18.67799949645996;;14.5;;13.779999732971191;
2022-01-26;168.3800048828125;;53.0099983215332;;237.86000061035156;;93.0999984741211;;134.22999572753906;;84.23999786376953;Investment company Optas, LLC (Current Portfolio) buys Vanguard Small Cap ETF, Vanguard ESG U.S. Stock ETF, Vanguard ESG International Stock ETF, Schwab Emerging Markets Equity ETF, Discovery Inc, sells Vanguard Extended Market Index ETF, Verizon Communications Inc, Moderna Inc, Novartis AG, Biogen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Optas, LLC.PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and builSouthfield, MI, based Investment company Deroy & Devereaux Private Investment Counsel Inc (Current Portfolio) buys Hasbro Inc, ALLETE Inc, Six Flags Entertainment Corp, Medtronic PLC, Sonos Inc, sells SeaWorld Entertainment Inc, Alaska Air Group Inc, Brinker International Inc, Ubisoft Entertainment, Penske Automotive Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Deroy & Devereaux Private Investment Counsel Inc.The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.;79.13999938964844;;57.119998931884766;Gregory Zuckerman, author of ‘A Shot to Save the World’, joins Yahoo Finance's Editor-in-Chief, Andy Serwer, for a discussion about what COVID-19 will look like in the future.Investment company Optas, LLC (Current Portfolio) buys Vanguard Small Cap ETF, Vanguard ESG U.S. Stock ETF, Vanguard ESG International Stock ETF, Schwab Emerging Markets Equity ETF, Discovery Inc, sells Vanguard Extended Market Index ETF, Verizon Communications Inc, Moderna Inc, Novartis AG, Biogen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Optas, LLC.Rye Brook, NY, based Investment company Meyer Handelman Co (Current Portfolio) buys Activision Blizzard Inc, Edwards Lifesciences Corp, Kyndryl Holdings Inc, AAR Corp, Cardinal Health Inc, sells iShares Latin America 40 ETF, Palo Alto Networks Inc, Nestle SA, AstraZeneca PLC, Sylvamo Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Meyer Handelman Co.Yahoo Finance's Anjalee Khemlani details the record-breaking daily COVID-19 deaths as the Omicron wave continues and the beginning of Pfizer and BioNTech's clinical trial for an Omicron vaccine.Valneva SE (NASDAQ: VALN) has started booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is intended to provide both homologous and first heterologous booster data to complement previous positive Phase 1/2 booster results. The data are not intended for the initial regulatory approval process, which Valneva expects to finalize in the coming weeks. Related: Three doses of Valneva's COVID-19 Vaccine Neutralizes Omicron Variant, Lab Study SThe FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.;62.2400016784668;Investment company Optas, LLC (Current Portfolio) buys Vanguard Small Cap ETF, Vanguard ESG U.S. Stock ETF, Vanguard ESG International Stock ETF, Schwab Emerging Markets Equity ETF, Discovery Inc, sells Vanguard Extended Market Index ETF, Verizon Communications Inc, Moderna Inc, Novartis AG, Biogen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Optas, LLC.New York, NY, based Investment company Braun Stacey Associates Inc (Current Portfolio) buys Marvell Technology Inc, Arista Networks Inc, Lamar Advertising Co, Netflix Inc, Signet Jewelers, sells Adobe Inc, Vertiv Holdings Co, Comcast Corp, PayPal Holdings Inc, Bristol-Myers Squibb Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Braun Stacey Associates Inc.Investment company Moseley Investment Management Inc (Current Portfolio) buys Berkshire Hathaway Inc, Liberty Broadband Corp, Brookfield Asset Management Inc, CarMax Inc, Cable One Inc, sells Vanguard Total World Bond ETF, PayPal Holdings Inc, Direxion Daily Financial Bull 3x Shares, CRISPR Therapeutics AG, Dover Motorsports Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Moseley Investment Management Inc.Kansas City, MO, based Investment company Sterneck Capital Management, LLC (Current Portfolio) buys Great Ajax Corp, Hertz Global Holdings Inc, ETCT EMQQ The Emerging Markets Internet and Ecomme, Invesco Golden Dragon China ETF, Kyndryl Holdings Inc, sells Invesco KBW Premium Yield Equity REIT ETF, FIRST TRUST SENIOR FLOATING RATE 2022 TARGET TERM , KraneShares CSI China Internet ETF, Alibaba Group Holding, Unilever PLC during the 3-months ended 2021Q4, according to the most recent filings of thBristol Myers Squibb volunteers cultivate a passion for STEM in the curious young minds of tomorrow’s scientists;51.31999969482422;Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.;44.150001525878906;Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.Unilever will operate as five divisions rather than three in a bid to drive growth. Some analysts expect divestitures to come.Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.;14.300000190734863;;38.93000030517578;;14.619999885559082;Investment company Hohimer Wealth Management, Llc (Current Portfolio) buys Dell Technologies Inc, Nexstar Media Group Inc, Fiserv Inc, Vanguard Dividend Appreciation FTF, Cleveland-Cliffs Inc, sells Albertsons Inc, iShares 1-3 Year Credit Bond ETF, Global Payments Inc, Public Storage, Las Vegas Sands Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hohimer Wealth Management, Llc.;181.55999755859375;Berwyn, PA, based Investment company Stanley-Laman Group, Ltd. (Current Portfolio) buys Robinhood Markets Inc, SiTime Corp, Snap Inc, Ambarella Inc, Certara Inc, sells NVIDIA Corp, Repligen Corp, Salesforce.com Inc, MSCI Inc, Autodesk Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Stanley-Laman Group, Ltd..;11.779999732971191;;126.08000183105469;;116.16000366210938;;19.219999313354492;;30.729999542236328;;38.06999969482422;;17.790000915527344;;26.649999618530273;;25.489999771118164;;40.400001525878906;;104.58000183105469;;24.649999618530273;;55.029998779296875;;2.9100000858306885;;4.289999961853027;;;;10.649999618530273;;5.349999904632568;;33.13999938964844;;36.25;Turning Point Therapeutics (TPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).;45.119998931884766;;11.279999732971191;;15.739999771118164;;27.34000015258789;;4.329999923706055;;46.380001068115234;;18.520000457763672;The nature of investing is that you win some, and you lose some. Anyone who held Nurix Therapeutics, Inc. ( NASDAQ:NRIX...;18.940000534057617;;4.880000114440918;;16.450000762939453;;9.359999656677246;;9.3100004196167;;23.479999542236328;;26.43000030517578;;15.079999923706055;;13.850000381469727;;17.670000076293945;;18.70800018310547;;13.390000343322754;;13.960000038146973;
2022-01-27;170.58999633789062;;53.369998931884766;;236.72000122070312;;95.44000244140625;Investment company Wcm Investment Management, Llc (Current Portfolio) buys Novo Nordisk A/S, Lam Research Corp, iShares MSCI EAFE ETF, Nu Holdings, Endava PLC, sells MercadoLibre Inc, HDFC Bank, Credicorp, Thoughtworks Holding Inc, Alibaba Group Holding during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Wcm Investment Management, Llc.;135.97000122070312;;85.13999938964844;Muncie, IN, based Investment company First Merchants Corp (Current Portfolio) buys Communication Services Select Sector SPDR Fund, Vanguard Short-Term Corporate Bond ETF, PayPal Holdings Inc, Vanguard Total International Bond ETF, Meta Platforms Inc, sells Ball Corp, Franklin Electric Co Inc, Eli Lilly and Co, Newell Brands Inc, The Walt Disney Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Merchants Corp.;80.58000183105469;;59.52000045776367;By Sam BougheddaIn this episode of Influencers, Andy is joined by ‘A Shot to Save the World’ author, Gregory Zuckerman, as they discuss the development of the COVID-19 vaccines and what the future holds for mRNA technology.‘A Shot to Save the World’ author, Gregory Zuckerman joins 'Influencers with Andy Serwer' to discuss the Trump Administration's role in developing the COVID-19 vaccines.Dr. Elizabeth Clayborne, Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance Live to discuss the staffing shortage in hospitals handling COVID patients, testing, masking, the importance of vaccines, long COVID symptoms, and re-infection rates.Investment company Moody Lynn & Lieberson, Llc (Current Portfolio) buys AbbVie Inc, Pfizer Inc, Northrop Grumman Corp, PepsiCo Inc, American International Group Inc, sells PayPal Holdings Inc, iShares MSCI Japan ETF, Intuitive Surgical Inc, Block Inc, Uber Technologies Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Moody Lynn & Lieberson, Llc.;63.86000061035156;Minneapolis, MN, based Investment company Foundry Partners, LLC (Current Portfolio) buys Cisco Systems Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Quest Diagnostics Inc, C.H.Investment company Avitas Wealth Management LLC (Current Portfolio) buys Vanguard Short-Term Inflation-Protected Securities, Amazon.com Inc, ASML Holding NV, Tesla Inc, The Walt Disney Co, sells iShares J.P.Investment company Great Diamond Partners, LLC (Current Portfolio) buys iShares 20+ Year Treasury Bond ETF, Ares Management Corp, iShares TIPS Bond ETF, iShares Expanded Tech-Software Sector ETF, SPDR Oil & Gas Exploration and Production ETF, sells IDEXX Laboratories Inc, iShares J.P.;52.86000061035156;;45.7400016784668;Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.Investment company Moody Lynn & Lieberson, Llc (Current Portfolio) buys AbbVie Inc, Pfizer Inc, Northrop Grumman Corp, PepsiCo Inc, American International Group Inc, sells PayPal Holdings Inc, iShares MSCI Japan ETF, Intuitive Surgical Inc, Block Inc, Uber Technologies Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Moody Lynn & Lieberson, Llc.;14.420000076293945;;38.68000030517578;;14.59000015258789;;177.07000732421875;;11.680000305175781;;120.54000091552734;;115.01000213623047;;19.139999389648438;;30.700000762939453;New York, NY, based Investment company Shufro Rose & Co Llc (Current Portfolio) buys Distillate U.S.Investment company Patten & Patten Inc (Current Portfolio) buys JPMorgan Equity Premium Income ETF, Delta Air Lines Inc, Lincoln Electric Holdings Inc, Planet Fitness Inc, Exact Sciences Corp, sells AT&T Inc, Hologic Inc, General Electric Co, SPDR Gold Shares ETF, NovoCure during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Patten & Patten Inc.;35.779998779296875;;16.700000762939453;;25.5;;23.549999237060547;;37.220001220703125;;102.19999694824219;;20.889999389648438;;51.97999954223633;;2.869999885559082;Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.;4.199999809265137;;;;10.359999656677246;;5.050000190734863;;33.150001525878906;;31.969999313354492;;44.2400016784668;;11.039999961853027;;14.670000076293945;;27.110000610351562;BILLERICA, Mass., January 26, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its Simoa® technology was instrumental in revealing high prevalence of Epstein-Barr virus (EBV) associated with multiple sclerosis (MS), according to a recent study published in the journal Science. Principal Investigator, Dr. Albert Ascherio, epidemiologist at the Harvard T.H. Chan School of Public Health, i;4.289999961853027;;42.33000183105469;;17.290000915527344;;17.149999618530273;;4.659999847412109;;16.040000915527344;;8.899999618530273;;9.5;;21.479999542236328;;24.1200008392334;;14.380000114440918;;13.25;;16.850000381469727;;18.70800018310547;;12.890000343322754;;13.819999694824219;
2022-01-28;171.7899932861328;;54.33000183105469;;245.10000610351562;;96.76000213623047;Investment company Colorado Capital Management, Inc. (Current Portfolio) buys Community Bank System Inc, WisdomTree Europe Quality Dividend Growth Fund, Abbott Laboratories, Novo Nordisk A/S, AbbVie Inc, sells JPMorgan Ultra-Short Income ETF, iShares 1-3 Year Treasury Bond ETF, iShares Russell Mid-Cap ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Colorado Capital Management, Inc..;137.9199981689453;;85.91000366210938;The pharmaceutical industry is an excellent place to look for dividend stocks.  Since no one can predict illnesses in advance -- or the timing of the need for lifesaving medicines -- the demand for the drugs that pharma companies offer remains relatively constant regardless of economic conditions.  Let's examine one pharma company that looks like an outstanding dividend stock to buy right now: Novartis (NYSE: NVS).Investment company Krilogy Financial LLC (Current Portfolio) buys iShares iBonds Dec 2030 Term Corporate ETF, iShares J.P.For example, at their current share prices, both Novartis (NYSE: NVS) and Chevron (NYSE: CVX) yield more than 3%.  If you buy shares of Novartis today, you'll collect around 3.7% just in dividend income at the current payout level.  The pharmaceutical company has increased its annual dividend payments for 24 years in a row --  and a hike this year would make it a Dividend Aristocrat.;80.9000015258789;"Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.J&J (JNJ) reports mixed fourth-quarter results. FDA issues CRL to Merck (MRK) and Pfizer's (PFE) pipeline candidates. FDA approves AbbVie's (ABBV) Skyrizi for a second indication.Tokyo, M0, based Investment company MU Investments Co., Ltd. (Current Portfolio) buys Parker Hannifin Corp, Nucor Corp, Best Buy Co Inc, Pfizer Inc, Ross Stores Inc, sells General Dynamics Corp, Aptiv PLC, Intel Corp, Merck Inc, Accenture PLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, MU Investments Co., Ltd..Merck & Co. Inc. and partner Ridgeback Biotherapeutics said Friday that data from six preclinical studies of its molnupiravir COVID-19 pill showed ""consisent antiviral activity"" against the omicron variant of the coronavirus that causes COVID-19. The preclinical studies were conducted independently in Belgium, Czech Republic, Germany, Poland, the Netherlands and the U.S. Molnupiravir is currently authorized for use in 10 countries, including the U.S., the U.K. and Japan. ""Based on its mechanismKENILWORTH, N.J. & MIAMI, January 28, 2022--Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron VariantRedmond, WA, based Investment company Private Advisory Group LLC (Current Portfolio) buys PowerShares QQQ Trust Ser 1, Lululemon Athletica Inc, FIRST TR EXCH TRD, Etsy Inc, Meta Platforms Inc, sells International Business Machines Corp, iShares MSCI China ETF, FIRST TR EXCH TRD, Vonage Holdings Corp, NVIDIA Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Private Advisory Group LLC.";59.29999923706055;Zug, V8, based Investment company Starr International Co Inc (Current Portfolio) buys Celularity Inc, sells Moderna Inc, AstraZeneca PLC, Johnson & Johnson during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Starr International Co Inc.Yahoo Finance's Jared Blikre breaks down the sector action as stocks head lower into the close. ;64.91000366210938;Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.Radnor, PA, based Investment company Stevens Capital Management Lp (Current Portfolio) buys VanEck Gold Miners ETF, Boeing Co, Financial Select Sector SPDR, iShares iBoxx USD High Yield Corporate Bond ETF, Tesla Inc, sells The Energy Select Sector SPDR Fund, Health Care Select Sector SPDR, Netflix Inc, American Tower Corp, UnitedHealth Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Stevens Capital Management Lp.PRINCETON, N.J., January 28, 2022--BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3BMilford, CT, based Investment company Wright Investors Service Inc (Current Portfolio) buys Tesla Inc, Marriott International Inc, Caterpillar Inc, Cisco Systems Inc, Ameriprise Financial Inc, sells Abbott Laboratories, Altria Group Inc, PayPal Holdings Inc, Charter Communications Inc, KLA Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Wright Investors Service Inc.Investment company Hunter Perkins Capital Management, LLC (Current Portfolio) buys Canadian Pacific Railway, U.S.Dividend stocks are worth serious consideration, especially given the current state of the economy.  Let's look at two companies to consider -- both of which are excellent, dividend-paying companies and look like steals at current levels: AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY).  Pharma giant AbbVie offers a dividend yield of 4.01%, significantly higher than the S&P 500's average of 1.27%.;52.7400016784668;"The biotech faces stiffer competition and growing pains as it makes a transition to a postpandemic vaccine market. Its big pile of cash should help.Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical cancer. The application for the monoclonal antibody as the second-line of treatment in the patients was withdrawn ""after the companies and the FDA were not able to align on certain post-marketing studies."" The FDA had accepted the supplemental application for priority review in September,Regeneron Pharmaceuticals Inc and its partner Sanofi voluntarily withdrew their application with the U.S. drug regulator for the expanded use of their anti-cancer drug Libtayo in patients with advanced cervical cancer.  The application for the monoclonal antibody as the second-line of treatment in the patients was withdrawn ""after the companies and the U.S. Food and Drug Administration were not able to align on certain post-marketing studies"", the companies said on Friday.  The FDA had accepted the supplemental application for priority review in September.Shares of Regeneron Pharmaceuticals Inc. were down 0.1% in premarket trading on Friday after the company and Sanofi said they will no longer seek Food and Drug Administration approval for Libtaya as a second-line treatment for cervical cancer. The therapy is currently approved to treat two forms of skin cancer and a type of lung cancer. The companies said they made the decision to withdraw the application for Libtaya because they were not able to ""align"" on post-marketing studies with the FDA; hYahoo Finance's Jared Blikre breaks down the sector action as stocks head lower into the close. ";45.25;In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether they think GlaxoSmithKline should have accepted Unilever's offer.  Keith Speights: One of the big stories in recent days was that GlaxoSmithKline (NYSE: GSK) revealed that it turned down an offer of more than $68 billion from Unilever (NYSE: UL) to buy the combined consumer health unit of Glaxo and Pfizer (NYSE: PFE).;14.399999618530273;;39.459999084472656;Growth investing is one of two main fundamental investment strategies, the other being value investing.  Investors employing a growth investing strategy will typically place the majority of their portfolio in growth stocks, which are shares of companies with earnings or sales expected to grow at a significantly faster rate than the rest of the market.  The primary way that investors expect to earn profits from growth investing is through capital gains.Investment company Oxler Private Wealth LLC (Current Portfolio) buys Ford Motor Co, Verizon Communications Inc, Zoom Video Communications Inc, Shake Shack Inc, Royalty Pharma PLC, sells AT&T Inc, Newmont Corp, Biogen Inc, Barrick Gold Corp, Beyond Meat Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Oxler Private Wealth LLC.;14.630000114440918;Viatris (VTRS) closed the most recent trading day at $14.59, moving -0.21% from the previous trading session.;189.99000549316406;;11.680000305175781;;127.62000274658203;;119.76000213623047;;19.610000610351562;;31.450000762939453;Tokyo, M0, based Investment company MU Investments Co., Ltd. (Current Portfolio) buys Parker Hannifin Corp, Nucor Corp, Best Buy Co Inc, Pfizer Inc, Ross Stores Inc, sells General Dynamics Corp, Aptiv PLC, Intel Corp, Merck Inc, Accenture PLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, MU Investments Co., Ltd..;37.459999084472656;;17.899999618530273;;25.030000686645508;;23.770000457763672;;38.59000015258789;;107.83999633789062;;22.299999237060547;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization. This strategic partnership will accelerate I-Mab's commercialization strategy with an execution plan and timeline to commercialize its innovativePasadena, CA, based Investment company Dorsey Wright & Associates (Current Portfolio) buys Coterra Energy Inc, Fortinet Inc, Icon PLC, Alcon Inc, Eni SpA, sells RH, Acadia Healthcare Co Inc, Cemex SAB de CV, POSCO, I-MAB during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Dorsey Wright & Associates.";52.56999969482422;;2.950000047683716;OPKO Health (OPK) closed at $2.87 in the latest trading session, marking a -1.37% move from the prior day.Shares of Opko Health (NASDAQ: OPK) were crashing 32.3% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence.  The steep decline came after Opko and its partner, Pfizer (NYSE: PFE), announced after the market close on Jan. 21, 2022 that the U.S. Food and Drug Administration (FAD) issued a Complete Response Letter (CRL) for the Regulatory Filing for approval of human growth hormone somatrogon.  The FDA's decision was surprising considering that the human growth hormone has already received approvals in several other countries.;4.21999979019165;;;;10.649999618530273;;5.170000076293945;;33.970001220703125;;33.7599983215332;;45.29999923706055;;11.25;Investment company Edmonds Duncan Registered Investment Advisors, LLC (Current Portfolio) buys VanEck Vectors Semiconductor ETF, Erasca Inc, Concentrix Corp, Tenet Healthcare Corp, Palo Alto Networks Inc, sells WisdomTree Japan Hedged Equity Fund, PayPal Holdings Inc, Alphabet Inc, Boeing Co, Walmart Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Edmonds Duncan Registered Investment Advisors, LLC.;14.949999809265137;;28.18000030517578;;4.360000133514404;Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.;42.119998931884766;;17.65999984741211;Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?Advanced four wholly owned and internally developed programs into clinical development Strengthened balance sheet with year-end cash and investments totaling $433 million Anticipate multiple clinical milestones in 2022 SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2021 and pr;17.860000610351562;;4.940000057220459;;15.8100004196167;;9.319999694824219;;9.329999923706055;BARRANQUILLA, Colombia, January 28, 2022--Procaps Group Announces Appointment of Melissa Angelini as Investor Relations Director;22.299999237060547;;24.899999618530273;;14.670000076293945;;14.010000228881836;;17.260000228881836;;18.27899932861328;;13.260000228881836;;14.430000305175781;
2022-01-31;172.2899932861328;;52.689998626708984;;245.38999938964844;;99.87000274658203;;136.88999938964844;Bank of America, AbbVie, and Microsoft are highlighted in this Investment Ideas article.The healthcare sector offers income-seeking investors plenty of attractive stocks to consider.  AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) especially stand out.  In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss which of these two dividend stocks is the better pick right now.;86.91000366210938;;81.4800033569336;Merck & Co's new antiviral pill, once touted as a potential game changer for treating COVID-19, is the last choice among four available options for at-risk patients given its relatively low efficacy and potential safety issues, U.S. doctors, healthcare systems and pharmacies told Reuters.  A rival oral treatment from Pfizer Inc, Paxlovid, is in high demand, followed by an intravenous antibody therapy made by GlaxoSmithKline and Vir Biotechnology.  With supplies of those products tight, doctors facing a surge of cases caused by the Omicron variant are also turning to Gilead Sciences Inc's remdesivir, an antiviral that needs to be given as three daily infusions to help high-risk COVID patients avoid hospitalization.Rival antiviral pills from Pfizer Inc and Merck & Co  that demonstrated efficacy in trials of adults with COVID-19 who are at high risk of serious illness are now both in use.  Here is an explanation of the differences in the two pills.  Trial data provided by the two companies suggest that Pfizer has the more effective pill.;58.209999084472656;Yahoo Finance's Ines Ferre joins the Live show to break down how stocks are moving in early trading.;64.88999938964844;Over the 13-year period covering the end of the 2008 financial crisis until the fourth quarter of 2021, the biotech industry as a whole crushed the performance of most major U.S. stock indexes.  This prolonged bull market was fueled by a mix of tailwinds such as record low interest rates, massive fiscal stimulus by the U.S. government, and the insights and discoveries flowing out of the human genome project.;52.0;Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use of Dupixent (dupilumab). The positive opinion covers Dupixent as an add-on maintenance treatment for severe asthma children aged 6 to 11 years with type 2 inflammation who are inadequately controlled on two maintenance therapies. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. RelatedCHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children aged 6 to 11Dupixent is the only biologic to show improved lung function in a randomized Phase 3 trial for children aged 6 to 11Data further reinforce well-established safety profile of Dupixent PARIS and TARRYTOWN, N.Y. – January 3;44.81999969482422;;14.460000038146973;"CAMBRIDGE, Mass., January 31, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (""Takeda"") today announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI® [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease (VWD) receiving on-demand therapy.";40.0099983215332;;14.970000267028809;;198.33999633789062;;11.739999771118164;;132.8699951171875;;121.63999938964844;;19.950000762939453;;31.90999984741211;;42.63999938964844;;19.309999465942383;;27.239999771118164;;26.040000915527344;;40.27000045776367;;111.05999755859375;;25.25;;55.68000030517578;;3.130000114440918;;4.630000114440918;;;;11.119999885559082;;5.820000171661377;;35.86000061035156;;37.22999954223633;;46.79999923706055;;11.850000381469727;;15.890000343322754;;30.440000534057617;;4.429999828338623;;46.369998931884766;LEXINGTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the appointment of Christopher Rovaldi as Keros' Chief Operating Officer, effective as of February 1, 2022. Mr. Rovaldi previously served as a consultant to;18.6200008392334;;18.889999389648438;;5.329999923706055;;16.979999542236328;;9.529999732971191;;9.550000190734863;;26.1299991607666;A look at the shareholders of Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) can tell us which group is most...;28.1200008392334;"PLANO, Texas, January 31, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced that the company has initiated a rolling submission of a New Drug Application (""NDA"") to the U.S. Food and Drug Administration (""FDA"") for omaveloxolone for the treatment of patients with Friedreich’s ataxia. The rolling submission allows Reata to submit portions of the regulatory application to the FDA for review";15.109999656677246;;14.75;;17.700000762939453;;19.799999237060547;;14.859999656677246;;15.430000305175781;
2022-02-01;170.8800048828125;Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.Warren Buffett has given Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) shareholders a lot through the years.  Most importantly, under his direction, Berkshire has handily beaten the market.  Here are three Buffett dividend stocks to buy in February.Apple Inc., Tesla, Inc., and Johnson & Johnson are highlighted in this Analyst Blog article.In this article, we discuss 10 high yield REIT dividend stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 High Yield REIT Dividend Stocks For 2022. REIT dividend stocks offer investors a reliable source of passive income, and due to the high yields often delivered by […]Clayton, MO, based Investment company HM Capital Management, LLC (Current Portfolio) buys ProShares UltraShort S&P500, Automatic Data Processing Inc, Walmart Inc, Johnson & Johnson, Microsoft Corp, sells ProShares UltraPro Short S&P 500 ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HM Capital Management, LLC.Investment company Insight Wealth Strategies, LLC (Current Portfolio) buys ISHARES TRUST, iShares TIPS Bond ETF, iShares iBoxx USD Investment Grade Corporate Bond , Vanguard Tax-Exempt Bond ETF, IDEXX Laboratories Inc, sells ISHARES TRUST, ISHARES TRUST, iShares MSCI USA ESG Optimized ETF, iShares Core S&P 500 ETF, BTC iShares MSCI EAFE Value ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Insight Wealth Strategies, LLC.In this article, we will take a look at the 10 stocks making big moves on quarterly results. You can skip our detailed analysis of these companies and go directly to the 5 Stocks Making Big Moves on Quarterly Results. Notable stocks from technology, communication services, industrial and healthcare sectors, including Microsoft Corporation (NASDAQ:MSFT), AT&T […]Dr. Shikha Jain, Assistant Professor of Medicine at University of Illinois Chicago, joins Yahoo Finance Live to discuss hospitals dealing with COVID surges and staff shortages, medical supply shortages, COVID misinformation from media figures such as Joe Rogan, and vaccine mandates issued by private companies.;53.06999969482422;;248.27999877929688;The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.;102.5999984741211;Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.;137.0;"Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.Investment company James Hambro & Partners (Current Portfolio) buys Netflix Inc, Pool Corp, Union Pacific Corp, Amazon.com Inc, Aon PLC, sells Comcast Corp, Fidelity National Information Services Inc, Mondelez International Inc, Lockheed Martin Corp, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, James Hambro & Partners.AbbVie (NYSE: ABBV) will present further analyses on HUMIRA® (adalimumab) and the investigational uses of risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) at the 17th Congress of European Crohn's and Colitis Organisation (ECCO), to be held February 16-19. AbbVie will present 26 abstracts, including 8 oral presentations, 8 digital oral presentations and 10 posters from a broad range of studies across its inflammatory bowel disease (IBD) portfolio.AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Warren Buffett has given Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) shareholders a lot through the years.  Most importantly, under his direction, Berkshire has handily beaten the market.  Here are three Buffett dividend stocks to buy in February.A bear market isn't going to stop these stocks from delivering a steadily growing stream of dividend payments.The research-based biopharmaceutical company AbbVie is scheduled to report its latest quarterly numbers on Wednesday. In our last technical review back on December 7, we wrote that ""The bulls are back in charge with ABBV.These income stocks, with yields ranging from 4.1% to 11.3%, can be your rock during periods of heightened volatility.Investment company Baron Silver Stevens Financial Advisors, LLC (Current Portfolio) buys Vanguard Value ETF, Vanguard Dividend Appreciation FTF, Vanguard Tax-Exempt Bond ETF, VANGUARD BD IDX FD, BTC iShares Core MSCI EAFE ETF, sells BTC iShares MSCI USA Min Vol Factor ETF, iShares Core High Dividend ETF, BTC iShares MSCI Emerging Markets Min Vol Factor E, BTC iShares MSCI EAFE Min Vol Factor ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, BarBristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.";88.18000030517578;The companies have been studying the merits of a joint offer for the Sandoz business, which could be valued at around $25 billion, according to the report.  Other buyout firms are also considering bids, Bloomberg News said.  Last year, Novartis announced a strategic review of its generics unit, Sandoz, after years of revamping the business, as price pressures mount in the off-patent drug sector.Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.With stocks off to one of their worst starts to the year since the 2008-2009 financial crisis, it’s no longer crazy to talk about a sustained period of market volatility or a prolonged “risk off” environment on Wall Street.  If ever there was a time to consider sleepy but stable dividend stocks, now is the time.  The following five stocks are all names that, frankly, haven’t done so well over the last 12 months.Springfield, MO, based Investment company SignalPoint Asset Management, LLC (Current Portfolio) buys Exact Sciences Corp, iShares Russell 1000 Value ETF, Ncino Inc, Invesco Variable Rate Preferred ETF, Advanced Micro Devices Inc, sells Invesco S&P 500 Equal Weight Technology ETF, Invesco S&P 500 Equal Weight Health Care ETF, Invesco S&P 500 Equal Weight Financials ETF, Invesco S&P 500 Equal Weight Consumer Discretionar, Invesco S&P 500 Equal Weight Industrials ETF during the 3-months ended 2021QThe European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.;81.91999816894531;Investment company Alphinity Investment Management Pty Ltd (Current Portfolio) buys Accenture PLC, PepsiCo Inc, Merck Inc, McDonald's Corp, Microsoft Corp, sells Target Corp, Visa Inc, Otis Worldwide Corp, HCA Healthcare Inc, Nike Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Alphinity Investment Management Pty Ltd.Dr. Shikha Jain, Assistant Professor of Medicine at University of Illinois Chicago, joins Yahoo Finance Live to discuss hospitals dealing with COVID surges and staff shortages, medical supply shortages, COVID misinformation from media figures such as Joe Rogan, and vaccine mandates issued by private companies.Garden City, NY, based Investment company United Asset Strategies, Inc. (Current Portfolio) buys Belpointe PREP LLC, ISHARES TRUST, The Walt Disney Co, Communication Services Select Sector SPDR Fund, Invesco S&P 500 Pure Value ETF, sells iShares Russell 2000 ETF, WisdomTree Floating Rate Treasury Fund, iShares Core MSCI Emerging Markets ETF, Comcast Corp, Altice USA Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, United Asset Strategies, Inc.;57.68000030517578;New York, NY, based Investment company Northstar Group, Inc. (Current Portfolio) buys Philip Morris International Inc, AstraZeneca PLC, Pfizer Inc, Autodesk Inc, iShares iBonds Dec 2024 Term Corporate ETF, sells iShares iBonds Dec 2021 Term Corporate ETF, NextEra Energy Inc, Alibaba Group Holding, Becton, Dickinson and Co, iShares iBonds 2021 Term High Yield and Income ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Northstar Group, Inc..Dr. Shikha Jain, Assistant Professor of Medicine at University of Illinois Chicago, joins Yahoo Finance Live to discuss hospitals dealing with COVID surges and staff shortages, medical supply shortages, COVID misinformation from media figures such as Joe Rogan, and vaccine mandates issued by private companies.;65.19000244140625;Investment company Cahaba Wealth Management, Inc. (Current Portfolio) buys Southern Co, iShares Core 1-5 Year USD Bond ETF, Vanguard Large Cap ETF, BTC BlackRock Ultra Short-Term Bond ETF, SPDR Portfolio Aggregate Bond ETF, sells American Water Works Co Inc, Global Payments Inc, iShares Russell 1000 ETF, NVIDIA Corp, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cahaba Wealth Management, Inc..A bear market isn't going to stop these stocks from delivering a steadily growing stream of dividend payments.Greenville, SC, based Investment company Canal Insurance CO (Current Portfolio) buys Weibo Corp, Pfizer Inc, Northrop Grumman Corp, Bristol-Myers Squibb Co, Intel Corp, sells APA Corp, Tesla Inc, MP Materials Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Canal Insurance CO.The new company's approach, which is expected to enter an early-stage clinical trial this year, could both activate and suppress the immune system's response to solid tumors.Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.;51.630001068115234;Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.;45.189998626708984;;14.579999923706055;The new biotech startup has launched with drugs licensed from Takeda Pharmaceutical Co., which also has an ownership stake in the company.;40.560001373291016;Healthcare, one of the largest and most complex sectors, is composed of a broad range of companies that sell medical products and services.  The healthcare sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and healthcare providers.  The healthcare sector has caught investors’ attention since some of these companies have received regulatory approval for drugs to treat COVID-19 and begun distributing vaccines.Trenton, NJ, based Investment company State of New Jersey Common Pension Fund D (Current Portfolio) buys Canadian Pacific Railway, Airbnb Inc, Lucid Group Inc, Rivian Automotive Inc, Vale SA, sells JD.com Inc, Alibaba Group Holding, Enterprise Products Partners LP, NetEase Inc, Xtrackers USD High Yield Corporate Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, State of New Jersey Common Pension Fund D.;15.069999694824219;Investment company Weaver Consulting Group (Current Portfolio) buys Brainstorm Cell Therapeutics Inc, Uber Technologies Inc, Kite Realty Group Trust, iShares S&P 500 Value ETF, Direxion Daily S&P 500 Bull 3X Shares, sells iShares Core 1-5 Year USD Bond ETF, , Moderna Inc, Vanguard Total Bond Market ETF, Credit Suisse X-Links Gold Shares Covered Call ETN during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Weaver Consulting Group.Finding stocks that look undervalued is great, but sometimes shares of companies look cheap because the market has little faith in their prospects.  Of course, investors need to do their due diligence before making a final decision.  With that in mind, let's look at a healthcare company that is about as cheap as it gets right now: generic drug manufacturer Viatris (NASDAQ: VTRS).Investment company Bray Capital Advisors (Current Portfolio) buys iShares 1-3 Year Credit Bond ETF, Raytheon Technologies Corp, Fiserv Inc, The Walt Disney Co, Shoals Technologies Group Inc, sells ProShares Ultra S&P500, Booking Holdings Inc, Bristol-Myers Squibb Co, Kimberly-Clark Corp, Organon during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bray Capital Advisors.;202.88999938964844;New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.;12.020000457763672;;135.13999938964844;;121.2699966430664;;20.5;;32.9900016784668;JERSEY CITY, N.J., February 01, 2022--Organon to report 4th Quarter and full year 2021 earningsHealthcare, one of the largest and most complex sectors, is composed of a broad range of companies that sell medical products and services.  The healthcare sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and healthcare providers.  The healthcare sector has caught investors’ attention since some of these companies have received regulatory approval for drugs to treat COVID-19 and begun distributing vaccines.Edina, MN, based Investment company Accredited Investors Inc. (Current Portfolio) buys iShares MSCI EAFE ETF, iShares Russell Mid-Cap Growth ETF, iShares S&P Mid-Cap 400 Value ETF, iShares Russell 2000 Value ETF, Vanguard Dividend Appreciation FTF, sells Alphabet Inc, Tactile Systems Technology Inc, Alibaba Group Holding, Ford Motor Co, L3Harris Technologies Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Accredited Investors Inc..Darien, CT, based Investment company Bourgeon Capital Management Llc (Current Portfolio) buys PayPal Holdings Inc, The Walt Disney Co, Organon, Caterpillar Inc, Discovery Inc, sells Valero Energy Corp, Qualcomm Inc, Medtronic PLC, NVIDIA Corp, BlackRock Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bourgeon Capital Management Llc.;42.970001220703125;;20.239999771118164;;27.520000457763672;;27.079999923706055;;40.970001220703125;;112.73999786376953;BOSTON, February 01, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:00 a.m. ET.;26.610000610351562;;57.5099983215332;STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will present at the following upcoming investor conferences: 2022 Guggenheim Oncology Conference on Thursday, February 10 from 10:00-10:25 am ET.Cowen 42nd Annual Health Care Conference on Monday, March 7 from 1:30-2:00 pm ET.Barc;3.059999942779541;;4.710000038146973;;;;11.0600004196167;The new company's approach, which is expected to enter an early-stage clinical trial this year, could both activate and suppress the immune system's response to solid tumors.;6.090000152587891;"CULVER CITY, Calif., February 01, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer (NK) cells in people living with HIV by ImmunityBio’s IL-15 superagonist Anktiva (N-803). Anktiva stimulates latent HIV replication (the ""kick"") in CD4 memory cells allowing the previously hidden infected cells to be revealed and eliminated (the ""kill"") by CD8 and NK ce";37.560001373291016;;39.02000045776367;;47.040000915527344;;11.539999961853027;;16.649999618530273;;32.16999816894531;;4.619999885559082;;49.34000015258789;;18.950000762939453;;18.84000015258789;;5.480000019073486;;17.389999389648438;;9.529999732971191;;9.3100004196167;;26.559999465942383;;29.530000686645508;;15.5;Topline data now anticipated in mid-year 2022, followed by a regulatory submission in first half of 2023A total of 457 subjects are enrolled in the STRATUM studySeborrheic dermatitis affects 10 million people in the U.S. WESTLAKE VILLAGE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the last subject in its STRATUM;14.949999809265137;;17.780000686645508;;18.969999313354492;;14.579999923706055;;15.40999984741211;
2022-02-02;172.77000427246094;Investment company Sterling Financial Planning, Inc. (Current Portfolio) buys BTC iShares U.S. Treasury Bond ETF, Johnson & Johnson, BTC iShares MSCI USA Quality Factor ETF, iShares National Muni Bond ETF, iShares Core U.S.New York, NY, based Investment company Gabalex Capital Management LLC (Current Portfolio) buys Honeywell International Inc, The Walt Disney Co, Berkshire Hathaway Inc, Visa Inc, Meta Platforms Inc, sells Verizon Communications Inc, Materials Select Sector SPDR, Johnson & Johnson, Merck Inc, PepsiCo Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Gabalex Capital Management LLC.Investment company Trinity Wealth Management, LLC (Current Portfolio) buys First Trust Energy AlphaDEX Fund, Invesco Optimum Yield Diversified Commodity, Tesla Inc, iShares Fallen Angels USD Bond ETF, iShares TIPS Bond ETF, sells Invesco S&P 500 Equal Weight ETF, iShares 1-3 Year Credit Bond ETF, Vanguard Total Stock Market ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Trinity Wealth Management, LLC.Here are three stocks to buy now if you're anxious about the stock market.  The main reason behind the stock market's recent tumult is that investors are concerned about interest rates rising.  Dollar General (NYSE: DG) stands out as a stock that should perform well during both good and bad economic periods.The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th, when the S&P 500 Index was trading around the […]Dr. Payal Patel, infectious diseases physician at the University of Michigan, joins Yahoo Finance Live to discuss expectations that Pfizer will seek authorization for its COVID vaccine for children under 5 and why that is another step in protecting children's public health.Family Medicine Physician Dr. Marie-Elizabeth Ramas joins Yahoo Finance Live to discuss Pfizer seeking authorization for its COVID vaccine for children under 5, the Omicron wave, and mask mandates.And a look at market news including whether other card companies will benefit from the lift in consumer spending American Express saw in the fourth quarter.Investment company Defender Capital, LLC. (Current Portfolio) buys Landec Corp, Mirion Technologies Inc, Altria Group Inc, Apple Inc, JPMorgan Chase, sells Nuance Communications Inc, Invesco Dynamic Software ETF, Viasat Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Defender Capital, LLC..The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.The three largest U.S. drug distributors and drugmaker Johnson & Johnson have agreed to pay $590 million to resolve claims by hundreds of Native American tribes that the companies fueled an opioid epidemic in their communities.  Tuesday's deal came after the distributors, McKesson Corp , AmerisourceBergen Corp and Cardinal Health Inc , along with J&J last year proposed paying up to $26 billion to resolve similar claims by states and local governments.The three largest U.S. drug distributors and drugmaker Johnson & Johnson have agreed to pay $590 million to resolve claims by hundreds of Native American tribes that the companies fueled an opioid epidemic in their communities.  Tuesday's deal came after the distributors, McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, along with J&J last year proposed paying up to $26 billion to resolve similar claims by states and local governments.The three largest U.S. drug distributors and drugmaker Johnson & Johnson have agreed to pay $590 million to resolve claims by Native American tribes that the companies fueled an opioid epidemic in their communities, according to court filings.  Tuesday's deal came after the distributors, McKesson Corp , AmerisourceBergen Corp and Cardinal Health Inc , along with J&J last year proposed paying up to $26 billion to resolve similar claims by states and local governments.After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.;53.86000061035156;;250.8300018310547;"Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced a new collaboration to help improve health outcomes for 10 million children and adolescents living with chronic, non-communicable diseases (NCDs) through 2025.Investment company Foster Group, Inc. (Current Portfolio) buys Vanguard Total Bond Market ETF, Vanguard Short-Term Inflation-Protected Securities, iShares Core MSCI International Developed Markets , Vanguard Russell 2000 Index Fund, Avantis U.S.Novo Nordisk on Wednesday rejected allegations by a U.S. congressional investigative committee that it has engaged in manoeuvres to increase net prices on life-saving insulin in tandem with competitors on the U.S. market.  The report by the House Oversight Committee, the main investigative body of the U.S. House of Representatives, alleged that Novo had raised its insulin drug prices to the detriment of diabetes patients between 2001 and 2019.  Referring to Novo, Eli Lilly and Sanofi, which account for some 90% of the U.S. insulin market, the report released in December cited internal documents saying the three drugmakers had ""intentionally and strategically raised their prices in lockstep.""Novo Nordisk on Wednesday rejected allegations by a U.S. congressional investigative committee that it has engaged in manoeuvres to increase net prices on life-saving insulin in tandem with its competitors on the U.S. insulin market.  The report, released in December by the House Oversight Committee, the main investigative body of the U.S. House of Representatives, alleged Novo had increased prices on its insulin drugs to the detriment of diabetes patients between 2001 and 2019.  Referring to Novo Nordisk and rival drugmakers Eli Lilly and Sanofi, which own some 90% of the U.S. insulin market, the report cited internal documents saying they had ""intentionally and strategically raised their prices in lockstep.""Salem, OR, based Investment company Oregon Public Employees Retirement Fund (Current Portfolio) buys Eli Lilly and Co, Costco Wholesale Corp, Intuit Inc, NVIDIA Corp, Accenture PLC, sells Berkshire Hathaway Inc, The Walt Disney Co, PayPal Holdings Inc, Target Corp, Tesla Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Oregon Public Employees Retirement Fund.Investment company TFG Advisers LLC (Current Portfolio) buys Eli Lilly and Co, Colgate-Palmolive Co, Air Products & Chemicals Inc, Carlisle Inc, Freeport-McMoRan Inc, sells AT&T Inc, Vanguard Total International Bond ETF, WisdomTree Emerging Markets ex-State-Owned Enterpr during the 3-months ended 2021Q4, according to the most recent filings of the investment company, TFG Advisers LLC.Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Wednesday, Feb. 9, 2022. Jake Van Naarden, CEO of Loxo Oncology at Lilly and president, Lilly Oncology and David Hyman, M.D., chief medical officer, Lilly Oncology, will participate in a virtual fireside chat at 12 p.m., Eastern time.Investment company Gitterman Wealth Management, LLC (Current Portfolio) buys Independence Realty Trust Inc, NextEra Energy Inc, Digital Realty Trust Inc, Intuit Inc, Crown Castle International Corp, sells iShares Core S&P 500 ETF, Vanguard Short-Term Corporate Bond ETF, BTC iShares Core MSCI EAFE ETF, Vanguard Mortgage-Backed Securities ETF, Vanguard Growth ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Gitterman Wealth Management, LLC.Tokyo, M0, based Investment company Nomura Asset Management Co Ltd (Current Portfolio) buys Blackstone Secured Lending Fund, Thermo Fisher Scientific Inc, Eli Lilly and Co, Amgen Inc, Fortinet Inc, sells BTC iShares MSCI USA Value Factor ETF, Chegg Inc, Alibaba Group Holding, Pinterest Inc, Johnson Controls International PLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Nomura Asset Management Co Ltd.Eli Lilly and Under Armour made the list of stocks that have dropped sharply, but have room to rise, Barclays says.Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.In 2021, the COVID-19 vaccine marketed by Pfizer (NYSE: PFE) was one of the leaders in this new but highly lucrative market.  In December, the company earned Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for an oral COVID-19 therapy called Paxlovid.Let's look at a healthcare company that recently got bad news from regulators: Eli Lilly (NYSE: LLY).  On Jan. 24, the U.S. Food and Drug Administration (FDA) announced that it was updating the emergency use authorization granted to several coronavirus treatments.  The FDA specifically targeted bamlanivimab and etesevimab, marketed by Eli Lilly, and REGEN-COV, owned by Regeneron Pharmaceuticals.";106.58999633789062;"Novo Nordisk on Wednesday rejected allegations by a U.S. congressional investigative committee that it has engaged in manoeuvres to increase net prices on life-saving insulin in tandem with competitors on the U.S. market.  The report by the House Oversight Committee, the main investigative body of the U.S. House of Representatives, alleged that Novo had raised its insulin drug prices to the detriment of diabetes patients between 2001 and 2019.  Referring to Novo, Eli Lilly and Sanofi, which account for some 90% of the U.S. insulin market, the report released in December cited internal documents saying the three drugmakers had ""intentionally and strategically raised their prices in lockstep.""Novo Nordisk on Wednesday rejected allegations by a U.S. congressional investigative committee that it has engaged in manoeuvres to increase net prices on life-saving insulin in tandem with its competitors on the U.S. insulin market.  The report, released in December by the House Oversight Committee, the main investigative body of the U.S. House of Representatives, alleged Novo had increased prices on its insulin drugs to the detriment of diabetes patients between 2001 and 2019.  Referring to Novo Nordisk and rival drugmakers Eli Lilly and Sanofi, which own some 90% of the U.S. insulin market, the report cited internal documents saying they had ""intentionally and strategically raised their prices in lockstep.""Shares in Novo Nordisk rose more than 3% on Wednesday after the Danish drug developer delivered a better-than-expected earnings outlook for 2022 despite missing fourth quarter operating profit expectations.  The world's largest diabetes drug developer expects to generate sales growth of between 6% and 10% in local currencies in 2022 and deliver operating profit growth of 4% to 8%.  ""This reflects an underlying unchanged positive growth momentum for Novo Nordisk,"" Sydbank analyst Soren Lontoft told Reuters, adding that he would be raising his estimates.Financial report for the period 1 January 2021 to 31 December 2021 Operating profit increased by 8% in Danish kroner and by 13% at constant exchange rates (CER) to DKK 58.6 billion.Sales in International Operations increased by 12% in Danish kroner (14% at CER), and sales in North America Operations increased by 10% in Danish kroner (14% at CER).Sales within Diabetes and Obesity care increased by 13% in Danish kroner to DKK 121.6 billion (15% at CER), driven by GLP-1 sales growth of 28% in DanisBagsværd, Denmark, 1 February 2022 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme";138.6199951171875;Investment company Argent Advisors, Inc. (Current Portfolio) buys iShares 10-20 Year Treasury Bond ETF, Pinnacle West Capital Corp, AbbVie Inc, Duke Energy Corp, BTC iShares MSCI USA Min Vol Factor ETF, sells Origin Bancorp Inc, Chevron Corp, Alphabet Inc, Kimberly-Clark Corp, Walmart Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Argent Advisors, Inc..Investment company Demars Financial Group, LLC (Current Portfolio) buys iShares TIPS Bond ETF, Medical Properties Trust Inc, Phillips 66, Equity Lifestyle Properties Inc, AbbVie Inc, sells Vanguard Intermediate-Term Government Bond ETF, Digital Realty Trust Inc, Sprott Physical Gold and Silver Trust, Fidelity MSCI Utilities Index ETF, Cerner Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Demars Financial Group, LLC.Investment company Meridian Wealth Advisors, LLC (Current Portfolio) buys Vanguard S&P 500 ETF, Vanguard Mid-Cap ETF, JPMorgan Ultra-Short Income ETF, Main Street Capital Corp, Kimbell Royalty Partners LP, sells AT&T Inc, Veritex Holdings Inc, , Dow Inc, Kyndryl Holdings Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Meridian Wealth Advisors, LLC.AbbVie reported fourth-quarter earnings that were roughly in line with Wall Street expectations, and its 2022 earnings guidance surpassed analyst projections.AbbVie (ABBV) delivered earnings and revenue surprises of 0.61% and 0.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Shares of AbbVie Inc. gained 1.4% in premarket trading on Wednesday after the company beat earnings expectations and generated more sales than expected of its top-selling rheumatoid arthritis drug, Humira. AbbVie had earnings of $4.0 billion, or $2.26 per share, in the fourth quarter of 2021, compared with $36.0 million, or 1 cent per share, in the same quarter a year ago. Adjusted earnings per share were $3.31, against a FactSet consensus of $3.28. The company reported revenue of $14.8 billionAbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2021.The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th, when the S&P 500 Index was trading around the […]New York, NY, based Investment company Axel Capital Management, LLC (Current Portfolio) buys Silvergate Capital Corp, Riot Blockchain Inc, Meta Platforms Inc, Shopify Inc, NextEra Energy Inc, sells Grayscale Bitcoin Trust, PayPal Holdings Inc, Zebra Technologies Corp, Block Inc, Twitter Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Axel Capital Management, LLC.Investment company Greystone Financial Group, LLC (Current Portfolio) buys iShares U.S. Preferred Stock, SPDR Blackstone Senior Loan ETF, Lockheed Martin Corp, Cigna Corp, Cardinal Health Inc, sells iShares 1-3 Year Treasury Bond ETF, iShares 3-7 Year Treasury Bond ETF, Raytheon Technologies Corp, Norwegian Cruise Line Holdings, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Greystone Financial Group, LLC.Beaufort, SC, based Investment company Verity & Verity, LLC (Current Portfolio) buys LyondellBasell Industries NV, Verizon Communications Inc, Enbridge Inc, AbbVie Inc, Vanguard High Dividend Yield Indx ETF, sells AT&T Inc, Microsoft Corp, Vanguard Dividend Appreciation FTF, The Walt Disney Co, Schwab US Aggregate Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Verity & Verity, LLC.Investment company Leonard Rickey Investment Advisors P.L.L.C. (Current Portfolio) buys BTC iShares MSCI USA Min Vol Factor ETF, iShares TIPS Bond ETF, Vanguard Total International Stock, The Energy Select Sector SPDR Fund, Nike Inc, sells Vanguard Emerging Markets Government Bond ETF, Micron Technology Inc, eBay Inc, iShares MSCI All Country Asia ex Japan Index Fund, Alpine Immune Sciences Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, LeonThe pharma giant is tackling new competition for its blockbuster drug, but there remains more to do.;85.91000366210938;Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.Novartis  said Wednesday its Sandoz generics unit has received interest from private equity, as the Swiss drug maker reported higher earnings and sales for the fourth quarter and raised its 2021 dividend.  In its earnings statement, Novartis (ticker: NVS) said the strategic review of Sandoz, first announced last October, was progressing and the company would provide an update, at the latest, by the end of 2022.  Chief Executive Vas Narasimhan said Sandoz was attracting interest from both private equity and other generic players.Novartis expects sales and core operating profit to rise around 5% this year, below some analysts' expectations, as the Swiss drugmaker weighs up interest in its generics business Sandoz from potential suitors.  The pharmaceuticals company raised the prospect in October of divesting Sandoz after years of revamping it, as price pressures mount in the off-patent drug sector.  Alongside quarterly results on Wednesday, Novartis reiterated it would give an update on the matter by the end of 2022 and that it could still retain the business.Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)Sandoz sales grew +2% (cc, 0% USD) and core operating income in line with prior year (0% cc, 0% USD) Full year net sales grew +4% (cc, +6% USD) driven by strong Innovative Medicines performance Innovative Medicines (IM) grew +6% (cc, +8% USD), Sandoz declined -2% (cc, 0% USD)Strong performance ofBoston, MA, based Investment company Polaris Capital Management, LLC (Current Portfolio) buys FedEx Corp, Allison Transmission Holdings Inc, Wabash National Corp, Pacira BioSciences Inc, Computer Programs and Systems Inc, sells Coca-Cola Europacific Partners PLC, Jazz Pharmaceuticals PLC, ALLETE Inc, Diamondback Energy Inc, American Woodmark Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Polaris Capital Management, LLC.Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit (NYSE: NVS) Sandoz, Bloomberg reports, citing people close to the matter. The publication said that the private equity firms are discussing a potential joint offer for the Novartis unit. Separately, Advent International, Hellman & Friedman, and KKR & Co. are sizing up their approaches, Bloomberg's sources said. Sandoz is a sizable target, and some private equity funds could partner to bid(Bloomberg) -- Blackstone Inc. and Carlyle Group Inc. are in talks about potentially teaming up on a bid for Swiss drugmaker Novartis AG’s generics unit, in what could rank as one of the biggest-ever buyout deals, people with knowledge of the matter said. Most Read from BloombergTeen Who Demanded $50,000 From Elon Musk Is Now Targeting More Billionaire JetsCovid-Infected HIV Patient Developed Mutations, Study ShowsSeaWorld Makes $3.4 Billion Takeover Bid for Cedar FairBe Warned — the Turbulence;82.01000213623047;Investment company Everett Harris & Co (Current Portfolio) buys Bank of America Corp, Becton, Dickinson and Co, Comcast Corp, Anheuser-Busch InBev SA/NV, Wells Fargo, sells Novartis AG, , Baidu Inc, The Estee Lauder Inc, Quest Diagnostics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Everett Harris & Co .Jennifer Zachary, Merck’s General Counsel, on how we can provide more legal services to those in needAbbVie (ABBV) delivered earnings and revenue surprises of 0.61% and 0.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Beaufort, SC, based Investment company Verity & Verity, LLC (Current Portfolio) buys LyondellBasell Industries NV, Verizon Communications Inc, Enbridge Inc, AbbVie Inc, Vanguard High Dividend Yield Indx ETF, sells AT&T Inc, Microsoft Corp, Vanguard Dividend Appreciation FTF, The Walt Disney Co, Schwab US Aggregate Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Verity & Verity, LLC.Nashville, TN, based Investment company Pinnacle Financial Partners Inc (Current Portfolio) buys iShares 0-5 Year TIPS Bond ETF, Merck Inc, Microchip Technology Inc, Marvell Technology Inc, PayPal Holdings Inc, sells iShares 3-7 Year Treasury Bond ETF, Amgen Inc, AT&T Inc, Intel Corp, Verizon Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Pinnacle Financial Partners Inc.Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.;59.0099983215332;Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.;64.80000305175781;Investment company Royal Harbor Partners, LLC (Current Portfolio) buys iShares MSCI Global Multifactor ETF, Goldman Sachs ActiveBeta U.S.Investment company First Bank & Trust (Current Portfolio) buys Daktronics Inc, Amgen Inc, Bristol-Myers Squibb Co, Realty Income Corp, British American Tobacco PLC, sells Pfizer Inc, Canadian Imperial Bank of Commerce, Cisco Systems Inc, , Electronic Arts Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Bank & Trust.Chicago, IL, based Investment company Oak Ridge Investments Llc (Current Portfolio) buys Tesla Inc, R1 RCM Inc, TechTarget Inc, Lantheus Holdings Inc, The AZEK Co Inc, sells LHC Group Inc, Salesforce.com Inc, Everbridge Inc, EPAM Systems Inc, Inovalon Holdings Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Oak Ridge Investments Llc.Tokyo, M0, based Investment company Nomura Asset Management Co Ltd (Current Portfolio) buys Blackstone Secured Lending Fund, Thermo Fisher Scientific Inc, Eli Lilly and Co, Amgen Inc, Fortinet Inc, sells BTC iShares MSCI USA Value Factor ETF, Chegg Inc, Alibaba Group Holding, Pinterest Inc, Johnson Controls International PLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Nomura Asset Management Co Ltd.;52.540000915527344;"Investment company Stonehage Fleming Financial Services Holdings Ltd (Current Portfolio) buys Sea, MercadoLibre Inc, iShares Genomics Immunology and Healthcare ETF, ArcelorMittal SA, ARK 3D Printing ETF, sells Li Auto Inc, Infosys, STMicroelectronics NV, MP Materials Corp, Sony Group Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Stonehage Fleming Financial Services Holdings Ltd.Novo Nordisk on Wednesday rejected allegations by a U.S. congressional investigative committee that it has engaged in manoeuvres to increase net prices on life-saving insulin in tandem with competitors on the U.S. market.  The report by the House Oversight Committee, the main investigative body of the U.S. House of Representatives, alleged that Novo had raised its insulin drug prices to the detriment of diabetes patients between 2001 and 2019.  Referring to Novo, Eli Lilly and Sanofi, which account for some 90% of the U.S. insulin market, the report released in December cited internal documents saying the three drugmakers had ""intentionally and strategically raised their prices in lockstep.""Novo Nordisk on Wednesday rejected allegations by a U.S. congressional investigative committee that it has engaged in manoeuvres to increase net prices on life-saving insulin in tandem with its competitors on the U.S. insulin market.  The report, released in December by the House Oversight Committee, the main investigative body of the U.S. House of Representatives, alleged Novo had increased prices on its insulin drugs to the detriment of diabetes patients between 2001 and 2019.  Referring to Novo Nordisk and rival drugmakers Eli Lilly and Sanofi, which own some 90% of the U.S. insulin market, the report cited internal documents saying they had ""intentionally and strategically raised their prices in lockstep.""";45.70000076293945;Emma Walmsley, CEO of the pharmaceutical company and a Microsoft director, spent $1 million to buy the software stock in late January.Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.Profits fell far short of expectations and management offered financial forecasts that appeared to disappoint Wall Street.Britain's GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.  The settlement, announced by GSK on Tuesday, relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018  infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds.  HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.The FDA has approved ViiV Healthcare's Apretude (cabotegravir extended-release injectable suspension) for use in adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. ViiV Healthcare is majority-owned by GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited. Apretude is given first as two initiation injections administered one month apart and then every two months after that. PatiInvestment company Field & Main Bank (Current Portfolio) buys iShares MSCI Emerging Markets ETF, Devon Energy Corp, S&P MidCap 400 ETF, iShares Russell 2000 Growth ETF, Tesla Inc, sells Alibaba Group Holding, First Solar Inc, SVB Financial Group, Sherwin-Williams Co, Southwest Airlines Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Field & Main Bank.;14.619999885559082;;41.0;;15.300000190734863;Let's take a look at Viatris' fundamentals and valuation to answer these questions.  What led Viatris' Board of Directors to hand out a huge raise to shareholders?  Viatris' average analyst estimate for non-GAAP earnings per share (EPS) is $3.71 for 2021.Investment company Waddell & Associates, Llc (Current Portfolio) buys BTC BlackRock Short Maturity Bond ETF, PowerShares QQQ Trust Ser 1, Amazon.com Inc, II-VI Inc, Deere, sells Driven Brands Holdings Inc, WisdomTree Emerging Markets ex-State-Owned Enterpr, AT&T Inc, The Interpublic Group of Inc, Viatris Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Waddell & Associates, Llc.Investment company Avestar Capital, LLC (Current Portfolio) buys Alphabet Inc, Avantis U.S. Equity ETF, FIRST TR EXCH TRD, Marvell Technology Inc, Cigna Corp, sells Janus Henderson Small Cap Growth Alpha ETF, ARK Fintech Innovation ETF, First Trust NASDAQ CEA Cybersecurity ETF, Siren Nasdaq NexGen Economy ETF, Global X Autonomous & Electric Vehicles ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Avestar Capital, LLC.Investment company Bell Bank (Current Portfolio) buys Vanguard Total Stock Market ETF, Vanguard S&P 500 ETF, Ares Capital Corp, Hanesbrands Inc, SPDR Portfolio S&P 500 High Dividend ETF, sells Utilities Select Sector SPDR ETF, MetLife Inc, Conagra Brands Inc, Healthcare Services Group Inc, Gentex Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bell Bank.Investment company Wesleyan Assurance Society (Current Portfolio) buys Autodesk Inc, PayPal Holdings Inc, Mastercard Inc, Yum China Holdings Inc, Visa Inc, sells Viatris Inc, Westinghouse Air Brake Technologies Corp, Organon during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Wesleyan Assurance Society.;204.1300048828125;Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.;11.970000267028809;;128.63999938964844;;120.47000122070312;;20.770000457763672;;33.33000183105469;Investment company Asahi Life Asset Management Co., Ltd. (Current Portfolio) buys Organon, Applied Materials Inc, TJX Inc, HP Inc, Charter Communications Inc, sells Bank of America Corp, Citigroup Inc, Brighthouse Financial Inc, Chipotle Mexican Grill Inc, Humana Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asahi Life Asset Management Co., Ltd..Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is designating International Women's Day (IWD) on March 8 as a day to recognize the growing health disparities women face that have been exacerbated by the COVID-19 pandemic. Since its inception, IWD has focused on accelerating gender parity. Organon recognizes the need for a global effort to address her health and is starting with its own employees by providing paid time off this year for all employees to atteJERSEY CITY, N.J., February 02, 2022--Organon Announces Paid Time Off in recognition of International Women's Day;41.349998474121094;;19.389999389648438;;27.030000686645508;;27.34000015258789;;40.459999084472656;;109.31999969482422;;23.510000228881836;;54.849998474121094;;3.0399999618530273;A look at the shareholders of OPKO Health, Inc. ( NASDAQ:OPK ) can tell us which group is most powerful. Institutions...Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.;4.900000095367432;;;;10.510000228881836;;5.699999809265137;;38.02000045776367;;36.58000183105469;SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Guggenheim Healthcare Talks 2022 Oncology Day on February 9 and the 11th Annual SVB Leerink Global Healthcare Conference on February 16. Dr. Countouriotis is scheduled to participate in fireside chats at 2 p.m.;45.15999984741211;;11.100000381469727;;15.869999885559082;LAUSANNE, Switzerland, February 02, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the virtual Guggenheim Oncology Conference on Wednesday, February 9th at 9:30 a.m. EST.The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...;31.790000915527344;;4.760000228881836;Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...;46.810001373291016;;18.670000076293945;;17.8799991607666;SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on February 1, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 135,000 shares of its common stock to seven new non-exe;5.320000171661377;;17.940000534057617;;9.5600004196167;;9.5;MIAMI, February 02, 2022--Procaps Group Announces Capacity Expansion Plans in the United States with Construction of New Gummy Manufacturing Facility in Florida;24.790000915527344;;27.829999923706055;;14.859999656677246;;14.079999923706055;;17.030000686645508;;19.360000610351562;;13.4399995803833;;15.550000190734863;
2022-02-03;172.75999450683594;Healthcare giant Johnson & Johnson (NYSE: JNJ) released its fourth-quarter earnings last week.  Johnson & Johnson's consumer health business has been in the spotlight of late as the company is spinning it off.  In fact, consumer health was the slowest-growing area of Johnson & Johnson's operations in Q4 with medical device revenue rising by 4.1% and pharmaceutical sales jumping 16.5% -- although that number is a bit inflated, as you'll see in the next section.In this article, we discuss 10 income stocks with over 10 years of dividend increases. If you want to skip our detailed analysis of these stocks, go directly to 5 Income Stocks with Over 10 Years of Dividend Increases. Owing to strong earnings in 2022, companies are set to spend even more on distribution of […]Investment company Greenhouse Wealth Management, LLC (Current Portfolio) buys Eli Lilly and Co, Johnson & Johnson, Oracle Corp, ESS Tech Inc, sells Apple Inc, iShares Gold Trust, Verizon Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Greenhouse Wealth Management, LLC.Healthcare giant Johnson & Johnson (NYSE: JNJ) reported its fourth-quarter results on Jan. 25, 2022.  In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli talk about what investors should like about J&J's latest update.  Johnson & Johnson was the first big healthcare company to announce its Q4 results, and the company provided its update on Tuesday.Investment company Concentrum Wealth Management (Current Portfolio) buys Apple Inc, Confluent Inc, Invesco DB Base Metals Fund, iShares U.S.Drugmaker Johnson & Johnson said on Wednesday it would take a non-cash impairment charge of about $610 million in the first quarter over its decision to stop the development of a skin disease treatment.  The drug, bermekimab, is a human monoclonal antibody that was being tested for the treatment of chronic skin diseases atopic dermatitis and hidradenitis suppurativa.  J&J said it had decided to terminate the development of the drug for atopic dermatitis following the availability of additional efficacy data.Dr. Ezekiel Emanuel, former White House Health Policy Adviser, joins Yahoo Finance Live to discuss the United States' COVID-19 vaccination and infection rates, anti-viral therapeutics, testing resources, hospitalizations, and China's zero-COVID strategy.Sorrento Therapeutics Chairman and CEO Henry Ji joins Yahoo Finance Live to discuss the Covishield antibody Sorrento is developing, the timeline for getting FDA approval, cancer treatment research, and the pharmaceutical biotech sectors.Is Johnson & Johnson stock a buy after the firm guided to at least $3 billion in sales of its Covid shot this year? Is JNJ stock now a buy?Johnson & Johnson (NYSE: JNJ) and the three U.S. drug distributors agreed to pay about $590 million to resolve claims from over 400 Native American tribes to settle lawsuits over the opioid epidemic. That proposed settlement, though, did not resolve lawsuits and potential claims by the country's 574 federally recognized Native American tribes and Alaska Native villages, which experienced disproportionately high rates of opioid overdoses. The deal came after the distributors, McKesson CorporationAt Johnson & Johnson Consumer Health, our mission is total health – for individuals at every stage of life, for communities around the world, and for our planet. We understand how important it is f...Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.In this article, we will look at 10 dividend stocks in Crispin Odey’s hedge fund portfolio. If you want to skip our detailed analysis of these stocks and Odey Asset Management’s history and past performance you can go to 5 Dividend Stocks in Crispin Odey’s Hedge Fund Portfolio. Mr. Odey’s Early Beginnings Crispin Odey is […]AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.;53.380001068115234;"Merck & Co said on Thursday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir.  The drugmaker said sales of the COVID-19 drug were $952 million in the fourth quarter, and it expects another $5 billion to $6 billion in molnupiravir sales in 2022.  Merck developed the antiviral pill - and shares the profits equally - with Ridgeback Biotherapeutics.Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.The European Union's drug regulator said on Thursday it would support a filing for approval of an upgraded COVID-19 vaccine targeting only the new Omicron variant if that is the quickest way to broaden the offering of available shots.  Speaking to journalists in a briefing, the European Medicines Agency's (EMA) head of vaccines strategy, Marco Cavaleri, reiterated that he encouraged pharmaceuticals companies to explore not only a monovalent shot tailored to the Omicron variant but also versions that address a combination of variants.South Africa's Afrigen Biologics has used the publicly available sequence of Moderna's COVID-19 mRNA vaccine to make its own version of the shot, which could be tested in humans before the end of this year, Afrigen's top executive said on Thursday.  It is also the first mRNA vaccine designed, developed and produced at lab scale on the African continent.  The World Health Organization (WHO) last year picked a consortium including Afrigen for a pilot project to give poor and middle-income countries the know-how to make COVID-19 vaccines, after market leaders of the mRNA COVID vaccine, Pfizer , BioNTech and Moderna, declined https://www.reuters.com/world/africa/exclusive-who-backed-vaccine-hub-africa-copy-moderna-covid-19-shot-2021-09-14 a WHO request to share their technology and expertise.The prices of drugs used to treat COVID-19 for those at risk of serious illness are ""reasonably aligned"" with how much they help patients, according to a draft report from drug-pricing research organization the Institute for Clinical and Economic Review (ICER).  The report assessed Pfizer Inc's Paxlovid and Merck & Co's molnupiravir - both recently authorized antiviral pills - as well as sotrovimab, an intravenous monoclonal antibody drug developed by GlaxoSmithKline Plc and Vir Biotechnology Inc.  The U.S. government has paid around $530 for a 5-day course of Paxlovid, $700 per five-day course of molnupiravir, and $2,100 for a course of sotrovimab - the lone available antibody treatment shown to work against the now dominant Omicron variant of the virus.CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 3, 2022Five corporate bigwigs will report fourth-quarter 2021 earnings results next week. These are: HAS, PFE, TWLO, CDW and NLY.Merck (NYSE: MRK) has high hopes for gefapixant, an experimental drug that it's referred to as a ""pipeline in a product.""  In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli discuss why the FDA gave a thumbs-down to gefapixant.It depends on exactly why the FDA decided not to approve the two companies' growth hormone therapy.Gilead's success could be inversely proportional to Pfizer's success with its COVID-19 pill.Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc are highlighted in this Screen of the Week article.Milwaukee, WI, based Investment company Sadoff Investment Management Llc (Current Portfolio) buys iShares U.S.Investment company WP Advisors, LLC (Current Portfolio) buys PayPal Holdings Inc, Booking Holdings Inc, Uber Technologies Inc, iShares MSCI Emerging Markets ETF, Autodesk Inc, sells Janus Henderson Short Duration Income ETF, Alibaba Group Holding, Coinbase Global Inc, Itau Unibanco Holding SA, Clorox Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, WP Advisors, LLC.Novavax (NASDAQ:NVAX) made a strong move to the upside earlier this week on a regulatory filing that was long overdue. The stock is now a pale shadow of its old self, having pulled back notably from its all-time high of $331.68 reached on Feb. 9, 2021. Source: vovidzha / Shutterstock.com Novavax held a lot of promise by virtue of it being among the earliest to venture into Covid-19 vaccine research. For that matter, the stock had picked up some momentum even ahead of its Covid-19 vaccine foray,Dr. Ezekiel Emanuel, former White House Health Policy Adviser, joins Yahoo Finance Live to discuss the United States' COVID-19 vaccination and infection rates, anti-viral therapeutics, testing resources, hospitalizations, and China's zero-COVID strategy.Sorrento Therapeutics Chairman and CEO Henry Ji joins Yahoo Finance Live to discuss the Covishield antibody Sorrento is developing, the timeline for getting FDA approval, cancer treatment research, and the pharmaceutical biotech sectors.Investment company Smith Group Asset Management, LLC (Current Portfolio) buys Zebra Technologies Corp, Pfizer Inc, American Express Co, EPAM Systems Inc, Westlake Chemical Corp, sells PayPal Holdings Inc, Encompass Health Corp, U.S.Cincinnati, OH, based Investment company Truepoint, Inc. (Current Portfolio) buys Avantis Emerging Markets Equity ETF, Vanguard Intermediate-Term Corporate Bond ETF, ProShares Bitcoin Strategy ETF, Schwab U.S.";244.80999755859375;"Covid-19 antibodies revenue was $1.06 billion in the quarter, up 22% from a year earlier and higher than Wall Street forecasts.Technology shares are falling, along with the broader market, after Facebook parent Meta said it sees revenue growth slowing. Oil fell while bond yields jumped.Yahoo Finance's Julie Hyman and Brian Sozzi discuss Meta shares plummeting amid TikTok competition, Qualcomm stock down after beating earnings estimates, and how Biogen, Merck, and Eli Lilly are performing after earnings.Dow Jones Industrial Average dropped while tech stocks dived Thursday, as Facebook stock crashed on weak earnings results.Investment company Greenhouse Wealth Management, LLC (Current Portfolio) buys Eli Lilly and Co, Johnson & Johnson, Oracle Corp, ESS Tech Inc, sells Apple Inc, iShares Gold Trust, Verizon Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Greenhouse Wealth Management, LLC.View more earnings on CISee more from BenzingaHershey Forecasts FY22 Sales, Profit Above Estimates On Higher PricesEli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.View more earnings on HSYSee more from BenzingaEli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 GuidanceCosmetics Maker Estee Lauder Boosts FY22 Forecast, Q2 Earnings Beat Expectations© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.View more earnings on LLYSee more from BenzingaLilly To Inject B In New Manufacturing Facility In North Carolina, USEli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.The On-Balance-Volume (OBV) line made a slight lower high in December for a bearish divergence when compared to the price action.  The Moving Average Convergence Divergence (MACD) oscillator is below the zero line.  The weekly OBV line has been stalled the past three months.Eli Lilly and Co deferred its timeline to complete application for accelerated approval of its experimental Alzheimer's drug, saying it expects such an approval to make little difference with Medicare's limited coverage terms.  Shares of Eli Lilly fell 2.6% to $244.21 on Thursday, after the drugmaker said it would complete the application sometime later in 2022, pushing away from first quarter, its initial timeline.Shares of Eli Lilly & Co. rose 0.4% in premarket trading Thursday, after the drug giant reported fourth-quarter profit and revenue that rose above expectations, as COVID-19 antibodies revenue topped $1 billion, which was well above forecasts. Net income fell to $1.73 billion, or $1.90 a share, from $2.12 billion, or $2.32 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share rose to $2.49 from $2.31, above the FactSet consensus of $2.45. Revenue grew 7.5% toEli Lilly and Co deferred its timeline to complete application for accelerated approval of its experimental Alzheimer's drug, saying it expects such an approval to make little difference with Medicare's limited coverage terms.  Shares of Eli Lilly fell 2.6% to $244.21 on Thursday, after the drugmaker said it would complete the application sometime later in 2022, pushing away from first quarter, its initial timeline.  The U.S. Centers for Medicaid and Medicare Services has restricted coverage for Alzheimer's drugs, including Biogen's controversial treatment Aduhelm, only to patients taking part in approved clinical trials.By Peter NurseBy Dhirendra TripathiWall Street will navigate a series of key S&P 500 earnings Thursday as investors look to forward projections from a host of companies amid concerns of rising inflation, Federal Reserve rate hikes and slowing consumer growth.Investment company Sustainable Insight Capital Management, LLC (Current Portfolio) buys Eli Lilly and Co, NXP Semiconductors NV, Netflix Inc, T-Mobile US Inc, NetApp Inc, sells Charter Communications Inc, Abbott Laboratories, Lam Research Corp, Broadcom Inc, Mohawk Industries Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sustainable Insight Capital Management, LLC.Investment company Provident Wealth Management, LLC (Current Portfolio) buys iShares Core MSCI Emerging Markets ETF, First Trust International IPO ETF, Microsoft Corp, PPG Industries Inc, Eli Lilly and Co, sells Pinnacle Financial Partners Inc, iShares Core S&P 500 ETF, Kyndryl Holdings Inc, iShares Core S&P Mid-Cap ETF, SPDR Portfolio S&P 500 Growth ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Provident Wealth Management, LLC.Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]";104.62999725341797;Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.;140.72999572753906;In this article, we discuss 10 income stocks with over 10 years of dividend increases. If you want to skip our detailed analysis of these stocks, go directly to 5 Income Stocks with Over 10 Years of Dividend Increases. Owing to strong earnings in 2022, companies are set to spend even more on distribution of […]Dow Jones Industrial Average dropped while tech stocks dived Thursday, as Facebook stock crashed on weak earnings results.Charlottesville, VA, based Investment company Chase Investment Counsel Corp (Current Portfolio) buys Eagle Materials Inc, National Fuel Gas Co, AbbVie Inc, UnitedHealth Group Inc, Ulta Beauty Inc, sells Comcast Corp, Meta Platforms Inc, Qorvo Inc, Amazon.com Inc, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Chase Investment Counsel Corp.We’re in the thick of earnings season, with more big reports due up after the close and again on Thursday. With that in mind, let’s look at a few top stock trades going into the back-half of the week. Top Stock Trades for Tomorrow No. 1: Advanced Micro Devices (AMD) Click to EnlargeSource: Chart courtesy of TrendSpider Advanced Micro Devices (NASDAQ:AMD) ripped higher at the open following better-than-expected earnings. However, those gains were halved just a few hours later. That said, just looAbbVie stock inched ahead Wednesday despite a sales miss for its biggest moneymaker, Humira, as biosimilar competition heats up.The U.S. health regulator said on Wednesday that it had approved the first generic version of AbbVie Inc's Restasis, a treatment used in increasing tear production in patients with dry-eye syndrome.  The approval was granted to Viatris Inc, which was formed through the merger of generic drugmaker Mylan Pharmaceuticals and Pfizer Inc's off-patent drug business in 2020.  AbbVie acquired Restasis, which was approved in the United States nearly two decades ago, through its $63 billion acquisition of Allergan https://reut.rs/3uknllO Inc in 2020.Bethesda, MD, based Investment company MV Capital Management, Inc. (Current Portfolio) buys Abbott Laboratories, AbbVie Inc, Fidelity Blue Chip Growth ETF, iShares Russell 1000 Value ETF, Clorox Co, sells iShares iBonds Dec 2021 Term Corporate ETF, Fidelity MSCI Consumer Discretionary Index ETF, BTC iShares Convertible Bond ETF, iShares Core MSCI Emerging Markets ETF, iShares MSCI Emerging Markets ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment companCincinnati, OH, based Investment company Truepoint, Inc. (Current Portfolio) buys Avantis Emerging Markets Equity ETF, Vanguard Intermediate-Term Corporate Bond ETF, ProShares Bitcoin Strategy ETF, Schwab U.S.AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.;86.41999816894531;Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.Novartis stock tumbled Wednesday as fourth-quarter earnings lagged and after the Swiss pharma behemoth scrapped a promising eczema drug.Investment company Clearview Wealth Advisors LLC (Current Portfolio) buys Schwab U.S. Tips ETF, iShares Core Total USD Bond Market ETF, BTC iShares MSCI USA Min Vol Factor ETF, Global X S&P 500 Covered Call ETF, Abbott Laboratories, sells iShares MBS ETF, Schwab 1-5 Year Corporate Bond ETF, SPDR Portfolio Short Term Treasury ETF, SPDR Portfolio Short Term Corporate Bond ETF, iShares 0-5 Year High Yield Corporate Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of t;79.01000213623047;"Merck & Co said on Thursday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir.  The drugmaker said sales of the COVID-19 drug were $952 million in the fourth quarter, and it expects another $5 billion to $6 billion in molnupiravir sales in 2022.  Merck developed the antiviral pill - and shares the profits equally - with Ridgeback Biotherapeutics.Technology shares are falling, along with the broader market, after Facebook parent Meta said it sees revenue growth slowing. Oil fell while bond yields jumped.Yahoo Finance's Julie Hyman and Brian Sozzi discuss Meta shares plummeting amid TikTok competition, Qualcomm stock down after beating earnings estimates, and how Biogen, Merck, and Eli Lilly are performing after earnings.The prices of drugs used to treat COVID-19 for those at risk of serious illness are ""reasonably aligned"" with how much they help patients, according to a draft report from drug-pricing research organization the Institute for Clinical and Economic Review (ICER).  The report assessed Pfizer Inc's Paxlovid and Merck & Co's molnupiravir - both recently authorized antiviral pills - as well as sotrovimab, an intravenous monoclonal antibody drug developed by GlaxoSmithKline Plc and Vir Biotechnology Inc.  The U.S. government has paid around $530 for a 5-day course of Paxlovid, $700 per five-day course of molnupiravir, and $2,100 for a course of sotrovimab - the lone available antibody treatment shown to work against the now dominant Omicron variant of the virus.Merck (MRK) delivered earnings and revenue surprises of 23.29% and 7.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Merck & Co. shares rose 0.8% premarket Thursday, after the drug company beat estimates for the fourth quarter after chalking up more than $950 million in sales from its COVID-19 antiviral molnupiravir. The company posted net income of $3.820 billion, or $1.51 a share, for the quarter, after a loss of $2.617 billion, or $1.03 a share, in the year-earlier period. Adjusted per-share earnings came to $1.80, well ahead of the $1.53 FactSet consensus. Sales rose 24% to $13.521 billion from $10.948 bilMerck & Co said on Thursday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir.  Merck developed the pill - and shares the profits equally - with partner Ridgeback Biotherapeutics.  Merck Chief Financial Officer Caroline Litchfield said in an interview it is possible the company could top those sales estimates for molnupiravir, which are based on already signed supply agreements for around 10 million courses of the drug.Merck & Co said on Thursday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir.  Merck developed the pill - and shares the profits equally - with partner Ridgeback Biotherapeutics.  Merck Chief Financial Officer Caroline Litchfield said in an interview it is possible the company could top those sales estimates for molnupiravir, which are based on already signed supply agreements for around 10 million courses of the drug.KENILWORTH, N.J., February 03, 2022--Merck Announces Fourth-Quarter and Full-Year 2021 Financial ResultsBy Peter NurseChattanooga, TN, based Investment company Barnett & Company, Inc. (Current Portfolio) buys iShares Russell 1000 Growth ETF, iShares Russell 1000 Value ETF, Intel Corp, iShares Russell Mid-Cap Growth ETF, Vanguard Mega Cap Growth ETF, sells General Motors Co, Diebold Nixdorf Inc, Vanguard Intermediate-Term Bond ETF, Delta Air Lines Inc, iShares Core U.S.Investment company JB Capital LLC (Current Portfolio) buys iShares Core Total USD Bond Market ETF, BTC iShares U.S.Investment company RMR Wealth Builders (Current Portfolio) buys Vanguard S&P 500 ETF, Vanguard Growth ETF, Vanguard Value ETF, iShares Core S&P Small-Cap ETF, WisdomTree Emerging Markets ex-State-Owned Enterpr, sells iShares Russell 1000 Growth ETF, iShares MSCI EAFE ETF, iShares Russell 1000 Value ETF, iShares Short Treasury Bond ETF, iShares Russell 2000 ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, RMR Wealth Builders.Investment company Stony Point Wealth Management Inc. (Current Portfolio) buys Vulcan Materials Co, Starwood Property Trust Inc, Altria Group Inc, Markel Corp, The Walt Disney Co, sells Dominion Energy Inc, Magnite Inc, WestRock Co, Visa Inc, Schwab U.S.Dr. Ezekiel Emanuel, former White House Health Policy Adviser, joins Yahoo Finance Live to discuss the United States' COVID-19 vaccination and infection rates, anti-viral therapeutics, testing resources, hospitalizations, and China's zero-COVID strategy.Sorrento Therapeutics Chairman and CEO Henry Ji joins Yahoo Finance Live to discuss the Covishield antibody Sorrento is developing, the timeline for getting FDA approval, cancer treatment research, and the pharmaceutical biotech sectors.We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]Investment company Smith Group Asset Management, LLC (Current Portfolio) buys Zebra Technologies Corp, Pfizer Inc, American Express Co, EPAM Systems Inc, Westlake Chemical Corp, sells PayPal Holdings Inc, Encompass Health Corp, U.S.Cincinnati, OH, based Investment company Truepoint, Inc. (Current Portfolio) buys Avantis Emerging Markets Equity ETF, Vanguard Intermediate-Term Corporate Bond ETF, ProShares Bitcoin Strategy ETF, Schwab U.S.Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.";57.33000183105469;Dr. Ezekiel Emanuel, former White House Health Policy Adviser, joins Yahoo Finance Live to discuss the United States' COVID-19 vaccination and infection rates, anti-viral therapeutics, testing resources, hospitalizations, and China's zero-COVID strategy.Sorrento Therapeutics Chairman and CEO Henry Ji joins Yahoo Finance Live to discuss the Covishield antibody Sorrento is developing, the timeline for getting FDA approval, cancer treatment research, and the pharmaceutical biotech sectors.Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.;64.06999969482422;Investment company Gries Financial Llc (Current Portfolio) buys iShares Commodities Select Strategy ETF, BTC iShares MSCI USA Min Vol Factor ETF, iShares MSCI ACWI Index Fund, Walgreens Boots Alliance Inc, Bristol-Myers Squibb Co, sells Avalara Inc, Cintas Corp, Apple Inc, AT&T Inc, CVS Health Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Gries Financial Llc.Investment company CM Management, LLC (Current Portfolio) buys Cadence Bank, Cadence Bank, Agnico Eagle Mines, Chesapeake Energy Corp, mCloud Technologies Corp, sells Cadence Bank, Cadence Bank, Travere Therapeutics Inc, BP PLC, EnLink Midstream LLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CM Management, LLC.Investment company Stonebridge Financial Planning Group, LLC (Current Portfolio) buys iShares TIPS Bond ETF, SPDR Blackstone Senior Loan ETF, Vanguard S&P 500 Value ETF, Vanguard FTSE All-World ex-US ETF, FIRST TR ETF VI, sells PIMCO Enhanced Short Maturity Active Exchange-Trad, Fidelity MSCI Communication Services Index ETF, First Trust Enhanced Short Maturity ETF, Invesco Preferred ETF, First Trust Global Wind Energy ETF during the 3-months ended 2021Q4, according to the most recent filings ofInsider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the third quarter. You can find articles about an individual hedge fund’s trades on numerous financial […];52.459999084472656;The European Union's drug regulator said on Thursday it would support a filing for approval of an upgraded COVID-19 vaccine targeting only the new Omicron variant if that is the quickest way to broaden the offering of available shots.  Speaking to journalists in a briefing, the European Medicines Agency's (EMA) head of vaccines strategy, Marco Cavaleri, reiterated that he encouraged pharmaceuticals companies to explore not only a monovalent shot tailored to the Omicron variant but also versions that address a combination of variants.Sony acquired Bungie games for $3.6 billion recently. What does the acquisition mean for Microsoft's gaming ambitions?Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.;44.91999816894531;"The prices of drugs used to treat COVID-19 for those at risk of serious illness are ""reasonably aligned"" with how much they help patients, according to a draft report from drug-pricing research organization the Institute for Clinical and Economic Review (ICER).  The report assessed Pfizer Inc's Paxlovid and Merck & Co's molnupiravir - both recently authorized antiviral pills - as well as sotrovimab, an intravenous monoclonal antibody drug developed by GlaxoSmithKline Plc and Vir Biotechnology Inc.  The U.S. government has paid around $530 for a 5-day course of Paxlovid, $700 per five-day course of molnupiravir, and $2,100 for a course of sotrovimab - the lone available antibody treatment shown to work against the now dominant Omicron variant of the virus.Investment company Tempus Wealth Planning, LLC (Current Portfolio) buys SPDR S&P Global Natural Resources ETF, GlaxoSmithKline PLC, Cognizant Technology Solutions Corp, Verizon Communications Inc, Activision Blizzard Inc, sells Vanguard International Dividend Appreciation ETF, Vanguard FTSE All-World Ex-US Small Capital Index , AT&T Inc, Kyndryl Holdings Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Tempus Wealth Planning, LLC.";14.4399995803833;Japan's Takeda Pharmaceutical Co said on Thursday nine-month profit surged 29% from a year earlier, driven by sales growth for its 14 major drug brands.  Takeda raised its full-year operating profit forecast 1.1% to 515 billion yen.  Takeda said it aims to distribute the first doses of the COVID-19 vaccine developed by Novavax Inc within Japan in early calendar 2022, subject to approval from regulators.OSAKA, Japan, February 03, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topline growth of its 14 global brands. Based on the strong third-quarter results and business momentum, the company upgraded forecasts for full fiscal year revenue, reported and core operating profit, reported and core EPS and free cash flow.;40.029998779296875;;15.130000114440918;Investment company Pathway Financial Advisors LLC (Current Portfolio) buys Goldman Sachs Access Treasury 0-1 Year ETF, Discipline Fund ETF, BRP Group Inc, American Century STOXX U.S.Quality Growth ETF, iShares MSCI Emerging Markets ETF, sells SPDR Bloomberg 1-3 Month T-Bill ETF, Pfizer Inc, Ross Stores Inc, iShares MSCI USA ESG Optimized ETF, Comcast Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Pathway Financial Advisors LLC.Viatris (VTRS) closed at $15.30 in the latest trading session, marking a +1.53% move from the prior day.;198.36000061035156;Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. ESTWALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month repo;11.920000076293945;;130.5399932861328;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the publication of new findings from its long-term safety study showing reductions in migraine frequency in patients treated with rimegepant 75 mg for the acute treatment of migraine in the February issue of Cephalalgia Reports. Cephalalgia Reports is a medical-neurological journal in the field of headache research and is an official journal of the International Headache Society.Investment company Emerald Advisers, Llc (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, HireRight Holdings Corp, Arhaus Inc, sells Chegg Inc, ORIC Pharmaceuticals Inc, BellRing Brands Inc, Trex Co Inc, Arena Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Advisers, Llc.;115.83999633789062;Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.;20.56999969482422;;32.91999816894531;Pasadena, CA, based Investment company Schnieders Capital Management Llc (Current Portfolio) buys PagerDuty Inc, 3M Co, iShares TIPS Bond ETF, National Health Investors Inc, California Water Service Group, sells Kimberly-Clark Corp, CenterPoint Energy Inc, NovoCure, , Target Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Schnieders Capital Management Llc.;40.939998626708984;;18.139999389648438;;25.780000686645508;;26.209999084472656;;40.290000915527344;Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.;105.23999786376953;Leola, PA, based Investment company Emerald Mutual Fund Advisers Trust (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, Karuna Therapeutics Inc, HireRight Holdings Corp, sells Chegg Inc, BellRing Brands Inc, Echo Global Logistics Inc, Tetra Tech Inc, ORIC Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Mutual Fund Advisers Trust.;23.43000030517578;;52.72999954223633;;3.200000047683716;MIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE® (extended release calcifediol) in Germany, the first launch of RAYALDEE outside the U.S. VFMCRP is OPKO’s commercial partner for RAYALDEE in Europe and selected markets outside the U.S., and the sales kick-off in Germany began with presentations by VFMCRP executives and several nephrology key opinion leaders. RIt depends on exactly why the FDA decided not to approve the two companies' growth hormone therapy.OPKO Health (OPK) closed at $3.04 in the latest trading session, marking a -0.65% move from the prior day.;4.679999828338623;;;;9.930000305175781;;5.340000152587891;;37.0099983215332;;35.18000030517578;Investment company Emerald Advisers, Llc (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, HireRight Holdings Corp, Arhaus Inc, sells Chegg Inc, ORIC Pharmaceuticals Inc, BellRing Brands Inc, Trex Co Inc, Arena Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Advisers, Llc.;44.599998474121094;;11.149999618530273;SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat beginning a;15.75;;31.25;;4.809999942779541;;43.41999816894531;;17.639999389648438;;17.459999084472656;;5.050000190734863;;17.299999237060547;;9.399999618530273;;9.5600004196167;;23.450000762939453;;26.530000686645508;Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) shareholders should be happy to see the share price up 12% in the last...;14.680000305175781;;14.09000015258789;;17.0;;19.360000610351562;;12.729999542236328;;15.0;"CAMBRIDGE, Mass. & MONTREAL, February 03, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February. Details are as follows:"
2022-02-04;171.6300048828125;"Westerly, RI, based Investment company New England Professional Planning Group Inc. (Current Portfolio) buys CVS Health Corp, Qualcomm Inc, AMETEK Inc, Cisco Systems Inc, iShares U.S.Johnson & Johnson on Thursday accused attorneys for people who have sued the pharmaceutical giant over its talc products of sharing confidential documents with Reuters in what it called a ""calculated effort"" to try its subsidiary's bankruptcy case in the press.  In a letter filed with the U.S. Bankruptcy Court in New Jersey, attorneys for J&J and LTL Management LLC, a bankrupt subsidiary that the company set up to hold its talc liabilities, claimed that lawyers for two committees representing plaintiffs shared at least two confidential documents with the news organization.  Lawyers for the plaintiffs' committees engaged in a ""calculated effort"" to ""try this case in the press rather than in the court,"" LTL attorney Gregory Gordon said in a court hearing shortly after the letter was filed.Investment company HMS Capital Management, LLC (Current Portfolio) buys PowerShares QQQ Trust Ser 1, WESCO International Inc, Lincoln Electric Holdings Inc, Eagle Materials Inc, Johnson & Johnson, sells Alerian MLP ETF, Cerence Inc, NeoGenomics Inc, Rio Tinto PLC, LHC Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HMS Capital Management, LLC.AmerisourceBergen and McKesson report earnings beats. McKesson stock and AmerisourceBergen stock hit new highs.Dr. Asha Shah, Director of Infectious Diseases at Stamford Health, joins Yahoo Finance Live to discuss the newest Omicron subvariant BA.2 and COVID-19 cases in general.Investment company Miller Howard Investments Inc (Current Portfolio) buys Johnson & Johnson, Snap-on Inc, iShares Select Dividend ETF, Whirlpool Corp, Targa Resources Corp, sells Allstate Corp, Amcor PLC, Sabra Health Care REIT Inc, BP PLC, Cracker Barrel Old Country Store Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Miller Howard Investments Inc .In this article, we discuss 10 dividend ETFs for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 Dividend ETFs for 2022. Investors who seek exposure to dividend stocks and a diversified portfolio often resort to dividend exchange traded funds. In a 2018 interview with CNBC, legendary value […]";53.0;AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.Four drug makers brought in more than $14 billion in sales of COVID-19 treatments in 2021, but the lucrative, new market will be tempered if the virus is kept under control this year.  The tally includes full-year sales of Eli Lilly & Co.’s  (LLY)  monoclonal antibodies ($2.2 billion), Gilead Sciences Inc.’s  (GILD)  COVID-19 antiviral Veklury ($5.5 billion), Merck & Co. Inc.’s  (MRK)  molnupiravir (nearly $1 billion), and Regeneron Pharmaceuticals Inc.’s  (REGN)  monoclonals ($5.8 billion), according to year-end earnings from those companies.Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.Investment company Gainplan LLC (Current Portfolio) buys iShares Russell 1000 Growth ETF, PowerShares QQQ Trust Ser 1, Lightspeed Commerce Inc, Wolfspeed Inc, Grab Holdings Inc, sells iShares Russell 1000 Value ETF, Netflix Inc, Salesforce.com Inc, Unity Software Inc, Snap Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Gainplan LLC.Investment company Advisor OS, LLC (Current Portfolio) buys Distillate U.S. Fundamental Stability & Value ETF, BTC BlackRock Short Maturity Bond ETF, Global X MLP & Energy Infrastructure ETF, Horizon Kinetics Inflation Beneficiaries ETF, VanEck Gold Miners ETF, sells Vanguard FTSE Europe ETF, S&P 500 ETF TRUST ETF, Vanguard Extended Market Index ETF, Vanguard S&P 500 ETF, iShares Cybersecurity and Tech ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment cValneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have reported further Phase 2 data for their Lyme disease vaccine candidate, VLA15. The Phase 2 trial, VLA15-221, compared the immunogenicity of VLA15 after administration of two or three primary series doses. In the sub-analysis of adult participants (18-65 years old), VLA15 was immunogenic with both vaccination schedules tested. These data are consistent with the strong immunogenicity profile observed for this age group in previous Phase 2 sPfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.CROX, PFE, and AAPL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 4, 2022Germany's expert panel on vaccine use has recommended Novavax Inc's (NASDAQ: NVAX) protein-based COVID-19 vaccine for primary immunization for people over 18 years. The advisory group known as STIKO said a booster shot should still be given with an mRNA vaccine, reported Reuters. mRNA technology is behind the two most commonly used COVID-19 vaccines from - Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA). Novavax's COVID-19 vaccine NVX-CoV2373 is a protein-basedHasbro Inc., Pfizer Inc., Twilio Inc., CDW Corp. and Annaly Capital Management Inc are highlighted in this Analyst Blog Article.Investment company Planned Solutions, Inc. (Current Portfolio) buys iShares Barclays GNMA Bond Fund, International Business Machines Corp, Vanguard Information Technology ETF, Nucor Corp, Pfizer Inc, sells Schwab Short-Term U.S.Investment company Guardian Wealth Advisors, LLC (Current Portfolio) buys BTC BlackRock Short Maturity Bond ETF, Pfizer Inc, Genuine Parts Co, Berkshire Hathaway Inc, Dover Corp, sells People's United Financial Inc, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Guardian Wealth Advisors, LLC.Investment company Mattern Capital Management, Llc (Current Portfolio) buys Target Corp, Vanguard Mid-Cap ETF, Pfizer Inc, iShares 0-5 Year TIPS Bond ETF, Tabula Rasa HealthCare Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mattern Capital Management, Llc.Covid-19 drug sales reflect how the rise and fall of the variants behind successive waves of the pandemic have forced changes to treatment approaches.Dr. Asha Shah, Director of Infectious Diseases at Stamford Health, joins Yahoo Finance Live to discuss the newest Omicron subvariant BA.2 and COVID-19 cases in general.In this article, we discuss the 10 best dividend stocks according to Tiger Cub Rob Citrone. You can skip our detailed analysis of Discovery Capital Management, and go directly to read 5 Best Dividend Stocks According to Tiger Cub Rob Citrone. Rob Citrone, also known as the emerging markets specialist, co-founded Discovery Capital Management in […]Dr. Anand Swaminathan, an assistant professor of Emergency Medicine at St Joseph's Regional Medical Center in New Jersey and an emergency medicine physician, joins Yahoo Finance Live to discuss how the U.S. airlines is pushing the White House administration to end international travel test requirements, vaccination rates, and spreading misinformation related to COVID-19.Nassau, C5, based Investment company PICTET BANK & TRUST Ltd (Current Portfolio) buys Alphabet Inc, Zoetis Inc, Amazon.com Inc, Nike Inc, Mastercard Inc, sells Pfizer Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, PICTET BANK & TRUST Ltd.Investment company Merrion Investment Management Co, LLC (Current Portfolio) buys iShares TIPS Bond ETF, ViacomCBS Inc, Canadian National Railway Co, Cheniere Energy Inc, Mondelez International Inc, sells Lockheed Martin Corp, Spirit AeroSystems Holdings Inc, PayPal Holdings Inc, Uber Technologies Inc, Madison Square Garden Sports Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Merrion Investment Management Co, LLC.Investment company Safeguard Investment Advisory Group, LLC (Current Portfolio) buys Dimensional U.S.Just 3 in 10 parents of children under 5 say they’ll get their child vaccinated right away once a COVID-19 vaccine is approved for their age group, according to new survey findings published this month by KFF, a healthcare think tank.  Parents are more willing to get their older children vaccinated: Just 33% of parents of 5- to 11-year-olds say their child has had at least one COVID-19 shot, though that’s up from 16% in November, while 61% of parents of 12- to 17-year-olds said their child had received at least one shot, up from just under 50% in November.  This week, Pfizer  and BioNTech  asked federal regulators to authorize Pfizer’s COVID-19 vaccine for children as young as 6 months.South Africa's Afrigen Biologics has used the publicly available sequence of Moderna Inc's mRNA COVID-19 vaccine to make its own version of the shot, which could be tested in humans before the end of this year, Afrigen's top executive said on Thursday.  It is also the first mRNA vaccine designed, developed and produced at lab scale on the African continent.  The World Health Organization (WHO) last year picked a consortium including Afrigen for a pilot project to give poor and middle-income countries the know-how to make COVID vaccines, after market leaders of the mRNA COVID vaccine, Pfizer, BioNTech and Moderna, declined https://www.reuters.com/world/africa/exclusive-who-backed-vaccine-hub-africa-copy-moderna-covid-19-shot-2021-09-14 a WHO request to share their technology and expertise.;242.27000427246094;AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.The board of Eli Lilly and Company ( NYSE:LLY ) has announced that it will be increasing its dividend on the 10th of...Covid antibodies helped Eli Lilly score a fourth-quarter beat on Thursday, but Eli Lilly stock dipped on a cloudy future for those drugs.Covid-19 drug sales reflect how the rise and fall of the variants behind successive waves of the pandemic have forced changes to treatment approaches.Blue Bell, PA, based Investment company Northstar Asset Management Llc (Current Portfolio) buys PayPal Holdings Inc, Vanguard ESG U.S.Investment company Merrion Investment Management Co, LLC (Current Portfolio) buys iShares TIPS Bond ETF, ViacomCBS Inc, Canadian National Railway Co, Cheniere Energy Inc, Mondelez International Inc, sells Lockheed Martin Corp, Spirit AeroSystems Holdings Inc, PayPal Holdings Inc, Uber Technologies Inc, Madison Square Garden Sports Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Merrion Investment Management Co, LLC.Eli Lilly (LLY) misses earnings estimates in the fourth quarter while revenues beat the same. Stock down in pre-market trading.Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.;99.66999816894531;Bagsværd, Denmark, 4 February 2022 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. Members of Executive Management have participated in a long-term incentive programme consisting of a one-year performance period (2018) and a three-year vesting period (2019-2021). The shares allocated have on 2 February 2;140.64999389648438;AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.Investment company Interchange Capital Partners, LLC (Current Portfolio) buys Vanguard Value ETF, BTC iShares MSCI USA Value Factor ETF, BTC iShares Core MSCI EAFE ETF, iShares Russell 1000 Value ETF, iShares MSCI Intl Quality Factor ETF, sells Apple Inc, PepsiCo Inc, Abbott Laboratories, Microsoft Corp, AbbVie Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Interchange Capital Partners, LLC.Companies that have cut their dividends after a spinoff—including International Paper and Abbott Laboratories—have a history of mixed performance.;86.27999877929688;AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.Investment company Curated Wealth Partners LLC (Current Portfolio) buys Ares Management Corp, iShares Russell 2000 ETF, Boyd Gaming Corp, iShares Russell 1000 Growth ETF, Vanguard S&P 500 ETF, sells Enterprise Products Partners LP, Landstar System Inc, IAA Inc, Novartis AG, First Hawaiian Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Curated Wealth Partners LLC.;78.55999755859375;AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.Investment company Oak Asset Management, LLC (Current Portfolio) buys Science Applications International Corp, Merck Inc, Bristol-Myers Squibb Co, American Campus Communities Inc, Edison International, sells Intuitive Surgical Inc, Microchip Technology Inc, AT&T Inc, Gilead Sciences Inc, Alibaba Group Holding during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Oak Asset Management, LLC.Deepak Khanna, president, Europe and Canada, demonstrates how “diversity is a fact, but inclusion is an act”KENILWORTH, N.J., February 04, 2022--Merck to Participate in the Guggenheim Oncology Conference 2022Honolulu, HI, based Investment company Cadinha & Co Llc (Current Portfolio) buys iShares 20+ Year Treasury Bond ETF, Newmont Corp, Cisco Systems Inc, Goldman Sachs Group Inc, Blackstone Inc, sells iShares 7-10 Year Treasury Bond ETF, Shell PLC, iShares MSCI Japan ETF, Verizon Communications Inc, Amgen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cadinha & Co Llc.Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.;55.720001220703125;Rating Action: Moody's assigns Caa1 rating to Covis' proposed second lien term loanGlobal Credit Research - 04 Feb 2022Upgrades first lien debt instruments to B1 from B2London, 04 February 2022 -- Moody's Investors Service (Moody's) has today assigned a Caa1 rating to the proposed $300 million backed senior secured second lien term loan to be borrowed by Covis Finco S.a r.l.  Parent company Covis Midco 2 S.a r.l., which provides respiratory and critical care drugs, is currently in syndication to refinance its entire capital structure.As a result of changes in the proposed capital structure, Moody's has also upgraded to B1 from B2 Covis' first lien debt instruments, including the backed senior secured first-lien term loan B (upsized to $550 million from $350 million) as well as pari passu ranking $100 million backed senior secured multicurrency revolving credit facility (RCF) and the proposed $350 million equivalent Euro-denominated backed senior secured notes (downsized from previously proposed $375 million).The existing debt ratings of Covis Midco 2 S.a r.l., including its B2 corporate family rating (CFR), are unchanged.ARCH, AZN, and AXTA have been added to the Zacks Rank #5 (Strong Sell) List on February 4, 2022Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the third quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]Montgomery College is ramping up efforts to transform its Germantown campus into a hub for life sciences and tech innovation, with a new executive on board and another project about to break ground.  Montgomery College announced Jan. 26 it had hired Mike Smith, former adviser to Montgomery County Executive Isiah Leggett and a veteran of Lantian Development Co. and LCOR Inc., as the new executive director of the Pinkney Innovation Complex for Science and Technology.  In the role, which Smith started Nov. 18, he's shaping the vision — and growth — at the 40-acre site on the community college's Germantown campus.AstraZeneca plc (NASDAQ: AZN) has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a cardiovascular drug. The drug will enter Phase 2a trials for peripheral artery disease (PAD) in 2H of 2022. Regio will take on all R&D and marketing costs for REG-101, previously known as MEDI5884, with financial backing from Hibiscus Capital Management and Innoforce. The molecule came from Medimmune, a formerly separate division AstraZeneca bought for $15.6 billion in 2007.Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.;64.98999786376953;The stock market reversed higher after the January jobs report came in much hotter than expected and Amazon.com surged on its earnings report.The Dow Jones Industrial Average fell Friday after January's jobs report. Amazon stock soared on earnings results, while Ford Motors dived.Investment company Oak Asset Management, LLC (Current Portfolio) buys Science Applications International Corp, Merck Inc, Bristol-Myers Squibb Co, American Campus Communities Inc, Edison International, sells Intuitive Surgical Inc, Microchip Technology Inc, AT&T Inc, Gilead Sciences Inc, Alibaba Group Holding during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Oak Asset Management, LLC.NEW YORK, February 04, 2022--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021Bristol Myers (BMY) delivered earnings and revenue surprises of 0% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Shares of Bristol Myers Squibb Co. were up 1.1% in premarket trading on Friday after the drug maker beat earnings expectations for the final quarter of the year. Bristol had earnings of $2.4 billion, or $1.07 per share, in the fourth quarter of 2021, after a loss of $10.0 billion, or $4.45 per share, in the same quarter a year ago. Adjusted earnings per share were $1.83, against a FactSet consensus of $1.80. The company reported revenue of $11.9 billion for the quarter, driven by double-digit grSales of the company's top-selling cancer drug Revlimid rose 1% to $3.33 billion in the quarter.  Bristol Myers still expects earnings and sales growth this year.  The company forecast 2022 earnings per share of $7.65 to $7.95 a share.By Peter NurseSolid sales for cancer and blood clot treatments helped Bristol-Myers posted stronger-than-expected fourth quarter earnings Friday.New York, NY, based Investment company Garnet Equity Capital Holdings, Inc. (Current Portfolio) buys Flex, Hertz Global Holdings Inc, Universal Display Corp, Caesars Entertainment Inc, Turning Point Brands Inc, sells ProShares UltraShort S&P500, WillScot Mobile Mini Holdings Corp, Freeport-McMoRan Inc, Bristol-Myers Squibb Co, Ballys Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Garnet Equity Capital Holdings, Inc..;52.08000183105469;"Regeneron (REGN) Q4 earnings beat estimates and sales record strong year-over-year growth on the solid performance of REGEN-COV as well as Eylea and Dupixent.Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.View more earnings on SNYSee more from BenzingaGSK To Get .25B As Settlement For HIV Treatment Drug Patent Row With GileadFDA Approves First Injectable For HIV Pre-Exposure Prevention - GSK, Pfizer Backed Treatment© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.French drugmaker Sanofi said it still expected its COVID-19 vaccine to complete phase 3 trial in the first quarter and reported a rise in fourth-quarter sales and earnings on Friday.  The group, which is hoping for a comeback after losing ground in the COVID-19 jab race, also said it was aiming for an increase in its earnings per share in the ""low double-digit"" in 2022.  For the whole of 2021, its earnings per share rose by 15.5% at constant exchange rates, while the company had guided for a rise of 14%.Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity Paris, February 3, 2022. Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019. Over the last 50 years, Sanofi has grown into a diverse, global healthcare leader, with a rich heritage of patient-centric scientific discovery. This history includes the first treatments for many rare diseases and the";44.79999923706055;GlaxoSmithKline (GSK) closed the most recent trading day at $44.92, moving -1.71% from the previous trading session.Investment company Xcel Wealth Management, LLC (Current Portfolio) buys Affirm Holdings Inc, Bloomin Brands Inc, Skyworks Solutions Inc, The Walt Disney Co, Medtronic PLC, sells AT&T Inc, Barrick Gold Corp, Meta Platforms Inc, Merck Inc, DraftKings Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Xcel Wealth Management, LLC.;14.699999809265137;;39.970001220703125;;15.130000114440918;Viatris Inc. (NASDAQ: VTRS) will host its investor event the morning of Monday, February 28, 2022, beginning at 8:30 a.m. ET.Investment company Summit Wealth & Retirement Planning, Inc. (Current Portfolio) buys JPMorgan Chase, Alaska Air Group Inc, Starbucks Corp, ETFMG Prime Mobile Payments ETF, Victory Capital Holdings Inc, sells VanEck J.P.Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis®. There are no remaining legal or regulatory barriers, and the company is launching immediately.;200.9499969482422;;11.869999885559082;;131.16000366210938;;121.80999755859375;;17.469999313354492;"HAMBURG, GERMANY / ACCESSWIRE / February 4, 2022 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance.Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs th";33.119998931884766;Johnstown, PA, based Investment company First National Trust Co (Current Portfolio) buys Caterpillar Inc, ViacomCBS Inc, Boston Scientific Corp, Fiserv Inc, Tesla Inc, sells Oracle Corp, The Home Depot Inc, Verizon Communications Inc, 3M Co, iShares iBoxx USD Investment Grade Corporate Bond during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First National Trust Co.;41.470001220703125;;18.190000534057617;;26.81999969482422;"HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel selective inhibitor targeting fibroblast growth factor receptors (“FGFR”) 1/2/3, in combination with chemotherapy or the anti-PD-1 therapy, toripalimab. The first patient received their first dose on January 22, 2022. The clinical trial is a m";26.709999084472656;;41.20000076293945;;108.86000061035156;;22.649999618530273;;52.099998474121094;;3.2300000190734863;;4.800000190734863;;;;10.460000038146973;Investment company Northwestern Mutual Investment Management Company, (Current Portfolio) buys iShares iBoxx USD Investment Grade Corporate Bond , Kore Group Holdings Inc, Bruker Corp, Construction Partners Inc, Alcoa Corp, sells iShares Core S&P 500 ETF, iShares iBoxx USD High Yield Corporate Bond ETF, Organogenesis Holdings Inc, FactSet Research Systems Inc, SolarEdge Technologies Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Northwestern;5.389999866485596;;38.11000061035156;;35.560001373291016;;45.29999923706055;;11.449999809265137;;16.1299991607666;;32.33000183105469;;4.599999904632568;"Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.BRIDGEWATER, N.J., February 04, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ""Company"") announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2022.";47.650001525878906;;18.200000762939453;;17.5;;5.130000114440918;;17.75;;9.970000267028809;;9.5;;24.270000457763672;;26.440000534057617;Investment company Act Capital Management, Llc (Current Portfolio) buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, AirSculpt Technologies Inc, enVVeno Medical Corp, sells , Upstart Holdings Inc, Affirm Holdings Inc, Nektar Therapeutics, Nuance Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Act Capital Management, Llc.;14.8100004196167;;13.739999771118164;;17.139999389648438;MOUNTAIN VIEW, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the Guggenheim 2022 Oncology Conference on Thursday, February 10, 2022 at 1:00 p.m. EST. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’;18.010000228881836;;13.149999618530273;;14.600000381469727;
2022-02-28;164.57000732421875;;46.939998626708984;;249.9499969482422;;102.94999694824219;The Procter & Gamble Co., Chevron Corp., Novo Nordisk A/S, FedEx Corp. and Palo Alto Networks, Inc are highlighted in this Analyst Blog.;147.77000427246094;;87.45999908447266;;76.58000183105469;;60.880001068115234;;68.66999816894531;;52.45000076293945;;41.86000061035156;"GlaxoSmithKline Plc (NYSE: GSK) has halted enrollment and vaccination in three trials of its experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women. Last week, GSK paused a late-stage trial, dubbed ""GRACE,"" as well as two other studies based on safety recommendations from an independent committee. The Company said that further analysis is ongoing to understand safety data better. Also See: Glaxo's Q4 Pharma Sales Jump 20% Boosted By COVID-19 Treatment; Prepares ForHaleon, which makes brands including Sensodyne toothpaste, expects annual sales growth of between 4% and 6% in 2022.In this article, we will discuss the 15 most valuable UK companies in the world. You can skip our detailed analysis of these companies, and go directly to 5 Most Valuable UK Companies in the World. According to McKinsey’s Facing the future: Britain’s new industrial revolution report in May 2021, the UK’s economy is approaching […]";15.199999809265137;OSAKA, Japan & CAMBRIDGE, Mass., February 28, 2022--AAAAI Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients;39.2599983215332;;11.010000228881836;Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.Viatris (VTRS) delivered earnings and revenue surprises of -2.44% and 0.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?In the transaction, Viatris (Nasdaq: VTRS) will get a 13% ownership stake in Biocon and a seat on its board for $2 billion in cash and $1 billion in equity.Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd. for up to $3.335 billion. The company said the move is the first in a planned series of asset sales that could generate pretax proceeds of up to $6 billion by the end of 2023, as it moves to reshape its business. Under the terms of the deal, Viatris will receive $2 billion in cash upfront, and $1 billViatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment.  The proposed settlement would resolve litigation that began following public outrage in 2016 over Mylan's decision to raise the list price for a pair of EpiPen to $600 from $100 in 2008, fueling a debate about rising U.S. drug costs.  The lawsuit accused Mylan and Pfizer, which manufactured the EpiPen, of engaging in wide-ranging anticompetitive conduct that allowed them to maintain a monopoly over the market for the devices.(Reuters) -Viatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment.  The proposed settlement would resolve litigation that began following public outrage in 2016 over Mylan's decision to raise the list price for a pair of EpiPen to $600 from $100 in 2008, fueling a debate about rising U.S. drug costs.  The lawsuit accused Mylan and Pfizer, which manufactured the EpiPen, of engaging in wide-ranging anticompetitive conduct that allowed them to maintain a monopoly over the market for the devices.Wall Street thinks all three of these stocks could jump by double-digit percentages over the next 12 months.;196.6999969482422;;12.359999656677246;;118.70999908447266;Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.;112.38999938964844;;14.670000076293945;;37.33000183105469;;39.59000015258789;;16.81999969482422;;27.25;;26.469999313354492;;42.529998779296875;;105.0;;24.719999313354492;;56.59000015258789;;3.130000114440918;;3.0199999809265137;;;;10.239999771118164;;6.840000152587891;;39.959999084472656;Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 96.88% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?WAKIX® (pitolisant) Net Revenue Increased 62% Year-over-Year to $91.2 Million for Fourth Quarter 2021 and 91% to $305.4 Million for Full Year Achieved First Full Year of Profitability and Net income was $22.7 Million for the Fourth Quarter 2021 Average Number of Patients on WAKIX Increased to ~3,800 On Track to Initiate the Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia First Half of This Year Year-End 2021 Cash and Cash Equivalents of Approximately $234 Million Conference Call a;31.65999984741211;;41.380001068115234;;12.399999618530273;;16.700000762939453;;33.7400016784668;;4.53000020980835;;53.70000076293945;;16.170000076293945;;20.020000457763672;"SAN DIEGO and NAGOYA, Japan, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, and Sanwa Kagaku Kenkyusho Co., Ltd. (""Sanwa""), an established, fully integrated pharmaceutical company headquartered in Nagoya, Japan, today announced that the parties have entered into a strategic partnersh";5.739999771118164;;16.5;;8.920000076293945;;9.069999694824219;;23.969999313354492;;32.7400016784668;"By Sam BougheddaReata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?PLANO, Texas, February 28, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced financial results for the quarter and full year ended on December 31, 2021 and provided an update on the Company’s business operations and clinical development programs.The FDA has issued a Complete Response Letter (CRL) regarding Reata Pharmaceuticals Inc's (NASDAQ: RETA) application seeking approval for bardoxolone methyl for chronic kidney disease (CKD) caused by Alport syndrome. The agency concluded that it does not believe the submitted data demonstrates that bardoxolone effectively slows the loss of kidney function and reduces the risk of progression to kidney failure. The FDA has requested additional data to support the efficacy and safety of bardoxolone";17.799999237060547;;13.65999984741211;;16.68000030517578;;15.470000267028809;;13.100000381469727;"PRAX-114 Phase 2/3 monotherapy MDD Aria Study topline results expected in June 2022 PRAX-944 Phase 2a ET topline results expected in May 2022; to include open-label and placebo-controlled withdrawal data PRAX-222 seamless study in SCN2A-DEE expected to initiate in 2Q22 Cash and investments of $275.9 million as of December 31, 2021 supports runway into 2Q23 BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company transla";16.06999969482422;
2022-03-01;164.0;;45.75;;249.5;;103.5999984741211;Bagsværd, Denmark, 28 February 2022 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following were elected for the next four years: Elisabeth Dahl Christensen (newly elected)Liselotte Hyveled (newly elected)Mette Bøjer Jensen (re-elected)Thomas Rantzau (re-elected) As substitutes for the employee-elected board members, the following were elected: Anders KaaeKarina Bonde LenauJesper ThorningTanja Villum;147.69000244140625;;87.12000274658203;;76.33999633789062;;61.34000015258789;;68.62999725341797;;51.060001373291016;;41.54999923706055;With a gargantuan market cap in excess of $104 billion, GlaxoSmithKline (NYSE: GSK) is one of the world's biggest pharma players.  Then, it buys the property from the companies for cash, at which point it leases out the space to the prior owner.;15.0600004196167;;38.790000915527344;;10.149999618530273;Companies In The News Are: JLL, TGNA, XRAY, VTRS.The following are the top stories on the New York Times business pages.  - World's largest automaker Toyota Motor Corp. said on Tuesday that it would restart production in Japan after a cyber attack at a major supplier had forced the company to shut down its domestic production.  - Viatris Inc, the drugmaker previously known as Mylan, announced on Monday that it had agreed to pay $264 million to settle a class-action lawsuit that alleged the company was involved in an illegal scheme to monopolize the market for epinephrine auto-injector devices known as EpiPens, which are used to treat severe allergic reactions.Announcement: Moody's: Viatris' biosimilars transaction is credit positive but tempered by core earnings pressure and ongoing cash outlaysGlobal Credit Research - 28 Feb 2022New York, February 28, 2022 -- Moody's Investors Service commented that Viatris Inc.'s formation of a biosimilars partnership with Biocon Limited is credit positive for Viatris, based on a substantial cash inflow of $2 billion that will facilitate debt reduction.  There is no impact on Viatris' Baa3 senior unsecured rating or stable outlook.For additional information please see Moody's Issuer Comment on Viatris Inc. available on www.moodys.com.Please see www.moodys.com for any updates on changes to the lead rating analyst and to the Moody's legal entity that has issued the rating.This publication does not announce a credit rating action.Viatris stock tumbled Monday after reporting earnings and a plan to sell its biosimilars portfolio to Biocon Biologics. The deal closes later this year.In this article, we take a look at some of the notable stocks that are moving today. You can skip our detailed analysis of these stocks and go directly to Why These 5 Stocks Are Moving on Monday. All three major indexes are in the red today, with the S&P 500 down 1.10%, the Dow […]Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its business following a strategic review.Shares of Viatris (NASDAQ: VTRS), the biopharmaceutical company behind the Epi-Pen and Lipitor, are falling in response to the company's fourth-quarter earnings call.  The average investment bank analyst following Viatris expected a $0.23 per share profit in the fourth quarter.  The average analyst who follows Viatris expected the company to forecast $17.6 billion.Terms include $2 billion in cash up front, plus up to $335 million in additional cash payments to be paid in 2024, and $1 billion in convertible preferred equity that will give Viatris a 12.9% stake in Biocon Biologics.Canonsburg-based pharmaceutical company expects to sell between $4B and $6B more in noncore assets between now and 2023.;194.05999755859375;;12.329999923706055;;114.01000213623047;;108.83000183105469;;14.479999542236328;The nephrotic syndrome is a group of symptoms like proteinuria and oedema that indicate kidneys are not working properly. Diagnosis remains challenging and current treatment regimens are mostly symptomatic.;37.459999084472656;JERSEY CITY, N.J., March 01, 2022--Meghan Rivera Appointed US Managing Director, Organon;38.04999923706055;"Shares of Legend Biotech Corp. were up 8.6% in premarket trading on Tuesday, the day after the company said that the Food and Drug Administration had approved the CAR-T therapy it developed with Johnson & Johnson as a multiple myeloma treatment. J&J's stock was down 0.8% in premarket trading on Tuesday. Legend had inked the licensing and collaboration deal with J back in 2017. The treatment is approved for adults with relapsed or refractory multiple myeloma who have already received four lines oThe FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory multiple myeloma. The approval covers adult patients who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Johnson & Johnson's (NYSE: JNJ) Janssen BioteSOMERSET, N.J., March 01, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its first product, CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received four or more prior lines of therapThe U.S. health regulator has approved a therapy developed by Johnson & Johnson and its China-focused partner Legend Biotech Corp to treat a type of white blood cell cancer, the U.S. healthcare company said on Monday.  The Food and Drug Administration's decision paves the way for Legend's first approved product in the United States, at a time when the regulator has stepped up its scrutiny of drug trials conducted in China.  The Legend-J&J therapy was tested initially in China, and then in the United States and Japan.";16.579999923706055;* The RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics * CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer(R) * Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbHTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 1, 2022/ CureVac N.;27.989999771118164;"First homegrown innovative medicine approved in Macau based on China clinical dataHONG KONG and FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received approval to market fruquintinib (ELUNATE® in China), a selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) 1, 2 and 3, in the Macau Special Administrative Region. The approval follows the latest update to";28.3700008392334;Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Multiple late-stage clinical readouts expected in the next 18 months Conference call today at 8:00 AM EST CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases,;44.7400016784668;"Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -21.97% and 607.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Generated $15.1 million in full year 2021 EMPAVELI® (pegcetacoplan) net product revenues; demonstrated strong initial launch in U.S. and additional approvals granted worldwide On track to submit NDA for intravitreal pegcetacoplan in geographic atrophy in 2Q 2022, following Phase 3 DERBY and OAKS results and completion of recent pre-NDA meetingAdvanced broader pipeline, including four late-stage programs with systemic pegcetacoplan and three pre-clinical programsConference call scheduled today at";109.25;;26.360000610351562;In this article, we present the list of billionaire Ray Dalio’s top 10 small-cap stock picks. You can skip our comprehensive analysis of Bridgewater Associates’ history, investment philosophy, and hedge fund performance and go directly to Billionaire Ray Dalio’s Top 5 Small-Cap Stock Picks. Billionaire Ray Dalio is the co-chief investment officer of Bridgewater Associates, […];53.20000076293945;;3.0899999141693115;Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), to assist in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD) who may be eligible to participate in a Phase 3 clinical trial. PDCD affects less than 300 children in the UnitOPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.;2.940000057220459;;;;10.979999542236328;In this article, we look at why billionaire Stanley Druckenmiller just dumped 10 stocks from his portfolio. You can skip our comprehensive analysis of Duquesne Capital’s history, investment philosophy, and hedge fund performance and go directly to Billionaire Stanley Druckenmiller Just Dumped These 5 Stocks. Meta Platforms, Inc. (NASDAQ:FB), Moderna, Inc. (NASDAQ:MRNA), and Zoom Video […]Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.Nektar (NKTR) delivered earnings and revenue surprises of 2.47% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021.;6.550000190734863;;40.060001373291016;Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences fourth quarter and full year 2021 financial performance and provide a business update.  Before we start, I encourage everyone to go to the Investors section of the Harmony Biosciences website to find the press release and slides that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures.;30.790000915527344;On Track for TRIDENT-1 ROS1+ NSCLC Topline Data Disclosure and Pre-NDA Meeting Anticipated 2Q 2022Eighth Regulatory Designation Granted for Repotrectinib with Breakthrough Therapy Designation in ChinaOther Clinical and Preclinical Programs Continue to AdvanceCash, Cash Equivalents, and Marketable Securities of approximately $982 Million as of December 31, 2021, Expected to Fund Current Operations into Second Half of 2024 SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, In;41.529998779296875;;12.119999885559082;;16.559999465942383;LAUSANNE, Switzerland, March 01, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, DPhil, Chief Executive Officer, will participate in a fireside chat at Cowen’s virtual 42nd Annual Health Care Conference on Tuesday, March 8th at 2:10 p.m. EST.;31.600000381469727;Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 20.29% and 1.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?BILLERICA, Mass., March 01, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its executive leadership succession plan designed to leverage the Company’s strong foundation for growth. Effective April 25, 2022, Chairman and Chief Executive Officer Kevin Hrusovsky will become Executive Chairman of the Board and President Masoud Toloue will succeed Hrusovsky as CEO and join Quanterix’ BoardBILLERICA, Mass., March 01, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the fourth quarter and twelve months ending December 31, 2021.BILLERICA, Mass., March 01, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a collaboration with Eli Lilly and Company (Lilly) to advance the diagnosis, monitoring and treatment of Alzheimer’s disease. As part of the collaboration, Quanterix will receive a non-exclusive, world-wide license to Lilly’s proprietary P-tau217 antibody technology for potential near-term use in research uBILLERICA, Mass., February 28, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized by leading workplace culture and corporate brand reputation platform, Comparably, in its 2021 Best Places to Work Awards. Based on more than 1,000 ratings and 40 participants within Quanterix, the company amassed awards in the following five categories: Best Company for Diversity, Best;4.449999809265137;;53.529998779296875;;15.529999732971191;;19.56999969482422;SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of James Hassard as chief commercial officer. Mr. Hassard is a commercial leader with more than three decades of experience leading sales and marketing operations for both global and domestic b;5.800000190734863;;16.3799991607666;;8.789999961853027;;8.899999618530273;;22.079999923706055;Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, February 28, 2022--Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress;33.22999954223633;Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.;17.5;;13.319999694824219;SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7 at 2:50 p.m. ET. A live audio webcast of the discussion will be available by visiting the Events & Pres;17.0;;14.970000267028809;;13.079999923706055;BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the “Neuropsych” panel at Cowen’s 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 9:10 a.m. ET. The panel will be available via live w;16.059999465942383;Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-03-02;166.0399932861328;;47.70000076293945;;254.1699981689453;;104.66999816894531;"Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pharmaceutical industry trade group Tuesday about what they said were ""troubling price increases for brand name drugs"" in January.  A letter to Stephen Ubl, president of the Pharmaceutical Research and Manufacturers of America (PhRMA), was signed by 12 Democrats as well as Senator Bernie Sanders, an independent.  It asks PhRMA to explain the source of the price increases, and asks for information about research costs and revenue from the medicines.Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pharmaceutical industry trade group on Tuesday about what they said were ""troubling price increases for brand name drugs"" in January.  A letter to Stephen Ubl, president of the Pharmaceutical Research and Manufacturers of America (PhRMA) was signed by 12 Democrats as well as Senator Bernie Sanders, an independent.";149.57000732421875;;87.68000030517578;;76.66999816894531;;62.0;;68.8499984741211;;51.060001373291016;"Shares of Adagene Inc. jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi that is worth up to $2.5 billion. U.S.-listed shares of Sanofi were down 1.5%. Adagene will develop masked versions of up to four of Sanofi's antibodies in development. Per the terms of the deal, Sanofi will pay Adadene $17.5 million now; however, the milestone payments are worth up to $2.5 billion, and the company is eligible for royalties based on sales ofDenali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.";42.029998779296875;;15.100000381469727;A former head at Takeda's Center for External Innovation and a researcher at the Dana-Farber Cancer Institute have joined forces to launch NextRNA Therapeutics, a startup that aims to harness the potential of non-coding RNAs to make cancer and immunology drugs.Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.;39.189998626708984;;10.479999542236328;Viatris Inc. (NASDAQ: VTRS) today announced the company will participate in the following investor conferences:;195.00999450683594;;12.729999542236328;"Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the health and well-being of people, today announced it is partnering with Feeding America, the nation's largest domestic hunger-relief organization, to help ""box out hunger"" by collecting nonperishable food and raising money for local member food banks across the country.";118.7699966430664;;106.4800033569336;;14.40999984741211;an increasing rate of approvals in the long-run.To leverage the power of molecular data, Evotec is launching E.;39.36000061035156;JERSEY CITY, N.J., March 02, 2022--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022 at 9:10 a.m. EST.;37.61000061035156;;16.809999465942383;;26.190000534057617;;30.200000762939453;;46.40999984741211;WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences in March: Cowen 42nd Annual Health Care Conference: Fireside chat on Wednesday, March 9, 2022 at 12:50 p.m. ET.Oppenheimer 32nd Annual Healthcare Conference: Fireside chat on Wednesday, March 16, 2022 at 12:40 p.m. ET. The conference events will be avail;106.69000244140625;;25.690000534057617;;55.54999923706055;;3.190000057220459;;2.799999952316284;CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that management will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 12:50 p.m. ET. A live and archived webcast of the fireside chat will be available by visiting the Events & Presentations section of EQRx’s;;;10.75;;6.460000038146973;CULVER CITY, Calif., March 02, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced study results that further demonstrate the potential for use of memory-like cytokine-enriched natural killer (m-ceNK) cells for the treatment of cancer. ImmunityBio has successfully scaled the process of generating over 20 billion m-ceNK cells from a single extraction of white blood cells from a donor or patient, and reports promising clinical data supporting the ongoing;40.560001373291016;;30.1200008392334;SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference. Dr. Countouriotis’ session is scheduled to take place on Tuesday, March 8 from 11:10 a.m. to 11:40 a.m. ET. The session will be accessible via webcas;43.560001373291016;It is hard to get excited after looking at Emergent BioSolutions' (NYSE:EBS) recent performance, when its stock has...;12.479999542236328;"Strong Origination Volumes Drive SLRC to its Target Leverage Range; Declares Quarterly Distribution of $0.41 Per Share for Q1, 2022 NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the “Company” or “SLRC”) today reported net investment income of $14.9 million, or $0.35 per share, for the fourth quarter of 2021. For the fiscal year ended December 31, 2021, the Company reported net investment income of $60.9 million, or $1.44 per share. At December 31, 2021, net as";16.219999313354492;;32.709999084472656;;4.019999980926514;"Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?BRIDGEWATER, N.J., March 02, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") announced its results today for the fourth quarter and full year ended December 31, 2021.BRIDGEWATER, N.J., March 01, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®. The product will be marketed under the proprietary name RELEUKOTM.";51.97999954223633;;15.130000114440918;;19.809999465942383;;5.650000095367432;;16.6200008392334;;8.800000190734863;;9.260000228881836;;22.010000228881836;Arcturus Therapeutics (NASDAQ: ARCT) and Moderna (NASDAQ: MRNA) have more than a couple of things in common.  Both companies are biotechs that develop mRNA-based medicines, and both stocks soared over the past two years on optimism about their coronavirus vaccine candidates.  While it was ultimately Moderna that succeeded in bringing its product to the market, Arcturus is still working on its entry, not to mention a handful of other projects.;32.79999923706055;;18.299999237060547;WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference. Details for the company’s participation are as follows: Cowen 42nd Annual Health Care Conference (Virtual)Fireside Chat Date: Monday, March 7, 2022Fireside Chat Time: 2:50 p.m. EST Webcasts for;13.5;;17.030000686645508;;14.649999618530273;;13.050000190734863;;16.1299991607666;"Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.67% and 94.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass. & MONTREAL, March 01, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021."
2022-03-03;168.47999572753906;;47.83000183105469;;258.6400146484375;Eli Lilly and Incyte's arthritis drug baricitinib helped reduce the risk of death in hospitalised COVID-19 patients by 13% regardless of which other coronavirus treatment they were given, according to a large British study.  Over 8,000 patients were administered baricitinib in addition to usual care, at random, or usual care alone, as part of the so-called RECOVERY trial, scientists from the University of Oxford said on Thursday.  Results showed 546 patients in the usual care group died within 28 days but only 513 patients in the baricitinib group died where they were also given a corticosteroid like dexamethasone, tocilizumab or remdesivir.;104.2699966430664;Danish drugmaker Novo Nordisk has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.  Novo Nordisk now aims to generate annual obesity drug sales of more than 25 billion Danish crowns ($3.72 billion) by 2025, the company said at its capital markets day on Thursday.  Novo Nordisk was overwhelmed by initial demand for Wegovy, leading to supply shortages.Non-profit drugmaker Civica said on Thursday it expects to launch lower-cost versions of insulin in the United States by 2024, to help diabetic patients struggling with high prices for the life-sustaining medicine.  Civica, launched in 2018 to make generic drugs, said it would produce three copycat versions of insulin, and make them available at roughly the same price for all customers, once approved by U.S. health regulators.  The company's products, which would be available as both vials and pre-filled pens, are biosmilars to Sanofi SA's Lantus, Eli Lilly and Co's Humalog and Novo Nordisk's Novolog.Bagsværd, Denmark, 3 March 2022 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025. The Strategic Aspirations 2025 were introduced in 2019 to reflect the broad aspects of Novo Nordisk’s business including purpose and sustainability (ESG), the sustained growth opportunities until 2025 across therapy areas and geographies as well as future growth drivers of Novo Nordisk in the research and development pipelWestern drugmakers and medical device companies warn their plans to keep selling products to Russia may be complicated by economic sanctions targeting the country and its major banks in punishment over Moscow's invasion of Ukraine.  Sanctions levied by the United States, Britain, Europe and Canada against Russia do not apply to medicine and medical equipment, and the industry has a responsibility under international humanitarian law to continue supplying these products, industry trade groups, policy experts and company officials said.;150.41000366210938;;86.13999938964844;;77.1500015258789;;60.06999969482422;;69.11000061035156;;50.18000030517578;AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory syncytial virus (RSV). The data showed that a single dose of nirsevimab met the primary efficacy endpoint reducing the incidence of medically attended lower respiratory tract infections caused by RSV by 74.5% compared to placebo. The trial also evaluated nirsevimab in infants with congenital heart disease, chronic lung disease, and prematurity.Non-profit drugmaker Civica said on Thursday it expects to launch lower-cost versions of insulin in the United States by 2024, to help diabetic patients struggling with high prices for the life-sustaining medicine.  Civica, launched in 2018 to make generic drugs, said it would produce three copycat versions of insulin, and make them available at roughly the same price for all customers, once approved by U.S. health regulators.  The company's products, which would be available as both vials and pre-filled pens, are biosmilars to Sanofi SA's Lantus, Eli Lilly and Co's Humalog and Novo Nordisk's Novolog.Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy infants1,2Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dosePivotal Phase 3 results published in The New England Journal of Medicine Paris, March 3, 2022. The New England Journal of Medicine (NEJM) today published detailed;41.45000076293945;The respiratory syncytial virus, which is common, causes mild symptoms in healthy adults, but can lead to life-threatening disease in infants.;15.029999732971191;;38.5;NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buy;10.40999984741211;In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedrop treatment.  Since Viatris launched the drug in the U.S. immediately after the FDA approval, let's dig into what it could mean for patients and how much a boost the news could be for the pharma stock.  Dry eye disease is a condition characterized by either a lack of tear production or tears not working correctly that can lead to eye redness, a stinging or burning sensation in the eyes, watery eyes, and sensitivity to light.In this week's episode of Motley Fool Money, Motley Fool analyst Olivia Zitkus and Motley Fool contributor Keith Speights, along with host Chris Hill, discuss a new wave of biosimilar drugs and the challenges (and opportunities for investors) that they present.  Shopify's (NYSE: SHOP) strong growth in 2021 being followed by an expectation for slightly less growth in 2022.;188.80999755859375;;11.770000457763672;;115.81999969482422;;105.5199966430664;Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.- Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter - Demand for SKYTROFA® (lonapegsomatropin-tcgd), the only FDA-approved once-weekly somatropin, continues to grow in the U.S. - Conference call today at 4:30 pm ET COPENHAGEN, Denmark, March 02, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the full year;14.289999961853027;;39.02000045776367;;36.130001068115234;;16.010000228881836;;24.3700008392334;"HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces: (a) the retirement of Mr. Christian Hogg after almost 22 years with the Company, including 15 years as Executive Director and Chief Executive Officer (“CEO”); and(b) the appointment of Dr. Weiguo Su, who has been with the Company for about 17 years, including about 10 years as Chief Scientific Officer (“CSO”) and almost five years asOncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE® growth and the 2021 launches of SULANDA® and ORPATHYS®; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS® in lung cancer, kidney and gastric cancer during 2021; Broad late-stage development program – currently enrolling 13 registration studies on 6 assets – with enrollment on the 691 patient FRESCO-2 global Phase III of fruquintinib now complete. Company to Host Annual Results Ca";29.350000381469727;;44.18000030517578;;102.44000244140625;;22.790000915527344;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for TJ-CD4B, a novel Claudin 18.2 x 4-1BB bispecific antibody, for the treatment of gastric cancer including cancer of gastroesophageal junction.";54.060001373291016;;3.1500000953674316;;2.880000114440918;;;;10.600000381469727;;6.25;;41.63999938964844;;27.6200008392334;;41.9900016784668;;11.90999984741211;;14.770000457763672;ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?LAUSANNE, Switzerland, March 03, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided business updates.;31.510000228881836;The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.;4.139999866485596;;49.84000015258789;;14.130000114440918;;18.90999984741211;;5.559999942779541;;16.6200008392334;;8.180000305175781;;9.5600004196167;;20.350000381469727;;31.030000686645508;;17.670000076293945;;12.8100004196167;;15.460000038146973;;13.75;Company announcement – No. 6 / 2022 Zealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021 Copenhagen, DK and Boston, MA, U.S. March 3, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that it will host a conference call on March 10, 2022 at 4 pm CET (10 am ET) following the announcement of results f;12.84000015258789;;14.970000267028809;
2022-03-04;169.47999572753906;;48.650001525878906;;262.8699951171875;A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. and Incyte Corp. , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The newMerck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 15, 2022. Patrik Jonsson, Lilly senior vice president, president of Lilly Immunology and Lilly USA, and chief customer officer, will participate in a fireside chat at 10:15 a.m., Eastern time.According to a British study, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients in the standard of care group died within 28 days, compared to 513 patients in the baricitinib group who died where they were also given;104.11000061035156;;150.55999755859375;;84.73999786376953;"Shareholders approve 25th consecutive dividend increase to CHF 3.10 (+3.3%) per share for 2021; representing a 3.9% yield1 and approximately 57% payout of free cash flowShareholders confirm Dr. Joerg Reinhardt as Chair of the Board of Directors as well as all other members who stood for re-election; Ms. Ana de Pro Gonzalo and Mr. Daniel Hochstrasser newly elected to the Board of DirectorsShareholders elect KPMG AG as statutory auditor and approve all other proposals of the Board of Directors, in";77.83000183105469;;57.470001220703125;;69.36000061035156;;48.47999954223633;Experts predict 40,000 more jobs coming to the state's life sciences industry. Here's how companies are trying to fill them.;40.18000030517578;Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.Microsoft, SpaceX, Airbnb and GlaxoSmithKline are among the businesses helping the country fend off cyberattacks, supplying painkillers and providing internet service during Russia’s assault.Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.;15.050000190734863;;38.41999816894531;;10.199999809265137;;178.8000030517578;;11.170000076293945;;113.0999984741211;;104.52999877929688;;13.5;;38.81999969482422;;35.279998779296875;;15.789999961853027;;21.56999969482422;;28.3799991607666;;43.5099983215332;;98.9000015258789;;21.149999618530273;;49.68000030517578;;3.059999942779541;OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -1.25% move from the prior day.;3.0899999141693115;;;;10.5;Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.;6.090000152587891;;40.2400016784668;;27.56999969482422;;41.59000015258789;;11.289999961853027;;14.079999923706055;"This morning, we issued a press release announcing our fourth quarter and year-end 2021 financial results and business update.  On today's call, Chris Martin, chief executive officer; Jennifer Herron, chief commercial officer; Joe Camardo, chief medical officer; and Jenn Creel, chief financial officer, will discuss recent business highlights and review our fourth quarter and full year 2021 financial results before opening the call for questions.";29.709999084472656;BILLERICA, Mass., March 03, 2022--Quanterix to Participate in The Cowen 42nd Annual Health Care Conference On March 9;4.039999961853027;;49.099998474121094;;13.729999542236328;;18.34000015258789;;5.119999885559082;;15.479999542236328;;7.699999809265137;;9.449999809265137;;18.850000381469727;;32.15999984741211;;16.790000915527344;;11.970000267028809;;15.680000305175781;;13.029999732971191;;12.770000457763672;;14.420000076293945;Investors can approximate the average market return by buying an index fund. While individual stocks can be big...
2022-03-07;172.2100067138672;;47.97999954223633;;261.6400146484375;Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted shareFY 2021 net loss was $(0.66) per basic and diluted share and adjusted non-GAAP net income* was $2.64 per basic and $2.59 per diluted shareEarly trends1 indicate that Q1 2022 revenue is expected to be in the range of $120 million - $130 million and adjusted non-GAAP earnings per share* in the range of $3.80 - $4.10Commenced shipment of vasopressin, a generic al;100.8499984741211;LRT Capital Management, an investment management firm, published its fourth-quarter 2021 investor letter – a copy of which can be downloaded here. A return of +30.47% was recorded by the LRT Economic Moat strategy year-to-date, putting its 24-month return to +4.34%. Spare some time to check the fund’s top 5 holdings to have a clue […];149.4499969482422;;83.54000091552734;;77.7300033569336;;56.5;"Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:​AZN). This milestone has been triggered by the initiation of start-up activities for SAFFRON, the first global Phase III study for ORPATHYS® in combination with TAGRISSO® in epidermal growth factor receptor (“EGFR”)-mutated non-small cell lung cancer (";68.7699966430664;The pharma major has a strong drug portfolio and is on track for a steady 2022The weekly OBV line is acting as a leading indicator as it has broken out to a new high ahead of prices.  In this daily Point and Figure chart of BMY, below, we can see that prices made a new high for the move up to refresh the uptrend.In this article, we discuss 10 safe dividend stocks to buy today. If you want to skip our detailed analysis of what constitutes a safe dividend stock, as well as the first five stocks on our list, then go directly to 5 Safe Dividend Stocks to Buy Today. Many companies have a long history of […];48.59000015258789;By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Since Our Last Update Since our last update , DarioHealth Corp. (NASDAQ:DRIO) has shared several new announcements with investors. These material events include adding seven new contracts in 2022, raising $40 million in proceeds from a direct offering and closing a $30 million agreement with Sanofi. Highlights since our last;39.459999084472656;In this article, we discuss the best high dividend stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best High Dividend Stocks to Buy Now. Global dividends soared 14.7% on an underlying basis last year, reaching a new high of $1.47 trillion, following the COVID-19 […]WARREN, N.J., March 07, 2022--Natean®, a new eco-conscious oral healthcare brand offers four nature-inspired toothpastes that deliver essential oral care benefits;14.819999694824219;;37.9900016784668;;9.880000114440918;With shares of the generic medication manufacturer Viatris (NASDAQ: VTRS) collapsing by around 28% in the last five days after its weak fourth-quarter earnings report, I don't blame anyone who's looking for the door.  It's still possible that the stock could be worth holding in the long term, but for now, shareholders aren't experiencing any deficit of reasons to sell, so let's look at the three most important ones.  The biggest reason to consider selling Viatris stock right now is that revenue growth failed to materialize in 2021.;163.66000366210938;Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly net return of 2.86% was recorded by the fund for the fourth quarter of 2021, beating its Benchmark, the MSCI All Country World Small Cap Index, […]LRT Capital Management, an investment management firm, published its fourth-quarter 2021 investor letter – a copy of which can be downloaded here. A return of +30.47% was recorded by the LRT Economic Moat strategy year-to-date, putting its 24-month return to +4.34%. Spare some time to check the fund’s top 5 holdings to have a clue […];11.289999961853027;;115.16999816894531;;105.55999755859375;;13.119999885559082;;38.41999816894531;;34.25;;14.729999542236328;;18.709999084472656;"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:​AZN). This milestone has been triggered by the initiation of start-up activities for SAFFRON, the first global Phase III study for ORPATHYS® in combination with TAGRISSO® in epidermal growth factor receptor (“EGFR”)-mutated non-small cell lung cancer (";28.920000076293945;;42.709999084472656;;99.3499984741211;;20.90999984741211;;53.060001373291016;;3.119999885559082;;3.059999942779541;;;;10.119999885559082;;5.909999847412109;;43.2599983215332;;25.0;;41.16999816894531;;11.579999923706055;;14.0;;27.65999984741211;;3.9000000953674316;;50.08000183105469;;13.75;;18.360000610351562;;4.96999979019165;;15.710000038146973;;7.449999809265137;BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that Antoine Yver, MD, MSc, has been appointed Executive Vice President and Chairman of Development. In this newly created role reporting to the CEO, Dr. Yver will be accountable for the Company’s overall develop;8.930000305175781;;17.8799991607666;;31.270000457763672;;16.510000228881836;;12.229999542236328;Initial data from pivotal FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022 Targeted enrollment achieved in pivotal FIREFLY-1 study Topline results from pivotal FIREFLY-1 study expected in Q1 2023 Current cash provides runway into 2024 and through multiple expected key clinical milestones SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing ta;15.6899995803833;;12.831999778747559;;13.420000076293945;;14.350000381469727;"CAMBRIDGE, Mass. & MONTREAL, March 07, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500 at the 2022 ESMO Targeted Anticancer Therapies (TAT) Congress."
2022-03-08;168.72000122070312;;47.439998626708984;;259.92999267578125;;102.30999755859375;;147.14999389648438;AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and NVIDIA Corporation (NVDA).COPENHAGEN, Denmark, March 08, 2022--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20), for the treatment of follicular lymphoma (FL). Epcoritamab is being co-developed by Genmab and AbbVie (NYSE: ABBV).;80.11000061035156;Voyager Therapeutics Inc.'s stock gained 16.8% in premarket trading on Tuesday after the gene therapy company said it inked a deal with Novartis [n: nvs] worth up to $1.7 billion. Novartis will pay $54 million upfront to license Voyager's novel adeno-associated virus (AAV) capsids for use with the gene therapies it's developing. There are several additional milestones included in the deal that would bring the total value up to $1.7 billion. Voyager's stock is down 28.5% over the past year, whileNovartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene therapies for neurological diseases, with an option to access capsids for two other targets. Data suggest that AAV capsids emerging from Voyager's TRACER platform (Tropism Redirection of AAV by Cell type-specific Expression of RNA) may show broad and improved distribution to neurons in the cortex and deeper brain regions. Voyager will receive $54License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets Novartis agreement marks second recent major transaction to leverage Voyager’s TRACER technology following October 2021 Pfizer agreement Strengthened leadership with appointment of Al Sandrock, Jr., M.D., Ph.D., to Board of Directors and Board Executive Committee, promotion of Robin Swartz to ch;76.94999694824219;;57.689998626708984;;67.73999786376953;Bristol Myers Squibb (BMY) closed at $68.77 in the latest trading session, marking a -0.85% move from the prior day.Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.;50.20000076293945;Sanofi recognized by S&P as one of the most sustainability-committed companies Paris, March 8, 2022. Sanofi was today recognized as one of the most sustainability-committed companies in an ESG Evaluation (Environment, Social, Governance) performed by Standard & Poor’s Global Ratings (S&P). The ESG Evaluation awarded Sanofi a score of 86 out of 100 points, one of the highest scores across all sectors globally. Sanofi’s ESG profile was awarded 80 points for its solid fundamentals, completed with a;39.97999954223633;;14.329999923706055;"Patients infected with the Omicron variant of SARS-CoV-2 remain contagious for just as long as patients infected with earlier variants, according to a small study.  Researchers took blood samples from 56 newly-diagnosed patients, including 37 with Delta infections and 19 with Omicron infections.  Regardless of which variant or whether or not they had been vaccinated or boosted, study participants ""shed live virus for, on average, about 6 days after symptoms (began), and... about one in four people shed live virus for over 8 days,"" said Dr. Amy Barczak of the Massachusetts General Hospital in Boston, who coauthored a report posted on medRxiv https://www.medrxiv.org/content/10.1101/2022.03.01.22271582v1 ahead of peer review.";37.66999816894531;;9.949999809265137;;161.19000244140625;;10.949999809265137;;117.45999908447266;;105.7699966430664;;12.930000305175781;;36.650001525878906;;36.54999923706055;;15.0600004196167;;18.1299991607666;;30.780000686645508;;42.5;;101.91999816894531;;20.030000686645508;;57.4900016784668;;3.0899999141693115;;3.319999933242798;;;;10.34000015258789;;6.190000057220459;;44.4900016784668;;25.40999984741211;SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that due to a conference schedule change, the fireside chat with President and CEO Athena Countouriotis, M.D., will now take place on Tuesday, March 8 from 2:50 to 3:20 p.m. ET. The session will be accessible via webcast through the Investors page of www.tptherapeutics.com. About Tur;41.279998779296875;;11.430000305175781;;13.920000076293945;;27.049999237060547;;3.990000009536743;;50.08000183105469;;13.279999732971191;;18.639999389648438;;5.039999961853027;;15.550000190734863;;7.610000133514404;;9.199999809265137;Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Procaps Group, S.A...;18.1200008392334;;30.899999618530273;;15.680000305175781;;12.40999984741211;;16.270000457763672;;12.789999961853027;;13.239999771118164;;13.770000457763672;Repare Therapeutics Inc (NASDAQ: RPTX) has announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR trial of RP-3500. RP-3500 is a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for solid tumors with specific synthetic-lethal genomic alterations. The analysis confirmed the recommended phase 2 dose (160mg 3 days/4 days off). Anemia was the most common reported toxicity, with less than 25% o
2022-03-09;169.36000061035156;;48.75;;262.7900085449219;Eli Lilly (LLY) closed the most recent trading day at $259.93, moving -0.65% from the previous trading session.Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio® (abemaciclib) development programs will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, April 8 - 13, 2022.;105.05999755859375;BAYRY vs. NVO: Which Stock Is the Better Value Option?;148.83999633789062;Make hay while the sun shines. This old saying was certainly in full effect for the past decade when it came to the markets. But today, market forces we haven’t seen for a decade are making dividend stocks much more attractive again. Imagine we were living in a lovely estuary, growing fat on growth stocks in a lovely, placid environment. It wasn’t always safe, but the risks were relatively low. Then, we’re swept out to sea — the big, open, overwhelming sea. That’s how a lot of investors are feelMicrosoft, Amazon.com, NVIDIA, AbbVie and HSBC Holdings are included in this blog.Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-concentration, citrate-free biosimilar adalimumab that references Humira, in the U.S. The settlement fully resolves all pending U.S. disputes between the two companies related to the adalimumab biosimilar, including the International Trade Commission (ITC) case filed in December 2021. AbbVie alleged that Alvotech developed AVT02 through the theft ofGiven the remarkable volatility we’ve seen this year, it’s a wonder there are any uptrend stocks left to find. As the saying goes, though, “There’s always a bull market somewhere.” It’s an observation that holds even in volatile 2022. U.S. stocks topped out just days into the new year and that has allowed volatility to flourish. First, the worry was about inflation and the Fed’s hikes. Of course, the specter of what will happen next as a result of Covid is always a pressure point. Now, as if thoAbbVie (NYSE: ABBV) announced that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech.;82.1500015258789;"Voyager will engineer capsids — the ""heads"" of viruses, which are used to carry gene therapies into the cells of patients — for Novartis AG in a deal worth up to $1.8 billion.";77.79000091552734;;60.43000030517578;;68.12999725341797;NEW YORK, March 09, 2022--Bristol Myers Squibb to Participate in Upcoming Investor Conferences on March 16Given the remarkable volatility we’ve seen this year, it’s a wonder there are any uptrend stocks left to find. As the saying goes, though, “There’s always a bull market somewhere.” It’s an observation that holds even in volatile 2022. U.S. stocks topped out just days into the new year and that has allowed volatility to flourish. First, the worry was about inflation and the Fed’s hikes. Of course, the specter of what will happen next as a result of Covid is always a pressure point. Now, as if thoB-NOW celebrates the achievements of women around the world while advocating for equal opportunities and gender diversity.;51.93000030517578;Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated severe hemophilia A patients aged 12 and above. The study met the primary endpoint, showing clinically meaningful prevention of bleeds in patients receiving weekly prophylaxis with efanesoctocog alfa over a period of 52 weeks. The median annualized bleeding rate (ABR) was 0 with a mean ABR of 0.71. The key secondaEfanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection) In the key secondary endpoint, efanesoctocog alfa demonstrated superiority in prevention of bleeding episodes, showing a statistically significant and clinically meaningful reduction in;41.34000015258789;Pfizer said early Wednesday that it had begun a trial of its Covid-19 antiviral pill Paxlovid in children as young as six. The treatment is currently approved in the U.S. for people aged 12 and older.;14.399999618530273;;38.380001068115234;;10.279999732971191;Shares of Viatris (NASDAQ: VTRS) fell 24.4% in February, according to data provided by S&P Global Market Intelligence.  The stock has since fallen even further.  The healthcare stock's big drop on Feb. 28 came after the company announced in its fourth-quarter earnings report that it was selling its biosimilars portfolio to Biocon Biologics, a privately held company in India, for up to $3.335 billion.;173.69000244140625;;11.479999542236328;;121.97000122070312;;104.8499984741211;;14.15999984741211;;36.459999084472656;;38.40999984741211;Legend Biotech Corporation ( NASDAQ:LEGN ) is possibly approaching a major achievement in its business, so we would...;16.610000610351562;;19.770000457763672;;34.939998626708984;;46.459999084472656;;107.55999755859375;;21.489999771118164;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational research data of enoblituzumab (also known as TJ271) and preclinical data of TJ-C64B will be presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting, to be held April 8-13, 2022.";60.22999954223633;;3.2100000381469727;;3.5;CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Wednesday, March 23, 2022, at 8:00 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update. A live webcast can be accessed by visiting the Investors section of the Company’s;;;11.050000190734863;;6.769999980926514;;45.84000015258789;"Harmony Biosciences Holdings, Inc. (""Harmony"" or the ""Company"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that its executive leaders will participate in the following upcoming virtual conferences:";27.799999237060547;;42.20000076293945;;11.970000267028809;Posters will feature programs with best-in-class potential including ERK1/2 inhibitor ERAS-007, SHP2 inhibitor ERAS-601, and CNS-penetrant KRAS G12C inhibitor ERAS-3490SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present six poster presentations at the upcoming Ame;14.699999809265137;;28.399999618530273;;4.03000020980835;;53.959999084472656;;14.109999656677246;SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held from April 8-13, 2022 in New Orleans, LA. Details of the poster presentations are as follows: Title: Ex-vivo inhibition of;19.75;;5.559999942779541;;16.489999771118164;;8.329999923706055;;9.260000228881836;;19.899999618530273;;33.08000183105469;;17.010000228881836;;12.819999694824219;;16.559999465942383;;13.0600004196167;;13.760000228881836;;13.460000038146973;"CAMBRIDGE, Mass. & MONTREAL, March 08, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500 and a poster presentation of initial discovery and validation data of the novel Synthetic Let"
2022-03-10;169.66000366210938;If you're seeking companies that can raise their payouts over the long term, consider these three stocks.In this article, we discuss the 10 consumer stocks that pay dividends. If you want to skip our detailed analysis of these dividend stocks, go directly to 5 Consumer Stocks that Pay Dividends. 2022 is certainly proving to be an uncertain time-period for investors, just like 2021, which was just like 2020. Amidst such economic […];49.20000076293945;;266.0199890136719;Saturna Capital, an investment management firm, published its “Amana Funds” fourth-quarter 2021 investor letter – a copy of which can be downloaded here. For the fourth quarter of 2021, the Amana Income Fund Investor Shares returned 13.76% and the Institutional Shares returned 13.85%. The Amana Growth Fund sprinted to a strong finish in the fourth […]Futures fall after Wednesday didn't trigger a market follow-through day. Crude oil prices are rising with a key inflation report due.Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;104.45999908447266;Saturna Capital, an investment management firm, published its “Amana Funds” fourth-quarter 2021 investor letter – a copy of which can be downloaded here. For the fourth quarter of 2021, the Amana Income Fund Investor Shares returned 13.76% and the Institutional Shares returned 13.85%. The Amana Growth Fund sprinted to a strong finish in the fourth […];149.1699981689453;AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULIPTA™ in the United States), an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily (QD) and 30 mg twice daily (BID) doses, across the 12-week treatment period. The stUntil recently, Viatris (NASDAQ:VTRS) was considered a value play among drug stocks. But after its recent earnings report, and announced sale of a key asset? The generic drug maker has been deemed a “value trap,” and has experienced a sharp plunge in price. Falling by about 23% right after the news, and down around 32.5% in the past month, it may take some time for Viatris to bounce back. Another generic drug maker, Teva Pharmaceutical (NYSE:TEVA), has sold off in recent weeks, too, after reportThe suit involved a biosimilar — that is, generic — version of the arthritis drug, which generated more than $20 billion in sales worldwide last year.;82.97000122070312;Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.;77.88999938964844;;60.900001525878906;While the market can sometimes bid up shares of excellent companies to sky-high prices, it isn't always necessary to break the bank to invest in quality businesses.  Let's look at two pharmaceutical giants that fit the bill: AstraZeneca (NASDAQ: AZN) and Bristol-Myers Squibb (NYSE: BMY).  In the past 12 months, several developments have helped AstraZeneca ensure a bright future.;68.41999816894531;While the market can sometimes bid up shares of excellent companies to sky-high prices, it isn't always necessary to break the bank to invest in quality businesses.  Let's look at two pharmaceutical giants that fit the bill: AstraZeneca (NASDAQ: AZN) and Bristol-Myers Squibb (NYSE: BMY).  In the past 12 months, several developments have helped AstraZeneca ensure a bright future.Saturna Capital, an investment management firm, published its “Amana Funds” fourth-quarter 2021 investor letter – a copy of which can be downloaded here. For the fourth quarter of 2021, the Amana Income Fund Investor Shares returned 13.76% and the Institutional Shares returned 13.85%. The Amana Growth Fund sprinted to a strong finish in the fourth […];51.400001525878906;Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia ABioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.;40.83000183105469;Until recently, Viatris (NASDAQ:VTRS) was considered a value play among drug stocks. But after its recent earnings report, and announced sale of a key asset? The generic drug maker has been deemed a “value trap,” and has experienced a sharp plunge in price. Falling by about 23% right after the news, and down around 32.5% in the past month, it may take some time for Viatris to bounce back. Another generic drug maker, Teva Pharmaceutical (NYSE:TEVA), has sold off in recent weeks, too, after report;14.5;;38.5099983215332;;10.119999885559082;"Is the business really in as much trouble as it seems, or are investors overreacting, making Viatris a potentially appealing contrarian buy today?  Viatris reported its year-end results on Feb. 28, and the numbers didn't necessarily look horrible.  In its earnings release, Viatris also announced that it would be selling its biosimilars to Biocon Biologics for more than $3.3 billion in pre-tax consideration, calling it ""the first in a series of expected initiatives anticipated to unlock up to an additional $6 billion in pre-tax proceeds by the end of 2023.""Until recently, Viatris (NASDAQ:VTRS) was considered a value play among drug stocks. But after its recent earnings report, and announced sale of a key asset? The generic drug maker has been deemed a “value trap,” and has experienced a sharp plunge in price. Falling by about 23% right after the news, and down around 32.5% in the past month, it may take some time for Viatris to bounce back. Another generic drug maker, Teva Pharmaceutical (NYSE:TEVA), has sold off in recent weeks, too, after report";172.0;;11.270000457763672;;122.20999908447266;;102.48999786376953;;13.699999809265137;;35.97999954223633;;37.0;;16.770000457763672;;18.479999542236328;;35.380001068115234;;46.45000076293945;;108.3499984741211;BOSTON, March 10, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming virtual investor conferences:;18.520000457763672;;60.02000045776367;;3.2799999713897705;;3.490000009536743;;;;10.930000305175781;;6.550000190734863;;45.650001525878906;Biotech stock Harmony Biosciences is near the buy point of a new cup base, putting it among growth stocks to watch.;27.84000015258789;SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its participation in the following investor conferences: March 15, 34th Annual Roth Conference, CFO Paolo Tombesi is scheduled to participate in one-on-one meetings. March 16, Oppenheimer 32nd Annual Healthcare Conference, President and CEO Athena Countouriotis, M.D., is scheduled to;39.540000915527344;;11.710000038146973;ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated clinically in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant mCRC Erasca previously signed a clinical trial collaboration and supply agreement with Pfizer for encorafenib for use in the same study Preclinical data support the potential of ERAS-007 to block MAPK pathway reactivation and limit resistance to encorafenib and cetuximab treatment SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Erasca,;14.289999961853027;;27.889999389648438;BILLERICA, Mass., March 09, 2022--Quanterix to Participate in Barclays Global Healthcare Conference;4.150000095367432;;54.41999816894531;LEXINGTON, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. “I am exceptionally proud of;14.0;SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in March: 32nd Annual Oppenheimer Healthcare ConferencePresentation: Tuesday, March 15 at 4:00–4:30 p.m. ET2nd Guggenheim Targeted Protein Degradation DayFireside chat: Wednesday, March 16, a;19.729999542236328;;5.360000133514404;;16.899999618530273;;8.489999771118164;;9.149999618530273;;19.549999237060547;;33.31999969482422;;17.59000015258789;;12.359999656677246;;17.3700008392334;;13.779999732971191;"Company Announcement – No. 8 / 2022 Zealand Pharma convenes its Annual General Meeting 2022 Copenhagen, 10 March, 2022 – Zealand Pharma A/S (the ""Company"") convenes the Annual General Meeting of the Company to be held on Wednesday April 6, 2022 at 3:00 pm (CEST) In accordance with Article 11.1 of the Company's Articles of Association the Annual General Meeting will be held as a completely electronic meeting without the possibility for shareholders to attend in person. Participation in the AnnualCompany announcement – No. 7 / 2022 Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. Full Year Results for 2021 Copenhagen, March 10, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced financial results for the 12-month period";13.34000015258789;;13.520000457763672;
2022-03-11;169.35000610351562;Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.Yale's Dr. Howard Forman says the U.S. has an important window to address the current pandemic — and those in the future — as COVID-19 cases decline around the world.;50.27000045776367;;266.29998779296875;The Dow Jones dipped as inflation spiked. Apple stock the worst blue chip performer. Amazon stock gained on stock split news.In this article, we present the list of the 10 biotech stocks hedge funds are talking about. You can skip our comprehensive analysis of the biotech industry, and go directly to 5 Biotech Stocks Hedge Funds Are Talking About. A broader exodus of investors from growth stocks, rising inflation and an expected hike in interest […];101.26000213623047;;149.05999755859375;Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.AbbVie Inc (NYSE: ABBV) and Gedeon Richter Plc have announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including gloAbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, incA corporate exodus from Russia in response to its military invasion of Ukraine has seen more than 300 U.S. and multinational companies sever business ties with the country – and the list seems to be growing by the minute. But even as many flee, a number of big-name firms have remained mum.AbbVie Inc (NYSE: ABBV) has reported data from the Phase 3 PROGRESS trial of atogepant (Qulipta) for the preventive treatment of chronic migraine in adults. The trial met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg and 30 mg doses, across the 12-week treatment period. In the U.S. population, patients in the atogepant 60 mg and 30 mg treatment arms experienced a decrease of 6.88 and 7.46 monthly mi;82.37000274658203;Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.;78.26000213623047;Why strong STEM opportunities for women are important during Women’s History Month and every monthMerck (MRK) closed at $77.89 in the latest trading session, marking a +0.13% move from the prior day.;60.29999923706055;;68.87000274658203;NEW YORK, March 11, 2022--Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022A solid strategy for investing is to buy shares of growth-oriented businesses and hanging on to them for the long haul.  While the temptation may be there to chase short-term trends and memes, the real potential to score some 10-baggers is through some solid growth stocks.  Three growing businesses that look unstoppable, not just in 2022 but for the very long term, are Bristol-Myers Squibb (NYSE: BMY), Ginkgo Bioworks (NYSE: DNA), and Veeva Systems (NYSE: VEEV).;50.709999084472656;Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.;40.560001373291016;"According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. ""These data show the persistence of viable SARS-CoV-2 in patients after sotrovimab infusions and the rapid development of spike gGlaxoSmithKline (GSK) closed the most recent trading day at $40.83, moving -1.23% from the previous trading session.";14.430000305175781;Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.;38.27000045776367;;10.020000457763672;;167.02000427246094;;11.109999656677246;;118.77999877929688;;102.18000030517578;;13.460000038146973;;35.83000183105469;;35.970001220703125;;15.6899995803833;;17.09000015258789;"HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) would like to provide an update on its status under the Holding Foreign Companies Accountable Act (the “Act”). On March 8, 2022, as expected in its implementation of the Act, the U.S. Securities and Exchange Commission (the “SEC”) provisionally named the Company as a Commission-Identified Issuer, following the Company's filing";33.52000045776367;;43.29999923706055;;102.9000015258789;;16.760000228881836;;58.869998931884766;;3.119999885559082;;3.809999942779541;;;;10.630000114440918;;6.010000228881836;;43.86000061035156;;26.899999618530273;;36.47999954223633;GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a treatment being developed for known or suspected acute cyanide poisoning. Under an existing multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), and in collaboration with th;11.380000114440918;;14.020000457763672;;25.959999084472656;;4.119999885559082;;51.75;;13.760000228881836;;19.299999237060547;SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on March 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,500 shares of its common stock to five new non-execu;5.21999979019165;;16.350000381469727;;8.069999694824219;;8.970000267028809;;18.399999618530273;;32.869998931884766;;16.850000381469727;;11.510000228881836;;17.110000610351562;;11.472000122070312;;12.380000114440918;;12.210000038146973;
2022-03-14;171.69000244140625;AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.Yahoo Finance's Anjalee Khemlani discusses the current outbreak of COVID-19 in China and what it means for the country's zero-COVID policy.Johnson & Johnson’s unwavering commitment to addressing some of the world's toughest health challenges hasn't gone unnoticed. Fortune just ranked Johnson & Johnson as a Top 50 All-Star on its World...This company began paying a dividend when James Madison was president. It hasn't missed a year since.;52.25;;269.0;"Eli Lilly, Nike, Micron Technology, Bayer Aktiengesellschaft, and Valero Energy are included in today's analyst blog.Office products retailer Staples ran a TV commercial several years ago that featured an ""easy button.""  Here's why they chose Eli Lilly (NYSE: LLY), Novartis (NYSE: NVS), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Prosper Junior Bakiny (Eli Lilly): Pharma giant Eli Lilly has performed well in the past 12 months, with its shares nearly tripling the return of the S&P 500.";101.73999786376953;Bagsværd, Denmark, 14 March 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act;152.10000610351562;AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.;84.06999969482422;"Office products retailer Staples ran a TV commercial several years ago that featured an ""easy button.""  Here's why they chose Eli Lilly (NYSE: LLY), Novartis (NYSE: NVS), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Prosper Junior Bakiny (Eli Lilly): Pharma giant Eli Lilly has performed well in the past 12 months, with its shares nearly tripling the return of the S&P 500.Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwideAcquisition further demonstrates Sandoz commitment to pioneer access for patients Basel, March 14, 2022 — Sandoz, a Novartis division, announced today that it has successfully acquired the UK-based medical and drug delivChildren with three copies of SMN2 treated presymptomatically achieved age-appropriate milestones, including standing and walking; required no ventilatory or feeding tube support; and had no serious, treatment-related adverse eventsPost-hoc analyses of START, STR1VE-EU and STR1VE-US indicated children with SMA Type 1 achieved or maintained important measures of bulbar function More than 1,800 patients have now been treated with Zolgensma globally across clinical trials, managed access programs a";77.77999877929688;FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.The industry tries to protect itself after a judge rules that wartime exclusions don’t apply to cyberattacks.;60.38999938964844;The Food and Drug Administration's approval on Friday of AstraZeneca's Lynparza as a treatment for some people with early-stage breast cancer could bring in $1.5 billion in annual revenue for the company. U.S.-listed shares of AstraZeneca were up 1.5% in trading on Monday. SVB Leerink analyst Andrew Berens told investors in a note on Monday that he expects rapid adoption of the therapy among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have previously receiEmergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.The FDA has declined to approve AstraZeneca Plc's (NASDAQ: AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and stuffiness. The FDA has issued a complete response letter following AstraZeneca's application to extend the use of Fasenra and requested additional clinical data from it. Fasenra raked in .26 billion in sales in 2021, jumping 33% from the previous year. The application by AstraZeThe FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-stage breast cancer with certain mutations. The agency approved Lynparza (olaparib) for patients with a form of genetically mutated high-risk early-stage breast cancer called BRCA-mutated HER2-negative, who have already been treated with chemotherapy either before or after surgery. The approval was based on results from a late-stage study. Lynparza showAstraZeneca Plc said on Monday the U.S. drug regulator declined to approve its asthma medicine, Fasenra, for treatment of chronic rhinosinusitis with nasal polyps, a condition characterised by benign growths that cause pain and stuffiness.  The London-listed drugmaker said the U.S. Food and Drug Administration (FDA) had issued a complete response letter following AstraZeneca's application to extend use of the treatment and requested additional clinical data from it.  Fasenra was AstraZeneca's first respiratory biologic and raked in $1.26 billion in sales in 2021, jumping 33% from the previous year.;69.23999786376953;PRINCETON, N.J., & SAN FRANCISCO, March 14, 2022--BMS and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial;50.33000183105469;Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in the Phase 2 AMEERA-3 trial. Results from the Phase 2 trial showed that the drug amcenestrant, given as a pill, did not have the desired effect compared to standard endocrine treatment against locally advanced or metastatic breast cancer. No new safety signals were identified, and the safety profile of amcenestrant in AMEERA-3 was con(Reuters) -Sanofi's shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker's drug development prowess.  Results from the Phase II AMEERA-3 clinical trial, keenly awaited by Sanofi investors, showed the drug amcenestrant, given as a pill, did not have the desired effect when compared to standard endocrine treatment against locally advanced or metastatic breast cancer, Sanofi said in a statement.  Sanofi said it would continue with two further trials, AMEERA-5 and AMEERA-6, trying to show amcenestrant could help much larger patient groups of women in early stages of cancer.By Peter NurseBy Dhirendra TripathiSanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer AMEERA-3 trial did not meet primary endpoint of improving progression-free survivalOngoing trials continue as planned, including AMEERA-5 and AMEERA-6 Paris, March 14, 2022. The Phase 2 AMEERA-3 clinical trial evaluating amcenestrant, an investigational optimized oral selective estrogen receptor degrader (SERD), did not meet its primary endpoint of improving progression-free survival;40.77000045776367;FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.;14.430000305175781;;37.97999954223633;;9.8100004196167;;165.3000030517578;;11.25;;118.56999969482422;;102.63999938964844;Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in which the body produces abnormally low levels of parathyroid hormone (PTH). 78.7% of TransCon PTH-treated patients achieved serum calcium levels in the normal range and independence from therapeutic levels of conventional therapy, compared to 4.8% for patients in the control group. The data also exhibited a statistically significant decre– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). – TransCon PTH demonstrated statistically significant improvements compared to control on all key secondary endpoints, which included measures evaluating patient-reported disease symptoms and impacts. – TransCon PTH was generally well-tolerated, with no discontinuations related to study drug. – On track to submit NDA during the third quarter and MAA during the;13.579999923706055;;32.36000061035156;;31.020000457763672;;16.079999923706055;;15.520000457763672;;30.040000915527344;;39.439998626708984;;100.25;;12.539999961853027;;56.38999938964844;;3.049999952316284;;3.690000057220459;;;;4.159999847412109;As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...Shares of Nektar Therapeutics Inc. tumbled 44.7% in premarket trading on Monday after the company said a combination of its experimental therapy bempegaldesleuk in combination with Bristol Myers Squibb Co.'s Opdivo failed as a treatment for melanoma. The companies had tested the combination against Opdivo in a Phase 3 clinical trial as a first-line treatment for patients with previously untreated unresectable or metastatic melanoma. After discovering the combination did not meet the study's primNektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pacific Standard Time (PST), following this morning's update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study in previously untreated unresectable or metastatic melanoma.PRINCETON, N.J., & SAN FRANCISCO, March 14, 2022--BMS and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial;5.21999979019165;;42.459999084472656;Russia's Ukraine invasion, a looming Fed rate hike and the return of Covid are big headwinds as the major indexes near their Feb. 24 lows.;24.729999542236328;;37.029998779296875;Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.;10.970000267028809;;13.539999961853027;;23.260000228881836;;4.050000190734863;;48.33000183105469;;12.9399995803833;;19.030000686645508;SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Caren Deardorf to the company’s board of directors. Ms. Deardorf has broad experience in biotechnology, building on over 20 years at Biogen where she led commercial efforts for neurological;5.070000171661377;;15.989999771118164;;7.559999942779541;;8.670000076293945;;17.639999389648438;SAN DIEGO, March 14, 2022--Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference;32.45000076293945;;15.739999771118164;;10.729999542236328;;14.619999885559082;;12.140000343322754;;10.90999984741211;;11.380000114440918;
2022-03-15;176.13999938964844;Novavax fans, investors and patients alike, are frustrated by FDA's delays in authorizing COVID-19 vaccine.Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 19th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team.Sector ETF report for FHLC;52.209999084472656;;275.4599914550781;"A growing number of drugmakers including Eli Lilly and Co, Novartis and Abbvie Inc are scaling back business in Russia after Moscow's invasion of Ukraine, but still pledge to continue supplying critical medicines.  U.S. drugmaker Lilly said it will send medicines for urgent medical conditions such as cancer and diabetes.  It is suspending sales of what it called ""non-essential medicines"" as well as all investments and promotions.Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.Eli Lilly's sales and earnings grew by double digits in 2021 due to its exceptional drug portfolio.U.S. drugmaker Lilly said it will send medicines for urgent medical conditions such as cancer and diabetes.  It is suspending sales of what it called ""non-essential medicines"" as well as all investments and promotions.  Swiss drugmaker Novartis also said it would stop  investments, marketing activities there and all scientific events organized by the company or external parties in Russia.Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.With Eli Lilly earning a spot on the list of new buys by top funds, LLY stock is setting up a new buy point as the market correction continues.While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...";102.44999694824219;;155.8800048828125;"Allergan, an AbbVie (NYSE: ABBV) company, today announced that LASTACAFT® (alcaftadine ophthalmic solution 0.25%) is now available without a prescription for the estimated 40% of Americans1 who live with ocular allergies. As demonstrated in clinical studies, one drop of LASTACAFT works in as little as three minutes to provide relief from itchy, allergy eyes lasting through 16 hours.2 Following the recent U.S. Food and Drug Administration approval of a complete prescription to over-the-counter (OAbbVie Inc. said Tuesday that it will partner with Scripps Research to develop new COVID-19 antivirals. ""Our SARS-CoV-2 research program has the potential to impact significantly the ongoing gaps in patient needs to move from pandemic to endemic COVID-19,"" Peter Schultz, president and CEO of Scripps Research, said in a news release. There are two authorized COVID-19 antivirals: Pfizer Inc.'s Paxlovid, and Merck & Co. Inc.'s molnupiravir. AbbVie's stock has gained 12.3% since the beginning of theAbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.";84.7300033569336;Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.Two that stand out right now are Novartis (NYSE: NVS) and Meridian Bioscience (NASDAQ: VIVO).  Novartis has an impressive pipeline and a generous dividend and yet its shares are down more than 5% this year.  Meridian Bioscience isn't as overlooked, but its shares should be doing even better considering the company's back-to-back years of record revenue.Novartis AG (NYSE: NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal muscular atrophy (SMA). The data demonstrated that children with three copies of the SMN2 backup gene who were treated presymptomatically achieved age-appropriate motor milestones, including standing and walking. In addition, a descriptive posthoc analysis of START, STR1VE-EU, and STR1VE-US (n=65) indicated children with SMA Type 1 achieved oNovartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.;78.63999938964844;Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC). The trial included mCRPC patients who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. After a planned interim analysis, Merck is discontinuing the study following an independent Data Monitoring Committee (DMC) recommendation. At the interim analysis, the combination of Keytruda anParis Mullen shares why it's so important to make self-care a daily habitMerck & Co. Inc. said Tuesday that it will stop a clinical trial evaluating Keytruda with AstraZeneca's Lynparza in advanced prostate cancer patients because the combination therapy doesn't work. The company said the drugs did not show an improvement in overall survival, which is one of the trial's primary endpoints. The companies will continue to test the Keytruda-Lynparza combination in patients with other types of cancers. The Food and Drug Administration last week approved Lynparza as a treaKENILWORTH, N.J., March 15, 2022--Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® in Combination with LYNPARZA® in Patients with mCRPC to Stop for Futility;61.369998931884766;Europe's drug regulator said on Tuesday it had begun reviewing AstraZeneca Plc's application for antibody-based COVID-19 therapy, a key step towards approval of the treatment in the region, but gave no timeline for a conclusion.  Infections from COVID-19 are still rising in parts of the world including Europe.  AstraZeneca's antibody cocktail, Evusheld, has already been authorised in the United States to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinicalAstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.Novavax fans, investors and patients alike, are frustrated by FDA's delays in authorizing COVID-19 vaccine.Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC). The trial included mCRPC patients who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. After a planned interim analysis, Merck is discontinuing the study following an independent Data Monitoring Committee (DMC) recommendation. At the interim analysis, the combination of Keytruda anMerck & Co. Inc. said Tuesday that it will stop a clinical trial evaluating Keytruda with AstraZeneca's Lynparza in advanced prostate cancer patients because the combination therapy doesn't work. The company said the drugs did not show an improvement in overall survival, which is one of the trial's primary endpoints. The companies will continue to test the Keytruda-Lynparza combination in patients with other types of cancers. The Food and Drug Administration last week approved Lynparza as a trea;69.75;"Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.Biotech  Nektar Therapeutics  and its partner  Bristol Myers Squibb  said early Monday that their cancer drug known as bempeg had failed in a trial in melanoma patients.  Shares of Nektar (ticker: NKTR) fell 61% in trading to $4.16 from its Friday close of $10.63.  Shares of Bristol Myers (BMY) were down 0.5%.The combination of Bristol-Myers Squibb Co.'s cancer immunotherapy drug Opdivo with an experimental Nektar Therapeutics Inc. drug — the center of a $1 billion-plus partnership signed four years ago — failed a late-stage trial.  The news sent San Francisco-based Nektar's stock down more than 60% Monday as President and CEO Howard Robin said the company plans ""substantial"" changes to operations.  The results of the Phase III metastatic melanoma study combining Nektar's  bempegaldesleukin — known simply as ""bempeg"" — in combination with Opdivo is hardly a surprise.Adding Nektar's most advanced drug to Bristol Myers' Opdivo didn't improve outcomes for melanoma patients — leading NKTR stock to crash Monday.A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.";51.83000183105469;"Rating Action: Moody's assigns first-time long term rating of Aa1 to L'Oreal; stable outlookGlobal Credit Research - 11 Mar 2022Milan, March 11, 2022 -- Moody's Investors Service (Moody's) has today assigned a first-time Aa1 long-term issuer rating to L'Oreal S.A. (L'Oreal or the company).  Concurrently, Moody's has affirmed L'Oreal's Prime-1 (P-1) commercial paper ratings and the P-1 backed commercial paper rating of its US subsidiary L'Oreal U.S.A. Inc. The outlook for both entities remains stable.The rating reflects the company's consistent track record of solid operating performance, underpinned by its leading market positions, as well as its exceptionally strong credit metrics, says Lorenzo Re, a Moody's Vice President - Senior Analyst and lead analyst for L'Oreal.The rating is also supported by L'Oreal's extremely prudent financial policy as reflected in its long track record of operating with very low leverage, adds Mr. Re.Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma Investment will accelerate the overall Sarclisa® development programSanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa® (isatuximab) PARIS, March 15, 2022. Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contrToday's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Coca-Cola Company (KO) and Adobe Inc. (ADBE).Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.";41.70000076293945;IDEAYA Biosciences Inc (NASDAQ: IDYA) has announced interim Phase 1 data for IDE397 in patients with solid tumors with methylthioadenosine phosphorylase (MTAP) deletion, estimated to represent approximately 15% of solid tumors. The observed steady-state plasma SAM exceeds the target of >60% reduction of plasma S-adenosyl methionine (SAM), a proximal PD biomarker of target engagement, across all evaluated cohorts. Cohort 5 showed a mean 77% reduction of steady state plasma SAM compared to baselinPfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline are part of today's Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Coca-Cola Company (KO) and Adobe Inc. (ADBE).Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.;14.489999771118164;;38.27000045776367;It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both...;9.960000038146973;;169.82000732421875;;10.720000267028809;;116.73999786376953;;109.44000244140625;;13.90999984741211;;32.290000915527344;;35.630001068115234;;16.520000457763672;;15.890000343322754;;28.979999542236328;;40.04999923706055;;104.8499984741211;;13.479999542236328;"I-Mab ( ""I-Mab"" or the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provides updates on the recent development relating to the Holding Foreign Companies Accountable Act (the ""HFCAA"") and its implementation. The U.S. Securities and Exchange Commission (the ""SEC"") released on March 8, 2022 a provisional list of issuers identified as ""Commission-Identified Issuers"" under the HFCAA becau";53.209999084472656;;3.319999933242798;;3.9700000286102295;;;;4.480000019073486;"Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.The combination of Bristol-Myers Squibb Co.'s cancer immunotherapy drug Opdivo with an experimental Nektar Therapeutics Inc. drug — the center of a $1 billion-plus partnership signed four years ago — failed a late-stage trial.  The news sent San Francisco-based Nektar's stock down more than 60% Monday as President and CEO Howard Robin said the company plans ""substantial"" changes to operations.  The results of the Phase III metastatic melanoma study combining Nektar's  bempegaldesleukin — known simply as ""bempeg"" — in combination with Opdivo is hardly a surprise.Adding Nektar's most advanced drug to Bristol Myers' Opdivo didn't improve outcomes for melanoma patients — leading NKTR stock to crash Monday.A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.";5.369999885559082;;43.81999969482422;;25.110000610351562;;38.209999084472656;GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: KeyBanc Life Sciences & MedTech Investor ForumMarch 22, 2022Company fireside chat scheduled for 1:30 pm easternhttps://wsw.com/webcast/key21/ebs/1521976 BofA Securities 2022 Healthcare ConferenceMay 10, 2022Presentation scheduled for 12:00 pm eastern Goldman Sachs 7th Annual Lev;10.670000076293945;;13.619999885559082;;24.049999237060547;;3.9700000286102295;;50.849998474121094;;13.4399995803833;;19.079999923706055;;4.940000057220459;;15.569999694824219;;7.840000152587891;;8.350000381469727;;18.559999465942383;;31.889999389648438;;15.979999542236328;WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 18,900 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 48,900 shares of Arcutis’ common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ B;10.479999542236328;;13.420000076293945;;11.979999542236328;;10.550000190734863;;12.119999885559082;
2022-03-16;174.52000427246094;In this article, we will discuss 10 dividend stocks in Rajiv Jain’s portfolio. You can skip our detailed analysis of GQG Partners’ past performance and recent developments, and go directly to Rajiv Jain’s GQG Partners Portfolio: 5 Dividend Stock Picks. Rajiv Jain founded GQG Partners, a Florida-based investment management firm, in 2016. In just over […]In turbulent times, some investors turn from speculative stocks that have their cash flows far in the future, to reliable and strong companies like Johnson & Johnson (NYSE:JNJ). The company has been around for years, has a recognized brand and strong product portfolio. For investors, it provides both a cash and equity return. Today, we will evaluate the cash - dividend returns of JNJ and see if the stock is a viable option.A look at what makes the stock a key name to hold in a dividend growth portfolio;52.91999816894531;;276.44000244140625;The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial's Independent Data Monitoring Committee. This follows a formal interim assessment that met prespecified criteria for positive efficacy, announced the Medical Research Council (MRC) Population Health Research Unit at the University of Oxford, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY).Health care stocks represent the only defensive sector that is also relatively immune to inflationary risks.;106.23999786376953;A $5,000 investment can give investors enough skin in the game to make a strong profit, plus earn a decent dividend along the way.  Companies that offer both growth opportunities and recurring income can maximize investors' odds for a good return without requiring significant risk along the way.  Two stocks that check off those boxes are Novo Nordisk (NYSE: NVO) and Dell Technologies (NYSE: DELL).;156.0500030517578;"AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.About six weeks ago, AbbVie posted an earnings beat on a slight revenue miss (+7.4% y/y) for their fourth quarter.  AbbVie typically runs with a current ratio above the key ""one"" level for three quarters and then drops below that level in the fourth quarter.In this article, we will discuss 10 dividend stocks in Rajiv Jain’s portfolio. You can skip our detailed analysis of GQG Partners’ past performance and recent developments, and go directly to Rajiv Jain’s GQG Partners Portfolio: 5 Dividend Stock Picks. Rajiv Jain founded GQG Partners, a Florida-based investment management firm, in 2016. In just over […]For this week’s top stock trades, we’re focusing on strength. And I’m not taking the easy route by jumping on the commodity train either. Instead, I’m offering up two healthcare companies and one blue-chip industrial stock. I could have given healthcare a clean sweep with three picks, but the industrial name was too good to pass up. Plus, this isn’t a market for concentrated bets. Playing multiple stocks in different sectors offers at least some safety. 7 Cheap Stocks to Buy If You Only Have $10";84.63999938964844;;78.12000274658203;Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab). The global trial (ADG126-P001 / KEYNOTE-C98) will evaluate patients with advanced/metastatic solid tumors. The ADG126-P001 trial is expected to dose the first patients soon. The trial is designed to evaluate safety and tolerability and determine the recommended Phase 2 dose for ADG126 in combinaIn this article, we will discuss 10 dividend stocks in Rajiv Jain’s portfolio. You can skip our detailed analysis of GQG Partners’ past performance and recent developments, and go directly to Rajiv Jain’s GQG Partners Portfolio: 5 Dividend Stock Picks. Rajiv Jain founded GQG Partners, a Florida-based investment management firm, in 2016. In just over […]Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival.Drugmaker Merck and Co said on Wednesday it would not make further investments in Russia, but continue to supply life-saving medicines and vaccines to the country.  Merck joins a growing list of drugmakers, including Pfizer Inc, Eli Lilly, Novartis and Abbvie Inc , which are pausing investments or scaling back their business in Russia after Moscow's invasion of Ukraine.  Western companies have come under pressure to leave Russia, but the healthcare sector has not pulled out because medicines and medical devices and equipment are considered necessary for humanitarian reasons and are excluded from sanctions.Merck joins a growing list of drugmakers, including Pfizer Inc, Eli Lilly, Novartis and Abbvie Inc, which are pausing investments or scaling back their business in Russia after Moscow's invasion of Ukraine.  Western companies have come under pressure to leave Russia, but the healthcare sector has not pulled out because medicines and medical devices and equipment are considered necessary for humanitarian reasons and are excluded from sanctions.;61.959999084472656;Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival.;69.66000366210938;Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.Two biotech startups from the Bay State, two from Canada and one from California will take part in MassBio's first installment of its accelerator program MassBioDrive, culminating in an in-person Demo Day in May and cash stipends for each of the selected ventures.For this week’s top stock trades, we’re focusing on strength. And I’m not taking the easy route by jumping on the commodity train either. Instead, I’m offering up two healthcare companies and one blue-chip industrial stock. I could have given healthcare a clean sweep with three picks, but the industrial name was too good to pass up. Plus, this isn’t a market for concentrated bets. Playing multiple stocks in different sectors offers at least some safety. 7 Cheap Stocks to Buy If You Only Have $10;51.900001525878906;Sanofi SA (NASDAQ: SNY) and Seagen Inc (NASDAQ: SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein, and Sanofi currently has one ADC in development.Sanofi (SNY) is developing a subcutaneous formulation of its myeloma drug, Sarclisa. A pivotal study is expected to start in the second half of 2022.BOTHELL, Wash. & PARIS, March 16, 2022--Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has oSanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer Paris, March 16, 2022. Sanofi and Seagen Inc. (Nasdaq:SGEN) today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb);42.099998474121094;;15.020000457763672;Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.;39.0;;10.390000343322754;Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that, Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), the first approved generic version of AstraZeneca's Symbicort®. Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstrucViatris (VTRS) closed the most recent trading day at $9.96, moving +1.53% from the previous trading session.;178.64999389648438;;11.010000228881836;;122.0999984741211;;122.93000030517578;;14.90999984741211;;32.900001525878906;;39.04999923706055;;18.25;;19.010000228881836;;30.989999771118164;;45.2400016784668;Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan continued to reduce geographic atrophy (GA) lesion growth. These data will be included in the U.S. marketing application that the Company plans to submit in Q2 of 2022. In the OAKS study, pegcetacoplan reduced GA lesion growth with both monthly (22%) and every other month treatment (16%), and in the DERBY study, the percentages stood at 13% aShares of Apellis Pharmaceuticals Inc. gained 6.1% in premarket trading on Wednesday after the company shared longer-term clinical data demonstrating that intravitreal pegcetacoplan reduced geographic atrophy lesion growth at 18 months. The data, culled from two clinical trials, will be used in the new drug application that is expected to be submitted to the Food and Drug Administration in the second quarter of this year. The study's investigator said in a news release that the data shows the inBoth monthly and every-other-month pegcetacoplan continued to reduce GA lesion growth compared to pooled sham at 18 months with all p-values (nominal) below 0.05 Treatment effects in DERBY were comparable to OAKS during months 6-18Pegcetacoplan continued to demonstrate a favorable safety profile Combined 18-month data show the potential for improving treatment effects over timeData to be included in the NDA submission planned for Q2Conference call today at 8:30 a.m. ET WALTHAM, Mass., March 16,;110.41999816894531;;17.209999084472656;Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...;60.4900016784668;;3.4800000190734863;GeneDx, Inc., a leader in genomic analysis, today announced newly published research demonstrating the value of data sharing and research participation on a platform that supports clinician connections to rapidly uncover new gene-disease relationships, an approach which has resulted in publication of more than 200 new associations.;4.28000020980835;;;;4.630000114440918;;5.659999847412109;;47.720001220703125;;27.559999465942383;;39.13999938964844;;10.869999885559082;;13.899999618530273;;25.68000030517578;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...;4.099999904632568;;53.709999084472656;;13.920000076293945;;19.43000030517578;;5.199999809265137;;16.600000381469727;;8.5600004196167;;8.130000114440918;;20.889999389648438;;34.150001525878906;;16.25;;10.979999542236328;;14.529999732971191;;13.039999961853027;;10.670000076293945;;12.8100004196167;
2022-03-17;176.8000030517578;The digital healthcare provider's stock is falling hard this year, but that doesn't mean the business isn't thriving.Yahoo Finance's Anjalee Khemlani discusses the spread of the BA.2 coronavirus subvariant and President Biden appointing a new COVID czar.In this article, we will discuss some of the notable stocks getting crushed today. To take a look at some more stocks that are moving down, go to Why These 5 Stocks Are Getting Crushed on Wednesday. Despite the S&P 500 Index, the Dow Jones Industrial Average (DJIA) Index, and the NASDAQ Composite Index all […];54.2400016784668;;285.510009765625;;109.8499984741211;;158.58999633789062;The stock market had a big upward move on Wednesday, with investors eventually deciding that the Federal Reserve's stance on interest rates was consistent with what they wanted to see over the long run.  Although there's still considerable uncertainty about what 2022 will bring in terms of macroeconomic improvement and the unstable geopolitical situation, market participants always like having at least an idea of where policymakers at the Fed are likely to take things.  The size of the stock market pullback since November has been big enough that many stocks are still 20%, 30%, or even 50% below their best levels over the past year.Medical Properties Trust (NYSE: MPW), AbbVie (NYSE: ABBV), and Teladoc Health (NYSE: TDOC) all would have doubled your money, or more, if you had invested in them five years ago, based on their total returns.  Looking at each stock individually, all three are still good investments.  Medical Properties Trust is a real estate investment trust (REIT) that focuses on building and leasing hospital facilities, primarily general acute care hospitals.My biggest winner in 2022 so far is Devon Energy (NYSE: DVN).  This amounts to roughly 1.9% of the stock's current price and reflects an annualized dividend yield of 7.6%.  It's not surprising that Devon is performing well.AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for RINVOQ in gastroenterology and is supported by efficacy and safety data from three Phase 3 randomized, double-blind, placebo-controlled clinic;86.44000244140625;"These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2 2022.Because, unfortunately, nature does not cure disease, even though the words of French philosopher and historian Voltaire would have you believe otherwise: ""The art of medicine consists of amusing the patient while nature cures the disease,"" Voltaire had once famously said.  TheStreet has compiled a list of some of the most expensive drug treatments in the world that cure diseases ranging from progeria, when infants start to look elderly to spinal muscular atrophy, neuroblastoma and a rare blood disorder.  Swiss pharmaceutical giant Novartis  apparently sells the most expensive drug in the world that costs $2.1 million.";78.94000244140625;The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.Thirty five generic drugmakers around the world will make cheap versions of Pfizer Inc's highly effective COVID-19 oral antiviral Paxlovid to supply the treatment in 95 poorer countries, the U.N.-backed Medicines Patent Pool (MPP) said on Thursday.  Pfizer struck a deal last year with the group to allow generic drugmakers to make the pills for 95 low- and middle-income countries.  Paxlovid is expected to be an important tool in the fight against COVID-19 after it reduced hospitalizations in high-risk patients by around 90% in a clinical trial.KENILWORTH, N.J., March 16, 2022--LYNPARZA® Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial;63.66999816894531;"Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ: AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris (ravulizumab). Under the settlement agreement, Alexion and Chugai will withdraw patent infringement proceedings filed with the U.S. District Court for the District of Delaware and Tokyo District Court. Alexion will make a single payment of $775 million in Q2 of 2022, for which a charge will be recognized thBecause, unfortunately, nature does not cure disease, even though the words of French philosopher and historian Voltaire would have you believe otherwise: ""The art of medicine consists of amusing the patient while nature cures the disease,"" Voltaire had once famously said.  TheStreet has compiled a list of some of the most expensive drug treatments in the world that cure diseases ranging from progeria, when infants start to look elderly to spinal muscular atrophy, neuroblastoma and a rare blood disorder.  Swiss pharmaceutical giant Novartis  apparently sells the most expensive drug in the world that costs $2.1 million.WILMINGTON, Del., March 16, 2022--AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced further positive results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had c";70.5199966430664;Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.;52.599998474121094;;43.04999923706055;"The London-listed company will not start any new clinical trials in Russia or enrol more patients into existing studies, an update on its website https://www.gsk.com/en-gb/media/resource-centre/our-response-to-the-situation-in-ukraine/?linkId=100000115602796 showed on Thursday.  The healthcare sector has not pulled out of the country as medicines and medical devices and equipment are considered necessary for humanitarian reasons and are excluded from sanctions.  Merck, Pfizer, Eli Lilly, Novartis and Abbvie are also pausing investments or scaling back their businesses in Russia.Rating Action: Moody's assigns first time Baa1 ratings to GSK Consumer (aka Haleon); stable outlookGlobal Credit Research - 17 Mar 2022London, March 17, 2022 -- Moody's Investors Service (Moody's) has today assigned a Baa1 long-term issuer rating to GSK Consumer Healthcare Holdings (no.2) Limited (Haleon, or the company).  ""The high opening leverage is a key constraint on the credit profile but we expect the company to focus primarily on deleveraging thanks to its solid cash generation and public commitment to do so.""A full list of instruments is available at the end of this press release.RATINGS RATIONALEThe Baa1 issuer rating on Haleon primarily reflects its strong business profile in light of (i) the company's leading position in the consumer healthcare category as a whole and within several product segments, with a good degree of product diversification and scale in all key geographies globally and (ii) the strength of consumer healthcare as a category, characterised by steady volume growth and low price elasticity.";15.010000228881836;;39.779998779296875;;10.640000343322754;Manchin, other fossil fuel shills torpedoed the nomination of banking regulator Sarah Bloom Raskin because she wants to fight climate change;180.88999938964844;;11.229999542236328;;125.20999908447266;;118.48999786376953;;15.15999984741211;;34.34000015258789;These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2 2022.;39.0;;19.1200008392334;;19.1200008392334;;31.510000228881836;;46.84000015258789;Apellis said Wednesday it plans to ask the FDA to approve its eye-disease treatment in the second quarter, and APLS stock surged.;113.68000030517578;;16.700000762939453;;61.7599983215332;;3.6500000953674316;;4.269999980926514;;;;5.539999961853027;Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.;5.900000095367432;;49.81999969482422;"News from China, the Russia-Ukraine war and the Federal Reserve spurred a big market rally. But don't get too excited yet.Harmony Biosciences Holdings, Inc. (""Harmony"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological diseases, today announced applications open on ""World Sleep Day"", Friday, March 18, 2022, for its Patients at the Heart Program. This funding opportunity is open to nonprofit organizations that are working to support and address the challenges of people living with sleep disorders and rare neurological di";28.579999923706055;;39.68000030517578;;11.140000343322754;;14.630000114440918;"LAUSANNE, Switzerland, March 17, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2021, has been filed with the U.S. Securities and Exchange Commission (the ""SEC"").";27.920000076293945;;4.150000095367432;;54.400001525878906;;14.699999809265137;;19.420000076293945;;5.53000020980835;;16.59000015258789;;8.770000457763672;;8.40999984741211;;23.860000610351562;Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...;37.380001068115234;;17.1200008392334;;11.0600004196167;;15.90999984741211;;13.90999984741211;;11.109999656677246;;13.380000114440918;
2022-03-18;174.83999633789062;J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.In this article, we discuss the 10 dividend aristocrats that hedge funds love. If you want to skip our detailed analysis of dividend stocks, go directly to 5 Dividend Aristocrats Hedge Funds Love. Dividend paying stocks have a history of outperforming stocks that don’t offer dividend payments to shareholders. J.P. Morgan Asset Management found in a […]Following the devastation of the coronavirus pandemic, billions across the globe were looking forward to normalization. Then, Russia attacked Ukraine and all perdition broke loose. Rather than recovery, analysts are now worried about the prospect of stagflation, broadly defined as slowing economic growth and high inflation. This circumstance — a worst of both worlds — has investors thinking about stagflation stocks to buy. But how real is this economic threat? The last time the U.S. encounteredYahoo Finance reporter Anjalee Khemlani details the latest news on COVID-19 and how cases are expected to rise due to the emergence of a new variant in Europe.Since 1980, we’ve had six recessions. We aren’t there yet. But if we do get there, don’t fret too much. In five of the last six recessions, the S&P 500 was up a year later.;54.5099983215332;;287.6400146484375;FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate-to-severe ulcerative colitis in adults. This is the fourth indication for Rinvoq in the United States.The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.The Dow Jones moved higher as the stock market rally continued. Warren Buffett boosted Occidental Petroleum. Tesla stock rose.;111.47000122070312;;159.1999969482422;FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate-to-severe ulcerative colitis in adults. This is the fourth indication for Rinvoq in the United States.AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced Health Canada has approved SKYRIZI® (risankizumab), for the treatment of adult patients with active psoriatic arthritis. In PsA, SKYRIZI can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).;86.79000091552734;The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.;79.11000061035156;We are honored to have earned the designation VETS Indexes 5 Star Employer, as part of the 2022 VETS Indexes Employer Awards. The award recognizes the organization’s commitment to recruiting, hirin...Yahoo Finance reporter Anjalee Khemlani details the latest news on COVID-19 and how cases are expected to rise due to the emergence of a new variant in Europe.KENILWORTH, N.J., March 17, 2022--Merck’s KEYTRUDA Significantly Improved DFS Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA NSCLC Regardless of PD-L1 ExpressionTreatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.;63.22999954223633;"In a video message played to crew, P&O Ferries said it would replace the dismissed workers with cheaper agency staff.  - The Bank of England raised interest rates from 0.5 per cent to 0.75 per cent on Thursday, underlining its resolve to fight soaring inflation.AstraZeneca is braced to abandon efforts to get its Covid vaccine approved in the US if it is simply ""banging its head against a brick wall indefinitely"" with regulators.Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.An AstraZeneca Plc executive said the British drugmaker would consider not submitting its COVID-19 vaccine for approval in the United States if the regulatory process takes too long, the Financial Times reported on Thursday.  The company's research and development head, Mene Pangalos, said AstraZeneca would instead focus on selling the vaccine in other countries, though it will continue talks with the U.S. Food and Drug Administration, according to the report.  AstraZeneca did not immediately respond to a Reuters request for comment.";71.0199966430664;;52.09000015258789;Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.Sanofi moves forward with EUROAPI listing on Euronext Paris Sanofi will give its shareholders the opportunity to be part of EUROAPI’s new chapter of growth through an additional extraordinary dividend in kindEUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditionsThe French State, through the fund French Tech Souveraineté, intends to acquire 12% of EUROAPI’s capital for up to €150 million from Sanofi to become a long-term reference shareholder of EUROAPIAs plan;43.02000045776367;Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.;15.100000381469727;Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.;39.31999969482422;;10.65999984741211;Canonsburg-based pharmaceutical company Viatris Inc. said it prevailed in federal court against Biogen over a patent for a drug that had been launched as a generic in August 2020.Viatris Inc. (NASDAQ: VTRS) today announced that it is pleased with the decision by the United States Court of Appeals for the Federal Circuit denying Biogen's request that the Court reconsider its prior decision affirming the invalidity of Biogen's U.S. Patent No. 8,399,514, covering Tecfidera®. Following the Court's denial of Biogen's rehearing petition, the '514 patent remains invalid. Viatris' subsidiary Mylan Pharmaceuticals, Inc. launched the first therapeutically equivalent substitutable;191.42999267578125;WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 22-23, 2022. Tony J. Hunt, President & Chief Executive Officer, will participate in a fireside chat on Tuesday, March 22, at 9:45 a.m. EDT. A live webcast of the presentation will be accessible through Repligen’s Investor;11.210000038146973;;122.54000091552734;;117.44000244140625;;15.399999618530273;;35.08000183105469;;38.529998779296875;;19.920000076293945;;20.100000381469727;;32.66999816894531;;52.90999984741211;;117.83999633789062;;19.59000015258789;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2021 before the market opens on Tuesday, March 29, 2022, and host a conference call to discuss the results and provide a corporate update at 8:00 a.m. EST.";62.20000076293945;With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.;3.740000009536743;;4.150000095367432;;;;5.599999904632568;;5.920000076293945;;49.16999816894531;;30.260000228881836;;42.7599983215332;;11.260000228881836;;14.25;;28.799999237060547;;4.190000057220459;"BRIDGEWATER, N.J., March 17, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced it has been awarded a sub-license from the Medicines Patent Pool (MPP) to manufacture and commercialize a generic version of nirmatrelvir, co-packaged with ritonavir, in 95 low- and middle-income countries. Nirmatrelvir is an oral protease inhibitor co-packaged with ritonavir for the treatment of mild-to-moderate COVID-19.";54.77000045776367;;14.579999923706055;;19.84000015258789;;5.650000095367432;;16.719999313354492;;9.0;;8.420000076293945;;25.56999969482422;;39.02000045776367;;16.920000076293945;;10.930000305175781;;15.760000228881836;;14.130000114440918;;11.800000190734863;;13.979999542236328;
2022-03-21;175.8300018310547;In this article, we will look at 10 dividend ETFs to consider for retirement. If you want to skip reading about what ETFs are and how they differ from stocks and mutual funds, you can go directly to 5 Dividend ETFs to Consider for Retirement. What are ETFs An ETF, or exchange-traded fund, is a […]J&J, Pfizer, BioNTech, and Moderna have been highlighted in this Analyst Blog.;54.189998626708984;;289.6400146484375;;110.19000244140625;;160.0500030517578;Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.In this article, we will look at 10 dividend ETFs to consider for retirement. If you want to skip reading about what ETFs are and how they differ from stocks and mutual funds, you can go directly to 5 Dividend ETFs to Consider for Retirement. What are ETFs An ETF, or exchange-traded fund, is a […]AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, in Boston. Data across AbbVie and Allergan's diversified portfolio of medical and aesthetic dermatology products underscore the companies' deep-rooted commitment to advancing science and striving to redefine the standards of patient care.;86.08000183105469;;79.05999755859375;The global pharmaceutical industry grows in importance with each passing year. These two companies are prominent participants.;63.47999954223633;"The global pharmaceutical industry grows in importance with each passing year. These two companies are prominent participants.WILMINGTON, Del., March 21, 2022--New preclinical authentic ‘live’ virus data from Washington University School of Medicine demonstrated that EVUSHELDTM (tixagevimab co-packaged with cilgavimab) retains potent neutralizing activity against the emerging and highly transmissible Omicron SARS-CoV-2 BA.2 subvariant.1 The data also showed that EVUSHELD retains activity against Omicron BA.1 and BA.1.1.1(Bloomberg) -- Here’s the key business news from London-listed companies this morning:Most Read from BloombergUkraine Update: Mariupol Refuses Russia Ultimatum; Kyiv Mall HitHong Kong Signals Covid Shift by Cutting Flight Bans, QuarantineUkraine Update: Zelenskiy Says Some Opposition Parties SuspendedChina Eastern Boeing 737 Jet Crashes With More Than 130 on BoardRussia Uses Hypersonic Weapons as War Enters Bloodier PhaseAstraZeneca Plc: The pharmaceutical company said its Evusheld Covid treatme";71.05000305175781;Bristol Myers (BMY) gets FDA approval for a fixed-dose combination of Opdivo (nivolumab) and relatlimab to treat patients 12 years of age or older with unresectable or metastatic melanoma.In this article, we examined why Michael Burry warns of inflation and why he compares current conditions to 1977. We also reviewed inflation resistant top 6 stock picks of Michael Burry. You can skip our detailed discussion and jump directly to Michael Burry’s Top 3 Stock Picks. Michael Burry of Scion Asset Management, who is […]Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.The FDA approved Bristol-Myers Squibb & Co's (NYSE: BMY) fixed-dose combination of nivolumab and relatlimab, Opdualag, for patients 12 years of age or older with unresectable or metastatic melanoma. The approval is based on the Phase 2/3 RELATIVITY-047 trial, which compared Opdualag (n=355) to nivolumab alone (n=359). The trial met its primary endpoint, progression-free survival (PFS). Opdualag more than doubled the median PFS compared to nivolumab monotherapy, 10.1 months versus 4.6 months. ThePRINCETON, N.J., March 21, 2022--BMS to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific SessionArcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.Volastra will receive an upfront payment of $30 million, with the potential for an additional $1.1 billion in milestone payments.;50.95000076293945;;42.84000015258789;;15.119999885559082;;38.959999084472656;;10.770000457763672;Davis Funds, an investment management firm, published its “Davis Global Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. After outperforming for the previous five-, 10- and 15-year periods, Davis Global Fund underperformed in 2021. As a result, the earnings of Davis Global Fund portfolio companies have grown at […]Davis Funds, an investment management firm, published its “Davis Opportunity Fund” fourth-quarter 2021 investor letter – a copy of which can be downloaded here. For the year ended December 31, 2021, Davis Opportunity Fund delivered a return of 24.96%, reflecting real progress in the underlying business fundamentals across most of its holdings. Spare some time […];188.07000732421875;;10.890000343322754;;117.12000274658203;;111.58000183105469;;15.319999694824219;DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients. DNP may be triggered through the slightest touch upon which the body sends unprompted pain signals to the brain.;34.77000045776367;;38.22999954223633;;19.520000457763672;;19.959999084472656;;31.010000228881836;CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer, Tony Coles, M.D. will participate in a fireside chat at the Stifel 4th Annual CNS Day on Tuesday, March 29, 2022 at 9:00 a.m. EDT. The live webcast of the fireside chat can be accessed on the investor relations section of the Cerevel Therapeutics website here.;52.09000015258789;;116.06999969482422;;18.020000457763672;;59.97999954223633;;3.569999933242798;;3.5399999618530273;;;;5.690000057220459;;5.610000133514404;;49.27000045776367;;27.959999084472656;Enrollment target achieved for expansion cohort 6 (EXP-6) for repotrectinib in NTRK-positive TKI-pretreated advanced solid tumors Company anticipates second repotrectinib pre-NDA meeting in first quarter 2023 to discuss registration timeline for NTRK-positive advanced solid tumor patients Company remains on track to report top line ORR and DOR data and conduct a pre-NDA meeting for repotrectinib in ROS1-positive NSCLC, both anticipated in second quarter 2022 SAN DIEGO, March 21, 2022 (GLOBE NEWS;41.5;;9.880000114440918;;13.279999732971191;;27.65999984741211;;4.050000190734863;;50.849998474121094;;13.630000114440918;;19.0;SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Chris Robillard to the newly created position of chief business officer. Mr. Robillard brings more than a decade of experience designing and implementing corporate development strategies to;5.28000020980835;;16.979999542236328;;8.539999961853027;;8.600000381469727;;24.469999313354492;Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;37.779998779296875;;16.489999771118164;"WESTLAKE VILLAGE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, will host an Investor Day in Boston, MA on Monday, March 28, 2022 at 10:30 a.m. EDT. Frank Watanabe, President and Chief Executive Officer; Patrick Burnett, MD, PhD, FAAD, Chief Medical Officer; and Ken Lock, Chief Commercial Officer will present a comprehensive overview of the Company";9.829999923706055;;15.899999618530273;;13.510000228881836;;10.9399995803833;BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at Stifel’s 4th Annual CNS Day on Tuesday, March 29, 2022 at 11:30 a.m. ET. The fireside chat will be available via live webcast thr;13.670000076293945;
2022-03-22;175.0;Though the number of COVID cases has dramatically decreased since the beginning of the year, there’s still a significant number of people around the world who remain unvaccinated.Johnson & Johnson (JNJ) closed at $175.83 in the latest trading session, marking a +0.57% move from the prior day.Yahoo Finance Live details the spread of a new COVID variant in the U.S., health experts' predictions on the scale of an outbreak, renewed discussions around future booster shots and mask mandates, and Shanghai Disney closing down.;53.040000915527344;European countries, including the UK, German and France, lifted their COVID-19 restrictions 'too brutally' and are now struggling with rising cases again as the highly transmissible BA.2 variant spreads, according to the European head of the World Health Organization.Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.NEW YORK, March 22, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 3, 2022. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2022 Performance Report, to be issued that morning.Though the number of COVID cases has dramatically decreased since the beginning of the year, there’s still a significant number of people around the world who remain unvaccinated.The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.;285.0199890136719;In the latest trading session, Eli Lilly (LLY) closed at $289.64, marking a +0.7% move from the previous day.;109.61000061035156;Aeterna Zentaris Inc (NASDAQ: AEZS) provided an update for its ongoing pivotal Phase 3 study AEZS-130-P02 (the DETECT-trial) of macimorelin to diagnose childhood-onset growth hormone deficiency (CGHD). The DETECT trial investigates the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as a growth hormone stimulation test (GHST) in pediatric patients with suspected growth hormone deficiency (GHD). The study will include approximately 100 subjects in Europe and North Ameri;160.00999450683594;Abbvie (NYSE: ABBV) is currently firing on all cylinders. While the overall stock market has been falling since the beginning of the year, the pharma giant's shares have been northbound, up 17% this year.Two more pharmaceutical manufacturers have settled with the state of Rhode Island, worth a combined $107 million. Teva and Allergan were the last remaining defendants in Rhode Island’s sweeping opioid litigation.;85.91000366210938;"Swiss drugmaker Novartis said on Tuesday it was suspending capital investments, media advertising, and other promotional activities in Russia but remained committed to providing access to its medicine there.  ""Novartis condemns the war in Ukraine,"" it said in a statement, adding that ""while we remain committed to provide access to our medicine in Russia, we responsibly pause the initiation of new clinical trials and the enrolment of new study participants in existing trials.""  The move by Novartis follows similar steps by other drugmakers following sanctions against Moscow for its invasion of Ukraine.";79.30000305175781;Merck has a 130 year plus legacy of saving and improving lives around the world, and we remain committed to doing so. We are saddened by the invasion of Ukraine and stand united with the Ukrainian ...Pfizer Inc said on Tuesday it has agreed to sell up to 4 million courses of its oral COVID-19 antiviral treatment Paxlovid to UNICEF for use in 95 low-income countries.  The deal accounts just over 3% of Pfizer's projected production of 120 million Paxlovid courses for this year.  The company said the 95 countries covered in the UNICEF deal account for around 53% of the world's population.KENILWORTH, N.J., March 22, 2022--Review and Meta-Analysis of Real-World Studies Provide Evidence of Effectiveness of PREVYMIS in Preventing CMV Disease in Adults Undergoing AlloHCTYahoo Finance Live details the spread of a new COVID variant in the U.S., health experts' predictions on the scale of an outbreak, renewed discussions around future booster shots and mask mandates, and Shanghai Disney closing down.KENILWORTH, N.J., March 21, 2022--FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI H/dMMR Advanced Endometrial Carcinoma;63.65999984741211;Most children and adolescents with COVID-19 antibodies after SARS-CoV-2 infection usually still have the antibodies in their blood more than half a year later, new data shows.  Each provided three blood samples, at three-month intervals.  The first blood test showed infection-related antibodies indicating recovery from COVID-19 in one-third of the children, the researchers reported online Friday in Pediatrics https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2021-055505/185412/Durability-of-SARS-CoV-2-Antibodies-From-Natural.In this piece we will take a look at the 10 healthcare stocks to buy today according to Steven Cohen’s Point72 Asset Management. If you aren’t interested in the billionaire hedge fund owner’s background or the fund’s profile and want to jump straight to its top healthcare stock picks, then head over to 5 Healthcare […]Yahoo Finance Live details the spread of a new COVID variant in the U.S., health experts' predictions on the scale of an outbreak, renewed discussions around future booster shots and mask mandates, and Shanghai Disney closing down.Most children and adolescents with COVID-19 antibodies after SARS-CoV-2 infection usually still have the antibodies in their blood more than half a year later, new data shows.  Each provided three blood samples, at three-month intervals.  The first blood test showed infection-related antibodies indicating recovery from COVID-19 in one-third of the children, the researchers reported online Friday in Pediatrics https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2021-055505/185412/Durability-of-SARS-CoV-2-Antibodies-From-Natural.Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint. The lawsuit in Delaware federal court said that the use of Imfinzi to treat lung and bladder cancer infringes several patents on Bristol's immunotherapy Opdivo. From the complaint: AstraZeneca exploits Plaintiffs' inventions and infringes Plaintiffs' intellectual property rights by marketing a later-developed anti-PD-L1 antibody;70.81999969482422;In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.05, marking a +0.04% move from the previous day.Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint. The lawsuit in Delaware federal court said that the use of Imfinzi to treat lung and bladder cancer infringes several patents on Bristol's immunotherapy Opdivo. From the complaint: AstraZeneca exploits Plaintiffs' inventions and infringes Plaintiffs' intellectual property rights by marketing a later-developed anti-PD-L1 antibodyBristol Myers Squibb Co (NYSE: BMY) is pairing with New York-based biotech Volastra Therapeutics. The companies announced a multi-year R&D collaboration, with Bristol Myers paying $30 million upfront to Volastra and throwing in a potential $1.1 billion in milestones, plus an additional opportunity for royalties. Volastra, founded by Lewis Cantley, Olivier Elemento, and Samuel Bakhoum, closed an expanded $44 million seed round in April 2021. Also Read: FDA Approves Bristol-Myers' Opdualag, First;51.709999084472656;;43.22999954223633;;14.970000267028809;Aerium Therapeutics, a venture-backed startup, on Tuesday announced industry veteran Rajeev Venkayya will lead the company and released data that showed its two experimental monoclonal antibodies neutralized coronavirus variants, including Omicron and its fast-spreading subvariant BA.2, in lab studies.  Venkayya brings instant credibility to the new venture.  Takeda has vaccines against dengue and Zika in the works, and has been making and distributing COVID-19 shots for Moderna and Novavax in Japan during the pandemic.;38.810001373291016;;10.850000381469727;The S&P 500 is off to a forgettable start this year, but that creates multiple buying opportunities if you’re looking for cheap stocks. Savvy investors will want to pick up cheap stocks, which offer a healthy upside in the future. Luckily, the broad-based pullback has created an opportunity for investors to pick up multiple stocks with chump change. Cheap stocks typically belong to undervalued companies with strong fundamentals but seem to have fallen out of favor with investors. Understanding i;183.88999938964844;;11.079999923706055;;119.5;;123.33999633789062;;15.399999618530273;;35.349998474121094;;38.70000076293945;;19.579999923706055;;19.809999465942383;;33.279998779296875;;54.119998931884766;;119.25;;18.299999237060547;;63.779998779296875;;3.5999999046325684;;3.9700000286102295;;;;6.079999923706055;;6.039999961853027;;49.65999984741211;;29.440000534057617;;42.52000045776367;;9.699999809265137;;13.979999542236328;;29.239999771118164;;4.039999961853027;One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...;53.86000061035156;;14.630000114440918;;19.690000534057617;;5.550000190734863;NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conferences in March: Citi Winter Biotech Virtual Bus TourFormat: Fireside Chat - VirtualDate and Time: Tuesday, March 22nd, 11:00 a.m. ET – 11:40 a.m. ETConference Link: URL Maxim Group 2022 Virtual Growth ConferenceFormat: Company Presentation - V;17.8700008392334;;8.9399995803833;;8.529999732971191;;27.8799991607666;;39.599998474121094;;17.770000457763672;Arcutis Skin Insights: Uncovering Psoriasis Survey Arcutis Skin Insights: Uncovering Psoriasis Survey Arcutis Skin Insights: Uncovering Psoriasis Survey Arcutis Skin Insights: Uncovering Psoriasis Survey Arcutis Skin Insights: Uncovering Psoriasis Survey Arcutis Skin Insights: Uncovering Psoriasis Survey 64% of adults with plaque psoriasis who are on topical treatments reported ever having psoriasis in intertriginous areas, higher than previous epidemiological studies suggestAround three in four;9.739999771118164;;16.030000686645508;;13.210000038146973;;11.869999885559082;;14.449999809265137;
2022-03-23;174.33999633789062;In this article, we discuss the 10 blue-chip stocks with dividends. You can skip our comprehensive analysis of these blue-chip stocks which pay dividends, and go directly to 5 Blue Chip Stocks with Dividends. Blue-chip stocks are companies that have been in business for decades and are giants in their respective industries. Their market caps […]It has already been a turbulent year for investors, full of concerns ranging from geopolitical tensions and rampant inflation to interest rate hikes and the pandemic. The Russian invasion of Ukraine and rocketing crude oil prices have further deteriorated the sentiment among investors who buy Reddit stocks. As retail traders brace for a recession, we increasingly witness heated debates about which defensive stocks to buy during these challenging times. Participants on Reddit forums seem convince;52.189998626708984;"Moderna Inc said on Wednesday it will ask regulators to authorize its COVID-19 vaccine for children younger than 6 years old based on data showing it generated a similar immune response in young children as for adults in its clinical trial.  The Omicron variant of the coronavirus was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2- to 5-year-olds and 44% effective for children ages 6 months to 2 years.  Moderna said these results were consistent with the lower effectiveness against Omicron seen in adults who had received two doses of its vaccine.Moderna Inc. will seek an emergency use authorization from regulators in the U.S., Europe and elsewhere for its COVID-19 vaccine in babies, toddlers and preschoolers, after a late-stage trial found it produced virus-fighting antibodies that were just as strong as in young adults.Moderna's COVID-19 vaccine works in babies, toddlers and preschoolers the company announced Wednesday -- and if regulators agree it could mean a chance to finally start vaccinating the littlest kids by summer.Interim data from a late-stage study showed that the vaccine induced a strong neutralizing antibody response in children aged 6 months to under 6 years.Pfizer is recalling Accuretic due to its high levels of nitrosamine—a chemical compound which increases cancer-risk Shares in the American pharmaceutical giant have fallen 2.1% since the recall was announced.Moderna Inc said on Wednesday it will ask regulators to authorize its COVID-19 vaccine in children younger than 6 years old based on data showing it generated a similar immune response to adults in its clinical trial.  The Omicron variant of COVID-19 was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5 year olds and 44% effective for children 6 months to under 2 years old.  It said these figures were consistent with the lower effectiveness against Omicron seen in adults who had received two doses of its vaccine.Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the DayShares of Pfizer Inc. gained 0.2% in premarket trading on Wednesday after the company said the experimental ulcerative colitis drug it bought through the recent Arena Pharmaceuticals deal improved clinical remission rates. The findings came from a Phase 3 clinical trial evaluating the drug, etrasimod, in 354 patients with ulcerative colitis. Pfizer closed its $6.7 billion acquisition of Arena earlier this month. Pfizer's stock is down 10.2% so far this year, while the broader S&P 500 has declinePfizer Inc said on Wednesday its experimental treatment for an inflammatory bowel disease, acquired last year as part of its $6.7 billion deal for Arena Pharmaceuticals, succeeded in a late-stage trial.  The study was testing the efficacy and safety of etrasimod in patients with moderate to severe ulcerative colitis, a chronic inflammatory disease of the colon that leads to ulcers causing abdominal pain, bloody stools and incontinence.NEW YORK, March 23, 2022--Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). In the study, etrasimod patients achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 as compared with placebo. Statistically significModerna Inc is sponsoring sumo flags in its first such promotion in Japan, as the COVID-19 vaccine maker seeks to wrestle market share from compatriot Pfizer Inc.  The U.S. firm's introduction to the broader Japanese public was set back after some of its doses last year were found to be contaminated, although it has clawed back market share since with the help of a government-endorsed programme.  Now, as the government plans a fourth-dose vaccination programme, Moderna is looking to sumo to boost its public appeal as it seeks to expand beyond COVID-19 shots.TOKYO (Reuters) -Moderna Inc is sponsoring sumo flags in its first such promotion in Japan, as the COVID-19 vaccine maker seeks to wrestle market share from compatriot Pfizer Inc.  The U.S. firm's introduction to the broader Japanese public was set back after some of its doses last year were found to be contaminated, although it has clawed back market share since with the help of a government-endorsed programme.  Now, as the government plans a fourth-dose vaccination programme, Moderna is looking to sumo to boost its public appeal as it seeks to expand beyond COVID-19 shots.Thank you for standing by, and welcome to the fourth quarter 2021 Codex DNA Earnings conference call.  With me on the call today are Todd Nelson, our chief executive officer; Dan Gibson, our chief technology officer; and Jennifer McNealey, our chief financial officer.Pfizer Inc (NYSE: PFE) voluntarily recalls Accuretic (quinapril HCl/hydrochlorothiazide) and two authorized generic versions due to the presence of nitrosamine, N-nitroso-quinapril, above an acceptable level. Pfizer will recall six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets, and four lots of quinapril HCl/ hydrochlorothiazide tablets. Nitrosamines are common in water and foods, including cured and grilled meats, dairy products, and vegetables. Everyone is exp";284.19000244140625;;109.37000274658203;;158.4199981689453;Retirement planning is a challenge for mutual fund shareholders these days. But this portfolio has defied the market's year-to-date swoon.AbbVie (ABBV) closed the most recent trading day at $160.01, moving -0.02% from the previous trading session.;85.55000305175781;;79.7300033569336;"The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Europe's drug regulator is expected to give the go-ahead this week for AstraZeneca's antibody-based injection for preventing COVID-19 infections, two people familiar with the review said, following U.S. and UK approvals.  The treatment is meant for adults whose immune system is too weak to respond to vaccines and offers a new tool to ease the pandemic burden on healthcare systems.  Infections in Europe are on a sharp rise again this month, with the adult vaccination rate stagnating at a little over 83%.4D pharma plc (NASDAQ: LBPS) has announced interim results from Phase 1/2 study evaluating the combination of MRx0518 and Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for renal cell carcinoma (RCC). The Part B of its signal finding study of MRx0518 & Keytruda combo in solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI) had met its primary efficacy endpoint ahead of enrollment completion. The primary efficacy endpoint for Part B of the study is more than threeKENILWORTH, N.J., March 23, 2022--Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical OfficerSouth Korea's total coronavirus infections topped 10 million, or nearly 20% of its population, authorities said on Wednesday, as surging severe cases and deaths increasingly put a strain on crematories and funeral homes nationwide.  The Korea Disease Control and Prevention Agency (KDCA) reported 490,881 cases for Tuesday, the second highest daily tally after it peaked at 621,205 on March 16.  But the death toll nearly doubled in just about six weeks, with daily fatalities peaking at 429 last Friday, fuelling demand for funeral arrangements.South Korea's total coronavirus infections topped 10 million, or nearly 20% of its population, authorities said on Wednesday, as surging severe cases and deaths increasingly put a strain on crematories and funeral homes nationwide.  The Korea Disease Control and Prevention Agency (KDCA) reported 490,881 cases for Tuesday, the second highest daily tally after it peaked at 621,205 on March 16.  But the death toll nearly doubled in just about six weeks, with daily fatalities peaking at 429 last Friday, fuelling demand for funeral arrangements.Merck (MRK) closed at $79.30 in the latest trading session, marking a +0.3% move from the prior day.Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.";64.31999969482422;Europe's drug regulator is expected to give the go-ahead this week for AstraZeneca's antibody-based injection for preventing COVID-19 infections, two people familiar with the review said, following U.S. and UK approvals.  The treatment is meant for adults whose immune system is too weak to respond to vaccines and offers a new tool to ease the pandemic burden on healthcare systems.  Infections in Europe are on a sharp rise again this month, with the adult vaccination rate stagnating at a little over 83%.Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.;71.37999725341797;;51.59000015258789;"By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Fourth Quarter and Fiscal Year 2021 Financial and Operational Results On March 22, 2022, DarioHealth Corp. (NASDAQ:DRIO) published its fourth quarter and fiscal year 2021 operational and financial results and filed its Form 10-K for the period ending December 31, 2021. Dario hosted a conference call and webcast to discussRating Action: Moody's assigns Aa1 rating to L'Oreal's proposed notesGlobal Credit Research - 22 Mar 2022Milan, March 22, 2022 -- Moody's Investors Service (""Moody's"") has today assigned a Aa1 rating to the proposed senior unsecured notes offered by L'Oreal S.A. (""L'Oreal""), including different tranches with maturities between 2 and 4.25 years for a total amount of 3 billion.  The rating outlook is stable.Proceeds from the new notes issuance will be used for general corporate purposes, including the refinancing of the short-term debt raised for the share buyback from Nestlé S.A. in December 2021.A full list of affected ratings can be found at the end of this press release.RATINGS RATIONALEL'Oreal's Aa1 rating reflects the group's strong business profile and solid profitability, supported by its leadership in the global cosmetics industry and large portfolio of well-known brands.";42.90999984741211;"Rather than building small molecules ""from the bottom up,"" LifeMine is able to find drugs that exist in nature — in the genomes of fungi — and make minimal changes to make them suitable for humans.";14.979999542236328;;38.529998779296875;;10.880000114440918;;176.7899932861328;;10.369999885559082;;113.23999786376953;;117.13999938964844;;15.0600004196167;;35.34000015258789;;37.34000015258789;SOMERSET, N.J., March 23, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, was named Newcomer of the Year at the tenth annual Foreign Investment Trophy ceremony hosted by Flanders Investment & Trade (FIT).;19.149999618530273;;20.6299991607666;;32.869998931884766;;52.849998474121094;;114.62999725341797;;19.530000686645508;;64.19999694824219;;3.450000047683716;;3.9000000953674316;"First regulatory submissions for lead oncology programs aumolertinib and sugemalimab are expected to be ex-U.S. in 2H 2022; continuing to engage in discussions with the FDAContinue expanding the Global Buyers Club; goal is to have MOUs in place with payers and health systems that cover approximately 350 million lives by the end of 2022Strong cash position with expected runway into 2025; $1.7 billion in cash and cash equivalents as of December 31, 2021EQRx to host conference call and webcast toda";;;6.170000076293945;;5.829999923706055;;49.310001373291016;;28.93000030517578;;42.5;;8.970000267028809;;13.579999923706055;;28.690000534057617;;4.039999961853027;;53.20000076293945;;14.220000267028809;;19.030000686645508;;5.159999847412109;NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update. To access the webcast, please log in at https://wsw.com/webcast/cc/atai/1358298. The live and archived we;17.110000610351562;;8.989999771118164;;8.5;;27.3799991607666;;37.09000015258789;;17.579999923706055;;9.270000457763672;;15.970000267028809;;14.052000045776367;;11.210000038146973;;14.34000015258789;
2022-03-24;175.24000549316406;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.Moderna CEO Stéphane Bancel joins Yahoo Finance Live to discuss FDA authorization for the company's COVID-19 vaccine for children under 6, the outlook for an Omicron-specific vaccine, and the path forward for company growth after the pandemic.In this article we will be taking a look at the 10 best buy and hold forever dividend stocks. To skip our detailed analysis of dividend investing, you can go directly to see the 5 Best Buy and Hold Forever Dividend Stocks. Income or dividend investing is a strategy that is reputable for its utility and […]Somewhere around 5 a.m., deep inside a chicken coop, Frederick Shelton often gets ideas for his next patent.Here's why Moderna's stock isn't reacting more favorably to a potential COVID-19 vaccine breakthrough.Is Johnson & Johnson stock a buy as officials consider requests for more Covid booster shots from Pfizer and Moderna?(Bloomberg) -- A court ruling allowing Johnson & Johnson to use a controversial bankruptcy strategy to force cancer victims into potential settlement talks has raised the odds that other companies facing costly product-liability claims like 3M Co., and Dow Inc. may follow suit, analysts and legal experts say.Most Read from BloombergPutin Adviser Chubais Quits Over Ukraine War, Leaves RussiaWhere Mornings Would Get Darker Under Permanent Daylight Savings TimeChina Jet’s Nosedive From 29,000 Feet;52.59000015258789;Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis study on etrasimod meets goal.Moderna CEO Stéphane Bancel joins Yahoo Finance Live to discuss FDA authorization for the company's COVID-19 vaccine for children under 6, the outlook for an Omicron-specific vaccine, and the path forward for company growth after the pandemic.The FDA has granted Breakthrough Therapy Designation to Pfizer Inc's (NYSE: PFE) respiratory syncytial virus (RSV) vaccine candidate (PF-06928316 or RSVpreF) to prevent lower respiratory tract disease caused by RSV in 60 years of age or older. The positive results primarily inform the FDA decision of Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg vaccine in a human viral challenge model in healthy adults 18 to 50 years of age. In September 2021, PfizNEW YORK, March 24, 2022--Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.It nearly seems like a distant memory now, but the stocks of COVID-19 vaccine makers were once sizzling hot.  In 2020, shares of Novavax (NASDAQ: NVAX) skyrocketed 2,700%.  Moderna (NASDAQ: MRNA) stock more than quadrupled that year and soared even more at one point in 2021.Is money coming in or going out of shareholders' pockets?In the latest trading session, Pfizer (PFE) closed at $52.19, marking a -1.6% move from the previous day.Dr. Jeremy Faust, Brigham and Women’s Hospital emergency medicine physician and MedPage Today editor-in-chief, joins Yahoo Finance Live to discuss Moderna's vaccine for kids under 6 and the outlook for the COVID-19 BA.2 variant.Moderna stock tumbled Wednesday despite promising test results that could help it beat Pfizer to the finish line with a pediatric Covid shot.Here's why Moderna's stock isn't reacting more favorably to a potential COVID-19 vaccine breakthrough.Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.;287.69000244140625;The FDA sent a rejection letter to Eli Lilly And Co (NYSE: LLY) regarding its anti-PD-1 antibody sintilimab for the first-line treatment of nonsquamous non-small cell lung cancer. The complete response letter (CRL) follows a nearly unanimous Oncologic Drugs Advisory Committee (ODAC) recommendation against sintilimab's approval. The CRL includes a recommendation for an additional clinical study, specifically a multiregional clinical trial comparing standard of care therapy for first-line metastatThe agency asked Lilly and its China-based partner to conduct another trial of the immunotherapy in multiple regions.The U.S. Food and Drug Administration has declined to approve Eli Lilly and partner Innovent Biologics Inc's lung cancer drug that had been studied only in China, Lilly said on Thursday.  The decision comes after a panel of advisers to the regulator in February recommended that Lilly and China-based Innovent should be required to conduct a trial of sintilimab that is applicable to the U.S. population.  The U.S. regulator in a so-called complete response letter recommended an additional multi-regional clinical trial.Eli Lilly & Co. said Thursday it received a complete response letter (CRL) from the U.S. Food and Drug Administration regarding its Biologics License Application (BLA) for its treatment for non-small cell lung cancer. The CRL says the FDA can't approve the BLA for sintilimab in its present form, and includes a recommendation for an additional clinical study. The drug maker is assessing the next steps for sintilimab in the U.S. Lilly's stock, which was still inactive in premarket trading, has gaiEli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine sintilimab injection, a PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC). Sintilimab is being developed by Innovent Biologics, Inc. (HKEX: 01801) and Lilly.Omega Funds has launched a startup that intends to succeed where others have failed: by developing a suite of monoclonal antibodies that can both prevent and treat Covid-19.;108.9800033569336;"Second, the need for lifesaving medicines won't have subsided 10 years from today.  Let's consider two excellent candidates: Novo Nordisk (NYSE: NVO) and Incyte (NASDAQ: INCY).  Denmark-based Novo Nordisk delivered a strong performance last year.Diabetes and obesity drug maker Novo Nordisk will invest ""significantly"" in its supply chain capacity to avoid future supply shortages, the company's CEO Lars Jorgensen told its annual general meeting on Thursday.  Novo Nordisk's new obesity drug, Wegovy, faced supply constraints when it was launched in the United States in June last year, leading to shortages.  ""We are going to invest significantly in building resilience in our supply chain, so we are set up to grab the opportunities we have in the future,"" Jorgensen said, without providing further details.";160.27999877929688;Here are a couple strong, dividend-paying stocks to consider buying amid the current economic uncertainty and market volatility.;86.63999938964844;"FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis study on etrasimod meets goal.The FDA approved Novartis AG's (NYSE: NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate cancer that has spread to other parts of the body. Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments. The company said it had submitted marketing authorization for Pluvicto to the European Medicines Agency and other health authorities. According to Novartis, two late-stage studies evaluatiThe U.S. Food and Drug Administration approved Novartis AG's therapy for the treatment of patients with a type of advanced prostate cancer that has spread to other parts of the body, the drugmaker said on Wednesday.  Novartis' Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments.  The company bought the therapy as part of its $2.1 billion purchase of cancer drugmaker Endocyte in 2018.Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited treatment options FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standaAd hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited treatment options FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus stand";80.41000366210938;FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis study on etrasimod meets goal.;66.0199966430664;"The European Medicines Agency on Thursday recommended the use of AstraZeneca Plc's antibody drug for preventing COVID-19 infections at a time the region faces an increase in cases and stagnation in adult vaccinations.  The EMA said the drug, Evusheld, should be used in adults and adolescents above the age of 12 who were not exposed to the virus.  In comparison, other antibody drugs made by Regeneron Pharmaceuticals Inc, Eli Lilly and Co, and partners GlaxoSmithKline and Vir Biotechnology have already been approved to treat COVID-19 patients.AstraZeneca possesses a stacked, commercialized drug portfolio. And its pipeline of drug candidates is just as enviable.AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) and chemoradiotherapy did not achieve the primary goal of improving survival in patients with locally advanced cervical cancer. The Phase 3 study, dubbed ""CALLA,"" tested progression-free survival of patients with the combination against chemoradiotherapy alone. ""While the results were not what we hoped for, insights from the trial will advance our understanding and application of immunotherapy across our broad clinical development program,"" SuWILMINGTON, Del., March 24, 2022--AstraZeneca has partnered with The National Fish and Wildlife Foundation (NFWF) to plant and sustain one million trees in the United States by the end of 2025. This initiative is part of the Company’s flagship Ambition Zero Carbon program to decarbonize its global operations by eliminating, reducing and substituting for our greenhouse gas emissions, and become carbon negative across our value chain by 2030, in line with science-based targets. As part of its sustOmega Funds has launched a startup that intends to succeed where others have failed: by developing a suite of monoclonal antibodies that can both prevent and treat Covid-19.";72.41000366210938;By Tina DeignanSenior Vice President and US Business Unit Head for Immunology at Bristol Myers Squibb;51.189998626708984;;43.29999923706055;Omega Funds has launched a startup that intends to succeed where others have failed: by developing a suite of monoclonal antibodies that can both prevent and treat Covid-19.LifeMine Therapeutics Inc, a drug discovery startup that uses genetically-encoded small molecules, has partnered with GlaxoSmithKline plc (NYSE: GSK) to discover and develop drugs from fungal genomes. GSK will bring three targets for LifeMine to run through its proprietary drug discovery platform, which scans for fungi that could be a match to create a small-molecule drug. LifeMine will get $70 million from GSK through the deal, a sum that includes an equity investment in a 5 million funding rou;14.960000038146973;;38.52000045776367;;10.949999809265137;In the latest trading session, Viatris (VTRS) closed at $10.88, marking a +0.28% move from the previous day.;179.66000366210938;;10.380000114440918;;112.97000122070312;;116.7300033569336;COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced its intention to offer, subject to market and other conditions, US$500,000,000 aggregate principal amount of convertible senior notes due 2028 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the S;14.670000076293945;;35.29999923706055;;38.849998474121094;;19.40999984741211;;20.719999313354492;;34.060001373291016;;49.54999923706055;WALTHAM, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 7,446,809 shares of its common stock at a public offering price of $47.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by ApellisWALTHAM, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an underwritten public offering of $300 million of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. J.P. Morgan Secur;118.05999755859375;;20.0;;65.45999908447266;;3.4800000190734863;;4.139999866485596;Every investor in EQRx, Inc. ( NASDAQ:EQRX ) should be aware of the most powerful shareholder groups. Generally...;;;5.869999885559082;;5.989999771118164;;50.189998626708984;;29.59000015258789;;43.18000030517578;Zsolt Harsanyi, Ph.D. Appointed Chairman of the BoardKeith Katkin Appointed to the BoardEliminates Role of Executive ChairmanAppoints New Chairs of Audit, Strategic Operations, and Scientific Review Committees GAITHERSBURG, Md., March 23, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its board of directors (the “board”) has undertaken a series of changes consistent with its commitment to continuous improvement of best practices for corporate governance. Eff;9.130000114440918;;13.529999732971191;;28.549999237060547;;4.070000171661377;BRIDGEWATER, N.J., March 24, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that results from the pivotal Phase 3 RISE-PD clinical trial evaluating the novel investigational extended-release CD/LD formulation, IPX-203, in Parkinson’s disease patients with motor fluctuations, will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, WA.;53.97999954223633;;14.65999984741211;;19.34000015258789;;5.139999866485596;;17.0;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...;9.109999656677246;BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Genomic Medicines & Rare Disease Day on Thursday, March 31, 2022, at 11:00 am Eastern Time. Access to the live webcast of this event, as well as archived recordings, will be available under the “Events” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.;8.5;;28.079999923706055;;36.75;;17.690000534057617;;9.470000267028809;;16.010000228881836;;13.529999732971191;;11.569999694824219;;13.65999984741211;
2022-03-25;176.9199981689453;Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.The European Medicines Agency on Friday recommended the use of Johnson & Johnson and its partner Legend Biotech Corp's CAR-T therapy to treat multiple myeloma, nearly a month after the treatment was cleared in the United States.  The drug, Carvykti, was initially tested in China and later in the United States and Japan.  Drugs that have only been tested in China have faced increased scrutiny by the U.S. Food and Drug Administration.For retirees looking for a safe haven during the recent market mayhem, dividend stocks may be the answer.  A study from J.P. Morgan Asset Management, a division of big-bank JPMorgan Chase, shows why dividend stocks are so highly valued on Wall Street.  The report compared the performance of publicly traded companies that initiated and grew their payouts over a four-decade period (1972-2012) to stocks that didn't pay a dividend.Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.;52.779998779296875;The move could limit access to shots for the uninsured and throw Moderna into private market competition for the first time in its history.The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.The company's shares have soundly outperformed the market in the past year, mainly due to its COVID-19 vaccine, Comirnaty, which it developed in collaboration with BioNTech.  This could put downward pressure on the company's shares.  While that's a legitimate worry, there are excellent reasons to be optimistic about Pfizer's future.Novartis, Merck and Pfizer have been included in this Analyst Blog.It can be challenging for investors to make decisions when volatility is high.  Here are three brilliant stocks to buy in an uncertain market.  You won't find many stocks with a more reliable underlying business than Easterly Government Properties (NYSE: DEA).The lawsuit is a preemptive strike in a widening dispute over patents involving the makers of Covid-19 vaccines.Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.;289.0199890136719;Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.Pharma giant Eli Lilly & Company (NYSE: LLY) has performed splendidly in the past year, leaving both the broader market and the pharmaceutical industry in the dust.  Geopolitical tensions, which are already high, could escalate further and send Eli Lilly (along with the rest of the market) crashing.  If we put these marketwide worries aside, though, there is at least one key reason why the future looks bright for Eli Lilly.The FDA sent Eli Lilly back to the drawing board Thursday, but it might not be worth the hassle. Regulators rejected a lung cancer drug the...The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.Eli Lilly and Co. acquired the 415-acre site in March. It'll house the company's recently announced $1 billion pharmaceutical plant.The stock is trading above its 50-day and 200-day moving averages and those moving averages are sloping upward.;106.51000213623047;;161.3300018310547;AbbVie (NYSE:ABBV): The pharma giant has been expanding its portfolio to compensate for the upcoming loss of Humira exclusivity Chevron Corporation (NYSE:CVX): CVX stock recently hit a record high and the bullish sentiment will likely continue Cincinnati Financial Corporation (NASDAQ:CINF): CINF is a well-respected Dividend King with a profitable insurance business Source: Shutterstock Wall Street has been nervous since the start of the year. Amidst the soaring inflation and geopolitical turmoilIn this article, we discuss 10 dividend stocks better than cryptocurrencies. If you want to see some more stocks in this selection, 5 Dividend Stocks Better Than Cryptocurrencies. Cryptocurrencies took the finance world by storm in 2021, when pandemic-driven investing reached record highs and retail investors flocked to crypto trading. The crypto universe peaked in […]The Texas attorney general on Thursday ordered drugmakers Abbvie Inc and Endo International to turn over materials related to the sale of puberty blockers to children who believe they are transgender, part of an investigation into their off-label use.  The demand comes during a growing controversy over the use of medication given to halt the development of puberty and secondary sex characteristics in children as young as 8 who have been diagnosed with gender dysphoria.  Texas Attorney General Ken Paxton has said he is investigating whether pharmaceutical companies are promoting hormone therapies such as Supprelin LA and Lupron to children and their parents without disclosing potential long-term effects.Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.;86.86000061035156;"CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease (GvHD) is a serious and debilitating complication of stem cell transplants, with no established standard of care for patients who do not adequately respond to first-line steroid treatment3,4 Nearly half of patients experience either acute or chronic GvHD, or both, following allogeneic transplants3,4 Basel, MaPositive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial demonstrating high response rates in heavily pretreated patients; 69% experienced a complete response, with an 86% overall response rate and a remarkable safety profile1If approved, Kymriah may offer an effective, new treatment option to patients with advanced follicular lymphoma to break the cycle ofNovartis, Merck and Pfizer have been included in this Analyst Blog.The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.";81.33999633789062;KENILWORTH, N.J., March 25, 2022--Merck Receives Positive EU CHMP Opinion for KEYTRUDA for Patients With MSI-H or dMMR Tumors in Five Different Types of CancerIn this Teal Talks episode, health care influencers Dr. Marcella Nunez-Smith and Dr. Aletha Maybank discuss how the pandemic has impacted health equity and disparitiesKENILWORTH, N.J., March 25, 2022--Positive EU CHMP Opinion for KEYTRUDA Plus Chemo +/- Bev, as Treatment for Persistent, Recurrent or Metastatic Cervical Cancer PD-L1 (CPS ≥1);65.12999725341797;The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.Three that are excellent buys today are Teladoc Health (NYSE: TDOC), AstraZeneca (NASDAQ: AZN), and Intuitive Surgical (NASDAQ: ISRG).  Telehealth is a growing sector of healthcare, and a great way to gain exposure to that is by investing in a top company like Teladoc.  In 2022, Teladoc expects total visits to reach as high as 20 million and revenue to be around $2.6 billion -- for a year-over-year sales increase of at least 25%.A sustainability initiative is part of the Big Pharma company's effort to plant 50 million trees worldwide.(Bloomberg) -- European stocks retreated as market participants weighed manufacturing data that underscored the threat to economic growth from soaring raw material prices and the latest tensions around the war in Ukraine.Most Read from BloombergPutin Adviser Chubais Quits Over Ukraine War, Leaves RussiaChina Plane Crash Update: Debris Found Miles From Main WreckageRussia Central Banker Wanted Out Over Ukraine, Putin Said NoWall Street Is Scrambling For the Exits in Moscow — and Billions Are at S;73.27999877929688;Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.The FDA has extended the review period for Bristol Myers Squibb Co's (NYSE: BMY) supplemental application for Reblozyl (luspatercept-aamt) for anemia in adults with non-transfusion-dependent (NTD) beta-thalassemia. The agency has pushed the decision to June 27 from March 27, granted earlier under priority review. The application was based on results from the pivotal Phase 2 BEYOND study evaluating Reblozyl plus best supportive care. An application (Type II variation) is also under review by thePRINCETON, N.J., March 25, 2022--BMS Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License ApplicationThe Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.;51.529998779296875;The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.;43.279998779296875;The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.Both are riding business trends that make them solid bets: ASE Technology makes packaging for the in-demand semiconductor industry, and GlaxoSmithKline is an established pharmaceutical company that promises stability amid broader economic downturns.  ASE Technology isn't a semiconductor maker, but it's still crucial to the industry, providing front-end outsourced packaging, testing, and electronic services to manufacturers.  The global semiconductor materials market was worth $52.1 billion in 2021 and IMARC Group analysts expect a compound annual growth rate (CAGR) of 4.07% over the next five years, reaching a $61.3 billion market by 2027.GlaxoSmithKline (GSK) closed the most recent trading day at $43.30, moving +0.91% from the previous trading session.;14.930000305175781;;38.369998931884766;;11.1899995803833;;180.5500030517578;;10.529999732971191;;116.02999877929688;;114.38999938964844;COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced the pricing of its offering of US$500,000,000 aggregate principal amount of 2.25% convertible senior notes due 2028 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as a;14.420000076293945;;34.9900016784668;;36.880001068115234;"SOMERSET, N.J., March 25, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended Janssen Pharmaceutica NV’s marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed andThe European Medicines Agency on Friday recommended the use of Johnson & Johnson and its partner Legend Biotech Corp's CAR-T therapy to treat multiple myeloma, nearly a month after the treatment was cleared in the United States.  The drug, Carvykti, was initially tested in China and later in the United States and Japan.  Drugs that have only been tested in China have faced increased scrutiny by the U.S. Food and Drug Administration.";18.81999969482422;;18.459999084472656;;33.380001068115234;;49.279998779296875;;120.13999938964844;;17.790000915527344;;62.36000061035156;;3.509999990463257;;4.050000190734863;;;;5.619999885559082;;5.739999771118164;;51.130001068115234;;28.350000381469727;;44.20000076293945;;9.789999961853027;Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected in H2 2022 Robust balance sheet with cash of $459 million SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer;13.3100004196167;;27.239999771118164;;4.150000095367432;;51.099998474121094;;13.90999984741211;;18.959999084472656;;5.070000171661377;;17.84000015258789;;8.84000015258789;;8.880000114440918;;27.18000030517578;SAN DIEGO, March 25, 2022--Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit;36.33000183105469;;17.190000534057617;Pooled analysis of DERMIS-1 and DERMIS-2 demonstrated significantly more roflumilast-treated patients achieved Investigator Global Assessment (IGA) success (40%) at week 8 compared to vehicle (7%), consistent with results from the individual studiesNew post hoc analyses showed consistent efficacy regardless of baseline body surface area (BSA) and efficacy in psoriasis patients with knee and/or elbow involvementInterim results from an ongoing Phase 3 open-label, long-term study supports the previPreviously reported data demonstrated that roflumilast foam provided statistically significant improvement in disease severity and a favorable safety and tolerability profileImprovement on Investigator Global Assessment (IGA) Success and itch as early as week 2, the first timepoint measuredNew patient reported quality of life data shows improvement across all emotional, symptom, and functioning domains WESTLAKE VILLAGE, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Na;9.489999771118164;;15.210000038146973;;13.82699966430664;;11.09000015258789;;13.15999984741211;
2022-03-28;177.8300018310547;In this article, we discuss 10 dividend stock picks of legendary value investor Joel Greenblatt. If you want to see some more dividend stocks in his portfolio, click Legendary Value Investor Joel Greenblatt’s 5 Dividend Stock Picks. Joel Greenblatt is an American value investor and hedge fund manager, who received his MBA from The Wharton […];53.279998779296875;"The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.As of late February, about 146 million square feet of office space was under construction, projects wrapping up amid myriad change within the office world.Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.Pfizer's oral COVID-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world.  The world's largest randomised study of potential medicines for COVID-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment.  ""Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe COVID-19,"" said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have dominated the U.S. market since they became the first to launch their vaccines.  Today, Pfizer has fully vaccinated more than 124 million Americans.  Does this mean these players are a step ahead of Pfizer and Moderna?";291.6600036621094;"Innovent Biologics, Inc. (""Innovent"", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (""Lilly"", NYSE: LLY) today announced that in light of both parties' shared commitment to continue bringing innovative medicines to benefit Chinese patients and to leverage the strengths of each party in a win-win manner, parties will n";107.91000366210938;"Bagsværd, Denmark, 28 March 2022 – On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 22 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme i";161.97000122070312;"When faced with an investment decision, I hemmed and hawed for way more time than I should have.  Warren Buffett himself acknowledged recently that he and his investing team ""find little that excites us.""  A few of them are even in Buffett's investment portfolio.";86.98999786376953;;81.20999908447266;Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.In this article, we discuss 10 dividend stock picks of legendary value investor Joel Greenblatt. If you want to see some more dividend stocks in his portfolio, click Legendary Value Investor Joel Greenblatt’s 5 Dividend Stock Picks. Joel Greenblatt is an American value investor and hedge fund manager, who received his MBA from The Wharton […];65.37999725341797;Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have dominated the U.S. market since they became the first to launch their vaccines.  Today, Pfizer has fully vaccinated more than 124 million Americans.  Does this mean these players are a step ahead of Pfizer and Moderna?;73.11000061035156;Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.;51.83000183105469;Today sanofi-aventis Canada Inc. (Sanofi Canada) announced the expanded approval of Dupixent® (dupilumab injection) as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma. The approval is based on the pivotal VOYAGE phase 3 trial which enrolled 408 children aged six to 11 years with uncontrolled moderate- to severe asthma. The primary endpoint of the trial was the annualized rate of sevXenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency Xenpozyme represents first Sanofi therapy to be approved under the SAKIGAKE ‘fast-track’ designationApproval based on positive results from two separate clinical trials in children and adults demonstrating improvement in lung function (as measured by DLco) and reduction of spleen and liver volumes Paris, March 28, 2022. The Japanese Ministry of Health, Labor, and Wel;43.369998931884766;The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK and Vir said they are preparing a data package to support a higher dose for sotrovimab for the BA.2 subvariant. Related: AstraZeneca;14.520000457763672;OSAKA, Japan & CAMBRIDGE, Mass., March 28, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO® (lanadelumab) subcutaneous injection 300mg syringes for prophylaxis against acute attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older in Japan.1;37.9900016784668;;10.899999618530273;;179.57000732421875;;10.569999694824219;;117.4800033569336;;111.3499984741211;;14.619999885559082;;35.16999816894531;;35.869998931884766;;19.110000610351562;;18.579999923706055;;33.47999954223633;;48.099998474121094;;121.18000030517578;;16.850000381469727;;60.689998626708984;;3.5799999237060547;;4.0;;;;5.550000190734863;;5.71999979019165;;50.9900016784668;;28.25;;42.95000076293945;;9.630000114440918;;14.270000457763672;;27.59000015258789;;4.110000133514404;;52.5099983215332;;13.699999809265137;;19.049999237060547;;4.96999979019165;;18.049999237060547;DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2021 and gave updates on its business. Fourth Quarter 2021 Business Highlights In December 2021, we reported the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001, our proprietary inhalable;8.899999618530273;;8.699999809265137;;27.110000610351562;;30.170000076293945;;17.440000534057617;Differentiated profile of topical roflumilast aligned with unmet needs in multiple inflammatory dermatosesWell-prepared for the Company’s potential first launch ahead of PDUFA target action date of July 29Clinical program for topical roflumilast continues to advance with announcement of new long-term Phase 2 data in seborrheic dermatitis and three Phase 3 data readouts expected in 2022Topical roflumilast has potential to generate sales of ~$2 billion to ~$4 billion in the U.S. dermatology segmen;9.119999885559082;;14.989999771118164;;13.8149995803833;;10.930000305175781;;12.989999771118164;
2022-03-29;177.74000549316406;;52.7400016784668;;288.3900146484375;;110.19999694824219;The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.Novo Nordisk said on Monday the U.S. Food and Drug Administration has approved a higher dosage of 2 mg of Ozempic for the treatment of adults with type 2 diabetes.  Ozempic is now approved in the United States in doses of 0.5 mg, 1 mg and 2 mg, the company said.Bagsværd, Denmark, 28 March 2022 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2.0 mg dose of Ozempic® (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for the treatment of adults with type 2 diabetes. Ozempic® is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults. Further, Ozempic® is indicated to reduce the risk of major cardiovascular events such as h;162.17999267578125;;87.51000213623047;CVS's earnings could be dented by opioid litigation as well as changes affecting its pharmacy segment, Deutsche Bank says.Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Novartis AG (NVS), and Deere & Company (DE).Novartis (NVS) obtains positive CHMP opinion for the label expansion of Jakafi and Kymriah.;81.56999969482422;;65.94999694824219;AstraZeneca's antibody drug Evusheld, which is taken pre-emptively to prevent COVID-19, has been approved in the European UnionThe European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.;73.2300033569336;;51.41999816894531;In addition to reporting its fourth-quarter results, the clinical-stage biotech announced a lucrative new collaboration deal with Sanofi.By Sam BougheddaSanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against three oncology targets and three immunology/inflammation targets. IGM will receive a $150 million upfront payment. Sanofi has also expressed an interest in purchasing up to $100 million of IGM non-voting common stock in public financing. For each oncology target collaboration program, IGM will lead R&D activities and assume related costs thSanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets * Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets * Collaboration to create, develop, manufacture and commercialize new class of potential therapeutics combining the superior features of multi-valent IgM antibodies over conventional IgG antibodies for stimulating cell surfaceSanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver Dupixent peak sales ambition raised to more than €13 billion Chronic obstructive pulmonary disease 2023 pivotal readouts provide potential for additional Dupixent sales ambition upgrade13 potential new medicines currently in the clinic to treat chronic inflammatory diseases, with 17 readouts expected by the end of 2024 Paris, March 28, 2022. Tomorrow, Sanofi will host an Immunology Investor Eve;43.290000915527344;;14.850000381469727;;38.7400016784668;Royalty Pharma plc (Nasdaq: RPRX) today announced a charitable commitment totaling $7.5 million to The Leukemia & Lymphoma Society (LLS), a global leader in the fight against blood cancer. Through this five-year alliance, Royalty Pharma will support initiatives focused on reducing healthcare disparities in blood cancer care and treatment. Royalty Pharma is a founding donor of the LLS IMPACT grant program (Influential Medicine Providing Access to Clinical Trials) which awards funding to major can;11.180000305175781;Dividend stocks can be a great source of passive income that can help smooth out losses during market downturns.  The one thing better than a robust dividend stock, though, is a robust dividend stock that is trading at an attractive valuation.  Let's look at two stocks income-seeking investors would do well to buy at current levels: Merck (NYSE: MRK) and Viatris (NASDAQ: VTRS).;184.32000732421875;;10.75;;121.63999938964844;;119.4000015258789;;15.399999618530273;;35.31999969482422;"VANCOUVER, BC / ACCESSWIRE / March 29, 2022 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. (""Orogen"" or the ""Company"") is pleased to announce that Orogen's board of directors has elected independent board member Mr.";37.02000045776367;;19.200000762939453;;19.420000076293945;;34.97999954223633;;48.709999084472656;WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,117,021 shares at the public offering price of $47.00 per share. The exercise of the option to purchase additional shares brought the total numbe;124.62000274658203;;19.389999389648438;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced financial results for the 12 months ended December 31, 2021, and provided key business updates.";62.41999816894531;;3.75;Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.;4.400000095367432;;;;5.75;;6.28000020980835;;50.189998626708984;;29.149999618530273;SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he le;43.959999084472656;;9.699999809265137;;14.489999771118164;;29.139999389648438;;4.21999979019165;;55.09000015258789;;14.920000076293945;;19.670000076293945;;5.420000076293945;;18.030000686645508;;8.989999771118164;;8.390000343322754;;29.049999237060547;;34.540000915527344;;18.450000762939453;;9.630000114440918;;29.489999771118164;"In addition to reporting its fourth-quarter results, the clinical-stage biotech announced a lucrative new collaboration deal with Sanofi.The stock market has bounced sharply from its lows last month, and the gains looked poised to continue on Tuesday morning.  As of 8:15 a.m. ET, futures on the Dow Jones Industrial Average (DJINDICES: ^DJI) were up 187 points to 35,040, while S&P 500 (SNPINDEX: ^GSPC) futures had gained 25 points to 4,593 and Nasdaq Composite (NASDAQINDEX: ^IXIC) futures had risen 98 points to 15,083.  A couple of stocks did even better, rising more than 20% in premarket trading on Tuesday morning.By Sam BougheddaBy Sam BougheddaMOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public offering. In addition, IGM intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares at the public offering price, less underwriting discounts an– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate Development, Regulatory and Commercial Milestones – – Ongoing Progress in Clinical Programs with Two Phase 2 Studies of Two Doses of IGM-2323, 100 mg and 300 mg, in Patients with DLBCL and FL Initiated – – Company to Host Conference Call and Webcast Today at 8:00 a.m. EST – MOUNTAIN VIEW, Calif., MaMOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast today, Tuesday, March 29, 2022, at 8:00 am ET to discuss the Company’s global collaboration agreement with Sanofi, as recently announced. The conference call may be accessed by dialing (866) 649-1996 (domestic) or (409)";14.630000114440918;;11.09000015258789;;14.130000114440918;
2022-03-30;179.58999633789062;;52.439998626708984;;289.8900146484375;;112.54000091552734;Apple, The Procter & Gamble, Chevron, Novo Nordisk and Canadian Natural Resources Limited have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), The Procter & Gamble Company (PG), and Chevron Corporation (CVX).;163.75;;87.95999908447266;;82.4000015258789;;67.12000274658203;Nineteen million doses of COVID-19 vaccines in Indonesia's national stockpile have expired this year and 1.5 million more  are set to expire next month, as donated shots arrive with a short shelf life, a health official said on Wednesday.  Indonesia and many other developing nations are ramping up their vaccination campaign, aided by donations from wealthy countries, but they have been calling for donations with a longer shelf life.  Most of the expired doses were AstraZeneca's shot, and they also included Moderna's, she said.Nineteen million doses of vaccines in Indonesia's national COVID-19 stockpile have expired this year and 1.5 million more  are set to expire next month, as donated shots arrive with a short shelf life, a health official said on Wednesday.  Indonesia and many other developing nations are ramping up their vaccination campaign, aided by donations from wealthy countries, but they have been calling for donations with a longer shelf life.  Indonesia receives donations from the COVAX global vaccine sharing scheme and countries such as Australia and the United States.Yahoo Finance's Anjalee Khemlani details the latest COVID vaccines for various age groups authorized by the FDA, in addition to commenting on booster shot discussions and the Omicron BA.2 variant.;73.72000122070312;;51.599998474121094;"IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Availability of the Q1 2022 Memorandum for modelling purposes Paris, March 30, 2022. Sanofi announced today that its Q1 2022 Memorandum for modelling purposes is available on the ""Investors"" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q1-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparab";43.70000076293945;;14.430000305175781;(Bloomberg) -- The ongoing tech downturn has caused late-stage venture capital funds to pull back activity as risks to the economy mount, according to a senior executive at Sequoia Capital.Most Read from BloombergUkraine Update: Russia Says Kyiv Makes Rare Cross-Border StrikeRussia Says Ukraine Choppers Made Rare Cross-Border StrikeNever Had Covid? You May Hold Key To Beating the VirusPutin Says Gas Exports to Be Halted If Ruble Payments Not MadeUkraine Update: Red Cross Says Mariupol ‘Safe Pass;39.0;;10.989999771118164;Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Sesame Workshop, the nonprofit behind Sesame Street, is launching new bilingual resources made possible by Viatris Inc. (NASDAQ: VTRS) to support the social and emotional needs of families and caregivers across generations as they collectively continue to adapt to the impacts of the COVID-19 pandemic.NESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that the company has been granted U.S. Patent No. 11,167,003 entitled: “Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot syst;188.55999755859375;;11.8100004196167;;118.02999877929688;;116.0199966430664;;15.489999771118164;;35.810001373291016;;36.95000076293945;;19.299999237060547;"The companies face a steep scientific and commercial challenge, both in testing the vaccine and in finding a space for it in a well-established Covid-19 vaccine market.Shares of CureVac were up 1.2% in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine it's developing with GlaxoSmithKline . The study is being conducted in the U.S. and is set to enroll 210 adults. The company said it expects to have data in the second half of this year. ""Continued innovation and progress in the development of mRNA-based vaccines is a critical prerequisite to combat the evolving COVID* Phase 1 dose-escalation study started at clinical sites in the U. * Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseasesTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 30, 2022 / CureVac N.";19.780000686645508;;33.619998931884766;;49.470001220703125;Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.;123.0;;18.950000762939453;;59.650001525878906;;3.5399999618530273;;4.199999809265137;;;;5.570000171661377;Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;5.889999866485596;;49.86000061035156;;26.959999084472656;;41.779998779296875;;9.010000228881836;;14.779999732971191;;28.579999923706055;BILLERICA, Mass., March 29, 2022--Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation to Accelerate Alzheimer’s Disease Diagnostic Plasma Test Development;4.21999979019165;;53.65999984741211;;14.170000076293945;NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the UK Medicines and Healthcare products Re;19.0;;5.340000152587891;– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials – Eight new programs added to platform since January 2021 bringing total, as of today, to 13;18.0;;9.029999732971191;;8.5;;27.540000915527344;;30.8799991607666;Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;18.75;;9.829999923706055;;25.850000381469727;IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.MOUNTAIN VIEW, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting common stock at a price to the public of $23.00 per share. IGM expects to receive total gross proceeds of approximately $200.0 million from this offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by IGM. In addition, IGM has granted the underwr;16.049999237060547;Company announcement – No. 10 / 2022 Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations Dr. Adam Steensberg assumes the position of Chief Executive Office refocusing Zealand to better leverage its next-generation peptide platform to address unmet medical needs of patientsCommercial operations restructured to pursue partnerships for Zegalogue, V-Go and the glepaglutide and dasiglucagon late-stage clinical portfol;10.279999732971191;;14.399999618530273;The markets started 2022 with heavy losses – but the last two weeks have seen sharp gains that have lifted stocks back out of correction territory. The S&P 500 is up 11% from its March 14 trough, while the NASDAQ, which had fallen farther, had gained 16% in the last couple of weeks. Goldman Sachs' David Kostin sees an interesting pattern, as we go forward. According to the chief US equity strategist, institutional investors will pull back, while households will be the major source of purchase ac
2022-03-31;177.22999572753906;;51.77000045776367;;286.3699951171875;;111.05000305175781;;162.11000061035156;;87.75;;82.05000305175781;;66.33999633789062;AstraZeneca (AZN) has incremental revenue visibility from the antibody cocktail against covid-19 Pfizer (PFE) has a robust backlog of vaccine doses. Additional booster shot to provide revenue upside. Moderna (MRNA) continues to increase its backlog for 2022. Potential catalyst is vaccine for kids under six. Source: shutterstock.com/PhotobyTawat Covid-19 and its variants have been as unpredictable as the markets in the first few months of 2022. Earlier this year, there was growing optimism about;73.02999877929688;;51.34000015258789;"The company said the costs of financing would be linked to achieving concrete targets in terms of a cumulative number of patients being provided with essential medicines over the next five years.  ""We continue to make progress in our environmental, social and governance activities that are an essential part of our strategy and embedded into our business,"" said Sanofi chief financial officer Jean-Baptiste de Chatillon.Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines Paris, March 31, 2022. Sanofi successfully priced yesterday, March 30, 2022, its offering of a dual-tranche EUR 1.5 billion of notes (the “Notes”). It comprises an inaugural issue of sustainability-linked bond for a nominal amount of EUR 650 million of notes, tied to Sanofi’s commitment to improve access to essential medicines in low- and lower-middle-income countries via its global health nonprofitTruist has lowered the price target on IGM Biosciences Inc (NASDAQ: IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ: SNY) collaboration deal. Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi. However, the analyst keeps a Buy rating on the shares and believes that IGM offers ample room for near-term catalystsIGM Biosciences (IGMS) was on everyone’s radar Tuesday, with shares flying higher by 140% at one point. If there is one segment of the market where shares can take off in such a manner, it is the biotech space, and that always comes hot on the heels of a highly positive development. And obviously investors received one from IGM; Along with the business update, the company announced a major collaboration with French pharma giant Sanofi (SNY). IGM is working on the development of IgM antibodies, a";43.560001373291016;;14.319999694824219;;38.959999084472656;;10.880000114440918;NESS ZIONA, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable solutions mainly for neurological indications, announced today that two posters featuring clinical data on GA Depot will be presented at the forthcoming American Academy of Neurology annual meeting, to take place in-person in Seattle, WA, April 2 to 7, and virtually April 24 to 26. GA;188.08999633789062;;11.680000305175781;;118.56999969482422;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 13 abstracts, including two oral presentations, will be featured at the 2022 American Academy of Neurology (AAN) annual meeting being held April 2-7 in Seattle, WA and virtually from April 24-26. Building on its leadership in migraine, Biohaven is committed to advancing innovative treatments and transforming patient experiences while focusing on research that may drive better outcomes for people across the spectrum o;117.36000061035156;;15.130000114440918;;34.93000030517578;JERSEY CITY, N.J. & SAN DIEGO, March 31, 2022--Organon Enters into Global License Agreement to commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%);36.34000015258789;;19.610000610351562;;18.920000076293945;"HONG KONG, and SHANGHAI, China and FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its status under the Holding Foreign Companies Accountable Act (the “Act”), following the Company’s initial announcement on March 11, 2022. On March 30, 2022, as expected following its adoption of implementing rules pursuant to the Act, the U.S. Securities and Exchange Commission (the “SEC”) added HUTCHMED";35.0099983215332;Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy Poster presentations to include further evidence of tavapadon’s consistent pharmacokinetic and pharmacodynamic profile CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced an upcoming oral presentation and three poster pr;50.810001373291016;;126.79000091552734;;16.239999771118164;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC Group (including its affiliates) and Hony Capital (collectively, the ""Key Shareholders"") as well as its senior management team have voluntarily entered into a 180-days lock-up period commencing from March 31, 2022, and committed not to sell their shares in the Company d";56.439998626708984;;3.440000057220459;;4.130000114440918;;;;5.389999866485596;;5.610000133514404;;48.650001525878906;"Harmony Biosciences Holdings, Inc. (""Harmony"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the company was certified as a Great Place to Work® for the fourth consecutive year. This accolade is based on survey feedback from Harmony employees that evaluates workplace culture and the employee experience.";26.850000381469727;;41.060001373291016;;8.600000381469727;;14.6899995803833;;29.190000534057617;;4.170000076293945;;54.380001068115234;;14.010000228881836;;21.950000762939453;– Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 – – Advancing Phase 3 PATHFNDR Program Evaluating Paltusotine in Acromegaly – – Advancing a Preclinical Parathyroid Hormone Receptor Antagonist Program Using the Drug Development Paradigm Followed by Paltusotine, CRN04894, and CRN04777 – – Co-founded Radionetics Oncology with 5AM Ventures and Frazier Healthcare Partners – – Management Hosting Webcast and CResults Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call to Discuss Findings Today at 4:30 p.m. Eastern Time SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and;5.090000152587891;;18.290000915527344;;8.970000267028809;"– Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022 following recent FDA meeting; initial focus on Hemophilia B with and without inhibitors – – LB101 preclinical data expected to be shared at ASCO 2022; IND planned for late 2022 – – ZF874 Phase 1 update from multiple dose cohorts with PiMZ and PiZZ subjects expected in 2H 2022 – – Pipeline review led to dis";8.5;;26.959999084472656;;32.7599983215332;;19.260000228881836;;9.920000076293945;;26.729999542236328;"Truist has lowered the price target on IGM Biosciences Inc (NASDAQ: IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ: SNY) collaboration deal. Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi. However, the analyst keeps a Buy rating on the shares and believes that IGM offers ample room for near-term catalystsIGM Biosciences (IGMS) was on everyone’s radar Tuesday, with shares flying higher by 140% at one point. If there is one segment of the market where shares can take off in such a manner, it is the biotech space, and that always comes hot on the heels of a highly positive development. And obviously investors received one from IGM; Along with the business update, the company announced a major collaboration with French pharma giant Sanofi (SNY). IGM is working on the development of IgM antibodies, aAcquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.";15.550000190734863;;10.210000038146973;;14.239999771118164;
2022-04-01;178.19000244140625;;51.56999969482422;;292.6700134277344;;112.91000366210938;VANCOUVER, British Columbia, March 31, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce its financial results for the three and twelve-month periods ended December 31, 2021. All amounts are expressed in Canadian dollars, unless otherwise noted. This news release should be read together with Novo’s management’s discussion and analysis (the “Annual MD&A”) and audited consolidated financial statements (the “A;162.67999267578125;;87.69000244140625;FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.;83.5199966430664;;66.80999755859375;FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.;73.81999969482422;;52.20000076293945;(Reuters) -Sanofi plans to list its drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.  Having received approval from the French markets regulator, the listing on the Euronext Paris exchange is set to take place shortly after a May 3 Sanofi shareholder vote on the listing, the French pharmaceutical giant said on Friday.  Sanofi shareholders will receive one EUROAPI share for 23 shares held in the parent company.EUROAPI listing on Euronext Paris expected on May 6, 2022 French AMF approved EUROAPI’s listing prospectus EUROAPI first day of trading expected to occur on May 6, 2022 subject to the approval of the Distribution by the Ordinary and Extraordinary Shareholders’ Meeting to be held on May 3, 2022 Sanofi will host today a dedicated Capital Markets Day at 1:30 pm CET to present EUROAPI’s business in greater detailThe Distribution ratio will be one (1) EUROAPI share per twenty three (23) Sanofi shares;43.88999938964844;;14.510000228881836;OSAKA, Japan, April 01, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors will propose two new candidates for independent external directors at the 146th Ordinary Meeting of Shareholders on June 29, 2022. The new candidates, Kimberly A. Reed and John Maraganore, who – if approved – will join the Board effective June 29, will succeed Toshiyuki Shiga and Shiro Kuniya who have announced their intention to retire. In addition, Masami Iijima, if approved by the shareholde;39.36000061035156;;10.819999694824219;The site, which is 1.1 million square feet, had been a longtime drug manufacturing facility for Mylan NV and its successor company.;188.02000427246094;;11.930000305175781;;118.93000030517578;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that data from a Phase 1, single-center, open-label study evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women was published in the peer-reviewed journal, Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine.;115.97000122070312;;15.399999618530273;;35.150001525878906;;39.099998474121094;;19.15999984741211;;19.790000915527344;;37.150001525878906;;54.97999954223633;;131.80999755859375;;17.510000228881836;;56.900001525878906;;3.509999990463257;;4.409999847412109;;;;5.590000152587891;;5.809999942779541;;49.97999954223633;;28.760000228881836;;43.630001068115234;;8.449999809265137;;14.829999923706055;;30.469999313354492;;4.300000190734863;;59.45000076293945;;13.949999809265137;Aravive (ARAV) delivered earnings and revenue surprises of 3.12% and 36.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?;23.579999923706055;;5.320000171661377;;19.170000076293945;;9.079999923706055;;8.430000305175781;;28.90999984741211;;35.619998931884766;"PLANO, Texas, March 31, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced the completion of the rolling submission of a New Drug Application (""NDA"") to the U.S. Food and Drug Administration (""FDA"") for omaveloxolone for the treatment of patients with Friedreich’s ataxia. This NDA is supported by the efficacy and safety data from the MOXIe Part 1, Part 2, and MOXIe Extension studies. The FD";20.34000015258789;;10.5600004196167;;22.8700008392334;;15.5600004196167;;10.699999809265137;BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that data from its PRAX-944 essential tremor (ET) program will be presented at the upcoming 2022 American Academy of Neurology (AAN) Annual Meeting, which will take place in Seattle, W;14.5;
2022-04-04;176.47000122070312;;50.939998626708984;;291.4200134277344;;113.80999755859375;;161.88999938964844;;87.33000183105469;"Accenture's (ACN) goal behind joining the collaborative is to support and advance cardiovascular disease prevention through integrating innovation and emerging technologies.The drugmaker said it is integrating its pharmaceuticals and oncology units into two medicines units—one for the U.S. and one that focuses on the international market.ZURICH (Reuters) -Novartis said on Monday it was integrating its pharmaceuticals and oncology units into an innovative medicines (IM) business to simplify its structure, targeting savings of at least $1 billion by 2024.  ""Integrating pharmaceuticals and oncology business units into an innovative medicines (IM) business with separate U.S. and international commercial organizations will increase focus, strengthen competitiveness and drive synergies,"" the Swiss pharmaceutical company said in a statement.  It said it expects selling, general and administrative savings of at least $1 billion to be fully embedded by 2024 as a result of these changes.Ad hoc announcement pursuant to Art. 53 LR New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivityIntegrating Pharmaceuticals and Oncology business units into an Innovative Medicines (IM) business with separate US and International commercial organizations will increase focus, strengthen competitiveness and drive synergiesNew Strategy & Growth function combines corporate s";83.48999786376953;Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.KENILWORTH, N.J., April 04, 2022--Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access;66.66999816894531;;73.79000091552734;;52.54999923706055;The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board Paris, April 4, 2022. Sanofi launches today its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors. Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneerFDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitisThere are approximately 160,000 patients in the U.S. living with eosinophilic esophagitis who are currently treated, of whom approximately 48,000 have failed multiple treatments Paris and Tarrytown, N.Y., April 4, 2022. The U.S. Food and Drug Administration (FDA) h;43.75;;14.75;;39.7400016784668;;10.850000381469727;;186.91000366210938;;12.170000076293945;;119.0999984741211;;117.4000015258789;"Figure 1 Drilling progress Figure 2 Additional DPEM Loop location 3,520m Completed of the 18,000m Infill and Exploration Drill Program Detailed Metallurgical Testing Underway Hydrogeological Drill Holes Being Completed and Test Work Underway Scope for the Environmental Impact Assessment Submitted to Portuguese Environmental Authorities TORONTO, April 04, 2022 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX: ASND, OTCQB: ASDRF) (""Ascendant"" or the ""Company”) is pleased to provide an update on t";15.5;Evolution today announced that it has gone live with an extensive set of online casino services for multiple operators in the new, regulated online gaming market in the Canadian province of Ontario.;34.720001220703125;;39.47999954223633;;19.3700008392334;;20.770000457763672;;36.79999923706055;;58.34000015258789;WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 3:00 p.m. ET. The conference will be held in a virtual meeting format. The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s;136.19000244140625;;18.43000030517578;;59.75;;3.609999895095825;;4.300000190734863;;;;5.730000019073486;;6.139999866485596;;49.86000061035156;"Harmony Biosciences Holdings, Inc. (""Harmony"" or the ""Company"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs, will present a company update and host investor meetings at the upcoming 21st Annual Needham Virtual Healthcare Conference.";30.0;;43.209999084472656;;8.649999618530273;;14.989999771118164;LAUSANNE, Switzerland, April 04, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that a permanent J-code, J9359, has been issued for ZYNLONTA® by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2022.;30.649999618530273;;4.230000019073486;;63.04999923706055;;14.5;;24.649999618530273;;5.309999942779541;;19.8700008392334;;9.850000381469727;;8.5;;31.170000076293945;;36.439998626708984;Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same. Stock rises.;21.350000381469727;;10.670000076293945;;22.920000076293945;;15.9399995803833;Company announcement – No. 11 / 2022 Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference Copenhagen, DK and Boston, MA, U.S. April 4, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Chief Executive Officer Adam Steensberg and Chief Financial Officer Matthew Dallas are scheduled to participate in the 21st Annual Needham Virtual He;10.739999771118164;;14.739999771118164;
2022-04-05;177.61000061035156;;51.2400016784668;;292.489990234375;Germany's unlisted Boehringer Ingelheim said operating income rose 1.8% in 2021, driven by more prescriptions of diabetes drug Jardiance and demand for its veterinary drugs as people purchased pets during the pandemic.  Family-owned Boehringer said in a statement on Tuesday that full-year operating income came in at 4.7 billion euros ($5.16 billion), up from 4.6 billion a year earlier.  The diabetes treatment is increasingly used to cut the risk of cardiovascular disease in diabetic patients and also for the treatment of heart failure.;114.80999755859375;;163.42999267578125;;88.16999816894531;Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (FDA) has granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma, as well as produce gene therapy product for current and;83.72000122070312;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Japan has approved cancer drug Keytruda's pairing with another drug to treat certain kidney cancer patients.In this article, we discuss the 10 most profitable biotech companies in the world. You can skip our comprehensive analysis of the biotech industry, its history, performance, and outlook for future growth, and go directly to 5 Most Profitable Biotech Companies in the World. The biotechnology sector is estimated to grow from approximately $500 billion […]KENILWORTH, N.J., April 05, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will provide a detailed overview of the company’s broad and growing cardiopulmonary pipeline and portfolio at a virtual meeting with investors today starting at 10:00 AM ET. The company will give further insight into its ongoing late-stage clinical programs in atherosclerosis, heart failure, pulmonary arterial hypertension and thrombosis.Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;67.05000305175781;Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.Jason Day, pro-golfer and PGA Champion, joins AstraZeneca to launch the Getting Out of the Rough campaign, aimed to educate lung cancer patients and their caregivers about biomarker testing and the importance of completing a lung cancer diagnosis through this approach. The Getting Out of the Rough campaign features a six-episode video series, where Jason is joined by friends from the worlds of medicine and entertainment to discuss and learn about adapting after you or someone you love has been d;74.43000030517578;The European Commission (EC) has approved Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) combo for esophageal squamous cell carcinoma (ESCC). The approval covers the combo therapy as first-line treatment of adult patients with unresectable advanced, recurrent or metastatic ESCC with tumor cell PD-L1 expression ≥ 1%. The EC has also approved Opdivo with fluoropyrimidine- and platinum-based chemotherapy for the same indication in esophageal cancer. The EC also apPRINCETON, N.J., April 05, 2022--BMS Receives European Commission Approval for CAR T Cell Therapy Breyanzi for Certain Forms of Relapsed or Refractory Large B-cell LymphomaStocks that are held within Berkshire Hathaway's portfolio can be a great place for value-oriented investors to look for good buys.  The company, owned by Warren Buffett, isn't going to be holding high-risk meme stocks or shares of companies that are going to be incredibly volatile.  It can be a great place to start if you're thinking about safe stocks to hold over the long term.Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.Blueprint Medicines (NASDAQ:BPMC): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE:BMY): Food and Drug Administration (FDA) decision on a potentially blockbuster heart disease drug Coherus (NASDAQ:CHRS): several impending catalysts over next 15 months, with one coming up as early as April Tarsus Pharma (NASDAQ:TARS): key data readout is due which will determine the fate of the NDA filing for what could potPRINCETON, N.J., April 05, 2022--BMS Receives European Commission Approval for Opdivo with Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced, Recurrent....PRINCETON, N.J., April 05, 2022--BMS Receives European Commission Approval for Opdivo Plus Yervoy as First-Line Treatment for Patients with Unresectable Advanced, Recurrent....PRINCETON, N.J., April 05, 2022--BMS Receives European Commission Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive....Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.;52.900001525878906;;44.56999969482422;;14.649999618530273;OSAKA, Japan & CAMBRIDGE, Mass., April 05, 2022--Takeda and the New York Academy of Sciences announced the winners of the fourth Innovators in Science Award.;39.84000015258789;;10.670000076293945;;182.05999755859375;;11.850000381469727;;125.48999786376953;;115.7300033569336;;15.460000038146973;"HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April 2022.The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.";35.400001525878906;;38.40999984741211;;19.0;;20.100000381469727;;35.4900016784668;;59.209999084472656;Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.  Is Apellis Pharmaceuticals Stock A Buy?  Apellis Pharmaceuticals stock has risen more than 5% past a 50.12 entry in a first-stage cup with handle, meaning it's now out of a proper buy zone.;138.02999877929688;;17.059999465942383;;57.33000183105469;;3.490000009536743;;4.21999979019165;;;;5.639999866485596;ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.;5.789999961853027;;49.939998626708984;;27.729999542236328;;42.08000183105469;;8.270000457763672;;14.729999542236328;;30.459999084472656;BILLERICA, Mass., April 04, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its Simoa® technology supported a large international and comprehensive study to establish reference ranges of sNfL to assess disease activity and drug response in MS patients at the individual level, according to a recent study published in The Lancet Neurology. Researchers from the University Hospital Basel a;4.110000133514404;;63.27000045776367;;14.449999809265137;First in human study of drug-enhanced tumor infiltrating lymphocyte therapy in patients with gynecological malignanciesSAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and the lead candidate in its cellular therapy pSAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 2:15 PM ET. The event will be webcast live and may be accessed via the Investors section of the Nuri;24.229999542236328;;5.065000057220459;;18.829999923706055;;9.569999694824219;;8.5;;29.239999771118164;;35.880001068115234;The big shareholder groups in Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) have power over the company. Institutions...;20.93000030517578;;10.789999961853027;;23.540000915527344;;16.299999237060547;;10.930000305175781;;14.229999542236328;
2022-04-06;182.22999572753906;;52.869998931884766;;305.8399963378906;By Sam BougheddaWhy investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.GlaxoSmithKline's IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S. cases, federal health regulators said Tuesday, the Associated Press reported. That leaves just one antibody treatment that is still authorized for use, an Eli Lilly drug that still sees effective, after another Eli Lilly drug and one from Regeneron were deemed ineffective. The BA.2 subvariant accounts for 72% of new U.S. cases, accordingEli Lilly (LLY) closed at $292.49 in the latest trading session, marking a +0.37% move from the prior day.Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.;117.12999725341797;;168.91000366210938;;90.6500015258789;The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million. Under the Accelerated Approval Program, continued approval may be contingent upon veExtending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts Basel, April 6, 2022 — Sandoz today aVijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by atypical overgrowths and anomalies in blood vessels, the lymphatic system and other tissues2,3 Approval based on real-world data from EPIK-P1 study, which showed patients treated with Vijoice experienced reduction in the size of PROS lesions and improvement of PROS-related signs and symptomsNovartiA Swiss drugmaker has received approval from the FDA for its Durham facility that will manufacture the gene therapy treatment.;84.97000122070312;ClearBridge Investments, an investment management firm, published its “Sustainability Leaders Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Sustainability Leaders Strategy outperformed its Russell 3000 Index benchmark during the fourth quarter. On an absolute basis, the Strategy had gains in nine of 10 sectors in which […]How our colleague Col. Craig Maceri is using the skills he learned at Merck to help run a vaccination site for the National GuardA look at what could be one of health care's best dividends;69.06999969482422;WILMINGTON, Del., April 06, 2022--New, prolonged follow-up results from the Phase III CHAMPION-MG trial open-label extension (OLE) showed that ULTOMIRIS® (ravulizumab-cwvz) demonstrated long-term efficacy in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), with improvements in activities of daily living, muscle strength and quality of life, sustained through 60 weeks.1 ULTOMIRIS was also well tolerated throughout this analysis.Actors Julie Bowen, Anthony Anderson and Bellamy Young are featured in episodes of the campaign that stresses the importance of biomarker testing.;75.33999633789062;"Investors need to pay close attention to Bristol-Myers (BMY) stock based on the movements in the options market lately.Less than a month after finalizing the purchase of Trillium, Pfizer announced plans to buy Arena Pharmaceuticals for $6.7 billion.  Pfizer had especially great expectations for Arena's crown jewel, etrasimod.  When the acquisition was announced, Arena was already evaluating the experimental oral sphingosine 1-phosphate (S1P) receptor modulator in a couple of phase 3 studies targeting ulcerative colitis.The European Commission (EC) has approved Bristol Myers Squibb Co's (NYSE: BMY) Breyanzi (lisocabtagene maraleucel; liso-cel) in relapsed or refractory lymphoma settings. The approval for CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy covers diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more lines of systemic therapy. Breyanzi is delivered as a personalized treatment via a singleWhen you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.";54.13999938964844;;45.720001220703125;"The drugmaker is to cut nearly a third of its consumer healthcare products in Russia as executives across the pharmaceutical industry grapple with an ethical dilemma over their response to the war in Ukraine.GlaxoSmithKline said on Wednesday its consumer arm has stopped shipments of supplements and vitamins to Russia as a result of Moscow's invasion of Ukraine and would prioritise the supply of over-the-counter medicines for basic needs.  The British drugmaker has also reiterated that it would keep supplying essential medicines and vaccines to Russia.  GSK has however, halted clinical trials in the country and stopped as much direct involvement with Russia as possible.PHILADELPHIA, April 06, 2022--New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+Britain's GlaxoSmithKline said on Wednesday its consumer arm stopped imports of supplements and vitamins into Russia as the drugmaker seeks to minimise ties with Moscow over its invasion of Ukraine.  ""We have taken a precautionary approach to stop, to the fullest extent possible, any direct involvement and support to the Russian government and military.""GlaxoSmithKline's IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S. cases, federal health regulators said Tuesday, the Associated Press reported. That leaves just one antibody treatment that is still authorized for use, an Eli Lilly drug that still sees effective, after another Eli Lilly drug and one from Regeneron were deemed ineffective. The BA.2 subvariant accounts for 72% of new U.S. cases, accordingThe monoclonal antibody has been used in hospitalized Covid patients following its emergency use authorization last spring, but it has been ineffective in its current form against the latest Covid subvariant, BA.2.";14.670000076293945;;40.380001068115234;;10.6899995803833;In fact, that performance, along with the fact that the company's forward price-earnings ratio for the following two years was below 15, helped land the company on my 2022 Tax Loss Selling Recovery Portfolio.  Pharmaceutical name Viatris Inc.  , which was formed in late 2020 via the merger of Mylan and Upjohn, a legacy division of Pfizer  , was down 26% in 2021.  Unfortunately, 2022 has not been any better, and VTRS is down 25% year to date.Viatris (VTRS) closed the most recent trading day at $10.67, moving -1.66% from the previous trading session.Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.;177.9600067138672;Let's talk about the popular Repligen Corporation ( NASDAQ:RGEN ). The company's shares saw a double-digit share price...;11.5;;126.51000213623047;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it is the sole sponsor of the National Headache Foundation's (NHF) Veterans/Military Outreach program which aims to raise awareness about migraine, elevate the discussion about the disease among active-duty military and veterans, and inform primary care physicians (or healthcare providers) via its education program throughout the Veterans Affairs (VA) Medical Centers.;117.61000061035156;;15.010000228881836;;36.20000076293945;A look at what could be one of health care's best dividends;39.4900016784668;With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.;18.020000457763672;;19.6299991607666;;36.13999938964844;;57.95000076293945;;140.02000427246094;;16.690000534057617;;57.58000183105469;;3.4800000190734863;;4.329999923706055;;;;5.739999771118164;;5.590000152587891;;49.41999816894531;;28.309999465942383;;43.25;;8.279999732971191;Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader (KOL) Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center Company and KOL to discuss an overview of unmet medical needs and therapeutic opportunities in cancers driven by the RAS/MAPK pathway, with a particular focus on gastrointestinal cancers SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, an;14.470000267028809;;29.399999618530273;;4.090000152587891;;66.3499984741211;;13.819999694824219;;24.030000686645508;;4.920000076293945;;19.729999542236328;;9.729999542236328;;8.5;;29.90999984741211;;35.650001525878906;;20.780000686645508;Topline data anticipated in late Q3/early Q4A total of 432 subjects are enrolled in the ARRECTOR studyArcutis progressing topical roflumilast in four dermatological indicationsOver 3 million patients in the U.S. have plaque psoriasis in the scalp WESTLAKE VILLAGE, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the l;11.140000343322754;SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 3:45 p.m. ET. A live audio webcast of the discussion will be available by visiting the Events & Presenta;25.5;Every investor in IGM Biosciences, Inc. ( NASDAQ:IGMS ) should be aware of the most powerful shareholder groups. Large...;16.1200008392334;"Company announcement – No. 12 / 2022 Zealand Pharma's Annual General Meeting 2022 Copenhagen, April 6, 2022 - Today, Zealand Pharma A/S (""Zealand"") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2022 as a completely electronic meeting. At the meeting, all proposals presented to the General Meeting were adopted except for agenda item 10, which was withdrawn by the Board of Directors. The General Meeting acknowledged the management's report on Zealand's activities in the";11.34000015258789;;14.130000114440918;
2022-04-07;181.75999450683594;;55.15999984741211;;308.42999267578125;Buying and holding quality growth stocks can set you up for some strong returns over the years.  Three healthcare stocks that can help you build a strong, growth-oriented portfolio are Eli Lilly (NYSE: LLY), Globus Medical (NYSE: GMED), and Seagen (NASDAQ: SGEN).  Drugmaker Eli Lilly has a little bit of everything for investors.Eli Lilly rallied to a new high and was Wednesday's top S&P 500 performer. Norwegian Cruise Line led the big-cap losers.;121.80999755859375;Figure 1 Gold Crown and Edwards mining areas (looking North) Figure 2 Grant’s Hill mining area (looking South-West) Figure 3 Edwards ROM pad No lost-time injuries were recorded during the first quarter of 2022 (“Q1 2022”)Q1 2022 production of 13,378 oz Au from Beatons Creek conglomerate gold project (“Beatons Creek”), a 4.2% increase over the previous quarter and in line with guidance1Q1 2022 revenue of C$31.9 million (A$34.7 million)2, a 6.7% increase over the previous quarter, from the sale of;173.27999877929688;;91.4000015258789;The reorganization is the latest move from Vas Narasimhan, who took over the Swiss drugmaker in 2018.;86.80000305175781;Merck, CVS Health, American Tower, QUALCOMM and Analog Devices are part of top Analyst article.Today's Research Daily features new research reports on 16 major stocks, including Merck & Co. Inc. (MRK), CVS Health Corporation (CVS), and American Tower Corporation (AMT).Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.;71.01000213623047;The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...;77.26000213623047;Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.;55.52000045776367;Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) for use in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation. The inflammation is characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), inadequately controlled with medium to high dose inhaled corticosteroids (ICS) and another medicinal product for maintenance treatment. The approval is based on Phase 3 VODupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation Dupixent is the only biologic indicated in the European Union for severe asthma with type 2 inflammation, characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide Approval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung function and health-related quality of life for childrenDataRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled co;46.22999954223633;The reorganization is the latest move from Vas Narasimhan, who took over the Swiss drugmaker in 2018.(Bloomberg) -- Carrefour SA beat out telecom and media companies to top the list of mergers and acquisitions targets in Europe, as dealmaking starts to recover from its worst quarter since summer 2020.Most Read from BloombergCanada to Ban Foreigners From Buying Homes as Prices SoarMocked as ‘Rubble’ by Biden, Russia’s Ruble Roars BackUkraine Update: UN to Vote on Dropping Russia From Rights BodyRussia Skirts Nearer Default After Dollar Payment BlockedIndia to Face Significant Cost If Aligned WitVIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.;14.90999984741211;;40.83000183105469;;10.8100004196167;;180.86000061035156;Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.;11.399999618530273;;121.66000366210938;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the presentation of important findings pertaining to the benefit of Nurtec® ODT (rimegepant) in decreasing the burden of opioid use among a significant number of migraine patients in real world clinical practice. These findings were presented as a podium presentation at the American Association of Neurology 2022 Annual Meeting in Seattle, Washington.BiohavenPharmaHldg shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.;114.27999877929688;;15.279999732971191;;36.20000076293945;;40.5;;17.739999771118164;;18.020000457763672;;35.709999084472656;;56.40999984741211;;136.11000061035156;;15.989999771118164;;57.779998779296875;;3.450000047683716;;4.269999980926514;;;;5.769999980926514;;5.329999923706055;;49.88999938964844;"Harmony Biosciences Holdings, Inc. (""Harmony"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological diseases, is now accepting applications for the second annual Progress at the Heart program, which funds innovative programs that address disparities, injustice, and inequities in the rare neurological disease and sleep disorder communities.";26.68000030517578;;42.279998779296875;Insiders who bought Emergent BioSolutions Inc. ( NYSE:EBS ) stock in the last 12 months were richly rewarded last week...;8.170000076293945;;14.260000228881836;;29.6200008392334;;4.260000228881836;BRIDGEWATER, N.J., April 07, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2022 financial results on Wednesday, May 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 4, 2022.;67.04000091552734;;13.260000228881836;;22.989999771118164;;4.869999885559082;;18.8700008392334;;9.5;;8.5;;27.469999313354492;;35.779998779296875;;20.56999969482422;;11.149999618530273;;23.34000015258789;MOUNTAIN VIEW, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April 1, 2022 of its previously announced underwritten public offering of 8,695,653 shares of its non-voting common stock and, pursuant to the exercise in full by the underwriters of a 30-day option to purchase additional shares, 1,304,347 shares of its voting common stock, each at a price to the public of $23.00 per share. IGM received total gross proceeds of approximate;16.1200008392334;Company announcement – No. 13 / 2022 CORRECTION: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022 Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholdCompany announcement – No. 13 / 2022 Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022 Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder;10.970000267028809;;13.819999694824219;
2022-04-08;182.1199951171875;;55.16999816894531;;311.69000244140625;A decision from the Centers for Medicare and Medicaid Services effectively closed the door on the commercial future of Biogen’s Alzheimer's drug, Aduhelm.With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.;120.55999755859375;;174.9600067138672;;92.7300033569336;Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.;87.68000030517578;Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.KENILWORTH, N.J., April 08, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, April 28. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook.;71.13999938964844;With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.Apple (AAPL): Strong growth with emerging segments likely to help in sustaining the growth momentum. Robust cash flows will ensure dividend upside. Chevron (CVX): Among the top picks from the energy sector with a healthy balance sheet, low break-even assets, healthy cash flows and an attractive dividend yield. Pfizer (PFE): Strong growth and cash flow upside from the covid-19 vaccine business. Deep pipeline of drugs to ensure that growth sustains in the long-term. AT&T (T): A contrarian pick tha;77.7699966430664;Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.Regeneron and Bristol-Myers Squibb are part of today's Investment Idea article.Editor’s note: This column is part of InvestorPlace.com’s Best Stocks for 2022 contest. Sure Dividend’s pick for the contest is Bristol-Myers Squibb (NYSE:BMY) stock. As of the end of the first quarter of 2022, Bristol-Myers Squibb (NYSE:BMY) had generated total returns of 17.1%. This compares very favorably to the SPDR S&P 500 ETF Trust’s (NYSEARCA:SPY) loss of 4.9% over the same period. Source: InvestorPlace What most stood out about an investment in Bristol-Myers-Squibb at the end of 2021 wasThe trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.;56.75;Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.;46.63999938964844;With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.In the latest trading session, GlaxoSmithKline (GSK) closed at $46.23, marking a +1.12% move from the previous day.;15.029999732971191;BioLife Plasma Services is quickly expanding its presence in the greater Sacramento area with plans to open a Roseville facility.HilleVax, which is developing a vaccine to treat acute gastroenteritis, plans to trade on the Nasdaq under the ticker HLVX.;41.41999816894531;;11.039999961853027;Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2022 financial results on Monday, May 9, before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. EDT on May 9 to discuss the results.;169.97999572753906;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.;11.319999694824219;;118.4800033569336;It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...;111.06999969482422;;14.859999656677246;The programme further adds to a fast-growing pipeline in neurodegeneration that also includes EVT8683, which entered clinical development end of 2021. In contrast to previously nominated programmes, which are small molecule based, the newly designated project utilises an antisense-based approach.;35.869998931884766;;41.560001373291016;;17.690000534057617;;18.40999984741211;;34.900001525878906;;54.2599983215332;;135.4499969482422;;14.170000076293945;;60.06999969482422;;3.4000000953674316;;4.460000038146973;;;;5.510000228881836;;5.150000095367432;;49.790000915527344;;25.479999542236328;;41.630001068115234;GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the second quarter of 2022, and financial outlook for full year 2022. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – toll-free: (855) 766-6521Di;8.079999923706055;;13.84000015258789;;29.260000228881836;;4.460000038146973;;65.05000305175781;;14.819999694824219;Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -6.74% and 9.68%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix’s drug-enhanced tumor infiltrating lymphocyte (TIL) program Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Reports strong financial position with $385.7 million in cash and investments as of February 28, 2022 SAN FRANCISCO, April 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targete;23.040000915527344;;4.949999809265137;;19.0;;9.630000114440918;;8.5;;26.969999313354492;;32.9900016784668;;21.110000610351562;;11.09000015258789;;21.610000610351562;;16.1200008392334;;10.279999732971191;;11.239999771118164;
2022-04-11;179.83999633789062;;53.93000030517578;;308.9599914550781;At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. Lebrikizumab, an investigational IL-13 inhibitor, also showed improvements in itch, sleep interference, and qual;120.94999694824219;;169.8300018310547;;93.75;;86.62999725341797;IMV Inc (NASDAQ: IMV) announced safety and preliminary efficacy data of the combination of its lead immunotherapy candidate, maveropepimut-S (MVP-S), with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) from a Phase 2 basket study in advanced, metastatic bladder cancer. Seventeen subjects with advanced, metastatic bladder cancer, who on average had received two prior lines of therapy, were enrolled in the study. Five out of 17 subjects showed a response (2 confirmed complete responses (CRsMerck, (NYSE: MRK), known as MSD outside Canada and the United States, announced today that Health Canada has approved an expanded indication of GARDASIL®9 in individuals 9 through 45 years of age for the prevention of infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 and the following diseases associated with the HPV types included in the vaccine: Oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.1 This m;70.62999725341797;Blueprint Medicines Corp (NASDAQ: BPMC) announced proof-of-concept data from the Phase 1/2 SYMPHONY trial of BLU-945 for advanced EGFR-mutant non-small cell lung cancer (NSCLC). The data were shared at the American Association for Cancer Research (AACR) Annual Meeting 2022. The early readout from the phase 1/2 Symphony trial shows the first safety and clinical activity data. Results from the higher dose group hint at tumor shrinkage too. One patient treated with 400 mg once daily experienced a pJapan has cancelled the purchase of about 40 million Astrazeneca Plc COVID-19 vaccine doses it agreed to buy last year, a health ministry official said in parliament on Monday.  Japan had originally agreed to buy 120 million of the shots, with the bulk made domestically by Daiichi Sankyo Co. and other local partners.  About Astrazeneca 200,000 doses have been supplied to local governments in Japan, while 63 million doses have donated overseas, the official added.India began offering booster doses of COVID-19 vaccine to all adults on Sunday but limited free shots at government centers to front-line workers and people over age 60.;76.5;PRINCETON, N.J., April 11, 2022--Neoadjuvant Opdivo with Chemo Significantly Improves Event-Free Survival in Patients with Resectable NSCLC in Phase 3 CheckMate -816 TrialThe groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027;57.459999084472656;Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.;46.47999954223633;Shares of CureVac were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline said they signed an agreement with the German government for pandemic preparedness that includes mRNA vaccines. As part of the agreement, Germany has access to CureVac's mRNA manufacturing until 2029. The vaccines manufactured in this facility could be used for this pandemic or any future outbreaks of infectious diseases, the companies said. CureVac and GSK are developing a COVID-19 vaccine. CureV;14.8100004196167;;41.5;;10.699999809265137;;163.14999389648438;Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.;10.960000038146973;;109.5;;106.2300033569336;;14.430000305175781;;35.18000030517578;;40.68000030517578;;17.270000457763672;Shares of CureVac were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline said they signed an agreement with the German government for pandemic preparedness that includes mRNA vaccines. As part of the agreement, Germany has access to CureVac's mRNA manufacturing until 2029. The vaccines manufactured in this facility could be used for this pandemic or any future outbreaks of infectious diseases, the companies said. CureVac and GSK are developing a COVID-19 vaccine. CureV\- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK\- Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparednessTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 11, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based;17.110000610351562;;33.720001220703125;;53.41999816894531;In this article, we discuss 12 best US stocks to buy now. If you want to see some more stocks from this list, click 5 Best US Stocks to Buy Now. All major stock benchmarks saw their highest losses in two years in the first quarter of 2022, with the S&P 500 declining 4.6% and […];132.91000366210938;;14.029999732971191;;51.52000045776367;;3.2799999713897705;;4.21999979019165;;;;5.599999904632568;;4.929999828338623;;47.150001525878906;;24.649999618530273;;41.83000183105469;;7.96999979019165;;13.149999618530273;;28.760000228881836;;4.409999847412109;;62.38999938964844;;12.369999885559082;;22.229999542236328;;4.809999942779541;;19.020000457763672;;9.529999732971191;;8.020000457763672;;25.920000076293945;;32.90999984741211;;20.780000686645508;;10.979999542236328;;20.959999084472656;;13.680000305175781;;9.569999694824219;;10.369999885559082;
2022-04-12;179.89999389648438;;53.11000061035156;;308.0799865722656;Eli Lilly (LLY) closed at $308.96 in the latest trading session, marking a -0.88% move from the prior day.Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and AbbVie Inc. (ABBV).;117.4000015258789;Danish drugmaker Novo Nordisk is in a buy range after breaking out of a cup base and passing its 117.45 buy point.  The company produces drugs to combat diabetes, hormone disorders and obesity.  The FDA approved Novo Nordisk's drug Ozempic for treatment of type 2 diabetes on March 28.Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.;167.30999755859375;The FDA places a partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares fall.BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.AbbVie Inc (NYSE: ABBV) has announced new data from a Phase 2 trial of navitoclax combined with ruxolitinib in myelofibrosis patients at the American Association for Cancer Research annual meeting. The results presented at AACR 2022 were from REFINE Phase 2 trial, which included patients with myelofibrosis who had progressed on or had a suboptimal response to at least 12 weeks of ruxolitinib monotherapy. In the exploratory analysis of 32 evaluable patients, 12 (38%) had a ≥1 grade improvement inAbbVie (NYSE: ABBV) today announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis. The results were presented at the American Association for Cancer Research annual meeting (AACR 2022, abstract #LB108). Navitoclax is an investigational, first-in-class, oral BCL-XL/BCL-2 inhibitor that is designed to activate programmed cell death (apoptosis) in cancer cells. Navitoclax and its safety and efficacy are under evaluation as part of ongoingAlphabet, Amazon, AbbVie, Walmart, and Toyota Motor are part of top Analyst Blog.If so, there are some increasingly popular entrees on the biopharmaceutical industry's menu that deserve your attention.  Bristol Myers Squibb shares have risen 25% this year to reach an all-time high water mark for this well-established pharmaceutical giant.  New safety and efficacy results from a clinical trial with an experimental drug for patients with abnormally thick hearts called mavacamten have been pushing the stock higher this month.In this article, we discuss 10 best stocks to buy for beginners right now. If you want to see more stocks that might be suitable for investors just starting their trading journey, check out 5 Best Stocks To Buy For Beginners Right Now. For investors who are just beginning their trading journey, it is important […]Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and AbbVie Inc. (ABBV).AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;92.66999816894531;"BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.Swiss drugmaker Novartis will cut thousands of jobs worldwide as it combines its pharma and oncology businesses in a  reorganisation announced last week, Swiss newspaper Tages-Anzeiger reported on Tuesday, citing unnamed company sources.  More than 100 jobs could also disappear at Novartis's Swiss sites in Rotkreuz and Basel, the paper reported.  Contacted by Reuters, a Novartis spokesperson said efficiencies would come through leaner structures and would ""inevitably lead to roles being impacted"", but it was too early to give specific numbers.";85.62999725341797;Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.Britain will expand access to Pfizer's oral antiviral COVID-19 treatment to thousands more people by adding it to a trial to assess how best to use the drug in its highly vaccinated population, the health ministry said on Tuesday.  Paxlovid, a combination of Pfizer's new pill with an older antiviral ritonavir, was made available to thousands of people with compromised immune systems in Britain in February.  Paxlovid was shown to reduce the relative risk of death or hospitalisation by nearly 90% in clinical trials of high risk individuals given the treatment for five days.Merck (MRK) closed the most recent trading day at $86.63, moving -1.2% from the previous trading session.;68.61000061035156;Costco Wholesale, AstraZeneca, Medtronic, Sony Group, and Applied Materials are part of top Analyst Blog.;76.55000305175781;If so, there are some increasingly popular entrees on the biopharmaceutical industry's menu that deserve your attention.  Bristol Myers Squibb shares have risen 25% this year to reach an all-time high water mark for this well-established pharmaceutical giant.  New safety and efficacy results from a clinical trial with an experimental drug for patients with abnormally thick hearts called mavacamten have been pushing the stock higher this month.Bristol Myers Squibb (BMY) closed the most recent trading day at $76.50, moving -1.63% from the previous trading session.Bristol Myers Squibb Co (NYSE: BMY) announced results from the Phase 3 CheckMate -816 trial in resectable non-small cell lung cancer (NSCLC). The data showed that neoadjuvant treatment with three Opdivo (nivolumab) cycles combined with chemotherapy significantly improved event-free survival (EFS) than chemotherapy alone. With a minimum follow-up of 21.0 months, Opdivo with chemotherapy reduced the risk of disease recurrence, progression, or death by 37% across randomized patients when administerHealthcare stocks have posted positive returns this week, with Pharma companies trending at a 4.26% a 7-day return. Our Market analysis revealed that Bristol-Myers Squibb Company ( NYSE:BMY ) is both a growth and stable dividend stocks, and today we will explore the fundamentals behind the stock.;55.720001220703125;;46.529998779296875;Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.GlaxoSmithKline has racked up a series of recent HIV treatment wins and, on Monday, GSK stock flirted with a breakout.;14.760000228881836;"OSAKA, Japan & CAMBRIDGE, Mass., April 12, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO® (lanadelumab) in patients 2 to <12 years of age is complete and has met its objectives. The safety profile was consistent with that seen in the clinical program for patients 12 years of age and older; there were no serious adverse events and no dropouts due to adverse events.1(Bloomberg) -- U.K.-based biotech firm Engitix Ltd. and Japanese drugmaker Takeda Pharmaceutical Co. have agreed to extend their existing partnership in a deal could be valued at as much as $300 million.Most Read from BloombergU.S. Pullout of Locked-Down Shanghai Deepens China TensionsUkraine Update: U.S. Warns India Over Russian Energy ImportsEurope Moves to Arm Ukraine as Sanctions Fail to Sway PutinUkraine Update: Austria Chancellor to Meet Putin; New War FrontUkraine Seeks Russia Assets, Oil";41.810001373291016;;10.670000076293945;;156.7899932861328;;10.8100004196167;;108.95999908447266;;108.83999633789062;;13.390000343322754;FINANCIALS REFLECT GREAT PERFORMANCE * Group revenues significantly exceeded the revenue target, up 23% to € 618.0 m (+27% like for like, excluding portfolio and fx effects (2020: € 500.;34.9900016784668;;40.150001525878906;;17.489999771118164;;16.75;;34.31999969482422;;52.38999938964844;;136.0;;14.630000114440918;;51.5099983215332;;3.440000057220459;;4.079999923706055;;;;5.710000038146973;;5.010000228881836;;49.95000076293945;;24.790000915527344;;41.88999938964844;;7.909999847412109;;14.010000228881836;;27.950000762939453;;4.289999961853027;;62.720001220703125;;13.3100004196167;;22.219999313354492;;4.920000076293945;;19.420000076293945;;9.25;;8.020000457763672;;26.81999969482422;;34.560001373291016;;20.5;;11.029999732971191;;19.90999984741211;;13.25;;9.3100004196167;;11.3100004196167;"Repare Therapeutics Inc (NASDAQ: RPTX) presented updated data from its ongoing Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations. The data were featured at the AACR Annual Meeting included monotherapy Phase 1 (Module 1) results from 120 patients. RP-3500 monotherapy appeared to be safe and well-tolerated. Mild to moderate anemia was the most common treatment-related adverse event. RP-3500 monotherapy resulted in durable clinical benefit across tCAMBRIDGE, Mass. & MONTREAL, April 11, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including tho"
2022-04-13;180.66000366210938;;53.099998474121094;;302.6700134277344;;118.87999725341797;The Chautauqua International Growth fund has outperformed its peers amid market turmoil by sticking with its strategy and favored stocks, particularly in China and Canada.;158.9499969482422;Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the celebration of a milestone moment for BOTOX® Cosmetic (onabotulinumtoxinA). April 15, 2022, will mark 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between your eyebrows.1 It was the first product of its kind and has since received two additional aesthetic indications – in 2013 and 2017 – making BOTOX® Cosmetic tBy Sam BougheddaStocks initially rallied on the CPI report that was released before the open. However, a selloff in the bond market later in the day weighed on an already fragile equities market. With all of that in mind, let’s look at a few top stock trades for tomorrow. Top Stock Trades for Tomorrow No. 1: Walmart (WMT) Click to EnlargeSource: Chart courtesy of TrendSpider Not only has Walmart (NYSE:WMT) been one of the stronger retail stocks in the market, but it’s been one of the stronger stocks overall. Th;92.94000244140625;BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.In this piece, we will take a look at the ten biotechnology stocks to buy according to Ken Fisher’s Fisher Asset Management. If you want to skip the details about the billionaire hedge fund executive and simply want to learn about the top five stocks in this list, then take a look at 5 Biotech […];86.12999725341797;Merck and its legacy companies have been working to discover and develop vaccines for more than a centuryShionogi & Co stock slumped 16% in Tokyo after preclinical studies showed its experimental COVID-19 drug disturbed fetal development, triggering concerns about its approval. Kyodo News reported that the drug likely wouldn’t be recommended for pregnant women without giving attribution. The animal data, which showed harm when given at high doses, was submitted to Japanese regulators in February when the company sought a priority review required for conditional approval, a Shionogi spokesman said.;68.97000122070312;In this piece, we will take a look at the ten biotechnology stocks to buy according to Ken Fisher’s Fisher Asset Management. If you want to skip the details about the billionaire hedge fund executive and simply want to learn about the top five stocks in this list, then take a look at 5 Biotech […];76.87000274658203;Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.;56.70000076293945;Today, Sempre Health announced compelling outcomes achieved during the first year of its collaboration with Sanofi (Nasdaq: SNY), an innovative global healthcare company. The results coming out of this collaboration have already led to health plans expanding their Sempre programs for 2022-2023.COMBINED GENERAL MEETING OF MAY 3, 2022 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 3, 2022 at 2:30 p.m. (CET) at Paris Expo Porte de Versailles – 1, Place de la Porte de Versailles, Hall 5.1 – 75015 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the websi;46.849998474121094;The SAS Championship in Cary is starting a new golf competition that will host teams from Historically Black colleges and universities.Late-stage biopharmaceutical company Sierra Oncology (NASDAQ:SRRA) is up big today on news that GlaxoSmithKline (NYSE:GSK) will purchase the business. Indeed, SRRA stock is up a massive 38% so far today on the headline-grabbing acquisition news. Source: Oleg Ivanov IL / Shutterstock.com So, what do you need to know about Sierra lately? Well, this morning UK-based Glaxo announced it will buy Sierra for $1.9 billion. This values the California-based Sierra at roughly $55 per share, a 39% premium fGlaxo is paying a 39% premium for the rare cancer-focused biotech whose stock has already shot up 82% this year.GlaxoSmithKline agreed Wednesday to acquire a California biotechnology company in a stock deal valued at $1.9 billion.  Under the terms of the deal, GlaxoSmithKline (NYSE: GSK) will pay Sierra Oncology Inc.'s shareholders $55 for each share of stock they hold.  The proposed purchase price represents a premium of 39% to Sierra Oncology’s stock price of $39.52 per share at market close on Tuesday.The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.In this piece, we will take a look at the ten biotechnology stocks to buy according to Ken Fisher’s Fisher Asset Management. If you want to skip the details about the billionaire hedge fund executive and simply want to learn about the top five stocks in this list, then take a look at 5 Biotech […]Shares of Sierra Oncology Inc. soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline said it would buy the company for $1.9 billion. Sierra is developing treatments for rare types of cancer, including myelofibrosis, and announced in January that momelotinib met the primary and secondary endpoints in a Phase 3 clinical trial evaluating the experimental therapy as a treatment for myelofibrosis. GSK anticipates that momelotinib will start generating sales to its specialty medicines bGlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab mafodotin), building on GSK's commercial and medical expertise in hematology. If momelotinib is approved, GSK expects momelotinib will contribute to GSK's growing specialty medicines business, with sales expected to begin in 2023, with a positiveThe British pharmaceutical giant will buy Sierra Oncology in a deal centered on momelotinib, a drug to treat patients with a rare type of bone marrow cancer who have developed anemia.By Sam BougheddaBritain's GlaxoSmithKline sought to bolster its cancer business on Wednesday by agreeing a $1.9 billion deal to buy U.S. drug developer Sierra Oncology , the latest move to fend off pressure from activist shareholder Elliott.  GSK has been facing mounting calls to shore up its drug pipeline since Elliott built up a significant stake in the company last year.  Shareholders in Sierra, a cancer drug developer, will receive $55 per share of common stock in cash, which is a 39% premium to the company's closing price on Tuesday.DOW JONES NEWSWIRES By Ian Walker Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance. GlaxoSmithKline will pay $55 per share in cash, a 39% premium to its closing price of $39.Britain's GlaxoSmithKline sought to bolster its cancer business on Wednesday by agreeing a $1.9 billion deal to buy U.S. drug developer Sierra Oncology, the latest move to fend off pressure from activist shareholder Elliott.  GSK has been facing mounting calls to shore up its drug pipeline since Elliott built up a significant stake in the company last year.  Shareholders in Sierra, a cancer drug developer, will receive $55 per share of common stock in cash, which is a 39% premium to the company's closing price on Tuesday.;15.0;"OSAKA, Japan, April 13, 2022--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (""Takeda"") today provided an update on the status and announced the completion of the acquisition of its own shares, which has been carried out pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, based on the resolution of the Board of Directors’ meeting held on October 28, 2021.Details of the acquisition of shares is below.";42.439998626708984;NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253 or for international callers by dialing +1 (914) 80;10.989999771118164;Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is voluntarily recalling one batch of its Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), which is packaged in a 10 mL vial that is inside a carton. The batch is being recalled due to the potential for the label to be missing on some vials. Biocon Sdn manufactured this batch. Bhd. and was distributed by Mylan Specialty L.P. in the U.S. between December 9, 2021, and March 4, 2022. The company said that forBiogen’s (BIIB) Aduhelm looks like a market failure Approvals on treatments that don’t cure are now under challenge There can be no unlimited draw from a limited pool of funds Source: PictureDesignSwiss / Shutterstock.com When Biogen (NASDAQ:BIIB) stock got its Alzheimer’s drug Aduhelm approved last June, the stock spiked to nearly $420/share. It was due to open April 11 at $213. As I wrote recently, the whole biotech sector has gone into a spin. It’s not a coincidence. The way I see it, BiogenViatris (VTRS) closed the most recent trading day at $10.67, moving -0.28% from the previous trading session.;160.16000366210938;Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDTWALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27, 2022. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- month reporting period ended March 31, 2;10.779999732971191;;115.33000183105469;;115.41999816894531;;13.550000190734863;;34.97999954223633;(Bloomberg) -- WeWork Inc. is trying to strengthen its technology credentials with a new software product it hopes to sell to employers.Most Read from BloombergNetflix Tumbles as 200,000 Users Exit for First Drop in DecadeIn Defense of Elon Musk's Managerial ExcellenceTwitter Has a Poison Pill NowU.S. Stops Mask Requirement on Planes After Judge’s RulingPutin Calls Time on Foreign Listings in Fresh Hit to TycoonsThe co-working company will partner with the real estate software maker Yardi System;42.380001068115234;;18.489999771118164;;17.459999084472656;;34.75;CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the U.S. financial markets open. Management will host a conference call to discuss first quarter 2022 financial results and recent business updates on Tuesday, May 10, 2022 at 8:00 a.m. ET. To access the call, please;53.61000061035156;;143.3300018310547;;13.90999984741211;;53.54999923706055;;3.509999990463257;;4.309999942779541;;;;6.170000076293945;;5.300000190734863;;50.849998474121094;;31.020000457763672;In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85% and 82% at 12-month landmarks, respectivelyIn TKI-pretreated patients, cORR of 42% in those treated with 1 TKI and platinum-based chemotherapy (EXP-2), cORR of 28% in those treated with two TKIs (EXP-3), and cORR of 36% in those treated with 1 TKI (E;42.349998474121094;;8.579999923706055;ERAS-007 is a potent and selective small molecule ERK1/2 inhibitor with long target residence time, which promotes sustained RAS/MAPK pathway inhibition ERAS-601 is a potent and selective small molecule SHP2 inhibitor with broad anti-tumor activity that blocks oncogenic signal transduction to multiple pathways to delay the onset of therapeutic resistance ERAS-3490 is a CNS-penetrant KRAS G12C inhibitor with robust systemic and CNS activity in development for the treatment of KRAS G12C mutant lun;14.520000457763672;;27.15999984741211;;4.340000152587891;;65.66999816894531;;13.800000190734863;;27.639999389648438;SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. All of the shares to be sold in the offering are to be sold by Crinetics.;5.190000057220459;NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: PolarityTE, Inc. (NASDAQ: PTE), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), atai Life Sciences N.V. (NASDAQ: ATAI), and LIXTE Biotechnology (NASDAQ: LIXT). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new e;19.329999923706055;;8.970000267028809;;7.940000057220459;;29.670000076293945;;36.5;;21.920000076293945;;11.609999656677246;;20.889999389648438;;13.789999961853027;;9.680000305175781;BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the Company will host an Epilepsy Day from 8:30 a.m. to 11:30 a.m. ET on Wednesday, April 27, 2022 virtually and in New York City. During the event, Praxis’ management team will r;12.229999542236328;Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2022-04-14;179.89999389648438;;53.119998931884766;;301.8599853515625;Investors are seeking refuge in healthcare stocks as inflation and rates rise;118.19999694824219;;162.30999755859375;Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.AbbVie (NYSE: ABBV) will announce its first-quarter 2022 financial results on Friday, April 29, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.When it comes to AbbVie (NYSE: ABBV), investors have been worrying about one thing: an eventual drop in sales of its blockbuster Humira.  The immunosuppressive drug is used for various diseases, including rheumatoid arthritis.  First, it's important to note that Humira is a major drug for AbbVie.Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) announced topline results from the first cohort of the EPCORE NHL-1 phase 1/2 trial of epcoritamab (DuoBody-CD3xCD20). Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's DuoBody technology designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at leasHere's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with chimeric antigen receptor (CAR) T-cell theraCOPENHAGEN, Denmark & NORTH CHICAGO, Ill., April 13, 2022--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2, clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received priorAmerican Airlines led a travel revival Wednesday, while AbbVie and PayPal were stock market losers on key executive exits.AbbVie stock crumbled Wednesday after the company announced President and Vice Chairman Michael Severino will depart at the end of May.By Sam Boughedda;92.5199966430664;"Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does not properly drain fluid, causing eye pressure to build up3Sandoz manufactures high-impact medicines that bring savings to US patients and support the sustainability of the overall US healthcare system Basel, April 14, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announce";86.91000366210938;KENILWORTH, N.J., April 14, 2022--Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.;69.05000305175781;Poorer nations have refused tens of millions of AstraZeneca COVID-19 vaccines from the global programme COVAX, a document shows, the latest sign that its short shelf life is sapping demand for the shot.  It has so far distributed 1.4 billion jabs to 144 countries and is co-managed by the World Health Organization (WHO) and the vaccine alliance Gavi.  As it rushes to boost vaccination in poorer nations, COVAX assigned over 200 million doses to 61 less developed countries, including most African states, for the six months through September.;77.51000213623047;Bristol Myers Squibb’s internal, peer-to-peer Cancer Support Network is a ‘gamechanger’ for employee patients and caregivers.Less than two years after launching, cell therapy startup Be Biopharma Inc. has snagged $130 million as it plans to cater its engineered B cells toward cancer and rare disease patients.;55.75;Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine Results published today in the New England Journal of Medicine showed that treatment with rilzabrutinib resulted in a rapid and durable increase in platelet count in patients with heavily pretreated immune thrombocytopenia (ITP)Data support an acceptable safety profileRilzabrutinib is an investigational oral Bruton tyrosine kinase inhibitor (BTKi) for the trea;46.31999969482422;Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.GlaxoSmithKline's anemia of chronic kidney disease drug could be just months away from authorization in the European Union.GlaxoSmithKline (GSK) closed the most recent trading day at $46.85, moving +0.69% from the previous trading session.GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.;14.90999984741211;At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) says that licensor Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported Takecab (vonoprazan) Q4 FY21 sales of $221 million and $900 million in FY21. Phathom estimates that around 30% is from erosive esophagitis (EE), approximately 60% is from gastroesophageal reflux disease (GERD)/other, and less than 10% is from H. pylori. PHAT is positioning vonoprazan as an acid blocker, the analysts write. Related: Phathom's Vonopr;44.099998474121094;;10.960000038146973;;157.6699981689453;Much has been written about the life sciences industry in the wake of COVID-19.  The bottom line is that the bar for speed of innovation, regulation, and collaboration has been forever raised.  Repligen (NASDAQ: RGEN) -- a provider of bioprocessing systems -- is trying to step front and center.;10.760000228881836;;110.87999725341797;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved medication to both treat and prevent migraine attacks in adults.;112.8499984741211;;13.579999923706055;;34.900001525878906;;40.63999938964844;;17.43000030517578;;17.219999313354492;;32.470001220703125;;52.810001373291016;;137.6999969482422;;13.319999694824219;;53.56999969482422;;3.3399999141693115;;4.320000171661377;;;;6.159999847412109;;5.050000190734863;;51.540000915527344;;32.900001525878906;;41.400001525878906;;8.630000114440918;;14.1899995803833;;25.860000610351562;;4.119999885559082;"BRIDGEWATER, N.J., April 13, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin®. The product will be marketed under the proprietary name ALYMSYS® and represents the third bevacizumab biosimilar approved in the U.S.";64.62999725341797;;13.699999809265137;;26.0;;5.320000171661377;;19.420000076293945;;8.899999618530273;;8.0;;26.510000228881836;;34.11000061035156;;21.030000686645508;;11.319999694824219;;20.25;;13.789999961853027;;8.640000343322754;;11.470000267028809;
2022-04-18;177.66000366210938;;51.84000015258789;;298.82000732421875;"Shares of Nektar Therapeutics Inc. were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb's Opdivo. The combination was being tested in several types of cancer, including renal cell carcinoma and urothelial carcinoma. Wall Street now views Nektar as an ""autoimmune company"" based on its work with Eli Lilly & Co. to develop therapies for ulcerative colitis, atopic dermatitis, and psoriasis, amNektar Therapeutics is ending development of its cancer drug bempeg after the failure of two more trials of the drug in combination with Bristol Myers Squibb’s Opdivo.Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.";116.37000274658203;;159.36000061035156;J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.Dividend stocks can provide investors with recurring cash flow that they can use for just about any purpose.  One way investors can offset that risk is by investing in companies that regularly increase their payouts.  One of the top dividend growth stocks you can invest in right now is healthcare company AbbVie (NYSE: ABBV).;92.26000213623047;Here's why they chose Novartis (NYSE: NVS), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (Novartis): Regardless of whether you value growth, dividends, or just want a reasonably priced investment that you can hang on to for years, Novartis is a stock that you should consider adding to your portfolio.  The company has 20 assets that it believes could each generate at least $1 billion in annual revenue for the business.;86.06999969482422;The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a treatment for adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.1 This approval is based on the results from the Phase 3 KEYNOTE-522 trial, which demonstr;68.61000061035156;SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company. The master collaboration agreement enables the Parties to collaborate in the development and commercialization of AmoyDx assays that may cover any type of indication;76.75;"Shares of Nektar Therapeutics (NASDAQ: NKTR) were crashing 35.2% lower as of 10:51 a.m. ET on Monday.  The steep decline came after Nektar and Bristol Myers Squibb (NYSE: BMY) announced that they were ending the development program for bempegaldesleukin (bempeg) in combination with Opdivo.  This decision was based on dismal results from pre-planned analyses of two clinical studies evaluating the combo.Shares of Nektar Therapeutics Inc. were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb's Opdivo. The combination was being tested in several types of cancer, including renal cell carcinoma and urothelial carcinoma. Wall Street now views Nektar as an ""autoimmune company"" based on its work with Eli Lilly & Co. to develop therapies for ulcerative colitis, atopic dermatitis, and psoriasis, amNektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb Co (NYSE: BMY) have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. The decision follows the results from pre-planned analyses of two late-stage studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer. A preplanned interim analysis found that the investigational combination failed to improve on the overa";55.189998626708984;;46.20000076293945;The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.;14.699999809265137;CAMBRIDGE, Mass., April 18, 2022--Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.1 HAE is a rare genetic disease that results in recurrent attacks of edema (swelling) in various parts of the body, which can be burdensome, debilitating and potentially life-threatening.2,3,4 Approved by the U.S. Foo;44.095001220703125;NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on June 15, 2022, to shareholders of record at the close of business on May 20, 2022. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industr;10.710000038146973;;152.4499969482422;;10.600000381469727;;104.51000213623047;;107.1500015258789;;13.619999885559082;;33.380001068115234;;38.9900016784668;;16.010000228881836;;16.540000915527344;;31.5;;51.439998626708984;;129.72000122070312;;12.279999732971191;;49.189998626708984;;3.1700000762939453;;4.230000019073486;;;;4.739999771118164;"Shares of Nektar Therapeutics (NASDAQ: NKTR) were crashing 35.2% lower as of 10:51 a.m. ET on Monday.  The steep decline came after Nektar and Bristol Myers Squibb (NYSE: BMY) announced that they were ending the development program for bempegaldesleukin (bempeg) in combination with Opdivo.  This decision was based on dismal results from pre-planned analyses of two clinical studies evaluating the combo.Shares of Nektar Therapeutics Inc. were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb's Opdivo. The combination was being tested in several types of cancer, including renal cell carcinoma and urothelial carcinoma. Wall Street now views Nektar as an ""autoimmune company"" based on its work with Eli Lilly & Co. to develop therapies for ulcerative colitis, atopic dermatitis, and psoriasis, amNektar Therapeutics is ending development of its cancer drug bempeg after the failure of two more trials of the drug in combination with Bristol Myers Squibb’s Opdivo.Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.";4.760000228881836;;50.43000030517578;;30.0;;40.59000015258789;;8.260000228881836;;13.470000267028809;;25.0;;4.119999885559082;;61.97999954223633;;12.680000305175781;;22.940000534057617;;5.110000133514404;;19.079999923706055;;8.699999809265137;;7.900000095367432;;25.239999771118164;;31.170000076293945;;20.100000381469727;;11.130000114440918;;18.84000015258789;;;;8.4399995803833;;11.0;
2022-04-19;183.0800018310547;Is Johnson & Johnson stock a buy after the company suspended its Covid vaccines guidance? Is JNJ stock a buy right now?By Yasin EbrahimU.S. stocks rose on Tuesday even in the face of surging Treasury yields as a positive earnings reports helped investors shrug off potential risks from an aggressive rise in U.S. interest rates and the Ukraine war.  Johnson & Johnson rose 2.8% to a record high as the drugmaker's quarterly profit exceeded market expectations and it raised the dividend payout.  Shares of megacap companies like Microsoft Corp, Apple Inc and Amazon.com, typically sensitive to bond yields, jumped more than 1% despite hawkish comments from St. Louis Federal Reserve Bank President James Bullard.;50.18000030517578;Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.The stock is trying to settle below the $51 level.NEW YORK, April 19, 2022--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2022 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 28, 2022. We have designed the virtual Annual Meeting to ensure that our shareholders who attend the virtual-only Annual Meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.Pressure is mounting on Moderna and Pfizer to share vaccine technology with the developing world after the two biggest proxy advisers lent support to shareholder resolutions.  Institutional Shareholder Services has recommended that investors vote in favour of proposals by Oxfam America that would compel Moderna and Pfizer to commission third-party reports about transferring their vaccine technology.Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss earnings for Johnson & Johnson as well as the pharmaceutical industry company’s decision to suspend its vaccine sales guidance.A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.;297.010009765625;The proposal by an order of Roman Catholic nuns and a social-activist shareholder organization comes as biopharma spending on lobbying reaches into the tens of millions of dollars per year.Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.Here is how Brickell (BBI) and Eli Lilly (LLY) have performed compared to their sector so far this year.J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales. It cuts full-year outlook.When Christopher Chung arrived at EDPNC, the wheels were already in motion on the aggressive push for developing major manufacturing sites paired with generous incentives packages. After helping broker multiple major deals for new manufacturing, he says there is more to come if the state can stay ahead of the trends.Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.;114.41000366210938;;156.35000610351562;HCA Healthcare's (HCA) Q1 earnings are likely to reflect gain from better admissions and a higher revenue stream.J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales. It cuts full-year outlook.Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data from its leading eye care portfolio at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22 – 26 in Washington, D.C. Presentations will include new data on VUITYTM (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) in adults and XEN® Gel Stent, a surgical implant de;91.5999984741211;;85.79000091552734;Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.;68.27999877929688;The FDA has accepted for review AstraZeneca plc (NASDAQ: AZN) - Daiichi Sankyo's (OTC: DSNKY) supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for non-small cell lung cancer (NSCLC) setting. The application covers unresectable or metastatic NSCLC whose tumors have a HER2 (ERBB2) mutation and who have received prior systemic therapy. The application has also been granted Priority Review. Related: AstraZeneca's Stock Gain After Enhertu Meets Primary Endpoint InWILMINGTON, Del., April 19, 2022--AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of ENHERTU® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients in the US with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 (ERBB2) mutation and who have received a prior systemic therapy. The application has also been granted Priority Review.Investors worry Novavax's protein-based vaccine, an alternative to mRNA jabs, is too late to the market.;76.4000015258789;"A high-profile cancer partnership potentially worth $3.6 billion, which saw Bristol-Myers Squibb Co. pay Nektar Therapeutics Inc. $1 billion upfront, buy $850 million of the San Francisco company's stock and promise up to $1.8 billion in additional payments, is coming to an unsuccessful end.  The companies said they are ending the 50-month collaboration after the failure of two trials combining the cancer immunotherapy drug Opdivo from BMS (NYSE: BMY) with Nektar's (NASDAQ: NKTR) bempegaldesleukin, or ""bempeg,"" against types of cancer in kidneys and other organs.  As a result, the companies said, trials of the combination, including a pivotal study against bladder cancer and earlier-stage studies in kidney cancer and pediatric tumors, will also end.";55.20000076293945;Sionna Therapeutics, a cystic fibrosis–focused company advancing science that dates back to storied biotech Genzyme, has launched and revealed $150 million in funding.Tesla, Broadcom, Comcast, Sanofi and Infosys have been highlighted in this Analyst Blog.Life sciences giant Sanofi has moved into one of its towers at Cambridge Crossing, where Boston, Somerville and Cambridge meet, a stone's throw from I-93 and tracks heading into North Station. The move is more than just an address change for Sanofi. Executives see it as the start of a consolidation of the sprawling company’s identity, especially locally.Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Broadcom Inc. (AVGO), and Comcast Corporation (CMCSA).;45.88999938964844;Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.;14.5;OSAKA, Japan & CAMBRIDGE, Mass., April 19, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older. Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the va;44.20000076293945;;10.920000076293945;;154.0800018310547;;10.9399995803833;;104.55000305175781;;109.77999877929688;;13.609999656677246;;33.95000076293945;;38.25;;16.940000534057617;;17.3799991607666;;32.59000015258789;;52.25;;131.6999969482422;;12.84000015258789;;50.66999816894531;-- Collaboration Represents SpringWorks’ Eighth Clinical Collaboration and Highlights Continued Execution on Strategy to Advance Nirogacestat in Combination with BCMA Therapies --STAMFORD, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical trial collaboration a;3.2100000381469727;;4.480000019073486;;;;4.630000114440918;"A high-profile cancer partnership potentially worth $3.6 billion, which saw Bristol-Myers Squibb Co. pay Nektar Therapeutics Inc. $1 billion upfront, buy $850 million of the San Francisco company's stock and promise up to $1.8 billion in additional payments, is coming to an unsuccessful end.  The companies said they are ending the 50-month collaboration after the failure of two trials combining the cancer immunotherapy drug Opdivo from BMS (NYSE: BMY) with Nektar's (NASDAQ: NKTR) bempegaldesleukin, or ""bempeg,"" against types of cancer in kidneys and other organs.  As a result, the companies said, trials of the combination, including a pivotal study against bladder cancer and earlier-stage studies in kidney cancer and pediatric tumors, will also end.";4.989999771118164;;52.150001525878906;"Harmony Biosciences Holdings, Inc. (""Harmony"" or the ""Company"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's first quarter 2022 financial results on Tuesday, May 3, 2022. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.";31.84000015258789;;41.18000030517578;;8.720000267028809;;13.220000267028809;;25.31999969482422;;4.199999809265137;;63.279998779296875;;13.199999809265137;;23.110000610351562;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. The gross proceeds to Crinetics from the offerin;5.190000057220459;;19.059999465942383;;9.220000267028809;;8.09000015258789;;25.260000228881836;;31.559999465942383;;20.360000610351562;;11.010000228881836;;18.969999313354492;;;;8.279999732971191;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...;11.729999542236328;
2022-04-20;183.88999938964844;"In this article, we will take a look at the 11 stocks making big moves after releasing their financial results. You can skip our detailed analysis of these companies and go directly to the 5 Stocks Making Big Moves After Releasing Their Financial Results. Notable companies from the communication services, technology and healthcare sectors, including […]Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.Shares of Johnson & Johnson (NYSE: JNJ) rallied 3% on Tuesday, following the release of the healthcare behemoth's first-quarter financial results.  J&J's revenue grew by 5% to $23.4 billion.  The gains were driven by a 6.3% rise in the company's pharmaceutical sales and a 5.9% increase in medical device sales.The three main Wall Street benchmarks had their best days in over a month on Tuesday, with the Nasdaq closing up 2.2%, as investors responded to positive earnings and dovish comments from two U.S. Federal Reserve officials on interest rate rises.  Of the first 49 companies in the S&P 500 index to report quarterly earnings, 79.6% have exceeded profit estimates, as per Refinitiv data.  ""It certainly feels like every earnings season, especially since March 2020, is more important than the next, but particularly given where we sit in the economic cycle, the Fed's rate hike cycle, and the elevated inflation backdrop,"" said Max Grinacoff, equity derivatives strategist at BNP Paribas.Major U.S. stock benchmarks close sharply higher Tuesday, with gains led by the technology-heavy Nasdaq Composite, as investors weighed whether a raft of corporate earnings results will help markets break out of a recent rut.Johnson & Johnson slashed its 2022 guidance on Tuesday and cut its Covid vaccines outlook entirely — but JNJ stock popped at the open.(Bloomberg) -- Shares of Intuitive Surgical Inc., Abiomed Inc. and other medical-device makers rallied Tuesday after Johnson & Johnson reported stronger-than-expected sales from that division of the company.Most Read from BloombergNetflix Tumbles as 200,000 Users Exit for First Drop in DecadeIn Defense of Elon Musk's Managerial ExcellenceTwitter Has a Poison Pill NowPutin Calls Time on Foreign Listings in Fresh Hit to TycoonsU.S. Stops Mask Requirement on Planes After Judge’s RulingThe S&P SuperU.S. stocks ended higher on Tuesday, as investors used positive earnings to advance Wall Street's main indexes and took relief from two U.S. Federal Reserve officials offering more dovish comments on interest rate rises than one of their counterparts.  Shares of megacap companies, including Microsoft Corp , Apple Inc and Amazon.com Inc, rose even as Treasury yields extended a recent surge.  Of the 49 companies in the S&P 500 index that have reported quarterly earnings so far, 79.6% have exceeded profit estimates, as per Refinitiv data.J&J eyes virus outlook to determine future of its COVID-19 vaccine.This is Joe Wolk, executive vice president and chief financial officer of Johnson & Johnson.  Thank you for joining us today to discuss our company's first quarter 2022 financial results and full year 2022 outlook.Alabama on Tuesday reached $276 million in settlements with Johnson & Johnson, McKesson Corp and Endo International Plc, resolving claims that the companies fueled an opioid addiction crisis, the state attorney general said.  Under the settlement, drug distributor McKesson will pay $141 million toward the state's efforts to combat the opioid crisis, while drugmakers Johnson & Johnson and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement.All three of Wall Street's main indexes sailed higher on Tuesday as positive earnings reports emboldened investors amid more talk of aggressive policy steps to stem inflation and 30-year Treasury yields breaching 3% for the first time in three years.  Shares of megacap companies, including Microsoft Corp , Apple Inc and Amazon.com Inc, rose between 0.7% and 2.7%, even as Treasury yields extended a recent surge.  Johnson & Johnson advanced to a record high, before pulling back slightly, as its quarterly profit exceeded market expectations and it raised its dividend payout.(Reuters) -Alabama on Tuesday reached $276 million in settlements with Johnson & Johnson, McKesson Corp and Endo International Plc, resolving claims that the companies fueled an opioid addiction crisis, the state attorney general said.  Under the settlement, drug distributor McKesson will pay $141 million toward the state's efforts to combat the opioid crisis, while drugmakers Johnson & Johnson and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement.The Dow Jones was up more than 1% in afternoon trading Tuesday, helped in part by a bullish earnings report from Johnson & Johnson.The Nasdaq rallied nearly 2% on Tuesday, leading Wall Street's main indexes higher as investors focused on positive earnings reports while setting aside concerns about aggressive policy steps to stem inflation.  Shares of megacap companies, including Microsoft Corp , Apple Inc and Amazon.com Inc, rose between 0.9% and 3.0%, even as Treasury yields extended a recent surge.  Johnson & Johnson rose 3.5% to a record high as the drugmaker's quarterly profit exceeded market expectations and it raised its dividend payout.The stock market gained broadly Tuesday as housing news and lower oil prices lifted stocks, and as more earnings came in.Johnson & Johnson said its Covid-19 vaccine helped lift overall sales in its most recent quarter, but the company is backing off its full-year guidance on sales of the shot, saying there is a global supply surplus.";49.75;Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharmaceutical industry always remains in focus as investors scramble to find innovative companies working on treatments of diseases. The […]Pfizer (NYSE:PFE): A leading drug manufacturer whose balance sheet received a COVID-19 vaccine boost. Toronto-Dominion Bank (NYSE:TD): Strong dividend and earnings growth profile built in a highly regulated jurisdiction. Kimberly-Clark Corp. (NYSE:KMB): Supplies everyday essentials that the global population will need even a century from now. Lockheed Martin (NYSE:LMT): A defense stock that may give retirement portfolio defensiveness a new meaning. Brookfield Infrastructure Partners LP (NYSE:BIPSee which companies made IDEA Pharma's Pharmaceutical Invention and Innovation Index this year.J&J eyes virus outlook to determine future of its COVID-19 vaccine.Hospitalization rates for unvaccinated children ages 5 to 11  were twice as high as among those who were vaccinated during the record COVID-19 surge caused by the Omicron variant, according to a U.S. study released on Tuesday.  For every 100,000 unvaccinated children in the age group, 19.1 per were hospitalized with COVID-19 between mid-December and late February, compared with 9.2 per 100,000 vaccinated kids, the U.S. Centers for Disease Control and Prevention reported.  It found that among the 397 children who were hospitalized with COVID when Omicron was dominant, 87% were unvaccinated, one third had no underlying medical conditions, and 19% were admitted to an intensive care unit.;292.9200134277344;Despite a similar prevalence of the chronic condition, women diagnosed with heart failure have worse outcomes compared to men. A deeper look reveals that among Black and Latina women with heart failure, negative health outcomes are magnified due to significant health disparities and inequities that exist in the management of the condition. To address this critical unmet need, Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the launch of Hear Your Heart, a health initiatRobust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...;115.54000091552734;;156.6999969482422;"Big healthcare firms such as Bristol-Meyers, Cardinal Health, and AbbVie offer stability in this volatile market and, in some cases, steady dividends.In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharmaceutical industry always remains in focus as investors scramble to find innovative companies working on treatments of diseases. The […]Dragonfly Therapeutics, Inc. (""Dragonfly""), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced an expansion of its research collaboration with AbbVie (NYSE: ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases. AbbVie successfully licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019, in JRight now, I'm thinking of a biotech company that's a leader in its field, a healthcare services company that could represent the future of medical visits -- and a pharma player that's gaining in prescription drug market share.  Vertex Pharmaceuticals (NASDAQ: VRTX) recently did something it hasn't done in a long time.  The company's shares surpassed Wall Street's average 12-month forecast.The company's immunology drug Rinvoq was given the go-ahead to treat adult patients with moderate-to-severe ulcerative colitis.In the latest trading session, AbbVie (ABBV) closed at $156.35, marking a -1.89% move from the previous day.";91.23999786376953;KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.;86.45999908447266;The healthcare industry is crucial to the world because its products and services improve patients' quality of life.  An expanding global population, increased global economic output, and the essential nature of healthcare means that the industry should continue to thrive in the decades ahead.  The first healthcare stock that investors should consider buying to help them grow wealthier over time is health insurer and pharmacy chain CVS Health (NYSE: CVS).Scientists who made giant strides in the fight against viral diseases and vaccine historyFDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).KENILWORTH, N.J., April 20, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Joseph Romanelli will lead Human Health International, and join Merck’s Executive Team, effective August 1, 2022. He will report directly to Robert M. Davis, chief executive officer and president, Merck. As previously announced, Arpa Garay leads Human Health Global Marketing, and Jannie Oosthuizen leads Human Health U.S., both also reporting to Davis.;68.8499984741211;FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).Oxford BioMedica warned that uncertainty over the future of its contract to manufacture AstraZeneca’s Covid-19 vaccine would cause revenue to decline this year, sending its share price down 6 per cent.  The London-listed company said there was a “pause” in vaccine manufacturing while it was in talks with AstraZeneca about whether to extend the supply agreement.  The vaccine is not part of the UK drugmaker’s core business and was initially sold on a non-profit basis.Investors dumped shares in the company on the back of the news, which sent it to the bottom of the FTSE 250.;77.27999877929688;In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharmaceutical industry always remains in focus as investors scramble to find innovative companies working on treatments of diseases. The […];55.849998474121094;Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.See which companies made IDEA Pharma's Pharmaceutical Invention and Innovation Index this year.;45.84000015258789;Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.Unite, the union representing the workers at manufacturing sites across the UK, said the strike would be the first in the drugmaker’s history.  Unite members voted 86 per cent in favour of strike action.  GSK said it offered a pay increase of 4 per cent — but Unite said that was conditional on the union recommending it to its members, which it was not willing to do.In the latest trading session, GlaxoSmithKline (GSK) closed at $45.89, marking a -0.67% move from the previous day.;14.680000305175781;;44.220001220703125;;10.84000015258789;;156.19000244140625;Mid-cap healthcare companies have built up a combination of competitive advantages. This article looks at several top stocks in the segment.;11.140000343322754;;104.01000213623047;;109.58999633789062;;14.199999809265137;;33.349998474121094;;40.7400016784668;;17.139999389648438;;17.399999618530273;;33.27000045776367;;52.86000061035156;;132.9199981689453;;14.489999771118164;;49.72999954223633;;3.200000047683716;;4.639999866485596;;;;4.659999847412109;In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharmaceutical industry always remains in focus as investors scramble to find innovative companies working on treatments of diseases. The […];5.050000190734863;;52.060001373291016;;32.41999816894531;;40.95000076293945;;8.6899995803833;;13.029999732971191;;24.860000610351562;;4.070000171661377;;62.4900016784668;;13.489999771118164;;23.219999313354492;;5.090000152587891;"ATAI Life Sciences NV (NASDAQ: ATAI) is deploying a multipronged approach to accelerate the development of mental health treatments. The company operates a decentralized hub and spoke model in which each of ATAI's platform companies focuses on one lead compound in a single lead indication. ""We believe our three pillars of people, processes and enabling technologies maximize the probability of clinical success at our platform companies,"" Glenn Short, vice president of early development at ATAI, sNEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in April: Benzinga Psychedelics ConferenceFormat: Company Presentation – In Person & VirtualDate and Time: Tuesday, April 19th, 1:10 p.m. ET – 1:40 p.m. ETConference Link: URL The presentation and archived webcast will also be accessible";18.600000381469727;;9.369999885559082;;8.270000457763672;;24.469999313354492;Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19 vaccine candidate. Results from the efficacy analysis have been submitted to the Vietnam Ministry of Health by Vinbiocare on April 13 and shared with Arcturus in parallel with this filing. The Phase 3 vaccine efficacy portion of this study enrolled over 16,000 participants. The trial met its primary endpoint of prevention of virologicallSAN DIEGO, April 20, 2022--Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study;30.690000534057617;;20.760000228881836;;11.15999984741211;;18.940000534057617;;13.300000190734863;;8.300000190734863;;11.899999618530273;"CAMBRIDGE, Mass. & MONTREAL, April 20, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that preclinical data demonstrating inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306, a first-in-class small molecule candidate targeting PKMYT1, were published in Nature. SNIPRx®, Repare’s proprietary, genome-wide, CRISPR-based screening approach, was used to uncove"
2022-04-21;183.36000061035156;Markets have continued to be volatile for a while as inflation rages. In the past, dividend paying stocks have proven to be good hedges for these kinds of environments.Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.Novavax, which is still awaiting a federal decision for its stand-alone Covid vaccine, received early results that suggest it can move forward with its testing for the single shot for both viruses.;49.11000061035156;"Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.For pharma investors to be worth their salt, they need to appreciate the trends that drive the industry.  In the next few years, I expect the major pharmaceutical businesses of tomorrow to look and act more or less like they do today, but I also expect that many of the leading players today will struggle to maintain their status relative to their peers.  Most of the major pharmaceutical companies compete in a slew of different areas.Pfizer is one of the companies behind the leading coronavirus vaccine known as Comirnaty.  The fantastic commercial success that Comirnaty has had will help Pfizer lay a solid foundation for the future.  Pfizer's total revenue in 2021 soared by 92% year over year to $81.3 billion.CureVac and GSK's second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as it seeks to catch up with rivals' development work.  A study in mice showed that the bivalent vaccine candidate, designed to address the Beta and Delta variants of the coronavirus, elicited neutralizing antibody levels that were comparable to the monovalent vaccine candidates targeting only one of the variants.  ""During exposure of the vaccinated animals to either the Beta or the Delta variant, the bivalent mRNA vaccine significantly reduced the viral load in the animals,"" CureVac said in a statement on Thursday.Moderna plans to submit an application to the U.S. health regulator for emergency use authorization (EUA) of its COVID-19 vaccine among kids between the ages of six months to five years by end of the month, a company spokesperson said on Wednesday.  The Omicron variant was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5-year-olds and 44% effective for children aged 6 months to under 2 years.  Last week, Pfizer Inc and BioNTech said a third dose of the COVID-19 vaccine produced significant protection against the Omicron variant in healthy children from ages 5 to 11.In the latest trading session, Pfizer (PFE) closed at $49.75, marking a -0.86% move from the previous day.Novavax, which is still awaiting a federal decision for its stand-alone Covid vaccine, received early results that suggest it can move forward with its testing for the single shot for both viruses.";289.6099853515625;Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.;110.75;In today's IBD Screen Of The Day, the Stocks That Funds Are Buying filter reveals four compelling growth stocks near buy points of new bases. Three are in the energy field and one is a drugmaker. Novo Nordisk (NVO) has waffled a bit after breaking out above the 117.45 buy point of a cup base April 7, according to MarketSmith....;158.52000427246094;Markets have continued to be volatile for a while as inflation rages. In the past, dividend paying stocks have proven to be good hedges for these kinds of environments.;89.94999694824219;;86.2300033569336;A safe and high-yielding dividend stock can make for a great investment to hang on to for years.  The S&P 500's dividend yield is less than 1.4% today.  Merck & Co. (NYSE: MRK), Royal Bank of Canada (NYSE: RY), and Intel (NASDAQ: INTC) all pay more than double that amount.In the latest trading session, Merck (MRK) closed at $86.46, marking a +0.78% move from the previous day.;67.38999938964844;AstraZeneca plc (NASDAQ: AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo. There were no cases of severe disease or COVID-19-related deaths in the Evusheld group through the six-month follow-up. Related: EMA RecomWILMINGTON, Del., April 20, 2022--Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD™ (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six-month follow-up analysis, compared to placebo.1 There were no cases of severe disease or COVID-19 related deaths in the EVUSHELD group through the six-month follow-up.1Novavax, which is still awaiting a federal decision for its stand-alone Covid vaccine, received early results that suggest it can move forward with its testing for the single shot for both viruses.;77.55999755859375;Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.Warren Buffett is once again demonstrating why he's called the Oracle of Omaha.  While the S&P 500 is floundering, shares of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) have jumped close to 17% year to date.  A big part of Berkshire's impressive gain is due to even better performances from individual stocks in its portfolio.Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.;55.22999954223633;;45.689998626708984;"CureVac and GSK's second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as it seeks to catch up with rivals' development work.  A study in mice showed that the bivalent vaccine candidate, designed to address the Beta and Delta variants of the coronavirus, elicited neutralizing antibody levels that were comparable to the monovalent vaccine candidates targeting only one of the variants.  ""During exposure of the vaccinated animals to either the Beta or the Delta variant, the bivalent mRNA vaccine significantly reduced the viral load in the animals,"" CureVac said in a statement on Thursday.";14.550000190734863;;43.59000015258789;;10.649999618530273;;153.47000122070312;;11.279999732971191;;102.66999816894531;;106.05000305175781;;14.0600004196167;;32.77000045776367;JERSEY CITY, N.J., April 21, 2022--Organon To Report First Quarter Results and Host Conference Call on May 5, 2022;39.09000015258789;;16.8799991607666;"CureVac and GSK's second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as it seeks to catch up with rivals' development work.  A study in mice showed that the bivalent vaccine candidate, designed to address the Beta and Delta variants of the coronavirus, elicited neutralizing antibody levels that were comparable to the monovalent vaccine candidates targeting only one of the variants.  ""During exposure of the vaccinated animals to either the Beta or the Delta variant, the bivalent mRNA vaccine significantly reduced the viral load in the animals,"" CureVac said in a statement on Thursday.\- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study\- Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals\- Technology adaptation for bivalent approach for COVID-19 vaccines potentially allows for broader protection against emerging variantsTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 21, 2022/ CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing";16.1299991607666;;30.850000381469727;;50.869998931884766;Nearly seven in ten GA patients believe the impact on their independence and quality of life due to their visual decline is worse than they expected Majority of patients feel the disease negatively affects aspects of everyday life like the ability to read, drive, and travelThree out of four patients attributed their vision loss to a natural part of aging prior to their GA diagnosis, reinforcing the opportunity for broad disease education WALTHAM, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Apellis;126.22000122070312;;14.170000076293945;(Bloomberg) -- Chinese biotechnology firm I-Mab is exploring options including a sale of the business amid takeover interest from other global drugmakers, according to people familiar with the matter.Most Read from BloombergKremlin Insiders Alarmed Over Growing Toll of Putin’s War in UkraineNetflix Rout Is Worst Since 2004, Punishing Roku and Disney, TooAckman Loses More Than $430 Million on 3-Month Netflix BetRussia Test-Fires Nuclear-Capable ICBM in Warning to U.S. AlliesUkrainian Troops Risk;47.119998931884766;;3.0299999713897705;;4.420000076293945;;;;4.5;Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.;4.380000114440918;;50.86000061035156;;30.90999984741211;;39.08000183105469;;8.149999618530273;;12.699999809265137;;24.520000457763672;;4.010000228881836;;59.33000183105469;;12.710000038146973;;21.15999984741211;;4.880000114440918;;17.489999771118164;;9.029999732971191;;8.270000457763672;;22.59000015258789;;29.40999984741211;;20.209999084472656;;10.970000267028809;;18.65999984741211;;13.479999542236328;Company announcement – No. 14 / 2022 Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors for 2022 Copenhagen, DK and Boston, MA, US., April 20, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces a share-based long-term incentive program for Zealand’s Board of Directors in accordance with Zealand's Remuneration P;8.220000267028809;;11.75;
2022-04-22;181.5399932861328;J&J (JNJ) reports mixed first-quarter results and cuts full-year outlook. AstraZeneca (AZN) and Glaxo (GSK) provide FDA updates.Healthcare giant Johnson & Johnson  got a number of price target bumps from sell-side fundamental analysts this week following its latest earnings report.  With the shares trading near their highs, let's dig into the charts and indicators to see if the current price advance has staying power.  The 12-day price momentum study shows lower highs from March into April even as prices made higher highs -- this is a bearish divergence and tells us that the pace of the rise is slowing.Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target have been included in this Analyst Blog.Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Roche Holding AG (RHHBY), and Raytheon Technologies Corporation (RTX).;48.130001068115234;"Can federal agencies that fund early research tap a 42-year-old law to exercise ""march-in"" rights to get a drug made for a lower price? And could that stifle innovation?A European Medicines Agency (EMA) committee on Friday recommended approving the use of Pfizer and BioNTech's COVID-19 vaccine, Comirnaty, as a booster for adults who have previously been inoculated with other vaccines.  The recommendation from Europe's drug regulator comes days after global COVID-19 cases surpassed 500 million, according to a Reuters tally, as the highly contagious BA.2 sub-variant of Omicron surges in many countries.  Some European countries are now seeing a slower uptick in new cases, or even a decline, but the region is still reporting over 1 million cases about every two days, according to the Reuters tally published on Thursday.One stock that has been performing incredibly well in the past few years and has the potential to be a solid long-term buy is healthcare giant Pfizer (NYSE: PFE).  Pfizer is leaner and more focused on growth now after spinning off its off-patent business, Upjohn, in 2020.  In the past 10 years, Pfizer's stock has done a fairly good job of mirroring the markets, with total returns (which include dividends) coming in just a bit below the S&P 500.The World Health Organization (WHO) on Thursday endorsed the use of Pfizer Inc's oral COVID-19 antiviral treatment in high-risk patients after an analysis of trial data by the U.N. agency showed the therapy dramatically cut the risk of hospitalisation.  Of existing COVID-19 treatments, Pfizer's Paxlovid is by far the most potent, the WHO said.  Other therapies include Merck & Co's rival pill molnupiravir, Gilead Sciences' intravenous remdesivir and antibody treatments.These are the healthcare stocks with the best value, fastest growth, and most momentum for May 2022.";278.7300109863281;Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.Eli Lilly (LLY) closed at $289.61 in the latest trading session, marking a -1.13% move from the prior day.These are the healthcare stocks with the best value, fastest growth, and most momentum for May 2022.Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;110.69999694824219;"In an attempt to achieve the company's ultimate goal to have zero environmental impact, Novo Nordisk Indonesia has initiated various activities, including switching the company's delivery method from air freight to sea freight and launching an internal campaign called ""Plastic Funtastic: Turning Your Plastic Waste into Something Fantastic"".";154.99000549316406;Style Box ETF report for FLQLThese are the healthcare stocks with the best value, fastest growth, and most momentum for May 2022.;89.20999908447266;Opinion based on Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to MET exon 14 (METex14) skipping1Tabrecta® (capmatinib) is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally2METex14 skipping is a recognized oncogenic driver occurri;84.58999633789062;Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;65.86000061035156;It's especially wise to turn to dividend stocks since they have historically outperformed their non-dividend-paying peers.  On that note, let's look at two excellent dividend stocks that you can buy and hold forever: AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK).  AstraZeneca is a U.K.-based drugmaker with an exciting lineup of drugs, including an exciting oncology division.J&J (JNJ) reports mixed first-quarter results and cuts full-year outlook. AstraZeneca (AZN) and Glaxo (GSK) provide FDA updates.Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others and the biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.;75.75;In the latest trading session, Bristol Myers Squibb (BMY) closed at $77.56, marking a +0.36% move from the previous day.;54.2400016784668;Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others and the biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.;44.869998931884766;J&J (JNJ) reports mixed first-quarter results and cuts full-year outlook. AstraZeneca (AZN) and Glaxo (GSK) provide FDA updates.In the latest trading session, GlaxoSmithKline (GSK) closed at $45.69, marking a -0.33% move from the previous day.;14.390000343322754;"OSAKA, Japan & CAMBRIDGE, Mass., April 22, 2022--Takeda (TSE:4502/NYSE:TAK) (""Takeda"") today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, Portugal between April 23 and 26, 2022. The exploratory data presented at both meetings provide an opportunity to share important new analyses of LIVTENCITY™ (m";42.68000030517578;;10.279999732971191;;145.60000610351562;;11.029999732971191;;106.58999633789062;;105.91999816894531;;13.720000267028809;Yahoo Finance Live’s Julie Hyman and Brian Sozzi discuss first quarter earnings for Snap.;32.2599983215332;;38.75;;16.18000030517578;"TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022/ CureVac N. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (""mRNA""), will report financial results, and provide business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022.";16.0;;30.860000610351562;;48.2400016784668;;123.5;;13.210000038146973;;47.33000183105469;;2.930000066757202;The Covid-19 health crisis isn’t over for South Florida biotech firms that continue to hone their technologies in hopes of saving lives.Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 5.61% and 3.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;4.349999904632568;;;;4.559999942779541;Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m. Pacific Standard Time (PST), to outline a new strategic plan for the company and provide updates for the company's research and development pipeline.;4.230000019073486;;50.970001220703125;;30.600000381469727;;37.2599983215332;;8.100000381469727;;12.640000343322754;;24.0;Quanterix Corp (NASDAQ: QTRX) received FDA breakthrough device designation for multiple sclerosis (MS) diagnostic. Quanterix designed its Simoa neurofilament light chain (NfL) plasma test as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting MS (RRMS). According to a news release, the company designed the digital immunoassay to quantitatively measure NfL in human serum and plasma. It has shown promise in conjunction with clinical, imaging, aBILLERICA, Mass., April 22, 2022--Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis;3.9100000858306885;;59.0;;12.550000190734863;;21.020000457763672;;4.78000020980835;;17.0;;9.0;;8.0;Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...;21.260000228881836;;29.219999313354492;;20.18000030517578;;10.529999732971191;;18.219999313354492;;13.0;Company announcement – No. 15 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, April 22, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging manage;8.699999809265137;;11.680000305175781;
2022-04-25;186.00999450683594;"In this article, we discuss 10 dividend challengers for 2022. To check out some more dividend stocks in this list, click 5 Dividend Challengers for 2022. Dividend challengers are companies that offer five to nine years of consecutive dividend growth. While it may not seem like a significant period of increasing dividends, it identifies dividend […]Well folks, earnings season is certainly heating up. In the last week or so, several more well-known companies announced their earnings for the first-quarter earnings season. Everyone from streaming giants to big banks to top tech companies are opening their books, revealing their quarterly numbers and sharing guidance for the coming quarters. Today I’d like to take you through some of the biggest earnings from this week: Netflix (NASDAQ:NFLX), Tesla (NASDAQ:TSLA), Bank of America (NYSE:BAC), IBIn this article, we discuss 10 healthcare stocks for an income portfolio. If you want to see more healthcare dividend stocks, click 5 Healthcare Stocks for an Income Portfolio. The healthcare, pharmaceuticals, and biotech space is a big opportunity for investors as the advancement in treatments and therapies for oncology, immunology, and certain rare diseases […]San Francisco will square off on Monday against Walgreens Boots Alliance and three other companies accused of fueling an opioid crisis in the city, the first trial to target  manufacturers, distributors and pharmacies over the addictive pain medicines.  San Francisco has alleged that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd and AbbVie Inc's Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a ""public nuisance"" by flooding the city with prescription opioids and failing to prevent the drugs from being diverted for illegal use.Johnson & Johnson (the Company) (NYSE: JNJ) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery resear";48.95000076293945;Pfizer Inc (NYSE: PFE) said it is voluntarily recalling five batches of its Accupril blood pressure tablets after finding elevated levels of a potential cancer-causing agent in the medicine. Accupril is indicated for hypertension to lower blood pressure. It is also indicated for the management of heart failure as adjunctive therapy when added to conventional therapy. The drug giant said it was not aware of any reports of adverse events related to the recalled batches, which were distributed in t;285.20001220703125;As the S&P 500 has slipped this year, shares of big pharmaceutical firms have offered shelter. Earnings this week from the group will put it to the test.The U.S. industrial market is off to a busy start in 2022 as demand remains high for logistics, e-commerce and manufacturing space everywhere.Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.;113.72000122070312;"Bagsværd, Denmark, 25 April 2022 – On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 22 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme i";156.3000030517578;In this article, we discuss 10 healthcare stocks for an income portfolio. If you want to see more healthcare dividend stocks, click 5 Healthcare Stocks for an Income Portfolio. The healthcare, pharmaceuticals, and biotech space is a big opportunity for investors as the advancement in treatments and therapies for oncology, immunology, and certain rare diseases […]In this article, we discuss 10 blue chip dividend stocks with over 3% yield. If you want to see some more dividend paying blue chip stocks, click 5 Blue Chip Dividend Stocks with Over 3% Yield. A blue chip stock refers to a company with mature operations, stable performance, and financially sound balance sheets. These […];90.44000244140625;;85.44000244140625;KENILWORTH, N.J., April 25, 2022--Merck Receives Positive EU CHMP Opinion for KEYTRUDA for High-Risk Early-Stage TNBCFive Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.;65.95999908447266;Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.WILMINGTON, Del., April 25, 2022--AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single priming dose of the anti-CTLA4 antibody added to Imfinzi (durvalumab) for the treatment of patients with unresectable hepatocellular carcinoma (HCC). A supplemental BLA (sBLA) also has been submitted for Imfinzi in this indication. This novel dose and schedule of the combination is called the STRIDE regimen (SiThe FDA has accepted for review AstraZeneca Plc's (NASDAQ: AZN) marketing application for tremelimumab as a single priming dose added to Imfinzi (durvalumab) for unresectable hepatocellular carcinoma (HCC). This novel dose and schedule of the combination is called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab). A supplemental marketing application has also been submitted for Imfinzi in this indication. Also Read: AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical;76.05000305175781;When a new “rash” appears on the skin, many people may not associate it with psoriasis. That was the case for Royce Thomas when he noticed what he thought was rash or a bug bite. Royce, senior terr...;54.540000915527344;;45.13999938964844;Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.;14.569999694824219;;42.310001373291016;;10.390000343322754;;148.63999938964844;;11.319999694824219;Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines helping to improve people's health and well-being for more than 110 years, today announced the completion of the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, a German company that holds 89.88% of the ordinary shares and 1.08% of the preferred shares of Biotest AG, a European healthcare company specialized in innovative hematology and clinical immunology.;109.58999633789062;;108.29000091552734;;13.1899995803833;;32.5099983215332;;39.08000183105469;;16.920000076293945;;15.930000305175781;;32.47999954223633;;49.400001525878906;;127.56999969482422;;12.65999984741211;;47.38999938964844;;2.9800000190734863;;4.949999809265137;;;;4.71999979019165;;4.190000057220459;CULVER CITY, Calif., April 25, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the first participants have been enrolled in a study that is part of an 800-site master protocol trial for non-small cell lung cancer (NSCLC). The Lung Cancer Master Protocol trial (Lung-MAP) includes a study of Anktiva™ (N-803) plus Keytruda (pembrolizumab) versus investigator choice of standard-of-care chemotherapy in patients with non-small cell lung cancer (NSCL;50.029998779296875;;32.5;;38.279998779296875;;8.489999771118164;;12.630000114440918;;24.399999618530273;;3.869999885559082;;58.709999084472656;;12.84000015258789;;22.110000610351562;;4.96999979019165;;16.520000457763672;;9.050000190734863;;8.510000228881836;;22.09000015258789;;29.239999771118164;;21.260000228881836;;10.579999923706055;;18.280000686645508;;12.359999656677246;;8.8100004196167;;12.9399995803833;
2022-04-26;184.67999267578125;Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.Johnson & Johnson reported impressive numbers in its most recent earnings, and Curaleaf is set to post first quarter results in early May. Let's take a look at why these two companies are best bets for investors who are looking to earn the big bucks over the long haul.  Johnson & Johnson is the parent company of popular brands like Listerine, Neutrogena, and Benadryl, which have captured the market globally.  Johnson & Johnson operates through three segments: Consumer Health, Pharmaceutical, and MedTech (previously known as Medical Devices).In this article, we discuss 10 stocks to buy now according to James Katz’s Humankind Investments. If you want to skip our detailed analysis of Katz’s history, investment philosophy, and hedge fund performance, go directly to 5 Stocks to Buy Now According to James Katz’s Humankind Investments. James Katz is a socially conscious investor, as […]In the aftermath of its Q1 earnings call on April 19, Johnson & Johnson (NYSE: JNJ) Chief Financial Officer (CFO) Joe Wolk had a few quick words to say about the company's decision to stop offering financial guidance about its coronavirus vaccine sales.  Just like that, Wolk opened a can of worms that's liable to leave investors wondering about the future financial health of two key players in the coronavirus vaccine market: Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE).  If one of the world's most successful pharmaceutical businesses is starting to de-emphasize sales of its COVID shots, it could mean that the heyday of the coronavirus vaccine market is drawing to a close.Healthcare juggernaut Johnson & Johnson (NYSE: JNJ) has remained a favorite of dividend-focused investors.  Johnson & Johnson's popular brands Listerine, Neutrogena, Benadryl, and more remain customers' favorites.  To concentrate more on its core healthcare business, viz.By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT On April 11 th , Bioasis Technologies Inc. (OTC:BIOAF) announced a research collaboration with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (NYSE:JNJ). As part of the deal, Bioasis will provide access to its xB 3 platform to Janssen in order for the latter to research, develop and commercialize new products.Walgreens Boots Alliance and Teva Pharmaceutical Industries Ltd ignored the health risks when they created new markets for opioids, a lawyer for the city of San Francisco told a judge on Monday during opening statements of the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.  Richard Heimann, a lawyer for the city, said on Monday that the prescription drug industry was complicit in expanding the market for opioids, regardless of the public health risks.;49.029998779296875;"The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.In this article, we discuss 10 stocks to buy now according to James Katz’s Humankind Investments. If you want to skip our detailed analysis of Katz’s history, investment philosophy, and hedge fund performance, go directly to 5 Stocks to Buy Now According to James Katz’s Humankind Investments. James Katz is a socially conscious investor, as […]U.S. President Joe Biden's administration is aiming to expand access to COVID-19 oral antiviral treatments like Pfizer Inc's Paxlovid by doubling the number of locations at which they are available, the White House said on Tuesday.  Pharmacies participating in the federal pharmacy program for distributing antiviral treatments will be able to order the free treatments directly from the U.S. government starting this week.In the aftermath of its Q1 earnings call on April 19, Johnson & Johnson (NYSE: JNJ) Chief Financial Officer (CFO) Joe Wolk had a few quick words to say about the company's decision to stop offering financial guidance about its coronavirus vaccine sales.  Just like that, Wolk opened a can of worms that's liable to leave investors wondering about the future financial health of two key players in the coronavirus vaccine market: Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE).  If one of the world's most successful pharmaceutical businesses is starting to de-emphasize sales of its COVID shots, it could mean that the heyday of the coronavirus vaccine market is drawing to a close.Pfizer Inc. said Tuesday that an experimental Lyme disease vaccine it's developing with Valneva SE will move into a Phase 3 clinical trial that includes children who are at least 5 years old, based on ""positive"" results among pediatric participants from the Phase 2 study. The Phase 3 trial is expected to begin in the third quarter. The companies said in a news release that the vaccine candidate was more immunogenic in pediatric participants compared with adults in the Phase 2 study. Pfizer's stoPresident Joe Biden's administration is pushing to expand availability of COVID-19 antiviral treatment Paxlovid, developed by Pfizer Inc. , and is moving to raise awareness of the pill and taking steps to make it easier to access, the Associated Press reported. Paxlovid was originally in short supply after being approved for use in December, but as cases have fallen from their January peak, supply is improving. The White House said Tuesday it is stepping up outreach to doctors, letting them knowSAINT-HERBLAIN, France & NEW YORK, April 26, 2022--Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with inclusion of pediatric participants in their planned Phase 3 trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be inPresident Joe Biden's administration is taking steps to expand availability of the life-saving COVID-19 antiviral treatment PaxlovidPresident Joe Biden's administration is aiming to expand access to COVID-19 oral antiviral treatments like Pfizer Inc's Paxlovid by doubling the number of locations at which they are available, the White House said on Tuesday.  Pharmacies participating in the federal pharmacy program for distributing antiviral treatments will be able to order the free treatments directly from the U.S. government starting this week.Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.";282.8299865722656;The biotech Nektar Therapeutics aims to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers Squibb.The company also is closing a longtime R&D center in India but keeping open a manufacturing center in Alabama.Nektar Therapeutics said on Monday it would lay off about 70% of its workforce, or more than 500 employees, after stopping the development of its key cancer drug earlier in the month.  The company scrapped all clinical trials of the drug, bempegaldesleukin, including those in combination with Bristol Myers Squibb Co's cancer drug Opdivo, after the therapy failed to meet the main goal in several studies.  The layoffs are expected to result in a charge of between $150 million and $160 million, most of which would be recorded in the second quarter, Nektar said.Big Pharma executives argue that prescription drug price hikes are necessary for R&D. Not everyone agrees with that rationalization, however.The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.;109.77999877929688;;156.17999267578125;The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.AbbVie (ABBV) closed at $156.30 in the latest trading session, marking a +0.85% move from the prior day.Big Pharma executives argue that prescription drug price hikes are necessary for R&D. Not everyone agrees with that rationalization, however.;88.95999908447266;Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.View more earnings on NVSSee more from BenzingaEMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer SettingFDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K DrugsDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Novartis  said earnings and sales rose in the first quarter of the year, boosted by its key drugs, including heart failure treatment Entresto.  Net income was $2.2 billion, up from $1.8 billion in the same quarter the previous year, on sales that grew to $12.53 billion from $12.41 billion.  Analysts expected sales of $12.62 billion.Novartis AG Chief Executive Officer Vas Narasimhan discusses the company's product pipeline, performance and outlook after first-quarter profit climbed thanks to a boost from new drugs including the blockbuster heart medicine Entresto. Narasimhan speaks on Bloomberg Television.(Reuters) -Novartis said on Tuesday its first quarter core operating income rose 3%, helped by a rebound at generic drugs unit Sandoz and a surge in prescriptions for heart failure treatment Entresto.  The Swiss drugmaker's quarterly core operating income rose to $4.08 billion, short of the average analyst estimate of $4.13 billion, according to Refinitiv data, as sales growth of some drugs including arthritis and psoriasis treatment Cosentyx fell short of expectations.  Quarterly revenue from Entresto jumped 42% to $1.1 billion, ahead of a market consensus of $1 billion.Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating income +5% (cc, 0% USD)Strong performance of key growth brands including Entresto, Kesimpta, Cosentyx and ZolgensmaSandoz sales grew +8% (cc, +2% USD) and core operating income +26% (cc, +21% USD), benefiting from a lower prior year comparison as business dynamics continued to normalize from COVID impacThe CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.;84.4800033569336;Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.Amgen, Chevron, Coca-Cola, Visa and Merck have been included in this Analyst Blog.;65.05999755859375;Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.Alphabet, Amazon.com, Chevron, Berkshire Hathaway and AstraZeneca have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and Chevron Corporation (CVX).;75.58999633789062;Alexandria Real Estate's (ARE) reports better-than-anticipated first-quarter 2022 performance attributable to healthy leasing activity and solid internal growth.They aren't the most exciting stocks out there, but these long-term winners have what they need to keep climbing.The company also is closing a longtime R&D center in India but keeping open a manufacturing center in Alabama.;53.90999984741211;Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.Sanofi teams up with McLaren Racing to accelerate industrial excellence Paris, April 26. Sanofi announces today that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company’s ambition to attain world-class standards of manufacturing excellence. Following a successful pilot in 2021 with McLaren Racing, both companies have decided to extend their collaboration across multiple sites in seven countries, covering more than 100 production l;44.38999938964844;Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.;14.329999923706055;"OSAKA, Japan & CAMBRIDGE, Mass., April 26, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards (FOYA). In the Supply Chain category, Takeda was awarded for its implementation of a new patient-focused supply chain for its allogeneic mesenchymal stem cell therapy; and Takeda’s vaccine production facility in Sing";41.83000183105469;;10.289999961853027;Viatris (VTRS) closed the most recent trading day at $10.39, moving +1.07% from the previous trading session.;142.55999755859375;;10.880000114440918;;103.43000030517578;;103.22000122070312;;12.119999885559082;While the global pandemic caused huge turbulence in the markets 2 years ago, it provided the tailwinds that were seldom seen in recent history for some companies. Online entertainment was high on that list, with companies like Snap, Inc. (NYSE: SNAP) becoming multi-baggers, despite being almost permanently on the verge of profitability. Yet, no external environment remains permanently favorable. As the monetary stimulus unwinds, we see the valuation come down to more reasonable levels. Meanwhile;31.65999984741211;;37.91999816894531;;16.030000686645508;;14.859999656677246;;30.979999542236328;;46.439998626708984;WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022 at 4:30 p.m. ET. To access the live call by phone, please pre-register for the call here. The conference ID is 7978519. A live audio webcast of the event and accompanying slides may also be a;121.62000274658203;;11.899999618530273;;45.16999816894531;;2.7899999618530273;;4.800000190734863;;;;4.329999923706055;The biotech Nektar Therapeutics aims to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers Squibb.Shares of Nektar Therapeutics were down 5.7% in premarket trading on Tuesday, the day after the company said it will lay off 70% of its workforce. As of Dec. 31, the company employed 740 workers. Nektar last week halted development of bempegaldesleukin, an experimental cancer therapy it was testing in combination with Bristol Myers Squibb's Opdivo. At least two executives, chief medical officer Dr. Dimitry Nuyten and chief commercial officer John Northcott, are leaving the company as a result ofThe company also is closing a longtime R&D center in India but keeping open a manufacturing center in Alabama.Nektar Therapeutics said on Monday it would lay off about 70% of its workforce, or more than 500 employees, after stopping the development of its key cancer drug earlier in the month.  The company scrapped all clinical trials of the drug, bempegaldesleukin, including those in combination with Bristol Myers Squibb Co's cancer drug Opdivo, after the therapy failed to meet the main goal in several studies.  The layoffs are expected to result in a charge of between $150 million and $160 million, most of which would be recorded in the second quarter, Nektar said.Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts that will be most impactful to the company's future, including its NKTR-358, NKTR-255 and several core research programs. In connection with this new strategic plan, Nektar also announced a cost restructuring plan aimed at ensuring Nektar has significant capital to fund key programs through value-enhancing data and other milestones without a need to raise increment;3.7850000858306885;;46.93000030517578;;30.670000076293945;;37.02000045776367;;8.15999984741211;;11.630000114440918;;23.110000610351562;;3.8399999141693115;;53.0;;11.729999542236328;;20.969999313354492;;4.599999904632568;;15.109999656677246;;8.4399995803833;;7.769999980926514;;19.489999771118164;;26.719999313354492;;19.920000076293945;;9.770000457763672;;16.6299991607666;;11.510000228881836;;8.180000305175781;;11.600000381469727;
2022-04-27;182.10000610351562;;49.7400016784668;;285.0899963378906;;111.55999755859375;Bagsværd, Denmark, 27 April 2022 – At Novo Nordisk’s Annual General Meeting on 24 March 2022, it was decided to reduce the company’s B share capital from DKK 354,512,800 to DKK 348,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 6,000,000 divided into 30,000,000 B shares of DKK 0.20 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares aNovo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX).Johnston County is growing at a rapid pace, but can it maintain balance between urban and rural? Local leaders say yes.;157.6199951171875;;89.41000366210938;Biofourmis is health care's new virtual care unicorn, with a valuation of $1.3 billion and CVS Health coming on board as an investor, the company announced Tuesday.Novartis AG (NYSE: NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic ESCC, regardless of PD-L1 expression. Novartis intends to submit these data to regulatory autRATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC)1 Positive readout in first-line ESCC adds to clinical evidence for tislelizumab in esophageal cancer and follows FDA and EMA filing acceptances for second-line setting Results support development of tislelizumab in potentially synergMolecular Partners AG (NASDAQ: MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be authorized. Vas Narasimhan also noted that the current omicron wave of SARS-Cov-2, and the lower incidents of hospitalization associated with it, have made clinical investigations challenging to execute in this evolving envirImage source: The Motley Fool.  Novartis (NYSE: NVS)Q1 2022 Earnings CallApr 26, 2022, 8:00 a.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood morning, and good afternoon, and welcome to the Novartis Q1 2022 results release conference call and live webcast.An unexpected business contributed 8% to Novartis' first-quarter sales growth, but Novartis stock fell on light overall sales.;84.41000366210938;Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan have been included in this Analyst Blog.Absci Corp.’s announcement last week that it had opened a New York office had been in the works for a few months, founder and CEO Sean McClain said in a Tuesday interview.  Why New York, where the Vancouver-based synthetic biology company has leased space in Carnegie Hall Tower?  “We’re very excited to be on both coasts,” said McClain, who was attending an investor conference in Boston.Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX).;66.19000244140625;The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC: DSKYF) and AstraZeneca Plc's (NASDAQ: AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of adjuvant chemotherapy. Related: AstraZeneca's Stock Gain After Enhertu Meets PrimWILMINGTON, Del., April 27, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. Patients with hormone receptor (HR)All sectors increased underlying payouts in the first quarter but oil companies led the growth.;75.80999755859375;;54.34000015258789;Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,527,121,390 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n;45.439998626708984;Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.The British drugmaker's antibody treatment for Covid-19 generated sales of £1.3 billion during the quarter.Sales of coronavirus drug Xevudy reached £1.3 billion over the first quarter of this year.Earnings per share were 35.6 pence in the quarter, a jump from 21.3 pence in the same quarter the year prior. Adjusted earnings per share--a closely-watched metric--were 32.8 pence, which the company said is 43% higher than the year prior.(Bloomberg) -- Here’s the key business news from London-listed companies this morning:Most Read from BloombergRussia to Cut Gas to Poland and Bulgaria, Making Energy a WeaponUkraine Latest: Russia Says It Cut Gas Flows to Poland, BulgariaRussia Warns of Nuclear War Risk as Ukraine Talks Go OnElon Musk Lands Deal to Take Twitter Private for $44 BillionTech Stocks Fall Postmarket on Drag From Earnings: Markets WrapGlaxoSmithKline Plc: The pharmaceutical giant expects to make less profit from its c;14.430000305175781;;42.9900016784668;;10.359999656677246;;157.50999450683594;Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results f;10.710000038146973;Johnston County is growing at a rapid pace, but can it maintain balance between urban and rural? Local leaders say yes.;104.2300033569336;NEW YORK & NEW HAVEN, Conn., April 27, 2022--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month. VYDURA®, an orally disintegrating t;103.27999877929688;;12.109999656677246;;32.41999816894531;;39.220001220703125;;15.989999771118164;;15.380000114440918;;30.420000076293945;;46.29999923706055;;117.95999908447266;;12.460000038146973;;44.279998779296875;;2.7699999809265137;;4.800000190734863;First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated Stage IV non-small cell lung cancer (NSCLC)Oral presentation featuring the primary analysis from Phase 2 GEMSTONE-201 study of sugemalimab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (ENKTL), a rare and aggressive form of Non-Hodgkin lymphomaInitial presentation on the activity of aumolertinib in patient;;;4.260000228881836;;3.7300000190734863;;46.150001525878906;"Harmony Biosciences Holdings, Inc. (""Harmony"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the initiation of its Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study.";30.440000534057617;;36.470001220703125;;8.039999961853027;Ms. Liu, currently chief legal officer at Seagen, brings decades of business and legal experience and will also join Erasca’s audit committeeSAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings;11.720000267028809;;22.280000686645508;;3.869999885559082;;52.439998626708984;;11.720000267028809;;20.829999923706055;;4.599999904632568;;15.0600004196167;;8.579999923706055;;8.029999732971191;;19.020000457763672;SAN DIEGO, April 27, 2022--Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022;25.90999984741211;;19.770000457763672;If there’s one thing certain, it’s that markets are unpredictable – and that unpredictability is increasing. The reasons are multiplying: high inflation is rising higher, wages are not keeping up, Russia’s invasion of Ukraine has started Europe’s largest war since 1945, and energy and food commodities – key ingredients in the inflation mix – are sure to rise in price as a result of that fighting. It will be interesting to see, in the coming weeks, just how these cross currents impact the markets;9.020000457763672;;17.600000381469727;;11.40999984741211;;8.319999694824219;Live event in New York City and webcast to start at 8:30 a.m. ETBOSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today will host its 2022 Epilepsy Day live in New York City and via webcast from 8:30 to 11:30 a.m. ET. “We are excited to share a deepe;11.239999771118164;
2022-04-28;183.4600067138672;;50.5099983215332;;297.2699890136719;"View more earnings on LLYSee more from BenzingaThe Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma CandidatesDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Eli Lilly (LLY) beats first-quarter estimates for both earnings and sales and ups its sales outlook for 2022. The stock rises in pre-market trading.GDP Declined in First QuarterAmgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.GDP reported the first negative quarter since Q2 2020, which was considered the ""heart"" of the pandemic.Meta Platforms soared on a welcomed earnings report, helping the stock market bounce Thursday morning. While earnings buoyed stocks, the U.S. economy shrank in the first quarter. The Nasdaq was up 0.5% and the S&P 500 gained 0.Shares of  Eli Lilly  rose Thursday after the drugmaker reported first-quarter earnings and sales that topped Wall Street estimates and boosted revenue guidance for the year.  Analysts surveyed by FactSet expected Lilly (ticker: LLY) to earn $2.29 a share in the quarter on sales of $7.3 billion.  Eli Lilly raised its sales forecast for 2022 to $28.8 billion to $29.3 billion, up from previous guidance of $27.8 billion to $28.3 billion.Eli Lilly & Co. Inc. said Thursday that its experimental weight-loss drug, tirzepatide, demonstrated ""superior weight loss"" compared to placebo in a Phase 3 clinical trial that enrolled 2,539 participants. Lilly said the study's participants lost between 16.0% and 22.5% of their body weight, on average. Participants were either obese or overweight with at least one comorbidity. None had diabetes. The most common adverse event was gastrointestinal. ""Tirzepatide is the first investigational mediciA couple bearish divergences indicate that the pace of the advance in the giant drugmaker's shares is slowing.Lilly (LLY) delivered earnings and revenue surprises of 12.93% and 3.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?";110.19000244140625;Bagsværd, Denmark, 28 April 2022 – Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from daily insulin. The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec compared to insulin degludec. From an overall baseline HbA1c of 8.13%, once-weeklyMeta Platforms soared on a welcomed earnings report, helping the stock market bounce Thursday morning. While earnings buoyed stocks, the U.S. economy shrank in the first quarter. The Nasdaq was up 0.5% and the S&P 500 gained 0.;156.30999755859375;Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.Quality dividend stocks like these can see portfolios through good times and bad. Buy these and hold them forever. AbbVie (ABBV): 3.64% forward yield. The market is overreacting to recent news with this pharmaceutical giant. Best Buy (BBY): 3.86% forward yield. An economic slowdown may not affect its ability to keep raising its dividend. ConAgra Brands (CAG): 3.46% forward yield. Its status as a defensive stock may outweigh concerns about inflationary pressures. Darden Restaurants (DRI): 3.28% fAbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;90.22000122070312;Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.;88.58000183105469;Merck (MRK) beats Q1 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.Merck's mega-blockbuster Keytruda was given the nod to treat patients with a type of endometrial cancer in the U.S.Yahoo Finance's Ines Ferré breaks down trending tickers as earnings continue to roll in.Yahoo Finance Live’s Julie Hyman and Brian Sozzi discuss first quarter earnings for Merck.Merck (MRK) delivered earnings and revenue surprises of 18.23% and 5.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Merck & Co. Inc. shares rose 1.9% in premarket trade Thursday, after the drug company topped estimates for the first quarter, buoyed by more than $3 billion in sales of its COVID-19 antiviral. The company posted net income of $4.310 billion, or $1.70 a share, for the quarter, up from $2.745 billion, or $1.08 a share, in the year-earlier period. Adjusted per-share earnings came to $2.14, ahead of the $1.83 FactSet consensus. Sales rose 50% to $15.901 billion from $10.627 billion, also ahead of th(Reuters) -Merck & Co on Thursday reported quarterly profit and sales that beat estimates and raised its full-year forecasts on strong demand for top-selling cancer drug Keytruda, its Gardasil vaccine and COVID-19 antiviral pill molnupiravir.  The U.S. drugmaker's shares rose 1.8% to $85.90 before the opening bell as revenue rose 50% to $15.9 billion, with most of the growth coming from sales of molnupiravir, which was approved in November.  Analysts had expected sales of $14.7 billion, according to Refinitiv data.Merck & Co posted better-than-expected first-quarter earnings and raised its full-year sales estimate on strength from its top-selling cancer drug Keytruda, human papillomavirus (HPV) vaccine Gardasil and its COVID-19 antiviral pill molnupiravir.  Revenue in the quarter rose 50% from a year ago to $15.9 billion, with most of that growth coming from sales of molnupiravir, which was approved in November.  Total sales were more than $1 billion above analyst estimates of $14.7 billion, according to Refinitiv IBES data.KENILWORTH, N.J., April 28, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2022.Former U.S. Surgeon General Dr. Jerome Adams joins Yahoo Finance Live to discuss the potential end to the pandemic, COVID-19 application submissions, and the availability of quality masks.Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.;67.22000122070312;Merck (MRK) beats Q1 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.WILMINGTON, Del., April 28, 2022--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the US for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease.1-5Former U.S. Surgeon General Dr. Jerome Adams joins Yahoo Finance Live to discuss the potential end to the pandemic, COVID-19 application submissions, and the availability of quality masks.Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.;77.19999694824219;Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.;54.40999984741211;Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.French healthcare group Sanofi's first-quarter adjusted earnings gained 16.2% on sales growth of its bestselling drug Dupixent and a rebound in demand for prescription-free drugs.  First-quarter business operating income, or adjusted earnings before interest and tax, rose to 3.07 billion euros ($3.23 billion), surpassing the average analyst estimate of 2.84 billion euros posted on the company's website.  Revenue from eczema and asthma treatment Dupixent jumped over 45% to 1.61 billion euros, beating an analyst consensus of 1.58 billion euros, on prescriptions in dermatitis, asthma and certain nasal infections.(Reuters) -French healthcare group Sanofi's first-quarter adjusted earnings gained 16.2% on sales growth of its bestselling drug Dupixent and a rebound in demand for prescription-free drugs.  First-quarter business operating income, or adjusted earnings before interest and tax, rose to 3.07 billion euros ($3.23 billion), surpassing the average analyst estimate of 2.84 billion euros posted on the company's website.  Revenue from eczema and asthma treatment Dupixent jumped over 45% to 1.61 billion euros, beating an analyst consensus of 1.58 billion euros, on prescriptions in dermatitis, asthma and certain nasal infections.Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1 Paris, April 28, 2022 Q1 2022 sales growth of 8.6% at CER driven by Dupixent® and CHC Specialty Care grew 17.8% driven by Dupixent® (€1,614 million, +45.7%)Vaccines were up 6.8% reflecting strong PPH franchise as well as gradual recovery of Travel vaccinesGeneral Medicines core assets up 4.7% driven by Rezurock® and overall GBU sales broadly stable (-0.7%)CHC continued strong growth momentLet us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.;45.7400016784668;By Sam BougheddaView more earnings on GSKSee more from BenzingaThe Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In ZentalisPublic-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice.In this article, we will discuss some of the notable stocks soaring on Wednesday. To take a look at some more stocks that are gaining, go to These 5 Stocks Are Soaring Today. The US equity market is in the green today. The S&P 500 Index is up 0.96% as of 12:16 PM ET and […];14.59000015258789;Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare metabolic and rare neurodegenerative diseasesThe global market access and expansion partnership initially established in 2015 aims to provide an efficient and timely diagnosis to patientsDiagnosis remains crucial for patients, leading them towards suitable readily available t;43.54999923706055;;10.489999771118164;Rising costs mean less disposable income for consumers, which can make it more difficult to grow savings and pay bills.  Viatris (NASDAQ: VTRS), Hasbro (NASDAQ: HAS), and JPMorgan Chase (NYSE: JPM) all pay attractive yields that are well above the average S&P 500 payout of 1.4%.  Healthcare company Viatris is a relatively new stock, coming into existence in 2020 through a merger between pharmaceutical company Mylan and Pfizer's off-patent business Upjohn.;153.63999938964844;Shares of biotech company Repligen (NASDAQ: RGEN) are up an impressive 10.1% as of 11:15 a.m. ET Wednesday, according to data from S&P Global Market Intelligence.  The rally is in response to the release of quarterly sales and earnings figures that both topped analysts' expectations.  For the three-month stretch ending in March, Repligen Corporation turned record-breaking revenue of $206.4 million into operating earnings of $0.92 per share.;11.079999923706055;;97.73999786376953;;98.5;;12.279999732971191;;33.0;;39.650001525878906;;16.579999923706055;5 million as of December 31, 2021. EU confirms no obligation to repay upfront payment for Advanced Purchase Agreement for first-generation candidate, CVnCoVTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 28, 2022 / CureVac N.;15.199999809265137;;30.40999984741211;;44.869998931884766;;115.0;;12.850000381469727;;44.220001220703125;;2.819999933242798;;5.389999866485596;;;;4.210000038146973;Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.;3.740000009536743;CULVER CITY, Calif., April 28, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, in Chicago.;45.90999984741211;;30.299999237060547;91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+ months with median DOR follow-up of 3.7 months 36-67% cORR by BICR in China subpopulation across three TKI-pretreated cohorts (EXP-2, EXP-3, and EXP-4)Zai Lab plans to discuss topline TKI-naïve data with Chinese health authority in the fourth quarter of91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+ months with median DOR follow-up of 3.7 months 36-67% cORR by BICR in China subpopulation across three TKI-pretreated cohorts (EXP-2, EXP-3, and EXP-4)Zai Lab plans to discuss topline TKI-naïve data with Chinese health authority in the fourth quarter of;36.61000061035156;;7.440000057220459;;11.680000305175781;;22.31999969482422;Quanterix Corporation (QTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;3.950000047683716;;53.630001068115234;;11.300000190734863;;20.809999465942383;Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.Humana (HUM) still has $2 billion remaining under its share repurchase authorization.;4.420000076293945;;14.789999961853027;;8.850000381469727;;8.25;;20.040000915527344;;26.40999984741211;;19.799999237060547;;8.970000267028809;;17.81999969482422;;11.010000228881836;;8.59000015258789;;11.34000015258789;
2022-04-29;180.4600067138672;;49.06999969482422;;292.1300048828125;"The Dow Jones declined modestly Friday morning, while the S&P 500 and Nasdaq fell solidly on the final trading day of April. Apple and Amazon stock led key earnings late Thursday. Chevron and Exxon Mobil reported before Friday's open.Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.Smart Beta ETF report for FVDEli Lilly topped first-quarter expectations and raised its sales outlook for 2022, prodding LLY stock to pop Thursday.Joining me on today's call are: Dave Ricks, Lilly's chair and CEO; Anat Ashkenazi, chief financial officer; Dr.  During this conference call, we anticipate making projections and forward-looking statements based on our current expectations.Yahoo Finance's Jared Blikre breaks down how stocks are faring as companies report earnings and expectations for upcoming earnings from Robinhood, Apple, and Amazon.";114.0;"Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.Bagsværd, Denmark, 29 April 2022 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 31/2022 dated 27 April 2022, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 29 April 2022. Number ofEuropean shares on Friday rose to their highest in a week as strong earnings reports and a rally in miners boosted risk appetite at the end of a volatile month dominated by concerns about slowing global growth.  The pan-European STOXX 600 index rose 0.7%, trimming its monthly declines to 1.2%.  Worries about faster interest rate hikes, Russian gas supplies, China's COVID-19 lockdowns and lofty valuations in the U.S. technology sector triggered sell-offs in global equities this month, with the STOXX 600 sinking to a one-month low at one point.Shares in Novo Nordisk jumped on Friday after the firm lifted its 2022 sales and operating profit guidance on the back of forecast-beating first-quarter earnings, driven by strong sales of its newer diabetes and obesity treatments.  Novo Nordisk now expects sales growth of 10-14% in local currencies, up from a previous estimate of 6-10%.  ""Insanely strong start to the year by Novo Nordisk and a significant upward adjustment,"" Jyske Bank analyst Henrik Laustsen said in a note.Financial report for the period 1 January 2022 to 31 March 2022 Operating profit increased by 28% in Danish kroner and by 18% at constant exchange rates (CER) to DKK 19.1 billion.Sales in International Operations increased by 18% in Danish kroner (13% at CER), and sales in North America Operations increased by 33% in Danish kroner (24% at CER).Sales within Diabetes and Obesity care increased by 27% in Danish kroner to DKK 36.7 billion (20% at CER), mainly driven by GLP-1 diabetes sales growth of";146.8800048828125;A market rally attempt is underway, but the major indexes lost ground. Apple and Facebook led key earnings. Elon Musk will buy Twitter.AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.The stock market dropped Friday after Amazon, Apple and others reported lackluster earnings and guidance.The company's mega-blockbuster Humira—used to treat rheumatoid arthritis—will face competition from so-called biosimilars in the U.S. next year.View more earnings on ABBVSee more from BenzingaThe Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover BidThe Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma CandidatesDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarteAbbVie (ABBV) delivered earnings and revenue surprises of 0.32% and 0.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Shares of AbbVie Inc. were down 3.4% in premarket trading on Friday after the company missed on revenue in the first quarter of the year. AbbVie had earnings of $4.5 billion, or $2.51 per share, in the first quarter of 2022, up from $3.5 billion, or $1.99 per share, in the same quarter of 2021. Adjusted earnings per share were $3.16. The FactSet consensus was $3.14. The company said it had revenue of $13.5 billion for the quarter, up from $13.0 billion, against a FactSet consensus of $13.6 billi(Reuters) -AbbVie Inc missed Wall Street estimates for first-quarter sales, hurt by European competition for its blockbuster drug Humira and lower demand for its newer drug Rinvoq, sending shares of the company down 7% on Friday.  Sales of the rheumatoid arthritis drug, Humira, fell 2.7% to $4.74 billion in the first quarter, below estimates of $4.91 billion, as it faces competition from cheaper biosimilar copies in Europe.  Sales of Rinvoq, one of the drugs AbbVie has been betting on to drive growth post 2023, missed estimates in the quarter as the U.S. health regulator issued narrower guidelines in December.AbbVie Inc missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq.  Sales of the world's best selling drug, Humira, fell 2.7% to $4.74 billion in the first quarter, below estimates of $4.91 billion as it faces competition from cheaper biosimilar copies in Europe.  AbbVie has been hoping that peak sales of its other rheumatoid arthritis drug Rinvoq and plaque psoriasis treatment Skyrizi would exceed that of Humira eventually, and the company has been working to gain expanded approvals for both drugs.AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2022.By Sam Boughedda;88.02999877929688;Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.;88.69000244140625;"Merck's Keytruda-chemotherapy combo could soon be approved to treat cervical cancer in the European Union.Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.Companies In The News Are: TWTR, PYPL, MRK, MCD.KENILWORTH, N.J., April 29, 2022--European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI-H or dMMR Tumors in Five Different Types of CancerKENILWORTH, N.J., April 29, 2022--European Commission Approves KEYTRUDA Plus Chemo for Patients With Persistent, Recurrent or Metastatic Cervical Cancer PD-L1 (CPS ≥1)Merck reported better-than-expected first-quarter sales and earnings, helped by its Covid pill. In response, Merck stock rose Thursday.Merck CFO Caroline Litchfield discussed the state of M&A in the biotech sector, the Covid-19 pandemic, and the future of Keytruda.Yahoo Finance's Anjalee Khemlani details the latest information surrounding Moderna's FDA filing to authorize a COVID vaccine for children, as well as looking at Merck's Q1 earnings beat attributed to its COVID treatment pill.At this time, I would like to welcome everyone to the Merck & Co Q1 sales and earnings conference call.  Speaking on today's call will be Rob Davis, president and chief executive officer; Caroline Litchfield, chief financial officer; and Dr. Dean Li, president of Merck Research Labs.Yahoo Finance's Jared Blikre breaks down how stocks are faring as companies report earnings and expectations for upcoming earnings from Robinhood, Apple, and Amazon.";66.4000015258789;Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.The Anglo-Swedish drugmaker reported sales of $11.4 billion, above the analyst consensus for $10.9 billion.AstraZeneca PLC plans to open a research-and-development center in a new Boston Properties Inc. building in Cambridge’s Kendall Square and to move Alexion Pharmaceuticals’ headquarters to the site from the Seaport District.  The European life sciences giant (Nasdaq: AZN) will move about 1,500 employees to a facility to be built at 290 Binney St., Alexion spokesperson Lisa Taylor confirmed Friday.  AstraZeneca acquired Boston-based Alexion last year in a blockbuster $39 billion deal.View more earnings on AZNSee more from BenzingaThe Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma CandidatesSix US States Probing Mysterious Liver Inflammation In Kids: BloombergDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All riThe Anglo-Swedish drugs giant said sales of its Oxford/AstraZeneca vaccine will decline later in 2022 as demand wanes.(Bloomberg) -- Here’s the key business news from London-listed companies this morning.Most Read from BloombergElon Musk Offloads $4 Billion of Tesla Shares, Pledges No More SalesUkraine Latest: Germany Says Won’t Block a Russian Oil EmbargoPutin Is Losing So Here’s How He’ll Make the War WorseUkraine’s Forces Get Boost From Arsenal of Old-Fashioned ArtilleryFour European Gas Buyers Made Ruble Payments to RussiaAstraZeneca Plc: The pharmaceutical giant reported first-quarter results that beat ana(Reuters) -AstraZeneca's COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company charges more in some places, CEO Pascal Soriot said on Friday, the latest drugmaker to warn about a global supply glut.  The comments come after the company reported better-than-expected first-quarter profit and sales driven by the vaccine, its second bestseller last year raking in $3.9 billion.  Approval in the United States has been delayed.Yahoo Finance's Anjalee Khemlani details the latest information surrounding Moderna's FDA filing to authorize a COVID vaccine for children, as well as looking at Merck's Q1 earnings beat attributed to its COVID treatment pill.;75.2699966430664;Core PCE Inflation at a 40-Year High in March.MyoKardia, co-founded by a Stanford University professor, developed the drug as part of a portfolio of treatments for genetic heart conditions.The Dow Jones declined modestly Friday morning, while the S&P 500 and Nasdaq fell solidly on the final trading day of April. Apple and Amazon stock led key earnings late Thursday. Chevron and Exxon Mobil reported before Friday's open.Inflation was clear and present in March, but a large chunk of it was due to food and energy prices.This Earth Month, learn how a Bristol Myers Squibb facility in the UK has transformed its reputationBristol Myers (BMY) delivered earnings and revenue surprises of 2.08% and 3.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?View more earnings on BMYSee more from BenzingaRead Why Did Bristol Myers and Nektar End .6B Immuno-Oncology ProgramDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Shares of Bristol Myers Squibb Co. were down 1.9% in premarket trading on Friday after the company told investors to expect less revenue from its cancer drug Revlimid and lower adjusted EPS for the full year of 2022. Bristol had net income of $1.2 billion, or 59 cents per share, in the first quarter of 2022, down from $2.0 billion, or 89 cents per share, in the same quarter a year ago. Adjusted earnings per share were $1.96, against the FactSet consensus of $1.91. The company said it had revenueDrugmaker Bristol Myers Squibb posted slightly better-than-expected first-quarter earnings on Friday on growth of sales of its blood thinner Eliquis and cancer drug Opdivo, but said it no longer expects sales growth in 2022 due to stiff generic competition overseas for blood cancer drug Revlimid.  The first-quarter dropoff in sales of Revlimid, which lost some patent protection this year, was not as sharp as expected.  Still, Bristol Myers cut its full-year sales forecast for Revlimid by $500 million, to $9 billion to $9.5 billion.NEW YORK, April 29, 2022--Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022, which reflect robust in-line product growth, increased adoption of new product portfolio and strong commercial execution.By Geoffrey SmithBristol Myers Squibb said on Thursday the U.S. Food and Drug Administration (FDA) approved its oral heart disease drug Mavacamten, making it the first cardiac myosin inhibitor to be permitted for use in the country.  Mavacamten, which Bristol Myers acquired in its $13 billion buyout of MyoKardia in 2020, will be used in the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy.PRINCETON, N.J., April 29, 2022--U.S. Food and Drug Administration Approves Camzyos (mavacamten);52.25;Sanofi stock rose Thursday on strong revenue growth for the company's allergic conditions treatment, Dupixent.;45.279998779296875;Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.;14.539999961853027;;42.58000183105469;;10.329999923706055;;157.24000549316406;Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022;10.729999542236328;;89.16999816894531;;91.2699966430664;;12.0;;32.33000183105469;;40.150001525878906;;17.09000015258789;My name is Sarah Fakih, and I'm the vice president of corporate communications and investor relations at CureVac.  On the call with me are Franz-Werner Haas, the chief executive officer of CureVac, Klaus Edvardsen, our chief development officer, and Pierre Kemula, chief financial officer of CureVac.;15.09000015258789;;29.280000686645508;;43.529998779296875;;111.45999908447266;;12.539999961853027;"I-Mab (""I-Mab"" or the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced today the appointments of Mr. Richard Yeh as Chief Operating Officer and Dr. John Hayslip as Chief Medical Officer. The two key appointments add greater depth and breadth of industry experience to the Company's leading management team, further accelerating its global ambition in innovation and to become a specialt";42.90999984741211;;2.700000047683716;;5.190000057220459;CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Friday, May 13, 2022 at 8:00 a.m. ET to report its first quarter 2022 financial results and provide a business update. A live webcast can be accessed by visiting the Investors section of the Company’s website at investors.;;;4.130000114440918;Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;3.630000114440918;;45.040000915527344;;29.440000534057617;;32.380001068115234;Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25% and 3.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36MTemporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG, Md., April 28, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2022. “Emergent remains focused on our strategic plan to grow within public health threat markets where we can positively impact patients and customers,”;7.28000020980835;;11.770000457763672;;22.190000534057617;;3.859999895095825;;53.0099983215332;;11.069999694824219;Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...;20.31999969482422;;4.289999961853027;;14.5600004196167;;8.720000267028809;;8.0;;19.3799991607666;;25.3799991607666;;20.190000534057617;;8.520000457763672;;16.739999771118164;;11.281999588012695;;8.100000381469727;;11.0;
2022-05-02;178.63999938964844;Yahoo Finance's Julie Hyman and Brian Sozzi discuss Pfizer saying its COVID-19 treatment pill has failed as a preventive therapy in a clinical trial.;48.34000015258789;;289.55999755859375;;113.83999633789062;Bagsværd, Denmark, 2 May 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) as follows: Blackrock holds as of 25 April 2022 B shares equal to 4.99% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of thNovo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.Bagsværd, Denmark, 2 May 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated personNovo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.;147.8699951171875;;87.6500015258789;In fact, Narasimhan has proven to be a deal maker.  Here is a sampling of what Novartis has bought since he took over as CEO in February 2018.  Avexis, and what would become gene therapy Zolgensma, for $8.7 billion in April 2018.;87.6500015258789;Yahoo Finance's Julie Hyman and Brian Sozzi discuss Pfizer saying its COVID-19 treatment pill has failed as a preventive therapy in a clinical trial.As market volatility takes hold, these safe stocks to buy can help stabilize your portfolio ASML Holding (ASML) – Profitability growth will support a higher share price for ASML Comcast (CMCSA) – the market is discounting Comcast’s streaming unit CVS Health (CVS) – Cost-controls will lift profits Coca-Cola (KO) – strong branding initiatives will spur sales Merck & Co (MRK) – Immunology and cardiovascular drug pipeline shows promise Micron Technology (MU) – strong margins justify a rebound in thi;66.43000030517578;Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the first-quarter earnings call that can help it to reduce its dependence on Spikevax.;75.08000183105469;Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.;53.060001373291016;;44.720001220703125;For companies in the sector, April really was the cruelest month. The SPDR S&P Biotech exchange-traded fund lost almost 18%.;14.489999771118164;;42.349998474121094;;10.210000038146973;;158.82000732421875;;10.789999961853027;;93.5199966430664;;91.05000305175781;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...;12.0;;32.08000183105469;;41.93000030517578;;17.18000030517578;Shareholders in CureVac N.V. ( NASDAQ:CVAC ) may be thrilled to learn that the analysts have just delivered a major...;12.229999542236328;"HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKTHONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for surufatinib for the treatment of pancreatic (“pNETs”) and extra-pancreatic (non-pancr";30.860000610351562;;44.959999084472656;;112.7300033569336;;13.75;;45.029998779296875;;2.799999952316284;Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx, joins Sema4 as CEO and will serve on Board of Directors Eric Schadt, founder and former CEO of Sema4, to serve as President and Chief Research & Development Officer and to continue to serve on Board of Directors Sema4 closes $200 million private placement from leading growth and life sciences investo;5.159999847412109;;;;4.5;;3.9800000190734863;;45.099998474121094;Harmony Biosciences Holdings, Inc. (HRMY) stock is up this year, rising 6% so far.;32.810001373291016;;33.779998779296875;;7.909999847412109;;11.920000076293945;Investing in stocks comes with the risk that the share price will fall. And unfortunately for ADC Therapeutics SA...;23.350000381469727;;4.03000020980835;;55.560001373291016;;11.960000038146973;;20.280000686645508;;4.579999923706055;;14.649999618530273;;8.680000305175781;;7.650000095367432;;21.190000534057617;;26.899999618530273;;21.34000015258789;Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...;9.279999732971191;;19.100000381469727;;11.416999816894531;;8.800000190734863;;11.550000190734863;
2022-05-03;178.2899932861328;(Reuters) -Washington has reached a $518 million settlement with drug distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, ending a months-long trial over the companies' alleged role in fueling the opioid epidemic in the state.  McKesson will pay $197 million, while AmerisourceBergen and Cardinal will each contribute $160.5 million to the settlement.In this article, we discuss the 10 stocks that Jim Cramer says you should buy. If you want to read about some more stocks that Jim Cramer says you should buy, go directly to Jim Cramer Says You Should Buy These 5 Stocks. Jim Cramer, the former hedge fund manager and present journalist investor, has […]Shares of Johnson & Johnson (NYSE: JNJ) climbed a mere 1.82% in April, according to data from S&P Global Market Intelligence.  At another time, that would be cause for alarm, but after a month in which the S&P 500 index dropped 8.8% and the iShares US Pharmaceuticals ETF dropped 3.32%, Johnson & Johnson's steadiness is worth noting.  How did Johnson & Johnson keep chugging when so many other stocks fell?;49.290000915527344;;288.07000732421875;Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.With the market searching for a bottom, Tesla, Microsoft, Eli Lilly and other leading stocks try to recharge as May kicks off.Looking for the best growth stocks to buy? Start by identifying the seven traits of winning stocks, then use IBD screens to find stocks showing them now.Shares of drugmaker Eli Lilly  got a price target bump by Mizuho on the strength of weight-loss drug tirzepatide.  The On-Balance-Volume (OBV) line has moved sideways since August and has failed to confirm the price gains.  The weekly OBV line is different from the daily line.The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding common stock.With several core products showing strength, along with their Covid-19 antibodies, Eli Lilly updated their 2022 EPS guidance.Heavy demand for pesticides and fertilizers has led to strength in IBD's agricultural chemicals industry group.;113.18000030517578;;149.60000610351562;Pfizer posted a sharp rise in revenue for the first quarter, thanks largely to its Covid-19 vaccine.While major indices are down, there are still some hot stocks outperforming the broader market. Chevron Corporation (CVX) is Warren Buffett’s favorite energy stock. AbbVie Inc. (ABBV): Wells Fargo says this pharma stock can run 36% higher. PepsiCo, Inc. (PEP): A dividend king, this consumer staple stock is diversified enough to perform well in both good economic times and bad. Source: Shutter_M / Shutterstock It’s not all bad out there. Despite major indices continuing to fall around the world,;87.4800033569336;Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.A new biotech startup by the name of Dianthus Therapeutics is launching with the goal of making drugs for autoimmune disorders a little less burdensome.;87.0999984741211;A colleague reflects on his time as caregiver after both parents were diagnosed with chronic heart failure;67.16999816894531;;75.05000305175781;;53.41999816894531;Technology in health care has skyrocketed as a result of the pandemic, though shaking out which platforms and strategies are the most useful is still a work in progress.Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.;45.119998931884766;Mobilizing Our Brothers Initiative (MOBI) is teaming up with local New York-based Entertainers, Entrepreneurs and Community Based Leaders for their signature MOBItalks presented by ViiV Healthcare accelerate initiative. MOBItalks, a free personal and professional development series for Black gay men, creates distinguished experiences while encouraging attendees to live stronger, longer, and healthier.The conspiracy also involved the scientist's sister, a former GlaxoSmithKline researcher who set up a rival company in China.;14.5600004196167;;42.70000076293945;;10.399999618530273;Viatris (VTRS) closed the most recent trading day at $10.21, moving -1.16% from the previous trading session.Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;161.49000549316406;LRT Capital Management, an investment management firm, published its first-quarter 2022 investor letter – a copy of which can be downloaded here. A return of -7.37% was recorded by the LRT Economic Moat strategy for the first quarter of 2022, resulting in a 12-month return of +16.72%. In the LRT Economic Moat strategy, as of […];11.149999618530273;;90.0999984741211;Biohaven Pharmaceutical Holding Company Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;92.0999984741211;;12.109999656677246;;32.439998626708984;;40.97999954223633;;17.31999969482422;;13.039999961853027;;30.56999969482422;;44.61000061035156;WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, announced today that renowned hematologist Peter Hillmen, MB ChB, PhD, will join the company as head of hematology engagement, effective May 23, 2022. “For more than two decades, Dr. Hillmen has been at the leading edge of research in PNH, so we are thrilled to welcome him to the Apellis team,” said Cedric Francois, MD, PhD, chief executive oMonthly and every-other-month treatment with pegcetacoplan showed a continuous and clinically meaningful reduction in the growth of both extrafoveal and foveal lesions at month 18 (all p-values nominal) Continued to demonstrate a robust effect in patients with extrafoveal lesions Showed an improved effect in patients with foveal lesions Ten presentations, including three oral presentations, showcase Apellis’s leadership in retina WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceu;116.94000244140625;BOSTON, May 03, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 8:00 a.m. ET.;13.6899995803833;;45.52000045776367;;2.890000104904175;;4.699999809265137;;;;4.510000228881836;;4.050000190734863;;37.18000030517578;Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?WAKIX® (pitolisant) Net Revenue of $85.3 Million for First Quarter 2022 Increase of 43% vs. the Same Period in 2021 WAKIX Surpasses $500 Million in Cumulative Net Revenue Since Launch Initiated Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia Conference Call and Webcast to be Held Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company focused on delivering;33.119998931884766;;33.369998931884766;"Fuad El-Hibri, founder of Gaithersburg biopharmaceutical company Emergent BioSolutions Inc., died April 23 in his Potomac home.  The cause was pancreatic cancer, according to an obituary published on Legacy.com  He “died peacefully at home early Saturday surrounded by family and loved ones,” Emergent wrote in a statement published on the company’s website.  El-Hibri is survived by his wife, Nancy; daughters Faiza (Mitch) and Yusra (Travis) El-Hibri; son Karim (Carley) El-Hibri; and mother Elisabeth El-Hibri; as well as three grandchildren, brother Samir (Rima) El-Hibri; and sister Yasmine El-Hibri Gibellini.";7.599999904632568;SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2022 Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat at 1;12.0;LAUSANNE, Switzerland, May 03, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Monday, May 9, 2022 at 8:30 a.m. ET to report financial results for the first quarter 2022 and provide business updates.;23.139999389648438;BILLERICA, Mass., May 03, 2022--Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022;4.010000228881836;;54.310001373291016;;11.239999771118164;In this piece, we will take a look at the ten best stocks to buy under $20 according to Jeremy Green’s Redmile Group. If you want to skip the details about the hedge fund, then take a look at the 5 Best Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group. Jeremy Green […];20.25;;4.400000095367432;;14.359999656677246;;8.75;;7.570000171661377;;21.510000228881836;;26.5;"PLANO, Texas, May 02, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2022, and provide an update on the Company’s business operations and clinical development programs on May 10, 2022, before the U.S. financial markets open.";21.510000228881836;;9.5;;18.600000381469727;;11.90999984741211;;8.399999618530273;BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will provide a corporate update and report financial results for the first quarter 2022 on Monday, May 9, 2022, after the U.S. financial markets close. Management will provide a;11.539999961853027;
2022-05-04;180.1999969482422;Moderna CEO Stephane Bancel joins Yahoo Finance Live to discuss earnings, COVID-19 vaccine sales growth, creating new boosters for the fall, funding for future sales, and the process for approving a vaccine for young kids.In this article, we discuss the 12 best American stocks to buy in 2022. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best American Stocks To Buy in 2022. The beginning of 2022 brought along something investors hadn’t witnessed since the early days of 2020: […]Style Box ETF report for OUSAStyle Box ETF report for MGV;49.65999984741211;;294.8999938964844;In this article, we discuss the 12 best American stocks to buy in 2022. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best American Stocks To Buy in 2022. The beginning of 2022 brought along something investors hadn’t witnessed since the early days of 2020: […]Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11, 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat on Tuesday, May 10 at 7:40 p.m., Eastern time.;113.91000366210938;"Bagsværd, Denmark, 3 May 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated personBagsværd, Denmark, 3 May 2022 — As part of the up to DKK 24.0 billion 2022 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 4.4 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules”). For that purpose, Novo Nordisk A/S has appointed Skandinaviska Enskilda BaBagsværd, Denmark, 3 May 2022 — Novo Nordisk A/S has today entered into an agreement to purchase 4,207,500 B shares of DKK 0.20 to a value of DKK 3,402 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2022 share repurchase programme of up to a total of DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. The transaction price is DKK 808.51 per share and has been calculated as the three-day volume weighted average market price from 29 Apri";151.58999633789062;If anyone knows that it takes money to make money, it's Warren Buffett.  Investing $100,000 in each of these three Buffett dividend stocks can make you more than $12,800 in combined passive income per year.;88.2699966430664;With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for postmenopausal women living with HR+/HER2- aBC1 When used 1L, Kisqali plus fulvestrant added nearly 16 months of survival benefit to the lives of patients compared to fulvestrant alone, with a 33% relative reduction in the risk of death1 Kisqali is the only CDK4/6 inhibitor-fulvestrant combination to demonstrat;88.5199966430664;Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market.KENILWORTH, N.J., May 04, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Executive Vice President and Chief Financial Officer Caroline Litchfield will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference.;66.75;"Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market.WILMINGTON, Del., May 04, 2022--AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer (BTC).The FDA has accepted AstraZeneca plc’s (NASDAQ) supplemental marketing application seeking approval for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, for locally advanced or metastatic biliary tract cancer (BTC). Under the Priority Review status, the FDA action date is during the third quarter of 2022. BTC is a group of rare and aggressive cancers that occur in the bile ducts and gallbladder. The application was based on an interim analysis of the TOPAZ-1 Phase 3 trialInvestment firm All Blue Capital would be advised by Alan Barge, former oncology head at British drugmaker AstraZeneca Plc, in its bid to acquire drug developer Zymeworks Inc, according to a press statement seen by Reuters.  All Blue late last month approached Vancouver, Canada-based Zymeworks, which is developing antibody therapies for cancer, with a $773 million acquisition offer.  Barge recently joined All Blue as oncology drug development advisor and would assist the firm in ""reversing the value-destructive measures"" that Zymeworks implemented over the past twelve months, according to the statement.AstraZeneca has become a household name thanks to its Covid-19 vaccine, though the company produces many other drugs to justify its $200 billion market cap.";76.30999755859375;NEW YORK, May 04, 2022--Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference;52.4900016784668;Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.Foundation S: Sanofi’s new philanthropic spearhead Paris, May 4, 2022. Sanofi today launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines. Serge WeinbergChairman ofAnnual General Meeting of May 3, 2022 Approval of the financial statements for the fiscal year 2021Distribution of a cash dividend of €3.33 per share and a dividend in kind of EUROAPI shares, at a ratio of one (1) EUROAPI share per twenty-three (23) Sanofi shares, with payment as of May 10, 2022Board composition: renewals and appointment of three new Independent Directors Paris, May 3, 2022. The Combined General Shareholders’ Meeting of Sanofi was held on May 3, 2022 at Paris Expo Porte de Versa;45.15999984741211;1 in 5 Americans provide care to family members or loved ones,1 a task that's inherently connected with physical pain. With many caregivers also dealing with the added challenges of experiencing joint pain, GSK Consumer Healthcare (LSE/NYSE: GSK) today announced Voltaren Arthritis Pain Gel is partnering with actress and caregiver Jennie Garth for the launch of CareWalks, an initiative dedicated to those who care for others.;14.760000228881836;;43.20000076293945;;10.520000457763672;Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.;167.74000549316406;;11.390000343322754;;96.44999694824219;;94.22000122070312;;12.220000267028809;"HAMBURG, GERMANY / ACCESSWIRE / May 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022.The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.";33.189998626708984;;40.380001068115234;Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...;17.790000915527344;;12.380000114440918;;31.979999542236328;;45.95000076293945;;122.16999816894531;;13.760000228881836;;47.810001373291016;;3.0;Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;4.380000114440918;;;;4.659999847412109;Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;4.400000095367432;;38.29999923706055;At this time, I would like to welcome everyone to the Harmony Biosciences first quarter 2022 financial update conference call.  Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences' first quarter 2022 financial performance and provide a business update.;33.529998779296875;;33.849998474121094;;7.929999828338623;;12.260000228881836;LAUSANNE, Switzerland, May 04, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that its executives will be participating in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 1:40 pm ET.;23.760000228881836;;3.7300000190734863;"Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?BRIDGEWATER, N.J., May 04, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") announced its results today for the first quarter ended March 31, 2022.";54.41999816894531;;11.600000381469727;;20.309999465942383;;4.380000114440918;NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR portion of its website. Please visit the atai investor relations website at https://ir.atai.life to view Q1’22 financial results and press release. A video interview with atai Life Sciences CEO Florian Brand, CSO Srinivas;13.850000381469727;;8.75;;7.650000095367432;;22.59000015258789;;27.0;;21.989999771118164;;9.729999542236328;;18.850000381469727;;12.239999771118164;;8.739999771118164;BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 5:00 p.m. ET (2:00 p.m. PT). The fireside chat will be ava;11.630000114440918;
2022-05-05;176.75999450683594;FATE reports a narrower loss and higher collaboration revenues in the first quarter.Yahoo Finance's Emily McCormick reports on how dividend-paying stocks are performing amid heightened market volatility.Dividend Kings are stocks that have increased their payouts for 50 years or longer.  Although they don't always provide investors with the highest yields, you're likely to see your dividend income rise from holding these types of investments over the years.  A couple of Dividend Kings you won't have to worry about paying low payouts today are Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT).Pfizer (NYSE: PFE) just delivered the best quarter in the company's history.  Pfizer is poised to shatter these two biopharmaceutical industry records in 2022.  Pfizer's Comirnaty already holds the title as the best-selling drug in a single year.;48.45000076293945;;292.3699951171875;United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.;112.79000091552734;;152.17999267578125;AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.A more populous and aging global population is almost a guarantee that quality healthcare stocks will do well over the long haul.  Here are three healthcare stocks that have proven to be reliable dividend growers, and each looks like a solid buy for this month.  With a $145 billion market capitalization and operations in 150 countries, Medtronic (NYSE: MDT) is the largest pure-play medical devices stock in the world.Most stocks have fallen, with the S&P 500 index in correction territory and the Nasdaq Composite index in bear territory again.  In 2012, Vertex Pharmaceuticals (NASDAQ: VRTX) became the first company to win U.S. approval of a drug that treated the underlying cause of cystic fibrosis (CF).  Vertex has achieved remarkable success in the subsequent years with a virtual monopoly in the CF market.;86.20999908447266;Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.;88.01000213623047;;64.94999694824219;Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.WILMINGTON, Del., May 05, 2022--High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF). The trial was conducted in patients with HF with mildly reduced or preserved ejection fraction (defined as left ventricular ejection fraction [LVEF] greater than 40%).WILMINGTON, Del., May 05, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.WILMINGTON, Del., May 05, 2022--Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS® (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) compared to the external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial.;76.25;Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease. Learn more about HCM, its impacts and its symptoms.Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.;51.47999954223633;;44.38999938964844;;14.460000038146973;;40.77000045776367;"Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605 million Announced transactions of up to $450 million in Q1 20222022 guidance reaffirmed: Adjusted Cash Receipts(1) expected to be $2,225 to $2,300 million NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial meaRoyalty Pharma plc's ( NASDAQ:RPRX ) price-to-earnings (or ""P/E"") ratio of 41.8x might make it look like a strong sell...";10.050000190734863;;158.50999450683594;;11.289999961853027;;96.33000183105469;;90.22000122070312;COPENHAGEN, Denmark, May 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2022 financial results and provide a business update. Conference Call Details DateWednesday, May 11, 2022Time4:30 p.m. ET/1:30 p.m. Pacific TimeDial In (U.S.)844-290-3904Dial In (International)574-990-1036Access Code6876568 A live webcast of the c;11.930000305175781;;34.869998931884766;"JERSEY CITY, N.J., May 05, 2022--Organon (NYSE: OGN) (the ""company""), today announced its results for the first quarter ended March 31, 2022.";38.529998779296875;;16.6200008392334;;11.199999809265137;;28.739999771118164;;44.560001373291016;"The analysts covering Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) delivered a dose of negativity to shareholders...Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -4.41% and 12.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Generated $12.1 million in Q1 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesReported 18-month data with intravitreal pegcetacoplan in geographic atrophy (GA); on track to submit NDA in 2Q 2022Completed enrollment in potentially registrational Phase 2 study in amyotrophic lateral sclerosis (ALS); data expected mid-2023 Cash and investments of $965.3 million as of March 31, 2022 with expected cash runway into Q1 2024Conference call scheduled today at 4:30 p.m. ET WALTHAM, Mass., May 04,";118.87000274658203;BOSTON, May 05, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2022 and provided a general business update.;12.9399995803833;"I-Mab (""I-Mab"" or the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding Foreign Companies Accountable Act (the ""HFCAA"").";43.79999923706055;– Activities to Enable the Topline Analysis from Phase 3 DeFi Trial Underway with Data Expected in the Second Quarter – – Long-Term Data from the Phase 2 NCI-Sponsored Clinical Trial of Nirogacestat in Patients with Progressing Desmoid Tumors to be Presented at ASCO – – Initial Data from the DREAMM-5 Sub-Study Evaluating Nirogacestat in Combination with GSK’s BLENREP in Patients with Relapsed or Refractory Multiple Myeloma Also to be Presented at ASCO – – Announced Clinical Trial Collaboration a;2.740000009536743;;4.079999923706055;;;;4.440000057220459;;3.9600000381469727;;37.349998474121094;;31.06999969482422;Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreeme;32.279998779296875;;7.380000114440918;;11.319999694824219;;22.65999984741211;;3.549999952316284;;50.4900016784668;LEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended March 31, 2022. “The first quarter of fiscal 2022 saw positive momentu;10.390000343322754;;19.0;;4.010000228881836;;12.09000015258789;;8.489999771118164;;7.539999961853027;;20.200000762939453;SAN DIEGO, May 05, 2022--Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial;25.09000015258789;;21.020000457763672;WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 135,900 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 324,200 shares of Arcutis’ common stock to 49 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Boa;8.989999771118164;;17.610000610351562;;11.489999771118164;Company announcement – No. 15 / 2022 Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10am ET) to Present First Quarter Results for 2022 Copenhagen, DK and Boston, MA, U.S. May 5, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that it will host a conference call on May 12, 2022 at 4 pm CET (10 am ET) following the announcement of results fo;8.130000114440918;;10.84000015258789;We can readily understand why investors are attracted to unprofitable companies. For example, although...Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-05-06;176.3699951171875;A new study conducted by researchers at Harvard Medical School among others has found that the omicron variant of the coronavirus that causes COVID-19 is just as severe as earlier variants, and not more transmissible but no less severe as previously thought.Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's decision to limit the use of Johnson & Johnson COVID-19 vaccines amid blood clot concerns. Elon Musk gathers funds from wealthy allies in Twitter bid, J&J Covid-19 vaccine is restricted by FDA over clotting risk, e-commerce retailers temper 2022 forecasts as consumers change habits, and other news to start your day.U.S. regulators on Thursday strictly limited who can receive Johnson & Johnson's COVID-19 vaccine due to a rare but serious risk of blood clots,the Associated Press reported. The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J'svaccine. U.S. authorities for months have recommended that Americans starting their COVID-19 vaccinations use the Pfizer or Moderna shots instead. COVID cases continue to rise acrFDA follows CDC to recommend limitations to J&J COVID-19 vaccine use.By Liz MoyerStyle Box ETF report for SPLVThe FDA says the single-dose shot should be given only to those who request it or cannot receive other vaccines.The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J's vaccine.The U.S. health regulator said on Thursday it was limiting the use of Johnson & Johnson's COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome, the latest setback to the shot that has been eclipsed by rivals.  The J&J shot, which received U.S. clearance in February 2021 for adults, can be administered in cases where authorized or approved COVID-19 vaccines are not accessible or if an individual is less keen on using the other two shots, the Food and Drug Administration said.  J&J is one of the three vaccines in use in the United States.;49.040000915527344;;296.8999938964844;Many big pharma companies have outperformed the market since the beginning of the year.  One of them is Eli Lilly (NYSE: LLY), a drugmaker known in part for its lineup of diabetes medicines.  Zooming out, Eli Lilly has also performed better than most of its peers in the past year -- and that's because the company has a lot going its way.Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.In this article, we discuss 10 biotech penny stocks that Redditors love. If you want to read about some more biotech stocks popular on Reddit, go directly to 5 Biotech Penny Stocks Redditors Love. The bull market around the biotech sector has cooled in recent weeks as interest rates rise and push investors towards safer […];111.3499984741211;Novo Nordisk – major shareholder announcement Bagsværd, Denmark, 6 May 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 29 April 2022 holds B shares equal to 5.06% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 3;152.8300018310547;Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.In this article, we discuss 10 biotech penny stocks that Redditors love. If you want to read about some more biotech stocks popular on Reddit, go directly to 5 Biotech Penny Stocks Redditors Love. The bull market around the biotech sector has cooled in recent weeks as interest rates rise and push investors towards safer […]Adding defensive healthcare stocks can be a great way to ride out continued volatility in the market. AbbVie (ABBV): Investors are overreacting to this venerable big pharma company’s recent earnings report. Amgen (AMGN): An established biotech company with a high forward dividend yield (3.33%). Baxter International (BAX): A reasonably-priced medical products provider on track to deliver strong results. Quest Diagnostics (DGX): Focus will soon shift to the evergreen nature of its main testing bus;85.81999969482422;"Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.The U.S.-listed shares of Novartis AG fell 2.6% in afternoon trading Thursday, after the Switzerland-based drug maker said it was ""temporarily"" suspending delivery of its cancer treatments Lutathera and Pluvicto in the U.S., as part of a quality review of its production sites in Millburn, New Jersey and Ivrea, Italy. The delivery suspension follows the company's ""temporary, voluntary suspension"" of production of its radioligand therapy production sites in New Jersey and Italy, which is due to ""aNovartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing.  ""Novartis is conducting a thorough review of the situation and currently expects to resolve the issues and resume some supply in the next six weeks"", the Swiss company said.";88.38999938964844;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.;64.36000061035156;Thanks to population growth and aging, the global pharmaceutical market is expected to grow from $1.3 trillion in 2020 to $1.6 trillion by 2025.  Let's take a look at three pharma stocks to consider buying right now that could be great fits in a diversified dividend stock portfolio.  The first stock to think about purchasing now is Sanofi (NASDAQ: SNY).Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.BostInno found a couple of deals where large, public companies acquired Boston startups and the financial details flew under the radar.FDA follows CDC to recommend limitations to J&J COVID-19 vaccine use.Regardless of whether you're a brand-new or longtime investor, the past four months have been challenging.  Since the beginning of the year, the broad-based S&P 500 and nearly 126-year-old Dow Jones Industrial Average have declined more than 10% from their highs, which officially puts both indexes in correction territory.  The Nasdaq 100 -- an index comprising the 100 largest nonfinancial companies listed on the Nasdaq exchange -- is in a bear market, with a decline of 22% as of this past weekend.In this article, we discuss the 11 best UK stocks to invest in now. In order to skip our detailed analysis of these stocks and the latest market situation, go directly to 5 Best UK Stocks To Invest In Now. The United Kingdom economy is experiencing some pains right now, with inflation hurting the purchasing […]The FDA has approved AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKYF) Enhertu (trastuzumab deruxtecan) for adult patients with unresectable or metastatic HER2-positive breast cancer. The approval covers patients who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of therapy. Also Read: Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Break;76.66999816894531;The company met analyst expectations for revenue and profitability, yet that's not necessarily a good thing.;51.400001525878906;"Thanks to population growth and aging, the global pharmaceutical market is expected to grow from $1.3 trillion in 2020 to $1.6 trillion by 2025.  Let's take a look at three pharma stocks to consider buying right now that could be great fits in a diversified dividend stock portfolio.  The first stock to think about purchasing now is Sanofi (NASDAQ: SNY).Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.  ""What a remarkable day it is,"" said EuroAPI Chief Executive Karl Rotthier after ringing the opening bell in Paris.  Sanofi shareholders will receive one EuroAPI share for 23 shares held in the parent company.(Bloomberg) -- EuroAPI, Sanofi’s pharmaceutical-ingredients spinoff, rose on its first trading day in Paris, in an early sign that appetite is recovering in Europe’s dormant listings market.Most Read from BloombergChina Orders Government, State Firms to Dump Foreign PCsStocks Crater as Fed-Policy Jitters Rock Trading: Markets WrapElon Musk’s Fixer Is Quietly Tending the World’s Biggest FortuneU.S. Forgives $6.8 Billion in Public Service Worker Student LoansFiona Hill Says Putin Sensed West’s Wea";44.09000015258789;;14.640000343322754;;39.720001220703125;;9.949999809265137;;156.97000122070312;;12.5600004196167;;90.25;Biohaven Pharmaceutical (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -2.86% and 31.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;83.08000183105469;;11.430000305175781;;34.77000045776367;;36.119998931884766;;15.640000343322754;;10.15999984741211;;25.434999465942383;;40.65999984741211;Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.WALTHAM, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 8:40 a.m. PT . The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available;106.87000274658203;Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.;12.119999885559082;;39.29999923706055;;2.619999885559082;MIAMI, May 05, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2022 after the close of the U.S. financial markets on Monday, May 9, 2022. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 9th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants;3.7200000286102295;;;;4.349999904632568;Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;3.700000047683716;;35.220001220703125;;26.799999237060547;Turning Point Therapeutics Inc (NASDAQ: TPTX) entered into an exclusive license agreement with LaNova Medicines Limited to develop and commercialize LM-302, in the U.S. and the rest of the world, excluding Greater China and South Korea. LM-302 is a novel antibody-drug conjugate (ADC) targeting Claudin18.2, a protein expressed in many gastrointestinal cancers, including gastric, gastroesophageal junction, and pancreatic cancer. LM-302, which going forward will be identified as TPX-4589, is curren;31.469999313354492;;6.96999979019165;;10.949999809265137;ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;22.549999237060547;;3.4000000953674316;;47.595001220703125;;9.5600004196167;;18.030000686645508;;3.859999895095825;"In this article we will discuss some new stock picks of Cathie Wood’s hedge fund. You can skip this part and go directly to see the top 5 New Stock Picks of Cathie Wood in 2022. Despite huge criticism and losses, Cathie Wood’s hedge fund ARK Investment continues to attract investors amid promises of future […]NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline ""atai Life Sciences to Announce First-Quarter 2022 Financial Results"" by atai Life Sciences N.V. (Nasdaq: ATAI), please note the first and second paragraphs, which contained statements referencing the 2022 IR financial results posting and executives on the video interview, as well as forward-looking statements, have been modified. The corrected release follows: atai Life Sciences N.V. (Nasdaq: ATAI) (“ata";12.0;;7.989999771118164;;7.5;;18.719999313354492;Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months after a low-dose (5 mcg) booster. The study also exhibited that booster vaccination generated strong immune responses, both with respect to response magnitude and duration of response for at least three months post-boost. Twelve participants in this arm received 5 mcg of ARCT-154 at least five months;23.110000610351562;;19.399999618530273;Increasing commercial preparations in advance of our Prescription Drug User Fee Act (PDUFA) action date of July 29, 2022 for roflumilast cream for the treatment of plaque psoriasis in adults and adolescentsCompleted enrollment of the sole pivotal Phase 3 trials of roflumilast foam in both seborrheic dermatitis and scalp and body psoriasisEnrolling pivotal Phase 3 trials of roflumilast cream in atopic dermatitisStrong financial position with approximately $345 million in cash, cash equivalents, a;8.399999618530273;;17.5;$150 Million Payment to IGM from SanofiMOUNTAIN VIEW, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), has expired in connection with the Company’s previously announced exclusive worldwide collaboration agreement with Sanofi. In connection;11.619999885559082;;8.079999923706055;;10.5600004196167;"Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass. & MONTREAL, May 05, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022."
2022-05-09;177.3300018310547;"Most of us use terms like ""coulda, shoulda, woulda"" as we detail a dream scenario in which a small investment can make us a millionaire several times over.  Let's take a look at the pharmaceutical company's more recent past to see what an initial $10,000 investment a decade ago would shape up to today.  In 2012, CEO Bill Weldon had led Johnson & Johnson for ten years but had proven unsuccessful in raising the stock price beyond the mid-$60 range, where it had hovered for most of his tenure.Blue-chip stocks are under pressure as the market swoons, but this represents an opportunity. Apple (AAPL): Has one of the best businesses and continues to navigate supply chain problems well. Alphabet (GOOGL, GOOG): Robust financials while the stock is trading at a nice discount from the highs. Procter & Gamble (PG): Durable consumer staples company with strong stock momentum. Johnson & Johnson (JNJ): Dependable medical company with diverse business and strong financials. Source: Shutterstock ICOVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.  Executives at the biggest COVID vaccine makers including Pfizer Inc and Moderna Inc said they believe most people who wanted to get vaccinated against COVID have already done so - more than 5 billion people worldwide.  In the coming year, most COVID vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said.";48.63999938964844;"Is Pfizer stock a buy after the company kept its 2022 sales outlook despite beating Comirnaty estimates? Is PFE stock a buy right now?The German biotech company earned €14.24 a share in the first quarter from revenue of €6.37 billion.BioNTech's first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer , but the German biotech firm is still forecasting a full-year decline in vaccine sales.  ""As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance,"" finance chief Jens Holstein said.  BioNTech stood by its 2022 vaccine revenue guidance of 13 to 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.(Bloomberg) -- BioNTech SE’s first-quarter sales soared past expectations as the German biotech said early research hinted that an omicron-adapted booster might provide broader protection than another dose of its original Covid-19 shot. Most Read from BloombergMarcos Jr. Leads With 61% of Votes Counted: Philippines UpdateStocks Slide in Broad-Based Rout Amid Fed Anguish: Markets WrapDay Trader Army Loses All the Money It Made in Meme-Stock EraEU Push to Ban Russian Oil Is Stalled by Hungarian DeBioNTech , the U.S-listed German biotech, said its first-quarter profit more than tripled to €3.7 billion ($3.9 billion), or €14.24 per share, from €1.13 billion, or €4.39 per share, as revenue jumped to €6.38 billion from €2.05 billion, mostly on its share of COVID-19 vaccine sales from Pfizer and Fosun Pharma as well as direct sales to customers in Germany and Turkey. Analysts polled by FactSet had expected earnings of €9.70 per share on sales of €4.59 billion. In the first quarter of 2022, BiFRANKFURT (Reuters) -BioNTech's first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer, but the German biotech firm is still forecasting a full-year decline in vaccine sales.  ""As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance,"" finance chief Jens Holstein said.  BioNTech stood by its 2022 vaccine revenue guidance of 13 to 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.BioNTech said first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer , but the German biotech firm reaffirmed its forecast for a full-year decline in vaccine sales.  ""As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance,"" finance chief Jens Holstein said.  BioNTech reiterated its 2022 vaccine revenue guidance of between 13 billion and 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.  Executives at the biggest COVID vaccine makers including Pfizer Inc and Moderna Inc said they believe most people who wanted to get vaccinated against COVID have already done so - more than 5 billion people worldwide.  In the coming year, most COVID vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said.";289.2300109863281;The market correction suffered a violent sell-off late in the week. Apple is a relative winner but an absolute loser.;106.25;;150.9600067138672;AbbVie Inc. ( NYSE:ABBV ) shareholders might be concerned after seeing the share price drop 13% in the last month. But...;83.4800033569336;;87.63999938964844;If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...;62.58000183105469;COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.  Executives at the biggest COVID vaccine makers including Pfizer Inc and Moderna Inc said they believe most people who wanted to get vaccinated against COVID have already done so - more than 5 billion people worldwide.  In the coming year, most COVID vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said.DB DB Logo NEW YORK, May 08, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, May 10 and Wednesday, May 11, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, Hong Kong, Germany, Portugal, South Africa, Spain and the UK will respond to questions during formal presentati;76.2699966430664;;50.91999816894531;;43.15999984741211;;14.329999923706055;;37.529998779296875;;10.479999542236328;"Shares of Viatris (NASDAQ: VTRS) were popping on Monday, rising 5.4% as of 11:21 a.m. ET after jumping as much as 9.9% earlier in the morning.  The solid gain came after the drugmaker announced its first-quarter results before the market open.  Viatris reported first-quarter revenue of $4.18 billion, down 5% year over year and below the average analyst estimate of $4.23 billion.Viatris executives suggested the Canonsburg-based pharmaceutical company could spend at least $1 billion and as much as $4 billion in share repurchasing when all is said and done after the company's pending sale of its biosimilar business along with future divestitures.  Viatris (NASDAQ: VTRS) told Wall Street analysts in its first-quarter conference call Monday that it anticipated as much as $4 billion in net proceeds from the deal with Biocon Biologics Ltd. and other future deals after taking into account taxes and its plans to pay down debt.  ""Conceptually, hypothetically ... we could be deploying all of that for share buyback, that is clearly possible,"" CFO Sanjeev Narula said.Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?First-Quarter 2022 Results Reflect Strong Operational Start to the Year";145.5;;11.829999923706055;DB DB Logo NEW YORK, May 08, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, May 10 and Wednesday, May 11, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, Hong Kong, Germany, Portugal, South Africa, Spain and the UK will respond to questions during formal presentati;83.13999938964844;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, plans to hold its upcoming first quarter 2022 earnings call and webcast, reporting financial results for the quarter ended March 31, 2022, and provide a review of recent accomplishments and anticipated upcoming milestones, on Wednesday, May 11, 2022 at 8:30 a.m. ET. The earnings;78.9000015258789;COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference. Company executives will participate in a fireside chat hosted by BofA on Thursday, May 12. Details EventBofA Securities 2022 Healthcare ConferenceLocationLas Vegas, NVDateThursday, May 12, 2022Time1:40-2:10 p.m. Eastern Time /10:40-11:10 a.m. Pacific Time A live webcast of the event will be available on th;10.779999732971191;;34.720001220703125;;33.540000915527344;SOMERSET, N.J., May 09, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO and Chief Executive Officer (CEO) since September 2020. Dr. Huang will continue to serve as CEO of;15.350000381469727;;9.949999809265137;DB DB Logo NEW YORK, May 08, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, May 10 and Wednesday, May 11, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, Hong Kong, Germany, Portugal, South Africa, Spain and the UK will respond to questions during formal presentati;22.18000030517578;;36.7599983215332;;93.97000122070312;;10.770000457763672;;33.86000061035156;;2.440000057220459;Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKODr. Gary Nabel, ModeX President and CEO, former Chief Scientific Officer at Sanofi and founder of NIH’s Vaccine Research Center, joins OPKO as Chief Innovation Officer and a member of OPKO’s Board of DirectorsAlexis Borisy, ModeX Lead Independent Director and a leading biotechnology entrepreneur and investor, joins OPKO’s Board of Directors Transaction to;3.490000009536743;;;;3.7100000381469727;;3.319999933242798;;33.540000915527344;;24.31999969482422;The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of Turning Point...;30.670000076293945;;6.179999828338623;;7.809999942779541;ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?LAUSANNE, Switzerland, May 09, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today reported financial results for the first quarter ended March 31, 2022 and provided business updates.LAUSANNE, Switzerland, May 09, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer. Dr. Martin will serve as a non-executive member of the Company’s Board of Directors and Chair of the Science and Technology Committ;18.5;;3.119999885559082;;43.52000045776367;;8.739999771118164;;16.489999771118164;;3.3399999141693115;;11.729999542236328;;7.46999979019165;;7.5;;16.610000610351562;;20.709999084472656;Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -90.32% and 89.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;18.84000015258789;;7.739999771118164;;15.359999656677246;;10.739999771118164;;7.389999866485596;;9.649999618530273;"CAMBRIDGE, Mass. & MONTREAL, May 09, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time."
2022-05-10;177.08999633789062;Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.Sector ETF report for IHEIn this article, we discuss 10 best dividend stocks under $10. If you want to see more cheap dividend payers, click 5 Best Dividend Stocks Under $10. The stock market tumbled further in April, with the Nasdaq Composite falling 13.3%, which was the worst monthly performance recorded since 2008. Similarly, the S&P 500 dropped 8.8% […]In this article, we discuss 10 dividend stocks for beginners. If you want to see more income stocks for investors starting out their investment journey, click 5 Dividend Stocks For Beginners. Some traders begin their investment journey in hopes of share price gains, but most retail and novice investors are interested in the stock market […];49.4900016784668;(Bloomberg) -- Pfizer Inc. said it will acquire Biohaven Pharmaceutical Holding Co. for $11.6 billion in cash to gain an approved treatment for migraine headaches. Most Read from BloombergMarcos Jr. Leads With 61% of Votes Counted: Philippines UpdateStocks Bounce Back in Countdown to Key CPI Data: Markets WrapStocks Sink to 13-Month Low as U.S. Curve Steepens: Markets WrapBiden Team Sees China Tilt Aided as Putin Falters in UkraineDay Trader Army Loses All the Money It Made in Meme-Stock EraPfizAs more doctors prescribe Pfizer's powerful COVID-19 pill, new questions are emerging about its performance, including why a small number of patients appear to relapse after taking the drug.Shares of Biohaven, which makes the migraine medication Nurtec ODT, soar following the announcement.Yahoo Finance Live’s Julie Hyman discusses reports that Pfizer will acquire biopharmaceutical company Biohaven in an all-cash deal.Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.View more earnings on BHVNSee more from BenzingaBioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 GuidanceResearchers Want Pfizer's Therapy Studied As Evidence Suggests Benefit for Long COVID Patients: ReutersDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Pfizer Inc said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd for about $11.6 billion in cash.  Pfizer will acquire all the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, a 78.6% premium to Biohaven's last closing price.  Biohaven shareholders, including Pfizer, will also get 0.5 of a share of a new publicly traded company that will retain Biohaven's non-migraine treatments that are in development stage.Pfizer Inc said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.  Biohaven shares jumped 70% to $141.31, while Pfizer was  up slightly at $48.83.  Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from COVID-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade.Pfizer Inc. said Tuesday it has entered a definitive agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion in cash. Biohaven is the maker of NURTEC ODT, a dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Under the terms of the deal, Pfizer will pay $148.50 for each Biohaven share, and shareholders will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's noUS pharmaceuticals group Pfizer has agreed to buy biotechnology group BioHaven for more than $11.8bn in cash, in what will be its biggest deal in more than five years, according to people with direct knowledge of the matter.  Pfizer will pay $152 per share to purchase the Connecticut-based company.  BioHaven specialises in developing drugs that target neurological diseases and rare disorders.NEW YORK & NEW HAVEN, CONN., May 10, 2022--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.Sector ETF report for IHENovavax’s Covid-19 vaccine still isn’t approved for use in the U.S. With the pandemic in full retreat and the majority of people now fully vaccinated, demand for Novavax’s vaccine is likely to be weak. Rival pharmaceutical companies Pfizer and Moderna have beat Novavax to market with multiple Covid-19 treatments. Source: rarrarorro / Shutterstock.com Any hope that pharmaceutical company Novavax (NASDAQ:NVAX) stock will gain widespread approval to bring a Covid-19 vaccine to market is now over. TBioNTech's first-quarter revenue tripled on the back of its Pfizer-partnered Covid vaccine, leading BNTX stock to pop Monday.;285.70001220703125;;107.44000244140625;;152.08999633789062;Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.In this article, we will discuss the 10 risk-free dividend stocks to buy amid rising economic uncertainty. If you want to skip reading about these stocks, you can go directly to 5 Risk-Free Dividend Stocks to Buy Amid Rising Economic Uncertainty. Amid rising interest rates and risks of a recession, investors are rushing towards value plays […];84.38999938964844;;87.80999755859375;RAHWAY, N.J., May 10, 2022--Merck To Present Data at ASCO Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Cancers With KEYTRUDA;63.63999938964844;;76.29000091552734;;52.16999816894531;;43.41999816894531;;14.520000457763672;;37.689998626708984;;10.460000038146973;Newell Brands and other hard-hit stocks led today's S&P 500 winners. Apache and other energy and commodity stocks were big losers.View more earnings on VTRSSee more from BenzingaElanco Animal Health Cuts FY22 Guidance After Q1 Earnings Beat Expectations MarginallyMadrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom LaunchDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.;147.69000244140625;;11.960000038146973;;140.0;(Bloomberg) -- Pfizer Inc. said it will acquire Biohaven Pharmaceutical Holding Co. for $11.6 billion in cash to gain an approved treatment for migraine headaches. Most Read from BloombergMarcos Jr. Leads With 61% of Votes Counted: Philippines UpdateStocks Bounce Back in Countdown to Key CPI Data: Markets WrapStocks Sink to 13-Month Low as U.S. Curve Steepens: Markets WrapBiden Team Sees China Tilt Aided as Putin Falters in UkraineDay Trader Army Loses All the Money It Made in Meme-Stock EraPfizShares of Biohaven, which makes the migraine medication Nurtec ODT, soar following the announcement.Yahoo Finance Live’s Julie Hyman discusses reports that Pfizer will acquire biopharmaceutical company Biohaven in an all-cash deal.Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -17.86% and 70.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Pfizer Inc said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd for about $11.6 billion in cash.  Pfizer will acquire all the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, a 78.6% premium to Biohaven's last closing price.  Biohaven shareholders, including Pfizer, will also get 0.5 of a share of a new publicly traded company that will retain Biohaven's non-migraine treatments that are in development stage.Pfizer Inc said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.  Biohaven shares jumped 70% to $141.31, while Pfizer was  up slightly at $48.83.  Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from COVID-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade.Pfizer Inc. said Tuesday it has entered a definitive agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion in cash. Biohaven is the maker of NURTEC ODT, a dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Under the terms of the deal, Pfizer will pay $148.50 for each Biohaven share, and shareholders will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's noBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the first quarter ended March 31, 2022, and provided a review of recent accomplishments during and anticipated upcoming milestones.NEW YORK & NEW HAVEN, CONN., May 10, 2022--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.By Peter Nurse;82.63999938964844;A favorable commodity pricing scenario is likely to have aided Vermilion Energy's (VET) earnings in Q1.;12.550000190734863;"HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (BMY) in targeted protein degradation, originally signed in 2018.Aim of the eight-year extension is to develop a broad pipeline of molecular glue degraders which are small, drug-like compounds.The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for an additional 8 years with the goal to further broaden and deepen the strategic alliance.";34.7599983215332;Last week, Organon & Co. ( NYSE:OGN ) insiders, who had purchased shares in the previous 12 months were rewarded...;35.16999816894531;;15.4399995803833;;10.140000343322754;;22.68000030517578;"On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents and marketable securities as of March 31, 2022; additional $37.5M from tavapadon risk-sharing arrangement received in April 2022 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Th";37.90999984741211;;100.95999908447266;;11.8100004196167;;37.29999923706055;;2.930000066757202;This is Yvonne Briggs with LHA.  Thank you all for joining today's call to discuss OPKO Health's financial results for the first quarter of 2022, as well as the recently announced ModeX Therapeutics acquisition.OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 6.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Conference call begins at 4:30 p.m. Eastern time todayMIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2022. Business Highlights Business highlights for the first quarter of 2022 and subsequent weeks include the following: Acquired ModeX Therapeutics, Inc. (ModeX), gains proprietary immunotherapy technology, new executives and Directors. ModeX is a privately held biotechnology company fo;3.3499999046325684;;;;3.869999885559082;;3.450000047683716;;35.13999938964844;;26.5;SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Administration (FDA) granted an eighth regulatory designation, and third Breakthrough Therapy designation, to lead drug candidate repotrectinib. Breakthrough Therapy designation (BTD) was granted for the treatment of patients with ROS1-positive metasta;30.399999618530273;;6.309999942779541;;7.889999866485596;;16.81999969482422;BILLERICA, Mass., May 10, 2022--Quanterix Corporation Releases Operating Results for First Quarter 2022BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;3.3299999237060547;;45.9900016784668;;9.199999809265137;Event will include guest speaker, Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer CenterSAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced it will host a research & development (R&D) day for analysts and investors that will be held on Thursday, May 26, 2022 from 8:00 a.m. to 11:00 a.m. ET in New York City. The R&D Day will;17.600000381469727;;3.390000104904175;;12.15999984741211;;7.309999942779541;;7.489999771118164;;16.579999923706055;Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, May 09, 2022--Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress;24.420000076293945;"Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?PLANO, Texas, May 10, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.";18.899999618530273;;7.659999847412109;;16.18000030517578;"MOUNTAIN VIEW, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 9:30 a.m. EST in New York. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors– Closing of Global Collaboration Agreement with Sanofi; $150 Million Upfront Payment to IGM – – Completed Public Equity Offering with Gross Proceeds of $230 Million – – Continued Advancement in Clinical Development of IGM-2323 and IGM-8444 – MOUNTAIN VIEW, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the first quarter ended March 3";11.100000381469727;Zealand Pharma A/S (NASDAQ: ZEAL) has amended its existing financing agreement with Oberland Capital Management LLC, under which Zealand will repurchase $50 million of note principal with a 1.2x prepayment premium. Oberland Capital will provide Zealand with up to $75.0 million in incremental capital, of which $50.0 million is to be reserved for M&A and $12.5 million following positive glepaglutide data. The updated financial agreement provides a runway extended beyond significant pipeline milestCompany announcement – No. 16/ 2022 Zealand Pharma Amends Financing Agreement with Oberland Capital as Part of Company’s Refocused Strategy Amendment reduces the outstanding note principal balance from $100 million to $50 million and removes any restrictions on the use of the cash Agreement includes access to an additional $75 million in incremental capital following specific eventsFinancial runway extended beyond significant pipeline milestones and into 2023 Copenhagen, DK and Boston, MA, U.S.;9.210000038146973;"Praxis Precision Medicines Inc (NASDAQ: PRAX) announced topline results from Part B of its Phase 2a study evaluating the safety and efficacy of PRAX-944 for essential tremor (ET). Treatment with PRAX-944 resulted in clinically meaningful improvements in function, supported by improvements in tremor amplitude. In the open-label period through Day 42, patients treated with PRAX-944 demonstrated mean improvement from a baseline of 42% in the daily living score. Following randomization, the differenPRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by statistically significant difference in the placebo-controlled randomized withdrawal phase PRAX-944 continues to be generally well-tolerated BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insighPRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results expected in June 2022 Epilepsy Day showcases largest targeted epilepsy portfolio in industry Cash and investments of $222.5 million as of March 31, 2022 supports runway into 3Q23 BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical";9.779999732971191;
2022-05-11;176.1300048828125;"Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.In this article, we discuss 10 dividend achievers to buy in 2022. If you want to see more stocks in this selection, click 5 Dividend Achievers to Buy in 2022. Dividend achievers are companies that have consistently raised their dividend payouts for at least 10 years. While it may not be as robust a dividend […]Johnson & Johnson on Wednesday appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of next year.  The world's largest health products company in November announced it would spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in its 135-year history.Johnson & Johnson (the ""Company"") (NYSE: JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as Chief Financial Officer Designate of the future, listed New Consumer Health Company.By Peter NurseIs Johnson & Johnson stock a buy after the company suspended its Covid vaccines guidance? Is JNJ stock a buy right now?In this article, we discuss 10 highest-yielding dividend aristocrats for 2022. If you want to see some more stocks in this selection, click 5 Highest-Yielding Dividend Aristocrats for 2022. Dividend aristocrats are S&P 500 constituents that have raised their dividends annually for at least 25 consecutive years. In the volatile macro backdrop, dividend stocks have […]";49.45000076293945;More than 2.8 million courses of Pfizer Inc’s COVID-19 oral antiviral treatment Paxlovid have been made available at pharmacies around the United States, with the Biden administration working to improve access to the drug.  As Paxlovid has become more widely used, some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement.  How common is a recurrence of COVID symptoms shortly after Paxlovid treatment?With the pandemic giving way to a wave of stressful economic news, Covid vaccine maker Pfizer is turning to the business of eliminating headaches....Pfizer will acquire migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal that sent BHVN stock rocketing.Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.The company is flush with cash as a result of sales of its Covid-19 vaccine and therapeutic, while some of its drugs will lose patent protection toward the end of the decade.The move to acquire the New Haven, Conn., biopharmaceutical company will give the New York drugmaker full ownership of the Nurtec migraine franchise.The stock market bounced back after a three-day sell-off, rising sharply in early trading Tuesday, as a handful of big moves punctuated the session.;286.69000244140625;Eli Lilly & Co. and Incyte said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with COVID-19. The treatment, also called baricitinib, will be used for patients who require oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first. The treatment has been avaEli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.The FDA approved Eli Lilly And Co's (NYSE: LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval. The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat COVID-19 in hospitalized adults and pediatric patients in November 2020. Related: Eli Lilly Achieve;103.80999755859375;Bagsværd, Denmark, 11 May 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated perso;151.9600067138672;Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and AbbVie Inc's (NYSE: ABBV) Allergan Plc are willing to pay more than $5 billion combined to resolve more than 3,500 lawsuits filed over highly addictive opioid painkillers, according to three people familiar with settlement talks. The people said the companies have been in mediation talks with plaintiffs for more than a year. While Teva and Allergan indicated a willingness to settle, no formal offer has been made or finalized, and talks are contAbbVie today announced positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy. The results showed that more patients treated with either dose of upadacitinib (15 mg or 30 mg once daily) achieved the co-primary endpoints of endoscopic response and clinical remission, as well as the secondary endpoint of endoscopicAbbVie, Qualcomm, Linde, CVS Health Corp, and Booking Holdings are part of Zacks top Analyst Blog.These are the 6 undervalued stocks you should buy for the long term that have low price-to-earnings (P/E) multiples, pay good dividends, and also have share buyback programs. McDonald’s (MCD): McDonald’s trades with a 2.23% dividend yield, 25x forward earnings and should do well as a result. The Allstate Corporation (NYSE:ALL) — The insurer has a new $5 billion buyback program and yields 2.64%. HP Inc. (NYSE:HPQ) — The computer printer maker has a 2.7% yield as well as a hefty, consistent buybacIt was a mixed day in the market and at this rate, the bulls will take anything that isn’t a bludgeoning. Tech helped lead the way higher, as did bonds. With all of this in mind, let’s look at a few top stock trades now. Top Stock Trades for Tomorrow No. 1: Tesla (TSLA) Click to EnlargeSource: Chart courtesy of TrendSpider Tesla (NASDAQ:TSLA) stock broke the April low on Monday and despite Tuesday’s rally, this level acted as resistance on the day. That said, Tesla is holding the 21-month movingToday's Research Daily features a real-time update on the Q1 earnings season and new research reports on AbbVie (ABBV), QUALCOMM (QCOM), and Linde(LIN).;84.04000091552734;If you have $5,000 you can afford to invest in the stock market right now, dividend stocks could be your best option.  Three income stocks that pay high yields and are backed by strong financials include Novartis (NYSE: NVS), Colgate-Palmolive (NYSE: CL), and Fortis (NYSE: FTS).;89.19000244140625;In this piece, we will take a look at the ten stocks to invest in under $20 according to Sio Capital. To skip the bottom five stocks in this list, head on over to 5 Stocks to Invest In Under $20 According to Michael Castor’s Sio Capital. Sio Capital is a hedge fund based out […];61.43000030517578;Sanofi SA (NASDAQ: SNY) and AstraZeneca plc (NASDAQ: AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV). Results from the Phase 3 MELODY and Phase 2b nirsevimab trials demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% against medically attended lower respiratory tract infections due to RSV in infants. In a separate pooled posthoc analysis of the trials, blood samples taken from infants dosed with nirsevimab;76.1500015258789;In this article, we discuss 10 dividend achievers to buy in 2022. If you want to see more stocks in this selection, click 5 Dividend Achievers to Buy in 2022. Dividend achievers are companies that have consistently raised their dividend payouts for at least 10 years. While it may not be as robust a dividend […];50.720001220703125;Sanofi SA (NASDAQ: SNY) and AstraZeneca plc (NASDAQ: AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV). Results from the Phase 3 MELODY and Phase 2b nirsevimab trials demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% against medically attended lower respiratory tract infections due to RSV in infants. In a separate pooled posthoc analysis of the trials, blood samples taken from infants dosed with nirsevimabNew nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single doseTwo analyses are being presented at the European Society for Paediatric Infecti;42.529998779296875;;13.930000305175781;Japan's Takeda Pharmaceutical Co said on Wednesday its 12-month operating profit slid 9.5%, although the country's largest drugmaker forecast a rebound for the current year.  Chief Executive Christophe Weber said that core operating profit, which strips out impairments and other non-recurring items, would likely exceed 1 trillion yen this fiscal year, and the company's financials would become clearer now that its 2019 absorption of Shire Plc is complete.  Takeda is domestically producing the COVID-19 vaccine, developed by Novavax Inc, which was approved by Japanese regulators last month.OSAKA, Japan, May 11, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas.;38.310001373291016;;10.390000343322754;;141.92999267578125;;12.550000190734863;;140.77999877929688;With the pandemic giving way to a wave of stressful economic news, Covid vaccine maker Pfizer is turning to the business of eliminating headaches....On Tuesday, the Nasdaq broke its biggest three-day losing streak since March 2020 and led the upside among the indexes.Pfizer will acquire migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal that sent BHVN stock rocketing.In this article, we will discuss some of the popular stocks trending on Tuesday. To take a look at some more stocks that are in the news, go to 5 Stocks Making Headlines Today. The S&P 500 Index and the Dow 30 Index are down 0.46% and 0.78%, respectively, as of 12:26 PM ET. Meanwhile, […]The company is flush with cash as a result of sales of its Covid-19 vaccine and therapeutic, while some of its drugs will lose patent protection toward the end of the decade.The move to acquire the New Haven, Conn., biopharmaceutical company will give the New York drugmaker full ownership of the Nurtec migraine franchise.The stock market bounced back after a three-day sell-off, rising sharply in early trading Tuesday, as a handful of big moves punctuated the session.;78.08000183105469;Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;10.890000343322754;;33.349998474121094;;34.0099983215332;;14.699999809265137;;9.899999618530273;;20.6200008392334;We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...;35.06999969482422;;96.95999908447266;;10.510000228881836;;34.88999938964844;;2.690000057220459;OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.Shares of Opko Health (NASDAQ: OPK) were jumping 13.5% higher as of 12:31 p.m. ET on Tuesday.  Opko also announced on Monday that it has acquired ModeX Therapeutics in an all-stock deal valued at $300 million.  The acquisition of ModeX could be good for Opko over the long term.;3.200000047683716;;;;3.5899999141693115;;2.680000066757202;;33.619998931884766;;25.5;Granted Third Breakthrough Therapy Designation (BTD) for Repotrectinib for the treatment of patients with ROS1-positive Metastatic NSCLC who have been Previously Treated with One ROS1 TKI and who have not Received Prior Platinum-Based ChemotherapyReported Positive Topline Data by BICR for Repotrectinib in ROS1+ NSCLC from Phase 1/2 TRIDENT-1 Study and Remain On-Track for Pre-NDA Meeting Anticipated Later This QuarterCompleted Enrollment into the Intermediate Dose Level Cohort for Elzovantinib in;27.969999313354492;Executives at contract vaccine manufacturer Emergent BioSolutions covered up quality control problems that led to more than 400 million doses of coronavirus vaccines needing to be trashed, congressional investigators said in a report Tuesday.;5.639999866485596;;6.929999828338623;;15.420000076293945;Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 26.87% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?;3.259999990463257;;41.97999954223633;You can invest in an index fund if you want to make sure your returns approximately match the overall market. In...;8.800000190734863;;16.860000610351562;SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on May 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 234,600 shares of its common stock to eight new non-executiv;3.130000114440918;;9.640000343322754;;6.010000228881836;;7.511000156402588;;13.039999961853027;The latest analyst coverage could presage a bad day for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ), with the...;22.709999084472656;;16.329999923706055;;7.050000190734863;Day One Beverages, the sparkling CBD water brand and exclusive CBD partner of USA Pickleball, has expanded its product line to include a new extra-strength, 2,000 mg CBD Recovery Cream, to provide both pickleball athletes and consumers alike with highly effective post-workout support, recovery and relief. Day One, along with USA Pickleball, is launching the co-branded topical product that has been formulated for competitive players and weekend warriors alike. Pickleball, the wildly popular paddl;13.270000457763672;;11.079999923706055;Company announcement – No. 17 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, May 10 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: Credit Suiss;8.75;BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences: Citi Biotech Virtual Co-Panel Day º ‘Mood Disorders/Mental Health’ panel on Wednesday, May 18, 2022 at 11;9.25;
2022-05-12;177.8699951171875;In this article, we discuss 10 value stocks with high dividend yields. If you want to check out more stocks in this list, see 5 Value Stocks with High Dividend Yields. According to Bank of America, high yielding stocks have outperformed so far in 2022. Savita Subramanian, head of U.S. equity and quantitative strategy at […]Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.In this article, we discuss 10 high-yield UK dividend stocks to buy now. If you want to read about some more high-yield UK dividend stocks, check out 5 High-Yield UK Dividend Stocks to Buy Now. In early May, the Bank of England raised interest rates from 0.75% to 1% to tackle rising inflation. The bank […]Smart Beta ETF report for DGROStyle Box ETF report for VONVSmart Beta ETF report for VYMIn this article, we discuss 11 best Vanguard stocks to buy now. If you want to see the top 5 Vanguard holdings, click 5 Best Vanguard Stocks to Buy Now. The Vanguard S&P 500 ETF invests in the S&P 500 Index, which consists of the largest 500 American companies. The fund aims to replicate the […];50.38999938964844;"Jean Hynes, manager of the Vanguard Health Care fund, is focused on big themes in healthcare—and stocks like Anthem and Eli Lilly.Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas"") will share new research during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Hybrid Congress from June 9-12. A total of 13 abstracts from the company's expanding portfolio of approved and investigational therapies will be presented across both meetings, underscoring the company's commitment to advancing treatment options foSeveral generic drugmakers that will produce versions of Pfizer's COVID-19 antiviral treatment Paxlovid have agreed to sell the medicine in low- and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on Thursday.  CHAI said it could not disclose the names of the manufacturers who have agreed to the price ceiling, because they are still in the early stage of product development and have not received regulatory approval.The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.  ""One weight on the sector has been a relative lack of M&A of late ... and we think this news may be just what the doctor ordered to restore sentiment,"" Piper Sandler analyst Christopher Raymond said.  Biotechs are coming off their worst April since 2002, and the crash in valuation has made them attractive M&A targets, especially when small drugmakers are grappling with a cash crunch, analysts say.Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.  ""One weight on the sector has been a relative lack of M&A of late ... and we think this news may be just what the doctor ordered to restore sentiment,"" Piper Sandler analyst Christopher Raymond said.  Biotechs are coming off their worst April since 2002, and the crash in valuation has made them attractive M&A targets, especially when small drugmakers are grappling with a cash crunch, analysts say.";291.79998779296875;"Many industry bigwigs reported solid results with some beating on earnings or revenues or both.The stock market tumbled Wednesday on a hot inflation report. A lack of investor fear suggests no market bottom yet.The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.Biogen and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway.Eli Lilly is the IBD Stock Of The Day after ""transformative"" data in obesity helped LLY stock retain its recent breakout.Arkansas's attorney general on Wednesday accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.  The lawsuit, filed in Pulaski County, Arkansas state court, targets Eli Lilly and Co, Novo Nordisk A/S and Sanofi SA, which together make the vast majority of the insulin drugs sold in the United States.Arkansas's attorney general on Wednesday accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing insulin costs.  The lawsuit, filed in Pulaski County, Arkansas state court, targets Eli Lilly and Co, Novo Nordisk A/S and Sanofi SA, which together make the vast majority of the insulin drugs sold in the United States.  It also names the nation's leading pharmacy benefit managers (PBMs) - UnitedHealth Group Inc subsidiary Optum Inc, CVS Health Corp's CVS Caremark and Cigna Corp's Express Scripts.";104.3499984741211;Biogen and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway.;154.2899932861328;AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7) and the European Hematology Association (EHA) Congress (June 9-17).AbbVie today announced the 2022-2023 class of recipients of the AbbVie Immunology Scholarship, which provides financial support to students living with chronic, immune-mediated diseases pursuing higher education in the United States. As part of AbbVie's leadership and commitment to the immunology community, the scholarship seeks to empower students as they pursue a degree and a life not defined by their diseases.The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.These Warren Buffett stocks are helping the Oracle of Omaha be a winner even in a down market. Occidental Petroleum (OXY): It was the best-performing stock in the S&P 500 in the first quarter. Chevron (CVX): Buffett added another 120 million shares of CVX stock to his portfolio. Bristol-Myers Squibb (BMY): Buffett has a comparatively “small” position of 5.2 million shares. Kraft Heinz (KHC): It’s been rough at times for KHC stock, but its finally a winner. Kroger (KR): The grocery store chain keIs AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?In this article, we discuss the 15 best income stocks to invest in. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best Income Stocks To Invest In. Stocks can be incredibly volatile, and 2022 has provided yet another reminder of that fact. With stocks […];85.37999725341797;Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker analysis of Piqray® plus fulvestrantData for Tafinlar® + Mekinist® in pediatric patients with BRAF V600 low-grade glioma to be featured in ASCO official press briefingFirst release of 96-week data on Scemblix® in Ph+ CML in chronic phase patients previously treated with ≥2 prior tyrosine kinase i;90.83000183105469;Several generic drugmakers that will produce versions of Pfizer's COVID-19 antiviral treatment Paxlovid have agreed to sell the medicine in low- and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on Thursday.  CHAI said it could not disclose the names of the manufacturers who have agreed to the price ceiling, because they are still in the early stage of product development and have not received regulatory approval.The fresh blow to Roche's hopes in a closely watched  class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say.  Roche said an interim analysis of an ongoing clinical trial showed that its experimental drug, tiragolumab, failed to meaningfully slow disease progression in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with its approved PD-L1 immunotherapy Tecentriq, versus Tecentriq alone.  The study will continue to evaluate whether the combination helps patients live longer, the gold standard for cancer treatments.The fresh blow to Roche's hopes in a closely watched  class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say.  Roche said an interim analysis of an ongoing clinical trial showed that its experimental drug, tiragolumab, failed to meaningfully slow disease progression in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with its approved PD-L1 immunotherapy Tecentriq, versus Tecentriq alone.  The study will continue to evaluate whether the combination helps patients live longer, the gold standard for cancer treatments.;61.45000076293945;"NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced that the presentations from the May 10th and 11th Depositary Receipts Virtual Investor Conference (“dbVIC”) are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, Hong Kong, Germany, Portugal, South Africa, Spain and the UK presented their equity stories andBURLINGAME, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Accumulus Synergy, a nonprofit organization working to develop an information and data exchange platform aimed at transforming how drug innovators and health authorities worldwide interact, today announced AstraZeneca (LSE/STO/Nasdaq: AZN) has joined Accumulus Synergy as a sponsor company. “There is tremendous industry excitement about our organization’s vision and our path towards making it a reality. The data and information exchange paradigAccording to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc (NYSE: EBS) might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards. Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination. ""Despite major red flags at its vaccine manufacturing facility, Emergent's executives swept these problems under the rug and continued to rake in taxpayer";76.30000305175781;BridgeBio Pharma Inc (NASDAQ: BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE: BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in the low- to mid-teens. BridgeBio will retain the option to acquire higher royalties in the U.S. in connectioPRINCETON, N.J., May 12, 2022--New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque PsoriasisThese Warren Buffett stocks are helping the Oracle of Omaha be a winner even in a down market. Occidental Petroleum (OXY): It was the best-performing stock in the S&P 500 in the first quarter. Chevron (CVX): Buffett added another 120 million shares of CVX stock to his portfolio. Bristol-Myers Squibb (BMY): Buffett has a comparatively “small” position of 5.2 million shares. Kraft Heinz (KHC): It’s been rough at times for KHC stock, but its finally a winner. Kroger (KR): The grocery store chain ke;51.220001220703125;The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.;42.470001220703125;;14.260000228881836;;38.95000076293945;;10.850000381469727;;144.07000732421875;Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...;12.520000457763672;NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced that the presentations from the May 10th and 11th Depositary Receipts Virtual Investor Conference (“dbVIC”) are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, Hong Kong, Germany, Portugal, South Africa, Spain and the UK presented their equity stories and;140.60000610351562;"Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.  ""One weight on the sector has been a relative lack of M&A of late ... and we think this news may be just what the doctor ordered to restore sentiment,"" Piper Sandler analyst Christopher Raymond said.  Biotechs are coming off their worst April since 2002, and the crash in valuation has made them attractive M&A targets, especially when small drugmakers are grappling with a cash crunch, analysts say.Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.  ""One weight on the sector has been a relative lack of M&A of late ... and we think this news may be just what the doctor ordered to restore sentiment,"" Piper Sandler analyst Christopher Raymond said.  Biotechs are coming off their worst April since 2002, and the crash in valuation has made them attractive M&A targets, especially when small drugmakers are grappling with a cash crunch, analysts say.";80.01000213623047;Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidismTransCon PTH U.S. FDA regulatory submission on track for Q3 and EU MAA for Q4 2022 Increasing uptake of SKYTROFA® (lonapegsomatropin-tcgd), with more than 1,200 unique patient prescriptions processed as of April 29, 2022Completed U.S. $575 million convertible notes offering strengthening balance sheet to build a sustainable leading g;11.050000190734863;;34.630001068115234;;35.16999816894531;;15.210000038146973;;9.720000267028809;NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced that the presentations from the May 10th and 11th Depositary Receipts Virtual Investor Conference (“dbVIC”) are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, Hong Kong, Germany, Portugal, South Africa, Spain and the UK presented their equity stories and;21.760000228881836;;36.63999938964844;Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan) WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that seven abstracts will be presented at the hybrid European Hematology Association (EHA) Congress to be held June 9-12 in Vienna, Austria. Data to be presented reinforce the robust efficacy and safety prof;99.91000366210938;;10.829999923706055;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...;35.34000015258789;;2.799999952316284;;3.309999942779541;;;;3.7300000190734863;;2.9700000286102295;;35.13999938964844;;29.329999923706055;;29.079999923706055;"GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record are eligible to participate in and ask questions during the Virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/EBS2022According to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc (NYSE: EBS) might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards. Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination. ""Despite major red flags at its vaccine manufacturing facility, Emergent's executives swept these problems under the rug and continued to rake in taxpayer";5.809999942779541;;6.96999979019165;;15.75;;3.4000000953674316;;41.4900016784668;;9.539999961853027;SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18th, 2022 at 11:00 a.m. ET. A live webcast, as well as a replay, will be available in the Investors section;17.709999084472656;;3.25;;9.630000114440918;;5.539999961853027;;7.429999828338623;;14.710000038146973;;22.6200008392334;;17.489999771118164;;6.949999809265137;;14.720000267028809;;10.25;Company announcement – No. 18 / 2022 Interim report for Q1 2022 Zealand Pharma Provides Update on Refocused Strategy Prioritizing Research and Development Copenhagen, DK and Boston, MA, U.S. May 12, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced financial results for the first three months of 2022. Financial results for the first three months of 2022 Revenue: DKK 1;9.069999694824219;;8.949999809265137;
2022-05-13;176.85000610351562;In this article, we discuss the top 12 electricity utility dividend stocks to buy. If you want to skip our detailed analysis of these stocks and the latest market situation, go directly to Top 5 Electric Utility Dividend Stocks To Buy. Inflation is cutting deep into the pockets of everyday citizens across the globe. In […]In this article, we discuss 10 defensive ETFs to buy before recession. If you want to read about some more defensive ETFs, go directly to 5 Defensive ETFs to Buy Before Recession. Sometimes, the best offense is a good defense. This is certainly the case at the stock market these days as inflation and rising […]How a stock reacts to earnings or other news can tell an investor more about the company than the news itself.Dividend Aristocrats are great places to be when the market waters get really rough. While they still get knocked down during bear markets, their dividends tend to offer a glimmer of certainty amid turbulent times. The payouts of Dividend Aristocrats have held up during past crashes, crises, and everything in between. With growing fear that we'll fall into a bear market and recession, insisting on quality may prove a wise decision. In this piece, we used TipRanks' Comparison Tool to evaluate thrAbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.Markets are still volatile and that’s due in large part to the inflation we’ve felt for some time. This environment creates uncertainty.;49.91999816894531;"The pill has become an increasingly important tool in the nation’s defense against COVID-19 as mask mandates have lifted and people have returned to their non-distanced lives.Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.(Bloomberg) -- Pfizer Inc.’s $11.6 billion acquisition of Biohaven Pharmaceutical Holding Co. included a rarely used structure that could become a larger part of Big Pharma’s playbook in light of a tougher antitrust regime.Most Read from BloombergSony PlayStation Staff Fume Over CEO’s Abortion CommentsUkraine Latest: US Senator Delays Aid Vote; Russia Eyes BorderCrypto Billionaires’ Vast Fortunes Are Destroyed in WeeksMore Than $200 Billion Wiped Off Cryptocurrency Market in a DayNike EscalatesSeveral generic drugmakers will produce cheaper versions of Pfizer Inc's (NYSE: PFE) COVID-19 antiviral treatment Paxlovid at $25/course or less for low- and middle-income countries, Reuters reported citing the Clinton Health Access Initiative (CHAI). CHAI said it could not disclose the manufacturers' names who have agreed to the price ceiling because they are still in the early stage of product development and have not received regulatory approval. In March, 35 generic drugmakers signed on to mStories circulating online in recent days that Pfizer said its COVID-19 vaccine is unsafe for pregnant women are not true, per reports.";291.6300048828125;"The Dow Jones Industrial Average rallied 250 points Friday. Twitter plunged after Elon Musk tweeted the deal is ""temporarily on hold.""Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.";106.04000091552734;;153.5;Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.The ones that pay dividends can deliver especially attractive total returns.  With that in mind, here are three dividend stocks you can buy and hold for decades.  AbbVie (NYSE: ABBV) offers one of the most impressive dividend pedigrees around.AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.;85.81999969482422;Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.;90.41000366210938;;63.13999938964844;Does the May share price for AstraZeneca PLC ( LON:AZN ) reflect what it's really worth? Today, we will estimate the...;75.80000305175781;NEW YORK & SEOUL, May 13, 2022--LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New YorkMany investors are still learning about the various metrics that can be useful when analysing a stock. This article is...;52.029998779296875;By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT On May 12, 2022, DarioHealth Corp. (NASDAQ:DRIO) published its first quarter 2022 operational and financial results and filed its Form 10-Q for the three month period ending March 31, 2022. Dario hosted a conference call and webcast to discuss results in further detail. During the quarter, 14 new business to business (B2B);43.31999969482422;;14.350000381469727;;39.939998626708984;;11.079999923706055;;150.39999389648438;;12.960000038146973;;141.0;"Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst BlogPfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.(Bloomberg) -- Pfizer Inc.’s $11.6 billion acquisition of Biohaven Pharmaceutical Holding Co. included a rarely used structure that could become a larger part of Big Pharma’s playbook in light of a tougher antitrust regime.Most Read from BloombergSony PlayStation Staff Fume Over CEO’s Abortion CommentsUkraine Latest: US Senator Delays Aid Vote; Russia Eyes BorderCrypto Billionaires’ Vast Fortunes Are Destroyed in WeeksMore Than $200 Billion Wiped Off Cryptocurrency Market in a DayNike Escalates";83.12000274658203;Biotech stock Ascendis Pharma reversed early losses Thursday to close with a gain despite a first-quarter miss for Skytrofa.;12.420000076293945;;34.939998626708984;;39.36000061035156;;15.65999984741211;;10.350000381469727;;23.899999618530273;;39.45000076293945;;103.9000015258789;;12.0;;39.189998626708984;;3.0299999713897705;;4.110000133514404;"New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line Stage IV NSCLCContinue to expect first regulatory submissions for aumolertinib and sugemalimab ex-U.S. in 2H 2022; constructive conversations with the FDA are ongoing to gain greater clarity on the regulatory path forward in the U.S.Continue to";;;3.990000009536743;;3.490000009536743;;37.97999954223633;;32.599998474121094;;28.739999771118164;;5.800000190734863;"Presented compelling preclinical data at 2022 AACR Annual Meeting supporting clinical development of potentially best-in-class programs Initial Phase 1b monotherapy data for ERAS-007 and Phase 1 monotherapy data for ERAS-601 expected in H2 2022; IND filing for ERAS-3490 on track for H2 2022 Strong balance sheet with cash of $422 million expected to fund operations into H2 2024 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company sin";7.389999866485596;LAUSANNE, Switzerland, May 12, 2022--ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation at the European Hematology Association 2022 Hybrid Congress (EHA2022), which will be held virtually and in Vienna, Austria from June 9-12, 2022.;18.790000915527344;;3.450000047683716;"BRIDGEWATER, N.J., May 13, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ""Company"") today announced that its investor relations or management team will attend the following investor conferences:";43.9900016784668;LEXINGTON, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need today announced that three abstracts will be presented from the KER-050 and ALK2 hematology programs at the 27th Annual Congress of the European Hematology Association (“EHA”;9.579999923706055;;18.75;Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in 2023Clinical Trial of CRN04777 in Congenital Hyperinsulinism Patients Planned to Begin in 2H22 Following Our Previous Announcement of Positive Top-Line Data from Phase 1 Multiple-Ascending Dose Cohorts Strengthened Balance Sheet by Raising Gross Proceeds of $125 Million in Successful Common Stock Offering SAN DIEGO, May 12,;3.640000104904175;;9.770000457763672;;5.400000095367432;;7.701000213623047;;16.979999542236328;;24.540000915527344;;17.93000030517578;;7.650000095367432;Initial data from pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG) expected in June 2022 Company plans to initiate pivotal Phase 3 FIREFLY-2 clinical trial evaluating tovorafenib as a first-line therapy in pLGG in the second quarter of 2022 Initiated Phase 1b/2 combination study with tovorafenib and pimasertib in RAF-altered solid tumors SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinic;14.5600004196167;;10.09000015258789;Company announcement – No. 20/ 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED] Copenhagen, DK and Boston, MA, May 12, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons dischargiCompany announcement – No. 19 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, May 12, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging manageri;10.350000381469727;;8.760000228881836;
2022-05-16;178.0800018310547;;50.66999816894531;;299.3800048828125;;103.23999786376953;Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.;155.47000122070312;;87.80999755859375;;92.31999969482422;;64.48999786376953;WILMINGTON, Del., May 15, 2022--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.1,2;76.91000366210938;;52.560001373291016;;44.369998931884766;;14.279999732971191;;40.2599983215332;;11.140000343322754;Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today published its 2021 Sustainability Report, outlining the company's 2021 achievements and progress across key areas including Access and Global Health, Employees, Environmental Stewardship and Community Engagement and including details on Viatris' continued efforts to support employees and their families while maintaining a stable supply of medicines during the ongoing COVID-19 pandemic.;149.9600067138672;The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.;13.140000343322754;;140.60000610351562;;84.7300033569336;;12.609999656677246;;35.43000030517578;;40.630001068115234;;15.449999809265137;;10.069999694824219;"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 and he will hold office until the next annual general meeting (“AGM”) of HUTCHMED when he will stand for re-election. The Board of HUTCHMED considers that the appointment of Mr Sun will provide significant benefits to HUTCHMED in view of his experieInmagene Biopharmaceuticals (""Inmagene"") announces that today the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (BTK) inhibitor, to proceed to the Phase I clinical trial. Inmagene is developing the drug candidate to potentially treat immunological diseases.";25.200000762939453;;38.84000015258789;;104.1500015258789;;11.989999771118164;;37.45000076293945;;2.9700000286102295;;4.5;;;;3.880000114440918;;3.890000104904175;A look at the shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) can tell us which group is most powerful. Insiders...;38.84000015258789;;32.47999954223633;SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a grou;28.6200008392334;"Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program.Emergent BioSolutions Inc (NYSE: EBS) has agreed to acquire Chimerix Inc's (NASDAQ: CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox. ""It exemplifies our thoughtful M&A strategy as part of our 2024 growth plan and positions us better to deliver value for our shareholders,"" said Robert Kramer, president & CEO of Emergent. Also See: Chimerix's CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical StudieShares of Chimerix Inc. shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent BioSolutions Inc. for up to $337.5 million plus royalties. Emergent BioSolutions shares were still inactive ahead of the open. Under terms of the deal, Chimerix will receive $225 million and up to $100 million in milestone payments. Chimerix could also receive $12.5 million in regulatory milestones, andExpands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threatTransaction to be funded with currently available funds; Expected to be accretive beginning with anticipated product deliveries to the U.S. government in 2022 GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Chimeri";5.989999771118164;;7.139999866485596;;17.899999618530273;;3.430000066757202;;44.06999969482422;;9.699999809265137;;20.280000686645508;;4.039999961853027;– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usability study in patients and COMPASS’ end of Phase 2 FDA meeting – Ended the first quarter with $335 million cash, maintaining atai’s position as a well-funded, leading mental health company Video int;10.149999618530273;;5.159999847412109;"– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024 – – Poster presentation at ASCO 2022 to highlight LB101 preclinical data in solid tumors; IND planned for late 2022 – – ZF874 for AATD Phase 1 update on track for 2H 2022; interim data from multiple dose cohorts with PiMZ and PiZZ subjects – – Cash and cash equivalents of $544.5 million as of March 31, 2022; Operational cash runway to mid-2024 – BOSTON and LONDON, M";7.699999809265137;;16.84000015258789;;25.270000457763672;;18.25;;7.849999904632568;;15.109999656677246;;10.050000190734863;;10.920000076293945;;8.59000015258789;
2022-05-17;178.82000732421875;;51.34000015258789;;301.3999938964844;;106.33999633789062;"The Food and Drug Administration approved an Eli Lilly diabetes drug it described as ""novel,"" prodding LLY stock closer to a breakout.";154.77999877929688;;87.91999816894531;;93.0;;65.63999938964844;AstraZeneca Plc (NASDAQ: AZN) posted full results from the positive MANDALA Phase 3 trial of PT027, an albuterol/budesonide fixed-dose combination rescue medication in patients with asthma. The data exhibited that PT027 at two different strengths of budesonide demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue. Compared with albuterol rescue, PT027 at the 180mcg albuterol/160mcg budesonide dose reduced the risk of a severe exacerbation;78.22000122070312;;52.900001525878906;A French court has ordered Sanofi SA (NASDAQ: SNY) to pay more than €400,000 in damages to a French family whose child had autism caused by its epilepsy drug Valproate. The court mentioned that the company failed to inform about known side effects. In January, the link was also recognized in a class-action ruling, potentially leading to millions of euros in compensation. However, Sanofi said it would file an appeal. The latest ruling, seen by Reuters, states that Sanofi must have known the riskSimilar to their American counterparts, the S&P Europe 350 Dividend Aristocrats offer investors dividend hikes and blue-chip stability.;44.709999084472656;Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.;14.3100004196167;;41.36000061035156;New capital deployment target of $10-12 billion over the next five yearsOutlook for 2020-2025 Adjusted Cash Receipts (1) (non-GAAP) CAGR raised to 11-14%Adjusted Cash Receipts (1) (non-GAAP) expected to grow 10% or more over this decade, positioning Royalty Pharma to be one of the fastest growing biopharma companiesDemand for capital to fund life sciences innovation to exceed $1 trillion in next decade NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host its ina;11.470000267028809;;154.67999267578125;;12.920000076293945;;141.77999877929688;;88.97000122070312;;13.069999694824219;Sernova Corp and Evotec SE (NASDAQ: EVO) have announced an exclusive global strategic partnership to develop cell therapy treatment for insulin-dependent diabetes. The companies will leverage their respective technologies and scientific expertise to develop an implantable iPSC-based (induced pluripotent stem cells) beta cell replacement therapy. The partnership provides Sernova a global exclusive option to license Evotec's iPSC-based beta cells to treat both type 1 and type 2 diabetes. Also ReadPartnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin-Producing Beta CellsPartners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent DiabetesEvotec to Make Strategic Equity Investment of CAD $27 M / €20 M in SernovaSernova / Evotec Joint Conference Call and Webcast at 8:30 am EDT May 17, 2022 LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/X* PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICE * THE GOAL IS THE DEVELOPMENT AND COMMERCIALISATION OF AN OFF-THE-SHELF BETA CELL REPLACEMENT THERAPY FOR INSULIN-DEPENDENT DIABETES * EVOTEC MAKES STRATEGIC € 20 M EQUITY INVESTMENT IN SERNOVA * EVOTEC/SERNOVA JOINT CONFERENCE CALL AND WEBCAST AT 8.30 AM EDT MAY 17, 2022HAMBURG, GERMANY, and LONDON, ON / ACCESSWIRE / May 17, 2022 / Evotec SE (Frankfurt;36.72999954223633;;41.88999938964844;;17.299999237060547;;10.5;;25.969999313354492;;42.15999984741211;;107.91999816894531;;12.699999809265137;;37.84000015258789;;3.0999999046325684;;4.760000228881836;;;;3.940000057220459;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...;4.039999961853027;;41.900001525878906;;36.09000015258789;;29.670000076293945;The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.A Durham biopharmaceutical company is selling its lone FDA-approved product, a smallpox treatment. But investors don't appear too happy about the deal.Emergent BioSolutions Inc. (NYSE: EBS) has inked a deal to acquire a smallpox treatment for up to $325 million, giving the Gaithersburg firm another avenue to feed the U.S. national stockpile.  The company said Monday it has entered into an agreement with Durham, North Carolina's Chimerix Inc. (NASDAQ: CMRX) for exclusive worldwide rights to Tembexa, the first drug approved by the Food and Drug Administration for the virus.  Under the deal, Emergent would pay Chimerix $225 million upfront in cash, and up to $100 million in milestone payments, which rely on the U.S. government exercising options to buy more product in the future.;6.170000076293945;;6.760000228881836;;18.5;;3.700000047683716;;46.13999938964844;;10.449999809265137;Company delivers on ambitious clinical development goal with four ongoing clinical trials in 2022SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small molecule NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase (BTK) in patients with relapsed B;21.270000457763672;;4.119999885559082;;11.119999885559082;;5.510000228881836;;7.329999923706055;;18.290000915527344;;27.84000015258789;;19.530000686645508;;8.59000015258789;;17.260000228881836;;11.48900032043457;Company announcement – No. 21 / 2022 Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device Deal includes $10 million USD upfront payment to Zealand and sales-based milestonesCertain inventory related to V-Go® and employees also included under the terms of the dealAgreement is part of Zealand’s refocused strategy to seek partners for commercial and late-stage assets while prioritizing research and development Copenhagen, May 17, 2022 – Zeala;10.949999809265137;;9.0600004196167;
2022-05-18;175.5;;50.400001525878906;;295.19000244140625;;103.5;;152.42999267578125;;87.68000030517578;Novartis can provide investors with a market-crushing 3.8% dividend yield -- and that isn't all the stock has to offer.The foundation is working with drugmaker Novartis to provide eligible patients in 28 low- and middle-income countries with breast cancer treatments.;92.0999984741211;;63.31999969482422;As North Korea battles its first known COVID outbreak, a lack of storage, chronic power shortages and inadequately trained medical staff pose acute challenges to inoculating its 25 million people - even with outside help, analysts said.  North Korea has not responded to offers of aid from South Korea and international vaccine-sharing programmes, but prefers U.S.-made Moderna and Pfizer over China's Sinovac or British-Swedish Astrazeneca shots, according to South Korean officials.  Sinovac or AstraZeneca vaccines can be transported and stored at normal refrigerator temperatures.AstraZeneca plc (NASDAQ: AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ Bio. AstraZeneca announced the deal but not its size. Also Read: AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B,;77.0199966430664;;52.38999938964844;;43.630001068115234;;14.15999984741211;;40.5099983215332;;11.270000457763672;;150.5500030517578;Moderna (NASDAQ: MRNA) and Repligen (NASDAQ: RGEN) are two companies that have seen their stock prices decrease even as they posted positive business results.  While Moderna may have been known to some investors prior to the pandemic, the biotech company has become a household name as it was able to bring to market its highly successful vaccine for COVID-19.  Prior to this, Moderna had nothing commercially available, so the sales growth over the past year-plus is from a base of zero revenue.;12.960000038146973;;141.72999572753906;;86.0;;12.390000343322754;;35.959999084472656;;40.68000030517578;;18.010000228881836;;8.90999984741211;;23.6200008392334;;43.52000045776367;;100.44000244140625;BOSTON, May 18, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a virtual event on Wednesday, May 25, 2022, at 8:00 a.m. ET. The one-hour webcast event will highlight progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT f;12.0600004196167;;35.220001220703125;;2.859999895095825;;4.650000095367432;;;;3.799999952316284;;3.759999990463257;;39.845001220703125;It might be of some concern to shareholders to see the Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) share price...;34.33000183105469;;28.34000015258789;;5.570000171661377;;6.449999809265137;;17.059999465942383;;3.4800000190734863;Every investor in Amneal Pharmaceuticals, Inc. ( NYSE:AMRX ) should be aware of the most powerful shareholder groups...;38.5;LEXINGTON, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced preliminary topline results from Part 1 of its Phase 1 clinical trial evaluating single and multiple ascending doses of KER-012 in healthy postmenopausal volLEXINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical study of RKER-012 on pulmonary arterial pressure and right ventricle hypertrophy in an established rodent model o;10.010000228881836;;19.90999984741211;;3.9200000762939453;;10.010000228881836;DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2022 and gave updates on its business. First Quarter 2022 Financial Highlights Cash position Cash was $270.8 million as of March 31, 2022, compared to $276.8 million as of December 31, 2021. We believe that our existing c;5.050000190734863;;8.380000114440918;This acquisition reaffirms Procaps Groups’ strategy to become one of the fastest growing pharmaceutical organizations in Latin America With FY2021 Net Revenues of $184 million, Grupo Somar is one of the most relevant independent pharma companies in Mexico MIAMI and BARRANQUILLA, Colombia, May 17, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced it has entered into a definitive agreement to ac;16.56999969482422;;27.18000030517578;;19.5;;7.579999923706055;;16.5;;11.699999809265137;;10.109999656677246;;8.859999656677246;
2022-05-19;173.94000244140625;;50.650001525878906;;286.2699890136719;;104.05000305175781;Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.;151.72000122070312;Carlisle Companies (NYSE: CSL), Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV) have all seen shares double over the past three years.  All three have the potential to double their shares again over the next three years because of their stability, consistent revenue growth, and attractive dividends.  Carlisle Companies was trading at $105.07 a little more than two years ago.;88.6500015258789;;92.08999633789062;;64.54000091552734;The European health regulator on Thursday endorsed the use of AstraZeneca's COVID vaccine, Vaxzevria, as a booster.  The recommendation, made by a committee of the European Medicines Agency (EMA), encompasses adults who have either been previously vaccinated by Vaxzevria or an mRNA vaccine, such as the ones made by Pfizer and BioNTech or Moderna.  The recommendation comes weeks after the EMA backed the use of Pfizer-BioNTech's Comirnaty as a booster for adults who have previously been inoculated with other vaccines.Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.Each of these stocks to buy are low-beta stocks with attractive dividend yields to help endure a recession. AstraZeneca (AZN): Strong growth visibility with a deep pipeline of drug candidates. A healthy dividend yield of 3.1%. Walmart (WMT): Focus on consumer spending to drive GDP growth will continue to benefit the company. Strong cash flows for dividends and share repurchase. AT&T (T): Mobility segment likely to create value with continued investments in 5G and fiber division. Deleveraging isAstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.;75.95999908447266;;53.060001373291016;;43.560001373291016;Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.;14.579999923706055;The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.;39.779998779296875;;11.6899995803833;Viatris Inc. and Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced today that Abevmy® (bevacizumab) is now available in Canada. Abevmy, co-developed by Viatris and Biocon Biologics, is a biosimilar to Roche's Avastin® (bevacizumab) and has been approved by Health Canada across four oncology indications.;154.6300048828125;;13.079999923706055;SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs. The article demonstrates the potential of GigaGen’s machine learning;141.0500030517578;;91.12999725341797;;13.069999694824219;(ALM), a global biopharmaceutical company focused on skin health, announced today a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.;36.56999969482422;;41.52000045776367;;19.40999984741211;;9.1899995803833;;24.440000534057617;;44.47999954223633;;104.06999969482422;We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...;12.199999809265137;"I-Mab (the ""Company"") (Nasdaq"" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m. EST on May 27th to present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) and the global clinical development plan.";35.41999816894531;;2.990000009536743;;4.650000095367432;;;;3.9100000858306885;;3.740000009536743;;39.130001068115234;;35.36000061035156;;31.690000534057617;Shares of  Emergent BioSolutions  were rising sharply Thursday.  The drugmaker produces a vaccine that can help prevent people from getting monkeypox.  The U.S. confirmed a case of monkeypox on Wednesday in a man in Massachusetts who recently traveled to Canada.Investors need to pay close attention to Emergent Biosolutions (EBS) stock based on the movements in the options market lately.Shares of Emergent BioSolutions (NYSE: EBS) were soaring by 12.1% as of 10:34 a.m. ET on Thursday.  The big gain came as concerns increased about a monkeypox outbreak in Europe.  Emergent BioSolutions makes ACAM2000, a vaccine for smallpox that can be used in people exposed to monkeypox in some cases.By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update SGX302 for Psoriasis Soligenix, Inc. (NASDAQ:SNGX) will be developing synthetic hypericin (the active ingredient in HyBryte) as part of a photodynamic therapy in mild-to-moderate psoriasis patients under the research name SGX302. Psoriasis is a common, chronic, noncontagious, multisystem inflammatory condition that;5.539999961853027;;7.010000228881836;;16.989999771118164;;3.4700000286102295;;36.130001068115234;Keros Therapeutics Inc (NASDAQ: KROS) announced preliminary topline results from Part 1 of its Phase 1 trial evaluating single and multiple ascending doses of KER-012 in healthy postmenopausal volunteers. KER-012 was generally well tolerated in Part 1 at dose levels up to 5 mg/kg, the highest dose level tested when administered as a single dose. While one subject withdrew consent after receiving a single 1.5 mg/kg dose of KER-012 and did not complete the safety follow-up, there were no discontinKeros Therapeutics Inc (NASDAQ: KROS) announced results from a preclinical study of RKER-012 in a mouse model of pulmonary arterial hypertension (PAH), a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. The data were shared at the American Thoracic Society International Conference. RKER-012 prevented increased pulmonary arterial pressure and right ventricle hypertrophy in a rodent PAH model, and KER-012 did not alter red blood cell number in non;9.979999542236328;;19.799999237060547;Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders should be happy to see the share price up 18% in the last...;3.9700000286102295;;9.819999694824219;;4.889999866485596;;7.869999885559082;;17.770000457763672;;27.68000030517578;;19.850000381469727;;6.880000114440918;;16.770000457763672;;13.789999961853027;Zealand Pharma A/S (NASDAQ: ZEAL) has announced topline results from its second Phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI), a condition in which individuals have abnormally high levels of insulin. Dasiglucagon met the trial's primary endpoint by demonstrating a statistically significant difference between treatment arms. The baseline intravenous glucose infusion rate (IV GIR) was 15.7 mg/kg/min. Dasiglucagon treatment resulted in a significant reducU.S.-listed shares of Zealand Pharma soared 21.2% in premarket trading on Thursday after the company said a Phase 3 clinical trial evaluating its investigational treatment for babies with a rare genetic disorder met the primary endpoint. Zealand is testing dasiglucagon as a treatment for pediatric patients with congenital hyperinsulinism, which causes excess insulin secretion and low blood sugar. The company said it plans to discuss submitting a new drug application to the Food and Drug AdministCompany announcement – No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI) Dasiglucagon met the primary endpoint with statistical significance - reducing the requirement for intravenous glucose by 55% compared to placebo in this pediatric patient population (ages 7 days to 12 months) when compared to placebo. Dasiglucagon treatment was assessed as well-tolerated in this study and 11 out of 12 patie;10.260000228881836;;8.569999694824219;
2022-05-20;176.97999572753906;;52.470001220703125;;298.8500061035156;;107.75;Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.;151.00999450683594;In this article, we discuss 6 stocks that Warren Buffett is selling in 2022. If you want to see more stocks that the billionaire sold, click Warren Buffett is Selling These 3 Stocks in 2022. Warren Buffett, the chief of Berkshire Hathaway, is perhaps the most renowned financier in the investment world, with decades of […]Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD).These six stocks to buy are useful to hedge your portfolio in a down market. These stocks provide stable dividends and have very low valuation metrics. Edison International (EIX): This electric utility company has a 4.2% dividend yield and a forward P/E of 15.24 times with good earnings growth. Chubb (CB): This property and casualty insurer has a 1.55% yield, a low 13.7x P/E and earnings growth forecasts. Cummins (CMI): This large engine maker has a low P/E, 2.88% yield and a low 33% payout rati;89.41999816894531;Positive opinion could expand the role of Cosentyx® (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indicationsSince its initial approval, Cosentyx has a proven sustained efficacy profile across several systemic inflammatory conditions and has treated more than 700,000 patients worldwide 1-11 BaPharmaceutical companies including Novartis and Roche have teamed up with global cancer organisations in an alliance aimed at getting more oncology medications to poorer countries.  Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries, and the disease burden is growing.  Without action, almost three in four cancer deaths are set to occur in these settings in the next decade.Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.;93.55000305175781;Rates could spike sooner rather than later. Prepare your portfolio.Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.RAHWAY, N.J., May 20, 2022--Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC MelanomaKevin Outterson has spent the better part of the last year in conversations with CARB-X's previous backers. Now, those efforts have yielded fruit: The organization has another $370 million to invest in research targeting drug-resistant bacteria.;66.20999908447266;FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).Kevin Outterson has spent the better part of the last year in conversations with CARB-X's previous backers. Now, those efforts have yielded fruit: The organization has another $370 million to invest in research targeting drug-resistant bacteria.;76.19000244140625;;54.400001525878906;The giant French drugmaker Sanofi (NASDAQ: SNY) isn't exactly an obvious candidate for a stock that's likely to beat the market, but its total return of around 8.5% this year is undoubtedly superior to the market's losses of more than 15.4%.  Let's take a peek at Sanofi to appreciate why it could be a great pick for the more conservative portion of your holdings.  Sanofi sells Dupixent, which treats atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.;44.52000045776367;Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Berkshire Hathaway Inc. (BRK.B), and S&P Global Inc. (SPGI).;14.720000267028809;;39.52000045776367;;11.800000190734863;;154.52999877929688;;13.069999694824219;;142.02999877929688;;95.4000015258789;;13.420000076293945;;37.63999938964844;;42.61000061035156;;18.729999542236328;;9.579999923706055;;24.940000534057617;;44.810001373291016;;104.52999877929688;;10.739999771118164;;37.189998626708984;;3.0899999141693115;;4.360000133514404;;;;3.880000114440918;;3.9100000858306885;;41.33000183105469;;36.7400016784668;;35.33000183105469;Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.(Bloomberg) -- Shares of companies that develop or make therapies to combat viral outbreaks, such as SIGA Technologies Inc. and Emergent BioSolutions Inc., rallied Thursday as the first case of monkeypox arrives in the US this year and new cases appear in the UK.Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightChina in Talks With Russia to Buy Oil for Strategic ReservesApple Shows AR/VR Headset to Board in Sign of Progress on Key Proje;5.78000020980835;;7.050000190734863;;17.200000762939453;;3.509999990463257;;36.869998931884766;;9.979999542236328;;20.520000457763672;;4.0;;10.039999961853027;;4.550000190734863;;7.880000114440918;;17.899999618530273;;28.780000686645508;;20.65999984741211;;7.199999809265137;;17.510000228881836;;12.739999771118164;;10.710000038146973;;8.449999809265137;
2022-05-23;179.44000244140625;;52.880001068115234;;302.6000061035156;;107.83999633789062;;148.02999877929688;"AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.AbbVie (NYSE: ABBV) today announced it will present positive data from a Phase 3 trial of cariprazine (VRAYLAR®; 1.5mg/day), Study 3111-301-001, for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant therapy. The study met its primary endpoint of statistically significant improvement using the Montgomery-Åsberg Depression Rating Scale (MADRS) total score in patients compared with placebo. These results will be presented (The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approving AbbVie Inc's (NYSE: ABBV) upadacitinib (Rinvoq, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for ulcerative colitis. The opinion covers the adult UC patients who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. Related: AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease MaintenanAbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.*";90.70999908447266;Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.;93.83000183105469;Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.;66.41000366210938;"An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.  The U.S. Preventive Services Task Force (USPSTF) last addressed the issue in 2012, finding insufficient evidence to assess routine screening for CKD in asymptomatic adults.  The change has not been announced in any public forums, a USPSTF spokesperson confirmed.Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis' equity at $113 million on a fully diluted basis. ""This acquisition will build upon our overall strategy to acquire differentiated, high-potential assets in attractive, yet often overlooked, disease areas where our capital and capabiliThe European Medicine Agency has approved AstraZeneca plc's (NASDAQ: AZN) COVID-19 vaccine, Vaxzevria, as a third-dose booster in adults following a committee endorsement last week. The vaccine can now be used as a booster following the two-dose Vaxzevria schedule or by those whom an mRNA vaccine has previously vaccinated, such as the ones from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) or Moderna Inc (NASDAQ: MRNA). Also Read: AstraZeneca In-Licenses New Suite Of COVID-19 Antibody CandAn influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.  The U.S. Preventive Services Task Force (USPSTF) last addressed the issue in 2012, finding insufficient evidence to assess routine screening for CKD in asymptomatic adults.WILMINGTON, Del., May 23, 2022--AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022.AstraZeneca PLC said Monday that its Covid-19 vaccine has been granted approval in the European Union as a third dose booster for adults.Drugmaker AstraZeneca said on Monday its COVID-19 vaccine, Vaxzevria, has been approved in the European Union by the bloc's drugs regulator as a third-dose booster in adults following a committee endorsement last week.  The vaccine can now be used as a booster following the two-dose Vaxzevria schedule or by those who have been previously vaccinated by an mRNA vaccine, such as the ones made by Pfizer and BioNTech or Moderna.  ""Ensuring a longer duration of immune protection is essential to the long-term management of COVID-19 globally, and boosters can address the waning of protection over time that has been seen with all primary vaccine schedules to date,"" Mene Pangalos, executive vice president of biopharmaceuticals R&D at AstraZeneca, said in a statement https://www.astrazeneca.com/media-centre/press-releases/2022/vaxzevria-approved-eu-third-dose-booster-covid-19.html.";76.69999694824219;;55.43000030517578;The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.;44.75;;14.979999542236328;;40.04999923706055;NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical roya;11.630000114440918;;153.38999938964844;;13.130000114440918;;143.0;Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as there was less than expected disease progression over the study. In the overall study population (N=213), the troriluzole and placebo groups had mBiohaven Pharmaceutical said on Monday its experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late-stage study.  Spinocerebellar ataxia (SCA) is a progressive disorder caused by the degeneration of cells in the brain and spinal cord and can lead to symptoms such as uncoordinated movement and muscle wasting.  Biohaven said patients in both the drug and placebo group showed a less-than-expected change in disease progression, which led to the study not reaching statistical significance.Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review a New Drug Application (NDA) for zavegepant nasal spray, the only small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in an intranasal formulation, for the acute treatment of migraine in adults. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the NDA is set for 1Q2023.Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with spinocerebellar ataxia (SCA). The primary endpoint, change from baseline to Week 48 on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA), did not reach statistical significance in the overall SCA population as there was less than expected disease progre;97.01000213623047;"- VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone - These results demonstrate the ability of TransCon technology to deliver consistent and reproducible results for patients across a broad range of geographies and populations COPENHAGEN, Denmark, May 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Commercial Officer, will retire and become a senior advisor to Ascendis Pharma - Endocrinology commercial team will continue to focus on building U.S. market leadership for SKYTROFA® (lonapegsomatropin-tcgd) and preparing for other anticipated TransCon™";13.300000190734863;;37.529998779296875;;39.95000076293945;;19.09000015258789;;9.609999656677246;;25.209999084472656;;44.41999816894531;;107.69000244140625;;11.350000381469727;;38.0;;3.0999999046325684;;4.300000190734863;;;;3.569999933242798;;3.809999942779541;CULVER CITY, Calif., May 23, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803, a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without Ta or T1 disease. The BLA is supported by the results of ImmunityBio;40.560001373291016;;36.689998626708984;;36.66999816894531;Shares of Emergent BioSolutions (NYSE: EBS) were jumping 12% as of 11:09 a.m. ET on Monday.  The big gain was due to increased concerns about the spread of monkeypox.  Emergent BioSolutions markets ACAM2000, a smallpox vaccine that could also help prevent monkeypox infection.The outbreak still consists of fewer than a hundred cases, according to the World Health Organization.Emergent BioSolutions, Chimerix and SIGA Technologies have been included in this Analyst Blog.During the week ended May 21, the World Health Organization (WHO) said it had found about 120 cases of confirmed or suspected monkeypox, a dangerous viral infection related to smallpox.  Monkeypox is endemic to central and west African countries, but the WHO keeps finding it in around a dozen countries where we aren't used to seeing monkeypox.  Since many of the new cases aren't associated with travel to monkeypox hot spots, it's highly likely that it's already spreading through communities.;5.559999942779541;After losing some value lately, a hammer chart pattern has been formed for Erasca, Inc. (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.;7.510000228881836;;17.010000228881836;;3.3499999046325684;;36.369998931884766;;10.109999656677246;;20.139999389648438;;3.869999885559082;;9.739999771118164;;4.489999771118164;;8.1899995803833;;18.06999969482422;;28.200000762939453;;21.31999969482422;;7.21999979019165;Phase 1b/2 combination study, FIRELIGHT-1, to leverage insights from pediatric development to evaluate potential synergistic effects of the two candidates among adolescents and adultsSOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the first patients have been dosed;18.75;;14.0;;9.819999694824219;BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. “We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impres;9.319999694824219;
2022-05-24;181.39999389648438;;53.40999984741211;;305.9599914550781;;107.9800033569336;Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors.  One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA).  On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.;149.11000061035156;AbbVie (NYSE: ABBV) investors might have a reason to start sweating. After a somewhat weak first quarter, the biopharma company's near future looks like it'll be one with a bit less revenue than expected.AbbVie (NYSE: ABBV) today announced accepted abstracts and presentations, including three oral presentations, three poster tours and 25 posters, at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress. The range of data accepted for presentation showcases AbbVie's commitment to discovering and delivering diverse and innovative solutions for the management of rheumatic diseases. The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually.;91.93000030517578;These six dividend stocks have higher than average yields and lower P/E multiples. These large-cap stocks have 20% better P/Es and dividend yields than the average of the S&P 500. Additionally, these stocks have positive earnings growth. JPMorgan (JPM) – This bank has a 3.41% dividend yield and a low 10.4x forward P/E. Earnings should rise 14% in 2023. Verizon (VZ) – This telecom company has a 5.17% dividend yield and a forward P/E of just 9.2 times, with earnings forecast to rise in 2023. Novar;94.63999938964844;Our Durham, N.C. site became one of the first Merck locations to adopt the OneTen initiative, with the goal of closing the wealth gap for Black AmericansRAHWAY, N.J., May 24, 2022--European Commission Approves KEYTRUDA Plus Chemo as Neoadjuvant Treatment, Then as Adjuvant Monotherapy After Surgery for TNBCThese blue-chip stocks with dividends pay investors to wait for a rally by the stock market and tend to be quite resilient. IBM (IBM): Its business is solid and it has been reporting strong results. The TJX Companies (TJX): This retailer is benefiting from high inflation and its adept management of supply chains. NXP Semiconductors (NXPI): It reported strong Q1 results and is getting a lift from powerful demand for automotive chips. Lumen Technologies (LUMN): This networking and cloud company is;66.6500015258789;An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.  The U.S. Preventive Services Task Force (USPSTF) last addressed the issue in 2012, finding insufficient evidence to assess routine screening for CKD in asymptomatic adults.The Serum Institute of India (SII), the world's biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling COVID-19 shots, its CEO told Reuters on Monday.  Africa was the only continent that did not have its own manufacturing capacity for COVID shots during the worst phases of the pandemic in the last two years, leaving it at the mercy of suppliers from overseas, including the SII.;77.12999725341797;;56.290000915527344;Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), UnitedHealth Group Incorporated (UNH), and Costco Wholesale Corporation (COST).;45.0;;14.9399995803833;;39.7400016784668;;11.529999732971191;Fortune released its annual Fortune 500 list on Monday, ranking the top publicly-traded companies by annual revenue. In total, 10 companies headquartered in the Pittsburgh region made the list, with companies moving up and down the rankings compared to last year.;151.42999267578125;;13.279999732971191;;142.60000610351562;The executive who replaces Michel Vounatsos will inherit a large-cap biotech facing significant challenges.The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.;90.5;;13.229999542236328;;37.52000045776367;;39.029998779296875;;18.450000762939453;;8.59000015258789;;25.059999465942383;;42.54999923706055;;105.41000366210938;;10.550000190734863;;33.68000030517578;;3.0299999713897705;;4.300000190734863;;;;3.390000104904175;;3.680000066757202;;41.5;;33.2599983215332;;33.33000183105469;Companies In The News Are: JPM, VMW, AVGO, EA, EBS.Instead, several countries are now experiencing a monkeypox outbreak.  Four stocks soared last week as a result of the recent headlines about the latest monkeypox outbreak.  One of them, Jynneos/Imvamune/Imvanex, has been approved in the U.S. and Canada for immunizing against smallpox and monkeypox.Siga Technologies stock is down amid concerns over Monkeypox, JPMorgan stock soars after forecasting its goal of 17% return on tangible equity, and VMware stock jumps on reports of Broadcom talks.;5.389999866485596;;7.050000190734863;;16.56999969482422;;3.299999952316284;"BRIDGEWATER, N.J., May 24, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ""Company"") today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2022 Jefferies Healthcare Conference held on June 8, 2022 in New York City. Mr. Patel will also be hosting a presentation which will begin at 8:00 AM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's websi";35.060001373291016;;9.920000076293945;;19.65999984741211;;3.7699999809265137;;8.989999771118164;;4.340000152587891;;7.769999980926514;;16.6299991607666;;27.09000015258789;;22.200000762939453;;7.28000020980835;;17.3700008392334;;12.789999961853027;;9.069999694824219;;8.84000015258789;
2022-05-25;179.6199951171875;;53.709999084472656;;307.010009765625;;105.25;Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).;151.9600067138672;Dividend stocks can be a great place to start looking.  A couple of Dividend Kings that have been doing particularly well this year are AbbVie (NYSE: ABBV) and Altria Group (NYSE: MO).  AbbVie is a top healthcare stock that yields 3.7% annually, which is more than double the S&P 500 average of less than 1.4%.Buying quality retirement stocks can provide both safety and growth to keep savings goals on track AbbVie (ABBV): With revenue concerns abating, it’s time to take a fresh look at this dividend king. Amgen (AMGN): This biotech giant has an ideal combination of in-market products and products in its pipeline. Apple (AAPL): Make this tech giant prove that the bears are right before abandoning its stock. Dollar General (DG): Inflation and a weakening economy will help keep the revenue coming. WesterAbbVie (NYSE: ABBV) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022. Richard A. Gonzalez, chairman and chief executive officer, will present at 10:00 a.m. Central Time.These are the healthcare stocks with the best value, fastest growth, and most momentum for June 2022.We highlight 3 ETFs with juicy dividend yields and excellent performanceThe episode explores three strong dividend-paying stocks from three different areas of the economy that investors might want to consider buying during the market downturn and holding for the long run.;91.25;Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).;93.75;Pharma stocks Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) have gained 23% and 5%, respectively, year to date.  Merck had five blockbuster products in 2021, including the top-selling cancer drug in the world, Keytruda.The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.RAHWAY, N.J., May 24, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the third quarter of 2022. Payment will be made on July 8, 2022 to shareholders of record at the close of business on June 15, 2022.;66.80999755859375;AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.;77.23999786376953;;55.849998474121094;Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.;44.970001220703125;Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.;14.90999984741211;;40.209999084472656;;11.84000015258789;;154.17999267578125;WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at three upcoming investor conferences. Craig-Hallum’s 19th Annual Institutional Investor conference being held June 1. Management will be hosting one-on-one meetings with investors who are registered to attend the conference.William Blair’s 42nd Annual Growth Stock Conference being held in Chica;13.069999694824219;;143.39999389648438;With the business potentially at an important milestone, we thought we'd take a closer look at Biohaven Pharmaceutical...;90.30000305175781;;13.239999771118164;;38.099998474121094;;39.15999984741211;;17.510000228881836;"Just because a business does not make any money, does not mean that the stock will go down. For example, although...* CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone * The partnership combines CureVac's mRNA technology with myNEO's platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses * Together with myNEO, CureVac aims to identify specific antigens for the development of novel mRNA cancer vaccinesTÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022/ CureVac N. (Nasdaq:CVAC), a gl2 million as of March 31, 2022, impacted by wind-down costs for first-generation COVID-19 vaccine programTÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (""mRNA""), today announced financial results for the first quarter of 2022 and provided a business update.";8.829999923706055;;26.90999984741211;CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8 at 10:30 am ET. The live webcast of the fireside chat can be accessed on the investor relations section of the Cerevel Therapeutics website here. A rep;40.88999938964844;;104.26000213623047;;10.630000114440918;;32.66999816894531;;3.0199999809265137;;4.630000114440918;;;;3.4600000381469727;;3.5;;43.20000076293945;;31.809999465942383;;33.7400016784668;;5.489999771118164;Shannon Morris, M.D., Ph.D., appointed as Senior Vice President of Clinical Development Amy Grekowicz Parker appointed as Vice President of Clinical Operations John Lo, Ph.D., appointed as Senior Commercial Advisor and member of Erasca’s newly expanded Research, Development, and Commercial Advisory Board SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies;7.159999847412109;;16.610000610351562;;3.430000066757202;;33.959999084472656;;10.1899995803833;;17.3700008392334;Patient Studies in Cushing’s Disease and Congenital Adrenal Hyperplasia to Initiate Later this Year Management Hosting Webcast and Conference Call Today to Discuss Findings at 8:00 a.m. Eastern Time SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced positive resu;3.8399999141693115;;8.989999771118164;;4.119999885559082;;7.769999980926514;;17.1299991607666;;26.8799991607666;;19.600000381469727;Nationwide Seborrheic Dermatitis Survey High burden of daily care Nationwide Seborrheic Dermatitis Survey Individuals with seborrheic dermatitis and healthcare providers agree that a treatment that would fit into the hair care routines of individuals with the disease would make patients lives easier Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S.Survey found that, among adults with seborrheic dermatitis who use treatments, only oNationwide Seborrheic Dermatitis Survey High burden of daily care Nationwide Seborrheic Dermatitis Survey Individuals with seborrheic dermatitis and healthcare providers agree that a treatment that would fit into the hair care routines of individuals with the disease would make patients lives easier Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S.Survey found that, among adults with seborrheic dermatitis who use treatments, only o;6.159999847412109;;15.630000114440918;;13.84000015258789;;8.84000015258789;;8.960000038146973;
2022-05-26;179.4600067138672;;53.9900016784668;;313.4599914550781;;106.5999984741211;"The market is incredibly volatile right now but these long-term stocks to buy and hold work well in any economy. Roper Technologies (ROP): This software conglomerate is a shrewd way to profit from long-term technological trends. Grupo Aeroportuario del Pacifico (PAC): Airports are an irreplaceable infrastructure asset with fantastic economics. McCormick (MKC): Younger consumers want more interesting foods and flavors; McCormick is delivering. Texas Instruments (TXN): Texas Instruments is a diver";150.57000732421875;Here are the seven the best dividend stocks to buy that offer a healthy retirement income. PepsiCo (NASDAQ:PEP): This inflation-resistant business will continue rewarding shareholders. Intel (NASDAQ:INTC): With a strong product lineup in the coming months, Intel could reestablish its dominance in its business segments. Fifth Third Bancorp (NASDAQ:FITB): FITB has healthy loan and deposit growth and exposure to profitable markets in the U.S. Morgan Stanley (NYSE: MS): The investment banking giantAmgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.You know that you can count on them for leadership in their market and earnings growth.  Here, I'll focus on three companies that stand out for their strong market positions: a biotech company and a medical device company that each dominate their fields, and a pharmaceutical player on the way to winning in market share.  Vertex Pharmaceuticals (NASDAQ: VRTX) is the worldwide leader in cystic fibrosis (CF) treatment.SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.;91.26000213623047;In this article, we will look at the top 15 stocks sold by investing legend Mario Gabelli in Q1 2022. If you want to see the top 5 stocks sold by Gabelli in Q1, go to Mario Gabelli is Selling These 5 Stocks in 2022. Mario Gabelli is an Italian-American investor, financial analyst, and hedge […]Biotechnology giant Regeneron's (NASDAQ: REGN) eye medication EYLEA is one of the best-selling blockbuster drugs around, generating $9.4 billion sales globally in 2021.  The drug is approved for a number of eye diseases and has been a mainstay for Regeneron for the past decade.  Although its patents are nearing the end of their lifespan, Regeneron has a number of new treatments that will step in to replace lost revenue.;92.30999755859375;Pharmaceutical giant Merck & Co. is expanding its presence in Greater Boston, this time with nearly 160,000 additional square feet at its Bent Street facility in Cambridge, where it plans to hire another 100 or so people over the next few years.;66.69999694824219;Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and NextEra Energy, Inc. (NEE).;77.58999633789062;;55.5;;44.41999816894531;;14.84000015258789;On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains.  Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases.  The company's stock is up more than 9% this year, currently trading at just shy of $15.;40.0099983215332;;12.010000228881836;;159.1699981689453;Today we will run through one way of estimating the intrinsic value of Repligen Corporation ( NASDAQ:RGEN ) by taking...;13.199999809265137;On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains.  Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases.  The company's stock is up more than 9% this year, currently trading at just shy of $15.;143.17999267578125;;88.72000122070312;;13.550000190734863;;38.560001373291016;;39.349998474121094;;18.850000381469727;;9.0600004196167;;26.959999084472656;;41.95000076293945;;106.62999725341797;;11.3100004196167;;30.829999923706055;;3.059999942779541;;4.75;;;;3.4600000381469727;;3.4200000762939453;;42.5099983215332;;32.599998474121094;;32.189998626708984;;5.539999961853027;;7.260000228881836;;16.8799991607666;;3.490000009536743;;33.41999816894531;;7.880000114440918;Data to be discussed at Nurix R&D Day at 8:00 a.m. ET today May 26SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of NX-2127, an orally administered degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory activity. The first expansion cohorts will foc;17.100000381469727;;3.9000000953674316;;9.130000114440918;;4.269999980926514;;7.900000095367432;;16.610000610351562;;27.799999237060547;"PLANO, Texas, May 26, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (""FDA"") has accepted for filing and granted Priority Review of its New Drug Application (""NDA"") for omaveloxolone for the treatment of patients with Friedreich’s ataxia. The FDA indicated that at this time it has not identified any potential review issues. The NDA is supported";19.65999984741211;;5.75;;16.31999969482422;;13.800000190734863;Company announcement – No. 23 / 2022 Zealand Pharma launches long-term incentive program for Zealand’s Corporate Management and employees for 2022 Copenhagen, DK and Boston, MA, May 25, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of an updated long-term incentive program (the “LTIP”) for Zealand’s Corporate Managemen;8.380000114440918;;8.710000038146973;
2022-05-27;181.08999633789062;The S&P 500 has fallen by 17% since the start of the year, the Nasdaq Composite is down by almost 28%, and many popular growth stocks have been struggling, including big names like Tesla (NASDAQ: TSLA) and Moderna (NASDAQ: MRNA), which have performed even worse than the indexes.  Beta is a measure of an investment's volatility based on how closely its performance mirrors that of the broader market.  If a stock's beta value is greater than 1, it has in the past exhibited wider swings than the market -- and you can generally expect that it will continue to do so.;53.90999984741211;;323.4800109863281;The pharma stock Eli Lilly (NYSE: LLY) has surged 13% higher year to date.  Let's dive into Eli Lilly's fundamentals and valuation to find out.  Eli Lilly reported $7.8 billion in revenue for the first quarter ended March 31, up 14.8% from the year-ago period.The Dow Jones Industrial Average rose Friday on inflation data. Seven top stocks to buy and watch include Tesla supplier Livent.;107.73999786376953;For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...;150.0;If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share...AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and U-ACHIEVE (maintenance) – evaluating upadacitinib (RINVOQ®) in patients with moderately to severely active ulcerative colitis who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase 3 clinical trials – ADVANCE, MOTIVATE (induction studies) and FORTIFY (maintenance study) – evaluating risankizumab (SKYRIZI®) in patients with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.These seven high-yield retirement stocks to buy are among the top picks to build a retirement portfolio that will provide a stable income. Amcor (AMCR): Is a global leader in developing and producing responsible packaging. 3M Company (MMM): This conglomerate has a company history of 120 years. AbbVie (ABBV): A global biopharmaceutical company with a wide range of therapeutic areas. Cardinal Health (CAH): An integrated healthcare services and products company operating intentionally. Chevron (CVXAbbVie  , the research-based biopharmaceutical company that was spun off from Abbott Laboratories  in 2013, has made an impressive move higher the past nine years.  Recently, ABBV pulled back from an April high but the correction is showing signs it is over.  In the daily bar chart of ABBV, below, we can see that the shares declined below the 50-day moving average line and its slope is cresting.;91.45999908447266;Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life science companies / associations in search of sustainable solutions to curb AMRSandoz, as largest global provider of generic antibiotics1, is committed to a pragmatic and balanced approach to address this growing global health threat Basel, May 27, 2020 — Sandoz is pleased to announce the appointment of;93.08000183105469;This could partly explain why the pharma stock Merck (NYSE: MRK) has rallied 21% year to date while the S&P 500 index has dropped 18% during that time.  Last month, Merck reported results for the first quarter, ended March 31.  For the quarter, Merck recorded $15.9 billion in net sales, which represented a 49.6% increase over the year-ago period.Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.;67.4000015258789;"Over the past six months, the market has fallen sharply thanks to a toxic combination of fears about a looming recession, rising inflation, and rising interest rates.  Growth stocks and unprofitable companies have been especially hard hit.  Sanofi (NASDAQ: SNY) is a multinational pharma giant with a market cap in excess of $135 billion, and its shares are up by over 17% from six months ago.European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.WILMINGTON, Del., May 27, 2022--The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis (LN).Although cancer screening and diagnosis was hit by the coronavirus pandemic, resulting advances in medical technology and greater diversity in clinical trials could help treatments in the future, an AstraZeneca executive said.  Testing and diagnosis rates for cancer dropped by 15% to 25% over the past two years as people skipped routine checkups, Dave Fredrickson, executive vice president of oncology at AstraZeneca, told the Reuters Global Markets Forum in Davos.  ""What that means is that we are diagnosing cancer patients late,"" Fredrickson said this week, with cancer outcomes being best when diagnosed early.";76.13999938964844;The European Commission approved J&J's (JNJ) BCMA-directed CAR-T cell therapy, Carvykti to treat patients with multiple myeloma who have already received multiple treatments.Tesla, Procter & Gamble, Bristol-Myers Squibb, Wells Fargo and Intuit have been included in this Analyst Blog.;55.150001525878906;Over the past six months, the market has fallen sharply thanks to a toxic combination of fears about a looming recession, rising inflation, and rising interest rates.  Growth stocks and unprofitable companies have been especially hard hit.  Sanofi (NASDAQ: SNY) is a multinational pharma giant with a market cap in excess of $135 billion, and its shares are up by over 17% from six months ago.;44.060001373291016;;14.770000457763672;CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash., May 26, 2022--Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association;41.27000045776367;;12.25;;170.0399932861328;Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov brings to the director role nearly 30 years of relevant experience, including his current position as Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. D;13.109999656677246;;143.3699951171875;;88.79000091552734;;13.920000076293945;;38.900001525878906;;42.72999954223633;;19.350000381469727;;9.5600004196167;;27.25;;42.61000061035156;;107.51000213623047;Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT for psychosis in Alzheimer's disease. Mizuho believes Karuna management did a commendable with laying out the data supporting their decision to move their lead asset KarXT forward in Alzheimer's disease psychosis (ADP). The analysts believe that the asset should help mitigate side effect concerns as;8.270000457763672;"I-Mab (the ""Company"") (Nasdaq"" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced preliminary data of its ongoing Phase 2 clinical trial (NCT04322006) with uliledlimab (also known as TJD5, or TJ004309), a differentiated CD73 antibody, and its global clinical development plan.";18.360000610351562;;3.200000047683716;;5.179999828338623;In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 months versus placebo plus chemotherapy in people with previously untreated Stage IV non-small cell lung cancer (NSCLC)In a Phase 2 trial, sugemalimab treatment resulted in durable responses in people with relapsed or refractory extranodal natural killer/T-cell lymphoma, with approximately half of patients achieving a response and approximately one third achieving a complete responseI;;;3.5399999618530273;An investment climate that's suddenly turned chilly may leave promising companies out in the cold.;3.9200000762939453;;43.63999938964844;;36.15999984741211;SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies Healthcare Conference on June 8 and the 43rd Annual Goldman Sachs Healthcare Conference on June 14. Dr. Countouriotis is scheduled to present a company overview in New York on June 8 at 11 a;35.220001220703125;;5.610000133514404;;7.389999866485596;;17.940000534057617;;3.4600000381469727;"BRIDGEWATER, N.J., May 27, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced that the U.S. Food and Drug Administration (""FDA"") has approved the Company’s Biologics License Application (""BLA"") for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®. The product will be marketed under the proprietary name FYLNETRA™.";35.150001525878906;;9.020000457763672;;16.790000915527344;;4.070000171661377;;9.59000015258789;;4.179999828338623;;8.010000228881836;;20.8799991607666;;29.6299991607666;"Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same. Stock rises.Shares of Reata Pharmaceuticals Inc. were up 2.4% in trading on Thursday after the company said the Food and Drug Administration granted priority review to the company's experimental treatment for Friedreich's ataxia, a rare nervous system disease. The regulator is now set to make a decision on omaveloxolone by Nov. 30. ""If approved, we are looking forward to a commercial launch in early 2023,"" Reata CEO Warren Huff said in a news release. Reata's stock is up 4.3% so far this year, while the S&P";20.989999771118164;Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ: ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for ARQT. The most important catalyst is the potential approval of roflumilast cream in plaque psoriasis around July 29, 2022, transforming Arcutis from a developmental- to a commercial-stage company. Mizuho believes the three ongoing Phase 3 clinical programs remain underappreciated by investors. Rela;5.71999979019165;;16.559999465942383;;13.9399995803833;;8.40999984741211;;8.930000305175781;
2022-05-31;179.52999877929688;In this article, we discuss 10 new stock picks of billionaire David Harding. If you want to see more stocks in this selection, click 5 New Stock Picks of Billionaire David Harding. David Harding, the billionaire chief of the London-based Winton Capital Management, disclosed in February this year that his quantitative funds were up 8.8%, […]AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog;53.040000915527344;;313.44000244140625;The Dow Jones Industrial Average fell Tuesday. Bitcoin soared, while oil prices jumped to a two-month high on a partial Russian oil embargo.;110.4000015258789;;147.3699951171875;;90.94000244140625;Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap and tools to improve approvability, accessibility, acceptability and affordability (4As) of biosimilarsSandoz launched initiative to support improved healthcare access, equity and sustainability Basel, May 31, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced the lauNovartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.;92.02999877929688;AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst BlogGerman supplier of chemicals and materials used in making semiconductors, Merck KGaA, said on Tuesday it had signed a contract to open a semiconductor base in the Chinese city of Zhangjiagang, describing it as its largest single electronics business investment in the country.  The new 69-acre base will house production plants for thin film materials and electronic specialty gasses, warehouses, and operation centers.;66.4800033569336;AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog1. What are nasal vaccines?  Nasal vaccines are administered, as the name suggests, through the nose.  More accurately called intranasal vaccines, these vaccines are liquids that can be given as a spray or through a dropper or syringe.;75.44999694824219;Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.;53.25;The setback could raise fears about the future of the French company's consumer division, which is also seeing delays in an OTC version of Tamiflu.The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.By Peter NurseFDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved Acceptance marks another important step in advancing Dupixent for a broad range of diseases with underlying type 2 inflammation Paris and Tarrytown, N.Y. May 31, 2022. The U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License ApplicationDupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved;43.900001525878906;GSK signs an agreement to acquire Affinivax, Inc. for a $2.1 billion upfront payment. The company is looking to boost its vaccine pipeline with this acquisition.The announcement sent the consumer goods giant to the top of the FTSE 100 after months of the stock underperforming compared to the index.GSK plc (NYSE: GSK) agreed to acquire U.S. biotech Affinivax for up to $3.3 billion, Reuters reports. The purchase price includes $2.1 billion upfront and $1.2 billion in potential milestones. Affinivax offers GSK its next-generation vaccines under development, the most advanced for pneumonia, meningitis, bloodstream infections, and sinusitis. Affinivax's newer vaccine technology aims to strengthen the breadth of immunity against a pathogen such that an immune-boosting adjuvant is not necessary.GSK has been under pressure to shore up its pipeline.GlaxoSmithKline is buying Boston-based biotech Affinivax in a transaction worth up to $3.3bn, bolstering its vaccines business with new technology.  The UK drugmaker, which is one of the world’s largest vaccine developers, expects to pay $2.1bn up front and “milestone” payments of up to $1.2bn, if Affinivax’s new vaccine for bacterial pneumococcal infections succeeds in trials.  The deal is the largest since a three-part transaction with Swiss drugmaker Novartis in 2014 — when GSK sold its oncology business, bought Novartis’s vaccines business, and the companies merged their consumer health units into a joint venture.By Geoffrey Smith;14.40999984741211;"CAMBRIDGE, Mass. & OSAKA, Japan, May 31, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (""Takeda"") today announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7 in Chicago, Ill. and the 30th Congress of the European Hematology Association (EHA), June 9-12 in Vienna, Austria. Takeda’s latest research in oncology focuses on enhancing and improving patient care whileCAMBRIDGE, Mass. & OSAKA, Japan, May 31, 2022--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (TSE:4502/NYSE:TAK) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax™ (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022.Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional periodCAMBRIDGE, MA. and OSAKA, JAPAN / ACCESSWIRE / May 31, 2022 /Moderna, Inc.";41.13999938964844;;12.270000457763672;;164.47000122070312;;12.880000114440918;;143.72999572753906;;84.51000213623047;;13.84000015258789;;37.959999084472656;;42.290000915527344;;18.799999237060547;The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.;10.520000457763672;;26.1299991607666;;41.45000076293945;;104.31999969482422;;8.699999809265137;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinical trial (TALLER) of highly differentiated long-acting recombinant human growth hormone eftansomatropin alfa (also known as TJ101), which is being investigated as a weekly treatment for pediatric growth hormone deficiency (PGHD) in China. The primary endpoint is an";18.940000534057617;;3.0;;5.559999942779541;CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare ConferenceFireside Chat: Thursday, June 9, 2022, 11:30 a.m. PT / 2:30 p.m. ET Goldman Sachs 43rd Annual Global Healthcare ConferenceFireside Chat: Tuesday, June 1;;;3.4800000190734863;;3.759999990463257;;43.599998474121094;;35.369998931884766;;32.959999084472656;;5.420000076293945;;6.840000152587891;;16.860000610351562;;3.630000114440918;;33.79999923706055;;10.09000015258789;Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.;16.75;;3.9800000190734863;;10.020000457763672;;4.5;;8.510000228881836;;19.8799991607666;;28.280000686645508;Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.;20.8799991607666;;6.21999979019165;;16.780000686645508;;14.390000343322754;PRESS RELEASE – NO. 1 / 2022 Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide A total of five presentations with Zealand Pharma products have been accepted for presentation at the American Diabetes Association (ADA) Abstracts include oral presentation of data from a Phase 1 Multiple Ascending Dose Trial with dapiglutide Data highlight and reinforce the Comp;8.300000190734863;;9.180000305175781;
2022-06-01;177.7100067138672;On May 20, the S&P 500 briefly crossed into bear market territory. That’s what Wall Street calls it when a stock registers a 20% drop from its highs. Investors are trying to come to terms with the new realities that come with a bear market. After a very long bullish run, the transition won’t likely be smooth. Short term the sellers have control, so they are selling rallies. Therefore, it is important that we structure portfolios that take that into account. Below are seven stocks to buy that wouAlthough there are a lot of successful strategies to make money on Wall Street, riding Warren Buffett's coattails has, arguably, been one of the most profitable for the past 57 years.  Since the Oracle of Omaha, as Buffett has come to be known, became CEO of conglomerate Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in 1965, he's overseen the creation of close to $695 billion for his company's shareholders, and has led Berkshire's Class A shares (BRK.A) to an annual average return of 20.1%.  In other words, when Warren Buffett buys shares of a publicly traded company, Wall Street and investors rightly take notice.Grantham remains ultra bearish. But this trio may offer some protection.Wall Street is becoming increasingly concerned about a recession. According to Goldman Sachs CEO David Solomon, there is “probably a 30% chance of a recession as you look forward to the next 12 to 24 months.” We are also starting to see a slowdown in the housing market with new home sales dropping by 16.6% which was worse than expected. The ISM New Orders Index has also weakened from above 60 at the start of the year to 53.5 in April. There is also weakness developing in cyclical stocks such as;52.369998931884766;;311.0799865722656;The Dow Jones Industrial Average rallied Wednesday, as software leader Salesforce surged on better-than-expected earning results.Motley Fool contributor Marc Rapport speaks with Joel Marcus, CEO and founder of Alexandria Real Estate Equities (NYSE: ARE).  To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.Shares of Eli Lilly & Co. fell 4.0% in afternoon trading Tuesday, to pullback from the previous session's record close, after the drug maker disclosed that its largest shareholder sold nearly $64 million worth of its shares. In a Form 4 filing with the Securities and Exchange Commission, the company said;110.33000183105469;;146.02000427246094;"As U.S. doors open to more competition, investors will want to take a deeper look into the product portfolio.AbbVie (NYSE: ABBV) today announced the presentation of full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib (RINVOQ®), an oral therapy, in adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and patients with treatment-refractory active ankylosing spondylitis (AS) with an inadequate response (IR) to biologic disease-modifying antirheumatic drugs (bDMARDs). Both studies met the primary endpoint of Assessment of SpondyloArthritisForget the old adage ""sell and May and go away."" Any time is a good time to buy dividend stocks. That's true even when the stock market is highly volatile -- as it is now.  There are two important prerequisites, though.";89.63999938964844;Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of cardiovascular events.;91.13999938964844;Scientists at Merck are committed to research and development for people diagnosed with prostate cancerBearish stock market conditions are creating extreme fear for investors. Many investors who are low on cash and highly exposed to stocks feel demoralized by the falling prices. To regain control, investors need to differentiate between companies that will recover in the long term and those that will not. The stocks to buy and hold are those where the company is financially sound. In addition, financially sound businesses will have manageable debt. They are also typically companies that did not lMotley Fool contributor Marc Rapport speaks with Joel Marcus, CEO and founder of Alexandria Real Estate Equities (NYSE: ARE).  To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.;66.12000274658203;;74.95999908447266;“I never questioned my goal of becoming a Black neuroscientist because I had already met one, and for that, I am forever grateful,” said Kaelyn Brown, who first joined the Science Club for Girls (S...PRINCETON, N.J., June 01, 2022--Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study....;53.209999084472656;Sanofi said Wednesday that the Food and Drug Administration granted a Breakthrough Therapy designation to the hemophilia A treatment it's developing with Swedish Orphan Biovitrum AB . The company said it plans to ask the FDA to approve efanesoctocog alfa this summer. The experimental therapy has previously been granted Orphan Drug status and has been given a Fast Track designation in the U.S. The U.S.-listed shares of Sanofi have gained 6.3% this year, while the broader S&P 500 is down 13.3%.Biotech stocks have never really managed to recreate the success they had in 2020 amid the Covid-19 outbreak. For a second year in running, the sector is caught in a rut, underperforming the beaten-down broader market. The SPDR S&P Biotech ETF (NYSEARCA:XBI) and the iShares Biotechnology ETF (NASDAQ:IBB) are down about 40% and 25%, respectively, year-to-date. The steeper pullback of the former shows more pain in the mid-cap space, given the heavy weighting of the stocks in the index. It may notSwedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and Sanofi (EURONEXT:SAN) (NASDAQ:SNY) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with haemophilia A, a rare and life-threatening bleeding disorder, based on data from the pivotal XTEND-1 phase 3 study. Sanofi and Sobi collaborate on the development and commercialisation of efanesoctocog alfa.FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDADesignation is based on XTEND-1 Phase 3 study data demonstrating a clinically meaningful prevention of bleeds and superiority in prevention of bleeding episodes compared to prior prophylaxis factor treatmentEfanesoctocog alfa is a novel and investigational factor VIII therapy designed to provide normal to near;43.040000915527344;"The merged word reflects GlaxoSmithKline’s optimism about its soon-to-be demerged consumer business.  On Wednesday, the pharma group published the prospectus for Haleon, which is set to become one of the 20 largest companies on the London stock market when it floats next month.  The demerger is meant to unlock value.Pfizer Inc. (NYSE: PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE: GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and the maker of Sensodyne toothpaste and Advil pain relievers. Also Read: GSK To Scoop Clinical Stage US Biotech Affinivax For $3.3B To Shore Up Vaccine Business GSK has fileStock futures edge higher, but inflation worries linger; Fed begins 'quantitative tightening' with balance sheet run-off; Salesforce shares leap after Q1 earning beat, profit forecast boost; Pfizer to exit consumer healthcare JV with GlaxoSmithKline and Elon Musk weighs-in on work-from-homeGlaxoSmithKline announced Tuesday a $3.3 billion deal to buy pneumonia vaccine-maker Affinivax. But GSK stock dipped at the close.The deal puts GSK in a stronger position to compete with Pfizer and Merck, which are also active in vaccine development.";14.180000305175781;;40.689998626708984;;12.069999694824219;These stocks are incredibly cheap, and aren't as risky as their low multiples suggest they might be.;166.6999969482422;;12.59000015258789;;144.16000366210938;;84.83000183105469;;13.399999618530273;;37.75;;42.650001525878906;;18.600000381469727;;9.34000015258789;"HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK® (tazemetostat) has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (“Hainan Pilot Zone”), under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients wi";26.40999984741211;;41.349998474121094;WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GA is a leading cause of blindness that;101.91000366210938;;8.619999885559082;;19.610000610351562;;2.990000009536743;;5.690000057220459;;;;3.549999952316284;;3.309999942779541;;42.790000915527344;;33.41999816894531;;32.16999816894531;;5.019999980926514;;6.550000190734863;LAUSANNE, Switzerland, June 01, 2022--ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 9:00 am ET.;16.469999313354492;;3.700000047683716;"BRIDGEWATER, N.J., June 01, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced the commercial launch of LYVISPAH®, a baclofen oral granules (5, 10 and 20 mg) specialty product approved by the U.S. Food and Drug Administration (""FDA"") for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders.";32.95000076293945;;9.539999961853027;;17.25;;3.6500000953674316;;9.680000305175781;;4.5;;8.520000457763672;;18.389999389648438;;27.450000762939453;;20.290000915527344;;6.559999942779541;;15.970000267028809;MOUNTAIN VIEW, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 3:00 p.m. EST in New York. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of t;14.289999961853027;Company announcement – No. 3 / 2022 Zealand Pharma announces directed issue and private placement corresponding to approx. 6.6 % of existing share capital NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENCompany announcement – No. 2 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, May 31, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging manageria;8.079999923706055;;8.75;
2022-06-02;177.14999389648438;Exxon Mobil, PepsiCo, and JPMorgan Chase are among the biggest payers of dividends in absolute dollars, and they have solid yields to boot. Then there’s Apple and Microsoft.Johnson & Johnson (JNJ) closed at $177.71 in the latest trading session, marking a -1.01% move from the prior day.Needham analyst says medtech company would be a good fit for an acquisitionNovavax says the FDA has inspected its India manufacturing site, paving the way for COVID-19 vaccine authorization soon.;52.68000030517578;;302.42999267578125;The ideal scenario for this Lilly stock option trade for the stock to stay between 300 and 335 for the next two weeks.Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Eli Lilly, ConocoPhillips, PNC Financial Services, Equinix, and Freeport-McMoRan are part of Zacks top Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), ConocoPhillips (COP), and The PNC Financial Services Group, Inc. (PNC).;112.6500015258789;;146.75;;89.79000091552734;;90.0;;66.97000122070312;Novavax says the FDA has inspected its India manufacturing site, paving the way for COVID-19 vaccine authorization soon.;75.06999969482422;"PRINCETON, N.J., June 02, 2022--Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19Shares of Immatics gained 9.0% in premarket trading on Thursday after the company said its deal with Bristol Myers Squibb Inc. has expanded to include several off-the-shelf TCR-T and/or CAR-T programs. Bristol's stock was up 0.4%. The agreement pairs Immatics' adoptive cell therapy platform with therapies being developed by Bristol Myers Squibb. Per the terms of the deal, Immatics will receive $60 million upfront and up to $700 million in milestone payments as well as royalties on net product saTUEBINGEN, Germany & HOUSTON & NEW YORK, June 02, 2022--Immatics N.V. (NASDAQ: IMTX, ""Immatics""), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have expanded their strategic alliance to pursue the development of multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs.Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.";53.439998626708984;(Bloomberg) -- Regeneron Pharmaceuticals Inc. agreed to buy the immune-oncology drug Libtayo from partner Sanofi for as much as $1.1 billion, revisiting a deal that helped the French company re-enter the field of cancer research. Most Read from BloombergOne-Third of Americans Making $250,000 Live Paycheck-to-Paycheck, Survey FindsElon Musk’s Ultimatum to Tesla Execs: Return to the Office or Get OutApple Plans to Make the iPad More Like a Laptop and Less Like a PhoneJamie Dimon Says JPMorgan Is BThe FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.Regeneron Pharmaceuticals said on Thursday it would buy the global rights to cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900 million.  The companies signed a collaboration agreement in 2015 under which they jointly marketed the drug in the United States, while Sanofi was responsible for selling it outside the country.  Worldwide profits from Libtayo were split equally.Regeneron Pharmaceuticals Inc. announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s stake in the Regeneron-Sanofi collaboration on cancer treatment Libtayo. Under terms of the deal, Regeneron will make an upfront payment of $900 million, and Sanofi will be entitled to a $100 million regulatory milestone and up to $100 million in sales-related milestone payments. Sanofi will also receive an 11% royalty on global Libtayo sales. Sanofi's U.S.-listSanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab) Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of LibtayoSanofi will also be entitled to a $100 million regulatory milestone payment as well as sales-related milestone payments of up to $100 million over the next two years Paris, June 2, 2022. Sanofi restructures its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. Under the amended and restatedRegulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.;43.38999938964844;GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.Pfizer will sell down its stake in Haleon, its consumer health joint venture with GlaxoSmithKline, after a London listing planned for July 18.  The US drugmaker has committed to selling its shares in a “disciplined manner” and has formed an “orderly marketing” agreement with GSK to ensure that the two sellers do not destabilise stock in the new independent company.  Albert Bourla, Pfizer’s chief executive, said the joint venture was “not strategic” for the drugmaker, but it is “very important that we create the best healthcare consumer company in the world”.;13.9399995803833;Takeda UK Ltd. today announced that the National Institute for Health and Care Excellence (NICE), the health technology appraisal body in England and Wales, has published its Final Appraisal Document (FAD) recommending Revestive® ▼ (teduglutide) once daily subcutaneous injection as an option for people living with Short Bowel Syndrome (SBS) aged 1 year and above.[ii] Individuals should be stable following a period of intestinal adaptation after surgery.[vii];40.560001373291016;;12.109999656677246;;172.36000061035156;;12.880000114440918;;145.99000549316406;;83.31999969482422;;14.0;;37.33000183105469;Organon Canada Inc., an affiliate of Organon (NYSE: OGN), a global women's healthcare company, which employs over 120 people across Canada, today announced the publication of the company inaugural Environmental, Social, and Governance (ESG) Report for 2021. The ESG report introduces the company's ESG platform, known as Her Promise, and details how the company is working to help women and girls achieve the full potential of their promise through better health. The publication of the ESG Report anSTOCKHOLM, June 02, 2022--Global women’s health company, Organon (NYSE: OGN), which employs 9,300 people globally, including 85 in its operations across the Nordics today announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report for 2021. The ESG report introduces the company’s ESG platform, known as Her Promise, and details how the company is working to help women and girls achieve the full potential of their promise through better health. The publication of;43.25;;18.829999923706055;;9.859999656677246;;27.030000686645508;;42.54999923706055;WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences in June: Jefferies Healthcare Conference: Fireside chat on Thursday, June 9, 2022 at 4:30 p.m. ET.Goldman Sachs 43rd Annual Global Healthcare Conference: Fireside chat on Wednesday, June 15, 2022 at 9:20 a.m. PT. The conference events will be available vi;104.47000122070312;;8.489999771118164;;20.149999618530273;;3.0899999141693115;MIAMI, June 02, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 2022 Jefferies Healthcare Conference taking place June 8-10, 2022 in New York City. Management will be participating in a fireside chat on Thursday, June 9th at 8:00 a.m. Eastern time and will be hosting one-on-one meetings with investors. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health’s website by clicking;5.46999979019165;;;;3.6600000858306885;;3.3399999141693115;;42.849998474121094;;34.15999984741211;;32.77000045776367;GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: Benchmark Healthcare House Call Virtual 1X1 ConferenceJune 2, 2022 NYSE Healthcare & Technology Virtual Investor Access DayJune 8, 2022 East Coast IDEAS ConferenceJune 22, 2022Pre-recorded presentation will be accessible beginning at 6:00 am EThttps://wsw.com/webcast/threepa37/eb;4.989999771118164;Proof-of-concept data from trial may support addition of ERAS-007 as a treatment option to overcome RAS/MAPK resistance to KRAS G12C inhibitorsSAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a trial to investigate the ERK1/2 inhibitor ERAS-007 in combination with a KRAS G12C inhibitor;6.820000171661377;;17.579999923706055;;3.5999999046325684;;33.7400016784668;;9.09000015258789;;18.0;;3.740000009536743;;10.520000457763672;;3.25;- Decision based on reassessment of commercial potential of lixivaptan following recent observation of ALT/AST elevations in ALERT Study - - Discontinuation of lixivaptan development expected to significantly reduce cash burn and extend cash runway into 2026 - - Company continues to focus on the development of its innovative high impact rare disease and immuno-oncology pipeline of investigational medicines for patients - BOSTON and LONDON, June 02, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceutica;9.050000190734863;Net Revenues Increased by 11% to U$ 86 million, with Adjusted EBITDA Up 15% Year-Over-Year to $9 MillionMIAMI and BARRANQUILLA, Colombia, June 02, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its preliminary financial results for the quarter ended March 31, 2022 (“Q1-22”). Preliminary Q1-22 Results Highlights Net revenues for Q1-22 totaled $86 million, an increase of 11% when compare;18.799999237060547;;28.59000015258789;;20.56999969482422;;6.670000076293945;;16.68000030517578;;13.057999610900879;Press Release - No. 2/2022 Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer David Kendall named Zealand Pharma CMOFollows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategyKendall has over 35 years of diabetes and metabolic disease experience including nearly two decades in the pharma industry Copenhagen, DK and Boston, MA, U.S. June 2, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company;8.25;;12.670000076293945;"The first half of 2022 hasn't been kind to biotech stocks, but the pain has been especially acute for the smallest drug developers with the earliest-stage pipelines.  On the first day of June, Repare Therapeutics  announced a new partnership with global titan Roche .  The up-and-coming drug developer will hand over the rights to its lead drug candidate in return for an upfront cash payment of $125 million and the potential to receive up to $1.2 billion in additional milestones over the next decade-plus.Shares of Repare Therapeutics Inc. jumped 24.5% in premarket trading on Thursday, the day after the company said it signed a worldwide licensing and collaboration agreement with Roche Holding AG to develop and commercialize Repare's experimental tumor treatment. The drug, camonsertib, is being tested as a way to treat tumors with specific synthetic-lethal genomic alterations. Roche will pay Repare $125 million upfront; the agreement also includes up to $1.2 billion in potential milestone paymentShares of Repare Therapeutics Inc. were trading higher in Wednesday's after-hours session, following news the company entered a worldwide license and collaboration agreement with Roche to develop and commercialize camonsertib.CAMBRIDGE, Mass. & MONTREAL, June 01, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific"
2022-06-03;176.4199981689453;Dividend stocks aren't just for investors looking for a reliable passive income stream. Companies that have a habit of rewarding their shareholders with increasing payouts often have solid businesses that generate growing revenue and profits.In this article, we discuss 10 stocks to buy according to John Rogers’ Ariel Investments. If you want to skip our detailed analysis of Rogers’ history, investment philosophy, and hedge fund performance, go directly to 5 Stocks to Buy According to John Rogers’ Ariel Investments. John W. Rogers acquired an interest in stocks while at Princeton […]Johnson & Johnson and AbbVie's big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Friday.  Patients aged 65 and older with mantle cell lymphoma (MCL) were given Imbruvica or a placebo along with a chemotherapy regimen of bendamustine and autoimmune drug rituximab.We highlight three Value ETFs that are beating the broader indexesA late-stage study of two rheumatoid arthritis drugs from Bristol Myers Squibb and Johnson & Johnson showed a significant drop in deaths among hospitalized COVID patients, a U.S. health agency said on Thursday.  However, both the drugs failed to meet the main goal of speeding up recovery compared with a placebo, the study of nearly 2,000 patients by National Institutes of Health (NIH) showed.  Those who received J&J's Remicade had 40.5% lower adjusted odds of dying than the placebo group, while those on Bristol Myers' Orencia had 37.4%.;53.20000076293945;FDA briefing documents in advance of next week's advisory committee meeting highlighted potential safety issues with Novavax's COVID-19 vaccine.The FDA accepts the EUA request from Pfizer (PFE) for its COVID-19 vaccine for use in kids below 5 years of age. The U.S. government plans to start vaccinating these kids in June, following an FDA panel advisory.The pharma giant said it would pay $76 a share for the biotech stock, up from Thursday's close of $34.16.Pharmaceutical behemoth Pfizer (NYSE: PFE) has racked up successes during the COVID-19 outbreak, as the first to enter the market with a vaccine in December 2020 and a pill treatment in December 2021.  Outside of the Covid space, Pfizer sells a number of megablockbusters such as blood-thinner Eliquis, breast-cancer drug Ibrance, pneumonia vaccine Prevnar, and arthritis treatment Xeljanz.  The company also sees higher growth coming from blockbuster drugs Vyndaqel for cardiovascular disease and Inlyta and Xtandi for cancer treatments.;301.6499938964844;"Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. Anne White, senior vice president and president, Lilly Neuroscience, and Mark Mintun, senior vice president, research and development – neuroscience and president, Avid Radiopharmaceuticals, will participate in a fireside chat at 1:40 p.m., Eastern time.The Dow Jones Industrial Average dropped after the jobs report. Tesla skidded after Musk said he had a ""super bad feeling"" about the economy.Did you know that in 2011, Eli Lilly (NYSE: LLY) reported revenue of $24.3 billion? At first glance, it may appear as though the company hasn't grown a whole lot, given that this past year its top line was $28.";112.41000366210938;Bagsværd, Denmark, 3 June 2022 – Novo Nordisk today announced headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) phase 3a trials with once-weekly insulin icodec. ONWARDS 1 (insulin naïve people with type 2 diabetes)ONWARDS 1 is a phase 3a, 78-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin glargine U100 (insulin glargine), both in combination with non-insulin anti-diabetic treatment, in 984 insulin-naïve peopl;147.1699981689453;The pharma stock AbbVie (NYSE: ABBV) has gained 9% as of the end of May, but still looks like it's a buy.  When AbbVie reported its first-quarter results on April 29, they topped analysts' consensus forecasts.  AbbVie recorded $13.5 billion in net revenue during the quarter, up 4.1% over the year-ago period.AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Johnson & Johnson and AbbVie's big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Friday.  Patients aged 65 and older with mantle cell lymphoma (MCL) were given Imbruvica or a placebo along with a chemotherapy regimen of bendamustine and autoimmune drug rituximab.;89.12000274658203;GlaxoSmithKline's consumer health unit, Haleon, is set to start trading on the LSE on July 18. Pfizer will sell its stake after the spin-off.;89.91000366210938;"Bringing your whole self to work allows you “to be happy not just in your personal life but also in your professional life""We went looking for the best long-term investment stocks as our topic for today. So far, 2022 has shown us that even some of the most robust shares can be vulnerable to volatility on Wall Street. The market continues to suffer the effects of high inflation, tightening monetary policy, and fears of a looming economic downturn. As a result, the NASDAQ 100 index has fallen 22.3% for the year to date (YTD), while the S&P 500 index has dropped 12.8%. Yet, the recent slowdown also provides an excellenWhen Fujifilm Diosynth Biotechnologies chose an engineering partner for its $2 billion Holly Springs facility, the decision came down to two primary factors – qualifications and vision.  After a lengthy process, Texas-based Jacobs Engineering (NYSE: J) came out on top.  The new facility, which will be the largest cell culture biopharmaceutical facility in North America, is set to create 725 jobs by 2028.";65.69999694824219;Apellis (APLS) submits a new drug application to the FDA for pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.;75.16999816894531;"Rising interest rates and fears of an economic slowdown have resulted in a 24% year-to-date dip in the Nasdaq Composite.  This explains how pharma stock Bristol-Myers Squibb (NYSE: BMY) has rallied 22% year to date.  Let's dive into Bristol-Myers' fundamentals and valuation to find out.Bristol-Myers Squibb has agreed to acquire Turning Point Therapeutics for $4.1bn in the latest in a series of bolt-on acquisitions by pharmaceutical companies looking to bolster their drug pipelines.  The New York-based drug company said on Friday it would pay $76 per share to buy the clinical-stage company, which has a drug candidate in the late stages of development that targets non-small cell lung cancer, which accounts for 80 per cent of all cases in the US.  The acquisition is the largest by BMS in just under two years and analysts said it could strengthen the company’s oncology portfolio as Turning Point has several early stage clinical assets targeting different cancers.The pharma giant said it would pay $76 a share for the biotech stock, up from Thursday's close of $34.16.In this article, we discuss 10 stocks to buy according to John Rogers’ Ariel Investments. If you want to skip our detailed analysis of Rogers’ history, investment philosophy, and hedge fund performance, go directly to 5 Stocks to Buy According to John Rogers’ Ariel Investments. John W. Rogers acquired an interest in stocks while at Princeton […]""With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile,"" said Bristol Myers CEO Giovanni Caforio.Shares of Turning Point Therapeutics Inc. more than doubled, up 116.7%, in premarket trading Friday, after the clinical-stage oncology company agreed to be acquired by biopharmaceutical company Bristol Myers Squibb Co. in an all-cash deal valuing Turning Point at about $3.77 billion. Bristol Myers' stock was little changed ahead of the open. Under terms of the deal, Turning Point shareholders will receive $76.00 for each Turning Point share they own, representing a 122.5% premium to Thursday's cBristol Myers Squibb said on Friday it would acquire drug developer Turning Point Therapeutics Inc for $4.1 billion in cash to gain access to promising targeted treatments for cancer.  Bristol Myers expects the drug to become a stand-of-care therapy for certain patients with non-small cell lung cancer, a lucrative market for drug developers, when it is approved.  Repotrectinib, which belong to a class of treatments known as tyrosine kinase inhibitors, is being tested to treat non-small cell lung cancer and other advanced solid tumors.(Reuters) -Bristol Myers Squibb Co said on Friday it will acquire drug developer Turning Point Therapeutics Inc for $4.1 billion in cash to help bolster its arsenal of cancer drugs.  Bristol Myers will pay $76 per Turning Point share, a 122.5% premium to its last closing price.  The deal ""will surprise many investors who over the past year have begun to believe late-to-market targeted oncology drugs are likely to be commercial failures,"" Stifel analyst Bradley Canino said.NEW YORK & SAN DIEGO, June 03, 2022--Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022.By Daniel ShvartsmanIn the latest trading session, Bristol Myers Squibb (BMY) closed at $75.07, marking a +0.15% move from the previous day.A late-stage study of two rheumatoid arthritis drugs from Bristol Myers Squibb and Johnson & Johnson showed a significant drop in deaths among hospitalized COVID patients, a U.S. health agency said on Thursday.  However, both the drugs failed to meet the main goal of speeding up recovery compared with a placebo, the study of nearly 2,000 patients by National Institutes of Health (NIH) showed.  Those who received J&J's Remicade had 40.5% lower adjusted odds of dying than the placebo group, while those on Bristol Myers' Orencia had 37.4%.";53.529998779296875;Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Regeneron Pharmaceuticals (NASDAQ: REGN) had a day to forget, at least as far as its stock was concerned.  Regeneron announced that it's buying out its partner Sanofi's (NASDAQ: SNY) stake in Libtayo, the cancer drug on which they've collaborated.  Under the terms of the arrangement, Regeneron would hold the exclusive development, commercialization, and manufacturing rights to the medication worldwide.Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,527,121,390 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nRegeneron will gain exclusive worldwide development, commercialization, and manufacturing rights to the drug Libtayo.;42.720001220703125;"In the latest trading session, GlaxoSmithKline (GSK) closed at $43.39, marking a +0.81% move from the previous day.GlaxoSmithKline's consumer health unit, Haleon, is set to start trading on the LSE on July 18. Pfizer will sell its stake after the spin-off.GlaxoSmithKline (LSE: GSK) (NYSE: GSK) – Go ahead and revel in that ramen, indulge on pizza and savor even the sauciest of wings without fear. After more than a decade spent helping consumers fight back against heartburn caused by their favorite foods, TUMS®, America's #1 heartburn brand*, is waving the metaphorical white flag to encourage consumers to give up the food fight and ""Love Food Back"" instead, no matter the meal.";13.8100004196167;;40.52000045776367;;11.710000038146973;;165.19000244140625;Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;12.579999923706055;;145.99000549316406;;86.30000305175781;;13.770000457763672;;37.18000030517578;;46.0;;18.18000030517578;;9.609999656677246;;27.84000015258789;;45.529998779296875;Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Apellis (APLS) submits a new drug application to the FDA for pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.;107.0999984741211;;8.529999732971191;;21.59000015258789;;2.950000047683716;;5.480000019073486;;;;3.630000114440918;;3.6500000953674316;;44.689998626708984;;74.58999633789062;"The pharma giant said it would pay $76 a share for the biotech stock, up from Thursday's close of $34.16.""With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile,"" said Bristol Myers CEO Giovanni Caforio.Shares of Turning Point Therapeutics Inc. more than doubled, up 116.7%, in premarket trading Friday, after the clinical-stage oncology company agreed to be acquired by biopharmaceutical company Bristol Myers Squibb Co. in an all-cash deal valuing Turning Point at about $3.77 billion. Bristol Myers' stock was little changed ahead of the open. Under terms of the deal, Turning Point shareholders will receive $76.00 for each Turning Point share they own, representing a 122.5% premium to Thursday's cBristol Myers Squibb said on Friday it would acquire drug developer Turning Point Therapeutics Inc for $4.1 billion in cash to gain access to promising targeted treatments for cancer.  Bristol Myers expects the drug to become a stand-of-care therapy for certain patients with non-small cell lung cancer, a lucrative market for drug developers, when it is approved.  Repotrectinib, which belong to a class of treatments known as tyrosine kinase inhibitors, is being tested to treat non-small cell lung cancer and other advanced solid tumors.(Reuters) -Bristol Myers Squibb Co said on Friday it will acquire drug developer Turning Point Therapeutics Inc for $4.1 billion in cash to help bolster its arsenal of cancer drugs.  Bristol Myers will pay $76 per Turning Point share, a 122.5% premium to its last closing price.  The deal ""will surprise many investors who over the past year have begun to believe late-to-market targeted oncology drugs are likely to be commercial failures,"" Stifel analyst Bradley Canino said.By Daniel Shvartsman";32.2400016784668;Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;5.650000095367432;SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 2022 Jefferies Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a presentation at 8:00 am Eastern Time on Fr;7.199999809265137;;16.68000030517578;;3.490000009536743;;34.58000183105469;;10.569999694824219;Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127, DeTIL-0255, and NX-1607 programsSAN FRANCISCO, June 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for three of its wholly-owned investigative therapies, NX-2127, DeTIL-0255 and NX-1607, each currently;18.389999389648438;;3.690000057220459;;10.670000076293945;;3.2300000190734863;Drug development is time-consuming, expensive, and full of failure.  From 2011 to 2020, only 7.9% of drug candidates that began a phase 1 clinical trial earned approval from the U.S. Food and Drug Administration (FDA).  Centessa Pharmaceuticals  was founded to attack the inefficiency of drug development head on.;9.399999618530273;;19.979999542236328;;31.709999084472656;;21.209999084472656;;7.019999980926514;;16.510000228881836;;13.470000267028809;Company announcement – No. 26 / 2022 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN APress release – No. 3/ 2022 Zealand Pharma to Participate in Upcoming Investor Conferences Copenhagen, DK and Boston, MA, U.S. June 3, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in June: Jefferies 2022 Global Healthcare ConferenceDate: Friday, June 10, 2022Presentation: 8:00 a.m. EST / 12:;8.59000015258789;;13.130000114440918;Repare Therapeutics (RPTX) signs a licensing agreement with Roche (RHHBY) to develop its lead candidate for solid tumor indications.After the market closed Wednesday, Repare Therapeutics (NASDAQ: RPTX) announced that it had entered into a licensing and collaboration deal with Roche (OTC: RHHBY) for its experimental cancer drug, camonsertib, also known as RP-3500.  In the wake of that news, Repare shares skyrocketed, and were up by 36.5% as of 11:58 a.m. ET on Thursday.  The spectacular gain for Repare Thursday seems to be warranted, especially in light of the details of its agreement with the Swiss healthcare giant.
2022-06-06;176.39999389648438;Johnson & Johnson (NYSE: JNJ) and AbbVie Inc (NYSE: ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL). The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR and rituximab maintenance. Median progression-free survival (PFS) was 80.6 months with ibrutinib combined with bendEmergent BioSolutions Inc (NYSE: EBS) said Johnson & Johnson (NYSE: JNJ) had breached an agreement by failing to buy the company's minimum quantity of COVID-19 vaccines. Emergent said J&J had failed to provide required forecasts for the number of vaccines it needed and had wound down the agreement instead of fulfilling minimum requirements. Also Read: Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco. Under the terms of the Agreement, Emergent had agreed to provideIn this article, we discuss the 10 stocks that Ray Dalio was wrong about. If you want to read about some more stocks that Ray Dalio was wrong about, go directly to Ray Dalio Was Wrong About These 5 Stocks. The past few months have not been kind to stocks as the market becomes more […]The termination notice comes about a week after J&J had initially informed Emergent of its intent to end the pact based on the contract manufacturer's breaches, including failure to supply COVID-19 vaccine drug substance, J&J said.  Emergent said earlier on Monday that J&J breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.Contract manufacturer Emergent BioSolutions Inc said on Monday U.S. drugmaker Johnson & Johnson had breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.  Emergent said J&J had failed to provide required forecasts for the amount of vaccines it needed and had wound down the agreement instead of fulfilling minimum requirements.  If the agreement is terminated, Emergent said https://www.sec.gov/ix?doc=/Archives/edgar/data/1367644/000136764422000096/ebs-20220606.htm J&J would owe it roughly $125 million to $420 million.;53.2599983215332;NEW YORK, June 06, 2022--Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The investment will expand the production of active pharmaceutical ingredient (API) and registered starting materials (RSMs) used in the manufaPfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.Pfizer Inc (NYSE: PFE) announced overall survival (OS) results from the Phase 3 PALOMA-2 trial of Ibrance (palbociclib) combined with Novartis AG's (NYSE: NVS) Femara (letrozole) in breast cancer setting compared to placebo. After a median follow-up of seven and a half years, Ibrance/Femara combo failed to extend the lives of those breast cancer patients compared with Femara alone. Patients on the Ibrance-Femara combo lived a median of 53.9 months versus 51.2 months for those in the solo FemaraThis mega-cap stock will become the first in the pharmaceutical industry to reach a major sales milestone.CPI inflation data is out on Friday. Plus, earnings and investor days from Pfizer, Vail ResoResorts, AMD, DocuSign, NIO, Campbell Soup, and more.Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.;303.3599853515625;"The Dow Jones Industrial Average rallied 200 points Monday, as Apple jumped ahead of the company's WWDC 2022 event, while Twitter stock dived.""These five-year results ... showing empagliflozin was associated with a decreased risk of hospitalization for heart failure and for death, are encouraging data for adults with type 2 diabetes,"" said co-lead investigator Dr. Elisabetta Patorno.Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that Jardiance® (empagliflozin) was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adults with type 2 diabetes in routine care. Relative risk reductions were 50% versus dipeptidyl peptidase-4 (DPP-4) inhibitors and 30% versus glucagon-like peptide 1 (GLP-1) receptor agonists. The";112.1500015258789;;146.52999877929688;Johnson & Johnson (NYSE: JNJ) and AbbVie Inc (NYSE: ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL). The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR and rituximab maintenance. Median progression-free survival (PFS) was 80.6 months with ibrutinib combined with bendCases of monkeypox continue to crop up around the world.  According to the World Health Organization (WHO), at least 27 countries, mainly in Europe and North America, have confirmed cases.  Other reports have found confirmed cases in more than 30.;88.66999816894531;Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in patients ages 1 to 17 years old with BRAF V600 low-grade gliomas (LGG) requiring first systemic treatment1 If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer who are in need of a more efficacious and convenient option that can be adminiPfizer Inc (NYSE: PFE) announced overall survival (OS) results from the Phase 3 PALOMA-2 trial of Ibrance (palbociclib) combined with Novartis AG's (NYSE: NVS) Femara (letrozole) in breast cancer setting compared to placebo. After a median follow-up of seven and a half years, Ibrance/Femara combo failed to extend the lives of those breast cancer patients compared with Femara alone. Patients on the Ibrance-Femara combo lived a median of 53.9 months versus 51.2 months for those in the solo Femara;89.83999633789062;TD Ameritrade Head Trading Strategist Shawn Cruz joins Yahoo Finance Live to discuss volatility, IMX score dip, client buys and sells, and the outlook for investor uncertainty.Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.;63.52000045776367;"Insiders were net buyers of AstraZeneca PLC's ( LON:AZN ) stock during the past year. That is, insiders bought more...AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKYF) Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy. Financial Times wrote 'oncologists are hopeful a drug developed by AstraZeneca and Daiichi Sankyo will change how doctors treat the most common type of late-stage breast cancer."" Detailed results from the DESTINY-Breast04 Phase 3 trial showed that Enhertu reduced the risk of disease progression or de";75.25;Subhashish Banerjee, MD, vice president & disease area head, Rheumatology and Dermatology at Bristol Myers Squibb, shares how the company is leveraging a pathways-based approach to advance research...Macroeconomic headwinds everywhere are dampening stock market prospects. Growth stocks are especially prone to market selling pressure. Speculators generally assume that all growth companies will face a severe slowdown in the months ahead. Their corresponding stock fell into cheap value territory on market pessimism. Those cheap growth stocks will not stay that way for long. The discount between its fair value and market price will shrink. As the company’s business grows despite the near-term ecPRINCETON, N.J., June 06, 2022--Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo Plus Yervoy ....PRINCETON, N.J., June 06, 2022--Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo Plus Yervoy in First-Line....Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.;53.20000076293945;Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.;42.810001373291016;The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.PHILADELPHIA, June 06, 2022--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.The FDA has approved GSK Plc's (NYSE: GSK) Priorix vaccine to prevent measles, mumps, and rubella (MMR) in those aged one year and above. The vaccine can be given in two doses. It may also be administered as a second shot to previously vaccinated individuals with the first dose of another MMR-containing vaccine. According to a government study released last month, child vaccination rates in the U.S. fell during the COVID-19 pandemic as many children skipped doctor appointments and states eased v;13.819999694824219;;40.40999984741211;;11.770000457763672;Downturns are a great time to load up on high-quality dividend stocks.  Falling share prices pump up dividend yields, and that means you'll get more bang for your buck in the long run, assuming that the stocks you buy eventually return to growth.  Viatris (NASDAQ: VTRS) manufactures a smorgasbord of common generic drugs and it also produces reputable brands like EpiPens, Viagra, and Lipitor.Shares of Viatris (NASDAQ: VTRS), a biopharmaceutical company known for its branded, generic, and biosimilar therapies, saw its shares rise 18.8% in May, according to data provided by S&P Global Market Intelligence.;165.39999389648438;;12.789999961853027;;145.07000732421875;;85.19000244140625;;13.920000076293945;;37.470001220703125;;46.0;;16.329999923706055;;9.75;;25.889999389648438;;43.150001525878906;;102.83000183105469;BOSTON, June 06, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming investor conferences:;8.369999885559082;;21.719999313354492;;2.759999990463257;;4.590000152587891;;;;3.549999952316284;;3.569999933242798;CULVER CITY, Calif., June 06, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a leading clinical-stage immunotherapy company, today announced new positive data from the company’s pivotal Phase 2/3 trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (QUILT 3032) and Phase 2 trial in advanced pancreatic cancer (QUILT 88). The results, which were presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrate the strong and diverse grow;44.630001068115234;"Harmony Biosciences Holdings, Inc. (""Harmony"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced results of a post-hoc analysis from the pivotal data evaluating the clinical impact of WAKIX® (pitolisant) on the reduction of excessive daytime sleepiness (EDS) and cataplexy in adults with a high burden of narcolepsy symptoms. The analysis was presented as a poster at the 36th Annua";74.75;;30.799999237060547;Emergent BioSolutions Inc (NYSE: EBS) said Johnson & Johnson (NYSE: JNJ) had breached an agreement by failing to buy the company's minimum quantity of COVID-19 vaccines. Emergent said J&J had failed to provide required forecasts for the number of vaccines it needed and had wound down the agreement instead of fulfilling minimum requirements. Also Read: Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco. Under the terms of the Agreement, Emergent had agreed to provideThe termination notice comes about a week after J&J had initially informed Emergent of its intent to end the pact based on the contract manufacturer's breaches, including failure to supply COVID-19 vaccine drug substance, J&J said.  Emergent said earlier on Monday that J&J breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.Contract manufacturer Emergent BioSolutions Inc said on Monday U.S. drugmaker Johnson & Johnson had breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.  Emergent said J&J had failed to provide required forecasts for the amount of vaccines it needed and had wound down the agreement instead of fulfilling minimum requirements.  If the agreement is terminated, Emergent said https://www.sec.gov/ix?doc=/Archives/edgar/data/1367644/000136764422000096/ebs-20220606.htm J&J would owe it roughly $125 million to $420 million.;5.5;;7.019999980926514;;16.670000076293945;BILLERICA, Mass., June 06, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix’ Board of Directors effective June 6, 2022.;3.3299999237060547;;32.33000183105469;;10.59000015258789;;18.0;;3.4000000953674316;;10.069999694824219;;3.180000066757202;BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that Saurabh Saha, MD, PhD, Chief Executive Officer and Gregory Weinhoff, MD, Chief Financial Officer, will participate in the following investor conferences: Event: Jefferies Healthcare ConferenceDate:;9.149999618530273;;18.510000228881836;;32.15999984741211;;20.549999237060547;Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle (P<0.0001) More than 50% of patients treated with roflumilast foam achieved an IGA score of clear at week eight Roflumilast foam was well-tolerated with a favorable safety and tolerability profile Data further support the potential of roflumilast foam as a best-in-class, once-daily, non-steroidal topical t;6.679999828338623;;16.469999313354492;;13.470000267028809;;1.8799999952316284;Praxis Precision Medicines Inc's (NASDAQ: PRAX) Phase 2/3 Aria Study of PRAX-114 for major depressive disorder (MDD) did not achieve statistical significance on the primary endpoint. The primary endpoint was the change from baseline in the total score of the 17-item Hamilton Depression Rating Scale (HAM-D17). The scale measures the frequency and intensity of depressive symptoms in individuals with major depressive disorder. Praxis said it will prioritize programs in movement disorders and epilepAria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus resources on Movement Disorders and Epilepsy franchises extends cash runway into 2024 BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today an;14.100000381469727;
2022-06-07;178.33999633789062;In this article, we discuss 10 best dividend stocks on Robinhood. You can skip our detailed analysis of these stocks and go directly to read 5 Best Dividend Stocks on Robinhood. Even after the pandemic, retail investors continue to flood the financial market, accounting for 8% of pre-market trades in March 2022, up from 2% […]In this article, we discuss the 10 stocks to buy before the next pandemic. If you wish to skip our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 5 Stocks to Buy Before the Next Pandemic. The Covid-19 pandemic tested the world’s readiness to deal with a global health […]Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.Spirit deal battle is amped up again as JetBlue sweetens its bid, Kohl’s holds talks over $8 billion bid, Apple unveils new laptops and text editing, and other news to start your day.Johnson & Johnson said on Monday it had formally informed Emergent BioSolutions Inc of its decision to terminate agreement with the contract manufacturer to make COVID-19 vaccine for the drugmaker.  The termination notice comes about a week after J&J had initially informed Emergent of its intent to end the pact based on the contract manufacturer's breaches, including failure to supply COVID-19 vaccine drug substance, J&J said.  Emergent said earlier on Monday that J&J breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.;53.959999084472656;Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.In this article, we discuss 10 best dividend stocks on Robinhood. You can skip our detailed analysis of these stocks and go directly to read 5 Best Dividend Stocks on Robinhood. Even after the pandemic, retail investors continue to flood the financial market, accounting for 8% of pre-market trades in March 2022, up from 2% […]In this article, we discuss the 10 stocks to buy before the next pandemic. If you wish to skip our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 5 Stocks to Buy Before the Next Pandemic. The Covid-19 pandemic tested the world’s readiness to deal with a global health […]In this article, we discuss the 10 undervalued blue-chip stocks to buy now. If you want to skip our analysis of these stocks, go directly to the 5 Undervalued Blue Chip Stocks to Buy Now. Blue-chip companies are considered to be established and large-scale organizations with a rich history of long-term stable financial performance. These […]Is Pfizer stock a buy with the FDA's advisory committee soon to consider its Covid shot in children? Is PFE stock a buy right now?Before deciding the fate of Novavax's (NVAX) COVID-19 vaccine, a document issued by the FDA suggests that the vaccine may cause heart problems like myocarditis/pericarditis.In this article, we take a look at the 10 biggest hospital companies in the world. You can skip our detailed analysis of the healthcare industry and go directly to 5 Biggest Hospital Companies in the World. The healthcare sector is growing faster than the overall global economy, with healthcare making 10% of the global […]Approval of the Covid-19 vaccine for children under five years old would be good news for some parents, but not necessarily for shareholders.;312.1000061035156;A former human resources officer at Eli Lilly and Co sued the drugmaker on Monday, alleging she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs.  The plaintiff, Amrit Mula, alleges violations of an employee protection law and seeks unspecified damages.  The U.S. Department of Justice last year launched a criminal investigation into alleged manufacturing irregularities at an Eli Lilly plant in New Jersey following a Reuters story that detailed some of Mula's allegations.Eli Lilly And Co (NYSE: LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment. Additionally, patients treated with lebrikizumab maintained itch relief across the two trials over the one year. The fThe Dow Jones Industrial Average sold off Tuesday, as Target dived after warning profits would drop in the current quarter.Companies in The News Are: SIAC,LLY,SEDG,SAVE,JBLUDow Jones futures were lower after Monday's stock market action. The 10-year Treasury yield jumped back above 3%.Eli Lilly and Company (NYSE: LLY) today announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company's investigational IL-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 clinical trials (ADvocate 1 and 2) showed eight out of ten patients who achieved clinical response (EASI-75*) with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with t(Reuters) -A former human resources officer at Eli Lilly and Co sued the drugmaker on Monday, alleging she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs.  The plaintiff, Amrit Mula, alleges violations of an employee protection law and seeks unspecified damages.  The U.S. Department of Justice last year launched a criminal investigation into alleged manufacturing irregularities at an Eli Lilly plant in New Jersey following a Reuters story that detailed some of Mula's allegations.New data from a mechanism of action study and new analyses of the global registration program for Eli Lilly and Company's (NYSE: LLY) Mounjaro™ (tirzepatide) injection were presented at the American Diabetes Association's® (ADA) 82nd Scientific Sessions®, adding to the robust body of data about Mounjaro for the treatment of adults with type 2 diabetes. More than 20 presentations on Mounjaro were accepted for disclosure at the ADA's Scientific Sessions.Eli Lilly delivered a promising update for its experimental obesity treatment over the weekend, leading LLY stock to pop Monday.;115.87000274658203;Novo Nordisk – major shareholder announcement Bagsværd, Denmark, 7 June 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section;149.13999938964844;When it comes to success with investing, Warren Buffett is hard to one-up, to say the least.  On that note, in the first quarter of this year, the Oracle of Omaha's company, Berkshire Hathaway (NYSE: BRK.A, BRK.B), sold 100% of his three million AbbVie (NYSE: ABBV) shares with a total value of around $410 million.  Contrary to his stated preference of holding stocks for extraordinarily long periods, Buffett only established his position in the company in the third quarter of 2020.AbbVie recently shared encouraging clinical trial results for patients taking Rinvoq to treat Crohn's disease.AbbVie (NYSE: ABBV) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver, June 9-12. A total of 29 abstracts, including two oral presentations and one late-breaker presentation, will cover a wide range of studies across AbbVie's migraine portfolio, and highlight the company's newest migraine treatment, atogepant (QULIPTA).AbbVie (ABBV) closed the most recent trading day at $146.53, moving -0.43% from the previous trading session.;88.87999725341797;Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week results1,2 Long-term safety remains consistent, with discontinuation rates due to adverse events more than three times lower in the Scemblix vs. Bosulif arm (7.7% vs. 26.3%)1,2 Updated results continue to support the use of Scemblix in patients with Philadelphia chromosome-positive CML in chroni;90.4800033569336;Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics announced that the Annals of Internal Medicine had published additional data from the Phase 3 MOVe-OUT trial of Lagevrio (molnupiravir) in non-hospitalized COVID-19 patients at high risk for progressing to severe disease. A lower proportion of molnupiravir-treated participants in the modified intent-to-treat population had an acute care visit or a COVID-19-related acute care visit versus a placebo. 7.2% of participants who received LagevriIn this article, we discuss the 10 stocks to buy before the next pandemic. If you wish to skip our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 5 Stocks to Buy Before the Next Pandemic. The Covid-19 pandemic tested the world’s readiness to deal with a global health […]RAHWAY, N.J. & MIAMI, June 07, 2022--Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT StudyRAHWAY, N.J., June 07, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will provide a detailed overview of the company’s oncology portfolio and pipeline at an investor event today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago at 7 a.m. CT/8 a.m. ET. At this year’s ASCO, data for Merck’s oncology portfolio and pipeline will be presented from nearly 120 abstracts in more than 25 cancer types.The Food and Drug Administration on Monday granted marketing approval to GlaxoSmithKline for Priorix, a vaccine to prevent measles, mumps and rubella in individuals a year or older.  Priorix is currently licensed in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand.  More than 800 million doses of the vaccine have been distributed to date.;65.58000183105469;Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.An up to 31% plunge in the Nasdaq is the perfect excuse to put your money to work in these three steady businesses.Countries in Europe and Asia have placed age restrictions on the jab, while it has yet to be approved for use in the US.Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.;76.58999633789062;NEW YORK, June 07, 2022--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Goldman Sachs’ 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, June 15, 2022. Adam Lenkowsky, Senior Vice President and General Manager, U.S. Commercialization, will answer questions about the company at 9:20 a.m. PT/12:20 p.m. ET.Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.;53.689998626708984;Sanofi announces the opening of the company's new campus at Cambridge Crossing in Cambridge, Massachusetts. Governor Charlie Baker and Cambridge Mayor Sumbul Siddiqui plan to attend the ribbon-cutting ceremony in addition to Sanofi's CEO Paul Hudson and Executive Committee members, Global Head of Research and Development John Reed, M.D., Ph.D., and Global Head of Specialty Care Bill Sibold, for the official opening of one of the company's largest U.S. sites. The campus is designed to enhance colSanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people Paris, June 7, 2022. Sanofi today launches Action 2022, its global employee share ownership plan, open to 86 000 employees in 59 countries. The program, similar to programs carried out since 2013, clearly demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company. Paul HudsonChief Executive Officer of S;44.25;In this article, we discuss the 10 stocks to buy before the next pandemic. If you wish to skip our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 5 Stocks to Buy Before the Next Pandemic. The Covid-19 pandemic tested the world’s readiness to deal with a global health […]The Food and Drug Administration on Monday granted marketing approval to GlaxoSmithKline for Priorix, a vaccine to prevent measles, mumps and rubella in individuals a year or older.  Priorix is currently licensed in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand.  More than 800 million doses of the vaccine have been distributed to date.;13.770000457763672;"Takeda Canada Inc. (""Takeda Canada""), a values-based, R&D-driven biopharmaceutical leader, committed to discovering and delivering life-transforming treatments, welcomes Quebec's first policy for rare diseases. This policy is an important first step in acknowledging the unique complexities faced by Quebecers living with rare diseases and the changes needed to ensure ensure patients have access to the care and treatments they deserve.National Resilience Inc., the startup behind a string of manufacturing facilities for drug companies, plans to grow further in Massachusetts with the help of $1.2 billion in new venture funding.";41.31999969482422;;11.890000343322754;Amidst the volatility and declines on Wall Street, dividend stocks with high yields have become a prized commodity among investors. Growing fears that the economy is tipping into recession continue to draw investors into reliable stocks that offer passive income. Most dividend payers are primarily concentrated in industries that consumers rely on throughout the year, regardless of the economic environment. Such sectors typically include utilities, infrastructure, consumer staples and telecommuni;169.5;;12.789999961853027;;145.0;;89.12000274658203;– Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 – Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism on Monday, June 13 – PaTHway Trial results represent the second consecutive successful pivotal Phase 3 trial of a TransCon product candidate COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its pre;14.199999809265137;;37.810001373291016;;47.540000915527344;;16.520000457763672;;9.34000015258789;;28.790000915527344;;45.130001068115234;In this article, we discuss the top 10 stock picks of Frank Fu’s CaaS Capital. If you want to skip our detailed analysis of Fu’s history, investment philosophy, and hedge fund performance, go directly to Top 5 Stock Picks of Frank Fu’s CaaS Capital. Frank Fu’s early career was devoted to methods of trading that […]WALTHAM, Mass. and STOCKHOLM, Sweden, June 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced that the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), two rare and debilitating kidney diseases with similar underlying causes and no approved treatment. “Individuals with IC-WALTHAM, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to thirteen new employees with a grant date of June 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the com;110.0;;9.010000228881836;;23.100000381469727;;2.8499999046325684;;4.28000020980835;;;;3.640000104904175;;4.21999979019165;;45.5;;74.75;Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.;32.380001068115234;Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.Johnson & Johnson said on Monday it had formally informed Emergent BioSolutions Inc of its decision to terminate agreement with the contract manufacturer to make COVID-19 vaccine for the drugmaker.  The termination notice comes about a week after J&J had initially informed Emergent of its intent to end the pact based on the contract manufacturer's breaches, including failure to supply COVID-19 vaccine drug substance, J&J said.  Emergent said earlier on Monday that J&J breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.;5.730000019073486;;7.230000019073486;;17.34000015258789;;3.4000000953674316;"BRIDGEWATER, N.J., June 07, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced the release of its second annual (2021) Corporate Responsibility Report. The report showcases the Company’s continued progress in deepening its commitment to environmental, social, and governance (ESG) integration across Amneal strategy, culture and operations. Updates on actions the Company has taken in key ESG areas are highlighted alongside the social impacts of our business";32.400001525878906;;11.75;;19.56999969482422;SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in person in a fireside chat at the annual JMP Securities Life Sciences Conference, which is being held at the Lotte New York Palace on June 15-16, 2022. Details of the firesi;3.700000047683716;;10.819999694824219;;3.4100000858306885;;8.899999618530273;;19.540000915527344;;34.63999938964844;;21.399999618530273;;6.739999771118164;;17.329999923706055;;13.192999839782715;COMPANY ANNOUNCEMENT – NO. 27/ 2022 Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity Phase 1 trial showed multiple doses of dapiglutide were well-tolerated and data supports once-weekly dosingInvestigator-Initiated Phase 2 trial of dapiglutide in obesity anticipated to commence by early 2023Data presentations for dapiglutide and other pipeline progra;1.840000033378601;Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.;14.65999984741211;"CAMBRIDGE, Mass. & MONTREAL, June 07, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA."
2022-06-08;177.27999877929688;In this article, we discuss the 10 stocks that Jim Cramer is recommending in June. If you want to read about some more stocks that Jim Cramer is recommending in June, check out Jim Cramer is Recommending These 5 Stocks in June. Jim Cramer, the journalist investor and hugely successful former hedge fund manager, has […]Dividend stocks offer investors a way to earn a steady income from their investments without selling their shares. Investors may also use them as long-term investments for retirement. There are many different types of dividend stocks, but some popular ones include utilities, real estate investment trusts (REITs), healthcare providers and consumer staples companies. 7 Oversold Value Stocks to Buy for June Here’s a list of companies you can invest in. They’ve got an excellent track record and a stJohnson & Johnson (JNJ) closed the most recent trading day at $178.34, moving +1.1% from the previous trading session.FDA votes to recommend use of Novavax COVID-19 vaccine in adultsThe long-embattled neurodegenerative disease company will cease to exist after the deals are complete.An advisory panel to the U.S. Food and Drug Administration is due to meet later Tuesday to review the vaccine developed by Novavax Inc. as a potential fourth shot for American adults and will vote on whether the risks outweigh the benefits.Is Johnson & Johnson stock a buy after the company suspended its Covid vaccines guidance? Is JNJ stock a buy right now?;53.470001220703125;Pfizer's (NYSE:PFE) stock is up by a considerable 11% over the past three months. We wonder if and what role the...Pfizer is ramping up its production of pharmaceutical ingredients for its COVID-19 treatment Paxlovid.FDA votes to recommend use of Novavax COVID-19 vaccine in adultsRisk of heart inflammation from mRNA vaccines is being studied, creator says.;313.489990234375;The Dow Jones Industrial Average fell Wednesday, as Treasury yields jumped. Top stocks to buy and watch include cosmetics leader Ulta Beauty.Jim Cramer says smart investing is as simple as buying growth stocks when interest rates begin to fall.Yahoo Finance senior health reporter Anjalee Khemlani details Eli Lilly's type-2 diabetes drug approval by the FDA for use as a weight loss drug.Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.;115.95999908447266;"Bagsværd, Denmark, 07 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiat";149.25;For example, mature businesses like AbbVie (NYSE: ABBV) are often especially favorable for retirement savings, due to their stable growth and demonstrated ability to prosper over time.  Given that it might be necessary to hold shares and wait for years, could a stake in AbbVie be enough to grow your investment into millions?  As a leading global pharmaceutical company, AbbVie develops and commercializes drugs, and it owns the rights to a smorgasbord of moneymakers like Humira (the world's best-selling drug), Botox, and more.;87.3499984741211;;89.4800033569336;Nurses' clinical expertise and patient experience provide valuable insight across all divisions of our companyRAHWAY, N.J., June 08, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Robert M. Davis, chief executive officer and president, and Dean Y. Li, president, Merck Research Laboratories, will participate in a fireside chat at the live 2022 Goldman Sachs 43rd Annual Global Healthcare Conference.;64.72000122070312;;76.18000030517578;Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NEW YORK, June 08, 2022--Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2022 on Wednesday, July 27, 2022. Company executives will review financial results and address inquiries from investors and analysts during a conference call at 8:00 a.m. ET on the same date.In this article, we discuss the 11 best bear market stocks to invest in. If you wish to skip our detailed analysis of bear market stocks and the current market situation, go directly to 5 Best Bear Market Stocks To Invest In. A bear market is a situation where a benchmark index, like the S&P500 […];52.880001068115234;Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth Paris, June 8, 2022. Sanofi announces the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company. The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI). Based in Paris, it already brings together a team of over 75 expertsThe U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc's anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.  Dupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi and Regeneron said.FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthoodChildren treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trialLong-term safety data from a 52-week open-label extension tRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regulatory filings for this age group are underway by the European Medicines Agency and regulatory authorities in additional countries.Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.French pharmaceutical giant is doubling down on its growth plans in Greater Boston. (See its new digs here.);44.20000076293945;;13.5600004196167;FDA votes to recommend use of Novavax COVID-19 vaccine in adults;41.4900016784668;NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of bio;11.859999656677246;Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;167.08999633789062;;12.779999732971191;Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and the development of innovative diagnostic solutions, today announced that its Procleix Plasmodium Assay has obtained the CE mark, the first for an automated nucleic acid test (NAT) system specifically validated for screening blood donors for malaria.;144.75;;91.19999694824219;;14.199999809265137;;37.61000061035156;;49.54999923706055;;16.479999542236328;;11.390000343322754;;28.610000610351562;;43.849998474121094;Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.;111.0999984741211;;10.760000228881836;;26.0;;2.8399999141693115;;4.360000133514404;;;;3.7200000286102295;;4.210000038146973;;46.5099983215332;;74.97000122070312;;31.950000762939453;An advisory panel to the U.S. Food and Drug Administration is due to meet later Tuesday to review the vaccine developed by Novavax Inc. as a potential fourth shot for American adults and will vote on whether the risks outweigh the benefits.;5.760000228881836;;7.21999979019165;;18.229999542236328;;3.3399999141693115;;32.119998931884766;;11.8100004196167;;19.885000228881836;CRN04894 Selected for Oral PresentationSAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting. Crinetics recent;3.640000104904175;;11.15999984741211;;3.690000057220459;;9.130000114440918;;19.469999313354492;;34.7599983215332;;21.510000228881836;;7.050000190734863;;18.280000686645508;;13.829999923706055;;1.7999999523162842;;14.359999656677246;
2022-06-09;173.7100067138672;Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.It’s been a good week for Novavax.  The Gaithersburg biotech is now a step away from potentially getting its first product to market, after the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee gave its nod to Novavax’s experimental Covid-19 vaccine at its meeting Tuesday.  The FDA, which typically listens to the advisory committee’s recommendations, must now decide whether to greenlight the protein-based shot for emergency use authorization for adults in the U.S. The Centers for Disease Control and Prevention would then have to endorse its use.In this article, we discuss 10 best monthly dividend stocks to buy in June. You can skip our detailed analysis of dividend-paying stocks and their total returns over the years, and go directly to read 5 Best Monthly Dividend Stocks to Buy in June. As major stock exchanges in the US took a spill in […]NEW BRUNSWICK, N.J., June 8, 2022 /3BL Media/ - Johnson & Johnson (NYSE: JNJ) today published its 2021 Health for Humanity Report, which shares progress against its purpose-driven Health for Humani...;51.779998779296875;"Wood's flagship Ark Innovation ETF has sunk 53% so far this year, as her technology companies have hit the skids.The White House is readying for distribution of kids' COVID-19 vaccines next week.Moderna (NASDAQ: MRNA) shares climbed more than 2% yesterday after the company took a big step toward handling one of the world's biggest coronavirus challenges: protecting populations against new variants.  The biotech company said its booster candidate targeting the original coronavirus and the omicron variant showed ""superior"" performance against omicron.  Let's take a closer look at where Moderna stands today -- and the company's prospects considering this new element.NEW YORK, June 09, 2022--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).NEW YORK, June 09, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical, at the Storebrand Conference: Invest in the Future on Thursday, June 16, 2022 at 11:40 a.m. CEST (5:40 a.m. EDT).The U.S. government is preparing to launch vaccines for children below five in conjunction with educational and outreach efforts, pending approval by federal regulators, the Wall Street Journal reports. The government looks to provide ten million initial doses as the virus spreads nationwide, leaving the parents anxious. The vaccinations could begin by June 21, subject to the regulatory approval for Moderna, Inc (NASDAQ: MRNA), Pfizer, Inc (NYSE: PFE), and partner BioNTech SE (NASDAQ: BNTX). EquHere's what to watch in the markets on Thursday, June 9, 2022.It’s been a good week for Novavax.  The Gaithersburg biotech is now a step away from potentially getting its first product to market, after the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee gave its nod to Novavax’s experimental Covid-19 vaccine at its meeting Tuesday.  The FDA, which typically listens to the advisory committee’s recommendations, must now decide whether to greenlight the protein-based shot for emergency use authorization for adults in the U.S. The Centers for Disease Control and Prevention would then have to endorse its use.Pre-orders of vaccines for children under age 5 have been slow, but Biden administration senior officials say they are not alarmed and expect the pace to pick up after federal approvals later this month.  The administration expects vaccinations of young children to begin in earnest as early as June 21, if the Food and Drug Administration and the Centers for Disease Control and Prevention approve the vaccines in separate meetings slated for next week, officials told reporters on Wednesday.  The vaccines will be distributed to pediatricians, children's hospitals, local pharmacies and local health clinics, officials said.In the latest trading session, Pfizer (PFE) closed at $53.47, marking a -0.91% move from the previous day.In this article, we discuss 10 best monthly dividend stocks to buy in June. You can skip our detailed analysis of dividend-paying stocks and their total returns over the years, and go directly to read 5 Best Monthly Dividend Stocks to Buy in June. As major stock exchanges in the US took a spill in […]An FDA panel voted nearly unanimously in favor of Novavax's Covid shot on Tuesday. After yo-yoing Wednesday, NVAX stock settled up.Moderna, Novavax, BioNTech, and Pfizer shares are all in the red so far in 2022. Updated vaccines may not have an effect on the share prices.An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?";303.25;The Dow Jones Industrial Average fell Thursday after unemployment data. Tesla stock raced higher on news that May sales in China rebounded.Dow Jones futures: Indexes held support Wednesday, but market rally leaders sold off. Tesla China sales rose in May, but still ramping up.Eli Lilly (LLY) closed at $313.49 in the latest trading session, marking a +0.45% move from the prior day.Early results from a late-stage study in a rare blood disorder showed that patients given a placebo at some clinical trial sites in Eastern Europe performed better than those on drug.;112.80999755859375;Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Toyota Motor Corporation (TM), and Salesforce, Inc. (CRM).Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.Dramatic levels of weight loss are being attained in clinical trials of drugs originally developed for diabetes.;145.42999267578125;Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?;86.37999725341797;;88.0;;62.70000076293945;The development comes as the use of antibody treatments—once a mainstay for patients at high risk of developing severe Covid-19—has been complicated by the rise of the Omicron family of variants.;75.9800033569336;Kellie Calderon, MD, executive medical director at Bristol Myers Squibb, has built her career in both clinical practice as well as in the pharmaceutical industry. Through her experiences, she has l...Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.Bristol Myers Squibb (BMY) closed at $76.18 in the latest trading session, marking a -0.54% move from the prior day.Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.;51.97999954223633;Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.;43.040000915527344;GlaxoSmithKline (GSK) closed the most recent trading day at $44.20, moving -0.11% from the previous trading session.;13.529999732971191;OSAKA, Japan & CAMBRIDGE, Mass., June 09, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years (54 months) after vaccination in the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. These;41.08000183105469;;11.619999885559082;;159.35000610351562;;12.59000015258789;;144.5399932861328;Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that it will be presenting 31 abstracts, including three late-breakers and three oral presentations, at the 64th annual scientific meeting of the American Headache Society (AHS) being held from June 9-12 in Denver, CO.;86.63999938964844;;13.229999542236328;;36.38999938964844;The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...;45.75;;15.649999618530273;* Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer * Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigensTÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicine* Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023 * Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U. and Europe * Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development OfficerTÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.;10.319999694824219;;28.020000457763672;;41.689998626708984;;105.66000366210938;;10.300000190734863;;24.270000457763672;;2.740000009536743;;4.099999904632568;;;;3.509999990463257;;3.869999885559082;;46.58000183105469;Amid brewing economic concerns, investors seeking upside opportunities in the equities sector should consider biotech stocks to buy for one simple reason: extraordinary and permanent relevance. No matter what happens to the global markets, whether continued volatility or a fresh rally, people will always look to medical advancements to maintain and improve their health. Therefore, biotechs are somewhat detached from traditional economic barometers. Another major catalyst for no-brainer biotech s;74.63999938964844;Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.;31.5;Bavarian Nordic is the only company with a vaccine approved by the Food and Drug Administration. Its plant is closed until August.Amid brewing economic concerns, investors seeking upside opportunities in the equities sector should consider biotech stocks to buy for one simple reason: extraordinary and permanent relevance. No matter what happens to the global markets, whether continued volatility or a fresh rally, people will always look to medical advancements to maintain and improve their health. Therefore, biotechs are somewhat detached from traditional economic barometers. Another major catalyst for no-brainer biotech sOnce a problem confined to just one continent, Monkeypox is spreading and threatens to become a global issue. Since the United Kingdom first reported a confirmed Monkeypox case on May 7, many more cases have been reported in countries where the virus hasn’t been originally known to be present. Nearly 800 cases have been detected so far, and investors are rightfully researching Monkeypox stocks to buy to position themselves for a potential upside during the second quarter of 2022. According to th;5.550000190734863;The consensus price target hints at a 361.8% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;7.0;;17.3799991607666;;3.2200000286102295;;30.84000015258789;;10.949999809265137;;19.309999465942383;;3.369999885559082;;11.109999656677246;;3.690000057220459;;8.850000381469727;;17.1299991607666;;34.61000061035156;Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;21.700000762939453;;7.119999885559082;;17.739999771118164;;13.100000381469727;;1.75;;14.529999732971191;
2022-06-10;172.5500030517578;The U.S. hasn't yet entered a recession -- which is officially defined as two consecutive quarters of negative GDP growth -- but runaway inflation, stagnant wages, food shortages, rising interest rates, and geopolitical turmoil could all break this fragile economy's back in the near future.  If that happens, growth stocks will fall further as value stocks become even more attractive.  Altria is the top tobacco company in America.Investing for passive income can be a rewarding strategy.  Dividends are a cash expense for businesses, so great dividend stocks come from profitable companies that steadily grow over time.  Here are five dividend stocks with proven track records and dominant businesses that are simple to understand, making them perfect for the beginning dividend investor.(Bloomberg) -- Here’s the key business news from London-listed companies this morning.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelTrump’s Air Force One Deal Pains the Pentagon, Not Just BoeingUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenRetailers Should Heed Target’s Cautionary TaleGen Z, Millennials and Gen X All Basically Agree on WFHBank of England: The central bank has concluded that emergency planning at the UK’s biggest banks means nWe discuss the market outlook and investing strategies for the rest of 2022.To be a Dividend Aristocrat, a company must increase its dividend for 25 consecutive years. Additionally, the company must also be a member of the S&P 500.;49.970001220703125;"(Bloomberg) -- Here’s the key business news from London-listed companies this morning.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelTrump’s Air Force One Deal Pains the Pentagon, Not Just BoeingUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenRetailers Should Heed Target’s Cautionary TaleGen Z, Millennials and Gen X All Basically Agree on WFHBank of England: The central bank has concluded that emergency planning at the UK’s biggest banks means nWhether you call the strategy buy-and-hold, long-term investing, or anything else, one thing is abundantly clear: Patience is required. Investors that buy stocks with the intent to hold them forever will experience volatility. But it’s also a time-tested truth that the markets always win over the long-term. The current market is certainly volatile and undergoing a correction as the Federal Reserve increases rates. That is presenting opportunities for investors seeking stocks under $50. 7 Top-RatNovavax's authorization timeline differs from other first-time applicants, and ongoing submission of manufacturing data has given the FDA reason to slow the process.Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.Pre-orders of vaccines for children under age five have been slow, but Biden administration senior officials say they are not alarmed and expect the pace to pick up after federal approvals later this month.  The administration expects vaccinations of young children to start as early as June 21 if the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention approve the vaccines next week, White House COVID-19 response coordinator Ashish Jha said on Thursday.  ""We think that vaccinations would really start in earnest on Tuesday, June 21, and importantly, the vaccination program is going to ramp up in the days and weeks that follow,"" he said.Vaccinations could begin later in June if shots from Moderna and Pfizer are authorized by the Food and Drug Administration.";297.010009765625;The Dow Jones Industrial Average dived Friday on a hot inflation report in the wake of Thursday's stock market sell-off. DocuSign plunged on earnings.A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.;111.48999786376953;With the S&P 500 (SNPINDEX: ^GSPC) down about 16.2% from its January peak and seemingly still headed lower, most people aren't thinking about buying stocks.  As tough as it is to do so in a bearish environment, however, this is the time to be scooping up long-term growth stocks.  No, Microsoft (NASDAQ: MSFT) isn't the centerpiece of the computer technology world it was back in the 1990s and early 2000s.Novo Nordisk, Toyota Motor, Salesforce, Abbott Laboratories, Raytheon Technologies, and Equinor are part of Zacks top Analyst Blog.A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.;143.1999969482422;AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These preliminary findings show spleen volume and symptomatic improvement in this cohort. These data are consistent with previously observed data from relapsed/refractory patients in Cohort 1a1 and will be shared in an oral presentation at the 2022 EAbbVie (NYSE: ABBV) today announced five-year follow-up results from the Phase 3 CLL14 trial, finding that over 60 percent of patients with previously untreated chronic lymphocytic leukemia (CLL) who had received one-year fixed-duration combination treatment of VENCLYXTO®/VENCLEXTA® (venetoclax) plus obinutuzumab (GAZYVA®) continued to show longer progression-free survival (PFS) and higher rates of undetectable minimal residual disease (MRD) after four years off treatment.1 The findings were pre;85.05999755859375;;87.18000030517578;Merck & Co., Inc. ( NYSE:MRK ) is about to trade ex-dividend in the next 3 days. Typically, the ex-dividend date is one...Merck (MRK) closed the most recent trading day at $88, moving -1.65% from the previous trading session.;61.790000915527344;;75.08999633789062;In this article, we discuss the 10 best stocks to buy according to billionaire Chris Rokos. If you want to skip our detailed analysis of Rokos’ history, investment philosophy, and hedge fund performance, go directly to 5 Best Stocks to Buy According to Billionaire Chris Rokos. Christopher Charles Rokos was born on September 21, 1970, […]Bristol Myers Squibb (BMY) closed the most recent trading day at $75.98, moving -0.26% from the previous trading session.;50.90999984741211;European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.;43.79999923706055;European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.GSK plc (NYSE: GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial, it anticipates regulatory submissions in the second half of 2022. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. An Independent Data Monitoring Committee reviewed the interim analysis, and the primary endpoint was excGlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults, after reporting data showing the shot is the first to work in the vulnerable age group for the major infectious disease.  Vaccine makers including GSK, Pfizer, Moderna and Johnson & Johnson, are racing to find a jab for RSV.  The disease is common but can be severe in older adults and infants, causing 360,000 hospitalisations and 24,000 deaths a year.;13.390000343322754;;40.47999954223633;;11.199999809265137;;149.16000366210938;;11.930000305175781;;144.1199951171875;;82.77999877929688;;12.970000267028809;;35.459999084472656;;44.5099983215332;;14.59000015258789;;9.899999618530273;;25.8700008392334;;41.11000061035156;WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinforce the robust efficacy and safety profile of EMPAVELI®/Aspaveli® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with EMPAVELI resulted in;101.47000122070312;;9.520000457763672;;21.860000610351562;;2.559999942779541;;3.9600000381469727;;;;3.319999933242798;;3.390000104904175;;45.61000061035156;;74.47000122070312;;29.90999984741211;;5.380000114440918;;6.670000076293945;LAUSANNE, Switzerland, June 10, 2022--ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma. An overall response rate (ORR) of 70.1% and a complete response (CR) rate of 33.3% was observed with a median duration of response of 13.7 months for all responders in r/r Hodgkin lymphoma patients who were refractory or had relapsed after a median of 6 prior treatments, inc;16.440000534057617;BILLERICA, Mass., June 09, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chief Executive Officer, Masoud Toloue, will join the Goldman Sachs 43rd Annual Global Healthcare Conference for a fireside chat on June 16, 2022 at 8:40 a.m., EST.;3.180000066757202;;29.06999969482422;Keros Therapeutics will be hosting a conference call and webcast today, June 10, 2022, at 8:00 a.m. Eastern time. LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented additio;10.119999885559082;Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programsSAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative therapies, NX-2127 and NX-5948, each currently in Phase 1 development, at;18.59000015258789;;3.2899999618530273;;10.449999809265137;;3.7799999713897705;;9.039999961853027;;15.069999694824219;The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...;33.150001525878906;;21.100000381469727;;6.619999885559082;;15.350000381469727;;12.289999961853027;;1.7799999713897705;;13.789999961853027;
2022-06-13;170.80999755859375;In this article, we discuss the 10 defensive stocks that are considered as favorites among hedge funds. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Favorite Defensive Stocks of Hedge Funds. While growth stocks are known to generate headlines and excitement, they aren’t without […]Since becoming CEO of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) in 1965, billionaire Warren Buffett has run a master class on how to make money.  The first Buffett stock to buy and hold forever is healthcare conglomerate Johnson & Johnson (NYSE: JNJ).;47.90999984741211;;291.2799987792969;In this article we are going to estimate the intrinsic value of Eli Lilly and Company ( NYSE:LLY ) by taking the...Futures plunge, yields jump and Bitcoin dives as markets mull stagflation risks and a supersized Fed rate hike this week.;107.58000183105469;"Bagsværd, Denmark, 13 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiatInvestigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1 Atlanta, Georgia (US), 12 June 2022 – Today, Novo Nordisk announced results of once-weekly Sogroya® (somapacitan) injection in helping children achieve growth targets of annualised height velocity (AHV).1 These phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented today at the Endocrin";139.4199981689453;Licenses Revolutionary Skin Care Compound TFC-1067VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-106;82.52999877929688;;85.0;RAHWAY, N.J., June 13, 2022--FDA Accepts Application for Merck’s KEYTRUDA as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection;60.0099983215332;;73.58000183105469;Every investor in Bristol-Myers Squibb Company ( NYSE:BMY ) should be aware of the most powerful shareholder groups...Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.In this article, we discuss the 10 defensive stocks that are considered as favorites among hedge funds. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Favorite Defensive Stocks of Hedge Funds. While growth stocks are known to generate headlines and excitement, they aren’t without […];49.91999816894531;"Sanofi says new data show its Covid-19 vaccine can compete against Pfizer's, and may protect well against variants including Omicron BA.1 and Omicron BA.2.Sanofi said Monday that preliminary data shows that its experimental next-generation COVID-19 booster provided a 40-fold increase in antibody protection against BA.1, a subvariant of omicron, in adults who had been previously vaccinated with the mRNA shots. Next-generation vaccines and boosters are based on newer variants of SARS-CoV-2, compared with the currently available vaccines, which were designed to protect against the original strain of the virus first detected in 2019. Sanofi's next-genSanofi SA (NASDAQ: SNY) said the next-gen COVID-19 vaccine candidate it has developed with GSK Plc (NASDAQ: GSK) in two trials showed a potential to protect against the virus's main variants of concern when used as a booster. In the Phase 3 VAT02 Cohort 2 study, the vaccine candidate showed a 15-fold increase against the parent virus and a 30-fold increase against Beta strain in adults previously primed with mRNA COVID-19 vaccines. In particular, against omicron, preliminary data show a 40-foldSanofi and GlaxoSmithKline’s next generation Covid-19 vaccine could be used as a booster, after new data suggested that it elicited a strong immune response against the Omicron variant.  The French healthcare company said the “next-generation” booster jab delivered a “strong immune response” against variants of Covid, including Omicron, after two trials.  The vaccine makers said their jab increased antibodies to tackle the BA.1 Omicron strain by 40-fold in participants who had received two messengerRNA shots, the technology used in popular vaccines from Moderna and BioNTech/Pfizer.French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.  While the two companies' first experimental COVID shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is molded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations.  Sanofi said this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants who had an initial course of mRNA vaccines, a type made by BioNTech-Pfizer and Moderna.Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron Next-generation booster vaccine candidate delivers immune boost in adults primed with mRNA vaccines; with a stronger immune response compared to Pfizer-BioNTech’s Comirnaty booster vaccineNext-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability p";42.5;GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the second half of 2022.Sanofi and GlaxoSmithKline’s next generation Covid-19 vaccine could be used as a booster, after new data suggested that it elicited a strong immune response against the Omicron variant.  The French healthcare company said the “next-generation” booster jab delivered a “strong immune response” against variants of Covid, including Omicron, after two trials.  The vaccine makers said their jab increased antibodies to tackle the BA.1 Omicron strain by 40-fold in participants who had received two messengerRNA shots, the technology used in popular vaccines from Moderna and BioNTech/Pfizer.;13.170000076293945;;38.459999084472656;;10.770000457763672;;140.67999267578125;;11.8100004196167;;143.80999755859375;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced new data from three late-breakers and three oral presentations supporting the safety and efficacy of Nurtec® ODT (rimegepant) and zavegepant nasal spray for the treatment of migraine. The oral presentations included a first of its kind study in migraine reporting on the safety and benefits of Nurtec ODT when used as a preventive treatment and as-needed for acute treatment of migraine. The data were presented at the 64th An;79.95999908447266;;12.199999809265137;;34.20000076293945;JERSEY CITY, N.J., June 13, 2022--Organon announces first biosimilars business deal with a global license agreement with Henlius.;43.0099983215332;;13.180000305175781;;9.510000228881836;;24.030000686645508;;39.36000061035156;;96.36000061035156;;8.899999618530273;;20.049999237060547;HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80% and 87% of medical oncologists believe that nirogacestat compares favorably to Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) and that they are willing to switch current patients to nirogacestat, respectively. The analysts for;2.3399999141693115;;3.740000009536743;;;;3.1700000762939453;;3.0399999618530273;;44.529998779296875;;74.27999877929688;;28.329999923706055;Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Emergent...;4.989999771118164;;6.300000190734863;LAUSANNE, Switzerland, June 13, 2022--ADC Therapeutics SA (NYSE: ADCT) announced today it has appointed industry veteran David Gilman to the new role of Chief Business & Strategy Officer reporting to Chief Executive Officer Ameet Mallik effective July 1st. In this role, Mr. Gilman will be responsible for all business development and portfolio strategy efforts globally and he will serve on the Company’s executive leadership team.;15.0600004196167;;3.0199999809265137;;27.56999969482422;LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical study of RKER-012 on cardiac and pulmonary pathology in an established rodent model of pulmonary arterial hypert;9.619999885559082;;17.170000076293945;;3.0299999713897705;;9.8100004196167;;3.809999942779541;;8.944999694824219;;13.1899995803833;;30.959999084472656;;20.010000228881836;;14.960000038146973;Day One Biopharmaceuticals (NASDAQ: DAWN) shares are surging on initial data from the first 22 evaluable patients in the Phase 2 FIREFLY-1 trial for tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children. Initial data demonstrated an overall response rate (ORR) of 64% and a clinical benefit rate (CBR) of 91%. The data included 14 partial responses and six patients with stable disease. All patients with stable disease (Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib Topline results from the full FIREFLY-1 trial population expected in Q1 2023 Day One plans to initiate a pivotal Phase 3 clinical trial of tovorafenib in front-line pediatric low-grade glioma (pLGG), with first patient dosed expected in Q3 2022 Company to host conference call and webcast tomorrow, June 13, at 8:00 a.m. Eastern Time SOUTH S;13.760000228881836;;12.289999961853027;;1.8200000524520874;;13.529999732971191;
2022-06-14;168.19000244140625;The World Trade Organization is meeting this week to consider adopting an agreement that would make it easier to produce COVID-19 vaccines and treatments by waiving patent enforcement during health emergencies.Johnson & Johnson (JNJ) closed the most recent trading day at $170.81, moving -1.01% from the previous trading session.Yahoo Finance's Ines Ferre joins the Live show to discuss stock market performance ahead of Tuesday's FOMC meeting.The Dow Jones plummeted as indexes fell hard. Tesla stock and Apple stock struggled. Bitcoin fell hard amid a crypto meltdown.;47.91999816894531;;290.7900085449219;Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.1 The recommended dose is OLUMIANT 2-mg/day, with an increase to 4-mg/day if treatment response is inadequate. For patients with nearly complete or complete scalp hair loss, with or without suEli Lilly (LLY) closed the most recent trading day at $291.28, moving -1.93% from the previous trading session.The U.S. Food and Drug Administration said Monday it approved Eli Lilly & Co.'s Olumiant oral tablets to treat adults with severe alopecia areata.;106.12999725341797;;137.6199951171875;Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shares), compared with the 4.56% decline for the Russell 3000 Health Care Index […]Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. (ABBV), and TotalEnergies SE (TTE).AbbVie Inc (NYSE: ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated an overall response rate (ORR) of 63% and a complete response (CR) rate of 39%. Related: AbbVie - Genmab Post EpIllinois-headquartered AbbVie (NYSE:ABBV) is famous among pharmaceutical businesses for its diversified portfolio of medical treatments and solutions. ABBV stock is an outstanding deal at the current share price as AbbVie continues to develop industry-leading formulations through clinical trials. Some folks might hesitate to buy pharmaceutical stocks because clinical trials involve risk. That’s undeniable, but AbbVie is among the best in the business and there are multiple reasons to choose this;80.5199966430664;;84.5;The FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA NSCLC, following complete surgical resection, on Jan 29, 2023.In this article, we discuss 10 favorite dividend stocks of hedge funds. You can skip our detailed analysis of dividend paying stocks and go directly to 5 Favorite Dividend Stocks of Hedge Funds. According to a study by FactSet, dividend stocks returned 9.7% annually on average while the non-dividend paying stocks returned only 4.18% in […];59.2599983215332;One of the things that makes AstraZeneca (NASDAQ: AZN) a top growth stock is all of the different drugs it has contributing to its top line.  It has multiple blockbusters that generate more than $1 billion in annual revenue for its operations.  What should get investors even more excited, however, is the prospect that it could have another incredibly promising drug to count on: Enhertu.Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shares), compared with the 4.56% decline for the Russell 3000 Health Care Index […];72.87000274658203;;49.119998931884766;Results from two new studies are the latest indication that tweaking vaccines can nudge antibody responses in the direction of new variants, possibly helping to shore up immunity as the virus mutates.Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary regimen.;41.2400016784668;Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary regimen.;13.239999771118164;;38.20000076293945;;10.319999694824219;;144.1300048828125;It is hard to get excited after looking at Repligen's (NASDAQ:RGEN) recent performance, when its stock has declined 17...;11.399999618530273;;143.7100067138672;;81.23999786376953;;11.680000305175781;"Exscientia plc (NASDAQ: EXAI) announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist. The drug candidate is ​​co-invented and developed through a collaboration between Exscientia and Evotec SE (NASDAQ: EVO). Topline data confirmed Exscientia’s target product profile design, including potency, high receptor selectivity, and expected low brain exposure with no CNS adverse events reported. The study showed that observed human PK for EXS-21* STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S PROPRIETARY PLATFORM CAPABILITIES IN THE FIELD OF PROTEIN HOMEOSTASISHAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (""Janssen""). Evotec's innovative TargetAlloMod platforms will be evaluated to discover first-in-class no";33.130001068115234;;44.0;;13.510000228881836;;9.670000076293945;;24.350000381469727;;38.869998931884766;;98.94999694824219;;9.0600004196167;;20.290000915527344;;2.390000104904175;;3.799999952316284;Marketing authorization application is EQRx’s first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that the United Kingdom (U.K.)’s Medicines and Hea;;;3.2699999809265137;;2.9800000190734863;The World Trade Organization is meeting this week to consider adopting an agreement that would make it easier to produce COVID-19 vaccines and treatments by waiving patent enforcement during health emergencies.;44.470001220703125;;74.4000015258789;;27.68000030517578;;4.860000133514404;;6.070000171661377;ADC Therapeutics SA (NYSE: ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301) in relapsed or refractory Hodgkin lymphoma. Cami demonstrated a 70.1% overall response rate (ORR), with a 33.3% complete response (CR) rate. From a safety perspective, eight of 117 patients developed Guillain-Barré syndrome (GBS)/polyradiculopathy. HC Wainwright says that after considering the highly advanced nature of these patients, the respon;15.670000076293945;;3.069999933242798;;27.34000015258789;;9.65999984741211;;16.780000686645508;;3.2300000190734863;;10.420000076293945;;3.9600000381469727;;9.0;;12.899999618530273;;28.969999313354492;;19.81999969482422;;15.829999923706055;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. All of the shares of common stock are being offered by Day One. In addition, Day One intends to grant the unDay One said Monday more than 90% of patients with brain cancer benefited from its cancer drug, and the biotech stock skyrocketed.;14.270000457763672;;12.289999961853027;;1.909999966621399;;13.670000076293945;
2022-06-15;169.99000549316406;In this article, we discuss the top 10 dividend stocks to buy according to Peter S. Stamos’ Stamos Capital. You can skip our detailed analysis of Stamos’ past life and his hedge fund history, and go directly to read Top 5 Dividend Stocks to Buy According to Peter S. Stamos’ Stamos Capital. Peter S. Stamos […]Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.Interest rate hikes can be problematic for many cash-strapped businesses.  Taking on additional debt becomes more costly, with interest expenses chipping away at the bottom line.  One way investors can protect themselves from this risky situation is by investing in businesses that are flush with cash and that can easily absorb rate hikes.Dividend payments are an important source of stock-based compensation. Individual retail investors count on dividend payments for income, often when they are retired and no longer earning a salary. Others reinvest their quarterly dividend payments, helping to compound and grow their stock holdings in the process. For these reasons, many investors carefully scrutinize the dividend payouts of the companies in which they invest. The average dividend yield among companies listed on the S&P 500 indexYahoo Finance’s Ines Ferré joins the Live show to discuss how stocks are performing in intraday trading.;48.5099983215332;;292.989990234375;Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shares), compared with the 4.56% decline for the Russell 3000 Health Care Index […]State and local officials gathered with Eli Lilly and Co. executives to break ground on the pharmaceutical giant's $1 billion Concord campus. Eli Lilly announced in January its intention to bring the investment and the creation of nearly 600 jobs to The Grounds at Concord, the former Philip Morris site.;106.33000183105469;Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shares), compared with the 4.56% decline for the Russell 3000 Health Care Index […];138.08999633789062;Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?AbbVie (ABBV) closed at $137.62 in the latest trading session, marking a -1.29% move from the prior day.;81.36000061035156;;84.62999725341797;In this article, we discuss the top 10 dividend stocks to buy according to Peter S. Stamos’ Stamos Capital. You can skip our detailed analysis of Stamos’ past life and his hedge fund history, and go directly to read Top 5 Dividend Stocks to Buy According to Peter S. Stamos’ Stamos Capital. Peter S. Stamos […]The Mectizan Donation Program is the longest-running, disease-specific drug donation program of its kindIf the adage of selling in May and going away is true, then the market is in for a troubling summer. There is growing concern of an earnings recession. This is reminding investors about the importance of finding stocks that reward shareholders with regular dividend payments. With that in mind, this article is looking at undervalued Dow Stocks that investors can look at buying right now. Yes, I said “right now.” The companies on this list have a history of paying — and growing — their dividends.;60.56999969482422;In this article, we discuss the 10 affordable blue chip stocks to buy now. If you want to skip our detailed analysis of blue chip stocks and the current market situation, go directly to 5 Affordable Blue Chip Stocks To Buy Now. The stock market is not easy picking right now even for the most experienced […]The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, joined the A.Catalyst network as a result of the Declaration of Collaboration recently signed with AstraZeneca. The partnership highlights DoH's commitment to enhancing digital healthcare in the emirate and improving patient experience and outcomes. In an effort to attract leading international healthcare start-ups to Abu Dhabi, DoH seeks to expand collaboration with AstraZeneca to cocreate an inno;73.0199966430664;;48.9900016784668;;41.95000076293945;;13.289999961853027;;38.529998779296875;;10.699999809265137;;148.00999450683594;;11.40999984741211;;144.97999572753906;;83.19000244140625;;12.239999771118164;Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.;33.59000015258789;;43.560001373291016;;13.449999809265137;;10.170000076293945;;24.600000381469727;CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed Suneet Varma to serve as a member of its board of directors. Mr. Varma succeeds Morris Birnbaum, M.D., Ph.D., who announced that he is retiring from his role as Senior Vice President and Chief Scientific Officer of Internal Medicine at Pfizer Inc., and will therefore be stepping;41.16999816894531;;102.95999908447266;;9.789999961853027;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner MorphoSys AG (FSE: MOR; NASDAQ: MOR), felzartamab (also known as TJ202/MOR202) and TJ210 (also known as MOR210), are advancing globally through new license agreements.";20.969999313354492;;2.5199999809265137;;4.389999866485596;;;;3.359999895095825;;3.2100000381469727;;44.61000061035156;;74.9000015258789;;28.399999618530273;;4.820000171661377;;6.050000190734863;;16.790000915527344;;3.359999895095825;;28.25;;10.029999732971191;;17.65999984741211;;3.309999942779541;We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...;9.75;;4.260000228881836;;8.859999656677246;;13.3100004196167;;31.239999771118164;Insiders who bought Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) stock lover the last 12 months are probably not as...;20.549999237060547;;15.25;"There's nothing like a good clinical trial readout to get the blood pumping for a biotechnology industry that has been under a lot of pressure.  A market reacting to positive clinical trial data for Day One's experimental brain cancer treatment, tovorafenib, pushed its stock price 126% higher on Monday, June 13.  Day One's lead candidate, tovorafenib, is an oral, brain-penetrant, highly selective pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its upsized underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share. All shares of common stock are being offered by Day One. The grossMonday was a miserable day for most stock investors, as the S&P 500 tumbled 3.9%, putting the stock market officially back in bear market territory. Monday was a miserable day for stock investors, that is to say... unless you owned shares in Day One Biopharmaceuticals (DAWN). As the rest of the stock market collapsed in shambles around it, shares of small cap cancer researcher Day One more than doubled on Monday, after announcing ""positive initial data"" from its Phase 2 Firefly-1 trial of TovoraMost patients with the most common form of childhood brain cancer saw their tumors shrink by half. Now the company, which hopes to ask regulators next year to approve the drug, is eyeing a big fundraise as a result.";14.149999618530273;;;;1.9299999475479126;;13.470000267028809;
2022-06-16;170.0800018310547;In this article, we discuss the 15 important value stocks that are losing value in 2022. If you want to read about some more stocks that are losing value in 2022, go directly to These 5 Important Stocks are Losing Value in 2022. Value stocks have provided investors with some much-needed relief from a devastating […]Yahoo Finance senior health care reporter Anjalee Khemlani details the latest FDA advisory panel votes on Pfizer and Moderna's two-dose COVID vaccine for children.;47.47999954223633;"Today (June 15), a US Food and Drug Administration (FDA) panel for the first time endorsed a covid-19 vaccine for children under five years old; emergency use authorization (EUA), which would make the vaccines available, is expected to follow as early as Friday (we will update this article if/when that happens).  The endorsement comes after the FDA panel reviewed the clinical trial data for vaccines made by Moderna and Pfizer-BioNTech.What happened Shares of the top COVID-19 vaccine makers were sinking on Thursday. Pfizer (NYSE: PFE) stock was down 2% at 11:06 a.m. ET. Shares of Pfizer's partner, BioNTech (NASDAQ: BNTX), were down 6.Pharma giant Pfizer (NYSE: PFE) has grabbed plenty of headlines in the past couple of years thanks to its coronavirus-related work.  Although Pfizer is firing on all cylinders right now, there are plenty of reasons to be even more optimistic about the healthcare giant's future.  Pfizer's revenue and earnings have soared in the past year and a half thanks to Comirnaty, its COVID-19 vaccine, and Paxlovid, its COVID-19 treatment.A panel of advisers to the Food and Drug Administration on Wednesday gave its endorsement to both the Moderna and Pfizer vaccines for children below the age of five, the last group to be added to the vaccine program.With the Core Consumer Price Index (CPI) rising by 8.6% over the past 12 months, inflation is the word of the year, and many portfolios aren't fully ready for it.  The first thing to look for when you're evaluating a stock's ability to hold value through a patch of inflation is whether its products are something that buyers will be able to do without.  For instance, CVS Health (NYSE: CVS) sells a huge number of consumer health items that people need no matter their cost, like contact lens fluid and antacids.Akero Therapeutics Inc (NASDAQ: AKRO) announced a $25 million equity investment by Pfizer Inc (NYSE: PFE) at $9.90 per share. The company also announced a term loan facility providing Akero with access to up to $100 million from Hercules Capital Inc (NYSE: HTGC), of which $10 million will be drawn at transaction close. Together with existing cash, proceeds will support Akero's development of efruxifermin, including two ongoing Phase 2b trials in nonalcoholic steatohepatitis (NASH), manufacture oThe FDA VRBPAC committee unanimously recommends the approval of both Pfizer and BioNTech and Moderna's vaccines for young children, saying the benefits of the vaccines outweigh the risks.Pfizer (PFE) and its partner BioNTech initiate rolling submission, seeking authorization of the variant-adapted version of their COVID-19 vaccine.Moderna (NASDAQ: MRNA) has been a leader in the coronavirus vaccine race from the start.  It was the first to begin clinical trials of a vaccine candidate.  The Food and Drug Administration has not yet authorized the Moderna vaccine to be administered to those under 18.After an FDA panel “unanimously” voted to recommend that the agency approved Novavax’s (NASDAQ:NVAX) coronavirus vaccine, the outlook of NVAX stock has significantly improved. Nonetheless, I believe that the shares remain risky, and I recommend that only speculative, risk-tolerant investors buy them at this point. An FDA Approval Is Probably Assured, But Other Risks Remain Multiple news outlets have emphasized that the FDA almost always follows the recommendations of its panels. What’s more, sinLooking for a mutual fund that's a safe haven from a scary stock market? Check out tiny $24.7 million Archer Dividend Growth Fund.$25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 Million If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024 SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financingA panel of advisers to the Food and Drug Administration on Wednesdaygave its endorsement to both the Moderna and Pfizer vaccines for children below the age of five, the last group to be added to the vaccine program. Advisers to the Centers for Disease Control and Prevention will now meet Friday and Saturday to finalize their recommendations, possibly clearing the path for vaccination to start next week. In other news, Dr. Anthony Fauci, President Biden's chief medical adviser and the man who ledTakeaways from the Fed’s latest policy statement, Biden urges oil refiners to make more gasoline, Musk may use Twitter town hall to confirm deal, and other news to start your day.Before investing in Pfizer, read here to understand their core business, company history, and relevant news developments.";288.07000732421875;;105.69000244140625;;139.14999389648438;Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;81.8499984741211;In this article, we will look at 10 undervalued stocks in Ken Fisher’s 2022 portfolio. If you want to skip reading about Ken Fisher’s investment strategies and his views on the current market situation, you can go to 5 Undervalued Stocks in Ken Fisher’s 2022 Portfolio. Ken Fisher has been a value investor ever since […]COVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband Commission for Sustainable Development Working Group on Virtual Health and Care – co-chaired by the World Health Organization and the Novartis Foundation – provides learnings from 23 countries The report calls on health decision makers to act to prevent digital divides from increasing health inequities: cou;84.88999938964844;In this article, we will look at 10 undervalued stocks in Ken Fisher’s 2022 portfolio. If you want to skip reading about Ken Fisher’s investment strategies and his views on the current market situation, you can go to 5 Undervalued Stocks in Ken Fisher’s 2022 Portfolio. Ken Fisher has been a value investor ever since […]Retirement stocks should have reliable cash flows, higher dividend yields and represent a relatively low-risk business. Given the backdrop of high inflation and geopolitical turmoil, investors are increasingly focused on searching for high-quality retirement stocks to buy. In today’s uncertain stock market, long-term portfolios should consist of businesses insulated from inflation and market downturns. Americans have a longer life expectancy than before and concurrently face the highest inflatioYahoo Finance senior health care reporter Anjalee Khemlani details the latest FDA advisory panel votes on Pfizer and Moderna's two-dose COVID vaccine for children.;60.86000061035156;Yahoo Finance senior health care reporter Anjalee Khemlani details the latest FDA advisory panel votes on Pfizer and Moderna's two-dose COVID vaccine for children.;72.62000274658203;The stock market still faces various geopolitical and economic issues, including supply chain problems and interest rate hikes in the U.S. and elsewhere that may impact corporations' bottom lines.  Let's look at two stocks that fit the bill: Bristol Myers Squibb (NYSE: BMY) and Jazz Pharmaceuticals (NASDAQ: JAZZ).  Bristol Myers Squibb is a prominent drugmaker that currently boasts a forward price-to-earnings (P/E) ratio of 9.6.In the latest trading session, Bristol Myers Squibb (BMY) closed at $73.02, marking a +0.21% move from the previous day.McKesson, Bristol Myers Squibb, Merck, Vertex Pharmaceuticals, and Organon are all sitting on year-to-date gains.NEW YORK, June 15, 2022--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 par value common stock of the company. The dividend is payable on August 1, 2022 to stockholders of record at the close of business on July 1, 2022.NEW YORK, June 15, 2022--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022. Dr. Bhatt will serve as a member of the Science & Technology Committee of the Board of Directors.;49.279998779296875;;41.63999938964844;GlaxoSmithKline (GSK) closed at $41.95 in the latest trading session, marking a +1.72% move from the prior day.The AMR Industry Alliance, a life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR), is adopting its standards limiting toxic emissions. The Alliance published its Antibiotic Manufacturing Standard: Minimizing the risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from manufacturing human antibiotics. The Standard guides manufacturers in the global antibiotic supply chain to ensure that their antibiotics a;13.329999923706055;;38.31999969482422;;10.279999732971191;;141.02000427246094;;11.3100004196167;;145.0;;78.5999984741211;Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...;11.880000114440918;;32.810001373291016;;42.959999084472656;;13.229999542236328;;10.180000305175781;;22.899999618530273;;42.869998931884766;;100.27999877929688;;10.25;;20.469999313354492;;2.3299999237060547;;4.599999904632568;;;;3.240000009536743;;2.950000047683716;;42.47999954223633;Futures tumbled, threatening to wipe out Wednesday's market rally in a day two reaction to the biggest Fed rate hike since 1994.;74.48999786376953;;27.420000076293945;;4.579999923706055;;5.960000038146973;;16.030000686645508;;3.009999990463257;;28.6299991607666;;9.729999542236328;;17.020000457763672;;3.109999895095825;NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences in June: BIO International Conference Format: Company Presentation – In Person Date and Time: Thursday, June 16th, 2:45 p.m. ET – 3:15 p.m. ET Conference Link: URL H.C. Wainwright 1st Annual Mental Health Conference Format: C;10.050000190734863;;4.139999866485596;;8.600000381469727;;12.260000228881836;;30.93000030517578;;19.5;;15.050000190734863;A Relative Strength Rating upgrade for Day One Biopharmacetical shows improving technical performance.;13.569999694824219;;11.461999893188477;Company announcement – No. 29 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, June 15, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging manager;1.940000057220459;;12.949999809265137;
2022-06-17;169.4600067138672;Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.Yahoo Finance Live’s Brian Sozzi reports that the FDA has authorized Moderna and Pfizer COVID vaccines for children under the age of 5.If you are a retiree looking to boost your retirement income but do not like to research individual stocks, don't be disheartened.  You can still earn a decent amount of extra income by investing in dividend exchange-traded funds (ETFs).  There are several dividend ETFs available in the market, which collect dividends from the stocks they own on behalf of investors and then distribute those dividends to investors periodically.Dr. Paul Offit, Children’s Hospital of Philadelphia Vaccine Education Center Director and Professor of Pediatrics, explains the importance of FDA recommending COVID vaccines for children from Pfizer and Moderna and the symptoms parents should expect in vaccinated kids.Is Johnson & Johnson stock a buy after the company suspended its Covid vaccines guidance? Is JNJ stock a buy right now?;46.529998779296875;A modified coronavirus vaccine that targets the Omicron variant can be administered as a booster dose to broaden immunity, a technical advisory group set up the World Health Organization said on Friday.  Such a variant-adapted vaccine may benefit those who have already received the primary series of shots, the agency's panel on COVID-19 Vaccine Composition said, citing available data.  The vaccines could be considered for use globally by the agency once they get emergency use authorization or an approval by a stringent national regulatory authority.The FDA has granted emergency use authorization (EUA) to Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 Vaccine as a three 3-µg dose series for children six months through 4 years of age. Based on safety, tolerability, and immunogenicity data, the 3-µg dose was carefully selected as the preferred dose for children under five. The EUA is based on data from a Phase 2/3 trial that included 4,526 children six months through 4 years of age. In the trial, children received the thirdThe European Medicines Agency (EMA) started a rolling review on Friday of a variant-adapted COVID-19 vaccine from Moderna, as coronavirus cases linked to Omicron sub-variants see an uptick in the region.  U.S.-based Moderna's so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID, the original strain first identified in China, and the Omicron variant.  Last week, Moderna said its bivalent vaccine produced a better immune response against Omicron than the original shot.Yahoo Finance Live’s Brian Sozzi reports that the FDA has authorized Moderna and Pfizer COVID vaccines for children under the age of 5.Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine program into jeopardy.FDA advisory panel member Dr. Paul Offit says kids vaccines are a game-changer, for the roughly 20% aged 5 and under who are likely to get vaccinated.The Food and Drug Administration announced Friday that it authorized the COVID-19 vaccines developed by BioNTech SE /Pfizer Inc. and Moderna Inc. for children as young as six months old. The regulator said Moderna's two-dose vaccine is now authorized for children between the ages of 6 months old and 17 years old. It was previously authorized and is now fully approved for adults. The BioNTech/Pfizer shot, which had already been authorized for older children and teens, is now authorized in childreThe Food and Drug Administration decision came shortly before a widely anticipated meeting of advisers to the Centers for Disease Control and Prevention.NEW YORK & MAINZ, Germany, June 17, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for children 6 months through 4 years of age (also referred to as 6 months to less than 5 years of age). The 3-µg dose was carefully selected as the preferred dose for children under 5 years of age based on safety, tolerability, andThe U.S. Food and Drug Administration on Friday authorized two COVID-19 vaccines for children under 5, opening the door to vaccinating millions of the country's youngest children once the Centers for Disease Control and Prevention agrees.  The FDA authorized Pfizer-BioNTech's COVID-19 vaccine for children aged 6 months to 4 years and Moderna Inc's shot for those 6 months to 17 years.  Pfizer's is already authorized for those over the age of 5.Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.H Lundbeck AS (HLUYY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.Oxford Industries and Flagstar Bancorp have been highlighted as Zacks Bull and Bear of the Day.BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in over 1,200 women with moderate to severe pain associated with endometriosis were published in The Lancet. As previously reported, both studies achieved their co-primCVS Health Corp and Walmart Inc and Rite Aid Corp plan to provide COVID-19 vaccinations to young children in the United States if they are authorized by authorities, the companies said on Thursday.  The U.S. Food and Drug Administration is likely to authorize Moderna Inc's COVID-19 vaccine for children aged six months to under six years old and the Pfizer Inc /BioNTech vaccine for children aged six months to under five years old as soon as this week, with the Biden administration planning a rollout of the shots as early as next week.  The Pfizer/BioNTech shot is already authorized for children over the age of five.Dr. Paul Offit, Children’s Hospital of Philadelphia Vaccine Education Center Director and Professor of Pediatrics, explains the importance of FDA recommending COVID vaccines for children from Pfizer and Moderna and the symptoms parents should expect in vaccinated kids.White House press secretary Karine Jean-Pierre on Thursday said the Biden administration is encouraging officials in Florida to pre-order COVID-19 vaccines for the youngest children, after a reporter asked about Florida being theMichelle Keeffe, a former Pfizer executive, takes over at Syneos Health following a year where the company, with 28,000 workers worldwide, saw double-digit revenue growth. But she'll be tested as economic uncertainty starts to impact the pharmaceutical industry.As Bavarian Nordic A/S (OTC: BVNRY) was in the headlines recently due to the smallpox vaccine amid rising cases of monkeypox, the company is also getting ready to evaluate its COVID-19 booster, ABNCoV2, in a pivotal study. ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark using their proprietary capsid virus-like particle technology. The upcoming Phase 3 trial will include Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 shot in the cThe Swiss parliament failed to finance the government's plan to buy COVID-19 vaccines in 2023, forcing the cabinet to try to renegotiate contracts with Moderna and Pfizer/Biontech  for millions of doses.  With the two houses of parliament split over the funding request, budget rules required the adoption of the cheaper version of draft legislation, the SDA news agency said in a report posted on parliament's website.  Parliament approved spending 560 million Swiss francs ($579 million) instead of the requested 780 million.;290.8999938964844;Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.A Durham architecture firm has designed a swank new health and wellness facility for Walmart at the company’s headquarters in Arkansas.;105.58000183105469;;138.27999877929688;Allergan Aesthetics, an AbbVie company, and a global leader in medical aesthetics treatments, today launched 'The Future of Aesthetics' global trends report via a high-profile virtual event for media and industry. Commissioned by Allergan Aesthetics and independently developed by specialist trend forecasting agency Wunderman Thompson Intelligence, the report aims to help the industry understand the developments driving today's aesthetics market, and to highlight the key trends that may shape itAbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD).4 In two induction and one maintenance clinical trials, SKYRIZI demonstrated significant improvements in endoscopic response (defined as a decrease of greater than 50% from the baseline Simple Endoscopic Score in CD [SES-CD]When Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett speaks, Wall Street and investors wisely pay close attention.  While riding Buffett's coattails has been a moneymaking strategy for decades, it's equally important to take note of the stocks that the world's most successful investor and his investing team are selling or avoiding.  Thus far in 2022, Warren Buffett has overseen the aggressive selling of the following five stocks.;81.05999755859375;Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patientsSubmission builds on Sandoz’ well established biosimilar immunology portfolio in Europe Basel, June 17, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high;84.62000274658203;The Dow Jones Industrial Average won't be trading on Monday when the new Juneteenth federal holiday is observed.Merck & Co Inc (NYSE: MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a perennially speculated takeover target. Also Read: Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence. Talks haShares of Seagen Inc. shot up 14.7% toward a seven-month high in morning trading Friday, after The Wall Street Journal reported that Merck & Co. Inc. is looking into buying the cancer-focused biotechnology company. Meanwhile, drug-maker Merck's stock eased 0.2%. Although terms of a potential buyout were not mentioned in the report, Seagen's market capitalization was about $31.2 billion at current stock prices. Citing people familiar with the matter,Dr. Paul Offit, Children’s Hospital of Philadelphia Vaccine Education Center Director and Professor of Pediatrics, explains the importance of FDA recommending COVID vaccines for children from Pfizer and Moderna and the symptoms parents should expect in vaccinated kids.;61.09000015258789;"AstraZeneca plc (NASDAQ: AZN) is rumored to be eyeing take over of Mereo BioPharma Group plc (NASDAQ: MREO), according to a report in The Times. The Times' report says that ""Mereo would accept $5, equating to $500 million including American depositary receipts or ADRs. Evercore and Citigroup are said to be involved as advisers."" Mereo's lead drug, a TIGIT called etigilimab, is putting them in a race that disappointed after Roche Holdings AG (OTC: RHHBY) suffered failures. The company reported atMARKET PULSE AstraZeneca (azn) (uk:azn) is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma (mreo) The Times reported without attribution. AstraZeneca already is a partner of Mereo, ...Astrazeneca (AZN) closed the most recent trading day at $60.86, moving +0.48% from the previous trading session.Dr. Paul Offit, Children’s Hospital of Philadelphia Vaccine Education Center Director and Professor of Pediatrics, explains the importance of FDA recommending COVID vaccines for children from Pfizer and Moderna and the symptoms parents should expect in vaccinated kids.";73.7699966430664;When Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett speaks, Wall Street and investors wisely pay close attention.  While riding Buffett's coattails has been a moneymaking strategy for decades, it's equally important to take note of the stocks that the world's most successful investor and his investing team are selling or avoiding.  Thus far in 2022, Warren Buffett has overseen the aggressive selling of the following five stocks.In the latest trading session, Bristol Myers Squibb (BMY) closed at $72.62, marking a -0.55% move from the previous day.;49.20000076293945;;41.27000045776367;In the latest trading session, GlaxoSmithKline (GSK) closed at $41.64, marking a -0.74% move from the previous day.;13.119999885559082;Japan's yen is at its weakest in decades and inflicting high costs of imported food and fuel on households and businesses, but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda.  As the Bank of Japan reiterated its commitment to loose monetary policy on Friday, affirming its position as a standalone dove in a global environment of rising inflation, the yen edged back towards the 135.60-per-dollar lows it struck this week.  Nearly half of companies that responded to a Tokyo Shoko Research poll this week said the weaker yen would have a negative impact on their businesses.;39.349998474121094;;10.460000038146973;;142.75;;11.569999694824219;;145.13999938964844;;83.91999816894531;;12.199999809265137;;33.16999816894531;;46.22999954223633;;14.270000457763672;The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Insiders often own a large...;11.100000381469727;;23.920000076293945;;44.13999938964844;;104.97000122070312;;11.029999732971191;;21.84000015258789;;2.4200000762939453;;5.179999828338623;;;;3.4700000286102295;;3.1700000762939453;;43.97999954223633;;74.45999908447266;;28.549999237060547;;4.929999828338623;;6.349999904632568;;16.049999237060547;;3.190000057220459;;27.479999542236328;;11.119999885559082;;18.290000915527344;;3.25;Stephen Bardin will join as CFO Designate on June 27, 2022After a transition period, atai’s current CFO Greg Weaver will be moving into a part time strategic advisory role NEW YORK and BERLIN, June 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (Nasdaq: ATAI) (“atai” or the “Company”), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today that Stephen Bardin, currently Senior Vice President of Finance and Operations at Bri;10.550000190734863;;4.929999828338623;;8.489999771118164;;13.470000267028809;;30.950000762939453;;21.149999618530273;;15.789999961853027;;15.239999771118164;;12.329999923706055;;2.0799999237060547;;13.270000457763672;
2022-06-21;173.00999450683594;;48.11000061035156;;297.3399963378906;In this article, we discuss the 10 unknown biotech stocks that can explode in 2022. If you want to read about some more biotech stocks that can explode in 2022, go directly to 5 Unknown Biotech Stocks That Can Explode in 2022. As coronavirus cases recede across the world and countries open up their borders […]Futures rose as Bitcoin rebounded. It's a bear market, so stay safe. Tesla rival BYD is among a few stocks setting up.In the latest trading session, Eli Lilly (LLY) closed at $290.90, marking a +0.98% move from the previous day.;107.88999938964844;;143.47000122070312;In this article, we discuss the 10 unknown biotech stocks that can explode in 2022. If you want to read about some more biotech stocks that can explode in 2022, go directly to 5 Unknown Biotech Stocks That Can Explode in 2022. As coronavirus cases recede across the world and countries open up their borders […]AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for atogepant (QULIPTATM) to the U.S. Food and Drug Administration (FDA) to support the preventive treatment of chronic migraine in adults. If approved, atogepant (QULIPTA) would be the first gepant (oral calcitonin gene-related peptide [CGRP] receptor antagonist) approved for the broad indication of the preventive treatment of migraine, including episodic and chronic. The sNDA submission includeAbbVie (ABBV) closed at $138.28 in the latest trading session, marking a -0.63% move from the prior day.;81.48999786376953;A U.S. appeals court on Tuesday ruled that a patent related to Swiss drugmaker Novartis AG's blockbuster multiple sclerosis drug Gilenya was invalid, potentially paving the way for introduction of a cheaper generic version of the medicine.  The U.S. Court of Appeals for the Federal Circuit, which hears patent appeals, reversed https://tmsnrt.rs/3ObPtyI its own earlier ruling in the case.  The finding by a divided panel revives Chinese drugmaker HEC Pharm Co's bid to make a generic version of the drug.Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).;88.02999877929688;Merck & Co Inc (NYSE: MRK) presented results from the Phase 1/2 study, evaluating V116 in pneumococcal vaccine-naïve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). Data were shared at the International Symposium on Pneumococci and Pneumococcal Diseases. V116 targets serotypes that account for 85% of cases of invasive pneumococcal disease among individuals aged 65 and over in the U.S., including eight serotypes not currently covered by licensed vaccines. V116 met theIn this article, we discuss the 10 blue-chip stocks to buy according to billionaire Richard Chilton. If you want to skip our detailed analysis of Chilton’s investment philosophy, hedge fund returns, and history, go directly to 5 Blue Chip Stocks to Buy According to Billionaire Richard Chilton. Richard Chilton is an American billionaire investor who […]RAHWAY, N.J., June 21, 2022--Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for AdultsShares of Seagen (SGEN) rise after rumors of a buyout by Merck hit the market. However, a deal is not imminent at the moment.;62.83000183105469;"U.S.-listed shares of AstraZeneca were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its primary endpoints in a Phase 3 clinical trial. AstraZeneca is developing eplontersen with Ionis Pharmaceuticals Inc. ; shares in Ionis were up 5.1% on Tuesday. The rare disease can cause nerve damage and motor disability and affects about 40,000 people worldwide, the companies said. They also said they plan to seeIonis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).AstraZeneca plc (NASDAQ: AZN) and partner Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced a positive interim analysis of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). ATTRv-PN is a rare inherited condition characterized by an abnormal build-up of a protein called amyloid in the body's organs and tissues. In Phase 3 NEURO-TTRansform study, eplontersen met the main goals. Read Next: Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary GoWILMINGTON, Del., June 21, 2022--Results from the PROpel Phase III trial showed that LYNPARZA® (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, in combination with abiraterone significantly improved radiographic progression-free survival (rPFS) versus abiraterone alone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR)WILMINGTON, Del., June 21, 2022--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a statistically significant and clinically meaningful change from baseline for its co-primary endpoint of percent change in serum transthyretin (TTR) concentration,An interim analysis of AstraZeneca and partner Ionis Pharmaceuticals' eplontersen showed the experimental drug met the main goals in a late-stage trial in patients with a rare, fatal disease, the Anglo-Swedish drugmaker said on Tuesday.  Based on the results, the companies plan to file an application to market the therapy in the United States later this year in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).  The disease - which affects an estimated 40,000 patients globally - leads to peripheral nerve damage with motor disability within five years of diagnosis and, without treatment, is generally fatal within a decade, according to AstraZeneca.";76.47000122070312;The EMA validates Bristol Myers' (BMY) type II variation application for the label expansion of Breyanzi for treating relapsed/refractory large B-cell lymphoma after first-line therapy.;49.4900016784668;;41.77000045776367;;13.359999656677246;;40.11000061035156;;10.600000381469727;;145.85000610351562;;11.470000267028809;;145.0;;85.5;;12.079999923706055;;32.880001068115234;;47.58000183105469;;14.180000305175781;;11.729999542236328;;25.209999084472656;;43.86000061035156;;108.29000091552734;;11.880000114440918;;23.280000686645508;;2.390000104904175;;5.119999885559082;;;;3.6700000762939453;;3.2899999618530273;;45.709999084472656;;74.58000183105469;;29.149999618530273;GAITHERSBURG, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate were published in The Lancet Infectious Diseases. The article, Safety and immunogenicity of PXVX0317, an aluminum hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised;5.03000020980835;;6.78000020980835;;16.59000015258789;;3.059999942779541;;27.75;;11.630000114440918;;18.639999389648438;;3.359999895095825;;10.630000114440918;;4.869999885559082;;8.600000381469727;;14.5600004196167;;32.52000045776367;;21.40999984741211;;16.290000915527344;SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the closing on June 17, 2022 of its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,500,0;17.450000762939453;;12.329999923706055;;2.069999933242798;;13.6899995803833;
2022-06-22;175.74000549316406;Yahoo Finance's Anjalee Khemlani discusses the rollout of COVID vaccines for kids 6 months to 5 years, plus a new test that could indicate when a person needs a booster shot.;49.06999969482422;;306.69000244140625;"U.S. Senate Majority Leader Chuck Schumer on Wednesday said he will put bipartisan legislation on lowering insulin costs to a vote on the Senate floor ""very soon.""  ""The cost of insulin has skyrocketed in recent years and the Insulin Act will make this life-saving medication more affordable by capping the cost of insulin at $35 a month,"" Schumer said in a statement.  ""I will put this bipartisan legislation on the Senate floor very soon.""John Kornitzer explains why the Buffalo Flexible Income Fund has held up so well during the bear market.A market rally attempt gained steam as Tesla jumped but investors should be wary. Fed chief Jerome Powell is on tap again.The Federal Trade Commission said it would consider taking action against pharmacy-benefit managers and drugmakers, saying their deals raise drug prices.";107.33999633789062;;147.55999755859375;With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.AbbVie (NYSE: ABBV) announced today that Health Canada has approved a change in the marketing authorization for MAVIRET® (glecaprevir/pibrentasvir) to include its use for the treatment in paediatric patients 3 to 12 years old, weighing at least 12kg to less than 45kg.1 MAVIRET is now approved as an 8-week, pan-genotypic (GT1-6) treatment for treatment-naïve, chronic HCV patients, without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older.1**Style Box ETF report for FLQL;81.51000213623047;"Precision BioSciences Inc (NASDAQ: DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE: NVS) Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a ""safe harbor"" location in the genome as a potential one-time transformative treatment option for sickle cell disease and beta-thalassemia. Under the terms of the Agreement, Precision will deFinancing from new and existing investors will support continued development of a novel treatment for food allergy Jim Momtazee and George Montgomery to join Alladapt’s Board of Directors MENLO PARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced today the closing of a $119 million financing round led by Enavate Sciences, a portfoliAd hoc announcement pursuant to Art. 53 LRBasel, June 21, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for Gilenya. Novartis plans to file a petition seeking further review of this decision.In August 2020, the U.S. District Court for the District of Delaware issued a favorable decision in the Gilenya patent litigation and a permanent injun";89.16000366210938;RAHWAY, N.J., June 22, 2022--US FDA Approves VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and ChildrenRAHWAY, N.J., June 21, 2022--Results From Ph. 3 PROpel Trial of LYNPARZA® Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM EvidenceRAHWAY, N.J., June 21, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Chirfi Guindo will lead Human Health Marketing as chief marketing officer for Merck Human Health, and will join Merck’s Executive Team, effective July 1, 2022. Guindo will report directly to Robert M. Davis, chief executive officer and president, Merck. As previously announced, Jannie Oosthuizen leads Merck Human Health U.S., and Joe Romanelli will lead Merck Human Health InterSVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN). The analysts refrain from commenting on the probability of the deal happening. The analysis suggests that the short-term impact on EPS from the potential acquisition will likely be meaningfully dilutive. Related: Merck Shows Takeover Interest In Seagen: WSJ. According to SVB, the deal decreases forecasted GAAP EPS by -12%, -7%, and -2% in;63.54999923706055;Both drugmaker AstraZeneca (NASDAQ: AZN) and tech giant Apple (NASDAQ: AAPL) are in good shape to weather the current conditions and generate strong results for investors from here on out.  And of that total, it spent $85.8 billion on share repurchases plus $14.7 billion on dividend payments.With the Federal Reserve aggressively increasing interest rates by 75 basis points, equity markets have plunged. Amid the fear and uncertainties, I see a golden opportunity for investors to accumulate quality stocks. While I would selectively look at growth stocks, I would be overweight on certain blue-chip stocks in current market conditions. Coming back to the market correction and an opportunity to accumulate, the following point is worth noting: If we look at the equity market chart for decaGovernment seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech;76.55000305175781;Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.Bristol Myers Squibb encourages its workforce to pause, reflect and participate in a culture of inclusion in observance of Juneteenth;50.22999954223633;;41.970001220703125;;13.649999618530273;The agreement to take 600,000 square feet on Third Street is part of an effort to consolidate more of its operations in Kendall, the drug giant said Wednesday.CAMBRIDGE, Mass., June 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded technology;39.84000015258789;;10.630000114440918;;148.7100067138672;;11.539999961853027;;144.55999755859375;With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.;85.7300033569336;;12.460000038146973;"In a presentation titled ""Reaching the goal with higher speed and confidence"", CEO Dr Werner Lanthaler and CFO Enno Spillner presented Evotec SE's current strategic, scientific and technological developments, highlights of the 2021 business year and the commitment to sustainability/ESG. Evotec is committed to increasing the probabilities of success in research and development.";33.59000015258789;;47.77000045776367;;14.3100004196167;;11.6899995803833;;26.209999084472656;;43.97999954223633;WALTHAM, Mass. and NANTES, France, June 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Affilogic today announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins® targeting the transferrin receptor (TfR), which enables drugs to be transported across the blood brain barrier and into the central nervous system. TfR-specific Nanofitins, also known as brain;111.9800033569336;;11.489999771118164;;23.610000610351562;;2.490000009536743;;4.900000095367432;;;;3.8399999141693115;;3.5799999237060547;;47.81999969482422;;75.30000305175781;;30.170000076293945;;5.349999904632568;;6.559999942779541;;17.25;;3.0899999141693115;;26.440000534057617;;12.460000038146973;The new dean, one of the world’s top structural biologists, will be tasked with expanding the university’s global research by using molecular, cellular and developmental biology to advance drug, pharmacology and genetic engineering.;18.829999923706055;;3.5;;10.119999885559082;;5.050000190734863;;8.739999771118164;;15.430000305175781;SAN DIEGO, June 22, 2022--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4);32.36000061035156;;22.0;A Food and Drug Administration (FDA) approval for a highly anticipated treatment  is the kind of news that can make a company's stock skyrocket, even during a bear market -- like the one we're in now.  One company hoping for such success is Arcutis Biotherapeutics (NASDAQ: ARQT).  It has been developing a treatment for Seborrheic dermatitis -- a skin disorder that causes scaly skin, or dandruff-like flakes, on the face and scalp.;16.010000228881836;;17.6200008392334;;13.744999885559082;;2.119999885559082;;13.779999732971191;
2022-06-23;179.66000366210938;Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.Consider this column a twist on all those “30 Under 30” lists that business news outlets are so fond of publishing. In short, this is “7 Over 30″ but in this case, we’re looking at stocks to buy for those born before 1992. When looking for buy-and-hold stocks that can fund a comfortable retirement, you want to focus on a few characteristics. You want companies that dominate their industries. Companies with strong profit margins. Ones which pay rising dividends and have capital allocation policieEvery bear market is different. They have a variety of contributing causes. They don't last the same amount of time. But there's at least one thing that every bear market has in common: They all offer great opportunities for long-term investors.Indexes were on track to close higher Wednesday but slipped back into the negative near the end of the session.The Dow Jones rose despite a recession warning from Fed Chair Jerome Powell. Bitcoin tumbled again. Apple stock rose after a bullish call.When the market drops sharply, it creates an opportunity to buy quality stocks at a bargain.;50.09000015258789;;312.7200012207031;The market rally rebounded from losses but gains faded. Five stocks from a hot sector are near buy points.Precision BioSciences is developing gene-editing tools with several potential advantages over Crispr.A gene editing firm in the Triangle has landed a deal worth up to $1.4 billion with the global pharmaceutical company.;108.43000030517578;Camp Huronda, home of Diabetes Canada's camp for children and youth living with type 1 diabetes and one of nine camps established under the D-Camps banner, is opening its doors to youth, families, and staff for the first time in two years. Diabetes Canada's Camps (D-Camps) strive to foster lifelong connections and provide exceptional programming for kids living with type 1 diabetes in a medically supervised environment.;149.4499969482422;As prices go down, yields go up, and that dynamic has made both Target (NYSE: TGT) and AbbVie (NYSE: ABBV) excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks.  For quite some time, Target was the retail stock that could do no wrong.  The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble.;81.86000061035156;GSK and Novartis reinforced commitments on Thursday to tackle neglected tropical diseases, as world leaders and health experts gather in Rwanda to discuss ways to better combat illnesses affecting more than a billion people, mostly in impoverished communities.  GSK pledged to spend 1 billion pounds ($1.23 billion) over the next decade on developing medicines and vaccines to tackle neglected tropical diseases (NTDs), as well as infectious diseases such as malaria, tuberculosis and HIV, which disproportionately affect lower-income countries.  The London-based company, which pioneered the first malaria vaccine, has carved out, and will invest in, a specific global health unit that will not generate a profit for GSK.GSK and Novartis on Thursday reinforced  commitments to address neglected tropical diseases, as world leaders and health experts gather in Rwanda to discuss ways to better combat illnesses affecting more than a billion people, mostly in impoverished communities.  GSK pledged to spend 1 billion pounds ($1.23 billion) over the next decade on developing medicines and vaccines to tackle neglected tropical diseases (NTDs), as well as infectious diseases such as malaria, tuberculosis and HIV, which disproportionately affect lower-income countries.  The London-based company, which pioneered the first malaria vaccine, has carved out and will invest in a specific global health unit that will not generate a profit for GSK.Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD 100 million to advance R&D for Chagas disease, leishmaniasis, dengue and cryptosporidiosis, and USD 150 million for next-generation antimalarials and a new formulation for babies under 5kg with malariaAround the world, 1.7 billion people suffer from NTDs1, and there are 241 million cases of malaria2 BaseTafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with solid tumors that have a BRAF V600E mutation1,2 Approval supported by results from Phase II ROAR and NCI-MATCH studies demonstrating overall response rates up to 80% in patients with BRAF V600E solid tumors1,2 BRAF mutations drive tumor growth across more than 20 tumor types, including thyroid, brainPrecision BioSciences is developing gene-editing tools with several potential advantages over Crispr.A gene editing firm in the Triangle has landed a deal worth up to $1.4 billion with the global pharmaceutical company.;92.0;RAHWAY, N.J., June 22, 2022--CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ as an Option for Pneumococcal Vaccination in Infants and Children;64.44999694824219;"WILMINGTON, Del., June 23, 2022--Detailed results from the positive FoCus Phase III trial in Wilson disease showed that ALXN1840, an investigational once-daily, oral medicine, met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of care (SoC) arm (Least Square Mean Difference [LSM Diff] 2.18 µmol/L; p< 0.0001), including in patients who had been treated previously for an average of 10 years.1In the latest trading session, Astrazeneca (AZN) closed at $63.55, marking a +1.15% move from the previous day.";77.69000244140625;High inflation, slowing economic growth, future interest rate hikes, and geopolitical turmoil are among the most prominent concerns.  Pharma stock Bristol-Myers Squibb (NYSE: BMY) has rallied 19% this year.  This is because Bristol-Myers' forward price-to-earnings (P/E) ratio of 9.8 is significantly lower than the pharmaceutical industry average of 13.5.The market rally rebounded from losses but gains faded. Five stocks from a hot sector are near buy points.In the latest trading session, Bristol Myers Squibb (BMY) closed at $76.55, marking a +0.1% move from the previous day.Bristol Myers Squibb is the IBD Stock Of The Day as BMY stock bounds off its 50-day line, presenting investors with an early entry.;50.41999816894531;;42.75;WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. “As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team” said Jonathan Violin, Ph.D., ViridiaGlaxoSmithKline (GSK) closed at $41.97 in the latest trading session, marking a +0.48% move from the prior day.;13.729999542236328;;41.08000183105469;;10.729999542236328;;160.3300018310547;;11.899999618530273;;144.1999969482422;;91.47000122070312;;12.430000305175781;;34.91999816894531;;51.099998474121094;;14.930000305175781;"TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (""mRNA""), today announced the voting results of the Company's annual general meeting.";12.40999984741211;;28.6299991607666;;47.0;Apellis (APLS) expands its current research and development deal with privately held company, Affilogic, to develop targeted complement therapies for delivery into the brain.;115.0199966430664;;11.989999771118164;"I-Mab (""I-Mab"" or the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies in five different categories by leading global financial publication Institutional Investor, based on its 2022 All-Asia Executive Team survey. The awards recognize I-Mab's continued strong leadership, corporate governance, ESG strategy, and investor relations capabi";25.600000381469727;;2.630000114440918;;5.010000228881836;;;;4.159999847412109;;3.940000057220459;;51.29999923706055;Biotech stock United Therapeutics joins peers Vertex and Harmony Biosciences on the Breakout Stocks Index as it reenters a buy zone.;75.1500015258789;Bristol Myers Squibb is the IBD Stock Of The Day as BMY stock bounds off its 50-day line, presenting investors with an early entry.;32.34000015258789;;5.760000228881836;;6.880000114440918;;19.510000228881836;;3.2799999713897705;;26.770000457763672;;13.149999618530273;;19.399999618530273;;3.6500000953674316;;10.369999885559082;;4.889999866485596;The mean of analysts' price targets for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) points to a 127.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.;8.890000343322754;;16.020000457763672;;33.29999923706055;;22.139999389648438;;17.450000762939453;;18.790000915527344;;13.744999885559082;;2.3399999141693115;;14.609999656677246;
2022-06-24;182.2899932861328;Being able to adapt to ever-changing environments is a critical characteristic of consistently successful companies.It seems that aggressive, contractionary monetary policies have already paved way for another correction for equities. With inflation, aggressive rate hikes and fear of a recession, I would focus on large-cap stocks to buy. It’s worth noting that large-cap stocks generally have a low beta. As such, a big move in a short time period does not come often. However, with several headwinds, revised earnings and margin guidance have resulted in some knee-jerk reaction. Even for large-cap stocks. A goodCronobacter is the same bacteria that sickened at least four other infants after they had consumed Abbott Laboratories’ baby formula.The Dow Jones moved higher as yields fell. Tesla stock skidded after CEO Elon Musk voiced a warning. A Warren Buffett stock rose.Yahoo Finance's Rachelle Akuffo looks at Moderna's stock following a CDC panel's endorsement of its latest vaccine.Last week, Addex Therapeutics Ltd (NASDAQ: ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment. Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant constituted the basis for its original valuation assessment. Management indicated that the company now plans to focus o;51.59000015258789;;325.6199951171875;Wall Street is likely poised to scale back its forecasts for profits, with ugly consequences for stocks, so investors will want to identify companies that are immune.Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.;112.12000274658203;Environmental, social, and governance (ESG) investing is often used interchangeably with sustainable and socially responsible investing. To help investors choose ESG shares, MSCI (NYSE:MSCI), a leading supplier of investment decision support tools, provides the MSCI ESG Rating. These lettering system assigns the coveted AAA rating to the best ESG stocks and funds. The classification shows how a company manages financially relevant ESG investing risks and opportunities. Rating metrics include cli;152.33999633789062;The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).AbbVie today shared findings from the newly launched Emotional Impact Report, a survey of more than 300 chronic lymphocytic leukemia (CLL) patients, caregivers and healthcare providers (HCPs), which uncovered insights about the emotional journey associated with a CLL diagnosis.The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.;84.83000183105469;"The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower dMuch of the funding Congress earmarks for the NCI each year ultimately goes into very early-stage research.Novartis AG (NYSE: NVS) is pledging $250 million into R&D for new treatments of neglected tropical diseases (NTD) and malaria, with an aim to eliminate these diseases. ""Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done,"" CEO Vas Narasimhan said. Novartis is allocating $100 million toward four NTDs. In collaboration with Wellcome, the Novartis Institute for Tropical Diseases (NITD) is working to discover novel, curative anti-parasitic tThe FDA granted accelerated approval to Novartis AG's (NYSE: NVS) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer. Individuals as young as six years will be eligible to take the drug, making it the first BRAF/MEK inhibitor approved in pediatrics, NovaNovartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.";93.12999725341797;Merck executive Scott M. Wright shared his story of coming out in midlife — the response was overwhelmingMerck & Co Inc (NYSE: MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that the deal could be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to buy Seagen, which would bolster the pharma giant's cancer-drug portfolio, but no agreement was imminent. Related: SVB Leerink's Pro-forma Analysis Of Speculated Merck/SeagenRAHWAY, N.J., June 24, 2022--European Commission Approves KEYTRUDA as Adjuvant Treatment for Adult & Adolescent Patients With Stage IIB or IIC Melanoma After Complete ResectionThe talks have picked up pace and the two companies are scheduled to meet this week. The proposed takeover would be one of the largest of the year and would beef up Merck’s cancer-drug portfolio.Yahoo Finance's Rachelle Akuffo looks at Moderna's stock following a CDC panel's endorsement of its latest vaccine.These are six dividend income stocks with better yields than the S&P 500. The S&P 500 has a dividend yield of approximately 1.60% from a practical standpoint. The reason this is so is that the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) trades for $374.64 as of June 23, and its training 12-month (TTM) dividend payment is $6.01. That gives it a dividend yield of 1.60%. The Wall Street Journal reports that the actual index yield is 1.76%. But you cannot make that unless you buy an index fund like SPY or;66.9000015258789;AstraZeneca Plc (NASDAQ: AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess copper is compromised. The data showed that ALXN1840 met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of care (SoC) arm, including in patients who had been treated previously for an average of 10 years. In the trial, people taking AL;78.95999908447266;In the latest trading session, Bristol Myers Squibb (BMY) closed at $77.69, marking a +1.49% move from the previous day.;53.41999816894531;"Sanofi and GSK's joint Covid-19 vaccine has finally produced data that could challenge the dominance of the Pfizer and Moderna vaccines.The companies reported promising trial results for their Covid-19 vaccine that showed the shot—developed to target the Beta strain of the virus—was particularly effective against the Omicron variant.Sanofi and GlaxoSmithKline said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data to regulators. The recombinant protein booster protects against the original strain of the virus as well as the beta variant, a strain of the virus that is no longer in circulation but that shares mutations with omicron that allow both variants to ""escape"" antibodies. When this happens, people who are vaccinated or have been previoSanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. ""Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,"" Sanofi said in a statement. The bivalent vaccine targets the beta variant and the original strain of the virus. Related: Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential ALate-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.  The so-called bivalent vaccine targets the Beta variant - first identified in South Africa - as well as the original Wuhan strain of the virus.  In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.Sanofi and GlaxoSmithKline have reported promising results from trials of their Covid-19 vaccine, which has proved to be particularly effective against the Omicron strain of coronavirus.  The vaccine targets the original and the Beta strains of coronavirus but was also tested against the more recent Omicron variant.  When used as a first dose, it demonstrated a 64.7 per cent efficacy rate against symptomatic infection overall in adults, and was 72 per cent effective against infections caused by Omicron.Availability of the Q2 2022 Memorandum for modelling purposes Paris, France – June 24, 2022 - Sanofi announced today that its Q2 2022 Memorandum for modelling purposes is available on the ""Investors"" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q2-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various nonSanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19 Against Omicron, sequencing analysis performed to date shows 72% efficacy in all adults and 93.2% in seropositivesFavorable safety and tolerability profile First ever reported efficacy data in an Om";43.689998626708984;"Sanofi and GSK's joint Covid-19 vaccine has finally produced data that could challenge the dominance of the Pfizer and Moderna vaccines.The companies reported promising trial results for their Covid-19 vaccine that showed the shot—developed to target the Beta strain of the virus—was particularly effective against the Omicron variant.Sanofi and GlaxoSmithKline said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data to regulators. The recombinant protein booster protects against the original strain of the virus as well as the beta variant, a strain of the virus that is no longer in circulation but that shares mutations with omicron that allow both variants to ""escape"" antibodies. When this happens, people who are vaccinated or have been previoSanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. ""Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,"" Sanofi said in a statement. The bivalent vaccine targets the beta variant and the original strain of the virus. Related: Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential ASanofi and GlaxoSmithKline have reported promising results from trials of their Covid-19 vaccine, which has proved to be particularly effective against the Omicron strain of coronavirus.  The vaccine targets the original and the Beta strains of coronavirus but was also tested against the more recent Omicron variant.  When used as a first dose, it demonstrated a 64.7 per cent efficacy rate against symptomatic infection overall in adults, and was 72 per cent effective against infections caused by Omicron.";13.84000015258789;;43.20000076293945;;10.960000038146973;;165.8800048828125;;11.989999771118164;;143.7899932861328;;91.08999633789062;;13.029999732971191;;35.86000061035156;;52.86000061035156;;14.619999885559082;;13.010000228881836;;28.149999618530273;;46.2599983215332;;116.93000030517578;;12.350000381469727;;25.649999618530273;;2.640000104904175;;4.909999847412109;;;;4.03000020980835;;4.159999847412109;;51.66999816894531;The major stock market indexes are mixed and are trading near or at the lows of the day, with the Nasdaq composite and S&P 500 down from the last hour.  The Nasdaq composite is up 0.3% while the S&P 500 is down 0.3%.  Harmony Biosciences is up 4.8% and now extended from the 47.21 buy point of a cup-with-handle base.;75.16999816894531;HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer Center today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology. The initial focu;32.7599983215332;"Emergent BioSolutions Inc. said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aimed at people aged 18 through 65 years who have been exposed to anthrax for use along with recommended antibacterial drugs. A decision is expected by April of 2023. ""As we progress toward licensure of AV7909, which is designed to follow a two-dose immunization schedule and to elicit a faster immune response, we rGAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted). AV7909 is the company’s new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conju";5.929999828338623;;7.889999866485596;;18.790000915527344;;3.200000047683716;;28.559999465942383;;12.670000076293945;;19.610000610351562;;3.7899999618530273;;11.0;;4.599999904632568;;8.600000381469727;;16.139999389648438;;31.079999923706055;;20.610000610351562;;17.780000686645508;Downturns can bring a lot of pain, but they can also bring on plenty of opportunities, as lower stock prices start making costs of entry more attractive. Before taking advantage of these opportunities, however, investors need to find a recognizable signal that will set them apart. One popular signal to follow is the insider buying, the trades made by high-ranking company officers whose positions give them the ‘inside’ track on their company’s likely prospects – and therefore, of the stock’s pros;19.25;;13.954999923706055;;2.3399999141693115;;14.84000015258789;
2022-06-27;182.1199951171875;"Pfizer Inc. and partner BioNTech SE said the update to their COVID-19 booster shot showed a ""high immune response"" against the omicron variant, in time for an FDA meeting and as the daily average of COVID-19-related hospitalizations rose to a 3-month high.In this article, we discuss Cliff Asness’ short position on AMC and his top 10 stock picks. If you want to read about some more stocks in the Asness portfolio, go directly to Cliff Asness’ Short Position on AMC and His Top 5 Picks. 2022 is not the year of meme stocks, the darlings of […]The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.The Dow Jones Industrial Average turned lower Monday as the stock market rally continues. Top stocks to buy and watch include AutoZone.In this article, we discuss 10 dividend stocks with over 10% yield. You can skip our detailed analysis of dividend stocks’ past performance and latest trading trends, and go directly to read 5 Dividend Stocks with Over 10% Yield. Dividend stocks are in the limelight these days as risk of a recession grows and investors […]In this article, we discuss the 10 defensive stocks in billionaire Ray Dalio’s latest portfolio. If you want to skip our analysis of Dalio’s views on the macro-economic environment, go directly to 5 Defensive Stocks in Billionaire Ray Dalio’s Latest Portfolio. Ray Dalio, the founder of Bridgewater Associates, shared his sentiments on the economic environment […]These reliable businesses have delivered steadily growing profits to shareholders for decades, and they could keep it going indefinitely.";51.880001068115234;;327.2699890136719;In this article, we discuss the 10 biotech stocks that investors are watching. If you want to read about some more biotech stocks, go directly to Investors are Watching These 5 Biotech Stocks. The stock market plunge in the past few weeks because of soaring inflation and a hawkish central bank has also resulted in […]The Dow Jones Industrial Average turned lower Monday as the stock market rally continues. Top stocks to buy and watch include AutoZone.;112.88999938964844;"The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.In this article, we discuss the 10 biotech stocks that investors are watching. If you want to read about some more biotech stocks, go directly to Investors are Watching These 5 Biotech Stocks. The stock market plunge in the past few weeks because of soaring inflation and a hawkish central bank has also resulted in […]European Commission approves Merck's (MRK) Keytruda as an adjuvant treatment for adults and adolescent patients with stage IIB or IIC melanoma and who have undergone complete resection.Bagsværd, Denmark, 27 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiat";153.13999938964844;The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.In this article, we discuss the 10 biotech stocks that investors are watching. If you want to read about some more biotech stocks, go directly to Investors are Watching These 5 Biotech Stocks. The stock market plunge in the past few weeks because of soaring inflation and a hawkish central bank has also resulted in […]AbbVie ABBV is a research-based biopharmaceutical company known for its blockbuster drug Humira.  In this daily bar chart of ABBV, below, we can see that prices rallied back above the 50-day moving average line after touching/testing the rising 200-day line earlier this month.  The On-Balance-Volume (OBV) line weakened in April and May and bottomed in June suggesting a shift back to aggressive buying from aggressive selling.AbbVie kicks off its seventh Week of Possibilities today with approximately 15,000 employees volunteering in more than 50 countries to serve local communities around the world. From June 27 to July 1, AbbVie employees will work with trusted community partners to complete hands-on projects, including renovating schools, playgrounds and community centers, to benefit local communities impacting tens of thousands of people.AbbVie recently applied for FDA approval of its advanced Parkinson's disease drug candidate. This could be huge considering it's set to lose market exclusivity of Humira.AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAI;85.27999877929688;The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.In this article, we discuss the 10 biotech stocks that investors are watching. If you want to read about some more biotech stocks, go directly to Investors are Watching These 5 Biotech Stocks. The stock market plunge in the past few weeks because of soaring inflation and a hawkish central bank has also resulted in […];94.41000366210938;European Commission approves Merck's (MRK) Keytruda as an adjuvant treatment for adults and adolescent patients with stage IIB or IIC melanoma and who have undergone complete resection.RAHWAY, N.J., June 27, 2022--LYNPARZA® Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer;66.51000213623047;UnitedHealth, Chevron, AstraZeneca, SAP and Bayer ktiengesellschaftt are part of Zacks top Analyst Blog.In this article, we discuss the 10 biotech stocks that investors are watching. If you want to read about some more biotech stocks, go directly to Investors are Watching These 5 Biotech Stocks. The stock market plunge in the past few weeks because of soaring inflation and a hawkish central bank has also resulted in […]Yahoo Finance’s Jared Blikre breaks down how markets opened on Monday.The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.Shares in the Anglo-Swedish drugs giant fell 0.4% in afternoon trade in London.The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Enhertu (trastuzumab deruxtecan) as monotherapy for unresectable or metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2-based regimens. Enhertu is being jointly developed and commercialized by AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY). Also Read: AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease ProgressioAstraZeneca said on Monday two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio.  Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer.  The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca.;79.9800033569336;Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bristol-Myers...Of the top 10 stocks with the biggest market caps that have soared 20% or more year to date, seven are energy stocks.  It's much easier to find energy stocks that are in positive territory this year than to find those that aren't.  The second-biggest energy company, Chevron (NYSE: CVX), has also delivered impressive gains.;52.599998474121094;In this article, we discuss the 10 biotech stocks that investors are watching. If you want to read about some more biotech stocks, go directly to Investors are Watching These 5 Biotech Stocks. The stock market plunge in the past few weeks because of soaring inflation and a hawkish central bank has also resulted in […]The early case for the mRNA-based Covid-19 vaccines was that the adaptability of the technology meant they could be updated to match the virus as it evolved.;43.70000076293945;GSK plc (NYSE: GSK) announced promising interim results from the B-Clear phase 2b trial of bepirovirsen in people with chronic hepatitis B (CHB). The data showed that bepirovirsen reduced hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA after 24 weeks of treatment. In the group of 227 patients on standard therapy, 24 weeks of treatment with bepirovirsen resulted in 28% of patients with sharp reductions in two key biomarkers of CHB. Meanwhile, in the cohort of 230 patienThe early case for the mRNA-based Covid-19 vaccines was that the adaptability of the technology meant they could be updated to match the virus as it evolved.;14.0600004196167;OSAKA, Japan & PASADENA, Calif., June 27, 2022--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.;42.83000183105469;The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020;11.069999694824219;;164.8699951171875;;12.859999656677246;;144.00999450683594;Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;95.0999984741211;;13.050000190734863;;35.43000030517578;;52.540000915527344;;14.09000015258789;;13.220000267028809;"HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED managemen";29.049999237060547;;46.38999938964844;;117.76000213623047;;11.569999694824219;;26.690000534057617;;2.700000047683716;;4.800000190734863;;;;4.199999809265137;;3.9100000858306885;;52.119998931884766;;75.2699966430664;;32.650001525878906;The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.;5.610000133514404;;8.020000457763672;;18.15999984741211;;3.4000000953674316;;27.3700008392334;;12.279999732971191;;18.59000015258789;;3.6600000858306885;;10.949999809265137;;4.519999980926514;;8.680000305175781;;16.170000076293945;;32.91999816894531;;21.729999542236328;;17.389999389648438;;18.940000534057617;;13.75;;2.4800000190734863;;14.770000457763672;
2022-06-28;176.94000244140625;Investors might be skeptical to put their money in the stock market now given the current market scenario.  Excellent growth stocks are trading at a bargain now.  Investors new to dividend stocks can consider these three that belong to an exclusive group of Dividend Kings.In this article, we discuss 10 cheap dividend stocks with over 6% yield. You can skip our discussion on dividend stock investing, and go directly to read 5 Cheap Dividend Stocks with Over 6% Yield. According to research conducted by Fidelity, dividend stocks performed well during the inflationary periods in the past. In the 1940s […]Johnson & Johnson, Advanced Micro Devices, Union Pacific, Anheuser-Busch, and ServiceNow are part of Zacks top Analyst Blog.The Dow Jones Industrial Average rose 200 points Tuesday, looking to rebound from Monday's losses. Nike stock tumbled on weak guidance.Investors from all walks of life idolize Warren Buffett for his stock-picking prowess.  Buffett started investing in stocks when he was only 11, but he didn't become a billionaire until age 56, and there's been no looking back since.  Buffett's net worth right now is around $97 billion.Dow Jones futures were higher after Monday's stock market fall. Tesla sales are due out amid the new stock market rally.Sector ETF report for VHTOklahoma has reached a $250 million settlement with AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp to resolve allegations the drug distributors contributed to the opioid epidemic in the state, Oklahoma Attorney General John O'Connor said on Monday.  O'Connor said Oklahoma recovered more money from the distributors than the state would have received if it had joined a nationwide $26 billion settlement that was announced last year.Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).;50.65999984741211;;317.6199951171875;The Dow Jones Industrial Average rose 200 points Tuesday, looking to rebound from Monday's losses. Nike stock tumbled on weak guidance.Dow Jones futures were higher after Monday's stock market fall. Tesla sales are due out amid the new stock market rally.Today, we’ll introduce seven defensive stocks to buy for a bear market. As broader indices try to stabilize, investors are looking for robust shares that could hold up well in current volatility. InvestorPlace readers are keeping a close eye on the S&P 500 index, which has declined roughly 18% in 2022. Earlier in June, markets plunged after the U.S. Bureau of Labor Statistics (BLS) announced an inflation rate of 8.6% over the past 12 months. It was above the 40-year high of 8.5% recorded in MarcIn the latest trading session, Eli Lilly (LLY) closed at $327.27, marking a +0.51% move from the previous day.The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common stock.;108.30000305175781;Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.;152.49000549316406;In the latest trading session, AbbVie (ABBV) closed at $153.14, marking a +0.53% move from the previous day.Headquartered in Illinois, AbbVie (NYSE:ABBV) is a well-respected pharmaceutical businesses with a broad range of medical treatments and solutions. If you’re going to pick a pharmaceutical-market stock for a buy-and-hold position, you’d be hard-pressed to do much better than ABBV stock. With a market capitalization exceeding $273 billion, AbbVie is a true giant among drugmakers. Plus, the company has an extraordinarily broad drug portfolio as AbbVie addresses a wide range of conditions. Yet, inf;84.16999816894531;"ZURICH (Reuters) -Novartis said on Tuesday a previously announced restructuring programme could lead to 8,000 jobs being cut, or about 7.4% of its global workforce, including up to 1,400 in Switzerland.  The job cuts, previously projected by Chief Executive Vas Narasimhan to be in the ""single digit thousands"", are part of a restructuring programme the Swiss pharmaceutical group announced in April, targeting savings of at least $1 billion by 2024.  Novartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating its pharmaceuticals and oncology business units and would lead to eliminating roles across the organisation.Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).";91.88999938964844;Every investor in Merck & Co., Inc. ( NYSE:MRK ) should be aware of the most powerful shareholder groups. Insiders...Yahoo Finance markets reporter Jared Blikre examines today's market losses heading into the close, as well as the sector actions, Merck's historic movements in the pharmaceutical sector, Chinese stocks, and ARK ETF components.;65.93000030517578;The EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to AstraZeneca's (AZN) cancer drugs, Enhertu and Lynparza, for treating certain patients with breast cancer.The Dow Jones fell. The Donald Trump SPAC took a dive amid legal woes. Apple stock treaded water after an analyst call.GSK announced positive results in a late-stage study on a new Covid-19 vaccine targeted to combat the omicron variant.;78.69999694824219;Today, Bristol Myers Squibb Canada (BMS) announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for OPDIVO®, as a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.i OPDIVO® is the first immuno-oncology treatment to bring benefit in the adjuvant setting of UC and represents a potential new standard of care for patients at high risk of disease recurrence.iiThe Dow Jones Industrial Average rose 200 points Tuesday, looking to rebound from Monday's losses. Nike stock tumbled on weak guidance.According to a Reuters report, U.S. District Judge Jesse Furman in Manhattan refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co (NYSE: BMY) of delaying its Breyanzi cancer drug to avoid payments to former Celgene shareholders. The judge rejected Bristol Myers' claim that it was never properly notified about its alleged default on its merger obligations by the trustee representing the former Celgene shareholders. While two drugs were approved by the deadlines, the trusteePharmaceutical giant Bristol-Myers Squibb  has broken out to a new high for the move up.  The On-Balance-Volume (OBV) line has made a new high for the move up to confirm and support the recent price increase.  The MACD oscillator has turned lower but has crossed higher for what should soon be a new buy signal.Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.;52.13999938964844;Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease Approved for the treatment of the full spectrum of both late-onset Pompe disease and infantile-onset Pompe diseaseFirst new treatment option approved for the Pompe community in Europe in more than 15 years Paris, June 28, 2022 – The European Commission has granted marketing authorization for Nexviadyme® (avalglucosidase alfa), an enzyme replacement therapy (ERXenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD Paris, June 28, 2022. The European Commission (EC) has approved Xenpozyme® (olipudase alfa) as the first and only enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in pediatric and adult patients with ASMD type A/B or ASMD type B. The approval is based on positive data from the ASCEND and ASCEND-Peds clinical triInformation concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,527,121,390 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n;43.349998474121094;Ideaya Biosciences Inc (NASDAQ: IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta. Ideaya is collaborating with GSK plc (NYSE: GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase candidate in combination with niraparib, GSK's PARP inhibitor, in tumors with BRCA or other homologous recombination mutations or homologous recombination deficiency. The companiesGilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.GSK announced positive results in a late-stage study on a new Covid-19 vaccine targeted to combat the omicron variant.Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.;13.859999656677246;;42.560001373291016;;10.899999618530273;;165.42999267578125;;12.300000190734863;A multinational company that's already one of the largest employers in the Greater Triangle is taking steps toward a huge expansion that's years in the making.;144.4199981689453;;93.1500015258789;;12.710000038146973;;34.790000915527344;;52.61000061035156;;13.9399995803833;;13.300000190734863;;26.969999313354492;;44.380001068115234;;120.6500015258789;;11.359999656677246;;25.31999969482422;;2.569999933242798;;4.510000228881836;;;;4.019999980926514;;3.7300000190734863;;50.61000061035156;;75.05999755859375;;31.25;;5.409999847412109;;7.739999771118164;;17.1299991607666;;3.319999933242798;;26.030000686645508;;11.600000381469727;;17.739999771118164;;3.619999885559082;;10.0600004196167;;4.610000133514404;;8.630000114440918;;15.069999694824219;;30.540000915527344;;22.030000686645508;;17.1200008392334;;18.549999237060547;;13.75;;2.390000104904175;;13.729999542236328;
2022-06-29;176.99000549316406;"Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's vote to update its COVID-19 boosters.Runaway inflation may have you feeling down at the moment, but there's something you can do now that will provide you with an income stream that outpaces inflation.  The COVID-19 vaccine Johnson & Johnson (NYSE: JNJ) licensed from Oxford University didn't perform as well as vaccines from Pfizer or Moderna, but this isn't a reason to avoid the stock.  This conglomerate also generates reliable cash flows that it shares with investors in the form of a dividend that offers a 2.5% yield at the moment.A new COVID-19 booster strategy should focus on developing new shots that better protect against omicron and its subvariants.In this article, we will look at 10 best stocks under $50 according to billionaire Ray Dalio. If you want to skip reading about Ray Dalio’s investment philosophy and his hedge fund’s returns, you can go directly to 5 Best Stocks Under $50 According to Billionaire Ray Dalio. Ray Dalio is an American billionaire investor […]MeiraGTx Holdings plc (NASDAQ: MGTX) announced topline data from the Phase 1/2 study MGT009 of botaretigene sparoparvovec, gene therapy for X-linked retinitis pigmentosa (XLRP). Treatment with botaretigene sparoparvovec was found to be generally safe and well-tolerated. Significant improvements were demonstrated across retinal, visual functions, and functional vision in participants treated with botaretigene sparoparvovec compared to the randomized untreated control arm of the study at six monthJohnson & Johnson does not plan to update its COVID-19 vaccine, though other vaccine makers like Moderna Inc. , BioNTech SE and Pfizer Inc. , and Novavax Inc. are already working on new versions that aim to better protection against the currently circulating strains of the virus. ""The company will focus on supplying its COVID-19 vaccine in parts of the world where the pandemic remains an emergency and there is acute need,"" a J&J spokesperson told MarketWatch in an email on Tuesday. ""To date, two";50.939998626708984;"Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's vote to update its COVID-19 boosters.In this article, we will be taking a look at the top 10 stock picks of Mika Toikka’s AlphaCrest Capital. To skip our detailed analysis, you can go directly to see Top 5 Stock Picks of Mika Toikka’s AlphaCrest Capital. Established in 2013 by Mika Toikka, AlphaCrest Capital is headquartered in New York, with a […]Germany's BioNTech, Pfizer's partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.  In presentation slides posted on BioNTech's website for its investor day, the German biotech firm said its aim was to ""provide durable variant protection"".  As part of a push to further boost its infectious disease business, BioNTech said it was independently working on precision antibiotics that kill superbugs that have grown resistant to currently available anti-infectives.The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.Germany's BioNTech, Pfizer's partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.  The two partners, makers of the Western world's most widely used COVID-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages.The Food and Drug Administration’s vaccines advisers voted in favor of updating Covid-19 booster shots to protect specifically against the Omicron variant.European Commission president Ursula von der Leyen is no longer in possession of text messages that she exchanged with Pfizer chief Albert Bourla to seal a COVID-19 vaccine deal, the Commission said in a letter published on Wednesday.  In an interview in April 2021, von der Leyen revealed she had exchanged texts with Bourla for a month when they were negotiating a massive vaccine contract.  But in response to a public access request by a journalist because of the importance of the deal, the Commission did not share the texts, triggering accusations of maladministration by the EU's ombudsman, Emily O'Reilly.The pandemic-era bull market drove the values of many companies to lofty heights. Here's how those star performers are faring during a much more turbulent 2022.The FDA will need to make a final decision soon on the composition of the shots if they are to be ready for a vaccination drive planned to start in October.A new COVID-19 booster strategy should focus on developing new shots that better protect against omicron and its subvariants.Pfizer Inc and Moderna Inc said on Tuesday they will be ready with COVID-19 vaccines designed to combat the BA.1 Omicron variant that was dominant last winter earlier than those designed to target currently dominant subvariants.  Moderna said it would be ready with a ""couple of hundred million"" of bivalent vaccines designed to combat BA.1 by September, but it would be late October or early November if the vaccine maker needed to design a vaccine to combat the currently dominant BA.4 and BA.5 subvariants.  Pfizer said it has a significant amount of BA.1 vaccine produced already and is preparing to produce a large amount of vaccine against BA.4 and BA.5 subvariants.The pharmaceutical giant said about 1,400 roles in its Switzerland headquarters could be eliminated due to a restructuring plan.";323.0;The last doses of the drug, one of a few found to reduce the risk of severe disease even after Omicron, will be used up in late August unless Congress approves more pandemic funding, administration officials say.French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.  Sanofi said the new price, down from the prior out-of-pocket cost of $99, will be effective from July 1.  U.S. lawmakers have pulled up healthcare companies over rising costs of insulin and the U.S. House of Representatives in March passed a bill capping monthly out-of-pocket insulin costs for those with health insurance at $35.Eli Lilly and Co said on Wednesday it will supply additional doses of its COVID-19 antibody drug to the U.S. government in order to meet demand through late August.  As per the modified supply agreement with the government, Lilly will provide an additional 150,000 doses of bebtelovimab for about $275 million.  The drug has also shown effectiveness against the Omicron variant.Eli Lilly & Co. said Wednesday that it will supply the U.S. government with an additional 150,000 doses of its COVID treatment bebtelovimab for about $275 million. Delivery of the doses will begin immediately and be completed no later than Aug. 5. The company expects the government supply of bebtelovimab, including the new purchase, to meet demand through late August. Lilly expects the additional dose order to add about $275 million to 2022 revenue, and to boost earnings per share by 8 cents. ThEli Lilly and Company (NYSE: LLY) today announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately $275 million. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected to meet present demand through late August 2022. Bebtelovimab continues to maintain neutralization activity against the most common, and fastest growing, Omicron variants (BA.2.12.1 and BA.4/BA.5) in the United StateThe pharmaceutical giant said about 1,400 roles in its Switzerland headquarters could be eliminated due to a restructuring plan.;110.08000183105469;"Align Technology's (ALGN) focus on expanding its global operations, both in existing and emerging international markets, raises optimism.Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.The major stock market indexes continue losing their morning gains, as all deepened losses in the last hour and are now trading at the lows of the session.  The Dow Jones Industrial Average is holding up relatively better.  Looking at the 2022 outlook, says Jennifer Lee, senior economist at BMO Capital Markets, ""if consumers start to rein in their spending, the second half will be considerably weaker, as we anticipate.""";154.13999938964844;Let's look at two stocks worth investing $5,000 in right now for investors who want to score market-beating returns in the long run: AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG).  Shares of AbbVie have easily outperformed the market this year, but the company remains reasonably valued.  At these levels, AbbVie is an outstanding stock to buy considering the strength of its underlying business.Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;84.7699966430664;Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.The Swiss pharmaceutical giant’s job cuts, including 1,400 in Switzerland, are part of a previously disclosed restructuring plan aimed at saving some $1 billion in costs.The pharmaceutical giant said about 1,400 roles in its Switzerland headquarters could be eliminated due to a restructuring plan.A gene editing firm has added $50 million to its coffers shortly after landing a significant development agreement with a global pharmaceutical company.;92.51000213623047;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.RAHWAY, N.J., June 29, 2022--Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to MarketRAHWAY, N.J., June 29, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, July 28. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook.Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients not responding to existing therapies.;67.0199966430664;Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.The big shareholder groups in AstraZeneca PLC ( LON:AZN ) have power over the company. Insiders often own a large chunk...;78.27999877929688;;52.66999816894531;French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.  Sanofi said the new price, down from the prior out-of-pocket cost of $99, will be effective from July 1.  U.S. lawmakers have pulled up healthcare companies over rising costs of insulin and the U.S. House of Representatives in March passed a bill capping monthly out-of-pocket insulin costs for those with health insurance at $35.The Food and Drug Administration’s vaccines advisers voted in favor of updating Covid-19 booster shots to protect specifically against the Omicron variant.;43.77000045776367;PHILADELPHIA, June 29, 2022--GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma communityThe Food and Drug Administration’s vaccines advisers voted in favor of updating Covid-19 booster shots to protect specifically against the Omicron variant.GlaxoSmithKline (GSK) closed the most recent trading day at $43.35, moving -0.8% from the previous trading session.;13.850000381469727;;42.09000015258789;;10.8100004196167;;165.85000610351562;;11.300000190734863;;145.64999389648438;;94.19999694824219;;12.489999771118164;;34.56999969482422;;54.439998626708984;;13.869999885559082;;12.609999656677246;;27.0;;45.189998626708984;;124.9800033569336;"JMP Securities raised the price target on Karuna Therapeutics Inc (NASDAQ: KRTX) from $175 to $190 with a Market Outperform rating. The analysts note Karuna as the top pick ahead of imminent Phase 3 results for KarXT in schizophrenia. They note that results from the Phase 3 EMERGENT-2 trial are expected within weeks (estimated mid-July to mid-August), with high confidence levels (probability of success ~80%). ""Looking ahead to KarXT's commercial potential, we believe that in addition to robust e";10.880000114440918;;25.5;;2.5899999141693115;;4.579999923706055;;;;3.9600000381469727;;3.7699999809265137;;50.47999954223633;;75.30000305175781;;30.530000686645508;The White House will sharply expand availability of monkeypox vaccines while rolling out more testing capacity for the virus.;5.480000019073486;;7.789999961853027;LAUSANNE, Switzerland, June 29, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA® in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.;16.709999084472656;;3.319999933242798;;27.18000030517578;;12.510000228881836;;18.0;;3.680000066757202;;10.260000228881836;;4.989999771118164;;8.609999656677246;;15.399999618530273;;32.04999923706055;;22.1200008392334;;17.549999237060547;;18.440000534057617;;13.229999542236328;;2.509999990463257;;13.609999656677246;
2022-06-30;177.50999450683594;"Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moody's outlook for pharmaceutical industry as well as reports that Pfizer is looking to provide additional COVID-19 vaccine doses.(Bloomberg) -- The US Supreme Court turned away a challenge to New York’s Covid-19 vaccine requirement for health-care workers, rejecting an appeal from 16 people who objected to the shot on religious grounds.Most Read from BloombergUS Will Face High Gas Prices ‘as Long as It Takes,’ Biden SaysStock Doomsayers Vindicated in Historic First Half: Markets WrapThe Wheels Have Come Off Electric VehiclesDemocrats Weigh Paring Biden Tax Hike to Win Over ManchinSupreme Court Crimps Biden’s Climate AgendThe Food and Drug Administration on Thursday told COVID-19 vaccine makers that plan to update their boosters to add a BA.4 and BA.5 spike protein component to the new shots that are in development. These ""bivalent"" boosters should equally target the two subvariants of omicron as well as the original strain of the virus and are expected to be rolled out to Americans in the fall or winter. Earlier this week, the FDA's advisory committee on vaccines voted 19-2 that the COVID-19 boosters need to beThe Dow Jones Industrial Average dived 575 points Thursday after a key inflation reading, threatening to extend this week's losses.In this article, we discuss the 10 best electric utility stocks to invest in. If you want to skip our detailed review of electric utility stocks, go directly to 5 Best Electric Utility Stocks To Invest In. Tight supply in the energy markets and the subsequent rise in inflation has put US consumers in a tight […]An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.In the latest trading session, Johnson & Johnson (JNJ) closed at $176.99, marking a +0.03% move from the previous day.In this article, we discuss 10 dividend stocks to buy according to James Katz’s Humankind Investments. You can skip our detailed analysis of the hedge fund’s past performance and latest developments, and go directly to read Top 5 Dividend Stocks to Buy According to James Katz’s Humankind Investments. Humankind Investments is a quantitative asset management […]";52.43000030517578;"(Bloomberg) -- The US Supreme Court turned away a challenge to New York’s Covid-19 vaccine requirement for health-care workers, rejecting an appeal from 16 people who objected to the shot on religious grounds.Most Read from BloombergUS Will Face High Gas Prices ‘as Long as It Takes,’ Biden SaysStock Doomsayers Vindicated in Historic First Half: Markets WrapThe Wheels Have Come Off Electric VehiclesDemocrats Weigh Paring Biden Tax Hike to Win Over ManchinSupreme Court Crimps Biden’s Climate AgendOver the past year, Pfizer (NYSE: PFE) has been one of the safer stocks to hold.  The company has been acquiring businesses to get stronger and more diverse in a post-COVID world.  Is the stock worth buying today?The Food and Drug Administration on Thursday told COVID-19 vaccine makers that plan to update their boosters to add a BA.4 and BA.5 spike protein component to the new shots that are in development. These ""bivalent"" boosters should equally target the two subvariants of omicron as well as the original strain of the virus and are expected to be rolled out to Americans in the fall or winter. Earlier this week, the FDA's advisory committee on vaccines voted 19-2 that the COVID-19 boosters need to bePfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.""As the Covid pandemic continues to evolve and be highly unpredictable, we must remain vigilant in protecting those who are at greatest risk of getting very sick from Covid,"" said CEO Albert Bourla.In this article, we discuss the 10 European stocks billionaire Ray Dalio is shorting. You can skip our analysis of the economic environment and go directly to Billionaire Ray Dalio is Shorting These 5 European Stocks. Billionaire Ray Dalio’s Bridgewater Associates has gone short on European stocks by placing a $10.5 billion bet against them, […]The price increase is another signal that investors may be underestimating the durability of the drug company's revenue from the vaccine.An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.The Chef's Warehouse and AZEK are part of as Zacks Bull and Bear of the Day article.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced a new vaccine supply agreement with the U.S. government. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult omicron-adapted COVID-19 vaccines, subject to the FDA authorization. The doses are planned to be delivered as soon as late summer 2022 and continue into Q4 of 2022. Related: Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response AgPfizer Inc. said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness. PAXLOVID has previously been granted Emergency Use Authorization (EUA) for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval. ""Data from our clinical development program, coupled with the more than 1.7 million patients around thePfizer Inc said on Thursday it is seeking full U.S. approval for its oral COVID-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorization (EUA).  Pfizer said it submitted a New Drug Application for Paxlovid to the Food and Drug Administration for the treatment of COVID-19 in vaccinated and unvaccinated people at high risk for progression to severe illness.  That is basically consistent with the drug's current EUA, which Pfizer said covers 50% to 60% of the U.S. population, citing estimates from the U.S. Centers for Disease Control and Prevention.NEW YORK, June 30, 2022--Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for patients who are at high risk for progression to severe illness from COVID-19. PAXLOVID is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at leaApproval of Paxlovid, which has been available under an Food and Drug Administration authorization for use during the pandemic, would allow Pfizer to market and sell it commercially.By Peter NursePfizer's new COVID-19 vaccine candidate could be used as a fourth booster dose to protect against the Omicron variant, helping to further boost sales.Under the deal, the U.S. government will get 105 million doses and have the option to purchase more. The doses would be for a fall booster drive.Pfizer (PFE) closed the most recent trading day at $50.94, moving +0.55% from the previous trading session.Pfizer Inc and partner BioNTech SE said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.  The deal includes supplies of a retooled Omicron-adapted vaccine, pending regulatory clearance, according to Pfizer.  Drugmakers have been developing vaccines to target the Omicron variant that became dominant last winter.Pfizer Inc. and BioNTech SE said late Wednesday they have inked a new agreement with the U.S. government to supply 105 million doses of their COVID-19 vaccines, including a formulation adapted to target omicron variants, pending approval from the FDA. The two pharma companies said the doses are expected to be delivered as soon as late summer, and continue into the end of the year. Under the agreement, the U.S. has the option to buy up to 195 million additional doses, which would bring the totalPfizer Inc and BioNTech said on Wednesday they had signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine for delivery as soon as late summer this year.  The deal also includes an Omicron-adapted vaccine, pending regulatory clearance, Pfizer said.  Advisers to the U.S. Food and Drug Administration on Tuesday recommended a change in the design of COVID-19 booster shots this fall in order to combat more recently circulating variants of the coronavirus.NEW YORK & MAINZ, Germany, June 29, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the U.S. Food and Drug Administration (FDA). The doses are planned to be delivered as soon as latVaccine stocks rose Wednesday after a experts recommended including an omicron-fighting component in updated Covid boosters this fall.In this article, we discuss 10 dividend stocks to buy according to James Katz’s Humankind Investments. You can skip our detailed analysis of the hedge fund’s past performance and latest developments, and go directly to read Top 5 Dividend Stocks to Buy According to James Katz’s Humankind Investments. Humankind Investments is a quantitative asset management […]";324.2300109863281;Shares of drugmaker Eli Lilly (NYSE: LLY) have suffered the same occasional tumble that its pharma peers and the broad market have taken this year.  Whereas the Dow Jones Industrial Average is down 13% year to date and the Dow Jones Pharmaceutical Index is just slightly better than breakeven, Lilly shares are up more than 18% since the end of 2021.  Much credit goes to Eli Lilly's COVID-19 treatment combination of bamlanivimab and etesevimab although its diabetes treatment Trulicity has been a heavy hitter as well.The Dow Jones Industrial Average dived 575 points Thursday after a key inflation reading, threatening to extend this week's losses.Meta Platforms, Eli Lilly, The Home Depot, The Boeing Company, Vale are part of Zacks top Analyst Blog.The Dow Jones led the upside, while the Nasdaq and S&P 500 struggled to turn positive. Medical stocks continued to outperform.Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Eli Lilly and Company (LLY), and The Home Depot, Inc. (HD).Sanofi SA (NASDAQ: SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure. Sanofi, meanwhile, says that all commercially insured people are eligible for its co-pay assistance programs, regardless of income or insurance, “whThese are the healthcare stocks with the best value, fastest growth, and most momentum for July 2022.;111.43000030517578;Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.;153.16000366210938;Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moody's outlook for pharmaceutical industry as well as reports that Pfizer is looking to provide additional COVID-19 vaccine doses.In this article, we discuss 10 dividend stocks to buy according to Bernard Horn’s Polaris Capital Management. You can skip our analysis of Horn’s hedge fund and its performance, and go directly to read 5 Best Dividend Stocks to Buy According to Bernard Horn’s Polaris Capital Management. Polaris Capital Management is a Boston-based global and […]Shares of AbbVie (NYSE: ABBV) are up by about 13% this year, which is a lot better than the benchmark S&P 500 index, which has lost 20% over the same period.  With lots of high-margin revenue from top-selling drugs, there's a good chance that AbbVie stock will remain a safe haven even if the U.S. economy plunges into a deep recession.  The top-selling drug for AbbVie is Humira.;84.52999877929688;(Bloomberg) -- Novartis AG is leaning toward a spinoff of its generic-drug unit, as a challenging environment for leveraged buyouts makes a potential sale to private equity more difficult, people familiar with the matter said. Most Read from BloombergStock Doomsayers Vindicated in Historic First Half: Markets WrapThe Wheels Have Come Off Electric VehiclesDemocrats Weigh Paring Biden Tax Hike to Win Over ManchinUS Will Face High Gas Prices ‘as Long as It Takes,’ Biden SaysSupreme Court Crimps BidWith a market capitalization of $196 billion, Swiss drugmaker Novartis (NYSE: NVS) is the seventh-largest pharma company on the planet (tied with UK-based AstraZeneca).  This explains how Novartis delivered respectable overall net sales and earnings growth for the first quarter.  Thanks to Novartis' strong existing product portfolio, analysts believe that the company will generate 4.8% annual earnings growth over the next five years.An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The data showed that the tislelizumab / chemo combo significantly improved overall survival (OS) as a first-line treatment, regardless of PD-L1 status versus chemotherapy. Tislelizumab combo demonstrated a median OS of 17.2 months versus 10.6 months in patients receivingNovartis AG (NYSE: NVS) said that in early June, it restarted radioligand therapy (RLT) production at its sites in Ivrea, Italy, and Millburn, New Jersey. It also resumed delivering doses to patients in a phased approach, ahead of the expected six-week timeframe. The company has remediated the issues that led to a temporary, voluntary suspension of production in May. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identifiFirst-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal squamous cell carcinoma1 Statistically significant survival benefit with tislelizumab plus chemotherapy was observed regardless of PD-L1 status and consistent across all patient subgroups1 Novartis to discuss results of multi-regional RATIONALE 306 study, the seventh positive Phase III trial readout for tExecutives at electric car marker Tesla, drug maker Novartis and retailer Bed Bath and Beyond are cutting spending or jobs while others are shelving projects or deals as inflation rages and confidence in the world economy wanes.  Manufacturing growth is slowing worldwide as China's COVID-19 curbs and Russia's invasion of Ukraine disrupt supply chains and keep inflation at the highest in years, while the growing risk of a U.S. recession poses a new threat to the global economy.  More companies are now taking early action to help them weather any downturn, a preview that more drastic cuts may loom when earnings reports pour in next month.;91.16999816894531;Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moody's outlook for pharmaceutical industry as well as reports that Pfizer is looking to provide additional COVID-19 vaccine doses.An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.We are thrilled to announce that WEConnect International has named us a 2022 Platinum Top Global Supplier, Diversity & Inclusion Champion! The Platinum level of recognition denotes the highest leve...In the latest trading session, Merck (MRK) closed at $92.51, marking a +0.67% move from the previous day.Raymond James initiated coverage on Seagen Inc (NASDAQ: SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE: MRK) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable bidder. Related: Merck/Seagen PoMerck (MRK) possesses solid growth attributes, which could help it handily outperform the market.Seagen (SGEN) is riding on the strong uptake of its marketed drugs that are approved for different cancer indications. Further label expansion of these drugs should boost the top line.;66.06999969482422;Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moody's outlook for pharmaceutical industry as well as reports that Pfizer is looking to provide additional COVID-19 vaccine doses.Here are a couple of healthcare stocks to contemplate buying that could do well for shareholders in the years that lie ahead.  Elevance Health (NYSE: ANTM), formerly known as Anthem, is the third-largest publicly traded health insurer in the world, with a $117 billion market capitalization.  Due to an increase in instances of common diseases like cancer and diabetes, the demand for health insurance is positioned to rise moving forward.AstraZeneca Plc (NASDAQ: AZN) announced high-level results from a planned interim analysis of the AEGEAN Phase 3 trial of Imfinzi (durvalumab) combined with neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The data showed that Imfinzi plus neoadjuvant chemo before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete response (pCR) compared to neoadjuvant chemotherapy alone. Also Read: AstraZeneca's Imfinzi FlunWILMINGTON, Del., June 30, 2022--Positive high-level results from a planned interim analysis of the AEGEAN Phase III trial showed treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant chemotherapy before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete response (pCR) compared to neoadjuvant chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC).AstraZeneca said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery.  Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in patients with non-small cell lung cancer, the Anglo-Swedish drugmaker said.  The interim result is a boost to the company's oncology efforts - a major area of focus - following disappointing data for Imfinzi earlier in the year in another area of therapy.The Dow Jones rose despite Fed Chair Jerome Powell issuing an inflation warning. Tesla stock fell amid closure news. Apple stock rose.The major stock market indexes are all in the red in afternoon trading, bouncing back slightly from the last hour and holding above the lows of the day. The Dow Jones Industrial Average is nearly flat, while the small-cap Russell 2000 is getting hit the hardest.;77.0;Bristol Myers Squibb (BMY) closed the most recent trading day at $78.28, moving -0.53% from the previous trading session.;50.029998779296875;In this article, we discuss the 10 European stocks billionaire Ray Dalio is shorting. You can skip our analysis of the economic environment and go directly to Billionaire Ray Dalio is Shorting These 5 European Stocks. Billionaire Ray Dalio’s Bridgewater Associates has gone short on European stocks by placing a $10.5 billion bet against them, […]An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.The FDA has placed Sanofi SA's (NASDAQ: SNY) Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold. New enrollment in the U.S. is paused, and participants in the U.S. who have been in the trial for fewer than 60 days shall suspend the study drug. The participants who have completed at least 60-days in the trial should continue treatment. The FDA action was based on a limited number of drug-induced liver injury cases identified with tolebrutinib expoSanofi SA (NASDAQ: SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure. Sanofi, meanwhile, says that all commercially insured people are eligible for its co-pay assistance programs, regardless of income or insurance, “wh;43.529998779296875;;14.039999961853027;(Bloomberg) -- Takeda Pharmaceutical Co.’s shares might be trading at about half of their level before the $62 billion acquisition of Shire in 2018, but the drug pipeline and cash management are helping to change the market’s perception of the company’s long-term value, Chief Executive Officer Christophe Weber said.Most Read from BloombergTrump’s Final Scene Didn’t Go According to ScriptDemocrats Weigh Paring Biden Tax Hike to Win Over ManchinVenice Plans to Start Weeding Out Cheap TouristsFauci;42.040000915527344;Shares of Blueprint Medicines Corp. gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma , which acquires pharmaceutical royalties, worth up to $1.2 billion. Sixth Street will pay $250 million upfront for future royalties for two products, up to $400 million in a senior secured credit facility, and $260 million in a potential credit facility to support any buy-side business opportunities. Royalty Pharma will pay $175Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based mBlueprint Medicines Corporation (NASDAQ: BPMC) today announced strategic financing collaborations with Sixth Street and Royalty Pharma (NASDAQ: RPRX) for up to $1.25 billion, bringing significant non-dilutive, low-cost capital to drive innovation and growth.;10.470000267028809;;162.39999389648438;;11.880000114440918;;145.7100067138672;;92.95999908447266;;11.979999542236328;;33.75;Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the exclusive license agreement entered into on March 31, 2022 with Organon (NYSE: OGN), a global women’s healthcare company, has become fully effective. Under the agreement, Organon licensed global rights to XACIATO (clindamy;55.0;;13.609999656677246;;12.640000343322754;;26.440000534057617;;45.220001220703125;;126.51000213623047;;11.300000190734863;;24.6200008392334;;2.5299999713897705;;4.690000057220459;;;;3.799999952316284;;3.7200000286102295;The Los Angeles-based company is far different from Athenex, developing different kinds of cancer drugs and building its own business model around those plans, but it also has some notable similarities.;48.77000045776367;;75.25;;31.040000915527344;;5.570000171661377;;7.949999809265137;;16.190000534057617;The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...;3.180000066757202;;27.6299991607666;;12.670000076293945;NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients in U.K. with plans to expand to clinical sites in the U.S. SAN FRANCISCO, June 30, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the compa;18.649999618530273;;3.640000104904175;Dr. Chad Beyer will join as CEO on July 1, 2022NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Kures Therapeutics, Inc (“Kures”), an atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) company focused on developing treatment options to better manage addictions, depression, and pain, today announced the appointment of Chad E. Beyer, Ph.D., MBA, currently Senior Vice President of Research and Development at Promentis Pharmaceuticals, Inc (“Promentis”), as Chief Executive Officer of Kures, effective July 1;9.979999542236328;;4.869999885559082;;9.319999694824219;;15.739999771118164;;30.389999389648438;;21.309999465942383;;17.899999618530273;;18.030000686645508;;13.010000228881836;Company announcement – No. 30 / 2022 Total number of shares and voting rights in Zealand Pharma at June 30, 2022 Copenhagen, DK and Boston, MA, June 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a;2.450000047683716;;13.989999771118164;
2022-07-01;179.52000427246094;;52.310001373291016;;324.7099914550781;The Dow Jones Industrial Average rose Friday after the index staged its worst first-half performance since 1962. Chinese EV stocks reported strong sales.With the S&P 500 in bear market territory (a drop of 20% or more from its most recent highs) and persistent geopolitical and economic problems, it's not clear that the end of these troubles is in sight.  Eli Lilly's stock is up by an impressive 17% since the beginning of the year.  While the company has delivered solid financial results, perhaps the forward-looking market is more excited about its prospects.Lamb Weston, a maker of french fries, is the S&P 500's top performer in the second quarter. AT came in second.;111.63999938964844;Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.In this article, we discuss 10 defensive stocks that Ken Fisher loves. If you want to skip our detailed analysis of Fisher’s investment philosophy, hedge fund returns, and history, go directly to Ken Fisher Loves These 5 Defensive Stocks. Born in 1950, Kenneth Lawrence Fisher is an American investor, author, and founder of one of […];153.8000030517578;;84.36000061035156;Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.(Bloomberg) -- Novartis AG is leaning toward a spinoff of its generic-drug unit, as a challenging environment for leveraged buyouts makes a potential sale to private equity more difficult, people familiar with the matter said. Most Read from BloombergUS Will Face High Gas Prices ‘as Long as It Takes,’ Biden SaysThe Wheels Have Come Off Electric VehiclesCrypto Meltdown Claims Rolex and Patek Philippe as VictimsStock Doomsayers Vindicated in Historic First Half: Markets WrapUkraine Latest: Kyiv LaA global pharmaceutical giant with nearly 600 employees in the Triangle is cutting thousands of jobs as part of a company reorganization.Novartis prefers a spinoff of its generic drug unit over a potential sale to private equity firms, Bloomberg News reported on Thursday, citing people familiar with the matter.  A challenging macro environment for leveraged buyouts has made the sale route difficult and Novartis sees a separate listing of the Sandoz business as more likely, the report said.  The Swiss pharmaceutical group in October said it had started a strategic review of the Sandoz unit as price pressures mounted in the off-patent drug sector.;92.41999816894531;;65.94999694824219;WILMINGTON, Del., July 01, 2022--AstraZeneca presented data for IMFINZI® (durvalumab) combinations from the HIMALAYA and TOPAZ-1 Phase III trials at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL 2022) and the European Society for Medical Oncology’s World Congress on Gastrointestinal Cancer (ESMO World GI 2022).Oxford Biomedica plc (OTC: OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020. The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the original commitment, is expected to complete in the last quarter of 2022. Under the expanded deal, AstraZenOne of several medical stocks on the IBD 50 list of growth stocks, drug giant AstraZeneca is trying to break out of a new base as the stock market struggles to remain in a confirmed uptrend.  The U.K.- based maker of a wide variety of treatments is forming a double-bottom base, according to MarketSmith chart analysis.  Its drugs include a Covid vaccine and cancer drugs Tagrisso, Imfinzi and Lynparza.;76.83999633789062;;51.0099983215332;Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.Sanofi stock crumbled Thursday after the FDA slapped two of its final-phase studies with a hold, citing safety concerns.;44.6064453125;Retirement stocks are at the center of attention for millions of investors. Rising global tensions, declining markets and the expected recession have investors looking more closely at their longer-term saving plans, be it 401(k)s or IRAs. According to Alicia Munnell, director of the Center for Retirement Research at Boston College, the current selloff has erased around $3 trillion from retirement accounts stateside. This year’s declines on Wall Street remind us the importance of choosing robust;14.09000015258789;Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. The data demonstrated positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients. HAE attacks, which can involve serious and severely debilitating swelling in theOSAKA, Japan & CAMBRIDGE, Mass., June 30, 2022--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.1 There are currently no lo;42.7400016784668;Blueprint Medicines Corp. has struck deals with Sixth Street and Royalty Pharma plc to bring in up to $1.25 billion.;10.710000038146973;Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on August 8 to discuss the results.;166.52000427246094;;12.489999771118164;;145.30999755859375;;92.5999984741211;;12.600000381469727;;34.25;;55.84000015258789;;14.239999771118164;;13.449999809265137;;26.420000076293945;;45.43000030517578;;126.0999984741211;;11.489999771118164;;26.520000457763672;;2.630000114440918;;4.550000190734863;;;;3.75;Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Ms. Thomsen has served as SVP, Finance & Chief Accounting Officer of Nektar since 2008, and is a key member of our Executive Committee. Gil Labrucherie, the company's current Chief Operating Officer & Chief Financial Officer, will be departing the company to pursue another opportunity at a private biotechnology company.;3.990000009536743;;52.0;;75.11000061035156;;31.829999923706055;;5.820000171661377;;8.539999961853027;LAUSANNE, Switzerland, July 01, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appointed as the Company’s Chief Executive Officer in May 2022, will join the Board.;16.790000915527344;;3.359999895095825;;28.09000015258789;;13.319999694824219;;18.850000381469727;;3.6500000953674316;;10.149999618530273;;5.170000076293945;BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors. In addition, the Company an;8.510000228881836;;16.15999984741211;;30.440000534057617;;21.729999542236328;;19.950000762939453;"Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' ""short squeeze"" and investors' bargain hunting.";18.3700008392334;;12.890000343322754;;2.509999990463257;;13.9399995803833;"Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' ""short squeeze"" and investors' bargain hunting."
2022-07-05;178.13999938964844;;51.63999938964844;;327.17999267578125;The Dow Jones Industrial Average dived 600 points Tuesday, as Tesla stock dropped on weaker-than-expected second quarter deliveries.;111.23999786376953;AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.NVO and TMUS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 5, 2022.CHS, PTMN, RYI, NVO and TMUS have been added to the Zacks Rank #1 (Strong Buy) List on July 5, 2022.Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.;153.92999267578125;;84.27999877929688;;92.63999938964844;;65.51000213623047;The key asset to be acquired in the deal, which includes an $100 million upfront payment, is a new drug candidate that targets non-Hodgkin's lymphoma.AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.Don't feed the bear market, prepare for the next bull run. Tesla deliveries fell sharply in Q2 with BYD on tap.Growth stocks were the darlings of the market in the rally after March 2020. However, as equities get jittery on multiple macro-economic headwinds, large-cap stocks have found relatively higher interest. In general, large-cap stocks have low volatility and with established businesses, cash flows are robust. Investors therefore benefit from steady stock upside coupled with dividend gains. Additionally, there are large-cap stocks that have sustained dividend growth visibility. These are attractiveBy Peter NurseCarillon Tower Advisers, an investment management firm, published its “Carillon Eagle Growth & Income Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. The Carillon Family of Funds spans a range of investment objectives and asset classes designed for long-term investors. Along with the spike in oil prices, energy stocks […]AstraZeneca agreed to acquire biotechnology firm TeneoTwo Inc in a deal worth up to $1.27 billion on Tuesday, in a move to bolster its roster of therapies to treat blood cancers.  At the heart of the deal is the U.S.-based company's early stage experimental treatment for a form of Non-Hodgkin's lymphoma, a type of cancer that involves the growth of abnormal white blood cells that can lead to the emergence of tumours.  The Anglo-Swedish drugmaker - whose key blood cancer drug Calquence generated sales of more than $1.2 billion last year - plans to acquire all outstanding equity of TeneoTwo for an upfront payment of $100 million, with additional milestone-related payments of up to $1.17 billion.By Scott KanowskyAt the heart of the deal is the U.S.-based company's early stage experimental treatment for a form of Non-Hodgkin's lymphoma, a type of cancer that involves the growth of abnormal white blood cells that can lead to the emergence of tumours.  The Anglo-Swedish drugmaker - whose key blood cancer drug Calquence generated sales of more than $1.2 billion last year -  plans to acquire all outstanding equity of TeneoTwo for an upfront payment of $100 million, with additional milestone-related payments of up to $1.17 billion.  TeneoTwo's experimental drug, TNB-486, belongs to a class of bispecific antibodies that are engineered to redirect the immune system to recognise and kill cancer cells.;75.95999908447266;;50.18000030517578;;44.14763641357422;"CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus.  The German-based biotech company is seeking ""fair compensation"" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.";14.15999984741211;;43.150001525878906;A look at the shareholders of Royalty Pharma plc ( NASDAQ:RPRX ) can tell us which group is most powerful. Institutions...;10.5;;167.67999267578125;;11.970000267028809;;146.0;;95.38999938964844;;12.479999542236328;"* AS ""EVOTEC CELL ACCELERATOR"", THE HIGH-QUALITY CGMP CELL THERAPY MANUFACTURING SITE ADDS CAPACITY AND CAPABILITY * EVOTEC'S EVO CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC-BASED CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURINGHAMBURG, GERMANY / ACCESSWIRE / July 5, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Ba";34.20000076293945;;57.099998474121094;;14.09000015258789;"CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE (NASDAQ: BNTX) and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac’s intellectual property rights utilized in Comirnaty, BioNTech and Pfizer Inc’s (NYSE: PFE) mRNBERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus.  The German-based biotech company is seeking ""fair compensation"" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.  When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.Shares of BioNTech SE fell 0.9% in premarket trading Tuesday, after CureVac N.V. filed in Germany a patent infringement suit against the biotechnology company. CureVac said there were certain of its patents that were utilized in the manufacture and sale of BioNTech and Pfizer Inc.'s COVID-19 vaccine, Comirnaty. CureVac said while it doesn't seek an injunction, and won't take legal action to impede the production or sale of Comirnaty, it is seeking ""fair compensation"" for infringement of its pateCureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus.  The German-based biotech company is seeking ""fair compensation"" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.CureVac has filed a lawsuit in Germany against BioNTech, seeking compensation for what it said was infringement of its intellectual property rights, the vaccine maker said on Tuesday.  CureVac said that it claimed intellectual property rights based on more than two decades of work on mRNA technology that helped contribute to the development of COVID-19 vaccines.  The Germany-based company said it was not seeking an injunction, nor does it intend to take legal action that would impede the production, sale or distribution of the coronavirus vaccine made by BioNTech and Pfizer.TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (""mRNA"") today announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.";14.59000015258789;;30.6299991607666;;48.0099983215332;;132.0;;12.34000015258789;;27.459999084472656;;2.6500000953674316;;5.269999980926514;;;;3.930000066757202;;4.409999847412109;;52.650001525878906;;75.1500015258789;;33.2599983215332;;6.059999942779541;;8.850000381469727;;18.020000457763672;;3.319999933242798;;28.860000610351562;;13.8100004196167;Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders should be happy to see the share price up 26% in the last month...;19.899999618530273;;3.680000066757202;;10.920000076293945;;4.980000019073486;;8.699999809265137;;18.899999618530273;;36.4900016784668;;21.96500015258789;;19.309999465942383;;19.610000610351562;In the last year, multiple insiders have substantially increased their holdings of IGM Biosciences, Inc. ( NASDAQ:IGMS...;13.09000015258789;;2.5999999046325684;;14.210000038146973;
2022-07-06;178.3000030517578;;52.75;;330.1499938964844;Dividend stocks, in particular, could offer you a path to some significant wealth in your future.  A couple of stocks that are ideal for long-term dividend investors are Eli Lilly (NYSE: LLY) and Coca-Cola (NYSE: KO).  You may initially scoff at Eli Lilly's 1.2% yield.The Dow Jones Industrial Average fell Wednesday morning ahead of the highly-anticipated release of the minutes from last month's Fed meeting.The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).The FDA will decide whether to approve lecanemab on the basis of early-stage data showing that it can clear brain plaques.;110.48999786376953;The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.Novo Nordisk, Intel, Qualcomm, T-Mobile US and Sony Group are part of Zacks top Analyst Blog.Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Intel Corporation (INTC), and Qualcomm Inc. (QCOM).;152.52999877929688;;83.7300033569336;;93.12999725341797;;66.48999786376953;Companies in The News Are: F, STLA, AZN, CVX.Canada is to throw out almost 14m doses of AstraZeneca's Covid vaccine after it struggled to find a country that would accept them.Roland Buelow long ago understood that a biotech company's biggest value could come from early-stage clinical trials — and Buelow proved it again Monday in lining up a potential $1.2 billion cancer drug deal with AstraZeneca plc.  The deal is the third Buelow and his team have lined up with Big Pharma in two years.;76.22000122070312;Today, I have chosen six stocks hedge funds love. To simplify this, I decided to pick the top three stocks of two of the most watched hedge funds that are the most popular in the market. One of those funds is Michael Burry’s Scion Asset Management. We use the company’s 13-F holdings report from the first quarter (Q1) as shown by the Dataroma database, which shows the top three stocks his fund owns on a long-term basis. The other major fund is the Omega Advisors hedge fund. This is now mostly a f;50.040000915527344;;43.953914642333984;In the latest trading session, GlaxoSmithKline (GSK) closed at $43.30, marking a -1.03% move from the previous day.;14.279999732971191;;43.09000015258789;;10.300000190734863;Dividend stocks can be valuable assets to hold right now.  Two cheap dividend stocks that investors should consider buying today are Viatris (NASDAQ: VTRS) and Citizens Financial Group (NYSE: CFG).  At a forward price-to-earnings (P/E) multiple of just three, Viatris may look like a potential value trap from afar.;168.4499969482422;;11.199999809265137;;145.61000061035156;;89.5;;12.710000038146973;"HAMBURG, GERMANY and FRANCE / ACCESSWIRE / July 6, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).The resulting company, Aurobac Therapeutics SA";33.290000915527344;;56.849998474121094;;14.960000038146973;"Pfizer stock crashed into its 50-day line Tuesday after Germany's CureVac sued its Covid vaccine partner, BioNTech, for patent infringement.BioNTech is looking into taking legal steps against CureVac after the latter filed a patent lawsuit against it over its use of mRNA technology, BioNTech said on Wednesday, confirming a report by daily Welt.  ""We are looking at all legal options,"" said a BioNTech spokesperson.  CureVac is seeking ""fair compensation"" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday.The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.While the daily average of new COVID-19 cases have settled back into a low-100K range that has lasted for about seven weeks, hospitalizations took their first dip since mid-April and deaths ticked up to a 2 1/2-month high.CureVac says its intellectual property portfolio protects multiple inventions that are considered essential to Pfizer and BioNTech's Covid-19 vaccine.";14.069999694824219;"SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (""Inmagene"") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study is a multi-stage, double-blind, randomized, placebo-controlled, dose-escalation study in healthy volunteers,";30.0;;47.52000045776367;;130.85000610351562;;11.680000305175781;"I-Mab (""I-Mab"" or the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research and Development (R&D) Day on July 20, 2022.";27.860000610351562;Ayala Pharmaceuticals Inc (NASDAQ: Ayala) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. HC Wainwright reiterated the Buy rating on the stock with a price target of $18. The analyst says that Ayala's initial data is encouraging in the context of the clinical devel;2.740000009536743;;5.269999980926514;;;;3.9000000953674316;;4.519999980926514;;54.91999816894531;;75.18000030517578;;32.84000015258789;Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin AmericaProduct Supply Expected During the Fourth Quarter of 2022 and the First Half of 2023 REHOVOT, Israel and HOBOKEN, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that it has secured an $11.4 million agreement to supply VARIZIG®;6.159999847412109;;8.9399995803833;;18.709999084472656;;3.2200000286102295;;28.5;;14.430000305175781;;20.579999923706055;;3.9800000190734863;;10.880000114440918;;4.860000133514404;;8.649999618530273;;18.299999237060547;;36.4900016784668;;22.760000228881836;WESTLAKE VILLAGE, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 7,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 16,500 shares of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Bo;19.719999313354492;;20.149999618530273;;13.09000015258789;;2.630000114440918;;15.039999961853027;
2022-07-07;178.5;;53.41999816894531;;327.95001220703125;In this article we look at why Billionaire Jeffrey Talpins Just Fled From These 10 Healthcare Stocks. Click to skip ahead and see why Billionaire Jeffrey Talpins Just Fled From These 5 Healthcare Stocks. Moderna, Inc. (NASDAQ:MRNA), Thermo Fisher Scientific Inc. (NYSE:TMO), and Danaher Corporation (NYSE:DHR) are three of the healthcare stocks that billionaire money manager […]The stock market had some turbulence on Wednesday, and although most market benchmarks finished in positive territory, there's still plenty of uncertainty about the future.  Investors got the latest minutes from the Federal Reserve's monetary policy-setting body, and they revealed that the central bank remains ready and able to take aggressive action to curtail inflationary pressure, even if it means pushing the economy into recession.  After spending much of the day lower, the Dow Jones Industrial Average (DJINDICES: ^DJI), S&P 500 (SNPINDEX: ^GSPC), and Nasdaq Composite (NASDAQINDEX: ^IXIC) all rose modestly.;109.94000244140625;Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.;152.0;;84.4000015258789;;93.01000213623047;;66.91999816894531;(Bloomberg) -- Most Read from BloombergEx-Japan Leader Abe Assassinated in Shooting That Shocks NationUS Stocks Decline as Jobs Fuel Rate-Hike Bets: Markets WrapNetflix to Stream Johnny Depp’s Return to Film in FranceChina Considers $220 Billion Stimulus With Unprecedented Bond SalesUS Mortgage Rates Plunge to 5.3% in Biggest Drop Since 2008Boris Johnson announced his intention to resign as UK prime minister, bringing the curtain down on a tempestuous three years in office marred by a successionGovernments and manufacturers are tossing out doses by the millions because of waning demand, a sharp reversal from the rollout of Covid-19 vaccines.Yahoo Finance health reporter Anjalee Khemlani outlines the events surrounding the FDA's ban on Juul products and e-cigarettes, as well as Pfizer's Paxlovid COVID-19 treatment pill receiving an Emergency Use Authorization from the FDA.Market turmoil and international tensions don't seem to have affected investor interest in Sequoia Capital's China branch one bit. The Menlo Park firm's Chinese arm is about to close on $9 billion in fresh capital for four new funds, according to The Information.AstraZeneca Plc's (NASDAQ: AZN) COVID-19 antibody cocktail has been cleared for use in a medical tourism zone in China's southern province of Hainan, Reuters reported citing local media. The report mentioned that China allows early use of new medical products in the special zone in Qionghai city due to several preferential policies granted to the area to promote medical services to visitors. Related: Oxford Biomedica Inks New Three-Year Deal To Make AstraZeneca's COVID-19 Vaccine. Hainan Daily r;75.13999938964844;;50.220001220703125;RNA startup Skyhawk Therapeutics has added another big name to its nest of partners: Sanofi ADR.  Sanofi (Nasdaq: SNY) is paying the Waltham biotech $54 million up front and up to $2 billion or more in potential milestone payments to develop small molecules that modulate RNA splicing for oncology and immunology targets.  The companies aren't disclosing anything more specific than that, but the deal, which was announced Wednesday morning, involves multiple targets that Sanofi has identified in-house.;44.168025970458984;;14.479999542236328;;43.040000915527344;;10.420000076293945;;175.8000030517578;;11.119999885559082;;145.1999969482422;Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscle Atrophy (SMA).LARKSPUR, Calif., July 06, 2022--Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven's troriluzole and Vigeo's VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform tria;94.0;;12.9399995803833;;33.04999923706055;;56.08000183105469;;15.239999771118164;In this article, we will take a look at the 10 notable market movers to watch on Wednesday. If you want to see some other stocks making big moves today, go directly to 5 Notable Market Movers to Watch on Wednesday. Pulp and paper company Resolute Forest Products Inc. (NYSE:RFP), electric vehicle maker Rivian Automotive, […];14.880000114440918;;29.950000762939453;;48.880001068115234;WALTHAM Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to six new employees with a grant date of July 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company.;133.5500030517578;;11.84000015258789;;28.6299991607666;;2.799999952316284;;5.590000152587891;;;;3.930000066757202;;4.760000228881836;;55.45000076293945;;75.18000030517578;;33.45000076293945;GAITHERSBURG, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Sujata Dayal as a Class II director to serve on the board effective July 15, 2022, with an initial term expiring at the 2023 annual meeting of stockholders. Ms. Dayal was also appointed as a member of both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight. “We are pleased to welc;6.5;Erasca, Inc. (ERAS) closed the most recent trading day at $6.16, moving +1.65% from the previous trading session.;9.15999984741211;;19.25;;3.2899999618530273;;29.389999389648438;;15.470000267028809;;21.219999313354492;;4.269999980926514;;11.710000038146973;;5.739999771118164;;8.720000267028809;;18.950000762939453;;36.0;;22.950000762939453;;19.43000030517578;;20.829999923706055;;13.835000038146973;;2.799999952316284;;15.59000015258789;
2022-07-08;178.27999877929688;;53.16999816894531;;330.4700012207031;Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.If you start early, you don't need to invest all that much to grow your portfolio to $1 million.In this article, we discuss 10 best stocks to buy amid inflation in 2022 and beyond. If you want to see more stocks in this selection, check out 5 Best Stocks to Buy Amid Inflation in 2022 and Beyond. Situation After 2020 During 1991 and 2019, the average inflation was 2.3%. After the pandemic-induced recession […];109.02999877929688;Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropathy indication.LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.;152.85000610351562;;84.33999633789062;;92.77999877929688;;66.9800033569336;FDA grants priority review to Roche's (RHHBY) BLA for Lunsumio. AstraZeneca (AZN) announces a small acquisition. Pfizer (PFE) files NDA for Paxlovid.;75.37999725341797;Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.The fast-growing company initially took 32,500 square feet in the building that is under construction.;50.15999984741211;;43.16884231567383;In the latest trading session, GlaxoSmithKline (GSK) closed at $43.32, marking a +0.49% move from the previous day.;14.399999618530273;;42.959999084472656;;10.350000381469727;;175.5;;10.949999809265137;;145.5500030517578;Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.;93.61000061035156;;12.970000267028809;;32.75;;56.04999923706055;;14.600000381469727;;15.520000457763672;;29.100000381469727;;48.959999084472656;;136.8800048828125;;11.5;;29.149999618530273;;2.809999942779541;;5.599999904632568;;;;3.8299999237060547;;4.78000020980835;;54.75;Pharmaceutical companies develop treatments for patients with serious diseases, and when one of these companies has a drug candidate nearing application for review (and, hopefully, approval), the excitement with each piece of news can drive investors toward the company's stock.  Harmony Biosciences Holdings (NASDAQ: HRMY) is one such drugmaker that has experienced its own share price growth.  The company's success has hinged on its sole product, Wakix, which has been approved by the Food and Drug Administration (FDA) for treating people who suffer from excessive daytime sleepiness and cataplexy (muscle weakness) as a result of narcolepsy.Shares of Harmony Biosciences were rated a new buy by a sell side firm Thursday with a $64 price target. I have some technical price targets for HRMY, so let's compare notes.     In this daily bar chart of HRMY, below, we can see that prices have surged to new highs from a broadening pattern (similar to a backwards triangle) where prices swing up and down in higher highs and lower lows.;75.37999725341797;;33.689998626708984;Emergent BioSolutions Inc (NYSE: EBS) has agreed to create a collaboration with Ridgeback Biotherapeutics to expand the availability of Ebanga (Ansuvimab-zykl). FDA approved Ebanga in December 2020 for Ebola. Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga in the U.S. and Canada. Ridgeback Bio will serve as the global access partner for Ebanga, ensuring it remains available to patients in endemic countries frGAITHERSBURG, Md. and MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga™ (Ansuvimab-zykl). Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga™ i;6.699999809265137;;10.3100004196167;ADC Therapeutics SA (NYSE: ADCT) has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (OTC: BIOVF) for the development and commercialization of Zynlonta for all hematologic and solid tumor indications outside of the U.S., Greater China, Singapore, and Japan. ADC Therapeutics and Sobi intend to make Zynlonta available following a regulatory decision expected by Q1 of 2023. ADC Therapeutics will receive an upfront payment of $55 million. It is eligible to receive $50 miLAUSANNE, Switzerland, July 08, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan. The Marketing Authorization Application (MAA) for ZYNLONTA was validated by the European Medicines Agency (EMA) at the end of October 2021, and orphan d;19.170000076293945;;3.299999952316284;BRIDGEWATER, N.J., July 08, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 5, 2022.;29.020000457763672;;17.709999084472656;SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds to sell, in a registered direct offering, pre-funded warrants to purchase 2,869,440 shares of common stock at a price of $13.939 per pre-funded warrant for total gross proceeds of approximately $40 milliNurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -1% and 13.36%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?SAN FRANCISCO, July 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with an institutional investor to sell, in a registered direct offering, pre-funded warrants to purchase 3,945,480 shares of common stock at a price of $13.939 per pre-funded warrant for total gross proceeds of approximately $55 million, before dedNX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for certain B-cell malignancies NX-1607 IND cleared FDA for expansion of enrollment to U.S. clinical sites for patients with solid tumors Research engine achieved collaboration milestone for fifth consecutive quarter Strong financial position with $348.8 million in cash and investments as of May 31, 2022 SAN FRANCISCO, July 07, 2022 (GLOBE NEWSWIRE) -- Nur;21.1200008392334;;4.309999942779541;;12.850000381469727;;5.909999847412109;;8.779999732971191;;19.059999465942383;;35.880001068115234;;25.5;;19.600000381469727;;20.75;;14.970000267028809;;3.2699999809265137;;15.350000381469727;
2022-07-11;178.35000610351562;;52.88999938964844;;331.07000732421875;Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.Viewing insider transactions for Eli Lilly and Company's ( NYSE:LLY ) over the last year, we see that insiders were net...;109.54000091552734;Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.No thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study.1 London, UK, 11 July 2022 – Novo Nordisk announced that the phase 1 & 2 FRONTIER1 dose-escalation study in the treatment of people with haemophilia A met its primary safety endpoint.1 Interim results for the safety, tolerability and activity of next-generation Factor VIIIa (FVIIIa) mimetic Mim8 at different dosages were presented today at the International Society of Thrombosis;153.22999572753906;While arguably most financial advisors will recommend their clients to bulk up their portfolios with proven large-capitalization ideas, you can leverage the present market dynamics in a nuanced manner with overlooked blue-chip stocks to buy. Rather than go with the flavors of the week, you may enjoy higher-probability successes by dipping a bit beneath the radar. Why might this strategy be appropriate under the present context? For one thing, when everyone bets on the same horse, the payout forZacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;84.48999786376953;;94.30000305175781;;66.73999786376953;;75.55999755859375;;50.290000915527344;Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) presented results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated hemophilia A patients. The study met the primary efficacy endpoint, with once-weekly efanesoctocog alfa prophylaxis providing clinically meaningful bleed protection. The median and mean annualized bleeding rates (ABR) were 0.00 and 0.71, respectively. The study also demonstrated superior bleed protection over prior factor VIIISanofi SA (NASDAQ: SNY) announced data from the Phase 3 ATLAS-PPX study of once-monthly fitusiran (80 mg) in severe hemophilia A or B patients. The study included previously treated patients with a prior factor or bypassing agent (BPA) prophylaxis. The study met the primary endpoint and demonstrated fitusiran prophylaxis significantly reduced bleeding episodes compared to prior factor or BPA prophylaxis. The overall median annualized bleeding rate (ABR) was 0.0 for fitusiran prophylaxis, compare;43.097469329833984;Respiratory syncytial virus, or RSV, is a common illness, but it has proved quite challenging to treat.  It remains one of the few major infectious diseases without a vaccine.  RSV symptoms are typically mild, limited to a runny nose, cough, and fever.;14.420000076293945;"Dividend stocks are a great way to navigate volatile markets.  History has shown that companies with solid balance sheets, diverse revenue streams, and a rich tradition of increasing annual distributions to shareholders tend to be the best vehicles when it comes to staving off the negative effects of economic downturns.  With this insight in mind, my top two dividend stocks to buy right now are Icahn Enterprises (NASDAQ: IEP) and Takeda Pharmaceutical Company (NYSE: TAK).OSAKA, Japan, July 11, 2022--Takeda Pharmaceutical Company Limited (""Takeda"") (TOKYO:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange (""TSE"") in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/.";42.7599983215332;;10.050000190734863;;172.6199951171875;;11.039999961853027;;145.0;;90.7699966430664;;12.609999656677246;;32.70000076293945;;54.58000183105469;;13.09000015258789;The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.;15.0;;27.459999084472656;;46.68000030517578;;129.6699981689453;;10.270000457763672;;27.260000228881836;;2.7200000286102295;;4.78000020980835;;;;3.5299999713897705;;4.46999979019165;;54.70000076293945;;75.12000274658203;;32.15999984741211;;6.289999961853027;;9.40999984741211;"BOSTON & SHANGHAI & LAUSANNE, Switzerland, July 11, 2022--Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals (""Overland"") and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed in China with ZYNLONTA® in combination with rituximab compared to standard immunochemotherapy in the LOTIS-5 confirmatory Phase 3 global clinical trial in second-line or later, transplant ineligible patients with diffuse large B-cell lymphoma (DLBCL).";17.969999313354492;;3.309999942779541;;28.010000228881836;;16.84000015258789;;20.270000457763672;;4.21999979019165;;10.949999809265137;;5.269999980926514;;8.850000381469727;;18.049999237060547;;32.36000061035156;"PLANO, Texas, July 11, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" or ""we""), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022.";25.610000610351562;Arcutis Canada Inc., a medical dermatology company and subsidiary of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), announced today that Health Canada has accepted the New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) for the treatment of plaque psoriasis in adults and adolescents. The safety and efficacy of roflumilast cream remain under investigation, and market authorization in Canada has not yet been obtained.Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studiesIf approved, roflumilast cream would be the first and only topical PDE4 inhibitor for psoriasis in Canada Target action date of April 30, 2023 Arcutis is in process of establishing Canadian operations WESTLAKE VILLAGE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), today announced that Health Canad;18.459999084472656;;19.350000381469727;;14.970000267028809;;3.240000009536743;;14.510000228881836;
2022-07-12;175.85000610351562;;52.040000915527344;;323.5899963378906;California announced a plan to manufacture its own low-cost insulin for residents. Here's what we know and don't know about the initiative.;108.83000183105469;Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.Today, medical and energy stocks continue to be bought by mutual funds.  This screen tries to identify stocks that mutual funds are buying or adding to their holdings.  It compares other proprietary criteria found in MarketSmith, including Earnings Per Share Rating, Composite Rating, Relative Strength Rating and Sponsorship Rating.California announced a plan to manufacture its own low-cost insulin for residents. Here's what we know and don't know about the initiative.Novo Nordisk A/S (NYSE: NVO) announced the phase 3 results of the explorer7 study, assessing the efficacy and safety of prophylactic treatment with concizumab in people with hemophilia A or B with inhibitors. Concizumab achieved its primary goal, reducing spontaneous and traumatic bleeds by 86% in a prophylactic setting compared to a control arm. In March 2020, Novo Nordisk halted two Phase 3 studies and one Phase 2 trial after three patients experienced non-fatal blood clots. The FDA also placeNovo Nordisk A/S (NYSE: NVO) announced that the phase 1 & 2 FRONTIER1 dose-escalation study in treating people with hemophilia A met its primary safety endpoint. In the FRONTIER1 study, once-weekly and once-monthly under-the-skin administration of Mim8 was tolerated at all doses, regardless of inhibitor status. While six of seven participants in the lowest dose cohort still reported at least one bleed at higher doses (in dose cohorts two to four), only two of the 25 patients reported bleeds. Zer;152.4600067138672;AbbVie (ABBV) closed the most recent trading day at $153.23, moving +0.25% from the previous trading session.;83.94000244140625;;93.5999984741211;;66.72000122070312;Stocks fell from resistance Monday on China news and looming inflation data. Tesla, Twitter and Alibaba were big losers.;75.01000213623047;Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.Q: What approach is Bristol Myers Squibb taking to develop new therapies for immune-mediated diseases?;50.16999816894531;(Bloomberg) -- Cathay Innovation, a venture capital group backed by consumer conglomerate Unilever Plc and energy giant TotalEnergies SE, is raising 1 billion euros ($1 billion) to back tech startups.Most Read from BloombergThis Could Be the Start of a Dollar ‘Doom Loop’ Like No OtherWall Street Set for New ETF Gold Rush as Single-Stock Era BeginsSupply Chains Inching Back to Normal Brace for Headwinds of Softer DemandPakistan’s Imran Khan Leads Ruling Coalition in Key ElectionThe venture arm ofCalifornia announced a plan to manufacture its own low-cost insulin for residents. Here's what we know and don't know about the initiative.;42.251224517822266;With the help of nearly $400 million in royalties from a well-known drug targeting asthma and COPD, the company wrapped up one acquisition and launched another.PHILADELPHIA, July 11, 2022--GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses;14.40999984741211;;42.560001373291016;;10.220000267028809;;161.94000244140625;;10.569999694824219;;145.0;;90.05999755859375;;12.119999885559082;;32.86000061035156;;55.36000061035156;;13.239999771118164;;13.399999618530273;;26.760000228881836;;48.02000045776367;;130.32000732421875;;10.479999542236328;;28.8700008392334;;2.759999990463257;;4.510000228881836;;;;3.5799999237060547;;4.480000019073486;;54.310001373291016;;75.0199966430664;;31.309999465942383;;6.269999980926514;;9.109999656677246;Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...;18.170000076293945;;3.1700000762939453;The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...;28.940000534057617;;15.970000267028809;;20.329999923706055;;4.179999828338623;;10.789999961853027;;5.050000190734863;;8.819999694824219;;18.299999237060547;;33.959999084472656;;23.809999465942383;;17.8799991607666;;19.940000534057617;;;;3.3499999046325684;Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. The analyst notes that though NBI-827104 lags behind its competitors, the market opportunity will be attractive given the total addressable market estimated at ~$13 billion, with no recently approved drugs in ET. The following data readout for Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Praxis Precision Medicines In;15.170000076293945;
2022-07-13;175.44000244140625;;51.790000915527344;;322.4599914550781;H Lundbeck AS (HLUYY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.In this article, we discuss Jim Cramer’s latest predictions and 10 stock recommendations. If you want to read about some more stocks that Jim Cramer recommends, go directly to Jim Cramer’s Latest Predictions and 5 Stock Recommendations. Investors have been worried about rampant inflation and the macroeconomic effects of the efforts of the central bank […];110.12000274658203;;152.14999389648438;In this article, we discuss the 10 best bond ETFs to buy now. If you want to see more ETFs that would make great selections, click 5 Best Bond ETFs to Buy Now. Bond exchange traded funds exclusively or largely invest in bonds. These ETFs offer investors passive exposure to the bond market, with a […]The pharmaceutical industry is chock-full of companies that offer attractive dividends.  AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) especially stand out.  Probably the first thing most investors look at with a dividend stock is the yield.;83.01000213623047;;93.7699966430664;;66.30000305175781;An expert review of data from 79 real-world studies showed that AstraZeneca plc’s (NASDAQ: AZN) COVID-19 vaccine and the available mRNA COVID-19 vaccines provide equally effective protection against hospitalization and death following two doses. The currently available mRNA vaccines are offered by Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX). The study shows that Vaxzevria and the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines offer an equivalent degree of prCOVID-19 vaccines from AstraZeneca Plc (NASDAQ: AZN) and Pfizer Inc (NYSE: PFE) saved an estimated 12 million lives, Bloomberg reported citing a new analysis from Airfinity Ltd. The AstraZeneca vaccine developed by the University of Oxford saved 6.3 million lives, Airfinity said. The estimate for the Pfizer-BioNTech SE (NASDAQ: BNTX) shot was 5.9 million. According to the report, the companies swiftly scaled up production and delivered doses before other manufacturers. The findings build on a stAfter three years at the helm, Agios Pharmaceuticals Inc. CEO Jackie Fouse is stepping away from the corner office. Taking her place is Brian Goff, who was the chief commercial officer at Alexion Pharmaceuticals Inc. for four years.;74.52999877929688;Rhythm Pharmaceuticals, Inc. (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.;49.810001373291016;;41.72104263305664;;14.229999542236328;;42.38999938964844;;9.979999542236328;;165.6699981689453;;10.390000343322754;;144.9499969482422;;88.56999969482422;;12.420000076293945;;32.279998779296875;;55.04999923706055;;13.09000015258789;;13.470000267028809;"— 49% ORR amongst SAVANNAH patients with higher MET levels —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of results from the ongoing SAVANNAH global Phase II trial at the upcoming International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (“WCLC”), taking place August 6-9 in Vienna, Austria. SAVANNAH is a global";28.600000381469727;;48.02000045776367;;128.8699951171875;;10.020000457763672;;28.969999313354492;;2.7699999809265137;;4.420000076293945;;;;3.5299999713897705;;4.579999923706055;;53.93000030517578;;74.93000030517578;;31.5;;6.420000076293945;Erasca, Inc. (ERAS) closed the most recent trading day at $6.27, moving -0.32% from the previous trading session.;8.9399995803833;;18.299999237060547;;3.1700000762939453;;29.899999618530273;;16.540000915527344;;21.780000686645508;SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 12, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,500 shares of its common stock to six new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements mat;4.190000057220459;Wood's flagship Ark Innovation ETF has fallen 54% this year as her technology companies have stumbled.;11.229999542236328;;5.25;;8.6899995803833;;18.860000610351562;;35.849998474121094;;24.25;;19.06999969482422;;20.0;;14.470000267028809;;3.549999952316284;;15.180000305175781;
2022-07-14;175.67999267578125;;51.38999938964844;;326.8900146484375;;109.44999694824219;"The FDA awarded the Radnor company the lucrative voucher after its seizure drug Ztalmy was approved in March.Shares of Marinus Pharmaceuticals Inc. gained 7.9% in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for $110 million to Novo Nordisk . Marinus CFO Steven Pfanstiel told investors in a news release that the sale ""extends our cash runway into the fourth quarter of 2023."" Marinus received the voucher in March after it received approval from the Food and Drug Administration for Ztalmy, its treatment for seizures associated wiNovo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?";150.44000244140625;Uncertainty over elevated inflation, future interest rate hikes, and a potential recession has weighed heavily on financial markets in 2022.  Since prescription drugs are needed in all economic environments, pharma stocks have unsurprisingly trounced the broader markets.  AbbVie (NYSE: ABBV) and Bristol-Myers Squibb (NYSE: BMY) are two of the biggest and best pharma companies in the world that income investors should consider buying.Do you want to collect 10% of your investment back in dividends?  A safer approach is to invest in dividend growth stocks.  Over time, their increases will accumulate, and your recurring dividend income will rise.The last time inflation was this high, the IBM personal computer was less than one year old, and Dallas and The Jeffersons ranked among the most watched TV shows.  Market researcher EvaluatePharma projects that it could become the biggest pharma company based on prescription drug sales by 2028.  AbbVie is able to pass higher costs along to payers relatively easily.Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Raytheon Technologies Corporation (RTX), and Diageo plc (DEO).;82.5999984741211;The Food and Drug Administration delayed a decision on a proposed new esophageal-cancer treatment from Novartis and BeiGene until the agency can complete inspections in China.;93.87999725341797;;65.08000183105469;Futures signaled sharp losses for the market rally amid weak JPMorgan earnings and views for a massive Fed rate hike. Tesla's AI chief has left.HUTCHMED (China) Limited (NASDAQ: HCM) announced the first presentation of results from the ongoing SAVANNAH Phase 2 trial at the upcoming World Conference on Lung Cancer. The study is evaluating savolitinib in combination with AstraZeneca Plc's (NASDAQ: AZN) Tagrisso (osimertinib) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer patients with mesenchymal epithelial transition receptor driven tumors, following disease progression on Tagrisso. The abstract presents re;74.01000213623047;Uncertainty over elevated inflation, future interest rate hikes, and a potential recession has weighed heavily on financial markets in 2022.  Since prescription drugs are needed in all economic environments, pharma stocks have unsurprisingly trounced the broader markets.  AbbVie (NYSE: ABBV) and Bristol-Myers Squibb (NYSE: BMY) are two of the biggest and best pharma companies in the world that income investors should consider buying.In the latest trading session, Bristol Myers Squibb (BMY) closed at $74.53, marking a -0.64% move from the previous day.;49.459999084472656;"Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Phase 3 trial of Dupixent (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) met its primary endpoint of histological disease remission at 16 weeks. EoE is a chronic inflammatory disease that damages the esophagus and prevents it from working correctly. 68% of children on a higher dose and 58% of patients on a lower dose of Dupixent achieved histological disease remission compared to 3% of chilDupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent in people with eosinophilic esophagitis aged 12 years and older who weigh at least 40 kilogramsTrial met its primary endpoint, with 68% of patients on higher dose Dupixent and 58% on lower dose Dupixent achieving histological disease remissSanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum. The drugs comprise two product portfolios for CNS disorders, pain, and vascular diseases, Neuraxpharm said in a release. The first portfolio consists of 15 medicines for CNS disorders across psychiatry and neurology, Neuraxpharm explained. The roster includes drugs such as Nozinan, Tranxene, Tiapridal, Dogmatil and Largactil, which address diseases li";41.00733947753906;U.K. pharmaceutical firm GSK is spinning off its consumer health division on Monday, a long-anticipated step.Shares of Theravance Biopharma Inc. were up 13.8% in premarket trading on Thursday, the day after the company announced plans to sell the royalty rights to GlaxoSmithKline's Trelegy Ellipta to Royalty Pharma for $1.1 billion in cash and up to $450 million in potential milestone payments. Trelegy Ellipta is a treatment for asthma and chronic obstructive pulmonary disease. Theravance also outlined plans to reduce debt, including repaying the company's non-recourse Trelegy notes for about $420 millTheravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK plc’s (NYSE: GSK) TRELEGY ELLIPTA to Royalty Pharma (NASDAQ: RPRX) for over $1.5 billion. The transaction is intended to provide near-, mid-and long-term value to Theravance with an upfront cash payment of ~$1.1 billion, up to $250 million in additional milestone payments, and outer;14.140000343322754;;43.18000030517578;"Shares of Theravance Biopharma Inc. were up 13.8% in premarket trading on Thursday, the day after the company announced plans to sell the royalty rights to GlaxoSmithKline's Trelegy Ellipta to Royalty Pharma for $1.1 billion in cash and up to $450 million in potential milestone payments. Trelegy Ellipta is a treatment for asthma and chronic obstructive pulmonary disease. Theravance also outlined plans to reduce debt, including repaying the company's non-recourse Trelegy notes for about $420 millNEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference cFurther diversifies Royalty Pharma’s portfolio with market-leading respiratory therapyExpected to significantly add to long-term Adjusted Cash Receipts growth(1) (non-GAAP) NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and up to $300 million in additional paTheravance Biopharma, Inc. (""Theravance Biopharma"" or the ""Company"") (NASDAQ: TBPH) today announced it has entered into a definitive agreement to sell all of its units in Theravance Respiratory Company, LLC representing its 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA (""TRELEGY"") to Royalty Pharma (NASDAQ: RPRX) for over $1.5 billion in potential total value (the ""TRELEGY Royalty Transaction""). The transaction is intended to provide near";9.850000381469727;;162.75;For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...;9.680000305175781;;144.99000549316406;;85.56999969482422;;12.289999961853027;;31.850000381469727;;53.65999984741211;;12.649999618530273;;13.170000076293945;HUTCHMED (China) Limited (NASDAQ: HCM) announced the first presentation of results from the ongoing SAVANNAH Phase 2 trial at the upcoming World Conference on Lung Cancer. The study is evaluating savolitinib in combination with AstraZeneca Plc's (NASDAQ: AZN) Tagrisso (osimertinib) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer patients with mesenchymal epithelial transition receptor driven tumors, following disease progression on Tagrisso. The abstract presents re;26.920000076293945;;45.4900016784668;WALTHAM, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five oral presentations and two on-demand papers are being highlighted at the American Society of Retina Specialists Annual Scientific Meeting taking place July 13 -16, 2022 in New York City. New data include an analysis from the Phase 3 DERBY and OAKS studies, which showed the mean rate (slope) of GA lesion growth at 18When looking for the best stocks to buy and watch, focus on those with rising relative price strength.  One stock that fits that bill is ApellisPharmaceuticals stock, which saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 81 to 92.  When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.;131.82000732421875;;9.079999923706055;;28.93000030517578;;2.690000057220459;;4.570000171661377;;;;3.4100000858306885;Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.;4.400000095367432;;52.970001220703125;;74.88999938964844;;29.270000457763672;;6.889999866485596;;8.40999984741211;;17.56999969482422;;3.1500000953674316;;29.719999313354492;;16.079999923706055;;20.889999389648438;;4.150000095367432;;11.0600004196167;;4.980000019073486;;8.604999542236328;;17.25;;35.29999923706055;;23.93000030517578;;19.3799991607666;;19.649999618530273;;14.9399995803833;;3.380000114440918;;14.680000305175781;
2022-07-15;178.22999572753906;;51.75;;331.6000061035156;The cup without handle can yield perfectly timed entries and opportune profits, if you do your homework;114.2300033569336;Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.;153.6199951171875;Dollar Tree, AbbVie and Sysco are part of Zacks Investment Ideas article.Safe dividend stocks offer investors stable income while lowering overall portfolio risks. These stocks typically have substantive profits and cash flow to offer a respectable annual return. Rising interest rates and recession worries have shareholders seeking safety in such robust companies. So far in 2022, high-dividend paying exchange traded funds (ETFs) have seen record inflows of over $25 billion already. For example, the Vanguard High Dividend Yield ETF (NYSEARCA:VYM) has lost 9%, and theToday, we dive into three stocks that are poised to beat inflation and rise above any possible recession. All three names appear worth buying for the second half of 2022 and might be up for consideration as buy-and-hold stocks...;84.63999938964844;There's no company better known for its success in bringing both a vaccine and an anti-viral treatment to market to tackle the COVID-19 pandemic than Pfizer (NYSE: PFE).  The vast majority of this naturally came from Pfizer's COVID product portfolio.  The rare heart disease drugs Vyndaqel/Vyndamax and the anti-coagulant co-owned with Bristol-Myers Squibb called Eliquis helped to power Pfizer's non-COVID revenue higher in the quarter.;94.95999908447266;UnitedHealth Group's (UNH) second-quarter results gain from revenue growth stemming from solid segmental contributions and membership growth. A raised 2022 EPS view remains noteworthy.Hologic's (HOLX) Q3 results will likely gain from the continued uptake of its Panther instruments and an ongoing rebound in elective procedures.Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.: DLTR, LNTH and MRK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 15, 2022.IBCP, PBR, and MRK made it to the Zacks Rank #1 (Strong Buy) income stocks list on July 15, 2022.;67.36000061035156;;75.6500015258789;;50.47999954223633;Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.;42.05750274658203;Shares of Pinterest (NYSE: PINS) soared on Friday after The Wall Street Journal reported that an activist investor has taken a greater than 9% stake in the company.  As of 10:30 a.m. ET, Pinterest stock was up 14%.  Elliott Investment Management has taken a large stake in Pinterest and has reportedly been talking to the management team about ... something.Companies with interests in approved drugs or late-stage drugs can draw cash immediately by selling their sales-based royalty streams.GlaxoSmithKline (GSK) closed at $40.22 in the latest trading session, marking a -1.71% move from the prior day.;14.479999542236328;;43.93000030517578;NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on September 15, 2022, to shareholders of record at the close of business on August 19, 2022. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical iCompanies with interests in approved drugs or late-stage drugs can draw cash immediately by selling their sales-based royalty streams.;9.850000381469727;;166.77999877929688;;10.140000343322754;;145.99000549316406;;85.33000183105469;;12.359999656677246;;31.969999313354492;;53.45000076293945;;12.619999885559082;;13.079999923706055;"HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studiesHONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a Phase I trial in China of HMPL-A83, an investigational novel IgG4-type humanized anti-CD47 monoclonal antibody. The first patient received theHutchison China MediTech (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.";26.969999313354492;;46.06999969482422;;135.19000244140625;SVB Leerink initiated coverage on Karuna Therapeutics Inc (NASDAQ: KRTX) with an Outperform rating and a price target of $170. SVB notes that Karuna already has one positive schizophrenia study (EMERGENT-1) with KarXT. Thus, it only needs one of the two ongoing pivotal studies (EMERGENT-2 or EMERGENT-3) to file for psychosis in schizophrenia successfully. Related: JMP Views Positive Phase 3 Data Equivalent To 'Schizophrenia Blockbuster' For This Stock. The analysts also say that a second potenti;8.949999809265137;;29.540000915527344;STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company’s Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. (“AbbVie”) until his retirement last year, brings over 30 years of experience in global comme;2.759999990463257;;4.900000095367432;;;;3.5799999237060547;;4.5;;53.650001525878906;;74.6500015258789;;30.530000686645508;;6.650000095367432;;8.100000381469727;;18.0;;3.130000114440918;;30.56999969482422;;16.530000686645508;;20.709999084472656;;4.25;;11.380000114440918;;5.210000038146973;;8.739999771118164;;16.75;;35.630001068115234;Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) shareholders should be happy to see the share price up 22% in the last...;24.200000762939453;;19.139999389648438;;18.600000381469727;;15.039999961853027;;3.5799999237060547;;14.569999694824219;
2022-07-18;174.22999572753906;;50.75;;321.7699890136719;Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum have been included in this Analyst Blog.;112.9800033569336;;149.57000732421875;AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.Genmab A/S (NASDAQ: GMAB) has announced that AbbVie Inc (NASDAQ: ABBV) will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous epcoritamab (DuoBody-CD3xCD20) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in 2H of 2022. Epcoritamab is an investigational bispecific antibody. Genmab recently announced that the company would submit a biologics license application (BLA) for epcoritamab with FDA for relapsed/refractory large B-COPENHAGEN, Denmark, July 18, 2022--Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines Agency (EMA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in the second half of 2022. Genmab recently announced that the company will submit a biologics license aAbbVie (NYSE: ABBV) today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. The application is supported by the pivotal Phase 3 ADVANCE and PROGRESS studies evaluating the safety, efficacy, and tolerability of atogepant in adult patients with episodic migraine and chronic migraine, respectively.1,2;82.69999694824219;;92.33999633789062;Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.PMV Pharmaceuticals Inc (NASDAQ: PMVP) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate PC14586 in combination with Merck's Keytruda (pembrolizumab) for advanced solid tumors. PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation. PMV Pharma will evaluate PC14586 in combination with Keytruda as a separate arm of the company's ongoing Phase 1/2 PYNNACLE tIn this article, we discuss blue-chip dividend stocks with over 5% yield. You can skip our detailed analysis of dividend stocks and their returns over the years, and go directly to read 5 Blue Chip Dividend Stocks with Over 5% Yield. In May 2022, US inflation reached its 40-year high, with the consumer price index […]Merck and Block have been highlighted as Zacks Bull and Bear of the Day.Merck & Co. (MRK) is a $240 billion market cap pharmaceutical titan that's climbed over 20% in 2022. The firm is continuing to make acquisitions and many of Merck's fundamentals make it an attractive play for the second half of 2022;66.37000274658203;;73.73999786376953;;50.150001525878906;;41.2010612487793;GSK, previously operated as GlaxoSmithKline, on Monday completed the spinoff of its consumer product unit into a separate $36 billion business operating as Haleon.  The action is not expected to impact London-basked GSK’s Philadelphia operations in University City or Upper Providence, Montgomery County, where the Big Pharma company has about 4,000 employees involved in pharmaceutical research and development, marketing and administration.  Unilever at the start of the year made a $68 billion bid for GSK's consumer products division, but that offer was rejected in January.GlaxoSmithKline has spun-off its £31bn consumer arm in Europe's biggest listing in a decade.GSK plc (NYSE: GSK) has completed the demerger of the Consumer Healthcare business to form the Haleon Group. Reuters reported that shares in Haleon started trading at 330 pence on Monday morning, giving the business a market valuation of around £30.5 billion ($36.4 billion). The company's debut price was in line with market expectations, according to two bankers involved in the deal. However, Haleon's current valuation is lower than expected. Also Read: GSK Spurns $68.4B Bid From Unilever For ItEurope's biggest listing in a decade, Haleon, started trading on the London Stock Exchange on Monday. Haleon in the consumer-health business spinoff of GSK . The combined price of Haleon, 331.7 pence, and the remaining GSK, 1,383.40 pence, of 1715.10 pence, compares to GSK's Friday close of 1,719.20 pence. Haleon will start trading on a when-issued basis on the New York Stock Exchange on Monday, with full trading slated for Friday.By Geoffrey SmithThe pharmaceuticals giant completed the spinoff of its consumer-healthcare business, a bet that greater focus on innovative drugs and vaccines will help accelerate growth.;14.40999984741211;;43.709999084472656;;9.829999923706055;;160.4199981689453;;10.3100004196167;;145.66000366210938;AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.;85.5;;12.399999618530273;;31.200000762939453;;50.060001373291016;;13.15999984741211;;12.59000015258789;;26.34000015258789;;44.7599983215332;;127.5199966430664;;9.300000190734863;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data from a Phase 2 study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022,";28.469999313354492;;2.5799999237060547;;5.0;;;;3.5;;4.050000190734863;;52.4900016784668;;74.83000183105469;;30.15999984741211;;6.71999979019165;The consensus price target hints at a 288% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial Erasca previously signed CTCSAs with Lilly and Pfizer to evaluate cetuximab and encorafenib in combination with ERK1/2 inhibitor ERAS-007 SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK;7.769999980926514;;17.059999465942383;;3.1600000858306885;;27.799999237060547;;15.270000457763672;;19.399999618530273;;4.199999809265137;;11.449999809265137;;5.059999942779541;;8.614999771118164;;15.859999656677246;;34.459999084472656;;23.709999084472656;;18.1299991607666;The average of price targets set by Wall Street analysts indicates a potential upside of 84.6% in Day One Biopharmaceuticals, Inc. (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.;17.520000457763672;;15.350000381469727;;3.3499999046325684;;13.460000038146973;
2022-07-19;171.69000244140625;Johnson & Johnson CFO Joe Wolk sits down with Yahoo Finance's Anjalee Khemlani to discuss company earnings and COVID-19 vaccine demand.A global gauge of stocks climbed on Tuesday as equities rallied while the dollar was down for a third straight day as the door was opened for the European Central Bank to enact a bigger rate hike than expected this week.  Stocks on Wall Street advanced in broad rally, joining their European counterparts, with each of the 11 major S&P sectors climbing as the U.S. corporate earnings season heats up.  Johnson & Johnson shares gained 0.20% after posting results that beat expectations but cut its full-year outlook, citing a stronger dollar.;51.369998931884766;;326.20001220703125;;115.81999969482422;AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale have been included in this Analyst Blog.Today's focus goes to three growth stocks that make the Stocks That Funds Are Buying list.  Strong buying by mutual funds, hedge funds, banks, insurers, pension plans and the like go a long way in supporting the long-term price advances of great stocks.  Meanwhile, Ryan Specialty went public about a year ago.;149.74000549316406;J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.Illinois-headquartered pharmaceutical firm AbbVie (NYSE:ABBV) never ceases to innovate in the healthcare market. A big-bank analyst just raised his price target on ABBV stock and AbbVie’s diversified product portfolio enhances the company’s value to both patients and shareholders. Inflation is running hot and equities traders are worried about what the Federal Reserve will do next. Amid such an uncertain environment, investors should stick to high-conviction holdings. Pick out the best and filte;86.0;"Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.By Scott KanowskyNovartis AG (NYSE: NVS) has reported a core EPS of $1.56 in Q2 FY22 compared to $1.66 a year ago, beating the consensus of $1.52. Net sales were $12.78 billion, down 1% Y/Y or up 5% at constant currency (CC), missing the consensus of $13.01 billion. The increase was driven by volume growth of 12 percentage points, price erosion of 4 percentage points, and the negative impact of the generic competition of 3 percentage points. Q2 operating income of $2.23 billion declined by 30% at constant currenSwiss drugmaker Novartis said earnings at its generic drugs arm Sandoz would likely be flat this year rather than declining, adding that a strategic review over the unit's future was progressing as planned.  In a statement on Tuesday, Novartis confirmed its group guidance for 2022 core operating income to grow in a mid-single digit percentage range.  The company repeated previous guidance that it would provide an update on the future of Sandoz by the end of 2022.In a statement on Tuesday, Novartis confirmed its group guidance for 2022 core operating income to grow in a mid-single digit percentage range.  The company repeated previous guidance that it would provide an update on the future of Sandoz by the end of 2022.  Finance Chief Harry Kirsch told journalists in a call that improved growth prospects for Sandoz did not make a change in ownership less likely.Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33% cc), Kesimpta (+270% cc), Cosentyx (+12% cc), Kisqali (+43% cc) and Zolgensma (+26% cc)Sandoz sales grew +5% cc (-3% USD) benefiting from a return towards normal business dynamics, with growth across all business franchises Q2 core1 operating income grew +5% cc (-2% USD), mainly driven by higher salesQ2";92.36000061035156;Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.Companies in The News Are: SYF,DAL,BA,SGEN,MRK,SBUXStrong Invisalign adoption and continued growth in the iTero scanner installed base are likely to have driven Align Technology's (ALGN) Q2 performance.;68.16000366210938;In late June, US government advisers recommended redesigning the Covid vaccine to target the Omicron variant.  An updated vaccine, timed to coincide with flu jabs, would boost uptake.  The mRNA technology used by BioNTech/Pfizer and Moderna lends itself to the swift redesign of vaccines.The European Commission has approved AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu as monotherapy for unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. The approval is based on results from the DESTINY-Breast03 Phase 3 trial, in which Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1). Additional results from the DESTINY-Breast03 Phase 3 trial showed that;73.13999938964844;NEW YORK, July 19, 2022--Bristol Myers Squibb Announces Extension of Turning Point Tender Offer;51.599998474121094;;32.96084976196289;Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.Apple, UnitedHealth Group, Equinor, GSK and Eaton have been included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), UnitedHealth Group Incorporated (UNH), and Equinor ASA (EQNR).Investors cool on biggest London listing since Glencore in 2011 on worries about inflation and consumer confidence;14.65999984741211;;43.66999816894531;;10.069999694824219;;168.07000732421875;Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Webcast and Conference Call to Be Held Tuesday, August 2, 2022 at 8:30 a.m. EDTWALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2022 financial results on Tuesday, August 2, 2022. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and six- month reporting period ended June 3;10.619999885559082;;145.9499969482422;;87.94000244140625;;12.850000381469727;;31.56999969482422;;51.880001068115234;;13.930000305175781;;12.710000038146973;;27.559999465942383;;52.060001373291016;Apellis Pharmaceuticals stock rose sharply Tuesday after the drug developer said the U.S. Food and Drug Administration had granted priority-review designation to pegcetacoplan, its drug that aims to treat a cause of blindness that affects more than 1 million Americans.  Pegcetacoplan is an investigational therapy to treat geographic atrophy, a chronic progressive degeneration of the macula—a part of the retina.  Apellis describes the condition as “an advanced form of age-related macular degeneration (AMD) and a leading cause of blindness that impacts more than 5 million people worldwide, including one million people in the United States.”Shares of Apellis Pharmaceuticals Inc. jumped 24.5% in premarket trading on Tuesday after the company said it received a Priority Review designation from the Food and Drug Administration for its geographic atrophy treatment candidate. The target action date is Nov. 26, and the FDA said it does not plan to hold an advisory committee meeting. Apellis' stock is down 5.3% this year, while the broader S&P 500 has declined 18.9%.PDUFA target action date is November 26, 2022FDA has stated that it is not currently planning to hold an advisory committee meeting to discuss the application WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation for the intravitreal pegcetacoplan New Drug Application (NDA). Peg;133.25;;9.770000457763672;;30.739999771118164;;2.609999895095825;;5.150000095367432;;;;3.759999990463257;;4.360000133514404;;52.61000061035156;"Harmony Biosciences Holdings, Inc. (""Harmony"" or the ""Company"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's second quarter 2022 financial results on Tuesday, August 2, 2022. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.";74.72000122070312;;31.8799991607666;GAITHERSBURG, Md., July 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the third quarter of 2022, and financial outlook for full year 2022. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent’s website. To partic;7.28000020980835;In the latest trading session, Erasca, Inc. (ERAS) closed at $6.72, marking a +1.05% move from the previous day.;7.590000152587891;;17.770000457763672;;3.2799999713897705;;28.940000534057617;;16.270000457763672;;20.350000381469727;;4.409999847412109;;11.390000343322754;;5.0;;8.399999618530273;;17.540000915527344;;35.20000076293945;;24.829999923706055;Biotech stocks bottomed in mid-June and have seen some upward momentum since then. The recovery is in line with the broader market. But the industry has yet to get a lift from fundamental improvement. Click to EnlargeSource: Chart by TradingView We saw a flurry of activity in 2020 – the year when the Covid-19 pandemic first broke out. Biopharma companies, both big and small, jumped onto the Covid-19 drug and vaccine research bandwagon. While they were on it, most of them racked up unsustainable;19.3799991607666;;18.170000076293945;;15.986000061035156;;3.4800000190734863;;14.329999923706055;
2022-07-20;170.7100067138672;Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.In this article, we discuss 10 best long-term dividend stocks. You can skip our detailed analysis of dividend stocks and their recent performance, and go directly to read 5 Best Long-Term Dividend Stocks. Over the years, dividend stocks have contributed meaningfully to long-term total market returns. According to a report by Hartford Funds, from 1960 […]In this article, we talk about the 10 best healthcare stocks to buy now according to Motley Fool’s 1623 Capital. If you wish to skip our detailed analysis of 1623 Capital’s hedge fund performance and stock picks, go directly to 5 Best Healthcare Stocks To Buy Now According To Motley Fool’s 1623 Capital. 1623 Capital […]Many financial advisors, when asked how young people should invest, would say that such investors should be risk-seeking. The idea is that they have the benefit of time and that any losses will be overshadowed by big winners. Ideally, such investors will be farther ahead than their more risk-averse peers once they both become a bit older. Those same advisors will recommend that those investors then switch to steadier growth and lower-risk equities. The complete opposite is the advisor who recommPlease note that today's meeting may include forward-looking statements relating to, among other things, the company's future financial performance, product development, market position and business strategy, and the anticipated separation of the company's consumer health business.  This is Joaquin Duato, chief executive officer of Johnson & Johnson.The stock market closed higher on Tuesday on solid earnings reports and economic news, led by FAANG stocks.Gorsky had helped establish J&J as a major player in the rare diseases market and led the development of the healthcare giant's first single-shot COVID-19 vaccine.  As CEO, Gorsky also had to steer the company through some high-profile crises, including allegations that its Baby Powder contained cancer-causing asbestos and litigation that alleged it contributed to the opioid epidemic in the United States.  Gorsky, currently an executive chairman at J&J, had handed over the reins in January this year after almost a decade at the role.Communication services stocks led a broad rally on Wall Street, with Netflix (NFLX) surging ahead of its Q2 earnings report.Yahoo Finance markets reporter Ines Ferre breaks down the market rally action, as well as the sector gains, Dow Jones and Nasdaq leaders, semiconductor stocks, and the travel industry.Health care bellwether Johnson & Johnson topped second-quarter expectations Tuesday, but JNJ stock fell on its trimmed 2022 outlook.Shares of Halliburton  rose after the oilfield services provider posted a 41% increase in quarterly adjusted profit.  Toymaker Hasbro Inc reported quarterly profit ahead of expectations.  Truist Financial Corp also beat market estimates for quarterly profit, sending the bank's shares up.The CDC has unanimously recommends Novavax's latest COVID-19 booster vaccine for adults, awaiting the director's final approvalBy Oliver GrayIs Johnson & Johnson stock a sell after cutting its 2022 outlook amid currency concerns? Is JNJ stock a sell right now?Toy company Hasbro Inc beat market estimates for quarterly profit, sending the toymaker's shares up 0.8%.  Shares of Halliburton rose 1.2% after the oilfield services provider posted a 41% increase in quarterly adjusted profit.  Johnson & Johnson shares lost 1.6%, reversing earlier gains.J&J has had to cut its forecast for the second time this year due to foreign currency effects.J&J is winding down its COVID-19 vaccine manufacturing as demand wanes globally and as the company sits on excess supply.A soaring U.S. currency led pharma major Johnson & Johnson to trim its annual adjusted profit view and IBM Corp to warn of a nearly $3.5 billion hit.  Spiraling inflation initially led markets to price in a 100 basis points hike in interest rates in the upcoming Fed meeting later this month, until some policymakers signaled a 75 basis points increase.Stock market indexes gapped up at the start of Tuesday's session and lifted into Monday's highs.;50.81999969482422;;322.0299987792969;;113.58999633789062;;147.69000244140625;"AbbVie Inc (NYSE: ABBV) announced a strategic transaction to develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical (MIGS) device. This complementary alliance will support iSTAR Medical's development and commercial efforts for MINIject, and provide an opportunity to expand AbbVie's eye care business. MINIject received European approval in the last quarter of 2021 and launched commercially in select European countries in early 2022. iSTAR Medical is currBiogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject® device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance will support iSTAR Medical's development and commercial efforts for MINIject®, as well as provide an opportunity to expand AbbVie's eye care business, building on its glaucoma portfolio which includes drops, sustained release implants, anWhile rational traders participate in the equities market to see solid returns on their investments, the present paradigm encourages everyone to consider the best income stocks to buy now. Of course, no one is going to complain about robust capital gains; That is, until tax season. But the inflationary crisis we’re in drives more emphasis on passive income than ever before. As of this writing, the annual inflation rate for the U.S. is 8.6% for the 12 months ended May 2022, the largest annual inc";84.22000122070312;Learn about the forces driving the Chinese economy. China has the second largest GDP in the world but is not as developed as others in the top 10.Companies in The News Are: BA, NVS, TFC, IBMNVS earnings call for the period ending June 30, 2022.Swiss drugmaker Novartis delivered a mixed second-quarter report Tuesday, but Novartis stock popped on the company's bullish outlook.;89.6500015258789;AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.In this article, we discuss 10 best long-term dividend stocks. You can skip our detailed analysis of dividend stocks and their recent performance, and go directly to read 5 Best Long-Term Dividend Stocks. Over the years, dividend stocks have contributed meaningfully to long-term total market returns. According to a report by Hartford Funds, from 1960 […]Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.Lutz Staacke talks about finding a company that appreciates him for who he isThe strong demand for the cloud, data analytics, the Internet of Things and security products and solutions amid the ongoing digital transformation wave is likely to have boosted Infosys' (INFY) Q1 performance.The company said Keytruda, its blockbuster cancer drug, in combination with chemoraditation therapy showed improvement in event-free survival, or the period of time a patient remains free of complications compared to a placebo.  Keytruda showed a safety profile similar to previously reported studies, according to Merck.  The drug belongs to a class of treatments called PD-1 inhibitors, which work by boosting the immune system's ability to fight cancer cells.RAHWAY, N.J., July 20, 2022--Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaBy Peter NurseYahoo Finance markets reporter Ines Ferre breaks down the market rally action, as well as the sector gains, Dow Jones and Nasdaq leaders, semiconductor stocks, and the travel industry.The CDC has unanimously recommends Novavax's latest COVID-19 booster vaccine for adults, awaiting the director's final approvalMerck & Co Inc (NYSE: MRK) will stop for futility the Phase 3 LYNK-003 trial of Lynparza with or without bevacizumab for unresectable or metastatic colorectal cancer who have not progressed following first-line induction. The action follows the recommendation of an independent Data Monitoring Committee (DMC) after the DMC reviewed the data from a planned interim analysis. Related: Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients. Lynparza is a PARP inhibitor co-deHologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.;65.79000091552734;AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.Yahoo Finance’s Jared Blikre breaks down how markets opened on Wednesday.The CDC has unanimously recommends Novavax's latest COVID-19 booster vaccine for adults, awaiting the director's final approvalMerck & Co Inc (NYSE: MRK) will stop for futility the Phase 3 LYNK-003 trial of Lynparza with or without bevacizumab for unresectable or metastatic colorectal cancer who have not progressed following first-line induction. The action follows the recommendation of an independent Data Monitoring Committee (DMC) after the DMC reviewed the data from a planned interim analysis. Related: Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients. Lynparza is a PARP inhibitor co-deJ&J is winding down its COVID-19 vaccine manufacturing as demand wanes globally and as the company sits on excess supply.Stock market indexes gapped up at the start of Tuesday's session and lifted into Monday's highs.;72.81999969482422;Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.PRINCETON, N.J., July 20, 2022--Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with DisabilitiesIn the latest trading session, Bristol Myers Squibb (BMY) closed at $73.14, marking a -0.81% move from the previous day.;49.88999938964844;;32.96084976196289;Learn about the forces driving the Chinese economy. China has the second largest GDP in the world but is not as developed as others in the top 10.;14.479999542236328;;43.0099983215332;;9.970000267028809;;176.6999969482422;;10.600000381469727;;146.02000427246094;;90.25;;12.729999542236328;;31.65999984741211;;48.11000061035156;Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...;13.800000190734863;;12.770000457763672;;28.170000076293945;;50.810001373291016;'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.The FDA accepted Apellis Pharmaceuticals' application for an eye-disease treatment on Tuesday, leading APLS stock to surge.HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ: APLS) with a Buy rating and a $75 price target. The analyst expects Apellis's C3 inhibitor, pegcetacoplan, to be approved and become a blockbuster in geographic atrophy (GA) with peak sales of over $2 billion. Pegcetacoplan is already approved in IV formulation for a life-threatening blood disorder PNH under the brand name Empaveli, where it has shown itself to be more effective than Alexion's C5 inhibitors, the analyst;130.13999938964844;;10.079999923706055;;30.8700008392334;;2.640000104904175;;5.130000114440918;;;;4.019999980926514;;4.650000095367432;;53.060001373291016;;75.01000213623047;;31.639999389648438;J&J is winding down its COVID-19 vaccine manufacturing as demand wanes globally and as the company sits on excess supply.;7.880000114440918;;7.610000133514404;LAUSANNE, Switzerland, July 20, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in LOTIS-9, a Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in unfit and frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).;18.68000030517578;In this article, we talk about the 10 best healthcare stocks to buy now according to Motley Fool’s 1623 Capital. If you wish to skip our detailed analysis of 1623 Capital’s hedge fund performance and stock picks, go directly to 5 Best Healthcare Stocks To Buy Now According To Motley Fool’s 1623 Capital. 1623 Capital […];3.299999952316284;;30.649999618530273;A Lexington life sciences building that's set to wrap up construction this fall is now fully leased, with five companies taking space on a property once home to an office complex.  Greatland Realty Partners and Singerman Real Estate are developing the 180,000-square-foot facility, named Revolution Labs, at 1050 Waltham St. in Lexington.  Boston-based Greatland acquired the nearly six-acre site for $7 million in 2019, starting construction on the new facility after the town rezoned the property.;17.0;;21.18000030517578;;4.349999904632568;;12.350000381469727;;5.360000133514404;;8.399999618530273;;19.06999969482422;;34.029998779296875;;24.06999969482422;;19.239999771118164;;19.899999618530273;;17.440000534057617;;3.569999933242798;;14.859999656677246;
2022-07-21;171.30999755859375;In this article, we discuss 10 best dividend stocks to buy in 2022. You can skip our detailed analysis of dividend investment and performance of dividend stocks, and go directly to read 5 Best Dividend Stocks to Buy in 2022. In 2022, dividend stocks are gaining traction among investors due to the global market crash. […]In this article, we discuss 5 dividend stocks of all time. You can skip our detailed analysis of the past performance of dividend stocks, and go directly to read 5 Best Dividend Stocks of All Time. Dividend investing is all the rage with investors these days as they seek profitable options due to fears of a […]In this article, we discuss the 10 best value ETFs to invest in. You can skip our detailed analysis of these ETFs and the current market situation, and go directly to 5 Best Value ETFs To Invest In. Amid fears over recession and higher inflation levels, U.S. ETFs hauled in about $297.3 billion in the […]Johnson & Johnson (NYSE: JNJ) reduced its full-year sales and adjusted earnings guidance on Tuesday.  Citi cut its price target for Microsoft (NASDAQ: MSFT) this week as well.  This chart shows a big problem for Johnson & Johnson, IBM, and Microsoft.Sonali Pier, PIMCO managing director and portfolio manager, joins Yahoo Finance Live to examine the outlook on earnings amid the market's current relief rally and the benefits of a strengthening U.S. dollar.Multinational companies this earnings season have been pointing to a new problem impacting bottom lines: a strong dollar.;51.119998931884766;The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.President Joe Biden has tested positive for Covid-19, the White House said on Thursday.  The president was feeling “very mild symptoms” and has begun taking Paxlovid, Press Secretary Karine Jean-Pierre said in a statement.  Biden will isolate at the White House until testing negative, Jean-Pierre added, and will continue to carry out all duties fully during that time.UK competition authorities have cut £20mn from a £90mn fine against two pharma companies for overcharging the NHS for a life-saving epilepsy drug, after a long legal battle.  The Competition and Markets Authority on Thursday fined Pfizer and Flynn Pharma £70mn for exploiting regulatory loopholes to charge unfairly high prices for phenytoin sodium capsules — a drug that prevents seizures — for more than four years.  The ruling follows a legal battle between the companies and the CMA over an earlier decision to fine them £90mn.Pfizer and Merck could thrive during a recession. As recession fears have gripped the stock market, both have outperformed.Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.The company’s hiring spree and soaring stock led to an uptick in luxury home purchases by employees during the pandemic.The CMA said it has fined Pfizer £63 million and Flynn £6.7 million respectively after reassessing an initial investigation.Pfizer and Flynn Pharma were fined a total of 70 million pounds ($84 million) on Thursday by Britain's antitrust watchdog for overcharging the National Health Services (NHS) for a life-saving epilepsy drug.  The Competition and Markets Authority (CMA) in 2016 had fined Pfizer and Flynn about 90 million pounds for inflating prices for Epanutin by as much as 2,600% to 67.50 pounds for a 100mg pack before the companies won a 2018 appeal against the penalty.Big pharma stocks gained impressively during the pandemic years for obvious reasons. However, with the pandemic in the rear-view mirror, the best pharmaceutical stocks continue to perform remarkably well. This is a welcome surprise, considering how the equities and other risky assets have taken a beating of late. Inflation, interest rate hikes and geopolitical tensions have weighed down market returns, but Big pharma seems to be an anomaly. Regardless of the pandemic, the pharmaceutical industryIs Pfizer stock a sell after Wall Street reduced its expectations for 2022 sales and profit? Is PFE stock a sell right now?;326.9200134277344;The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.Style Box ETF report for FVDBig pharma stocks gained impressively during the pandemic years for obvious reasons. However, with the pandemic in the rear-view mirror, the best pharmaceutical stocks continue to perform remarkably well. This is a welcome surprise, considering how the equities and other risky assets have taken a beating of late. Inflation, interest rate hikes and geopolitical tensions have weighed down market returns, but Big pharma seems to be an anomaly. Regardless of the pandemic, the pharmaceutical industry;115.36000061035156;;147.75;The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.If your portfolio is teetering amid a turbulent bear market -- as pretty much everyone's is at the moment -- you need a plan to come out ahead, and you need to act on it.  Fruitful investments made today could have the benefit of a very long run-up once the bear market subsides, and mistakes made out of fear could have consequences for a long time, too.  Think about a business like Pfizer (NYSE: PFE), which has seen its shares fall by 11% so far this year despite widespread successes with hit products like Comirnaty, its coronavirus vaccine, and Paxlovid, its antiviral pill for COVID.AbbVie (NYSE: ABBV), today announced that Health Canada has approved RINVOQ® (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response to a biologic disease modifying anti-rheumatic drug (DMARD) or when use of those therapies is inadvisable. RINVOQ may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs (NSAIDS).2;85.88999938964844;Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.Swiss pharmaceutical giant Novartis (NYSE: NVS) prides itself on the breadth and depth of its oncology portfolio.  A month ago, Novartis appeared to be on the verge of addressing this gap, but now must wait a little longer to hear the Food and Drug Administration's (FDA) verdict.  After watching from the sidelines for the past decade as Merck's Keytruda and Bristol Myers Squibb's Opdivo generated mega-blockbuster sales, Novartis finally looked set to introduce its own competing drug into the market.Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic immune-mediated inflammatory diseasesSandoz is committed to supporting healthcare professionals to advance patient care and improve access to medicines sustainably and affordably Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and;90.13999938964844;Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.In this article, we discuss 5 dividend stocks of all time. You can skip our detailed analysis of the past performance of dividend stocks, and go directly to read 5 Best Dividend Stocks of All Time. Dividend investing is all the rage with investors these days as they seek profitable options due to fears of a […]F5 Networks' (FFIV) Q3 performance is likely to have benefited from the hybrid work environment and the ongoing digital transformation wave, which is boosting the demand for secured communication networks.Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.;65.36000061035156;Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.;73.04000091552734;The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.Meet some of the first cohort of diverse medical students dedicated to improving health equity who have been chosen to participate in the Robert A. Winn Clinical Investigator Pathway Program.PRINCETON, N.J., July 21, 2022--B MS Teams Up with Jack and Jill of America Inc. to Expand Tomorrow’s Innovators Program to Increase Black Representation in the Healthcare IndustryPharmaceutical giant Bristol Myers Squibb's (NYSE: BMY) purchase of Celgene turned it into a dominant player in oncology and hematology, and this year, the company has aggressively strengthened this position.  Following a string of successful deals and regulatory approvals, the company needs to move past some negative news to keep its momentum going.  Bristol Myers acquired Celgene for $74 billion at the end of 2019, gaining its current bestseller Revlimid, three late-stage drug candidates, and a strong early-stage pipeline.Big pharma stocks gained impressively during the pandemic years for obvious reasons. However, with the pandemic in the rear-view mirror, the best pharmaceutical stocks continue to perform remarkably well. This is a welcome surprise, considering how the equities and other risky assets have taken a beating of late. Inflation, interest rate hikes and geopolitical tensions have weighed down market returns, but Big pharma seems to be an anomaly. Regardless of the pandemic, the pharmaceutical industry;49.959999084472656;Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,527,121,390 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n;;;14.710000038146973;Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) met its primary endpoint. CIPD is a rare chronic autoimmune disease affecting the peripheral nervous system, resulting in progressive symmetric weakness and impaired sensory function in the arms and legs. Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment. Also Read: Takeda's HereditaOSAKA, Japan & CAMBRIDGE, Mass., July 21, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment when used as a;42.7400016784668;;9.880000114440918;;203.63999938964844;;10.5;;146.19000244140625;;90.08999633789062;;13.180000305175781;;31.760000228881836;JERSEY CITY, N.J., July 21, 2022--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company’s webcast and call scheduled for 8:30 a.m. EDT.Cognizant (NASDAQ: CTSH) today announced it has signed a new multi-year agreement with Organon (NYSE: OGN), a global women's health company, to help improve the company's delivery of healthcare products and crucial medicinal supply chain management.;49.5;;13.9399995803833;;13.5;;27.600000381469727;;52.599998474121094;The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.;131.5;;10.569999694824219;;30.3799991607666;;2.5399999618530273;Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and a few strategic agreements.;4.900000095367432;;;;3.9700000286102295;;4.619999885559082;;52.59000015258789;;74.79000091552734;Pharmaceutical giant Bristol Myers Squibb's (NYSE: BMY) purchase of Celgene turned it into a dominant player in oncology and hematology, and this year, the company has aggressively strengthened this position.  Following a string of successful deals and regulatory approvals, the company needs to move past some negative news to keep its momentum going.  Bristol Myers acquired Celgene for $74 billion at the end of 2019, gaining its current bestseller Revlimid, three late-stage drug candidates, and a strong early-stage pipeline.;31.6200008392334;;7.769999980926514;;7.559999942779541;;19.280000686645508;;3.3499999046325684;;30.149999618530273;;17.209999084472656;;20.6299991607666;;4.03000020980835;;12.3100004196167;;5.210000038146973;;;;18.520000457763672;Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;33.47999954223633;;22.690000534057617;;19.239999771118164;;19.6299991607666;;17.43000030517578;Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;3.5299999713897705;;13.989999771118164;
2022-07-22;172.1199951171875;Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.Mention retirement stocks and your mind probably goes to more conservative, relatively defensive equities. The tried and true method of seeking investments that withstand market cyclicality while steadily growing is a wise one. In other words, it isn’t one from which to deviate. 7 Best Bull Market Stocks to Buy Now And given the bear market we’re currently in, there are opportunities to be had. That means there’s a reasonable chance to benefit from the overall market slump, buy cheap, reliable rIn this article, we will look at 10 stocks least vulnerable to a recession. If you want to explore similar stock ideas, you can also read 5 Stocks Least Vulnerable to Recession. The Fed Resorting to Its Tools We are over two quarters into 2022 and there is havoc in the stock market. The Fed […]J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina have been included in this Analyst Blog.Novavax passed the finish line to gain authorization for its COVID-19 vaccine, and its first commercial product. But the company is still working on younger age group eligibility and boosters with the FDA.(Bloomberg) -- South Korean hedge fund J&J Investments Co. is increasing its position in Naver Corp. and other tech shares on expectations the nation’s equity market will stage a recovery from a brutal first half. Most Read from BloombergBiden Considers New Pause on Paying Back Student Loans, $10,000 ReliefStar Wars Knights of the Old Republic Game Paused Amid Studio ShakeupBiden Will Speak With Xi on Thursday as US-China Ties WorsenMajor Philippine Earthquake Kills 4, Triggers LandslidesCoinbasToday's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Cigna Corporation (CI), and Vertex Pharmaceuticals Incorporated (VRTX).Novavax CEO Stan Erck joins Yahoo Finance Live to discuss the CDC recommending Novavax’s COVID-19 vaccine for adults, COVID vaccine distribution, the vaccine demand, and the outlook for an Omicron vaccine.;51.22999954223633;"President Joe Biden has completed his first full day of treatment with antiviral drug Paxlovid and his symptoms due to COVID-19 ""have improved,"" said his physician, Dr. Kevin C. O'Connor, in a letter released Friday by the White House. Biden's symptoms remain characterized by a runny nose, fatigue and an occasional ""loose"" cough, and his voice is ""deeper this morning,"" the doctor wrote. O'Connor noted that he anticipated that Biden will respond favorably, and there has been ""nothing in the coursU.S. COVID cases and hospitalizations are rising again and are now trending at the highest level seen this summer so far, as the BA.5 omicron subvariant becomes dominant.AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.Two years after the onset of COVID-19 in the U.S., a new vaccine is coming to market -- who will it help?Amazon.com is buying One Medical for $3.9 billion cash, AT&T customers are paying their bills later than usual, federal prosecutors announce first crypto insider trading charges, and other news to start your day.Novavax passed the finish line to gain authorization for its COVID-19 vaccine, and its first commercial product. But the company is still working on younger age group eligibility and boosters with the FDA.The FTSE 100 and European stock markets were slightly up on Friday with the BT merger approval driving sentiment.(Bloomberg) -- China’s Xi Jinping wished US President Joe Biden a speedy recovery from Covid-19, as the two leaders prepare to speak over the phone to ease tensions between the two largest economies.Most Read from BloombergThree Arrows Founders Break Silence Over Collapse of Crypto Hedge FundTesla’s Bitcoin Dump Leaves Accounting Mystery in Its WakeRussian Missile Strike on Odesa Tests Day-Old Grain Export DealTrump Insiders Recall How He Spurned Pleas to Act as Riot RagedStudent Loan Borrowers(Bloomberg) -- President Joe Biden tested positive for Covid-19 on Thursday, finally contracting the virus whose control and ultimate defeat he had made a centerpiece of his campaign for the White House.Most Read from BloombergAmericans Who Can’t Afford Homes Are Moving to Europe InsteadMusk Lieutenant Scrutinized in Internal Tesla Purchasing ProbeThese Are the World’s Most (and Least) Powerful Passports in 2022Biden Contracts Covid as Pandemic Shows Its Staying PowerEx-Coinbase Manager ArrestedJoe Biden has contracted Covid-19 and has started taking Pfizer’s antiviral pill to combat the disease, the White House announced.  The 79-year-old US president tested positive on Thursday morning, according to White House press secretary Karine Jean-Pierre, and will work from isolation until he tests negative.  The White House said he is fully vaccinated with two additional booster shots and was experiencing “very mild symptoms”.Novavax CEO Stan Erck joins Yahoo Finance Live to discuss the CDC recommending Novavax’s COVID-19 vaccine for adults, COVID vaccine distribution, the vaccine demand, and the outlook for an Omicron vaccine.";328.75;Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks have bucked the bear market trend so far this year, gaining 6% and 20% respectively, compared to the S&P 500's loss of more than 17%.  Analysts at Morgan Stanley recently noted that obesity has the potential to become the next blockbuster pharma category, reaching a value of $54 billion in 2030.  The main reason for that projection is that treatment trends are showing more of a focus on upstream causes of diabetes and cardiovascular disease, rather than on treating the resulting diseases.In the latest trading session, Eli Lilly (LLY) closed at $326.92, marking a +1.52% move from the previous day.;114.55999755859375;Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks have bucked the bear market trend so far this year, gaining 6% and 20% respectively, compared to the S&P 500's loss of more than 17%.  Analysts at Morgan Stanley recently noted that obesity has the potential to become the next blockbuster pharma category, reaching a value of $54 billion in 2030.  The main reason for that projection is that treatment trends are showing more of a focus on upstream causes of diabetes and cardiovascular disease, rather than on treating the resulting diseases.;148.47000122070312;One way to maximize your odds for success is by investing in stocks that are both growing and pay dividends.  One potential option is drugmaker AbbVie (NYSE: ABBV).  AbbVie is facing that situation today as its hugely successful rheumatoid arthritis drug Humira will lose patent protection next year.AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.In the latest trading session, AbbVie (ABBV) closed at $147.75, marking a +0.04% move from the previous day.Looking for value stocks? Healthcare has been ignored over the last year.;85.87000274658203;J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.;90.11000061035156;Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.Merck & Co.  has had a few disappointments with trial results of some of its new blockbuster cancer drugs, but the charts of the pharmaceutical giant remain bullish and probably pointed higher in the weeks ahead.  The On-Balance-Volume (OBV) line shows a rise from September, telling us that buyers of MRK have been more aggressive than sellers.  A new high on the OBV line would be welcome.Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.Looking for value stocks? Healthcare has been ignored over the last year.;65.25;Novavax passed the finish line to gain authorization for its COVID-19 vaccine, and its first commercial product. But the company is still working on younger age group eligibility and boosters with the FDA.;72.94999694824219;PRINCETON, N.J., July 22, 2022--BMS Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination, Opdualag ....;49.83000183105469;;42.290000915527344;Shares of pharmaceutical company GlaxoSmithKline (NYSE: GSK) rose 25% on Thursday.  The company, on Monday, said that its former consumer healthcare division, under the name Haleon, listed on the London Stock Exchange.  GSK stock only rose a bit, but the 25% jump includes the added value of the new shares of Haleon as well.;14.609999656677246;;43.22999954223633;;9.550000190734863;;201.74000549316406;Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;10.5600004196167;;145.9499969482422;;88.51000213623047;;13.359999656677246;;31.959999084472656;;49.599998474121094;;13.399999618530273;;12.529999732971191;;26.719999313354492;;52.790000915527344;;128.77999877929688;;10.0;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody, in a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma,";28.270000457763672;;2.4200000762939453;;4.559999942779541;;;;3.680000066757202;;4.369999885559082;;51.02000045776367;;75.0;;31.25;;7.46999979019165;Erasca, Inc. (ERAS) closed the most recent trading day at $7.77, moving -1.4% from the previous trading session.;7.360000133514404;;16.8799991607666;;3.1600000858306885;;28.559999465942383;;15.819999694824219;;19.5;;3.890000104904175;If you love investing in businesses that are on the bleeding edge of biotechnology, psychedelics companies are right up your alley.  Despite substantial cultural baggage and significant legal hurdles, psychedelic medicines are proving themselves to be highly effective at treating mental illnesses like depression and post-traumatic stress disorder (PTSD), and that means they're likely to be quite lucrative for the developers.  On July 13, the Drug Enforcement Agency (DEA) said it was scheduling a public hearing for Aug. 22, so people would have a chance to comment on a proposed rule that would move five psychedelic compounds into the Schedule 1 category.;11.800000190734863;;4.510000228881836;;8.5;;16.90999984741211;;31.940000534057617;;21.520000457763672;;18.030000686645508;;18.610000610351562;;17.3799991607666;;3.2100000381469727;;12.960000038146973;
2022-07-25;172.4600067138672;In this article, we discuss 10 companies that recently raised their dividends. You can skip our detailed discussion on dividend stocks, and go directly to read These 5 Companies Recently Increased Their Dividends. In 2022, many companies raised their dividends steadily as their financial health recovered after the Covid-19 pandemic. Nearly 81% of the companies […]Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.Among successful money managers, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett is, arguably, in a class of his own.  Since becoming CEO of Berkshire in 1965, the Oracle of Omaha has led his company's shares to an average annual return of 20.1%, through Dec. 31, 2021.  Buffett's success is a reflection of a long list of factors, including his portfolio concentration, narrow investment focus, and love of dividend stocks.;51.77000045776367;"NEW YORK (Reuters) -A federal appeals court on Monday rejected Pfizer Inc's challenge to a U.S. anti-kickback law the drugmaker said prevented it from helping heart failure patients, many with low incomes, afford medicine that cost $225,000 per year.  A unanimous three-judge panel of the New York-based 2nd U.S. Circuit Court of Appeals rejected Pfizer's effort to directly cover co-pays for patients taking its Vyndaqel and Vyndamax drugs.  The court agreed with a lower-court judge that Pfizer's Direct Copay Assistance Program violated a ban on ""knowingly or willfully"" providing financial support to induce federally reimbursable drug purchases, even absent corrupt intent.BA.5 is the strain that likely infected President Joe Biden, who tested positive last week and is reportedly still suffering from a sore throat and body aches.Yellen says it’s not a recession as more data await, Boeing workers at 3 defense locations plan to strike, wildfires rage in California as Northeast sets heat records, and other news to start your day.The investment arm of insurance giant Munich Re initiated a position in Apple stock, and increased investments in Nvidia, Corning, and Pfizer.Paxlovid dominates antiviral treatment market but weak demand could cause supply glut, data group saysThe Conference Board's Consumer Confidence Index for July comes out Tuesday, and the Federal Open Market Committee announces its interest-rate decision on Wednesday.";331.54998779296875;;115.93000030517578;"Bagsværd, Denmark, 25 July 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiat";150.22000122070312;Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.AbbVie (NYSE: ABBV) and Allergan Aesthetics announced today that more than 30 abstracts, including seven podium presentations, will be presented during the upcoming TOXINS 2022 Conference, July 27-30 in New Orleans. Clinical studies, health economics, preclinical research, and real-world utilization data will highlight onabotulinumtoxinA (BOTOX® and BOTOX® Cosmetic) across approved and investigational indications.J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.;86.08000183105469;"J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EUMultiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that can drastically affect an individual’s everyday life and requires life-long treatmentSandoz is committed to accelerating patient access to potentially life-changing, high-quality treatments, while generating savings for healthcare systems and patients Basel, July 25";90.52999877929688;"NEW YORK (Reuters) -A former Goldman Sachs banker, a former FBI agent trainee, and a technology executive were among those charged on Monday with insider trading in separate schemes that together generated millions of dollars in profits, U.S. prosecutors said.  ""Each of the defendants charged today corrupted the integrity of the markets,"" Damian Williams, the top federal prosecutor in Manhattan and one of Wall Street's main cops, told reporters.  The U.S. Securities and Exchange Commission (SEC) filed related civil charges over the trading schemes.A former investment banker, a former FBI agent trainee and several others were charged on Monday with insider trading in separate schemes that together generated millions of dollars in illegal profits, U.S. prosecutors said.  Damian Williams, the top federal prosecutor in Manhattan, was expected to address the charges in a press conference.  Williams, nominated to the role by President Joe Biden, has made enforcement of financial crimes a focus since taking office last year.Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.In this article, we discuss 10 companies that recently raised their dividends. You can skip our detailed discussion on dividend stocks, and go directly to read These 5 Companies Recently Increased Their Dividends. In 2022, many companies raised their dividends steadily as their financial health recovered after the Covid-19 pandemic. Nearly 81% of the companies […]J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.";66.16000366210938;Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.WILMINGTON, Del., July 25, 2022--AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of ENHERTU® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients in the US with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-negative) breast cancer who have received a prior therapy in the metastatic setting. The application has been granted Priority Review.The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca Plc's (NASDAQ: AZN) Ultomiris (ravulizumab) for generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Ultomiris would be the first and only approved long-acting C5 complement inhibitor for AChR antibody-positive gMG in the EU if authorized. The positive opinion is based on results from the CHAMPION-MG Phase 3 trial, in which;72.83999633789062;;50.310001373291016;(Bloomberg) -- Stocks that offer a steady stream of income to investors will stand out as central banks continue to raise interest rates, with opportunities emerging in the UK and Brazil, Rupal Bhansali, chief investment officer of global equities at Ariel Investments.Most Read from BloombergWho Is Nicole Shanahan, Woman at Center of Musk-Brin Drama?Trump Is Plotting to Blow Up the ConstitutionShallow Recession Calls Are ‘Totally Delusional,’ Roubini WarnsCoinbase Faces SEC Probe on Crypto Listi;42.15999984741211;(Bloomberg) -- Stocks that offer a steady stream of income to investors will stand out as central banks continue to raise interest rates, with opportunities emerging in the UK and Brazil, Rupal Bhansali, chief investment officer of global equities at Ariel Investments.Most Read from BloombergWho Is Nicole Shanahan, Woman at Center of Musk-Brin Drama?Trump Is Plotting to Blow Up the ConstitutionShallow Recession Calls Are ‘Totally Delusional,’ Roubini WarnsCoinbase Faces SEC Probe on Crypto Listi;14.630000114440918;;42.959999084472656;;9.739999771118164;;197.07000732421875;;10.5600004196167;;146.0;;87.0199966430664;;13.180000305175781;;32.79999923706055;If you want to know who really controls Organon & Co. ( NYSE:OGN ), then you'll have to look at the makeup of its share...;50.5;;13.470000267028809;;12.390000343322754;;26.600000381469727;;54.34000015258789;;127.91999816894531;;10.619999885559082;;27.75;;2.450000047683716;;4.619999885559082;;;;3.7200000286102295;;4.210000038146973;;50.75;;75.0;;33.209999084472656;The World Health Organization has declared monkeypox a global health emergency amid more than 16,000 cases globally and five deaths.;7.849999904632568;;7.199999809265137;;16.709999084472656;;3.3299999237060547;;28.530000686645508;;15.829999923706055;In this article, we discuss Cathie Wood’s 10 favorite stock picks for the rest of 2022. If you want to see more stocks in this selection, click Cathie Wood’s 5 Favorite Stock Picks for the Rest of 2022. Cathie Wood, the chief of ARK Investment Management, has been making headlines recently as her hedge fund […];19.5;;3.7799999713897705;;11.579999923706055;;4.53000020980835;BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs. “We are very pleased to welcome Harris to our leadership team as we prepare for our SerpinPC program in Hemophilia B;8.6899995803833;;16.780000686645508;;30.920000076293945;;21.760000228881836;;17.65999984741211;;17.479999542236328;;17.34000015258789;;3.180000066757202;;12.600000381469727;
2022-07-26;173.67999267578125;Yahoo Finance's Ines Ferre joins the Live show to break down how stocks are moving in early trading.AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to counter Humira LOE.In this article, we will look at 10 dividend-paying REIT stocks to buy now. If you want to explore similar stocks, you can also take a look at 5 Dividend Paying REIT Stocks To Buy Now. With the ongoing macroeconomic situation that is distressing the stock market and industries worldwide, including the real estate industry, […];52.29999923706055;"Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the second quarter.U.S. stock markets are going through a historically turbulent period right now.  Rising interest rates, geopolitical unrest, supply chain woes, and record-setting levels of inflation have wreaked havoc on U.S. stock prices this year.  Billionaire super-investors like Bridgewater Associates' Raymond Dalio and Citadel's Kenneth Griffin haven't exactly shied away from buying certain equity classes this year, however.COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.  The lawsuit https://tmsnrt.rs/3PAjBo7, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.  The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.But Genuine Biotech's Azvudine appears far less effective than Pfizer's pill, tooDespite Paxlovid’s efficacy in reducing the risks for high-risk patients, uptake has been lower than expected.A federal appeals court on Monday rejected Pfizer Inc's challenge to a U.S. anti-kickback law the drugmaker said prevented it from helping heart failure patients, many with low incomes, afford medicine that cost $225,000 per year.  A unanimous three-judge panel of the New York-based 2nd U.S. Circuit Court of Appeals rejected Pfizer's effort to directly cover co-pays for patients taking its Vyndaqel and Vyndamax drugs.  The court agreed with a lower-court judge that Pfizer's Direct Copay Assistance Program violated a ban on ""knowingly or willfully"" providing financial support to induce federally reimbursable drug purchases, even absent corrupt intent.WASHINGTON—President Biden’s symptoms are improving after he tested positive for Covid-19 last week, one of his advisers and his doctor said.  “He’s doing just fine,” White House Covid-19 coordinator  said Sunday during an interview with CBS’s “Face the Nation.”  Mr. Biden is taking  Pfizer antiviral drug Paxlovid, which has been approved by federal authorities as a Covid-19 treatment.";331.55999755859375;;116.81999969482422;;150.8699951171875;AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to counter Humira LOE.Coca-Cola, Emerson Electric and AbbVie have been highlighted in this Investment Ideas article.AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.*This story covers five NYSE stocks to watch and consider buying.  In 2022, the NYSE's composite index is outperforming its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.Meeting the parameters to join the elite Dividend King group speaks volumes about these companies' well-established and thriving nature.;86.83999633789062;Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.;91.29000091552734;"Yahoo Finance's Ines Ferre joins the Live show to break down how stocks are moving in early trading.Shares of Seagen Inc. gained 2.5% in premarket trading on Tuesday after the company said an early-stage clinical trial evaluating its investigational treatment for urothelial cancer in combination with Merck & Co. Inc.'s Keytruda met its primary endpoint. Seagen is developing the therapy, enfortumab vedotin, with Astellas Pharma Inc. ; it received a Breakthrough Therapy designation in early 2020. The company said in a news release that the combination therapy generated a 64.5% confirmed objectivSeagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev (enfortumab vedotin-ejfv) in bladder cancer. The cohort evaluates Padcev with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) as first-line treatment for unresectable locally advanced or metastatic or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy. In patients treated with enfortumab vedotin and p";66.72000122070312;AstraZeneca announced looming approval for two drugs in Europe and an FDA review for a third med, leading AZN stock to inch higher Monday.;73.62999725341797;Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVAThis story covers five NYSE stocks to watch and consider buying.  In 2022, the NYSE's composite index is outperforming its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.;50.349998474121094;As part of its ongoing efforts to address disparities in underrepresented communities, Sanofi has announced a collaboration with Howard University College of Pharmacy for a two-year post-professional Doctorate in Pharmacy fellowship program. Sanofi's goal is to hire fellows into permanent full-time positions at the company, marking the first time a Howard University College of Pharmacy industry partner has committed to post-fellowship employment.Low profile startup Rona Therapeutics Inc has obtained exclusive rights worldwide to Sanofi SA's (NASDAQ: SNY) siRNA platform of chemical modification and delivery moiety. Rona Therapeutics will make an upfront payment to Sanofi, in addition to development and commercial milestones, as well as royalties on net sales of products. Deal terms were not disclosed. These rights will enable Rona to expand and accelerate its siRNA portfolio in liver and non-liver applications. Sanofi receives an exclusi;42.52000045776367;;14.550000190734863;President Joe Biden is making good progress in his recovery from COVID, he told reporters on Monday, and expects to be back to working in person by the end of the week.Novavax Inc. said Tuesday that its COVID-19 vaccine received authorization in Australia and Japan for teens. Both authorizations are for adolescents between the ages of 12 and 17 years old. In Japan, Novavax is partnering with Takeda Pharmaceutical Co. to manufacture and distribute the shots there. Novavax's stock is up 3.5% this year, while the S&P 500 is down 16.7%.;43.0;;9.920000076293945;U.S. stock markets are going through a historically turbulent period right now.  Rising interest rates, geopolitical unrest, supply chain woes, and record-setting levels of inflation have wreaked havoc on U.S. stock prices this year.  Billionaire super-investors like Bridgewater Associates' Raymond Dalio and Citadel's Kenneth Griffin haven't exactly shied away from buying certain equity classes this year, however.;202.0;Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;10.619999885559082;;146.0500030517578;;87.56999969482422;;12.9399995803833;;32.900001525878906;;43.4900016784668;"SOMERSET, N.J., July 25, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (""Legend Biotech""), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (""ADSs""), each representing two ordinary shares, in an underwritten public offering. All ADSs to be sold in the proposed offering will be offered by Legend Biotech. Legend Biotech also";13.579999923706055;COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.  The lawsuit https://tmsnrt.rs/3PAjBo7, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.  The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.;12.630000114440918;;25.610000610351562;CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss second quarter 2022 financial results and recent business updates on Monday, August 1, 2022 at 8:00 a.m. ET. To access the call, ple;55.689998626708984;;130.17999267578125;Looking at Karuna Therapeutics, Inc.'s ( NASDAQ:KRTX ) insider transactions over the last year, we can see that...;10.420000076293945;;28.440000534057617;;2.369999885559082;MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. financial markets on Thursday, August 4, 2022. OPKO’s senior management will provide a business update and discuss financial results as well as financial guidance during a conference call and live audio webcast on August 4th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OP;4.980000019073486;;;;3.940000057220459;;4.139999866485596;;50.599998474121094;Harmony Biosciences Holdings' (NASDAQ:HRMY) stock up by 8.1% over the past three months. Given its impressive...;74.87000274658203;Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.;34.38999938964844;;7.960000038146973;;7.289999961853027;ADC Therapeutics SA (ADCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Centene's (CNC) second-quarter results are likely to reflect growth in premiums.Teladoc Health's (TDOC) second-quarter results are likely to reflect growth in Subscription Access Fees.;16.670000076293945;;3.390000104904175;;31.790000915527344;;15.9399995803833;;20.549999237060547;;3.700000047683716;;12.399999618530273;;4.409999847412109;;8.6899995803833;;16.40999984741211;;29.729999542236328;;22.0;;17.809999465942383;;17.219999313354492;;17.3700008392334;;3.3299999237060547;;12.819999694824219;
2022-07-27;173.1999969482422;Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.In this article, we discuss top 25 dividend stocks. You can skip our detailed discussion on dividend investments and the historical performance of dividend stocks, and go directly to read Top 10 Dividend Stocks. With elevated recession fears and soaring inflation, investors are resorting to dividend-paying stocks considering their historical performance against inflation. According to […]It goes without saying that Warren Buffett has successfully invested through more than a couple of bear markets.  In particular, Buffett owns three stocks that are likely to keep growing during the bear market.  DaVita (NYSE: DVA) operates a global network of care and dialysis centers for patients with kidney diseases.When there's a market sell-off -- like in recent times -- it's a good idea to have a few dividend stocks in your portfolio.  AbbVie's dividend payments have more than doubled over the past five years.3M is facing claims related to its discontinued Combat Arms Earplugs version 2, which it sold to the U.S. military and consumers.;51.95000076293945;;328.94000244140625;TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.In this article, we discuss top 25 dividend stocks. You can skip our detailed discussion on dividend investments and the historical performance of dividend stocks, and go directly to read Top 10 Dividend Stocks. With elevated recession fears and soaring inflation, investors are resorting to dividend-paying stocks considering their historical performance against inflation. According to […]Both stocks could be winners for long-term investors, but one gets the nod when it comes to dividends.;116.93000030517578;;151.14999389648438;Let’s first define the dip. The S&P 500 is currently down 17.83% year-to-date. And it was down nearly 24% just over a month ago. That represents a significant dip and constitutes a bear market by some definitions. And while that overall dip has sheared massive amounts of money from the market capitalizations of companies across the board, there is still opportunity. In this case, we’ll focus on the inherent opportunity in so-called blue-chip stocks. So, what defines blue-chip stocks? Let’s startDrugmaker Merck & Co avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda by booking all the profits from the treatment outside of the United States, according to an ongoing investigation by Democrats on the Senate Finance Committee.  The committee's chairman Senator Ron Wyden of Oregon sent a letter to Merck Chief Executive Robert Davis on Wednesday criticizing the drugmaker for refusing to provide all the information the committee has requested.  Wyden's office provided a copy of the letter to Reuters.AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active Crohn's disease.4,11When there's a market sell-off -- like in recent times -- it's a good idea to have a few dividend stocks in your portfolio.  AbbVie's dividend payments have more than doubled over the past five years.;86.75;Merck, Novartis and others are seeking to revive the $48 billion market, which had shrunk after top-selling cholesterol and other drugs lost patent protection.;91.2300033569336;Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.Drugmaker Merck & Co avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda by booking all the profits from the treatment outside of the United States, according to an ongoing investigation by Democrats on the Senate Finance Committee.  The committee's chairman Senator Ron Wyden of Oregon sent a letter to Merck Chief Executive Robert Davis on Wednesday criticizing the drugmaker for refusing to provide all the information the committee has requested.  Wyden's office provided a copy of the letter to Reuters.Merck, Novartis and others are seeking to revive the $48 billion market, which had shrunk after top-selling cholesterol and other drugs lost patent protection.RAHWAY, N.J., July 26, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the fourth quarter of 2022. Payment will be made on Oct. 7, 2022, to shareholders of record at the close of business on Sept. 15, 2022.;67.48999786376953;Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.;74.80999755859375;Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.The major stock market indexes rose sharply in early trading as investors awaited today's Fed rate hike decision. The Nasdaq composite was up 2.6% while the S&P rose 1.2%. The Dow Jones Industrial Average gained 0.Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.The company effectively lowered its sales guidance for 2022 slightly, saying it now expects $46 billion in sales for the year.Bristol Myers (BMY) delivered earnings and revenue surprises of 7.82% and 3.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Bristol-Myers Squibb Co (NYSE: BMY) has posted Q2 revenues of $11.89 billion, an increase of 2% Y/Y, beating the consensus of $11.45 billion. Eliquis, Opdivo, Abecma, Opdualag, and Reblozyl drove sales growth, partially offset by the loss of exclusivity products (primarily Revlimid) and foreign exchange impacts. When adjusted for foreign exchange impacts, Q2 revenues increased 5%. Eliquis sales increased 16% to $3.23 billion, Opdivo sales increased 8% to $2.06 billion. Adjusted EPS of $1.93 cameBristol Myers Squibb Co on Wednesday reported bigger second-quarter profit than expected as sales of its blockbuster cancer drug Revlimid did not drop as steeply as feared despite competition from generic drugs.  The U.S. drugmaker cut its annual sales forecast slightly to $46 billion due to the impact of the strong dollar, sending its shares down 2.7% to $71.72 before the opening bell.  The profit beat was unlikely to excite investors since it was driven by products that do not have market exclusivity anymore, and newer treatments are still slow to launch, said Wells Fargo analyst Mohit Bansal.Shares of Bristol Myers Squibb were down 2.5% in premarket trading on Wednesday after the company lowered guidance for earnings per share for the year. Bristol had earnings of $1.4 billion, or 66 cents per share, in the second quarter of 2022, compared with $1.0 billion, or 47 cents per share, in the same quarter a year ago. Adjusted earnings per share were $1.93, against a FactSet consensus of $1.77. The company reported revenue of $11.9 billion for the quarter, up from $11.7 billion a year agoSolid cancer and blood clot treatment sales, as well as a smaller-than-forecast decline for Revlimid, helped deliver a top and bottom line beat for drugmaker Bristol Myers.(Reuters) -Bristol Myers Squibb Co on Wednesday reported bigger second-quarter profit than expected as sales of its blockbuster cancer drug Revlimid did not drop as steeply as feared despite competition from generic drugs.  The U.S. drugmaker cut its annual sales forecast slightly to $46 billion due to the impact of the strong dollar, sending its shares down 2.7% to $71.72 before the opening bell.  The profit beat was unlikely to excite investors since it was driven by products that do not have market exclusivity anymore, and newer treatments are still slow to launch, said Wells Fargo analyst Mohit Bansal.NEW YORK, July 27, 2022--Bristol Myers Squibb Reports Second Quarter Financial Results for 2022Bristol Myers Squibb Co on Wednesday reported higher-than-expected second-quarter profit as a dropoff in sales of its blockbuster cancer drug Revlimid, which now faces generic competition, was not as steep as projected.  The company cut its full year sales forecast slightly to $46 billion due to the impact of the strong dollar from $46.39 billion.  Bristol Myers reported second-quarter revenue of $11.89 billion, up from $11.7 billion a year ago.Merck, Novartis and others are seeking to revive the $48 billion market, which had shrunk after top-selling cholesterol and other drugs lost patent protection.;50.91999816894531;;43.540000915527344;GSK Plc's (NYSE: GSK) Q2 turnover reached £6.9 billion, up 19% Y/Y on the actual exchange rate (AER) and 13% on a constant exchange rate (CER) basis. Specialty Medicines turnover was £2.7 billion, up 44% AER, 35% CER, driven by consistent growth in all therapy areas, including sales of Xevudy. Sales of Xevudy (sotrovimab) for COVID-19 treatment stood at £466 billion. Related: GSK Completes Spin-Off Of Its Consumer Healthcare Business. Vaccines sales benefited from Shingrix's post-pandemic recoveWith the stock market still volatile and in a bottoming process, it’s a good time to find dividend stocks to buy on the dip. As the old saying goes, dividend stocks “pay you to wait.” In other words, even if the market sinks, forcing the lion’s share of equities to decline, stocks with dividends limit their owners’ losses and increase the overall profits that they will generate after the market has turned around. And given the market’s steep, largely all-encompassing selloff this year, plenty ofThe drugs giant reported a 19% rise in total sales, reaching £6.9bn, with quarterly figures beating expectations for £6.3bn.GSK has raised its full-year revenue and profit guidance after soaring sales of its shingles vaccine helped the UK drugmaker beat expectations in the second quarter of the year.  The pharmaceutical company expects sales to grow 6-8 per cent in 2022, up from its previous forecast of 5-7 per cent. The new guidance for adjusted operating profit growth is 13-15 per cent, above its previous forecast of 12-14 per cent.  The results are the first since GSK spun off its consumer health division Haleon this month.;14.6899995803833;BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome or a prioritized target in live cells to discover drug candidates for undruggable targets, including cancers. BridGene's IMTAC can identify hits for targets with shallow binding pockets. BridGene can also identify hits via live cell screening for targets with temporary binding pockets that only form;43.650001525878906;;10.069999694824219;Using payout ratios to evaluate the health of a dividend stock is a quick way for investors to assess if a payout is too good to be true and due for a cut.  Anything over 80% will likely raise some eyebrows, and at more than 100%, investors may skip a stock altogether.  Three stocks with payout ratios of more than 100% right now are Viatris (NASDAQ: VTRS), Altria (NYSE: MO), and Enbridge (NYSE: ENB).;205.7100067138672;;10.600000381469727;;146.57000732421875;;88.87000274658203;;13.239999771118164;;32.63999938964844;;48.209999084472656;SOMERSET, N.J., July 27, 2022--July 2022 Follow-On Pricing Announcement;13.479999542236328;Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.V. (NASDAQ: CVAC). CureVac, earlier this month, filed a lawsuit in Germany against BioNTech over its use of mRNA technology. Related: CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech. It did not rule out further legal action against BioNTech's p;12.670000076293945;;26.110000610351562;;57.400001525878906;WALTHAM, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, (i) certain holders have agreed to exchange with Apellis approximately $65.9 million in aggregate principal amount of Note;132.6199951171875;;10.699999809265137;;29.790000915527344;;2.4700000286102295;;5.239999771118164;;;;4.119999885559082;Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.;4.230000019073486;A new generation of vaccines is needed to continue fighting COVID-19, according to experts at the White House Tuesday.;51.2599983215332;;75.04000091552734;;35.52000045776367;The Centers for Disease Control and Prevention has reported 3,487 monkeypox cases in the U.S., so far.;8.109999656677246;;7.570000171661377;Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.LAUSANNE, Switzerland, July 27, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in the Phase 1b clinical trial evaluating ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and in combination with gemcitabine in patients with selected advanced solid tumors.;17.25;;3.559999942779541;;33.84000015258789;;16.06999969482422;;20.450000762939453;;3.890000104904175;;12.15999984741211;;4.550000190734863;;8.550000190734863;;17.030000686645508;;30.3700008392334;;22.25;;17.93000030517578;;17.729999542236328;;17.530000686645508;;3.5199999809265137;;12.84000015258789;
2022-07-28;174.1999969482422;By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT Fiscal Year 2022 Operational & Financial Results Bioasis Technologies Inc. (OTC:BIOAF) filed fiscal year 2022 operational and financial reports with SEDAR on June 14, 2022 for the twelve-month period ending February 28, 2022. The most impactful event for Bioasis occurred after the end of the reporting period where theTwo stocks within those categories worth considering right now are Johnson & Johnson (NYSE: JNJ) and Ross Stores (NASDAQ: ROST).  Healthcare giant Johnson & Johnson reported its most recent earnings numbers last week, and they proved to be resilient.  Johnson & Johnson anticipates operating sales growth of between 6.5% to 7.5% for the full year.In this article, we shall be going through the top 10 stock picks of Efrem Kamen’s Pura Vida Investments. To skip our detailed analysis of Kamen’s history, his investment strategy, and hedge fund performance, go directly and see Top 5 Stock Picks of Efrem Kamen’s Pura Vida Investments. Efrem Kamen currently serves as Managing Member […](Bloomberg) -- Africa, the only continent where monkeypox is endemic, has yet to receive vaccines for the virus as the infectious disease spreads around the world, the continent’s top health body said.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekAlito Decries 'Hostility to Religion' in First Public Remarks Since Abortion Decision Rockstar Games Cleaned Up Its Frat-Boy Culture — and Grand Theft Auto, TooBiden, Xi Plan In-Person Meet as Taiwan Tensions IntShares of Legend Biotech (NASDAQ: LEGN) rose 11.8% on Wednesday.  There are two reasons for the rise in the stock, both related to the Chinese biotech company's announcement this week that it plans to sell more than 8 million shares at a public offering price of $43 to raise $350 million.  Other investors may have piled in when they saw a potential deal.The drugmaker said it had reached an agreement in principle to pay up to $4.4 billion to settle lawsuits.GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.;50.720001220703125;Are you worried about how safe dividend stocks are right now?  One thing you can do is look at stocks that have a very low payout ratio and a healthy margin of safety in case inflation or a downturn in the economy chips away at the company's profitability.  A couple of top dividend stocks with incredibly low payout ratios are Pfizer (NYSE: PFE) and Costco Wholesale (NASDAQ: COST).GDP Growth Rate Contracts for Two Straight Quarters.;330.79998779296875;Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Merck (MRK) delivered earnings and revenue surprises of 11.98% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Innoviva (INVA) delivered earnings and revenue surprises of -90.91% and 4.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Pharmaceuticals giant Eli Lilly has formed a three-weeks tight pattern within the buy zone of flat base just before earnings.;116.38999938964844;;149.75;In this article, we discuss 10 high-yield but safe dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and go directly to read 5 High-Yield But Safe Dividend Stocks to Buy Now. Since the start of 2022, dividend stocks have fared well as compared to other market segments. Dividend companies […]Pfizer (PFE) delivered earnings and revenue surprises of 16.57% and 5.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?AbbVie Inc's (NYSE: ABBV) Allergan unit has agreed to pay more than $2 billion to resolve over 3,000 lawsuits filed by state and local governments over marketing its Kadian opioid painkiller, Bloomberg reported citing people familiar with the matter. The report mentioned that the settlement's complete terms, including the time of the payout and a list of internal Allergan documents to be made public, are still being worked on. The agreement is part of consolidated litigation before a federal judThe deal would settle more than 3,000 lawsuits filed by state and local governments, but complete terms of the settlement are still being chalked out, according to the report.  Israel-based Teva Pharmaceutical Industries on Tuesday announced a $4.35 billion proposed nationwide settlement of its U.S. opioid lawsuits.  AbbVie did not immediately respond to a Reuters request for a comment.AbbVie Inc's unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter.  The deal would settle more than 3,000 lawsuits filed by state and local governments, but complete terms of the settlement are still being chalked out, according to the report.  Israel-based Teva Pharmaceutical Industries on Tuesday announced a $4.35 billion proposed nationwide settlement of its U.S. opioid lawsuits.There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin.(Bloomberg) -- AbbVie Inc.’s Allergan unit has reached an agreement to pay more than $2 billion to resolve thousands of lawsuits filed by state and local governments over the marketing of its Kadian opioid painkiller, according to people familiar with the matter. Most Read from BloombergRockstar Games Cleaned Up Its Frat-Boy Culture — and Grand Theft Auto, TooFed Hikes 75 Basis Points Second Time, Signals Third Is PossibleBiden Considers New Pause on Paying Back Student Loans, $10,000 ReliefStar;87.26000213623047;The university and the Swiss drug maker are extending their research collaboration another five years.;89.94000244140625;"Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer immunotherapy drug.  Much of that beat came from better-than-expected sales of Merck's top-selling drug Keytruda and increased demand for its Gardasil vaccine, which protects against cancers caused by the human papillomavirus (HPV).  Merck Chief Executive Rob Davis said the proposed bill could have a ""highly chilling"" effect on innovation, but he does not see it hurting sales of Keytruda and Gardasil in the near-term, if it is passed.Yahoo Finance Live anchors discuss earnings for Merck and Pfizer.Sales of both the company's Covid-19 vaccine Comirnaty and antiviral drug Paxlovid were higher than anticipated.New collaboration expands our clinical trials efforts to four Historically Black Medical School clinical trial Centers of ExcellenceThe U.S. equities market remains in a dip no matter how you define it. Year-to-date, the Dow Jones Industrial Average is off by 12%. The S&P 500 is off by 16%. The Nasdaq has led the group, down 24% this year. The reason for this is that the Nasdaq is heavily tech-dominated, and tech has fared much worse as the Federal Reserve has ramped up successive rounds of rate hikes. But any way investors slice it, we’re still in the middle of a dip. And there are few, if any, signs that things won’t get wMerck & Co Inc's (NYSE: MRK) Q2 sales reached $14.60 billion, +28% Y/Y, beating the consensus of $13.87 billion. Excluding the foreign exchange impact and COVID-19 treatment sales, revenues were up 20%. Pharmaceutical sales increased 28% to $12.75 billion. The sales increased 16%, excluding Lagevrio (molnupiravir), primarily driven by oncology, vaccines, and hospital acute care products. COVID-19 treatment drug Lagevrio (molnupiravir) sales were $1.2 billion, lower than the $3.2 billion generateMerck (MRK) delivered earnings and revenue surprises of 11.98% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?(Reuters) -Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer immunotherapy drug.  Much of that beat came from better-than-expected sales of Merck's top-selling drug Keytruda and increased demand for its Gardasil vaccine, which protects against cancers caused by the human papillomavirus (HPV).  The results were reported a day after U.S. Democratic Senator Joe Manchin and Senate Democratic leader Chuck Schumer agreed on a bill to help curb drug prices.RAHWAY, N.J., July 28, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2022.Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer drug Keytruda.  Revenue in the quarter rose 28% from a year ago to $14.6 billion, topping the average Wall Street forecast of $13.9 billion.  Much of that beat came from sales of Merck's top-selling drug, the cancer immunotherapy Keytruda, which came in at $5.3 billion for the quarter, compared with analyst estimates of $4.9 billion.Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.";66.72000122070312;By Liz Moyer;74.69999694824219;Pharmaceutical giant Bristol-Myers Squibb (NYSE: BMY) is facing a steep patent cliff as the company's three top-selling drugs lose patent exclusivity in the coming years.  Fortunately, Bristol-Myers has just launched several highly anticipated drugs.  Blood cancer drug Revlimid has been Bristol-Myers' top-selling drug, bringing in $12.8 billion in sales in 2021.Bristol Myers Squibb expects a $10 billion or double-digit decline from its generics-facing products. BMY stock fell Wednesday.Image source: The Motley Fool.  Bristol Myers Squibb (NYSE: BMY)Q2 2022 Earnings CallJul 27, 2022, 8:00 a.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood day, and welcome to the Bristol-Myers Squibb second quarter results conference call.;50.91999816894531;Online availability of Sanofi’s half-year financial report for 2022 Paris, July 28, 2022. Sanofi announces that its half-year financial report for the period ending June 30, 2022 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K. This document may be found on the company’s corporate website: www.sanofi.com and downloaded from the “Investors” page, under the hSanofi SA (NASDAQ: SNY) posted a business net profit of €2.17 billion for Q2 FY22, +25.4% (+16.6% at CER). Sales reached €10.11 billion, +15.7% Y/Y (+8.1% at constant exchange rates (CER)). Business operating income rose 21.5% to €2.75 billion. Best-selling eczema drug Dupixent, consumer healthcare, rare disease, and vaccines drove the growth. Specialty Care grew 21.6%, driven by Dupixent +43.4% to €1.96 billion and double-digit growth in Rare Disease. Vaccines were up 8.7% due to a strong rebouFrench healthcare group Sanofi lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.  In a statement on Thursday, Sanofi said it now expects 2022 adjusted earnings per share to grow by about 15%, excluding the effect of currency swings.  Sanofi's second-quarter business operating income, or adjusted earnings before interest and tax, rose 21.5% to 2.75 billion euros ($2.81 billion), surpassing the average analyst estimate of 2.66 billion euros posted on the company's website.(Reuters) -French healthcare group Sanofi lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.  In a statement on Thursday, Sanofi said it now expects 2022 adjusted earnings per share to grow by about 15%, excluding the effect of currency swings.  Sanofi's second-quarter business operating income, or adjusted earnings before interest and tax, rose 21.5% to 2.75 billion euros ($2.81 billion), surpassing the average analyst estimate of 2.66 billion euros posted on the company's website.Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease Paris, July 28, 2022. Read the full press release Q2 2022 sales growth of 8.1% at CER driven by Dupixent®, Rare Disease, Vaccines and CHC Specialty Care grew 21.6% driven by Dupixent® (€1,963 million, +43.4%), and double-digit growth in Rare DiseaseVaccines up 8.7% due to strong rebound of Travel and Booster vaccines as well as continued PPH franchise growth General MediciLet's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.;42.93000030517578;Revenue from GSK's blockbuster shingles vaccine, Shingrix, more than doubled in the second quarter, but GSK stock fell early Wednesday.LONDON, July 27, 2022--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.i The approval extends the current indication in the US to include both lupus and ac;14.8100004196167;TOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline.  In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc.  The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline.  In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc.  The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.OSAKA, Japan, July 28, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance.;43.599998474121094;;9.779999732971191;;213.10000610351562;Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.;9.520000457763672;;146.3000030517578;The American Migraine Foundation (AMF) and Biohaven Pharmaceuticals (NYSE: BHVN) today announced findings from a new survey about migraine and its impact on mental health. The results of the Migraine and Mental Health Connection Survey reveal that the majority of healthcare professionals (HCPs) and people with migraine (PwM) strongly believe that migraine and mental health significantly impact each other. The survey also found that stigma surrounding migraine is a significant barrier PwM face in;86.23999786376953;;13.149999618530273;;32.45000076293945;JERSEY CITY, N.J., July 28, 2022--Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate;48.90999984741211;Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.Shares of Legend Biotech (NASDAQ: LEGN) rose 11.8% on Wednesday.  There are two reasons for the rise in the stock, both related to the Chinese biotech company's announcement this week that it plans to sell more than 8 million shares at a public offering price of $43 to raise $350 million.  Other investors may have piled in when they saw a potential deal.;13.479999542236328;;12.699999809265137;;25.5;;57.29999923706055;;127.58000183105469;;10.699999809265137;;29.829999923706055;;2.430000066757202;;5.199999809265137;CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Thursday, August 11, 2022 at 8:00 a.m. ET to report its second quarter 2022 financial results and provide a business update. A live webcast of the call will be available on the “Investor Relations” page of the Company’s web;;;4.050000190734863;;4.28000020980835;;50.33000183105469;;75.26000213623047;Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDASAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed within the second quarter. The feedback focuseImage source: The Motley Fool.  Bristol Myers Squibb (NYSE: BMY)Q2 2022 Earnings CallJul 27, 2022, 8:00 a.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood day, and welcome to the Bristol-Myers Squibb second quarter results conference call.;35.79999923706055;;7.889999866485596;Erasca, Inc. (ERAS) closed at $8.11 in the latest trading session, marking a +1.88% move from the prior day.;7.670000076293945;;17.0;BILLERICA, Mass., July 27, 2022--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced the validation of a laboratory developed test (LDT) to quantitatively measure phospho-Tau 181 (pTau-181) in plasma as an aid in diagnostic evaluation of Alzheimer’s disease (AD). Quanterix’ LDT – the first pTau-181 plasma test released for clinical use in the U.S. – is a quantitative immunoassay intended for the measurement;3.5899999141693115;;33.38999938964844;;15.970000267028809;;19.40999984741211;;3.9200000762939453;;12.079999923706055;;4.329999923706055;;8.5;;17.079999923706055;;30.049999237060547;;23.360000610351562;;17.389999389648438;;17.440000534057617;;17.639999389648438;;3.5399999618530273;;12.680000305175781;
2022-07-29;174.52000427246094;Yahoo Finance's Julie Hyman breaks down leading headlines including the Biden administration planning to offer updated COVID-19 booster shots in September, Euro Zone inflation, Instacart going public, and Shakira potentially facing jail time after being accused of tax fraud.The bear market is firmly in place so long as the economy worsens. The incoming recession is a necessary headwind. Although the Federal Reserve would like to avoid that outcome, it will try to avoid a slowdown. The Fed is raising interest rates at an astonishing rate to squash inflation. Until inflation subsides, the central bank will continue its stock unfriendly policy. Eventually, the market will shift from a downtrend and recession to flat growth. Companies that cut costs, protected profitab(Bloomberg) -- The lawyer who oversaw payments to victims of the Sept. 11 terrorist attacks will be appointed by a federal judge to estimate the total liability that Johnson & Johnson faces for claims that talc in its baby powder causes cancer.Most Read from BloombergRockstar Games Cleaned Up Its Frat-Boy Culture — and Grand Theft Auto, TooUS Economy Shrinks for a Second Quarter, Fueling Recession FearsThe Strong Dollar Is Wreaking Havoc Globally — And It’s Just Getting StartedBiden Considers Ne;50.5099983215332;"GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter resultsLos Angeles County has dropped a plan for a universal indoor face mask mandate as COVID cases and hospitalizations have stabilized, with community transmission expected to fall to ""medium"" from ""high"" in the coming weeks.Yahoo Finance's Julie Hyman breaks down leading headlines including the Biden administration planning to offer updated COVID-19 booster shots in September, Euro Zone inflation, Instacart going public, and Shakira potentially facing jail time after being accused of tax fraud.The Biden administration said it would spend $1.74 billion to buy 66 million doses of  Moderna  updated Covid-19 vaccine, as well as the option to purchase up to 234 million additional doses, as part of a fall booster campaign.  The deal Friday, which follows an agreement to buy 105 million doses of updated vaccines from  Pfizer  and partner  BioNTech SE  is expected to give the federal government enough shots for a booster push as early as September.  Under the latest deal, the U.S. government has the option to buy up to an additional 234 million doses from Moderna.People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-generation, Omicron-targeted vaccines expected in the fall, five vaccine experts told Reuters.  In many countries, including the United States, the BA.5 Omicron subvariant of the virus is surging, but current vaccines continue to offer protection against hospitalization for severe disease and death.  And, as the virus evolves, it is not known what version will be widely circulating in the fall or whether new vaccines - expected to target BA.4/5 in the United States and BA.1 in Europe - will be a good match.Biden says it’s not a recession but it isn’t up to him, Intel’s earnings missed by a mile, Pfizer and Merck results are boosted by Covid-19 drugs, and other news to start your day.The Biden administration has decided against offering COVID boosters to people under 50 for now, preferring to wait until retooled Pfizer and Moderna shots become available in September that could perform better against the omicron BA.5 subvariant, the New York Times reported Thursday. The reasoning is that it'll be worth it for those under 50 to wait slightly longer for the improved booster, rather than expand eligibility now with the older shot. While the older version is still highly effectivPfizer (NYSE: PFE) announced its second-quarter results before the market opened on Thursday.  Pfizer's shares fell around 4% in early trading following the announcement.  Here are seven ways that Pfizer is firing on all cylinders.When you think of exchange-traded funds (ETFs), you're probably thinking of investments that contain dozens of stocks, or even hundreds.  The advantage of investing in ETFs is that they can help you diversify.  Through these ETFs, investors can amplify their returns or even short a stock.The Biden administration is tweaking its COVID booster plans, according to a new report, and now expects to roll out retooled Pfizer and Moderna shots in September that could perform better against the omicron BA.5 subvariant.  All adults are expected to be eligible for the new boosters, and children may get approval too, the Times reported.At this time, I would like to turn the call over to Mr. Chris Stevo, senior vice president and chief investor relations officer.  Joining for the Q&A session, we will also have Angela Hwang, group president, Pfizer Biopharmaceuticals Group; Aamir Malik, our chief business innovation officer; William Pao, our chief development officer; and Doug Lankler, our general counsel.Pfizer stock tumbled Thursday after delivering a second-quarter beat almost entirely on the back of its Covid vaccine and antiviral pill.The company had told an FDA advisory panel that the shots could be ready by October, but the CEO said an earlier deliver seems to be feasible.Strong quarterly sales of Pfizer’s Covid-19 products helped offset mixed results from other products, and the drugmaker sees full-year revenue gains being offset by unfavorable currency effects.(Bloomberg) -- Pfizer Inc. raised the lower end of its earnings forecast for the year and reiterated its sales expectations despite unfavorable currency trends. The drugmaker continues to project its new Covid-19 products will bring in over $50 billion of revenue this year.Most Read from BloombergRockstar Games Cleaned Up Its Frat-Boy Culture — and Grand Theft Auto, TooBiden, Xi Plan In-Person Meet as Taiwan Tensions IntensifyUS Economy Shrinks for a Second Quarter, Fueling Recession FearsThe StOne looming problem for the pharma industry is a deal in Washington that could allow the government to negotiate drug prices for the first time.Is Pfizer stock a sell after Wall Street reduced its expectations for 2022 sales and profit? Is PFE stock a sell right now?Pfizer's (PFE) Q2 EPS and revenue both smashed analyst predictions, led by its vaccines business.";329.69000244140625;AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Eli Lilly (LLY) closed at $330.80 in the latest trading session, marking a +0.57% move from the prior day.Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.;116.05999755859375;Bagsværd, Denmark, 29 July 2022 – Novo Nordisk today announced headline results from the ONWARDS 3 and ONWARDS 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes. ONWARDS 3 (insulin-naïve people with type 2 diabetes)ONWARDS 3 is a phase 3a, double-blind 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec. Both are in combination with non-insulin anti-diabetic treatment in 588 people with type 2 diabetes who;143.50999450683594;"AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Management confirmed financial forecasts it had issued earlier. The drug company's second-quarter results were roughly in line with expectations.AbbVie Inc (NYSE: ABBV) reports Q2 adjusted EPS of $3.37, up 11.2% Y/Y and beating the consensus of $3.33. Overall sales increased 4.5% Y/Y (6.1% on an operational basis) to $14.58 billion, marginally missing the consensus of $14.62 billion. The immunology portfolio generated $7.21 billion in sales, +17.8% (+19.2% on an operational basis). Humira sales increased 5.8% to $5.36 billion. Skyrizi sales reached $1.25 billion (+85.9% Y/Y), and Rinvoq jumped 56.3% to $592 million. Hematologic oncologyShares of AbbVie Inc. were down 1.3% in premarket trading on Friday though the company met earnings and revenue expectations for the second quarter of the year. AbbVie had earnings of $924 million, or 51 cents per share, in the second quarter of this year, compared with $766 million, or 42 cents per share, in the same quarter a year ago. Adjusted earnings per share were $3.37, against a FactSet consensus of $3.32. The company reported that revenue increased to $14.58 billion in the second quarteAbbVie Inc has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday.  AbbVie faces more than 3,000 lawsuits from state and local governments around the country over the drug.  The charge comes days after Teva Pharmaceutical Industries Ltd announced a $4.35 billion settlement of opioid lawsuits.Dow Jones futures rose early Friday, along with S&P 500 futures and especially Nasdaq futures, as Apple and Amazon.com headlined another wave of overnight earnings. The stock market rally showed strength Thursday, shrugging off a post-Fed pullback and weak earnings to move modestly higher.(Reuters) -AbbVie Inc has agreed to pay up to $2.37 billion to resolve thousands of U.S. lawsuits against its Allergan unit over the marketing of opioid painkillers, state officials announced on Friday.  If finalized, the deal could end more than 3,000 lawsuits by state and local governments around the country.  ""We've worked hard to get the best result for Americans harmed by the opioid crisis, and it's rewarding to take another step in the right direction,"" Iowa Attorney General Tom Miller, who led negotiations with the company, said in a statement.AbbVie Inc has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday.  AbbVie faces more than 3,000 lawsuits from state and local governments around the country over the drug.  The charge comes days after Teva Pharmaceutical Industries Ltd announced a $4.35 billion settlement of opioid lawsuits.AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2022.AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*1This story covers five NYSE stocks to watch and consider buying.  In 2022, the NYSE's composite index is outperforming its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.";85.83000183105469;Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.;89.33999633789062;GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter resultsAstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.Biden says it’s not a recession but it isn’t up to him, Intel’s earnings missed by a mile, Pfizer and Merck results are boosted by Covid-19 drugs, and other news to start your day.MRK earnings call for the period ending June 30, 2022.Merck stock tumbled amid a broad pharma turndown Thursday despite racking up more than $5 billion in sales for cancer drug, Keytruda.Merck (MRK) beats on Q2 estimates for earnings and sales. The company continues to see robust growth in COVID drug sales and Keytruda and Gardasil sales.Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada. Stock down.A deal among Democrats makes it a little more likely the government will negotiate prices for some drugs. Drugmakers have generally opposed the legislation, but a bill's passage could remove an overhang.The drug giant reports second-quarter adjusted earnings of $1.87 a share, which is above analysts' estimates.;66.2300033569336;"GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter resultsAstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.Long-serving AstraZeneca boss Pascal Soriot said on Friday he expects to work with the new chairman-designate of the London-listed drugmaker, who will take over in 2023, for many years to come, suggesting he is not ready to retire.  The company said on Friday that Michel Demare will take over from outgoing Chairman Leif Johansson, who, like Soriot, has been in his leadership position for about a decade.  ""Michel and I will be working together and forming an excellent team for the many years to come,"" Soriot said on an analyst call after the company released its quarterly results.Revenues beat analyst expectations, jumping to $10.8bn (£8.8bn) in the quarter to 30 June.AstraZeneca Plc (NASDAQ: AZN) Q2 profits fell sharply on ballooning costs linked to its Alexion takeover. The net profit was down 68% Y/Y (75% on constant currency) to $247 million. Core EPS reached $1.72, +92% (+89% CC). The company clocked Q2 sales of $10.77 billion, +32% (+38% CC), beating the consensus of $10.53 billion. AstraZeneca's best-selling product Tagrisso for lung cancer saw revenues increase 7% to $1.4 billion, while sales of cardiovascular and diabetes treatment Farxiga jumped 51%AstraZeneca has raised its revenue guidance for the full year after strong sales of its Evusheld Covid-19 antibody treatment and drugs to treat cancer and rare diseases.  The Anglo-Swedish drugmaker now expects total revenue to increase by a low 20s percentage, up from its previous forecast for growth in the high teens.  AstraZeneca’s chief executive Pascal Soriot said the expected revenue rise would allow the company to boost investment in research and development.AstraZeneca Plc Chief Financial Officer Aradhana Sarin discusses the company's financial results, outlook and strategy. Cambridge, England-based Astra raised its outlook for 2022 revenue after second-quarter sales and earnings per share exceeded analysts' expectations, fueled by growth in all disease areas including Covid-19 medicines. Sarin speaks with Tom Mackenzie on ""Bloomberg Markets: Europe.""AstraZeneca on Friday said it now expected sales growth of more than 20% on an increase in prescriptions of its Evusheld injection to protect against COVID-19 after second-quarter profit topped analyst expectations.  The London-listed company raised its full-year revenue guidance, saying it expects it to rise by a percentage in the ""low twenties"" rather than the ""high teens"" forecast previously, keeping its profit forecast unchanged.  On Friday, the company also revealed the replacement for non-executive Chairman Leif Johansson - Michel Demaré will take over once Johansson retires next year.(Reuters) -AstraZeneca said it expected prescriptions of its COVID therapy to drive sales growth of more than 20% this year, as company reported second-quarter profit that topped analyst estimates.  The injection, called Evusheld, which is designed to protect against COVID infection for at least six months, has been deployed in many countries for people with compromised immune systems who see little or no benefit from vaccines.  The long-acting antibody therapy, launched in December last year, generated sales of $445 million in the quarter.";73.77999877929688;Bristol Myers Squibb said on Friday a trial evaluating a combination of its two cancer drugs failed to meet the primary goal to treat localized kidney cancer.  The combination of the two drugs - Yervoy and top selling cancer drug Opdivo - is already approved in the United States as a first line of treatment for patients with renal cell carcinoma that has spread.  However, the combination failed to meet the key endpoint of disease-free survival for patients who had localized form of the cancer and had undergone full or partial removal of the kidney.PRINCETON, N.J., July 29, 2022--BMS Provides Update on CheckMate -914 Trial Evaluating Opdivo Plus Yervoy as Adjuvant Treatment of Localized Renal Cell CarcinomaOne looming problem for the pharma industry is a deal in Washington that could allow the government to negotiate drug prices for the first time.This story covers five NYSE stocks to watch and consider buying.  In 2022, the NYSE's composite index is outperforming its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.;49.70000076293945;"GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter resultsRegeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.Thank you for joining us to review Sanofi's 2022 second quarter results, followed by a Q&A session.  For the Q&A, you have two options to participate: option one, click the raise hand icon at the bottom of your screen; or option two, submit your question by clicking the Q&A icon at the bottom of the screen.Sanofi stock ended flat Thursday despite lifting its profit guidance after blockbuster eczema drug Dupixent topped views.Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.";42.16999816894531;;14.609999656677246;;43.4900016784668;;9.6899995803833;;213.36000061035156;;8.880000114440918;;146.02000427246094;;85.52999877929688;;12.670000076293945;;31.719999313354492;;47.2400016784668;;13.0;;13.069999694824219;;26.290000915527344;;56.279998779296875;;130.25;;10.479999542236328;;29.8799991607666;;2.359999895095825;;5.449999809265137;;;;3.9600000381469727;;3.890000104904175;CULVER CITY, Calif., July 28, 2022--The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease. ImmunityBio, a leading clinical-stage immunotherapy company, filed the BLA based on positive results from a series of studies of the investigational treatment, including the o;50.72999954223633;;74.9800033569336;;34.63999938964844;Shares of Emergent BioSolutions (NYSE: EBS) were jumping 14.6% this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.  The stock's momentum began after the World Health Organization (WHO) director-general declared the global monkeypox outbreak as a Public Health Emergency of International Concern (PHEIC) on July 23.  Emergent BioSolutions markets smallpox vaccine ACAM2000, which can also be used to provide protection against infection by the virus that causes monkeypox.;7.539999961853027;;7.409999847412109;;15.989999771118164;;3.5399999618530273;;32.08000183105469;;15.960000038146973;;19.209999084472656;;3.859999895095825;;11.15999984741211;;4.320000171661377;A company's stock price rises and falls, but CEO pay tends to only go in one direction: up. Why do Boston's CEOs make so much money? What do their compensation packages look like? Which types of companies tend to pay the most?;8.199999809265137;;17.549999237060547;;30.68000030517578;;24.260000228881836;;17.1299991607666;The big shareholder groups in Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) have power over the company...;16.110000610351562;;17.639999389648438;;3.5299999713897705;;12.640000343322754;
2022-08-01;173.91000366210938;Yahoo Finance health care reporter Anjalee Khemlani discusses President Biden testing positive for COVID-19 after taking Paxlovid as well as the latest developments in the monkeypox outbreak.In this article, we discuss 15 dividend stocks for passive income. You can skip our detailed discussion on dividend income and dividend stocks’ performance, and go directly to read 5 Dividend Stocks for Passive Income. With growing inflation and recession risks this year, investors are piling up on dividend stocks like Exxon Mobil Corporation (NYSE:XOM), […]With that in mind, investors would be wise to start hedging their portfolios accordingly with companies that can better navigate these challenging economic waters.  Preeminent healthcare company Johnson & Johnson (NYSE: JNJ), with 60 consecutive years of dividend growth under its belt, is a poster child for stability.  Let's dig into J&J's fundamentals and valuation to arrive at an answer.Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.Smart Beta ETF report for VIG;50.61000061035156;"Yahoo Finance health care reporter Anjalee Khemlani discusses President Biden testing positive for COVID-19 after taking Paxlovid as well as the latest developments in the monkeypox outbreak.U.S. President Joe Biden feels good and is looking forward to getting back on the road as he continues to test positive for COVID-19 and maintains isolation procedures, White House spokesperson Karine Jean-Pierre said on Monday.  ""He's feeling fine,"" Jean-Pierre told reporters at a White House briefing.  Biden, 79, had just emerged from isolation on Wednesday after testing positive for COVID for the first time on July 21, when he tested positive again https://www.reuters.com/world/us/biden-feeling-well-continuing-isolation-after-testing-positive-covid-2022-07-31/ on Saturday in what his physician Kevin O'Connor described as a ""rebound"" case seen in a small percentage of patients who take the antiviral drug Paxlovid.President Joe Biden tested positive for COVID-19 for a second straight day on Sunday, in what appears to be a rare case of 'rebound' following treatment with the antiviral Paxlovid.Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.In this article, we discuss 10 high free cash flow stocks to buy in 2022. If you want to read about some more high free cash flow stocks to buy in 2022, go directly to 5 High Free Cash Flow Stocks to Buy in 2022. On July 27, the Federal Reserve in the United States […]Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.";324.1499938964844;Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.Here is how Alimera Sciences (ALIM) and Eli Lilly (LLY) have performed compared to their sector so far this year.In this article, we will take a look at the 10 most awaited earnings to watch in August. If you want to see some more highly anticipated earnings of the month, go directly to 5 Most Awaited Earnings to Watch in August. We are more than halfway through the second-quarter earnings season. However, several famous […];116.08999633789062;Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.;140.22000122070312;It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Amgen is fighting a $10.7 billion tax bill from the IRS, which says the biotech improperly shifted nearly $24 billion in profits to a Puerto Rico subsidiary to reduce its tax burden.;85.62999725341797;In this article, we discuss 10 undervalued high free cash flow stocks to buy amid recession. If you want to read about some more undervalued high free cash flow stocks, go directly to 5 Undervalued High Free Cash Flow Stocks to Buy Amid Recession. Prominent stocks in the United States like Apple Inc. (NASDAQ:AAPL), Microsoft […]Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems are part of Zacks top Analyst Blog.;88.52999877929688;Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.;65.6500015258789;Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.Innate Pharma SA's (NASDAQ: IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ: AZN) did not meet a pre-defined threshold for efficacy. Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued. There were no new safety findings. AstraZeneca plans to share the data in due course. Related: Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy ShGSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.;73.62000274658203;Rides have raised more than $12 million to help fund cancer research worldwide to date;48.900001525878906;GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.The Hatteras-backed company is growing its headcount, and lab space, as it advances treatments for blindness.;41.630001068115234;Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.;14.319999694824219;;42.77000045776367;;9.65999984741211;Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;212.55999755859375;;8.600000381469727;;146.00999450683594;;84.02999877929688;When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...;13.170000076293945;;31.829999923706055;;45.099998474121094;;12.920000076293945;;12.069999694824219;"Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with high MET2 levels and no prior chemotherapy Initiated six new trials thus far in 2022 with a further six starting, including with five new drug candidates FRESCO-2 Phase III, our first global multi-regional clinical trial, on track to read out in August 2022HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient received their first dose on July 29, 2022. The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma (";27.65999984741211;Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer’s disease psychosis Panic disorder selected as second indication for darigabat, planning underway for Phase 2 proof-of-concept Cash, cash equivalents and marketable securities of $531M as of June 30, 2022, expected to support operations into 2024 Conference call today at 8:00 a.m. E;55.7599983215332;Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;123.79000091552734;;8.529999732971191;;28.059999465942383;;2.4200000762939453;;5.070000171661377;;;;3.7699999809265137;;3.6500000953674316;;49.22999954223633;;74.95999908447266;;34.22999954223633;;7.199999809265137;;7.059999942779541;Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.;15.180000305175781;;3.5399999618530273;;29.799999237060547;;15.40999984741211;;18.190000534057617;;3.549999952316284;NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022. A video interview with atai management will be available at 8:30 a.m. (ET) at https://vimeo.com/atailifesciences. The archived video interview will be available in the “Events” sectio;10.979999542236328;;4.46999979019165;;8.359999656677246;;17.469999313354492;;29.860000610351562;"PLANO, Texas, August 01, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the second quarter ended June 30, 2022, and provide an update on the Company’s business operations and clinical development programs on August 8, 2022, before the U.S. financial markets open.";20.260000228881836;WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, will host a conference call for investors today at 8:30 a.m. EDT to discuss the U.S. Food and Drug Administration (FDA) approval of ZORYVE (roflumilast) cream 0.3% for treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. Dial;16.440000534057617;;15.420000076293945;;18.739999771118164;;3.2300000190734863;;11.699999809265137;
2022-08-02;172.9199981689453;Shares of Emergent BioSolutions (NYSE: EBS) are sinking today, down 11.8% as of 11:27 a.m. ET.  The primary problem for Emergent BioSolutions remains its contract development and manufacturing organization (CDMO) business.  In the recent quarter, Emergent actually reported negative CDMO revenue because of a reversal of previously recorded revenue related to its contract with Johnson & Johnson's Janssen unit.Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.In this article, we discuss 10 high free cash flow dividend stocks. You can skip our detailed discussion of free cash flow stocks, and go directly to read 5 High Free Cash Flow Dividend Stocks. With looming recession fears and a slumping economy, investors around the world are focusing on dividend stocks like The Coca-Cola Company […]Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.Since its debut in 1896, the Dow Jones Industrial Average (DJINDICES: ^DJI) has stood tall as the stock market's health barometer.  With the Dow declining as much as 19% from its all-time closing high in 2022, and the S&P 500 producing its worst first-half return in more than 50 years, bargains abound for opportunistic investors.  Among these 30 stalwart companies are three Dow stocks that are screaming buys in August.(Bloomberg) -- Apple Inc. tapped the US high-grade bond market Monday with a $5.5 billion sale in four parts. Most Read from BloombergSneakerhead Accused of Running Huge Air Jordan Ponzi SchemeThis Is How China Could Hit Back Over Pelosi’s Taiwan VisitChina Warns Airlines to Avoid ‘Danger Zones’ Around TaiwanThe longest portion of the offering, a 40-year security, yields 118 basis points over US Treasuries, down from initial price discussions in the 150 basis points range, according to people faIn this article, we discuss 10 best high-yield dividend champions to buy in August. You can skip our detailed analysis of dividend stocks, and go directly to read 5 Best High-Yield Dividend Champions to Buy in August. The current market situation and soaring inflation have investors worried about a possible recession. That’s why they are flocking to […]Apple  is gearing up for a four-part bond sale to fund stock buybacks.  Apple (ticker:  AAPL  ) is planning to use the proceeds from the sale for general corporate purposes, including buying back shares and paying dividends, the company said in a filing with the Securities and Exchange Commission.  Apple didn’t disclose how much money it was raising or what interest rates it will pay, but the latest report from Bloomberg said the offering was for $5.5 billion.;49.689998626708984;On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.The biotech's results and what management has to say about its plans will help to determine whether a rally will continue.Vaccine stocks haven't been the brightest of stars this year. The names that once soared in the triple -- and even quadruple -- digits have actually declined. I'm talking about biotech players Moderna (NASDAQ: MRNA), BioNTech (NASDAQ: BNTX), and Novavax (NASDAQ: NVAX).Pfizer and BioNTech appear to be beating Moderna in this market -- at least, so far.  The U.S. government has finalized supply agreements with Pfizer-BioNTech and Moderna that include the companies' respective omicron boosters.  First, Pfizer and BioNTech received a much larger initial order than Moderna.Oral antiviral Paxlovid saw stronger-than-expected sales in the first half of the year, but still hasn't captured the international markets.Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?;320.20001220703125;Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones.;114.45999908447266;Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the second quarter of 2022.;140.38999938964844;In this article, we discuss 10 latest earnings that surprised Wall Street. If you want to see more companies that posted noteworthy earnings recently, click 5 Latest Earnings that Surprised Wall Street. The S&P 500 index has gained about 8% in the last month, and 4.15% in the last 5 days as of market close […]In this article, we discuss 10 high free cash flow dividend stocks. You can skip our detailed discussion of free cash flow stocks, and go directly to read 5 High Free Cash Flow Dividend Stocks. With looming recession fears and a slumping economy, investors around the world are focusing on dividend stocks like The Coca-Cola Company […]Sosei Group Corporation and AbbVie Inc (NYSE: ABBV) announced a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate G protein-coupled receptor targets associated with neurological disease. The new agreement will leverage Sosei Heptares' StaR technology & structure-based drug design platform. The agreement expands the ongoing collaboration between Sosei Heptares and AbbVie, building on the first agreement signed inNew strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseasesSosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 02, 2Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?During a recession, dividends are especially important because they give you a cushion even if the stock price falls.;85.05999755859375;Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.Swiss drugmaker Novartis (NYSE: NVS) boasts a $207 billion market capitalization, which makes it the sixth-largest pharma stock in the world and the largest international-based pharma stock.  Here are a few reasons income investors should consider adding this stock to their portfolios.  Novartis had a decent second quarter for the period ended June 30.;87.61000061035156;Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Merck (MRK) is well positioned to outperform the market, as it exhibits above-average growth in financials.Merck (MRK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.;65.26000213623047;;73.27999877929688;;48.79999923706055;;41.18000030517578;;13.979999542236328;The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;42.470001220703125;;9.710000038146973;Investors will focus on top-line and bottom-line numbers when Viatris (VTRS) reports second-quarter results.;237.3800048828125;Repligen (RGEN) delivered earnings and revenue surprises of 26.39% and 9.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year)Strong organic revenue growth of 29% and strong base business growth of 41% for the quarter Revenue guidance raised to $790 - $810 million for full year 2022 WALTHAM, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s;8.289999961853027;;145.99000549316406;;86.87000274658203;;13.789999961853027;;31.770000457763672;;46.540000915527344;;12.5;;11.890000343322754;;28.6299991607666;;55.66999816894531;Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.WALTHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its second quarter 2022 financial results on Monday, August 8, 2022 at 4:30 p.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events an;123.87000274658203;;8.670000076293945;In this article, we discuss 10 52-week low stocks to buy now. If you want to see more stocks in this selection, check out 5 52-Week Low Stocks to Buy Now. The 52-week low for a stock reflects the least closing price the security has traded at over a 52-week timeline. Many investors seek out […];28.81999969482422;STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET. To access the live webcast please visit the Events & Presentations page within the Investors & Media;2.450000047683716;;5.070000171661377;;;;4.03000020980835;;3.7300000190734863;;55.41999816894531;Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 42.50% and 7.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,300 Signs New Agreement with Bioprojet Focused on Developing Innovative Therapeutics Based on Pitolisant, Expanding Harmony’s Opportunity in Narcolepsy Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study on Track with Site Activations and Patient Enrollment Conference Call and Webcast to be Held Today at 8:30 a.m. ET PLYMOUTH MEETI;74.80000305175781;;30.260000228881836;"Shares of Emergent BioSolutions (NYSE: EBS) are sinking today, down 11.8% as of 11:27 a.m. ET.  The primary problem for Emergent BioSolutions remains its contract development and manufacturing organization (CDMO) business.  In the recent quarter, Emergent actually reported negative CDMO revenue because of a reversal of previously recorded revenue related to its contract with Johnson & Johnson's Janssen unit.Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.Thank you for standing by, and welcome to the Emergent BioSolutions second quarter 2022 earnings conference call.  As is customary, today's call is open to all participants, and the call is being recorded and is copyrighted by Emergent BioSolutions.  During today's call, we may make projections and other forward-looking statements related to our business, future events, our prospects, or future performance.Emergent had positioned itself as a contract partner to develop and manufacture vaccines through the Covid crisis, but had a tough year of it.Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segmentResumes financial guidance; provides update to full year 2022 outlook GAITHERSBURG, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022. “Central to Emergent's mission - to protect and enhance life - is our ability to provide quality products and service";7.5;;7.190000057220459;LAUSANNE, Switzerland, August 02, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report financial results for the second quarter 2022 and provide business updates.;15.949999809265137;BILLERICA, Mass., August 01, 2022--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced it will host a conference call on Monday, August 8, 2022, to discuss its second quarter 2022 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company’s President and Chief Executive Officer, and Michael Doyle, the Company’s Chief Financial Officer.;3.619999885559082;;31.040000915527344;;16.549999237060547;;19.1200008392334;;3.819999933242798;;11.050000190734863;;4.519999980926514;;8.229999542236328;;17.360000610351562;"SAN DIEGO, August 01, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the market close on Tuesday, August 9 and will also host a conference call and webcast at 4:30 pm";31.479999542236328;;19.5;;17.530000686645508;SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The panel entitled “Bullseye - Targeted Oncology - Finding Needles in Plain Sight” will be held on Tues;16.43000030517578;;18.739999771118164;;3.0899999141693115;;11.880000114440918;
2022-08-03;174.58999633789062;Moderna CEO Stéphane Bancel speaks with Yahoo Finance’s Anjalee Khemlani about earnings, COVID-19 vaccine demand, the biotech company’s pipeline, and monkeypox vaccine development.In this article, we discuss 10 stocks that the strong dollar is crushing. If you want to see more stocks in this selection, check out Strong Dollar is Crushing These 5 Stocks. One of the biggest challenges presented to corporate America this earnings season was a strong dollar. Many prominent market leaders and multinationals with […]In this article, we discuss 10 Jim Cramer stocks to watch in August. If you want to see more of Jim Cramer’s latest stock picks, click 5 Jim Cramer Stocks to Watch in August. Mad Money’s Jim Cramer told investors on July 28 to use their heads rather than emotional rationale when picking stocks in […]NEW BRUNSWICK, N.J., August 02, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).The settlement reached with McKesson, AmerisourceBergen and Cardinal Health is the latest in a wave of others over the past year.;49.86000061035156;Moderna CEO Stéphane Bancel speaks with Yahoo Finance’s Anjalee Khemlani about earnings, COVID-19 vaccine demand, the biotech company’s pipeline, and monkeypox vaccine development.The market isn't putting too much faith in this drugmaker right now, and that could be a mistake.The company posts second-quarter earnings of $5.24 a share, well above the analyst consensus estimate of $4.58.The European Medicines Agency (EMA) is recommending Novavax's COVID-19 vaccine carry a warning of the possibility of two types of heart inflammation, an added burden for a shot that has so far failed to win wide uptake.  The heart conditions - myocarditis and pericarditis - should be listed as new side effects in the product information for the vaccine, Nuvaxovid, based on a small number of reported cases, the EMA said on Wednesday.The data seem likely to open a far larger market for a drug called Onpattro, which was responsible for $475 million of revenue last year.Vaxart (NASDAQ: VXRT) might just be gearing up to steal coronavirus vaccine market share from Moderna (NASDAQ: MRNA) in the next couple of years, making its investors wealthy in the process.  The biotech's vaccine tablets could have a few advantages that Moderna's shots don't, including one in particular, that might be a public health holy grail at the moment.  For Vaxart's stock to beat Moderna's next year, two things need to happen.Moderna Inc on Wednesday maintained its full-year COVID-19 vaccine sales forecast of $21 billion as canceled orders from low- and middle-income nations through the COVAX program offset gains from new booster dose orders.  Moderna shares jumped nearly 17% in morning trading after the company also announced a $3 billion share buyback plan.  Moderna has begun producing a redesigned booster shot targeting both the original coronavirus as well as the BA.4 and BA.5 Omicron subvariants.Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.;313.8299865722656;Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.;99.91000366210938;"COPENHAGEN (Reuters) -Shares in Danish drugmaker Novo Nordisk fell on Wednesday as news about its new obesity drug disappointed investors, even though the firm lifted its sales and operating profit forecasts for the year on strong first half results.  Novo Nordisk, whose main business is to develop diabetes and obesity drugs, now expects sales growth of 12-16% at constant exchange rates, up from a previous estimate of 10-14%.  Shares in Novo ended down 9.4% at the market close.3 August 2022 - Financial report for the period 1 January 2022 to 30 June 2022 Novo Nordisk's sales increased by 25% in Danish kroner and by 16% at constant exchange rates to DKK 83.3 billion in the first six months of 2022 Operating profit increased by 26% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 37.5 billion.Sales in International Operations increased by 15% in Danish kroner (10% at CER), and sales in North America Operations increased by 36% in Danish kroner (24% atLet us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.Bagsværd, Denmark, 3 August 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initia";141.1999969482422;Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUX™ XC for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. 1Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.;84.86000061035156;;87.62000274658203;"Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.Merck & Co Inc's (NYSE: MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy (docetaxel) did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for metastatic castration-resistant prostate cancer (mCRPC). The study showed modest trends toward improving both OS and rPFS for patients who received Keytruda + chemo combo than chemotherapy alone; however, these results did not meet statistical significance. Separately, MerckBuild and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.RAHWAY, N.J. & NUTLEY, N.J., August 03, 2022--Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA Plus LENVIMA Versus LENVIMA Monotherapy in uHCCRAHWAY, N.J., August 03, 2022--Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA Plus Chemotherapy in Patients With mCRPCBig pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.";65.31999969482422;;72.98999786376953;;48.84000015258789;Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate. Sales decreased 44% to $2.85 billion, surpassing the analysts' consensus of $2.79 billion. Total revenues excluding REGEN-COV and Ronapreve revenues increased by 20%. No REGEN-COV sales were recorded as the company had completed its final deliveries under its agreements with the U.S. government. Q2 U.S. Eylea sales increased 14% Y/Y to $1.62 billion. The company obtained theRegeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.;40.81999969482422;Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.;13.890000343322754;TAK vs. ZTS: Which Stock Is the Better Value Option?;42.849998474121094;;9.75;;240.39999389648438;Shares of the bioprocessing giant Repligen Corporation (NASDAQ: RGEN) are glowing green today.  Repligen's shares have cooled off slightly since hitting this high water mark early on in Tuesday's session.  Ahead of the opening bell, Repligen posted 2022 second-quarter financial results that topped Wall Street's consensus estimates for both its bottom and top lines.;8.569999694824219;;146.1699981689453;Doximity's (DOCS) fiscal first-quarter results are likely to reflect continued strength in its fax, e-signature and telehealth products.;88.97000122070312;;14.59000015258789;;32.56999969482422;;48.119998931884766;;12.649999618530273;;12.34000015258789;;28.149999618530273;;57.880001068115234;;128.47000122070312;;8.770000457763672;;31.040000915527344;;2.440000057220459;;5.230000019073486;;;;4.46999979019165;;4.150000095367432;;52.31999969482422;Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged.At this time, I would like to welcome everyone to the Harmony Biosciences second quarter 2022 financial update conference call.  Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences second quarter 2022 financial performance and provide a business update.  At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance.;75.25;;30.719999313354492;Emergent BioSolutions Inc's (NYSE: EBS) Q2 sales fell 39% Y/Y to $242.7 million, missing the consensus of $270.94 million. Revenues from contract development and manufacturing services decreased by $100.9 million due to lower combined revenues of $82.0 million from AstraZeneca Plc (NASDAQ: AZN) and Johnson & Johnson's (NYSE: JNJ) Janssen for COVID19 vaccine production. Anthrax vaccine sales increased 86% to $95.6 million. Naloxone products decreased 4% to $101.6 million. The company reported an;7.739999771118164;The average of price targets set by Wall Street analysts indicates a potential upside of 244% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.;7.329999923706055;Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?;17.030000686645508;Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;3.619999885559082;"BRIDGEWATER, N.J., August 03, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced that Deborah M. Autor has been appointed to the Company’s Board of Directors, effective July 29, 2022.";32.560001373291016;;18.1200008392334;SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr. Schlezinger is an industry veteran with extensive experience leading and developing human resources at high-growth private and public biopharma companies. “Eric is a proven leader in building and maintaining exceptional compa;19.899999618530273;;4.0;;11.0;;4.739999771118164;;8.260000228881836;;19.280000686645508;;32.90999984741211;;22.209999084472656;WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share, representing a premium to the closing price of $19.50 per share on August 2, 2022. In addition, Arcutis has grWESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock. All of the shares in the offering are being sold by Arcutis. The proposed offering is subject to market and other conditions, and there can be no;19.1299991607666;;17.6299991607666;;18.020000457763672;;3.2200000286102295;BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the “Got My Mind Set On You – Advancing Novel Epilepsy Targets” panel at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August;12.5;
2022-08-04;171.7899932861328;;49.86000061035156;;305.7900085449219;"On Thursday morning pharmaceutical giant Eli Lilly  released that firm's second quarter financial results.  In Lilly's defense, both the adjusted and GAAP EPS numbers are inclusive of $0.46 worth of acquired IPR&D and development milestone charges.  Reported gross margin increased 690 basis points to 78% of revenue largely driven by an excess inventory charge of $423M related to Covid antibodies that was recognized in Q2 2021 (the year ago comp).Wall Street edged lower on Thursday in choppy trading as losses in Apple Inc and energy companies dampened the bullish resolve of the major indexes that had rallied in the previous session to its best in a week.  Apple weighed the most on the S&P 500 and the Nasdaq, shedding 0.4%, a day after surging 3.8%, while the energy sector fell 1.6%, tracking lower oil prices on fears of a slowdown in demand.  ""It is really just a reflection of the strong gains that we had yesterday and so the market is digesting that,"" said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.The global tally of new cases of COVID-19 fell 9% in the week through July 31, according to the World Health Organization, but the trend did not hold for the U.S., which saw new cases climb 2% to mark the second-highest increase after Japan.Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties.By Liz Moyer";104.47000122070312;"Welcome, and thank you for joining the second quarter 2022 Novo Nordisk earnings conference call.  With me today, I have executive vice president and head of commercial strategy and corporate affairs, Camilla Sylvest; executive vice president and head of North America operations, Doug Langa; executive vice president and head of development, Martin Holst Lange; and finally, chief financial officer, Karsten Munk Knudsen.Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy on Thursday, saying there was nothing unusual about a slight delay in its availability.  Shares in the Danish diabetes and obesity drug maker fell by almost 10% on Wednesday, despite a significant upgrade to its financial outlook, with some analysts attributing the drop in part to lower-than-expected U.S. sales of Wegovy and a delay in when the drug is fully available later this year.  Citi analysts said in a note that the share price fall was an overreaction to the news, while on Thursday Novo Nordisk Chief Executive Lars Fruergaard Jorgensen told reporters such a delay was not unusual.Danish drugmaker Novo Nordisk missed quarterly views Wednesday, but raised its full-year outlook. Still, NVO stock tumbled.Novo Nordisk A/S (NYSE: NVO) reported Q2 sales of DKK41.27 billion, +25% Y/Y (+15% on a constant currency basis). Operating profit increased by 24% and (+10% at CER) to DKK18.39 billion. Net profit increased 10% to DKK13.32 billion. ""We are very pleased with the sales growth in the first half of 2022. The growth is driven by increasing demand for GLP-1-based diabetes treatments, especially Ozempic,"" Chief Executive Lars Fruergaard Jorgensen said in a statement. Also Read: Novo Nordisk Doubles 20";138.9199981689453;;85.2300033569336;;86.81999969482422;;66.29000091552734;;72.12000274658203;Bristol Myers Squibb leaders share the latest in the fieldIs the U.S. in a recession?  The country's gross domestic product declined for two consecutive quarters, which signals a recession according to a general rule of thumb.  With that in mind, let's look at two healthcare stocks that could get you through these challenging times and beyond: Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).NEW YORK, August 03, 2022--Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights;49.18000030517578;Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China Collaboration to accelerate the development and access of oncology medicines for cancer patients in ChinaClinical trial programs combining two of Sanofi’s prioritized oncology assets with sintilimab, the leading checkpoint inhibitor in China, to address some of the most prevalent solid tumors in China Sanofi to make an initial equity investment of €300 millionSanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses.;40.599998474121094;;13.930000305175781;;42.5099983215332;Strong growth in net cash provided by operating activities and Adjusted Cash Receipts(1)Announced transactions of up to $2.5 billion year-to-date, including $1.7 billion in upfront paymentsIncreased 2022 guidance: Adjusted Cash Receipts(1) expected to be $2,275 to $2,350 million NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP f;9.619999885559082;;243.3000030517578;Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022;9.09000015258789;;147.10000610351562;Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?ClearBridge Investments, an investment management company published its “ClearBridge Small Cap Growth Strategy” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund declined and underperformed the Russell 2000 growth benchmark. The letter states that the higher interest rate and current economic events influenced the performance […];91.55000305175781;COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at 4:30 p.m. Eastern Time (ET) to review its second quarter 2022 financial results and provide a business update. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Invest;14.90999984741211;"Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022.";32.40999984741211;JERSEY CITY, N.J., August 04, 2022--Organon reports results for the second quarter ended June 30, 2022;50.02000045776367;;13.699999809265137;;13.279999732971191;;29.5;;61.33000183105469;It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...;134.39999389648438;;9.050000190734863;;34.38999938964844;"– Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints – – Encouraging Preliminary Data from Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma Presented at ASCO; Combination Continues in Ongoing Phase 2 Trial and Expands into Additional Sub-Studies with Standard of Care Agents – – Mirdametinib Monotherapy and Comb";2.4000000953674316;;5.550000190734863;;;;4.420000076293945;;4.230000019073486;;52.36000061035156;;75.25;;32.7400016784668;;8.15999984741211;;7.860000133514404;;17.190000534057617;BILLERICA, Mass., August 03, 2022--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1:30 p.m. ET in Boston, MA. Toloue will also host one-on-one and group meetings with institutional investors that day.;3.4600000381469727;;33.119998931884766;;18.690000534057617;;21.0;SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D., vice president of clinical endocrinology, will review additional analyses from the preclinical and Phase 1 clinical studies of CRN04894 in an oral presentation at the 10th International Congress of Neuroendocrinology (ICN), being held August 7-10, 2022. CRN04894 is an investigational, oral, small molecule adrenocorticotropic hormone (ACTH) antagonist that is be;4.110000133514404;;12.170000076293945;;5.119999885559082;;8.199999809265137;;20.639999389648438;;35.33000183105469;;24.610000610351562;Arcutis Biothera shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022Atopic dermatitis affects approximately 26 million adults and children in the U.S. WESTLAKE VILLAGE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatologWESTLAKE VILLAGE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 22,200 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 44,500 shares of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee o;20.450000762939453;;18.440000534057617;;18.020000457763672;Company announcement – No. 31 / 2022 Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for 2022 Copenhagen, DK and Boston, MA, U.S. August 4, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 11, 2022 at 4 pm CET (10 am ET) following the announcement of results for the sec;3.309999942779541;;13.130000114440918;
2022-08-05;171.11000061035156;;49.27000045776367;;301.32000732421875;"By Liz MoyerCompanies in The News Are: COIN, BLK, META, LLY, CIA new class of treatments for obesity can have a big impact on public health and on the bottom lines of companies like Eli Lilly and Novo NordiskLLY earnings call for the period ending June 30, 2022.Eli Lilly slashed its 2022 earnings outlook Thursday after ""significantly"" missing forecasts, leading LLY stock to crumble.Wall Street's main indexes wobbled on Thursday as gains in high-growth stocks offset losses in energy shares, with investors looking ahead to monthly jobs report for clues on the pace of interest rate hikes by the Federal Reserve.  The tech-heavy Nasdaq hovered near a three-month high that it hit in the previous session, led by Amazon.com Inc and Advanced Micro Devices, while losses in Apple Inc and energy stocks weighed on the S&P 500.  ""It is likely that we will go into another downturn next year, but the question is how deep and that will depend on the Fed. The market at this point is leaning in the direction the Fed will go lighter and you're seeing stocks anticipate that.""Pieris Pharmaceuticals Inc (NASDAQ: PIRS) decided to end work on Cinrebafusp alfa (PRS-343), a 4-1BB/HER2 anticalin-based bispecific, as part of a strategic pipeline prioritization to focus its resources. The drug was slapped with an FDA clinical hold in July 2020. In August, Eli Lilly And Co (NYSE: LLY) announced a trial collaboration to contribute its ramucirumab (Cyramza) and paclitaxel for the Phase 2 study in HER2-positive gastric cancer. For the AstraZeneca plc (NASDAQ: AZN)-partnered progEli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.JAZZ's Q2 earnings and sales beat expectations on strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. The company affirms its 2022 guidance.The S&P 500 index was flat on Thursday as losses in Apple and energy firms dampened the bullish sentiment that had fueled a rally in the previous session, with investors awaiting monthly jobs data for cues on the path of future interest rate hikes.  Apple weighed the most on the benchmark index, shedding 0.3%, a day after surging 3.8%.  ""We are in this honeymoon period where past earnings have been good, including the ones just reported, and inflation looks like it is moderating,"" said Christopher Grisanti, chief equity strategist at MAI Capital Management.The pharmaceutical company cut its profit outlook for the year as the stronger U.S. dollar impacts results.";103.19999694824219;By Liz MoyerA new class of treatments for obesity can have a big impact on public health and on the bottom lines of companies like Eli Lilly and Novo NordiskIn this piece, we will take a look at the twelve best healthcare stocks to buy now. If you want to skip the details and head on to the top stocks in this list, then take a look at 5 Best Healthcare Stocks To Buy Now. Healthcare stocks are proving to be resilient in the […]Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.;138.0399932861328;Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.After the market's tepid reception to AbbVie's (NYSE: ABBV) latest earnings report on July 29, the drugmaker appears to face a fork in the road ahead.  Down one path is the potential decline of market share for its most profitable medicine and a further drop in the stock price.  The first reason AbbVie is approaching a critical point is that one of its engines of growth is sputtering -- more or less right out of the gate.AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.Executives at AbbVie, J&J, and Merck say the suggested changes in their current form would be 'chilling' or 'detrimental' to the development of new therapies.;85.56999969482422;;87.41000366210938;;66.02999877929688;;72.12000274658203;Executives at AbbVie, J&J, and Merck say the suggested changes in their current form would be 'chilling' or 'detrimental' to the development of new therapies.Faced with conflicting signs from all sides of the biotech economy, executives are left sorting out how to plan for growth.;49.709999084472656;By Liz MoyerInnovent Biologics Inc (OTC: IVBXF) and Sanofi SA (NASDAQ: SNY) have collaborated to develop and commercialize two Sanofi clinical-stage oncology assets - Phase 3 SAR408701 and Phase 2 SAR444245 combined with sintilimab. In addition to the collaboration and license agreement, Sanofi will invest €300 million in Innovent through the subscription of new common shares. SAR408701 (tusamitamab ravtansine) is an antibody-drug conjugate (ADC) targeting a cell-surface glycoprotein that is highly expresse;40.56999969482422;Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.;13.84000015258789;;42.45000076293945;;9.729999542236328;Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.;246.27000427246094;The bioprocessing equipment company is seeing growth prospects accelerate for its non-COVID-related revenue.;8.899999618530273;;146.97999572753906;Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -122.58% and 2.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the second quarter ended June 30, 2022, and provided a review of recent accomplishments during and anticipated upcoming milestones.;94.91000366210938;;14.289999961853027;;31.5;;49.849998474121094;"SOMERSET, N.J., August 05, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited financial results for the six-months ended June 30SOMERSET, N.J., August 04, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang ""Frank"" Zhang as Class II director of Legend Biotech, and Dr. Li Mao as Class III director of Legend Biotech. Mr. Heyman and Dr. Mao were i";13.760000228881836;;13.880000114440918;;33.470001220703125;;63.33000183105469;WALTHAM Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to two new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company;140.36000061035156;;8.630000114440918;;36.86000061035156;;2.2799999713897705;Image source: The Motley Fool.  Opko Health (NASDAQ: OPK)Q2 2022 Earnings CallAug 04, 2022, 4:30 p.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood day and welcome to the OPKO Health's second quarter 2022 financial results conference call.OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Aug. 04, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2022. Business highlights for the second quarter of 2022 and subsequent weeks include the following: Acquired ModeX Therapeutics, Inc. (ModeX), gained proprietary immunotherapy technology, seasoned scientific team, new executives and Directors. ModeX is focused on developing uni;5.699999809265137;;;;4.880000114440918;Nektar (NKTR) delivered earnings and revenue surprises of 15.84% and 7.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022.;4.489999771118164;;52.5;;74.97000122070312;;31.649999618530273;;8.960000038146973;;8.300000190734863;Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?;17.469999313354492;;3.180000066757202;"Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $559 million, an increase of 5% Y/Y, beating the consensus of $536.34 million. The increase was driven by growth across all three segments with solid broad-based performance in generics, including injectables. Adjusted EPS was $0.19, missed the consensus of $0.20, and was lower than the $0.23 posted a year ago. Adjusted EBITDA decreased 6% to $135 million, reflecting lower gross profit due to product mix and a tough comparison to theAmneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?BRIDGEWATER, N.J., August 05, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") announced its results today for the second quarter ended June 30, 2022.";37.349998474121094;"KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring sideroblast-positive and non-RS patients; 44% of high transfusion burden patients achieved transfusion independence KER-012 preliminary Phase 1 data exhibited encouraging treatment profile in healthy volunteers with improvements in biomarkers of bone formation with no clinically meaningful changes in red blood cell parameters Strengthened cash position";19.3799991607666;;22.200000762939453;;4.380000114440918;;15.800000190734863;;5.409999847412109;;7.650000095367432;;22.1299991607666;;35.70000076293945;;25.149999618530273;Received U.S. Food and Drug Administration (FDA) approval for ZORYVE™ (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis, in individuals 12 years of age and olderAnnounced positive topline results from pivotal Phase 3 trial of roflumilast foam in seborrheic dermatitis, with anticipated New Drug Application (NDA) submission in the first quarter of 2023Completed enrollment in INTEGUMENT-1, the first of two pivotal Phase 3 trials in subjects with atop;23.639999389648438;"Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023 Expanded development of tovorafenib with initiation of pivotal Phase 3 FIREFLY-2/LOGGIC clinical trial evaluating tovorafenib as a front-line therapy in pLGG Completed $172.5 million upsized public offering providing funding into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 04";18.93000030517578;;18.198999404907227;;3.2799999713897705;;12.529999732971191;"Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -5.81% and 68.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass. & MONTREAL, August 04, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022."
2022-08-08;170.1999969482422;;49.56999969482422;;302.5;In this article, we will take a look at the 10 healthcare stocks making moves after earnings. If you want to see some more healthcare companies moving on quarterly results, go directly to 5 Healthcare Stocks Making Moves After Earnings. The Healthcare sector is usually considered defensive. That’s because pharmaceutical companies, hospitals, medical device makers […]Eli Lilly and Company (NYSE: LLY) announced today the availability of a new, citrate-free formulation of Taltz® (ixekizumab) injection 80 mg/mL. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formulation. The new Taltz formulation significantly reduced injection site pain experienced by some people immediately following injection as shown by an 86% decrease in a visual analog scale (VAS) oIt looks like Eli Lilly and Company ( NYSE:LLY ) is about to go ex-dividend in the next three days. Typically, the...The administration of President Joe Biden and one of Indiana's largest employers have condemned the state's new ban on abortions, with the White House calling it another extreme attempt by Republicans to trample women's rights.;102.41999816894531;Bagsværd, Denmark, 8 August 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated per;140.33999633789062;;85.94000244140625;;88.48999786376953;;65.12000274658203;AstraZeneca Plc (NASDAQ: AZN) has reported preliminary results from the SAVANNAH Phase 2 trial of Tagrisso (osimertinib) plus savolitinib in epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels of MET overexpression and/or amplification, whose disease progressed on Tagrisso. Tagrisso plus savolitinib demonstrated an objective response rate (ORR) of 49%. The highest ORR was observed in patients with high levels of MET who were not treated with priorWILMINGTON, Del., August 08, 2022--Preliminary results from the SAVANNAH Phase II trial showed that TAGRISSO® (osimertinib) plus savolitinib demonstrated an objective response rate (ORR) of 49% (95% confidence interval [CI], 39-59%) in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels of MET overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with TAGRISSO.— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) and AstraZeneca PLC (“AstraZeneca”) (LON/STO/Nasdaq: AZN) today announce that preliminary results from the SAVANNAH Phase II trial showed that TAGRIS;73.80000305175781;;49.08000183105469;;40.310001373291016;;13.9399995803833;;43.130001068115234;;10.09000015258789;Foreign currrency exchange dragged on revenue at Viatris, although the pharmaceutical company said that its strategies have kept foreign exchange from impacting free cash flow and earnings.  Viatris (Nasdaq: VTRS) on Monday revised downward by $800 million its revenue guidance for the full year, from between $17 billion and $17.5 billion previously announced to $16.2 billion to $16.7 billion.Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Viatris Inc. (NASDAQ: VTRS) today reported strong results for the second quarter of 2022 and provided an update to its full year 2022 financial guidance.;250.4600067138672;;8.960000038146973;;147.14999389648438;;98.93000030517578;;14.34000015258789;;31.540000915527344;;49.529998779296875;;13.920000076293945;;13.930000305175781;— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) and AstraZeneca PLC (“AstraZeneca”) (LON/STO/Nasdaq: AZN) today announce that preliminary results from the SAVANNAH Phase II trial showed that TAGRIS— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to be submitted to an upcoming medical meeting — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J.,, Aug. 07, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that the pivotal global Phase 3 FRESCO-2 trial evalua;36.790000915527344;;62.33000183105469;;241.19000244140625;"Analysts said the results were strong enough that the drug could be the go-to treatment once it is approved.Shares of Karuna Therapeutics Inc. soared 42.6% in premarket trading on Monday after the company said its experimental treatment for schizophrenia met the primary endpoint in a Phase 3 clinical trial. Karuna told investors it expects to submit the therapy to the Food and Drug Administration in ""mid-2023."" RBC Capital Markets analyst Brian Abrahams expects the drug could generate $1.3 billion in annual sales, according to an investor note. The ""profile continues to look very differentiated from eTrial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and negative symptoms of schizophrenia, as measured by the PANSS positive, PANSS negative and PANSS negative Marder factor subscales KarXT was generally well tolerated, with a side effect profile substantially consistent with prior trBOSTON, August 08, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2022 and provided a general business update.BOSTON, August 08, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. The trial met its primary endpoint, with KarXT demo";8.699999809265137;;39.65999984741211;;2.450000047683716;;5.71999979019165;;;;4.869999885559082;;4.46999979019165;;54.0;;75.05999755859375;;30.549999237060547;;9.220000267028809;We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...;8.050000190734863;;16.489999771118164;;3.130000114440918;The recent 10% drop in Amneal Pharmaceuticals, Inc.'s ( NYSE:AMRX ) stock could come as a blow to insiders who...;36.619998931884766;;19.260000228881836;;22.049999237060547;;4.429999828338623;;12.0;;5.179999828338623;;7.829999923706055;;21.020000457763672;;24.059999465942383;"Reata Pharmaceuticals Inc (NASDAQ: RETA) completed a mid-cycle communication meeting with the FDA regarding the marketing application review status for omaveloxolone for Friedreich's ataxia. The FDA stated that it had not identified any new significant issues, but it continues to have concerns regarding the strength of the efficacy evidence. The agency did not identify any significant clinical safety issues. The FDA stated that the safety review is ongoing, and they are continuing to evaluate thReata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -6.32% and 70.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?PLANO, Texas, August 08, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.";24.8799991607666;The big shareholder groups in Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) have power over the company. Institutions...;24.389999389648438;;20.780000686645508;;18.299999237060547;;3.930000066757202;;13.079999923706055;
2022-08-09;170.17999267578125;;49.779998779296875;;303.0199890136719;In this article, we discuss the 10 stocks that Jim Cramer recommends buying as commodity prices decline. If you want to read about some more stocks that Jim Cramer recommends buying, go directly to Jim Cramer Recommends Buying These 5 Stocks as Commodity Prices Decline. The prices of commodities like oil, grains, metals, and paper […]Yahoo Finance senior columnist Rick Newman highlights the corporate backlash Indiana lawmakers are receiving after signing a new abortion ban into law.Eli Lilly said the new abortion law could hinder its ability to “attract diverse scientific, engineering and business talent from around the world.”;104.5999984741211;Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.;140.25;Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.Buying high-quality blue-chip stocks in a bear market could be a solid path to generating lucrative long-term returns. Blue-chip stocks are typically large-cap businesses in the mature stage of their business cycle. They boast solid business models, strong balance sheets, and positive free cash flow, which allow them to make significant dividend payments. Therefore, blue-chip stocks offer stability to investor portfolios during economic uncertainty and market volatility. While they are particulaValue stocks are always a sensible class of equities to consider as an investment. It’s all about finding stocks that are believed to be trading below where they should be based on fundamental metrics. Identifying value is part science and part art. The science requires calculating metrics that determine a given stock’s fundamentals. Basically, anything that can be measured can be considered fundamental. Price-to-earnings (P/E) ratios, revenue, net income, earnings per share (EPS), the list goes;87.1500015258789;;89.5199966430664;;65.88999938964844;AstraZeneca Plc (NASDAQ: AZN) reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in non-small cell lung cancer (NSCLC) without actionable genomic alterations. Datopotamab deruxtecan is jointly developed by Daiichi Sankyo (OTC: DSKNY) and AstraZeneca. The interim analysis demonstrated an overall;74.95999908447266;Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.;48.65999984741211;Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n;40.029998779296875;"Mersana Therapeutics Inc (NASDAQ: MRSN) announced a global collaboration that provides GSK plc (NYSE: GSK) an exclusive option to co-develop and commercialize XMT-2056. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and tumor cells. Mersana expects to initiate a Phase 1 trial of XMT-2056 to investigate its potential in a range of HER2-expressing tumors. The FDA recently granted an orphan drug designation to XMT-2056 for gastrGSK receives exclusive global license option for XMT-2056 Mersana to receive $100 million upfront option purchase feeIf GSK exercises its option, Mersana to receive exercise payment; potential for additional development, regulatory and commercial milestone payments, plus tiered double-digit royalties on net salesMersana to co-develop XMT-2056; retains options for U.S. profit-sharing and U.S. co-promotion Conference call today at 4:30 p.m. ET CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MePHILADELPHIA, August 08, 2022--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This resource will provide frequent and relevant data on trends to focus";13.819999694824219;;43.66999816894531;;10.460000038146973;;244.85000610351562;;8.819999694824219;;147.35000610351562;Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.;93.1500015258789;Ascendis Pharma  is scheduled to report second-quarter numbers after Wednesday's market close, so let's check out the charts of the biopharmaceutical company that is working in endocrinology and oncology.  In this daily bar chart of ASND, below, we can see that prices made a dramatic low in May and have subsequently recovered.  The On-Balance-Volume (OBV) line has strengthened since its early May low.;14.130000114440918;;31.389999389648438;;48.5099983215332;;13.529999732971191;;13.65999984741211;"SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (""Inmagene"") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in the United States, was dosed in a global Phase I trial of IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (“BTK”) inhibitor. Inmagene is developing the drug candidate to potentially treat immunological diseases. The Phase I study";39.77000045776367;;64.29000091552734;"Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -2.10% and 4.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Received U.S. FDA filing acceptance of NDA with Priority Review designation for intravitreal pegcetacoplan for treatment of geographic atrophy; PDUFA target action date of November 26, 2022Achieved $15.7 million in Q2 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesDosed first patient in Phase 3 VALIANT study in IC-MPGN and C3GCash and investments of $852.8 million as of June 30, 2022; expected cash runway into Q1 2024Conference call scheduled today at 4:30 p.m. ET WALTHAM, Mass., Aug. 0";228.4499969482422;"Karuna Therapeutics topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high.BOSTON, August 08, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX) (""Karuna""), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it has commenced an underwritten public offering of $600.00 million of its common stock. Karuna also intends to grant the underwriters a 30-day option to purchase an additional $90.0 million of its common stock offered in the public offerinWhat happened Karuna Therapeutics (NASDAQ: KRTX), a clinical-stage biotech, is having a record-breaking day. As of 2:25 p.m. ET, the company's shares were up by an eye-popping 70%, surging to an all-time high during Monday's trading session.The psychiatric drugmaker is riding high following positive results from a trial of a drug that works on the brain-immune-gut axis.";7.96999979019165;;36.0;;2.509999990463257;The analysts covering OPKO Health, Inc. ( NASDAQ:OPK ) delivered a dose of negativity to shareholders today, by making...OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.;5.760000228881836;;;;4.710000038146973;;4.340000152587891;;50.77000045776367;;75.04000091552734;Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinibInitiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer (NSCLC) Plan to provide detailed update for TRIDENT-1 registrational ROS1-positive NSCLC population and additional data for NTRK-positive solid tumor population, as well as SHIELD-1 Pha;29.719999313354492;It is hard to get excited after looking at Emergent BioSolutions' (NYSE:EBS) recent performance, when its stock has...;9.5;;7.96999979019165;ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 23.96% and 14.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?LAUSANNE, Switzerland, August 09, 2022--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2022 and provided business updates.;7.460000038146973;Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 0% and 20.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?BILLERICA, Mass., August 08, 2022--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced that E. Kevin Hrusovsky is stepping down as Executive Chairman of its Board of Directors.BILLERICA, Mass., August 08, 2022--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced operating results for the three months ended June 30, 2022.;3.0899999141693115;;36.970001220703125;;18.5;;21.209999084472656;;4.409999847412109;;11.579999923706055;;5.010000228881836;;7.800000190734863;;18.229999542236328;;21.350000381469727;"Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.PLANO, Texas, August 09, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, announced that on August 8, 2022, after the U.S. financial markets closed, we received a communication from the U.S. Food and Drug Administration (""FDA"") informing us that they have extended the review timeline for the New Drug Application (""NDA"") for omaveloxolone for the treatment of Friedreich’s ataxia by three months.";24.84000015258789;;22.75;"Day One Biopharmaceuticals, Inc. (DAWN) made it through our ""Recent Price Strength"" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.";23.1299991607666;IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 7.64% and 99.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing of Collaboration Agreement with Sanofi – MOUNTAIN VIEW, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent develo;16.670000076293945;NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”)REPRESENTING DEPOSITED ORDINARY SHARES OF:ZEALAND PHARMA A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 98920Y304 AND UNDERLYING ISIN: DK0060257814 Company announcement – No. 33 / 2022 Copenhagen, DK and Boston, MA, August 8, 2022 – Zealand Pharma A/S (“Zealand” or the “Company”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-headquartered biotechnology company focused on the discovery andCompany announcement – No. 32 / 2022 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market Zealand will consolidate trading to Nasdaq Copenhagen, the company’s primary and most liquid stock exchangeDecision is part of Zealand’s refocused strategy to prioritize R&D and streamline corporate operations Copenhagen, DK and Boston, MA, U.S. August 8, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnol;4.010000228881836;"PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for cent";11.930000305175781;
2022-08-10;170.6699981689453;;49.95000076293945;;304.6099853515625;In this article, we discuss the 10 stocks that US Politicians are selling. If you want to read about some more stocks that US Politicians are selling, go directly to US Politicians are Selling These 5 Stocks. Recession fears in the United States stock market have been gathering pace for the past few weeks, even […]Eli Lilly & Co. says Indiana's antiabortion law will hurt its hiring. That comes after the company donated to the politicians behind the law.;107.51000213623047;;140.94000244140625;Professional money managers have a strong preference for one stock sector in particular, along with cash dividends.In this article, we discuss 10 dividend ETFs to buy in August. You can skip our detailed analysis of dividend ETFs and their performance, and go directly to read 5 Dividend ETFs to Buy in August. Investing in dividend exchange-traded funds (ETFs) is a well-known strategy to generate a regular stream of income, especially in […]In this article, we discuss 10 stocks investors are buying amid “dire” pessimism. If you want to see more stocks in this selection, check out Investors are Buying These 5 Stocks as New Survey Shows “Dire” Pessimism. Bank of America carried out a week-long survey of hedge fund managers through July 15 that consisted of […];87.43000030517578;Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.;89.19000244140625;;66.30000305175781;Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.;74.86000061035156;Professional money managers have a strong preference for one stock sector in particular, along with cash dividends.Bristol Myers Squibb Co (NYSE: BMY) and 2seventy bio Inc (NASDAQ: TSVT) have announced topline results from KarMMa-3 Phase 3 trial of Abecma (idecabtagene vicleucel) for multiple myeloma. The trial compared Abecma to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen. The interim analysis demonstrated a statistically significant improvement in progression-free survival. Related Content:At just two years old, immunology startup GentiBio has signed a collaboration deal with a major pharmaceutical player — to the tune of up to $1.9 billion.PRINCETON, N.J., & CAMBRIDGE, Mass., August 10, 2022--Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) SEE RELEASE FOR FULL TITLE;45.20000076293945;;38.29999923706055;After disruptions at GSK plc (NYSE: GSK), supplies of rotavirus infection vaccine in children have either run out in Kenya, Tanzania, Senegal, and Cameroon or are close, Reuters reported citing officials close to the roll-out. According to the World Health Organization, up to 200,000 children die each year of contagious infection. The infection causes severe, dehydrating gastroenteritis in children under five years. GSK confirmed a shortfall of around 4 million doses of its Rotarix vaccine in 20In its Q2 earnings release, Vir Biotechnology Inc (NASDAQ: VIR) and its partner GSK plc (NYSE: GSK) said that they do not plan to file a marketing application for sotrovimab for COVID-19 at this time. The company also said it does not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial, citing evolving COVID-19 landscape and FDA discussions. Discussions with the FDA remain ongoing regarding the appropriate path forward for sotrovimab in the U.S. Related: Why Did FDA Pull Authoriza;14.220000267028809;;43.91999816894531;;10.770000457763672;Professional money managers have a strong preference for one stock sector in particular, along with cash dividends.;256.2099914550781;;8.970000267028809;;147.11000061035156;Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.;95.13999938964844;;13.130000114440918;"Evotec SE's (NASDAQ: EVO) subsidiary, Just - Evotec Biologics Inc, has expanded a multi-year partnership with Alpine Immune Sciences Inc (NASDAQ: ALPN) for ALPN-303 for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of their first-in-human program initiated in 2020, in which Just - Evotec Biologics delivered drug substance materials using their J.DESIGN continuous manufacturing platform for Alpine's ongoing Phase 1 studEvotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for";31.520000457763672;;48.880001068115234;;13.869999885559082;;14.140000343322754;;41.41999816894531;;66.44000244140625;;258.8900146484375;"BOSTON, August 10, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX) (""Karuna""), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an upsized underwritten public offering of 3,488,373 shares of its common stock at a public offering price of $215.00 per share. The gross proceeds to Karuna from the offering, before deducting the underwriting discounts and commiThough Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.";8.09000015258789;;29.489999771118164;;2.7100000381469727;;5.989999771118164;;;;4.849999904632568;;4.559999942779541;;52.439998626708984;;75.04000091552734;;30.5;GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: 12th Annual Midwest IDEAS Investor ConferenceChicago, ILAugust 24, 2022 – presentation scheduled at 5:15 PM central time https://www.wsw.com/webcast/threepa38/ebs/2021448 Wells Fargo 2022 Healthcare ConferenceBoston, MASeptember 8, 2022 – fireside chat scheduled at 9:10 AM easter;9.529999732971191;;8.069999694824219;"On today's call, Ameet Mallik, chief executive officer; Jennifer Herron, chief commercial officer; Joe Camardo, chief medical officer; and Jenn Creel, chief financial officer, will discuss recent business highlights and review our second quarter 2022 financial results before opening the call for questions.  As a reminder, this conference call may contain forward-looking statements.";8.5600004196167;A slide in revenue, a deepening net loss, and dispiriting guidance were the stimuli behind the monster drop in Quanterix (NASDAQ: QTRX) stock on Tuesday.  After the biotech reported its second-quarter results following market hours Monday -- and announced a high-level departure within its ranks -- investors traded the shares aggressively, with the stock losing over half its value.  The quarter saw Quanterix earn $23.5 million in total revenue, for a year-over-year decline of more than 7%.;3.140000104904175;;39.689998626708984;;19.809999465942383;;21.770000457763672;;4.679999828338623;;12.329999923706055;;4.75;"Centessa Pharmaceuticals plc (NASDAQ: CNTA) has decided to discontinue the development of ZF874 following a recent report of an adverse event involving elevated liver enzymes (AST/ALT) in a PiMZ subject dosed with 5 mg/kg in the Phase 1 study. ZF874, a pharmacological chaperone designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT), was in a Phase 1 study to treat AATD. As previously reported in November 2021, elevated liver enzymes were observed in a subject dosed with 15- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody® technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected across pipeline over next two years – – Cash and cash equivalents of $484.2 million as of June 30, 2022; Cash runway into 2026 – BOSTON and LONDON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceut";8.196999549865723;;17.479999542236328;"Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, August 09, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", ""Arcturus Therapeutics"", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2022, and provided corporate updates.";21.559999465942383;The FDA has extended the review timeline for Reata Pharmaceuticals Inc's (NASDAQ: RETA) marketing application seeking approval for omaveloxolone for Friedreich's ataxia by three months. The company recently submitted an updated Delayed-Start Analysis of the MOXIe Extension study using a March 2022 data cut-off, a new Propensity-Matched Analysis of MOXIe Extension data, and an analysis of the relevance of Nrf2, the target of omaveloxolone, to the pathophysiology of Friedreich's ataxia. Related: W;24.860000610351562;The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 122.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very well-tolerated steroid-free cream that rapidly clear plaques and reduces itch Arcutis committed to ensuring affordable access through responsible pricing, Arcutis Cares™ and ZORYVE Direct™ patient access support program WESTLAKE VILLAGE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-st;23.56999969482422;;25.719999313354492;;16.440000534057617;;4.769999980926514;;12.729999542236328;
2022-08-11;167.13999938964844;;48.290000915527344;;301.1700134277344;"Two dividend stocks that have been beating the markets by wide margins this year include Eli Lilly (NYSE: LLY) and ExxonMobil (NYSE: XOM).  Drugmaker Eli Lilly has seen its share price rise 9% thus far in 2022.  This month, Eli Lilly released its second-quarter numbers, which showed sales of $6.5 billion for the period ended June 30, down 4% year over year; however, this falls to a decline of just 1% when factoring out the impact of foreign currency exchange.Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hiring of a new chief commercial officer for Loxo@Lilly.";108.79000091552734;;142.0800018310547;At three years old, an Atlas Venture spinout focused on blood disorders is going public by merging with another local biotech company.;85.58000183105469;;88.93000030517578;;64.6500015258789;Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) decided to discontinue the development of oral SERD asset ZN-c5 and EGFR inhibitor ZN-e4 following the completion of existing clinical trials. The company will focus its capital on developing the WEE1 drug, ZN-c3, and BCL-2 inhibitor, ZN-d5. SVB Leerink says that the decision was not unexpected given the difficulty the SERD class has had demonstrating superiority to aromatase inhibitors in the metastatic settings and the cost needed to pursue developme;74.45999908447266;;43.41999816894531;"(Bloomberg) -- Sanofi, GSK Plc and Haleon Plc have lost a combined $40 billion in market value since Tuesday’s close amid mounting concerns about litigation around the recalled heartburn drug Zantac.Most Read from BloombergStriking Drop in Stress Hormone Predicts Long Covid in StudyThe Fed’s Damage to the Housing Market May Last YearsGarland Seeks to Unseal Trump Warrant, Says He Approved SearchChina Has Painted Itself Into a Semiconductor CornerThe Snowballing US Rental Crisis Is Sparing NowherEuropean-listed shares of drugmakers Haleon , GSK and Sanofi plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22. GSK shares dropped 10% in London, as Sanofi and Haleon also dropped sharply. Analysts at Deutsche Bank said they don't expect another glyphosate, but ""it is very possible we may see a liability of some billions of dollar magnitude incurred."" Analysts at Credit Suisse note Haleon's prospectus says indemnification """;35.72999954223633;Sterling fell 0.5% against the euro ahead of the numbers on Friday, which are expected to show further signs of a weakening British economy.;14.119999885559082;Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce;43.70000076293945;;10.960000038146973;;246.49000549316406;;8.979999542236328;;147.61000061035156;;104.80999755859375;"— U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022 — SKYTROFA revenue continued to double quarter-to-quarter, reaching €4.4 million in the second quarter — With anticipated growth in U.S. revenues and approximately €1 billion of cash, cash equivalents, and marketable securities on hand, Ascendis is positioned to fulfill Vision 3x3 and become cash flow positive — Conference call t";13.140000343322754;Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced its financial results for the first half-year of 2022.;31.690000534057617;;46.09000015258789;;13.390000343322754;;13.859999656677246;;35.630001068115234;CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced a private offering of $250.0 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act ofCAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of;65.45999908447266;;261.30999755859375;;7.960000038146973;;28.260000228881836;;2.5;;4.71999979019165;"Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA acceptance of EQRx’s first regulatory submission (aumolertinib) for review; first sugemalimab regulatory submission expected ex-U.S. in 2H 2022; continue to engage in constructive conversations with the U.S. FDAPresented compelling new clinical data at recent medical meetings, including results from a study of aumolertinib in patients with NSCLC and CN";;;4.949999809265137;;4.420000076293945;;50.90999984741211;;75.0;;29.889999389648438;;8.470000267028809;;8.119999885559082;;10.15999984741211;The heavy selling pressure might have exhausted for Quanterix Corporation (QTRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.The market might, just might, have over-reacted to the company's dispiriting second-quarter results the previous day.;2.9200000762939453;;37.75;;16.959999084472656;;20.59000015258789;SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 67,100 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements m;4.429999828338623;;12.600000381469727;;4.28000020980835;;8.0;;17.030000686645508;Shareholders in Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) may be thrilled to learn that the analysts have...;20.959999084472656;;24.829999923706055;;24.5;;24.799999237060547;;18.1299991607666;Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK and Boston, MA, U.S. August 11, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced financial results for the first half of 2022 and provided a corporate update. Key strategic objectives achieved Adam Steensberg, President an;4.239999771118164;;12.210000038146973;It is doubtless a positive to see that the Repare Therapeutics Inc. ( NASDAQ:RPTX ) share price has gained some 42% in...
2022-08-12;165.3000030517578;;50.11000061035156;;308.0799865722656;Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.;107.5;;142.60000610351562;In this article, we discuss 10 dividend ETFs that Redditors are buying in August. You can skip our detailed analysis of dividend ETFs and their performance this year, and go directly to check out why Redditors are Buying These 5 Dividend ETFs in August. Given the turbulent start to 2022 that the major U.S stock […];85.68000030517578;"Two children with spinal muscular atrophy have died after receiving Novartis AG's (NYSE: NVS) Zolgensma, a one-time gene therapy, spotlighting its risks and questioning the safety of genetic medicines like it. The deaths, which resulted from acute liver failure, occurred in Russia and Kazakhstan. According to GoodRx Holdings Inc's (NASDAQ: GDRX) report, Zolgensma is the most expensive drug in America, with an average one-time cost of $2.1 million. The patients developed acute liver failure fiveNovartis AG on Thursday reported two patient fatalities due to acute liver failure following treatment with Zolgensma gene therapy used to treat spinal muscular atrophy.  The company has notified health authorities in markets where the drug is sold, including the FDA, and has informed relevant healthcare professionals as an additional step.  ""While this is important safety information, it is not a new safety signal and we firmly believe in the overall favorable risk/benefit profile of Zolgensma,"" Novartis said in a statement.";91.0199966430664;;66.63999938964844;"The FDA has approved Daiichi Sankyo (OTC: DSNKY) and AstraZeneca plc's (NASDAQ: AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatoryWILMINGTON, Del., August 12, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by a Food and Drug Administration (FDA)-approved test, and who have received a prior systemic therapy.Large corporations are jumping on the ""green"" bandwagon left and right, which in turn is pushing firms that lease and manage car fleets to convert to electric vehicles (EVs) faster than they had ever thought possible.  In late 2020, fleet management company ALD set a to have 30% of its new cars electrified by 2025 - a goal that seemed like a stretch because as recently as 2019 only one in 200 of ALD's new vehicles was an EV or a hybrid.  But corporate clients chasing environmental, social and governance (ESG) goals pushed the leasing giant, a unit of Societe Generale, past that target in 2021.Large corporations are jumping on the ""green"" bandwagon left and right, which in turn is pushing firms that lease and manage car fleets to convert to electric vehicles (EVs) faster than they had ever thought possible.  In late 2020, fleet management company ALD set a to have 30% of its new cars electrified by 2025 - a goal that seemed like a stretch because as recently as 2019 only one in 200 of ALD's new vehicles was an EV or a hybrid.  But corporate clients chasing environmental, social and governance (ESG) goals pushed the leasing giant, a unit of Societe Generale, past that target in 2021.";75.56999969482422;Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.;44.369998931884766;"Amid signs that a more severe influenza season is approaching in the US, a panel of public health leaders today urged that people get vaccinated in preparation for the upcoming influenza season and warned that patients in high-risk populations tend to suffer significant flu-related health disparities.3Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.Merck (NYSE: MRK) is best known for the top-selling cancer drug in the world, Keytruda, which has produced a staggering $10.1 billion in sales through the first half of this year.  Keytruda comprised only 33% of the drugmaker's $30.5 billion in total first-half sales.  Merck has a pipeline of more than 100 projects under clinical development, which should give it enough firepower to grow revenue and profits with new product launches.Shares in GSK, Sanofi, Haleon and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.  The companies' share prices had fallen sharply this week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug's withdrawal from markets in 2019 and 2020.  Among other disclosures, recently listed Haleon had highlighted the risk of such lawsuits in its prospectus.Sanofi was upgraded to hold from sell at Deutsche Bank, after the heavy selling over the previous two days on worries about Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22. ""We think the Zantac knee-jerk is starting to look somewhat overdone. This doesn't make for an obvious buying opportunity in our view, but maintaining a sell at these levels feels egregious,"" said analyst Emmanuel Papadakis. Of companies also impacted by Zantac worries, GSK climbed 2.5% in e(Reuters) -European shares rose on Friday after drugmakers rebounded following a slump in the previous session, and Flutter fanned a rally in the travel and leisure sector after an upbeat earnings forecast.  The European healthcare sector gained 0.2%, with the STOXX 600 index also rising 0.2%.  ""We raise (European) pharma from marketweight to overweight, as our macro projections imply scope for 10%+ outperformance by the first quarter next year after the sharp recent pull-back,"" said Sebastian Raedler and Thomas Pearce, investment strategists at Bank of America.By Scott KanowskyPharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac.Shares of pharmaceutical company GSK (NYSE: GSK) -- formerly known as GlaxoSmithKline -- are down 9.4% as of 2:01 p.m. ET Thursday, according to data from S&P Global Market Intelligence, up slightly from an early intraday loss of 9.9%.  The sell-off stems from reports of potential litigation regarding ulcer and acid reflux treatment ranitidine, better known as Zantac.  After being sold for years, Zantac and other brand names of ranitidine were removed from the U.S. market by the FDA in early 2020 due to concerns the treatment could cause cancer.Sanofi, GSK, and Haleon had big market drops for two straight days after UBS weighed in with a downgrade of Sanofi.";36.029998779296875;The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.What happened Shares of Pfizer (NYSE: PFE) slipped 3.3% lower as of the market close on Thursday. The decline resulted from investors' concerns about litigation related to Zantac. The U.S. Food and Drug Administration (FDA) called for the heartburn drug to be pulled from the market in 2020 due to safety concerns.Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac.Shares of pharmaceutical company GSK (NYSE: GSK) -- formerly known as GlaxoSmithKline -- are down 9.4% as of 2:01 p.m. ET Thursday, according to data from S&P Global Market Intelligence, up slightly from an early intraday loss of 9.9%.  The sell-off stems from reports of potential litigation regarding ulcer and acid reflux treatment ranitidine, better known as Zantac.  After being sold for years, Zantac and other brand names of ranitidine were removed from the U.S. market by the FDA in early 2020 due to concerns the treatment could cause cancer.The Triangle office market had some healthy momentum going into the second half of 2022, but economic headwinds are on the way and a growing pipeline of companies are looking to downsize as remote work becomes the norm.;14.25;;44.20000076293945;;11.130000114440918;;251.35000610351562;;9.0;;147.75999450683594;;110.2300033569336;;13.970000267028809;;30.989999771118164;;46.97999954223633;;13.479999542236328;;13.859999656677246;;34.86000061035156;CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock at a public offering price of $35.00 per share, or approximately $253.8 million of shares of its common stock. In addition, Cerevel granted the uCAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced private offering of $300.0 million aggregate principal amount of 2.50% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under;67.94999694824219;;277.4200134277344;Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.;7.980000019073486;;29.190000534057617;;2.5199999809265137;Counterintuitively, week-to-date, as of Thursday afternoon, Opko stock was up by almost 10%, according to S&P Global Market Intelligence.  There was no ambiguity -- Opko fell notably short of expectations for the period.  Opko's steep drop in the diagnostics segment (53% year over year to just under $187 million) was worse than many projected, but it wasn't a shock.;4.820000171661377;;;;5.139999866485596;;4.519999980926514;;52.150001525878906;;75.4000015258789;;30.5;;9.770000457763672;Initial Phase 1b monotherapy data for ERAS-007 in HERKULES-1 and first-in-human Phase 1 monotherapy data for ERAS-601 in FLAGSHP-1 expected in H2 2022 IND filing for CNS-penetrant KRAS G12C inhibitor ERAS-3490 in KRAS G12C mutant NSCLC in H2 2022 Bolstered clinical, operational, and commercial leadership Strong balance sheet with cash, cash equivalents, and marketable securities of $391 million SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision o;10.300000190734863;;10.460000038146973;;3.1600000858306885;"BRIDGEWATER, N.J., August 11, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (""FDA"") for four generics products, including vasopressin injection 1mL (single-dose).";39.43000030517578;;16.729999542236328;;20.549999237060547;Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -30.65% and 75.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenital Adrenal Hyperplasia CRN04777 and CRN04894 Phase 2 Studies Expected to Commence Following Finalization of Study Protocols with Global Regulators SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CR;4.579999923706055;;13.329999923706055;;4.260000228881836;;7.929999828338623;;19.18000030517578;;21.020000457763672;;25.1299991607666;;26.56999969482422;;26.709999084472656;;16.200000762939453;;4.369999885559082;;11.930000305175781;
2022-08-15;166.08999633789062;Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.;49.75;;313.94000244140625;Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.Eli Lilly, CVS Health, Target, Chipotle Mexican Grill and FirstEnergy are part of The Zacks top Analyst Blog.;106.37000274658203;;142.2899932861328;;85.37999725341797;"Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.Novartis AG's (NYSE: NVS) Phase 3 CANOPY-A study of canakinumab (ACZ885) in non-small cell lung cancer (NSCLC) did not meet its primary endpoint of disease-free survival (DFS) versus placebo. No unexpected safety signals were observed. Findings from the trial will be presented at an upcoming medical meeting. The study evaluated canakinumab in adult patients with stages II-IIIA and IIIB completely resected (R0) NSCLC. ""We invested in the CANOPY program based on signals of reduced lung cancer inciEfforts by Novartis to show that an established anti-inflammatory drug could also suppress cancer growth were dealt a final blow when a third big lung cancer trial failed to produce the desired results.  The Swiss drugmaker said on Monday its canakinumab drug did not slow the progression of non-small cell lung cancer in a late-stage trial, when given to prevent relapse in patients that were diagnosed early enough for tumour-removal surgery.Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be presented at an upcoming medical meetingNovartis remains committed to pursuing new therapeutic options that can have a meaningful impact on the lives of people with lung cancer Basel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885";90.5999984741211;A run of good news this summer is what touched off a run-up for the sector, says Jefferies analyst Michael Yee.Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.In this article, we discuss the 10 famous value stocks that underperformed in 2022. If you want to read about some more value stocks, go directly to 5 Famous Value Stocks that Underperformed in 2022. As the United States economy prepares to enter the fourth quarter of 2022, investors are starting to get more optimistic […]Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.;66.80999755859375;Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.AstraZeneca Plc (NASDAQ: AZN) reported topline data from the DESTINY-Breast02 phase 3 trial of Enhertu (trastuzumab deruxtecan). The trial evaluated Enhertu versus (trastuzumab/capecitabine or lapatinib/capecitabine) in HER2 positive unresectable and/or metastatic breast cancer previously treated with T-DM1. The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS). The trial also met the key secondary eAstraZeneca said on Monday its cancer drug, Enhertu, developed with Japan's Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients, boosting prospects of more regulatory approvals.  Enhertu met the main goal of a late-stage study testing the drug against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer, the company said.  The HER2 protein contributes to the growth and spread of breast cancer.AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial.;74.52999877929688;;43.83000183105469;;34.95000076293945;;14.239999771118164;;43.93000030517578;;11.109999656677246;;255.72999572753906;;8.920000076293945;;148.0;;107.66000366210938;;13.800000190734863;;31.010000228881836;;46.720001220703125;;13.380000114440918;;13.890000343322754;;34.43000030517578;;68.63999938964844;;273.7099914550781;;7.96999979019165;;30.520000457763672;;2.609999895095825;;4.980000019073486;;;;4.909999847412109;;4.730000019073486;;50.900001525878906;;75.48999786376953;;30.5;The FDA issued a warning letter to Emergent BioSolutions Inc (NYSE: EBS), citing certain deficiencies at the company's troubled manufacturing facility in Baltimore, Maryland. The FDA pointed to equipment cleaning and maintenance deficiencies to prevent drug product contamination. Reuters reported that the agency also recommended that the company review its quality control process. Related: Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract. Emergent had said the FDA had last;10.680000305175781;;9.279999732971191;;10.180000305175781;;3.190000057220459;;40.119998931884766;;16.969999313354492;;22.3700008392334;;4.679999828338623;- Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections- Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI) study of PCN-101, database lock for the GRX-917 Phase 1 trial, completion of SAD portion of ongoing KUR-101 Phase 1 trial,- Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments - Flexible draw availability provides optionality to optimize liquidity and capital structure moving forward NEW YORK and BERLIN, Aug. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde;13.34000015258789;;3.890000104904175;;7.75;Today we will run through one way of estimating the intrinsic value of Procaps Group S.A. ( NASDAQ:PROC ) by taking the...;21.670000076293945;;20.610000610351562;;24.719999313354492;;25.0;;27.010000228881836;;16.8799991607666;;4.659999847412109;;12.25;
2022-08-16;167.57000732421875;Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.These widely owned companies are doling out between $11.1 billion and $18.5 billion in dividend income to their shareholders each year!Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.In this article, we discuss 10 important dividend increases to watch in August. You can skip our detailed analysis of dividend stocks and their importance, and go directly to read 5 Important Dividend Increases to Watch in August. The global dividend payments suffered a lot in the face of the pandemic in 2020. According to […];49.86000061035156;;310.30999755859375;Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index […];105.31999969482422;;142.5500030517578;Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.;85.81999969482422;;90.58999633789062;Merck Co & Inc (NYSE: MRK) and Orna Therapeutics announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in infectious disease and oncology. Merck will make an upfront payment to Orna of $150 million. In addition, Orna will be eligible to receive up to $3.5 billion in development, regulatory, and sales milestones. Orna will retain rights to its engineered circular RNA (oRNA) therapies (oRNA)-lipid nanoparticles (LNP) techMerck has been a laggard in the Covid-era race for messenger RNA technology, but it just announced a deal with privately held Orna Therapeutics.Merck and privately held Orna Therapeutics said Tuesday they have agreed to collaborate to discover and develop programs, including vaccines and therapeutics, in the fields of infectious disease and oncology. Under the terms of the deal, Merck will make an upfront payment of $150 million, to be expensed in the third quarter and included in non-GAAP results. Orna will be eligible to receive up to $3.5 billion in milestone payments on reaching certain regulatory and sales goals, as well as royaltiRAHWAY, N.J., August 16, 2022--FDA Accepts Submission of sNDA for LYNPARZA® in Combination With Abiraterone and Prednisone for Patients With mCRPC and Grants Priority ReviewRAHWAY, N.J. & CAMBRIDGE, Mass., August 16, 2022--Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA TechnologyThe FDA has accepted AstraZeneca Plc’s (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) combination regime for metastatic castration-resistant prostate cancer (mCRPC). Lynparza is being jointly developed and commercialized by AstraZeneca and Merck & Co Inc (NYSE: MRK). The application covers Lynparza combined with abiraterone and prednisone or prednisolone. Also Read: Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study. Under the priority rePraetorian Capital, an investment management firm, published its second-quarter 2022 investor letter – a copy of which can be downloaded here. During the second quarter of 2022, the fund declined by 15.69% net of fees. For 2022, the fund’s performance for the first half of the year, net of fees, was -2.58%. Given the fund’s […]In this article, we discuss 10 important dividend increases to watch in August. You can skip our detailed analysis of dividend stocks and their importance, and go directly to read 5 Important Dividend Increases to Watch in August. The global dividend payments suffered a lot in the face of the pandemic in 2020. According to […];66.73999786376953;"FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.WILMINGTON, Del., August 16, 2022--AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).The FDA has accepted AstraZeneca Plc’s (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) combination regime for metastatic castration-resistant prostate cancer (mCRPC). Lynparza is being jointly developed and commercialized by AstraZeneca and Merck & Co Inc (NYSE: MRK). The application covers Lynparza combined with abiraterone and prednisone or prednisolone. Also Read: Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study. Under the priority reGilead Sciences (NASDAQ: GILD) stock was off to a good start this week, rising by more than 5% on Monday against the modest (0.4%) gain of the S&P 500 index.  The prominent pharmaceutical company had some good news to impart about an important cancer drug.  Gilead announced that morning that its breast cancer treatment Trodelvy recorded ""statistically significant and clinically meaningful"" results in a phase 3 clinical trial.AstraZeneca is the IBD Stock Of The Day amid growing enthusiasm for its cancer drug, Enhertu. But AZN stock hit resistance Monday.Shares of Gilead Sciences Inc. were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic breast cancer. Gilead said it already filed an application with the Food and Drug Administration asking the regulator to approve the Trodelvy for this group of patients. It also said it expects to soon share full data from this clinical trial, which will help Wall Street analysts understand how Trodelvy will co";74.12999725341797;GEO Group's stock is the one Scion Asset Management now owns, and the prison facility REIT has rallied more than 12% in two days.NEW YORK & SAN DIEGO, August 16, 2022--Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from SEE RELEASE FOR FULL TITLE;44.810001373291016;By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 15, 2022, DarioHealth Corp. (NASDAQ:DRIO) published its second quarter 2022 operational and financial results in a press release and filed its Form 10-Q for the three-month period ending June 30, 2022. Dario hosted a conference call and webcast to discuss;35.2599983215332;Earlier today, IDEAYA Biosciences Inc (NASDAQ: IDYA) reported Q2 results, and shares have plunged 30% after the update. Investors are probably reacting as the company retained worldwide rights to IDE397 following GSK Plc (NYSE: GSK) waiver of its option to an exclusive license to further develop and commercialize IDE397. Related: Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK. The company retained and fully own all right, title, and interest in a;14.170000076293945;;44.349998474121094;;11.039999961853027;;252.38999938964844;;8.84000015258789;;148.00999450683594;;99.94999694824219;;13.710000038146973;;31.18000030517578;;45.95000076293945;Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.;13.739999771118164;;13.649999618530273;;32.0;;68.41000366210938;;263.69000244140625;;7.96999979019165;;30.149999618530273;;2.5899999141693115;;4.829999923706055;;;;4.679999828338623;Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on natural killer (NK) cell function and proliferation in multiple myeloma (MM).;4.550000190734863;;50.11000061035156;Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...;76.01000213623047;NEW YORK & SAN DIEGO, August 16, 2022--Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from SEE RELEASE FOR FULL TITLE;29.389999389648438;;9.949999809265137;;9.029999732971191;LAUSANNE, Switzerland, August 15, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced that it has completed a series of strategic transactions in which it:;9.770000457763672;;3.0;;39.869998931884766;;16.100000381469727;;22.0;;4.769999980926514;;12.09000015258789;;4.28000020980835;;7.800000190734863;;20.440000534057617;;19.729999542236328;;25.09000015258789;;24.239999771118164;;25.020000457763672;;19.06999969482422;;4.269999980926514;;11.789999961853027;
2022-08-17;167.5800018310547;In this article, we discuss 10 safe dividend stocks with over 4% yield. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read 5 Safe Dividend Stocks with Over 4% Yield. During the current market situation, of all the asset classes, dividend stocks seem to perform well this […]A Johnson & Johnson subsidiary urged a federal appeals court to uphold the controversial legal strategy it used to move to bankruptcy roughly 38,000 lawsuits linking its talc-based products to cancer.;49.27000045776367;;316.82000732421875;Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro.  It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets.  Early results suggest that the drug could help the company capture crucial share in these key segments.California Gov. Gavin Newsom recently announced the state will begin making its own insulin to help lower the cost of the diabetes medication. WSJ explains how insulin got so expensive in the U.S. and explores whether a policy initiative like California's could succeed in driving down costs. Photo Illustration: Ryan Trefes;104.80999755859375;Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro.  It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets.  Early results suggest that the drug could help the company capture crucial share in these key segments.;141.44000244140625;The generic drugmaker  Endo International  which faces thousands of lawsuits related to its alleged role in the opioid crisis, filed for bankruptcy late Tuesday morning, while announcing a plan to sell itself through a process administered by the bankruptcy court.  As part of its plan, Endo (ticker: ENDP) secured an agreement from creditors to acquire the firm through a $6 billion credit bid.  Other potential buyers could make higher offers through a process the company will ask the bankruptcy court to administer.I-Mab (NASDAQ: IMAB) disclosed in an SEC filing that AbbVie Inc (NYSE: ABBV) would discontinue the global Phase 1b study of lemzoparlimab combination therapy with azacitidine and venetoclax in myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML). This decision was not based on any specific or unexpected safety concerns. The study arose from the pact AbbVie and I-Mab inked in 2020 with $200 million upfront and more than a billion dollars in back-end payments. The partnership will coIn this article, we discuss 10 safe dividend stocks with over 4% yield. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read 5 Safe Dividend Stocks with Over 4% Yield. During the current market situation, of all the asset classes, dividend stocks seem to perform well this […]Allergan Aesthetics, an AbbVie company (NYSE: ABBV), invites consumers to experience the JUVÉDERM® difference. The JUVÉDERM® Collection of Fillers is the number one selling collection of dermal fillers on the market and offers the largest portfolio of fillers specifically designed for different areas of the face to address key patient concerns, enabling a customized treatment approach.1 Injectable dermal fillers are highly sought-after treatments among consumers who are looking to address key siRoche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.;85.22000122070312;Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.;91.04000091552734;Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.Pharma giant Merck & Co. will partner with local startup Orna Therapeutics on multiple vaccines and treatments for infectious diseases and cancer.The companies will work together to discover, develop, and commercialize multiple oRNA programs, including vaccines and therapeutics, for infectious diseases and cancer.Do you think I’d be writing for InvestorPlace if I knew the three top stocks to invest in right now? Of course not. Then again, no one knows the three best stocks to invest in at any given time. That’s why hedge fund investors like Jim Simons are so successful. His firm, Renaissance Technologies, uses mathematical and statistical methods to make money in the markets. He’s what’s known as a quant, short for quantitative analysis. Between 1988 and 2018, Renaissance generated an average annual retuInvestors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.What happened Shares of Moderna (NASDAQ: MRNA) had slid 4.2% lower at 11:26 a.m. ET on Tuesday after being down as much as 5.8% earlier in the day. The company didn't announce any negative news. However, there were a couple of factors that could be behind the decline.;66.41999816894531;AstraZeneca Plc (NASDAQ: AZN) has filed suit against former VP and head of investor relations Chris Sheldon as he prepares to start a new job at GSK plc (NYSE: GSK) in September, Bloomberg reported. In a London court filing, AstraZeneca argued that Sheldon would be violating a non-compete agreement, which he was paid more than $774,000 in shares to sign in 2021, Bloomberg reported. Sheldon worked at AstraZeneca for more than 18 years. He resigned earlier this month, effective immediately, accordMerck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.Pharma group alleges breach of non-compete agreement to delay start date of departing business development official;74.55999755859375;Kate Hermans has taken over the reins of Ambrx Biopharma Inc (NASDAQ: AMAM) as interim CEO following the abrupt departure of Feng Tian, who also served as chairman of the board of directors. The company did not provide information regarding the departure of Tian, who has been with Ambrx for nearly two decades. Interim CEO Hermans joined Ambrx last month as a board of directors member. Bristol Myers Squibb Co Inc (NYSE: BMY) moved out from a heart failure drug collaboration with Ambrx Biopharma iNEW YORK, August 17, 2022--Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio;42.18000030517578;"By Liz MoyerThe withdrawal of a plaintiff in GSK's first Zantac lawsuit but may not be “as significant as it appears”, say analysts from RBC Europe.Sanofi's finance chief said on Wednesday that a decline in the French company's share price in response to litigation threats and a cancer drug development setback was strongly exaggerated and posed a buying opportunity for savvy investors.  Sanofi earlier said it would stop further work on amcenestrant, once seen to have large potential against breast cancer, triggering a 5% drop in the share price.  Sanofi's share price was already not reflecting its earnings growth potential before last week, CFO Jean-Baptiste de Chatillon told Reuters.Sanofi SA (NASDAQ: SNY) said it would stop further work on breast cancer drug amcenestrant, putting pressure on Sanofi to bolster its drug development pipeline as it grows increasingly dependent on its best-seller, eczema and asthma treatment Dupixent. A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly-diagnosed advanced breast cancer was stopped early because an independent monitoring panel found no signs of it working. ""All other studies of amcenestrant, including in eBy Scott KanowskyBy Peter NurseSanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.  The move weighed on shares and mounted pressure on Sanofi to bolster its pipeline of drug candidates as it becomes increasingly dependent on its multi-billion best seller, fast-growing eczema and asthma treatment Dupixent.  Sanofi has also fallen far behind in the race to develop COVID-19 vaccines.Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.  The move weighed on shares and mounted pressure on Sanofi to bolster its pipeline of drug candidates as it becomes increasingly dependent on its multi-billion best seller, fast-growing eczema and asthma treatment Dupixent.  Sanofi has also fallen far behind in the race to develop COVID-19 vaccines.Sanofi provides update on amcenestrant clinical development program PARIS, August 17, 2022. Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positiveTuesday's news came days after shares of GlaxoSmithKline Plc , Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer.  The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.  Alexandra Walsh, an attorney for Bayer, said her client could not proceed for ""personal health reasons"" but had the right to refile his case within a year.";34.70000076293945;"AstraZeneca Plc (NASDAQ: AZN) has filed suit against former VP and head of investor relations Chris Sheldon as he prepares to start a new job at GSK plc (NYSE: GSK) in September, Bloomberg reported. In a London court filing, AstraZeneca argued that Sheldon would be violating a non-compete agreement, which he was paid more than $774,000 in shares to sign in 2021, Bloomberg reported. Sheldon worked at AstraZeneca for more than 18 years. He resigned earlier this month, effective immediately, accordThe FDA has accepted GSK plc's (NYSE: GSK) marketing application for momelotinib, a potential new medicine with a proposed differentiated mechanism of action for myelofibrosis patients with anemia. Myelofibrosis is a rare blood cancer. The U.S. FDA has assigned a Prescription Drug User Fee Act action date of 16 June 2023. The application is based on the results from crucial Phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary endpoints. The trial's primGSK plc’s (NYSE: GSK) first scheduled Zantac related-cancer trial has been dismissed by the plaintiff, noting that it did not settle the claim and has not paid anything in exchange for the voluntary dismissal. The company has approximately 3,000 lawsuits against it. A hearing for GSK’s multi-district Zantac-related cancer lawsuit will start in September in the Southern District of Florida, with the company looking to exclude plaintiffs’ causation experts. “The overwhelming weight of the scientifTuesday's news came days after shares of GlaxoSmithKline Plc , Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer.  The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.  Alexandra Walsh, an attorney for Bayer, said her client could not proceed for ""personal health reasons"" but had the right to refile his case within a year.Yahoo Finance health care correspondent Anjalee Khemlani details how the first case against pharmaceutical company GSK over its Zantac derivative was voluntarily dismissed.The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.  Tuesday's news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer.  The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.Pharma group alleges breach of non-compete agreement to delay start date of departing business development officialGilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.";14.199999809265137;;44.650001525878906;;10.75;;248.5;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.;8.65999984741211;;148.00999450683594;;96.79000091552734;;13.649999618530273;;30.8700008392334;INCHEON, Korea & JERSEY CITY, N.J., August 17, 2022--Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd);45.0;;13.180000305175781;;13.210000038146973;;32.16999816894531;;68.66999816894531;;261.2300109863281;;6.829999923706055;I-Mab (NASDAQ: IMAB) disclosed in an SEC filing that AbbVie Inc (NYSE: ABBV) would discontinue the global Phase 1b study of lemzoparlimab combination therapy with azacitidine and venetoclax in myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML). This decision was not based on any specific or unexpected safety concerns. The study arose from the pact AbbVie and I-Mab inked in 2020 with $200 million upfront and more than a billion dollars in back-end payments. The partnership will co;28.5;;2.5399999618530273;MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role as Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President and a Director of OPKO. He will remain as an employed advisor to the company through the end of December 2022 and continue as a consultant for the following nine months to assist in positioning t;4.820000171661377;;;;4.71999979019165;;4.309999942779541;;46.54999923706055;"Harmony Biosciences Holdings, Inc. (""Harmony"" or the ""Company"") (NASDAQ: HRMY), a pharmaceutical company focused on delivering innovative therapies that improve the health of people living with rare neurological diseases, today announced that Harmony's management will participate in the following upcoming investor conferences:";76.01000213623047;;28.43000030517578;;9.640000343322754;;8.859999656677246;;9.789999961853027;;2.5799999237060547;;37.790000915527344;;15.430000305175781;;21.479999542236328;;4.53000020980835;;12.0;;4.239999771118164;;7.699999809265137;;19.450000762939453;;19.31999969482422;;25.1200008392334;;24.06999969482422;;24.350000381469727;;19.540000915527344;;4.199999809265137;;12.229999542236328;
2022-08-18;166.77000427246094;Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Mayar Capital, an asset management firm, published its second-quarter 2022 investor letter – a copy of which can be downloaded here. For the three months ending March 31, 2021, Mayar Fund (Class A) was down 6.6% net of all expenses and fees, while the MSCI World Index declined by 5.2% in the same period. Since […]Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.;48.58000183105469;;316.7200012207031;;102.76000213623047;Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index (the […];141.2899932861328;You'll need to hold these stocks for many years to get the full benefit of their consistent dividend growth.Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index (the […]I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents. AbbVie Inc (NYSE: ABBV) is discontinuing the development of lemzoparlimab in its territories. The company noted that the discontinuation was not related to safety or efficacy concerns but rather a strategic decision based on the evolving competitive landscape. Related Content: AbbVie Calls Off Early-Stage Trial For I-Mab's CD47-Targeted Blood Cancer Candidate. I-Mab will continue;84.91999816894531;;91.4000015258789;Not only are we recognized by LATINA Style 50 Awards as one of the Top 50 Best Companies for Latinas to work in the United States, our Employee Business Resource Group (EBRG), Alianza, has been nam...Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.In this article, we discuss 10 small-cap stocks that pay dividends. You can skip our detailed discussion of small-cap investing and other small-cap dividend stocks, and go directly to read 5 Small-Cap Stocks that Pay Dividends. As the financial markets in the US remain choppy and recession fears grow, investors are exploring different investment options […]Merck, PepsiCo, Honeywell, Microsoft and PNC Financial have been highlighted in this Market Edge article.Anne Scheiber grew $5,000 into $22 million over 50 years. How'd she do it?Smead Capital Management, an investment management company, released its Smead Value Fund second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund returned -13.33% compared to the S&P 500 Index which lost 16.10% and the Russell 1000 Value Index posted a loss of 12.21%. The […];66.5;;74.1500015258789;Bristol Myers is a top drugmaker that investors can count on for long-term growth and dividend income.  In its most recent quarter, for the period ended June 30, the company reported revenue of $11.9 billion that rose 2% year over year.  The company's continued innovation makes it a promising investment.Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index (the […];41.189998626708984;Sanofi's run of bad luck continued Wednesday after the company scrapped a failed breast cancer drug, leading Sanofi stock to crumble.Sanofi SA (NASDAQ: SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5 trial in front-line ER+ metastatic breast cancer in combination with Pfizer Inc's (NYSE: PFE) Ibrance. The analyst lowered the price target to $52 and maintained the Outperform rating. Related content: Sanofi Ends Development Of Breast Cancer Drug Amcenestrant After Trial Failure. SVB previously expected a 2025 launch for amcenestrant and estimated €1.6 billionSanofi has abandoned development of a once-promising breast cancer drug called amcenestrant after a second failed clinical trial, dealing a blow to its pipeline of new treatments.  The French pharmaceutical group said on Wednesday that it had stopped all studies of the experimental drug following an analysis of late-stage trial data that showed it did not meet the efficacy threshold.  “This was a flagship drug in pipeline and important oncology asset,” wrote Credit Suisse analyst Jo Walton.Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.;34.25;GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.;14.180000305175781;;44.16999816894531;;10.59000015258789;;241.2100067138672;;8.380000114440918;;148.0399932861328;;94.58000183105469;;13.369999885559082;;30.729999542236328;;45.060001373291016;;12.5;"/ CureVac N.V.CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (""mRNA""), today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination.";13.270000457763672;;33.560001373291016;;65.5;;261.010009765625;;6.190000057220459;I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents. AbbVie Inc (NYSE: ABBV) is discontinuing the development of lemzoparlimab in its territories. The company noted that the discontinuation was not related to safety or efficacy concerns but rather a strategic decision based on the evolving competitive landscape. Related Content: AbbVie Calls Off Early-Stage Trial For I-Mab's CD47-Targeted Blood Cancer Candidate. I-Mab will continue;27.459999084472656;;2.5799999237060547;Opko Health (Nasdaq: OPK) announced Dr. Jon R. Cohen has retired as executive chairman and CEO of its BioReference Laboratories subsidiary.  Cohen also retired from his role as senior VP and director of Miami-based Opko, although he will remain an employed adviser to the company through the end of December, and then be a consultant for another nine months.  According to a filing with the U.S. Securities and Exchange Commission, Opko will pay Cohen $1 million in severance, plus the full acceleration and vesting of his stock options.;5.429999828338623;;;;4.679999828338623;;4.340000152587891;;46.34000015258789;;;;28.5;;9.0;;8.779999732971191;;9.510000228881836;;2.799999952316284;;37.880001068115234;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...;15.789999961853027;;21.200000762939453;;4.760000228881836;;13.5600004196167;;4.320000171661377;;7.5;;17.780000686645508;"SAN DIEGO, August 18, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", ""Arcturus Therapeutics"", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced updated data from its ongoing ARCT-154 booster clinical trial. The new results demonstrate broad neutralizing antibody response against Omicron variants of co";22.040000915527344;;25.989999771118164;;24.0;;22.729999542236328;;20.239999771118164;;3.7899999618530273;;12.270000457763672;
2022-08-19;169.30999755859375;In this article, we will take a look at the top 10 stock picks of Osman Ozsan’s Deuterium Capital Management. If you want to skip our discussion of Deuterium Capital Management’s history, investment philosophy, and hedge fund preference, go directly to Top 5 Stock Picks of Osman Ozsan’s Deuterium Capital Management. Deuterium Capital Management, LLC […]Two of these stocks together generate more than $1.6 billion in annual dividend income for Berkshire Hathaway.As the saying goes, past is not prologue. That simply means that what happened in the past doesn’t fully predict what will occur in the future. But when it comes to the stock market, there’s strong data to suggest that when the Fed hikes interest rates, certain sectors fare much better than others. Therefore, investors would be wise to focus on those sectors when picking stocks to buy. The data, compiled by Charles Schwab, indicates that six sectors, including communication services, energy, fin;49.150001525878906;;322.7699890136719;In this article, we will take a look at the top 10 stock picks of Osman Ozsan’s Deuterium Capital Management. If you want to skip our discussion of Deuterium Capital Management’s history, investment philosophy, and hedge fund preference, go directly to Top 5 Stock Picks of Osman Ozsan’s Deuterium Capital Management. Deuterium Capital Management, LLC […]In this article, we discuss BBBY bull Ken Griffin’s 10 favorite stock picks. If you want to read about some more stocks in the Griffin portfolio, go directly to BBBY Bull Ken Griffin’s 5 Favorite Stock Picks. Ken Griffin, the chief of Citadel Investment Group, was one of the worst-hit Wall Street titans last year […]Potential Eli Lilly and Company ( NYSE:LLY ) shareholders may wish to note that the Independent Director, Jackson Tai...These drugs could be the blockbusters of the decade. Also, an interview with LeCount Davis, the first Black CFP.;104.55000305175781;;141.85000610351562;JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar are included in this Analyst Blog.Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT).I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.;85.76000213623047;Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.Last week, Caribou Biosciences Inc (NASDAQ: CRBU) announced Q2 earnings and provided updated results from the Phase 1 ANTLER trial of the company's lead asset—CB-010 for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). HC Wainright reiterated the Buy rating while lowering the price target from $28 to $27. In six efficacy evaluable r/r NHL patients, CB-010 achieved a 100% objective response rate (ORR) and 100% complete response (CR) rate, with three of six patients (50%) maintainin;92.08000183105469;Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.In this article, we discuss 10 large-cap dividend stocks with over 5% yield. You can skip our detailed discussion on large-cap dividend investment, and go directly to read 5 Large-Cap Dividend Stocks with Over 5% Yield. Large-cap stocks are generally considered to be safer investments than small- and mid-cap stocks. These stocks are known to […];67.16999816894531;Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.;75.33000183105469;;41.27000045776367;Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.;34.060001373291016;Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.;13.899999618530273;TAK vs. ZTS: Which Stock Is the Better Value Option?;44.099998474121094;;10.569999694824219;One dividend stock picking up steam of late that investors should consider buying is Viatris (NASDAQ: VTRS).  The healthcare company recently reported earnings that were incredibly positive.  Viatris is a global pharmaceutical company that makes and sells branded, generic, and biosimilar drugs.;237.75;;8.430000305175781;;148.0500030517578;;92.58999633789062;;13.079999923706055;;30.65999984741211;;45.43000030517578;;12.079999923706055;"CureVac N.V. (NASDAQ: CVAC) and GSK plc (NYSE: GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a booster dose to previous COVID-19 vaccination. The candidate, CV0501, is meant to be administered as a booster dose following the previous COVID-19 vaccination. GSK used CureVac's ""second-generation mRNA backbone"" to develop the vaccine. CureVac will test CV0501 in up to 180 healthy, COVID-19 vaccinated adults. The participants will receive a single";13.020000457763672;;32.70000076293945;;64.91999816894531;;263.2699890136719;;6.010000228881836;"I-Mab (""I-Mab"" or the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2022, before the market opens on Tuesday, August 30, 2022. The Company's management will host conference calls with investors to provide updates on recent pipeline development, upcoming milestones, andI-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.";25.09000015258789;"Data from the Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Progressing Desmoid Tumors to be Presented in an Oral Presentation on Saturday, September 10 (16:55 CEST; 10:55 a.m. ET)STAMFORD, Conn., Aug. 19, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that data from the Phase 3 DeFi trial of nirogacestat,";2.5299999713897705;;5.519999980926514;;;;4.599999904632568;;3.9700000286102295;;47.08000183105469;;;;28.110000610351562;;8.5;The consensus price target hints at an 111.1% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;8.420000076293945;;9.229999542236328;;2.7100000381469727;;36.27000045776367;;15.609999656677246;;21.34000015258789;;4.519999980926514;;13.5;;3.8399999141693115;;7.65500020980835;;16.579999923706055;Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced updated data from its ongoing ARCT-154 booster clinical trial. The new results demonstrate a broad neutralizing antibody response against omicron variants of concern, including BA.5, lasting up to at least six months after administering a low-dose (5 mcg) ARCT-154 booster. “Our next generation low-dose self-amplifying (STARR™) mRNA technology continues to differentiate itself from conventional mRNA vaccine technology,” said Joseph Payne;20.68000030517578;;25.68000030517578;;23.940000534057617;;21.940000534057617;;19.149999618530273;Company announcement – No. 35 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, DK and Boston, MA, August 18, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 3,874 divided into 3,874 new shares with a nominal value of DKK 1 each.;3.7300000190734863;;12.399999618530273;
2022-08-22;167.58999633789062;"Also, I really like the idea of owning the shares - you have time - prior to the split into two firms.McDonald's Corporation has named three new members to its board of directors and announced the retirement of Sheila Penrose after 16 years on the board.  “Sheila has been a tremendous resource for me on our board of directors,” said Chris Kempczinski, McDonald's (NYSE: MCD) president and chief executive officer.  Joining the board Oct 1 will be Amy Weaver, president and chief financial officer of Salesforce; Jennifer Taubert , executive vice president and worldwide chairman, pharmaceuticals, at Johnson & Johnson; and Anthony Capuano, CEO of Marriott International.Financial Times reported that Johnson & Johnson (NYSE: JNJ) wants to use the “Texas two-step” bankruptcy strategy to block cases claiming its talc-based baby powder caused cancer in two US states. A New Jersey court will consider a request by a J&J subsidiary to stop New Mexico and Mississippi from proceeding with their lawsuits against the company. According to the legal experts, the decision could set a precedent over whether and to what extent corporations can use the Chapter 11 bankruptcy prJohnson & Johnson used the contentious “Texas two-step” bankruptcy strategy to halt 38,000 personal injury cases claiming its talc-based baby powder caused cancer.  A New Jersey court is set on Tuesday to consider a request by a J&J subsidiary to stop New Mexico and Mississippi from proceeding with their lawsuits against the parent company.  Legal experts say the decision could set a precedent over whether and to what extent corporations can use the Chapter 11 bankruptcy process to manage lawsuits alleging violations of state consumer protection regulations.";48.900001525878906;;323.1000061035156;Insiders are swooping in to buy as Mr. Market retreats;107.55000305175781;Novo Nordisk A/S (NYSE: NVO) has announced headline results from a Phase 2 trial of CagriSema, a once-weekly subcutaneous combination of semaglutide and amylin analog cagrilintide. In the trial, the mean baseline HbA1c was 8.4%, and the mean baseline body weight was 106 kg. After 32 weeks, people treated with CagriSema achieved an HbA1c reduction of 2.18%-points compared to a reduction of 1.79%-points for people treated with semaglutide and 0.93%-points with cagrilintide alone. Related: Novo NorBagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide. The trial investigated the efficacy and safety of a fixed dose combination of CagriSema (2.4 mg semaglutide and 2.4 mg cagrilintide) compared to the individual components semaglutide 2.4 mg and cagrilintide 2.4 mg, all administered once weekly, in 92 people with type 2 diabe;140.33999633789062;Two companies in this group are AbbVie (NYSE: ABBV) and Jazz Pharmaceuticals (NASDAQ: JAZZ).  AbbVie is a stable, blue-chip company that can deliver consistent revenue, profits, and growing dividends.  First, like its peers in the pharmaceutical industry, AbbVie sells products that consumers can hardly do without.;84.38999938964844;;91.16000366210938;;67.23999786376953;Futures fell sharply as the market rally pulls back. Elon Musk will hike Tesla FSD prices. Warren Buffett stock Occidental Petroleum surged Friday.There was only one woman in the 10 highest paid CEOs list.;74.55000305175781;Pharma stock Bristol Myers Squibb (NYSE: BMY) -- Up 20% year-to-date -- is one such example.  With more than 32,000 employees throughout 45 countries, Bristol Myers is one of the largest pharmaceutical companies in the world.  When Bristol Myers shared its financial results for the second quarter ended June 30 in late July, its revenue and non-GAAP (adjusted) diluted earnings per share (EPS) were better than expected.;40.959999084472656;Sanofi's recent stock rout underscores the pressure on the French drug maker to redouble its efforts in the hunt for new medicines.  Chief Executive Paul Hudson is entering his fourth year at the helm next month and has presided over a number of setbacks, most recently the failure of breast cancer pill amcenestrant, which Sanofi had touted as having strong commercial potential.  The ensuing drop in the share price compounded losses from an investor scare over litigation linked to alleged cancer risks of heartburn drug Zantac days earlier, resulting in a more than 14% slump over eight days.;34.04999923706055;The Suffolk port accounts for around a third of Britain's incoming shipping freight.There was only one woman in the 10 highest paid CEOs list.Smart Beta ETF report for RODM;13.819999694824219;OSAKA, Japan & CAMBRIDGE, Mass., August 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM), for the prevention of dengue disease caused by any serotype in individuals six years to 45 years of age. The use of QDENGA should be in accordance with official recommendations. QDENGA is the only;43.61000061035156;;10.350000381469727;;225.72999572753906;;8.329999923706055;;148.00999450683594;;89.5999984741211;;12.760000228881836;;30.3700008392334;;45.29999923706055;;11.289999961853027;;12.720000267028809;;32.599998474121094;;65.02999877929688;;267.82000732421875;;5.75;;25.280000686645508;;2.4600000381469727;;5.46999979019165;;;;4.539999961853027;;3.740000009536743;;46.869998931884766;;;;27.290000915527344;;8.470000267028809;;7.460000038146973;;8.9399995803833;Insiders are swooping in to buy as Mr. Market retreats;2.630000114440918;;35.959999084472656;;15.699999809265137;;21.280000686645508;;4.320000171661377;;13.520000457763672;;3.799999952316284;;7.599999904632568;;15.65999984741211;;21.190000534057617;;25.270000457763672;Arcutis Cares provides ZORYVE™ (roflumilast) cream 0.3% at no cost for financially eligible individuals who are uninsured or have Medicaid or Medicare Part D prescription coverage and cannot afford their medicationFirst ever PAP for a topical psoriasis product WESTLAKE VILLAGE, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announc;24.020000457763672;;20.5;;18.583999633789062;;3.759999990463257;;12.09000015258789;
2022-08-23;166.1300048828125;And it's not just the euro that investors need to watch, as the Japanese yen and British pound also lose ground to the greenback.(Bloomberg) -- 3M Co.’s attempt to block jury trials of more than 230,000 lawsuits accusing it of harming US soldiers faces a key test this week in front of a federal judge in Indianapolis.Most Read from BloombergSaudi Prince Says Oil’s Disconnect May Force OPEC+ ActionHome Sellers Are Slashing Prices in Pandemic BoomtownsStocks Knocked Down as Torrid Rally Hits a Wall: Markets WrapCredit Suisse Investment Bankers Are Bracing for Brutal Cutbacks‘House of the Dragon’ Debut Crashes HBO Max for ThoIn this article, we discuss 10 best high-yield dividend stocks for retirees in 2022. You can skip our detailed analysis of dividend investment for a retirement portfolio, and go directly to read 5 Best High-Yield Dividend Stocks for Retirees in 2022. Staying financially afloat during retirement in the US is hard and requires rigorous planning and […]The new director will add extensive franchising and real estate experience to the fast-food company's board.;48.0099983215332;;315.1000061035156;;106.56999969482422;;139.02000427246094;Top-rated large-cap stocks can offer a bit of security in volatile times. After the relief rally earlier this month, stocks may be in for another bout of weakness. Uncertainties like inflation, rising interest rates and a potential recession have still yet to be fully absorbed by the market. That may be a discouraging prospect for anyone looking for short-term opportunities. But if you invest in top-rated large-cap stocks with a long time horizon, further market volatility may work in your favorIn this article, we discuss 10 best high-yield dividend stocks for retirees in 2022. You can skip our detailed analysis of dividend investment for a retirement portfolio, and go directly to read 5 Best High-Yield Dividend Stocks for Retirees in 2022. Staying financially afloat during retirement in the US is hard and requires rigorous planning and […]There's no better time to build a strong watchlist of great companies than during a serious market correction.  In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.;83.4800033569336;Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.;90.19999694824219;Many high-yield dividend stocks have fared much better in the market downturn.  One is Merck's (NYSE: MRK) stock, which has surged 20% higher in 2022.  Let's take a dive into Merck's fundamentals and valuation to answer this question.RAHWAY, N.J., August 23, 2022--Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy.Sound Shore Management, an investment management firm, published its second-quarter 2022 investor letter – a copy of which can be downloaded here. The Sound Shore Fund Investor Class (MUTF:SSHFX) and Institutional Class (MUTF:SSHVX) declined 13.45% and 13.41%, respectively, in the second quarter of 2022, trailing the Russell 1000 Value Index (Russell Value) which declined 12.21%. As […];66.43000030517578;Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data. Abivertinib selectively inhibits EGFR-activating and resistant mutation with nearly 300-fold greater potency than wild-type EGFR. In these Independent Review Committee (IRC)-assessed preliminary data, Abivertinib showed significant treatment benefits in 209 response evaluablAmgen Inc (NASDAQ: AMGN) has announced topline results from the DAHLIA study crossover Phase 3 study of ABP 959, a biosimilar candidate to Soliris (eculizumab) in paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. Soliris was a centerpiece for Alexion's $39 billion takeover by AstraZeneca Plc (NASDAQ: AZN). The study demonstrated no clinically meaningful differences between ALONDON (Reuters) -AstraZeneca's Chief Executive Pascal Soriot warned on Tuesday new U.S. legislation capping drug prices would reduce the ability of companies to recoup their investment on developing new drugs and hurt innovation.  In a Reuters Newsmaker interview, he said the British drugmaker's top-selling cancer therapy Tagrisso as well as its potential blockbuster Enhertu would likely be negatively affected by the new law in the coming years.  Last week, a landmark law that included provisions to tackle the rising cost of medicines was passed in the United States, in a rare legislative defeat for the powerful pharmaceutical industry that set a precedent for curbing drug prices in the world's most lucrative market for medicines.Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.AstraZeneca may not stay in the vaccine business in the long run, its CEO told Reuters on Tuesday, showing how quickly fortunes have changed for the drugmaker that produced one of the first COVID-19 shots but has since lost out to rivals.  Production delays, probes by regulators following rare cases of severe side effects, and concerns about its relatively short shelf life compared with other shots have stymied adoption of the company's COVID-19 vaccine.  Now, in the third year of the pandemic amid a global vaccine supply glut, its use has diminished in much of the developed world as countries have inoculated large numbers of people and prefer Pfizer and Moderna's mRNA vaccines as boosters.;72.7699966430664;Today, Bristol Myers Squibb Canada (BMS) announced Health Canada's approval of OPDIVO® (nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks for three cycles for adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC) in the neoadjuvant setting.iThere's no better time to build a strong watchlist of great companies than during a serious market correction.  In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.;40.720001220703125;;33.72999954223633;;13.920000076293945;;43.45000076293945;;10.149999618530273;;224.00999450683594;;8.15999984741211;;148.0399932861328;;91.4800033569336;;11.680000305175781;;29.920000076293945;;46.060001373291016;;11.319999694824219;;12.3100004196167;"— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation at the Congress — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that initial results of the multi-regional clinical trial (“MRCT”) of fruquintinib";33.400001525878906;;66.38999938964844;;269.510009765625;;6.019999980926514;"I-Mab (""I-Mab"" or the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors. On the same day, the Company was also informed by Dr. Jingwu Zang, Chairman and Acting Chief Executive Officer of the Company, and other members of senior management of their";26.790000915527344;;2.4800000190734863;Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.;5.559999942779541;;;;4.53000020980835;;3.9000000953674316;;47.22999954223633;;;;27.290000915527344;;8.899999618530273;Erasca, Inc. (ERAS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.Initial focus of five-year collaboration will be on potentially best-in-class ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, which together comprise Erasca’s first MAPKlamp combination Additional Erasca programs, including KRAS G12D inhibitor ERAS-4, also will be investigated under the alliance SAN DIEGO and HOUSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing;7.739999771118164;;9.369999885559082;;2.5299999713897705;"BRIDGEWATER, N.J., August 22, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced its support of the creation of the bipartisan Congressional Domestic Pharmaceutical Manufacturing Caucus. This caucus will focus on securing America’s pharmaceutical supply chain by ensuring that essential medicines are manufactured in the U.S. This working group will led by Rep. Gus Bilirakis (R-FL), Rep. Earl L. ""Buddy"" Carter (R-GA), Rep. Chrissy Houlahan (D-PA), and Rep.";37.16999816894531;;16.299999237060547;Not many hedge managers have ignited as much controversy as Cathie Wood. The founder of Ark Invest has built her brand on running against the crowd. From her early embrace of tech stocks to her outspoken political conservatism, Cathie Wood has always been something of a lightning rod. Whether her investments and stock strategies are panning out or not, one thing has always been consistent. Wood has never deviated from her path, and continues to this day to urge investors to stay the path. Wood h;21.639999389648438;;4.420000076293945;;14.239999771118164;DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business. Second Quarter 2022 Financial Highlights Cash position Cash was $265.4 million as of June 30, 2022, compared to $276.8 million as of December 31, 2021. We believe that our existing;3.859999895095825;;7.375;;16.18000030517578;;22.0;;25.479999542236328;A total of 683 adults and children, age 6 years and older, have been enrolled in the INTEGUMENT-2 trialTopline data from both INTEGUMENT-1 and -2 trials expected by end of 2022Atopic dermatitis aﬀects approximately 26 million adults and children in the United States WESTLAKE VILLAGE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno- dermatology, today;24.5;;19.690000534057617;;19.40999984741211;;4.019999980926514;;11.930000305175781;
2022-08-24;165.5800018310547;Johnson & Johnson on Wednesday named former CVS Health Corp. CEO Larry Merlo as non-executive chair designate of its new consumer health company, which the company announced in November. Merlo will assume a board leadership role with the new consumer health company for its planned separation from J&J in 2023. In May, J named Thibaut Mongon as chief executive officer designate for its new consumer health company. Shares of J are down 2.9% in 2022, compared to a loss of 13.4% by the S 500 and a drNEW BRUNSWICK, N.J., August 24, 2022--Johnson & Johnson (NYSE: JNJ) today announced the appointment of Larry Merlo as Non-executive Chair Designate for the future, listed New Consumer Health Company’s Board of Directors. Merlo previously served as President and CEO of CVS Health and brings over 30 years of purpose-driven and transformative health leadership to the Board for the planned new company.;47.43000030517578;;318.8699951171875;;110.0199966430664;Novo Nordisk (NVO) completes the phase II study evaluating CagriSema, a combination of semaglutide and cagrilintide for treating type II diabetes.;137.91000366210938;These companies have raised their payouts to shareholders throughout multiple recessions, military conflicts, and a global pandemic.;83.61000061035156;;90.01000213623047;A phase II study is ongoing on Merck's (MRK) MK-2060 in people with end-stage renal disease receiving hemodialysis.Medtronic (MDT) posts better-than-expected results for the fiscal first quarter and maintains earnings and sales outlook for the full year.;67.63999938964844;Biotech giants Amgen (NASDAQ: AMGN) and AstraZeneca (NASDAQ: AZN) are great options.  In the second quarter, Amgen's revenue increased by an unimpressive 1% year over year to $6.6 billion.  What's to blame for the company's seemingly poor performance?WILMINGTON, Del., August 24, 2022--AstraZeneca will present new data supporting its ambition to redefine cancer care at the European Society for Medical Oncology (ESMO) Congress 2022, September 9 – 13, 2022.;72.41999816894531;;40.58000183105469;;33.529998779296875;If you're looking for a good place to park your funds at a rate that better keeps up with inflation, Medical Properties Trust (NYSE: MPW), Physicians Realty Trust (NYSE: DOC) and GlaxoSmithKline (NYSE: GSK) are healthcare stocks that all offer dividend yields of 5% or more.  All three are down so far this year, providing an opportunity get in now on solid companies that will pay you (in dividends) to be patient while you wait for their shares to bounce back.  Medical Properties Trust's shares are down more than 30% so far this year.;13.90999984741211;;43.45000076293945;;10.15999984741211;;229.86000061035156;WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the Nasdaq MarketSite in New York City from 8:20 to 11:30 a.m. EDT. The event will feature presentations by several members of the company’s leadership team and will include Q&A discussion between the audience and Repligen pan;8.069999694824219;;148.4199981689453;;96.68000030517578;;11.739999771118164;;30.059999465942383;;47.959999084472656;;11.1899995803833;;12.550000190734863;;32.7400016784668;;61.119998931884766;"Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced topline data at 24 months showing increased effects over time with intravitreal pegcetacoplan in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In a pre-specified analysis, monthly and every-other-month pegcetacoplan showed a clinically meaningful reduction in GA lesion growth from baseline compared to sham. Between months 18-24, the pegcetacoplan treatment effect accelerated compared to previous six-month periodsPegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth compared to sham (all p-values are nominal) DERBY: 36% monthly, p<0.0001; 29% every-other-month (EOM), p=0.0002OAKS: 24% monthly, p=0.0080; 25% EOM, p=0.0007 Consistent with expectations, no clinically meaningful difference on key functional endpoints observed at 24 months Continued to demonstrate a favorable safety profile Potential to become the first-ever treatment for GA with";267.6700134277344;;6.300000190734863;;27.389999389648438;;2.559999942779541;;5.369999885559082;;;;4.71999979019165;;4.159999847412109;;46.88999938964844;;;;27.0;With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts. For one thing, the risks are real. According to the New England Journal of Medicine, monkeypox is a zoonotic orthopox DNA virus related to the virus that causes smallpox. While cases have circulated for decades, research has been neglected and underfunded. Not only does in;9.1899995803833;Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 SAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commer;7.630000114440918;;9.789999961853027;;2.5799999237060547;;39.09000015258789;;17.200000762939453;;21.43000030517578;;4.659999847412109;;14.960000038146973;;3.930000066757202;;7.289999961853027;;16.540000915527344;;24.18000030517578;;23.850000381469727;;25.1200008392334;;20.100000381469727;;19.985000610351562;COMPANY ANNOUNCEMENT – NO. 36 / 2022 Copenhagen, DK and Boston, MA, August 24, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Henriette Wennicke as Zealand’s Chief Financial Officer starting November 1, 2022. Henriette Wennicke comes to Zealand with broad finance and business experience at large organizations, including in healthcare,;4.289999961853027;;12.609999656677246;
2022-08-25;167.1300048828125;"Is Johnson & Johnson stock a buy after it announced plans to switch to cornstarch-based baby powder? Is JNJ stock a buy now?Janssen Biotech Inc, a Johnson & Johnson (NYSE: JNJ) unit, received European conditional approval for Tecvayli (teclistamab) as monotherapy for relapsed or refractory multiple myeloma. Teclistamab is a T-cell redirecting bispecific antibody targeting both B-cell maturation antigen and CD3 discovered by Janssen scientists using Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) OmniAb OmniRat antibody discovery technology. Ligand's previously announced spin-off of OmniAb and merger (Business CoWarren Buffett is frequently called the ""Oracle of Omaha.""  Buffett's uncanny ability to pick stocks that beat the market over the long term seems to justify his nickname.  Do Buffett's recent moves spell doom for pharma stocks?Investing in blue-chip stocks is a stellar way to shield yourself from volatility. In addition, they generally carry hefty dividend payouts paired with a track record of excellence within their quarterly reports.In the latest trading session, Johnson & Johnson (JNJ) closed at $165.58, marking a -0.33% move from the previous day.Lower and middle income countries have faced severe vaccine inequity during the pandemic. Increased interest in manufacturing could be the key to equity.";47.900001525878906;Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?Pfizer's COVID antiviral Paxlovid appears to have little or no benefit for younger adults, although it still reduces the risk of hospitalization or death in seniors, according to a new Israeli study.For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Pfizer Inc. said Thursday a Phase 3 trial of older adults testing its bivalent RSV vaccine candidate achieved 85.7% efficacy in participants with more severe disease. RSV, or Respiratory Syncytial Virus, is a contagious virus that's defined by a group of respiratory symptoms that vary from mild to more severe. The virus affects the lungs and breathing passages of an infected individual and can be life-threatening to older and high-risk patients. About 336,000 older adults are hospitalized globalPfizer has said it will seek approval for a vaccine targeting respiratory syncytial virus in older adults after reporting positive trial data as rival groups race to develop a jab for a market that analysts estimate will generate up to $10bn of annual sales.  An application for regulatory approval will be submitted in the autumn, said Pfizer, which is hunting for new ways to boost revenues as sales of Covid-19 vaccines begin to moderate.  RSV is a contagious disease that can cause severe respiratory illness, particularly in older people and infants.Pfizer Inc said on Thursday its vaccine for Respiratory Syncytial Virus (RSV) was effective among older adults in a late-stage study and it plans to file for approval with the U.S. health regulator in the coming months.  There are no U.S. approved vaccines for RSV, a common virus that typically causes mild cold-like symptoms but can be fatal for young kids and older adults.  RSV is estimated to cause about 14,000 annual deaths among older adults in the United States.Infections caused by the virus are usually mild, but it can cause severe illness in babies and older people, so the commercial opportunities for a vaccine are huge.NEW YORK, August 25, 2022--Pfizer Inc. (NYSE: PFE) today announced positive top-line data from the Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease) investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. The bivalent vaccine candidate is composed of two preF proteins selected to optimize protection against RSV A and B strains.The United States plans to roll out an updated COVID-19 booster vaccine to include Omicron subvariants of the coronavirus.  ARE WE GETTING NEW VACCINES?  Pfizer Inc with partner BioNTech SE and Moderna Inc completed applications this week to the U.S. Food and Drug Administration for COVID-19 vaccine boosters retooled to target versions of the Omicron variant of the virus.Pfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.Pfizer's COVID antiviral Paxlovid appears to have little or no benefit for younger adults, although it still reduces the risk of hospitalization or death in seniors, according to a new Israeli study,Pfizer (NYSE: PFE) and Verizon Communications (NYSE: VZ) share at least a couple of things in common. Both stocks are down by double-digit percentages this year. Both are also longtime favorites of income investors.Pfizer, BioNTech, Moderna and Morphic are included in this Analyst Blog.;323.1400146484375;Eli Lilly and Company (NYSE: LLY) will attend Citi's 17th Annual BioPharma Conference on Wednesday, Sept. 7, 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:30 p.m., Eastern time.;111.4000015258789;;139.3300018310547;Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?The FDA approved AbbVie Inc's (NYSE: ABBV) Imbruvica (ibrutinib) for pediatric patients one year and older with chronic graft versus host disease (cGVHD) after the failure of one or more lines of systemic therapy. The approval is AbbVie's first pediatric indication for Imbruvica, marking the 12th FDA approval for Imbruvica and the first Bruton's tyrosine kinase inhibitor (BTKi) treatment approved for a pediatric patient population. This approval also marks the first approved treatment option forAbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.;83.41000366210938;"""They're good numbers for an organization our size,"" he said. This year also is shaping up as strong for revenue.Swiss pharma group Novartis plans to spin off its generic drugs business after a lengthy review of the division, which drew interest from private equity firms and even calls from politicians for it to be nationalised.  Spinning off its Sandoz division would create the largest generic drugs company in Europe by sales, Novartis said on Thursday, as it set out one of its most significant moves to focus on faster-growing and higher-margin drugs.  The move is one of the boldest steps yet by chief executive Vas Narasimhan to focus Novartis on more lucrative drugs that include those targeting cancer and rare diseases.Novartis AG (NYSE: NVS) suspended dosing in a Huntington's disease study because early signs of side effects were seen in some participants in the trial. The pharma giant wrote in a letter shared with the Huntington's Disease Society of America that there are concerns that ""branaplam might be causing peripheral neuropathy, which results from injury to the nerves located outside of the brain and spinal cord."" The trial's independent data monitoring committee recommended the suspension after a plaThe stay-behind business will consist of Novartis Innovative Medicines, which the company created by combining its pharmaceuticals and oncology units.Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.Novartis is planning to spin off its generics-and-biosimilars division and list it as a stand-alone company in Switzerland, a move the company said would enable it to focus on innovative medicines.Novartis AG (NYSE: NVS) plans to spin off Sandoz, its generics and biosimilars division, into a new publicly traded standalone company. According to Novartis, Sandoz, which generated nearly $10 billion in sales last year, will emerge as Europe's leading generics company with key strategic areas of Biosimilars, Antibiotics, and Generic Medicines. Related: Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz. The company initiated a strategic review of the business last October. TWith new investment from Merck & Company Inc., a Boston-based radiopharmaceuticals startup now has the backing of three Big Pharma companies.(Bloomberg) -- Novartis AG plans to spin off its Sandoz unit, creating the largest European generic and biosimilar drug company by sales. Most Read from BloombergA 129-Foot Superyacht Worth Millions Sinks Off the Italian CoastBiden Unveils Plan to Free Students from ‘Unsustainable Debt’Six Months of Putin’s War Unravels Russia’s Superpower ImageKorea Shatters Its Own Record for World’s Lowest Fertility RateGOP Fury Over ESG Triggers Backlash With US Pensions at RiskThe Swiss company is the latesThe Swiss pharmaceutical company said Sandoz would be based in Switzerland and listed locally alongside a an American depositary receipt program in the U.S.ZURICH/LONDON (Reuters) -Novartis plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday, acknowledging it had not received any formal offers for the business to date.  The company started a strategic review of Sandoz last October - examining a range of options, including retaining the business, spinning it off or selling it - following a protracted period of underperformance driven largely by mounting pricing pressures in the off-patent drug sector.  Apart from some preliminary interest, Novartis has not received any formal binding offers for Sandoz so far - but if any ""highly attractive"" bids did emerge Novartis would fully consider them, CEO Vas Narasimhan said in a conference call with analysts.Ad hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1 European generics company and a global leader in biosimilars, and a more focused Novartis Planned 100% spin-off would allow Novartis shareholders to participate fully in the potential future upside of both Sandoz and Novartis Innovative Medicines Sandoz is planned to be incorporated in Switzerland and to be lisBy Geoffrey Smith";90.2699966430664;The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.RAHWAY, N.J., August 25, 2022--LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast CancerWith new investment from Merck & Company Inc., a Boston-based radiopharmaceuticals startup now has the backing of three Big Pharma companies.;68.26000213623047;The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.The Japan regulatory authority has approved AstraZeneca Plc (NASDAQ: AZN) and Merck Co Inc's (NYSE: MRK) Lynparza (olaparib) for the adjuvant treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence. This approval was based on results from the OlympiA Phase III trial. In the trial, Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancThai drugmaker Siam Bioscience, owned by the country's king, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc's COVID-19 vaccine, government data shows.  The company is part of King Maha Vajiralongkorn's vast fortune, which includes land and property estimated at between $30 billion and $60 billion.  Founded in 2009 by the late King Bhumibol Adulyadej to produce biopharmaceuticals and improve public health, the company had since been loss-making and reported its first profit only in 2020 of 35.7 million baht ($995,000).;71.5;With new investment from Merck & Company Inc., a Boston-based radiopharmaceuticals startup now has the backing of three Big Pharma companies.;40.4900016784668;By Geoffrey Smith;33.72999954223633;;14.020000457763672;Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.;43.65999984741211;;10.170000076293945;;237.64999389648438;;8.1899995803833;;149.25999450683594;;93.91000366210938;;11.699999809265137;"Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co.";30.34000015258789;;47.290000915527344;;11.40999984741211;;13.069999694824219;;32.36000061035156;;59.310001373291016;;263.0799865722656;Cerevel Therapeutics more than doubled its cash balance to keep pace with Karuna Therapeutics in a head-to-head showdown.;5.949999809265137;;27.6200008392334;;2.5;;5.0;;;;4.739999771118164;;4.440000057220459;;48.06999969482422;;;;27.5;;8.289999961853027;;7.329999923706055;;10.050000190734863;;2.549999952316284;;39.540000915527344;;17.0;;21.280000686645508;;4.869999885559082;;15.140000343322754;;3.9800000190734863;;7.300000190734863;;16.579999923706055;;25.540000915527344;;23.625;;24.75;;20.200000762939453;;20.25;;4.340000152587891;;12.59000015258789;
2022-08-26;164.27000427246094;"The U.S. economy has contracted for two straight quarters, but that doesn't mean the country is in a recession.  The National Bureau of Economic Research declares when there's a recession, and it hasn't made that declaration thus far.  Two stocks which fit those criteria and that Warren Buffett's Berkshire Hathaway owns are Johnson & Johnson (NYSE: JNJ) and Kraft Heinz (NASDAQ: KHC).Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.In this article, we discuss 10 best Dogs of the Dow to invest in. You can skip our detailed analysis of Dogs of the Dow investment strategy and its returns, and go directly to read 5 Best Dogs of the Dow to Invest In. ‘Dogs of the Dow’ is an investment strategy that focuses on the […]MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS, AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS OR PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER. ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FO...Congress members Steve Cohen and Rosa DeLauro penned separate letters to U.S. Attorney General Merrick Garland demanding an update on the U.S. Department of Justice (DOJ) probe regarding Johnson & Johnson (NYSE: JNJ) talc sales. The investigation was opened in 2019. J&J repeatedly asserted that its product is asbestos-free and does not cause cancer. Even still, J&J last month said it would pull its talcum powder from the global market in 2023, citing a ""commercial decision."" The move comes aboutAbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patientsJ&J (JNJ) gets approval for Tecvayli (teclistamab) for the treatment of relapsed and refractory multiple myeloma. This marks the first approval for Tecvayli in any country.";46.81999969482422;"Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Pfizer's response to its Moderna lawsuit allegations.(Bloomberg) -- Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their Covid-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.Most Read from BloombergNearly 60,000 Sneakers in $85 Million Ponzi Scheme to Go on SaleGOP Fury Over ESG Triggers Backlash With US Pensions at RiskWorld’s Most Popular Password Manager Says It Was HackedA 129-Foot Superyacht Worth Millions Sinks Off the Italian CoastTrump’s Stash atPharmaceutical giant Pfizer (NYSE: PFE) experienced a tremendous windfall as one of the leading COVID-19 vaccine manufacturers during the pandemic.  Declining vaccine demand would undoubtedly impact Pfizer's business, but does that mean investors should run away from the stock?  COVID-19 vaccine demand could be in decline; fellow vaccine maker Novavax recently cut its sales forecast for 2022 from between $4 billion and $5 billion to between $2 billion and $3 billion, a result of declining demand for its COVID-19 vaccine.Some 16 million Americans of working age have long-term COVID and about 2 to 4 million are not working as they struggle with their symptoms, according to a new report from the Brookings Institution.NEW YORK & MAINZ, Germany, August 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. This application for a variation of the conditional marketing authorization (cMA) follows guidance from the EMA and International Coalition of Medicines Regulatory Authorities (ICMRA) to work tThe Cambridge company (Nasdaq: MRNA) alleged in a complaint filed in the U.S. District Court of Massachusetts Friday that Pfizer (NYSE: PFE) and BioNTech's vaccine, Comirnaty, violates three patents Moderna filed between 2010 and 2016.Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss Moderna’s decision to sue rival vaccine maker Pfizer over the delivery technology used in COVID-19 vaccines.Moderna Inc (NASDAQ: MRNA) has filed patent infringement lawsuits against Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) in the U.S. and Germany. Moderna believes that Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology, critical in creating Moderna's mRNA COVID-19 vaccine. In July, Pfizer and BioNTech filed a complaint seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.By Liz MoyerNovartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.In this article, we discuss 10 best Dogs of the Dow to invest in. You can skip our detailed analysis of Dogs of the Dow investment strategy and its returns, and go directly to read 5 Best Dogs of the Dow to Invest In. ‘Dogs of the Dow’ is an investment strategy that focuses on the […]""We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission,"" Moderna said.Moderna Inc. said Friday it is suing Pfizer Inc. and German partner BioNTech SE for infringing patents relating to its mRNA platform, the source of the COVID vaccines developed by the three parties. The suit is to be filed Friday in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany. ""This groundbreaking technology was critical to the development of Moderna's own mRNA COVID-19 vaccine, Spikevax,"" the company said in a statement. ""Pfizer and(Reuters) -Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.  The suit also would be filed also in the Regional Court of Duesseldorf in Germany, Moderna said in a news release.  ""We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic,"" Moderna Chief Executive Stephane Bancel said in the news release.US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemicBased on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.I generally associate growth stocks with an adrenaline rush. On the other hand, blue-chip stocks provide a peaceful night’s sleep. With global markets remaining significantly volatile, I would prefer to go overweight on blue-chip stocks. Blue-chip stocks offer two main advantages. First, these are low-beta stocks and therefore help in capital preservation. Second, these stocks provide investors with regular cash flow through dividends. Even if the stock remains sideways, dividends make the portfPfizer has been ranked first in its Covid-19 response, patient centricity, patient safety and bringing innovative, high-quality products amongst pharma companies in Asia in the 'Corporate Reputation of Pharma' survey by patient groups across the APAC region. Overall, the company is ranked second for its corporate reputation across Asian countries and regions.";315.55999755859375;Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion). The analyst says that the ongoing feedback from physicians/payers continues to boost the optimism for broader access, reimbursement, and adoption amid the previously unforeseen glucose and weight-lowering properties. Citi increased the price target to $370 from $285 with a Buy rating. Related: Eli LLilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.;108.69000244140625;;136.35000610351562;Growing your passive income can make it much easier to live off your investments during your retirement years.Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients;82.68000030517578;Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.Novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business Sandoz, as weaker drug prices and jittery financial markets present one of his biggest challenges in the years-long overhaul of the Swiss drugmaker.  Novartis said on Thursday it plans to spin off Sandoz on Swiss and U.S. stock exchanges next year, capping off a prolonged streamlining of the Basel-based drugmaker that began in 2014, preceding Narasimhan's appointment to CEO in 2018.A manufacturing facility in Wilson is scheduled to close as a global pharmaceutical company is in the midst of a major restructuring.;89.26000213623047;(Bloomberg) -- Merck & Co.’s talks to buy cancer-drug maker Seagen Inc. have stalled for now, threatening what would be the pharmaceutical giant’s biggest deal in more than a decade, according to people familiar with the matter.Most Read from BloombergNearly 60,000 Sneakers in $85 Million Ponzi Scheme to Go on SaleGOP Fury Over ESG Triggers Backlash With US Pensions at RiskFed’s Jackson Hole Conference Is Underway: Here’s What to ExpectWorld’s Most Popular Password Manager Says It Was HackedA 12Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.Merck & Co Inc (NYSE: MRK) and Seagen Inc (NASDAQ: SGEN) have not been able to agree on a buyout price, Bloomberg reported. The deal talks have been stalled, for now, threatening Merck's potentially the largest deal in more than a decade, according to people familiar with the matter. Previously, Merck and Seagen's deal was expected to be sealed within a few weeks, worth roughly $40 billion or more. Merck will still have a significant presence in oncology if the deal fails. It already has one ofMOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS, AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS OR PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER. ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FO...Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.J&J (JNJ) gets approval for Tecvayli (teclistamab) for the treatment of relapsed and refractory multiple myeloma. This marks the first approval for Tecvayli in any country.;66.31999969482422;Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.;71.19000244140625;Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS, AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS OR PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER. ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FO...;40.81999969482422;The Centers for Disease Control and Prevention (CDC) has published the updated Advisory Committee on Immunization Practices (ACIP) guidance granting preferential recommendation for specific flu vaccines in people age 65+ in its Morbidity and Mortality Weekly Report (MMWR), a journal highlighting the latest in public health news and communicating recommendations derived from science-based research.5Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.;33.189998626708984;Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.Jay Powell sounded hawkish on the outlook for rate rises from the central bank.;13.710000038146973;Finch Therapeutics Group Inc (NASDAQ: FNCH) will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Ltd (NYSE: TAK). Following a review of its pipeline, Takeda will terminate its collaboration with Finch, effective November 17, 2022, resulting in the return to Finch of worldwide rights to develop and commercialize FIN-524, FIN-525, and any other microbiome product candidates for inflammatory bowel disease (IBD). A;43.04999923706055;;9.880000114440918;;227.14999389648438;;7.960000038146973;;148.75;;90.30999755859375;;11.359999656677246;;29.690000534057617;;45.5;;10.289999961853027;The Cambridge company (Nasdaq: MRNA) alleged in a complaint filed in the U.S. District Court of Massachusetts Friday that Pfizer (NYSE: PFE) and BioNTech's vaccine, Comirnaty, violates three patents Moderna filed between 2010 and 2016.;12.40999984741211;;30.809999465942383;;55.83000183105469;;260.1300048828125;;6.0;;27.100000381469727;;2.309999942779541;;4.960000038146973;;;;4.380000114440918;;4.090000152587891;;47.599998474121094;;;;25.6200008392334;;8.359999656677246;;7.130000114440918;;9.479999542236328;;2.5199999809265137;;36.349998474121094;;15.430000305175781;;19.520000457763672;;4.679999828338623;;14.960000038146973;;3.950000047683716;;7.480000019073486;;15.010000228881836;;24.6200008392334;;24.459999084472656;The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 134.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.;24.09000015258789;;18.420000076293945;;18.920000076293945;;4.050000190734863;;12.039999961853027;
2022-08-29;163.0;Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.In this article, we will look at the 10 best index funds to diversify your portfolio. If you want to skip reading about the benefits of investing in index funds, you can go directly to the 5 Best Index Funds to Diversify Your Portfolio. Index funds are the go-to choice for investors looking to diversify […]Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.Bristol-Myers Squibb Co (NYSE: BMY) and Johnson & Johnson's (NYSE: JNJ) Janssen announced results from the Phase 2 AXIOMATIC-SSP dose-ranging study of the investigational oral factor XIa (FXIa) inhibitor, milvexian. The data showed that milvexian failed its primary endpoint, a composite endpoint measuring both the dose-response compared with placebo in stroke incidence and a biomarker known as brain infarctions, or lesions that may appear in the absence of a stroke. Also See: Bristol-Myers SquibThe Dow Jones Industrial Average has had a turbulent summer. Here are 6 notable stocks that are struggling.Sector ETF report for VHT;46.22999954223633;Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.In this article, we discuss 10 cash-rich defensive stocks to buy before recession. If you want to read about some more cash-rich defensive stocks to buy before recession, go directly to 5 Cash-Rich Defensive Stocks to Buy Before Recession. The average savings of daily Americans are drying up as the United States economy slows down. […]Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) have generated billions of dollars from their coronavirus vaccines.  Moderna and Pfizer both have asked the U.S. Food and Drug Administration (FDA) to authorize their omicron-specific boosters for the fall vaccination season.  Moderna was among the first to talk about its work on an omicron-specific booster.;310.1499938964844;;107.44000244140625;"Bagsværd, Denmark, 29 August 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme inLast week, our time-tested methodologies served investors well in navigating the market. Check out some of our last week's achievements.";135.7100067138672;Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.AbbVie (NYSE: ABBV) today announced it will present 23 abstracts at the 31st European Academy of Dermatology and Venereology (EADV) Congress, including a late-breaking oral presentation on long-term efficacy and safety data of SKYRIZI® (risankizumab) in psoriatic arthritis and real-world data from MEASURE-AD to assess the multidimensional burden of atopic dermatitis. This research demonstrates AbbVie's commitment to deepening the understanding of immune-mediated skin diseases by investing in stuNovartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.;82.25;The European Commission (EC) has approved Novartis AG's (NYSE: NVS) Scemblix (asciminib) for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). Scemblix is the first CML treatment in Europe that works by specifically targeting the ABL myristoyl pocket (also known as a STAMP inhibitor in scientific literature). Patients with CML generally receive oral tyrosine kinase inNovartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.;87.58999633789062;In this article, we discuss the 10 best dividend stocks to buy according to Israel Englander’s Millennium Management. You can skip our detailed analysis of the hedge fund’s returns and its investment strategy, and instead go directly to the 5 Best Dividend Stocks to Buy According to Israel Englander’s Millennium Management. Israel Englander founded Millennium […]Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.RAHWAY, N.J., August 29, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that research spanning 16 different cancer types will be presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, France from Sept. 9-13. The breadth of data showcases the continued impact of Merck’s portfolio of oncology medicines and the potential of Merck's innovative oncology pipeline.;65.83000183105469;"Additional readouts from Valneva SE's (NASDAQ: VALN) pivotal VLA2001-301 ""Cov-Compare"" trial of COVID-19 vaccine VLA2001 showed persistent and first positive heterologous booster results following AstraZeneca Plc's (NASDAQ: AZN) COVID-19 primary vaccination. After two months, neutralizing antibody titers induced by VLA2001 was non-inferior to AstraZeneca's COVID shot (ChAdOx1-S). GMT was 444.0, and ChAdOx1-S GMT was 411.8. Related: Valneva Cuts FY22 COVID-19 Vaccine Sales Outlook, Needs FundingAstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress. Farxiga (dapagliflozin) led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure over a median follow-up of 2.3 years. In the placebo group, 19.5% of patients either experienced cardiovascular death or worsened heart failure. Related: AstraZeneca's CEO Says There Are No COVID R";66.75;"Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.""Secondary strokes continue to be a serious health risk for stroke patients and we believe these data demonstrated the potential of milvexian to address a key unmet need in this population,"" Bristol Myers said.By Liz MoyerApple, Alibaba, Bristol-Myers Squibb, Tesla and Cigna are part of The Zacks top Analyst Blog.Bristol-Myers Squibb Co (NYSE: BMY) and Johnson & Johnson's (NYSE: JNJ) Janssen announced results from the Phase 2 AXIOMATIC-SSP dose-ranging study of the investigational oral factor XIa (FXIa) inhibitor, milvexian. The data showed that milvexian failed its primary endpoint, a composite endpoint measuring both the dose-response compared with placebo in stroke incidence and a biomarker known as brain infarctions, or lesions that may appear in the absence of a stroke. Also See: Bristol-Myers Squib";40.70000076293945;;33.11000061035156;IDEAYA Biosciences Inc (NASDAQ: IDYA) has achieved a preclinical development milestone in connection with ongoing IND-enabling studies for its Pol Theta Helicase Development Candidate. IDEAYA is collaborating with GSK plc (NYSE: GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase DC in combination with niraparib for BRCA harboring tumors or other homologous recombination mutations or homologous recombination deficiency. IDEAYA and GSK are targeting an IND submissionCureVac NV, a German biopharmaceutical company with U.S. headquarters in Boston, is back in the Covid-19 vaccine game — about a year after it abandoned its first attempt. The CEO detailed the company's approach this time.;13.770000457763672;;42.31999969482422;;9.869999885559082;;220.94000244140625;;7.710000038146973;;148.67999267578125;;87.97000122070312;;11.119999885559082;;29.350000381469727;;45.220001220703125;;10.380000114440918;CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.CureVac NV, a German biopharmaceutical company with U.S. headquarters in Boston, is back in the Covid-19 vaccine game — about a year after it abandoned its first attempt. The CEO detailed the company's approach this time.;12.180000305175781;;30.540000915527344;;58.099998474121094;;251.6999969482422;Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.;5.829999923706055;;26.700000762939453;;2.299999952316284;;4.599999904632568;;;;4.28000020980835;;3.9200000762939453;;45.2599983215332;;;;24.610000610351562;;8.229999542236328;;7.090000152587891;;9.270000457763672;;2.450000047683716;;36.650001525878906;;15.8100004196167;;19.790000915527344;;4.619999885559082;;16.149999618530273;The mean of analysts' price targets for GH Research PLC (GHRS) points to a 205.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.;4.019999980926514;BOSTON & LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that members of its management team will participate in the following investor conferences: Event: Morgan Stanley 20th Annual Global Healthcare ConferenceDate: Monday, September 12, 2022Location: New York;7.300000190734863;;14.65999984741211;;24.06999969482422;;24.43000030517578;Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.;23.3799991607666;;18.959999084472656;;17.170000076293945;;3.8499999046325684;;11.859999656677246;
2022-09-01;165.33999633789062;;46.630001068115234;;309.1300048828125;;104.52999877929688;"Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Forma Therapeutics Holdings Inc (NASDAQ: FMTX) for $20 per share in cash, representing a total equity value of $1.1 billion. The deal value offers a premium of 92% to Forma Therapeutics' volume-weighted average price per share over the past 30 days. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on treating sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead deveDanish drugmaker Novo Nordisk has agreed to buy Forma Therapeutics in a deal valued at $1.1 billion to expand its blood disorders portfolio, the companies said on Thursday.  ""We have an ambition to build a leading portfolio with standalone and combination treatments to tackle the complications and underlying causes of sickle cell disease,"" Novo Nordisk said in a statement.  Novo Nordisk, best known for its diabetes drugs, said it would pay 20 dollar per share, which is a premium of 92% to the U.S. company's volume-weighted average price per share over the past 30 days.Forma Therapeutics Holdings Inc. announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk in a deal with an equity value of $1.1 billion. Forma shares are halted for news until 8:30 a.m. Eastern, while the U.S.-listed share of Novo Nordisk were little changed. Under terms of the deal, Forma shareholders will received $20 in cash for each Forma share they own, which represents a 49.3% premium to Wednesday's closing price of $13.40, and implies a market capitalization of $957.""We have an ambition to build a leading portfolio with standalone and combination treatments to tackle the complications and underlying causes of sickle cell disease,"" Novo Nordisk said in a statement.  Novo Nordisk, best known for its diabetes drugs, said it would pay 20 dollar per share, which is a premium of 92% to the U.S. company's volume-weighted average price per share over the past 30 days.  The Danish group said it expected the deal, which had been unanimously approved by Forma Therapeutic's board, to close in the fourth quarter and it would not impact Novo Nordisk's full-year guidance.Bagsværd, Denmark and Watertown, Mass, US, 01 September 2022 – Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per share in cash, which represents a total equity value of USD 1.1bn. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorderSome think drugs could become mega-blockbusters";138.4499969482422;;80.33000183105469;FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.Novartis AG (NYSE: NVS) has appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down after seven years as research head. The company said the appointment of Marshall, currently senior vice president and global head of discovery sciences, preclinical development, and translational medicine at Merck & Co Inc (NYSE: MRK), takes effect on November 1. Before joining Merck in 2018, Marshall was a founder and cZURICH (Reuters) -Novartis said on Thursday it appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down after seven years as research head at the Swiss drugmaker.  The drugmaker said the appointment of Marshall, currently senior vice president and global head of discovery sciences, preclinical development and translational medicine at Merck & Co, takes effect on Nov. 1.  He cited Marshall's three decades of experience leading drug discovery and early development across large biopharma, biotech and academia.After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr. Marshall to shape next era of biomedical innovation and continue Novartis leadership in R&D Basel, September 1, 2022 — Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading research at;87.1500015258789;;61.790000915527344;AstraZeneca was downgraded by TheStreet.com's Quant Ratings service Wednesday. I subsequently looked at the charts of AZN and don't like what I see. Let's look together.      In this daily bar chart of AZN, below, we can see that prices recently turned lower to retest the rising 200-day moving average line.;69.08999633789062;;40.400001525878906;The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.Soon after the European Commission's (EC) approval, Sanofi SA (NASDAQ: SNY) scooped up the FDA's OK for the first approved therapy to treat symptoms not related to the central nervous system in patients with acid sphingomyelinase deficiency (ASMD). The indication includes a range of ailments under the umbrella of Niemann-Pick disease. Sanofi now has a rare pediatric disease priority review voucher, making it Sanofi's third PRV. The disease afflicts 1 in every 250,000 people. There are fewer thanXenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) Paris, August 31, 2022. The U.S. Food and Drug Administration (FDA) has approved XenpozymeTM (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. Xenpozyme is the first therapy indicated specifically for the treatment of ASMD, and is currently the only approved;31.690000534057617;The Serum Institute of India (SII), the world's biggest vaccine maker, has developed the country's first cervical cancer shot that will hit the market soon, the company and the government said on Thursday.  Cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020, according to the World Health Organization.  Two human papillomavirus (HPV) types, 16 and 18, are responsible for at least 70% of cervical cancers, and India's Department of Biotechnology said the Indian vaccine would work on HPV types 16 and 18, as well as 6 and 11.;13.739999771118164;;41.970001220703125;;9.569999694824219;;213.77999877929688;Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;7.739999771118164;;149.82000732421875;;89.08999633789062;COPENHAGEN, Denmark, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in three upcoming investor conferences in September. Details: EventCiti's 17th Annual BioPharma ConferenceLocationBoston, MADateWednesday, September 7, 2022Time3:30-4:15 p.m. Eastern Time / 12:30-1:15 p.m. Pacific TimeSpeaker(s)Scott Smith, Senior Vice President, Chief Financial Officer Event2022 Wells Fargo Healthcare ConferenceLocationBoston, M;10.670000076293945;LONDON, Ontario, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/ XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that it has completed the second and final tranche of its previously announced private placement with Evotec SE (FSE:EVT) (NASDAQ: EVO) of 2,709,800 common shares of the Company (“Common Shares”) at a price of $2.50 per share for total proceeds of $6,774,500. Upon completion of the second tranch;28.809999465942383;;46.77000045776367;;10.029999732971191;;13.029999732971191;;29.799999237060547;;63.58000183105469;WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences in September: Citi 17th Annual BioPharma Conference: Fireside chat on Wednesday, September 7, 2022 at 1:00 p.m. ET.Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 8, 2022 at 1:55 p.m. ET.Baird 2022 Global Healthcare Conference: Pr;255.8000030517578;BOSTON, September 01, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming investor conferences:;6.289999961853027;;27.31999969482422;;2.200000047683716;;4.980000019073486;;;;4.019999980926514;;4.139999866485596;;45.380001068115234;;76.01000213623047;;23.690000534057617;;8.670000076293945;;6.78000020980835;;9.210000038146973;;2.3399999141693115;"Amneal Pharmaceuticals Inc (NYSE: AMRX) submitted a marketing application to the FDA seeking approval for IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for Parkinson's disease. The submission is based on results from the pivotal Phase 3 RISE-PD clinical trial demonstrating more ""Good On"" time than immediate-release CD/LD. Related Content: Amneal Pharma Posts Mixed Q2 Earnings, Cuts Profit Outlook For 2022. IPX203 was dosed on average three times per day, andBRIDGEWATER, N.J., August 31, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD).";36.630001068115234;;16.389999389648438;SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in September: Wells Fargo Healthcare ConferenceFireside chat: Wednesday, September 7 at 3:45 – 4:15 p.m. ETBaird 2022 Global Healthcare Conference Fireside chat: Tuesday, September 13 at 10:50;19.670000076293945;;4.389999866485596;;15.5;;4.539999961853027;;7.300000190734863;;15.430000305175781;"SAN DIEGO, August 31, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has obtained an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA). The award provides $63.2 million over three years to sup";25.489999771118164;;26.8700008392334;WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference. Details for the company’s participation are as follows: Morgan Stanley 20th Annual Global Healthcare ConferenceFireside Chat Date: Tuesday, September 13, 2022Fireside Chat Time: 8:00 a.m. EDT The we;23.760000228881836;;19.8799991607666;;16.90999984741211;Company announcement – No. 37 / 2022 Total number of shares and voting rights in Zealand Pharma at August 31, 2022 Copenhagen, DK and Boston, MA, August 31, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end;3.25;;12.550000190734863;
2022-09-02;162.74000549316406;;45.70000076293945;;301.3299865722656;;102.23999786376953;Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying.Shares of Forma Therapeutics Holdings (NASDAQ: FMTX) were up by a healthy 49% as of 1:17 p.m. ET Thursday afternoon.  The small-cap biotech's stock is roaring higher in response to a $1.1 billion buyout agreement with Danish drugmaker Novo Nordisk (NYSE: NVO).  Novo Nordisk has agreed to pay $20 a share for Forma Therapeutics in cash.;136.27999877929688;;79.69999694824219;Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology and Venereology (EADV) Congress Phase IIb data on remibrutinib (LOU064), an oral Bruton’s tyrosine kinase inhibitor, for people living with chronic spontaneous urticaria to be highlighted at EADV Results of analysis at Week 52 from Phase IIb trial of ianalumab (VAY736), a dual mode of action B-ce;86.2300033569336;;60.689998626708984;;68.61000061035156;;40.08000183105469;Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;31.850000381469727;;13.579999923706055;Generally speaking, you want to focus your investments on companies with strong fundamentals, not just on companies that meet a certain price metric, such as stocks under $15. However, certain public firms offer compelling narratives that patient buyers can hold for the long run. To be clear, these stocks under $15 (as of this writing) tend to either be more speculative than normal or fly under the radar. In other words, you may have to hold onto them for several years to enjoy strong capital ap;42.06999969482422;;9.449999809265137;;210.33999633789062;;7.630000114440918;;149.66000366210938;;88.44000244140625;;10.729999542236328;;28.5;;46.130001068115234;Legend Biotech stock had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday.  As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.  Is Legend Biotech Stock A Buy?;9.699999809265137;Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales,  seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac's European patents, according to a regulatory filing on Friday.  In July, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the company and two subsidiaries for infringement of its intellectual properly rights.  Pfizer and BioNTech later filed a complaint with a U.S. district court, seeking a judgment that they did not infringe U.S. patents held by CureVac.;12.899999618530273;;29.540000915527344;;62.689998626708984;;254.4499969482422;;5.909999847412109;;27.040000915527344;;2.130000114440918;;4.730000019073486;;;;4.010000228881836;;4.289999961853027;;44.36000061035156;;;;23.010000228881836;;8.84000015258789;;6.429999828338623;;8.789999961853027;;2.200000047683716;;36.02000045776367;;16.030000686645508;;20.219999313354492;SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, will be presenting data from a planned two-year interim analysis from the ACROBAT Advance open label extension (OLE) study at the 35th Brazilian Congress of Endocrinology and Metabolism (CBEM) being held in S;4.360000133514404;;15.90999984741211;;4.710000038146973;;7.309999942779541;;14.319999694824219;;23.40999984741211;;24.110000610351562;Neha Krishnamohan Neha Krishnamohan WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Neha Krishnamohan has been appointed to the Arcutis Board of Directors and as a member of the audit committee. Following the appointment, the Board will be composed of 10 directors. “We are absolutely delighted to welcome Neha to the;23.799999237060547;;19.760000228881836;;16.90999984741211;;3.049999952316284;;12.539999961853027;
2022-09-06;163.17999267578125;;45.7599983215332;;306.82000732421875;;103.58999633789062;;137.58999633789062;;79.7699966430664;;86.41999816894531;;60.40999984741211;AstraZeneca's (AZN) Imfinzi plus chemotherapy becomes the first immunotherapy combination to get approval in the United States to treat advanced biliary tract cancerThe FDA approved AstraZeneca plc’s (NASDAQ: AZN) Imfinzi (durvalumab) for locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The approval was based on the results from the TOPAZ-1 Phase 3 trial. In an interim analysis of TOPAZ-1, Imfinzi plus chemotherapy reduced the risk of death by 20% versus chemotherapy alone. An estimated one in four patients treated with Imfinzi plus chemotherapy were alive at two years compared to one i;68.6500015258789;;39.59000015258789;Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced results from a Phase 3 open-label extension trial of Dupixent (dupilumab) as maintenance therapy in asthma patients aged 6 to 11. The trial assessed Dupixent when added to other asthma medications for uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation. Also read: Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years. Children treated with Dupixent in the exte;31.469999313354492;Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.;13.369999885559082;;41.900001525878906;;9.40999984741211;Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the BofA Global Research Global Healthcare Conference in London on Thursday, September 15, 2022. Chief Executive Officer Michael Goettler, President Rajiv Malik and Chief Financial Officer Sanjeev Narula will represent the company in a fireside chat scheduled at 4:45 p.m. BST / 11:45 a.m. ET.;212.77000427246094;;7.599999904632568;;149.61000061035156;;88.11000061035156;;10.670000076293945;;28.709999084472656;;43.97999954223633;;9.489999771118164;;12.180000305175781;;28.950000762939453;CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022. Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside chat at 9:20AM ET. The live webcast of the fireside chat can be access;58.0099983215332;;247.52999877929688;;5.590000152587891;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the results from its Phase 2 clinical study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be featured in a proffered paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2022, on Sa";26.010000228881836;;2.119999885559082;We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...;5.130000114440918;;;;3.759999990463257;;4.28000020980835;;44.52000045776367;;;;22.309999465942383;GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection. Emergent and CEPI (the Coalition for Epidemic Preparedness Innovations) are co-funding this program. “Over the last 24 years, Emergent’s mission;8.850000381469727;;6.03000020980835;LAUSANNE, Switzerland, September 06, 2022--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m. ET.;8.65999984741211;;2.25;;36.04999923706055;LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoskeletal disorders with high unmet medical need, today announced that Jasbir S. Seehra, Ph.D, President and Chief Executive Officer, and Keith Regnante, Chief Financial Officer, will participate in a firesideLEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoskeletal disorders with high unmet medical need today announced that two abstracts will be presented from the KER-012 and KER-050 programs at the American Society for Bone and Mineral Research (“ASBMR”) 2022;15.300000190734863;;19.989999771118164;Open label extension data from investigational compound paltusotine orally presented at the 35th Brazilian Congress of Endocrinology and Metabolism Lowered and maintained IGF-1 at levels comparable to prior injected somatostatin receptor ligands (SRL) Generally well-tolerated with a safety profile similar to that of injected SRLs Nearly 90% of participants preferred once daily oral paltusotine to injected SRLs SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX);4.210000038146973;;13.850000381469727;;4.739999771118164;;7.309999942779541;;13.75;;22.360000610351562;;21.079999923706055;WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that four abstracts for Arcutis’ topical roflumilast program in seborrheic dermatitis and psoriasis will be presented at European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan and virtually. Specifically, new data from the STRATU;23.56999969482422;;18.6200008392334;MOUNTAIN VIEW, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in three upcoming investor conferences in New York: Fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12 at 1:40 p.m. ESTFireside chat at the Baird 2022 Global Healthcare Conference on Tu;;;2.9000000953674316;;11.989999771118164;
2022-09-07;164.07000732421875;;46.130001068115234;;311.6000061035156;;104.83000183105469;Zealand Pharma A/S (NASDAQ: ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE: NVO) to commercialize Zegalogue (dasiglucagon) for injection. FDA approved Zegalogue for severe hypoglycemia in pediatric and adult patients with diabetes aged six and above. Under the terms of the agreement, Zealand will receive an upfront payment of DKK 25 million and is eligible to receive up to DKK 45 million in near-term development, regulatory, and manufacturing-based;138.7100067138672;;80.94000244140625;;86.87000274658203;;59.81999969482422;;68.76000213623047;;40.470001220703125;In the latest trading session, Sanofi (SNY) closed at $39.59, marking a -1.22% move from the previous day.The European Union's drugs regulator is just a few weeks away from deciding whether to approve Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) partnered COVID-19 vaccine, Reuters reported, citing Thomas Triomphe, Sanofi's executive vice-president for vaccines. The companies' bivalent vaccine targets the Beta variant as well as the original Wuhan strain of the virus. Trial results also showed that the shot confers protection against the Omicron variant. Sanofi and GSK hope to join the race for va;31.489999771118164;GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.- SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments - - SpringWorks to Supply Nirogacestat for GSK’s Global Blenrep Development Program and to Make Nirogacestat Commercially Available in Markets Where a Combination with Blenrep is Approved - - SpringWorks to Continue Retaining Full Global Commercial Rights to Nirogacestat - STAMFORD, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clThe European Union's drugs regulator is just a few weeks away from deciding whether to approve Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) partnered COVID-19 vaccine, Reuters reported, citing Thomas Triomphe, Sanofi's executive vice-president for vaccines. The companies' bivalent vaccine targets the Beta variant as well as the original Wuhan strain of the virus. Trial results also showed that the shot confers protection against the Omicron variant. Sanofi and GSK hope to join the race for va;13.3100004196167;"Takeda Canada Inc. (""Takeda"") is proud to announce a Rare Disease Fellowship in partnership with the Canadian Institutes of Health Research (CIHR). The fellowship will provide support and training to ensure participants emerge as scientific, professional, or organizational leaders within and beyond the health research enterprise. This specific opportunity seeks to support postdoctoral fellows focused on one or more rare disease disorders. A full list of research areas in rare diseases can be fou";42.709999084472656;NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 17th Annual BioPharma Conference on Thursday, September 8 at 11:20 a.m. ETMorgan Stanley’s 20th Annual Global Healthcare Conference on Monday, September 12 at 10:30 a.m. ETBank of America’s Global Healthcare Conference 2022 on Thursday, September 15 at 10:55 a.m. ET / 3:55 p.m. BST The webcasts;9.720000267028809;Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;222.3699951171875;;7.78000020980835;;150.19000244140625;Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;90.94999694824219;;11.079999923706055;;28.959999084472656;;43.880001068115234;;9.779999732971191;;12.4399995803833;;31.510000228881836;;64.25;Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;252.6199951171875;Karuna Therapeutics, Inc. (KRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;5.710000038146973;;27.8700008392334;Strengthens Financial Position to Over $600 Million in Cash, Cash Equivalents and Marketable Securities, Upon Closing of the FinancingSTAMFORD, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into a securities purchase agreement with a select group of institutional investors to issu- SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments - - SpringWorks to Supply Nirogacestat for GSK’s Global Blenrep Development Program and to Make Nirogacestat Commercially Available in Markets Where a Combination with Blenrep is Approved - - SpringWorks to Continue Retaining Full Global Commercial Rights to Nirogacestat - STAMFORD, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a cl;2.180000066757202;;5.239999771118164;;;;3.799999952316284;Nektar Therapeutics (Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as LY3471851 or NKTR-358) in patients with atopic dermatitis (AD) and plaque psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress.;4.510000228881836;;46.060001373291016;;;;22.739999771118164;Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.;9.399999618530273;;6.159999847412109;;9.470000267028809;The average of price targets set by Wall Street analysts indicates a potential upside of 73.2% in Quanterix Corporation (QTRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.;2.3299999237060547;"BRIDGEWATER, N.J., September 06, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022.";37.83000183105469;;16.1200008392334;;21.6200008392334;;4.289999961853027;NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi’s 17th Annual BioPharma Conference in BostonFormat: Industry PanelDate and Time: Wednesday, September 7th, 10:30 a.m. ET – 11:15 a.m. ETConference Link: URL H.C. Wainwright’s 24th Annual Global Investment Conference;12.979999542236328;;4.190000057220459;;7.889999866485596;;14.75;Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...;27.06999969482422;"Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.PLANO, Texas, September 06, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" or ""we""), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17th Annual BioPharma Conference on September 7 – 8, 2022 in Boston, Massachusetts.";21.540000915527344;;24.399999618530273;;19.1200008392334;;17.719999313354492;Press release – No. 4/ 2022 Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference Copenhagen, DK and Boston, MA, September 7, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference. Morgan Stanley 20th Annual GloZealand Pharma A/S (NASDAQ: ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE: NVO) to commercialize Zegalogue (dasiglucagon) for injection. FDA approved Zegalogue for severe hypoglycemia in pediatric and adult patients with diabetes aged six and above. Under the terms of the agreement, Zealand will receive an upfront payment of DKK 25 million and is eligible to receive up to DKK 45 million in near-term development, regulatory, and manufacturing-basedCompany announcement – No. 38 / 2022 Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to high-single to low-double digit royalties on worldwide net salesZealand will be responsible for certain planned development, regulatory, and manufacturing activities to support approval outside the U.S.Deal marks further execution on Zealand’s strategy to engage in commercial partnerships and prioritize R&;3.1700000762939453;Praxis Precision Medicines Inc (NASDAQ: PRAX) plans to start the PRAX-222 EMBRAVE study for pediatric patients with early-seizure-onset SCN2A developmental and epileptic encephalopathy (DEE). After collecting the safety and efficacy data from the first cohort of patients in the EMBRAVE study, the data will be evaluated and submitted to the FDA to seek authorization for further dose escalation. Praxis also announced that it intends to start the PRAX-562 Phase 2 study in pediatric patients with SCBOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the plan to start the PRAX-222 EMBRAVE clinical study for the treatment of pediatric patients with early-seizure-onset SCN2A developmental and epileptic encephalopathy (DEE), after the;12.609999656677246;"Viewing insider transactions for Repare Therapeutics Inc.'s ( NASDAQ:RPTX ) over the last year, we see that insiders...CAMBRIDGE, Mass. & MONTREAL, September 07, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the fireside chats are as follows:"
2022-09-08;165.38999938964844;;47.08000183105469;;315.5;;105.69000244140625;Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.;140.52000427246094;;81.26000213623047;;87.41999816894531;;60.31999969482422;A couple of no-brainer stocks that make for ideal buy-and-forget investments are AstraZeneca (NASDAQ: AZN) and Microsoft (NASDAQ: MSFT).  AstraZeneca is a robust healthcare company that has a broad portfolio of assets that can generate some promising growth.  In the first half of the year, the company reported $22 billion in revenue, which rose 48% year over year (when excluding the impact of foreign exchange).;69.37999725341797;;40.08000183105469;"Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis Nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo There are currently no approved medicines specifically indicated to treat prurigo nodularis; regulatory submissions for Dupixent are under Priority Review in the U.S. and under review in the European Union22 DupixentRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed positive results from the second of two Phase 3 trials (PRIME) evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis in a late-breaking session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress. These data, which were consistent with the detailed data from the first Phase 3 trial (PRIME2) in prurigo nodularis, show Dupixent significantly reduced itch and skin lesi";31.510000228881836;Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.A requirement under the U.S. law known as Obamacare that private insurance plans cover drugs that prevent HIV infection at no cost to patients violates both federal law and the Constitution, a federal judge ruled on Wednesday, siding with conservative lawyers who had challenged the measure on religious grounds.  Ruling in Fort Worth, Texas, U.S. District Judge Reed O'Connor found that the HIV pre-exposure prophylaxis, or PrEP, mandate stemmed from a recommendation by an advisory body formed in violation of constitutional requirements and could infringe upon the rights of employers under a law called the Religious Freedom Restoration Act.  The mandate is part of the Affordable Care Act (ACA), as Obamacare is formally called.SpringWorks Therapeutics Inc (NASDAQ: SWTX) has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (NYSE: GSK) for SpringWorks' nirogacestat with GSK's Blenrep. SpringWorks will receive a $75 million equity investment from GSK, and it is eligible to receive up to $550 million in milestone payments. In May, SpringWorks announced positive topline results from the DeFi Phase 3 trial evaluating nirogacestat in adult patients with progressing desmoid tumor;13.5;;42.9900016784668;;9.680000305175781;;227.17999267578125;If you've been investing long enough, you may have heard that historically September is not a great month for stock market returns.  In that spirit, I'm turning my attention to three healthcare stocks I think are strong buys for September and beyond.  Moderna (NASDAQ: MRNA) has become a household name due to its successful coronavirus vaccine.;8.180000305175781;Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.;150.9199981689453;;100.37999725341797;;11.199999809265137;;29.360000610351562;;43.619998931884766;;9.680000305175781;;13.140000343322754;— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-breaking, proffered paper presentation at ESMO — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to discuss the full trial results and the unmet medical need in colorectal cancer — HONG KONG and SHANGHAI and FLORHAM PARK, N.J.;32.18000030517578;;68.52999877929688;WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 64 new employees with a grant date of September 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the comp;246.4499969482422;;5.699999809265137;;28.229999542236328;;2.2100000381469727;;5.139999866485596;;;;3.759999990463257;;4.75;;47.70000076293945;;;;23.0;;8.34000015258789;Erasca Inc (NASDAQ: ERAS) announced preliminary Phase 1/1b monotherapy data for ERAS-007 and ERAS-601 in solid tumor settings. A retrospective pooled analysis of all trials evaluating ERAS-007 or ERAS-601 in advanced solid tumors included Erasca's ongoing HERKULES-1 and FLAGSHP-1 trials and Asana BioSciences' previously completed ASN007-101 trial. Key findings from the retrospective pooled interim analysis of ERAS-007 and ERAS-601 show that 23% (6/26) of patients with RAS/MAPK-altered non-colore23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601 ERAS-007 and ERAS-601 had favorable safety and tolerability profiles with largely non-overlapping treatment-related adverse events that support combination development Initiation of ERAS-007 plus ERAS-601 MAPKlamp trial in RAS/MAPK-altered, including BRAF-driven, solid tumors anticipated to begin in fir;6.519999980926514;;9.3100004196167;;2.3499999046325684;;38.470001220703125;;16.0;Nurix Therapeutics, Inc. (NRIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).;21.0;SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-person at the Lotte New York Palace Hotel. Details of the Crinetics presentation are as follows:Date & Time: Available on-demand beginning at 7:00 a.m. Eastern Time on Monday, September 12, 2022Webcast Link:https://jour;4.289999961853027;;13.34000015258789;;4.090000152587891;;7.599999904632568;;15.119999885559082;;27.06999969482422;Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;22.09000015258789;LifeArc today announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been acquired by ArcutisBiotherapeutics, Inc. (NASDAQ: ARQT), a California-based early commercial stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology. LifeArc was Ducentis' largest investor, recognising the transformational potential of its science anLeverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitisLead indication, atopic dermatitis, is a rapidly growing, significantly underserved market with large unmet needCheckpoint agonism is a promising emerging pathway for the treatment of atopic dermatitis, with preclinical and clinical validation data suggesting a durable biologic responseDS-234 offers a potential best-in-class profile, as well as a highly;24.889999389648438;;21.260000228881836;;17.719999313354492;;3.380000114440918;BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 10:30 a.m. ET. The event will be;13.029999732971191;
2022-09-09;165.7100067138672;;47.84000015258789;;317.70001220703125;;108.52999877929688;;141.4199981689453;The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.Starting the session following Labor Day weekend in the red, it’s clear that even so-called S&P 500 stocks to buy are feeling the heat. Toward the end of August, Federal Reserve chair Jerome Powell presented a less-than-encouraging picture for future monetary policy. Essentially, Powell remains concerned about multidecade highs in inflation. Therefore, he aims to tackle it through higher interest rates. Fundamentally, then, even the best S&P 500 stocks to buy face a major paradigm shift. For decSometimes combining two good concepts works very well. For example, Dave & Busters (NASDAQ:PLAY) has made a great deal of money by combining fun video games and tasty food. To help investors find the best dividend stocks to buy in September, I’m going to similarly attempt to combine two of my favorite investing ideas: dividend stocks and energy. As I’ve written in previous columns, dividend stocks are great because they pay investors while they wait for the stock market to turn itself around. En;82.5999984741211;Novartis AG (NYSE: NVS) has announced results from a new pooled exploratory analysis of the MONALEESA Phase 3 program of Kisqali + endocrine therapy (ET) in advanced breast cancer patients. In a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer, Kisqali + ET confirmed nearly one year of additional overall survival (OS) benefit. This subgroup analysis found that patients with visceral metasPharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on Friday, citing inability to use the U.S. site to full capacity.  The site with about 246 employees specialises in producing pharmaceutical oral solid dosage products for distribution mostly in U.S. and Canadian markets.  It said the decision to close the site had come before it announced a strategic review of Sandoz, which it plans to spin off to sharpen the group's focus on patented prescription medicines.New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with challenging visceral metastases1Kisqali plus endocrine therapy reports a median OS of approximately five years in patients with visceral metastases, adding a nearly one-year survival benefit compared to ET alone in this harder-to-treat population1Kisqali is a unique CDK4/6 inhibitor, consistently demonstrat;87.33999633789062;;60.849998474121094;Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.WILMINGTON, Del., September 09, 2022--Positive long-term follow-up results from the PAOLA-1 and SOLO-1 Phase III trials of LYNPARZA® (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, with or without bevacizumab demonstrated clinically meaningful improvements in overall survival (OS). Further results showed class-leading progression-free survival (PFS) in combination with bevacizumab for homologous recombination deficien;70.16000366210938;;40.79999923706055;Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) presented detailed results from the second of two Phase 3 trials (PRIME) evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis. Prurigo nodularis patients experience intense, persistent itch with thick skin lesions (nodules) that can cover most of the body. Related: Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids. These data, consistent with;31.889999389648438;In the latest trading session, GSK (GSK) closed at $31.51, marking a +0.06% move from the previous day.Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.;13.720000267028809;;43.630001068115234;The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...;9.880000114440918;;233.57000732421875;;8.529999732971191;;150.7100067138672;;101.37999725341797;;11.489999771118164;;29.829999923706055;;44.5099983215332;;9.680000305175781;;13.970000267028809;HUTCHMED (China) Limited (NASDAQ: HCM) announced summary results of the 691-patient trial of fruquintinib. These results have been shared in an abstract of the upcoming presentation at the European Society for Medical Oncology Congress 2022. The MRCT FRESCO-2 study demonstrated that treatment with fruquintinib resulted in a statistically significant and clinically meaningful increase in the primary overall survival (OS) endpoint and key secondary progression-free survival (PFS) endpoint compared;31.079999923706055;;67.56999969482422;Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.;248.99000549316406;;5.769999980926514;;28.350000381469727;;2.2100000381469727;;5.340000152587891;;;;3.740000009536743;;4.639999866485596;;47.0099983215332;;;;25.06999969482422;;8.5;SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern;6.170000076293945;;10.100000381469727;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...;2.309999942779541;;38.970001220703125;;15.869999885559082;;21.030000686645508;;4.349999904632568;;13.920000076293945;;4.039999961853027;;7.300000190734863;;15.430000305175781;;26.5;;20.43000030517578;Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle (P<0.0001)More than 60% of patients treated with roflumilast foam achieved an itch response at Week 8, with significant improvements at the 2-and 4-week assessmentsStatistically significant improvements compared to vehicle on all secondary endpoints including scaling and erythema (redness)Roflumilast foam wasArcutis Biotherapeutics Inc (NASDAQ: ARQT) has agreed to acquire LifeArc's portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. The agreement values Ducentis at up to $400 million, including an upfront cash payment of $16 million, Arcutis stock valued at approximately $14 million, and future contingent payments based on development and commercial success. Ducentis' lead pre-clinical as;25.540000915527344;;21.25;;19.09000015258789;Company announcement – No. 39 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, DK and Boston, MA, September 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 7,802 divided into 7,802 new shares with a nominal value of DKK 1 each;3.4100000858306885;;12.75;
2022-09-12;165.63999938964844;;47.7599983215332;;315.2200012207031;;109.33000183105469;Bagsværd, Denmark and Redmond, WA, US, 12 September 2022 – Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and data science capabilities. Through the partnership, Microsoft is providing AI technology, foundational science models and expertise and is working alongside Novo Nordisk’s data scientists and domain experts from early research and de;142.24000549316406;AbbVie Inc (NASDAQ: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials of Skyrizi (risankizumab) in active psoriatic arthritis. Results showed that at week 100 of the open-label extension period, patients receiving SKYRIZI reported improvement in skin and joint symptoms, with more than half of patients in KEEPsAKE 1 and 2 achieving a 90% reduction in the Psoriasis Area and Severity Index (PASI 90). Additionally, the data demonstrated no new observed safety signals tThis pair of Midwestern companies have outperformed in recent years, and their futures look brighter than ever.;83.5999984741211;"Novartis AG (NYSE: NVS) announced the results from two Phase 3 studies (SUNSHINE and SUNRISE) of Cosentyx (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS). HS is a chronic, inflammatory skin condition affecting up to one in 100 people worldwide, resulting in painful, disfiguring lesions. The data showed that Cosentyx demonstrated rapid and sustained relief from signs and symptoms of HS with a favorable safety profile. These Phase 3 data have been submitted to European regulatoryNovartis AG (NYSE: NVS) is investing in next-generation biotherapeutics to create a fully integrated, dedicated $300 million to bolster its capacity and capabilities for early technical development of biologics. Spanning both drug substance and drug product development, the multi-year investment will be implemented across existing Novartis locations in Switzerland, Slovenia, and Austria. ""The science of developing biologics is increasingly sophisticated, and we are excited to meet its challenges";88.16000366210938;;61.75;WILMINGTON, Del., September 12, 2022--Updated results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), in combination with standard-of-care chemotherapy demonstrated a clinically meaningful and durable overall survival (OS) benefit as a treatment for patients with advanced biliary tract cancer (BTC).;72.36000061035156;"""We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis,"" said Bristol Myers' chief medical officer Samit Hirawat.Late Friday,  Bristol Myers Squibb  (ticker: BMY) announced that the Food and Drug Administration had approved its oral plaque psoriasis treatment deucravacitinib, which will be marketed under the name Sotyktu.  More surprising than the approval was the FDA’s decision not to require a so-called “black-boxed warning” on the drug’s label, which the agency uses when a drug carries significant safety risks.  Investors had been concerned that similarities between TYK2 inhibitors and another class of drugs, known as Janus kinase inhibitors, which have been the subject of significant FDA safety concerns, would lead the agency to put a black box on Sotyktu.This blue chip big pharma stock offers investors a recession-proof business, a rising top line, and a solid dividend.Yahoo Finance Live anchors discuss stock performance for Bristol-Myers Squibb amid FDA drug approval.";41.4900016784668;;32.45000076293945;AnaptysBio Inc (NASDAQ: ANAB), a clinical-stage biotechnology company focused on immunology therapeutics, has sold its royalty interest on future global net sales of Zejula (Niraparib) to a wholly-owned subsidiary of DRI Healthcare Trust for up to $45 million. GSK Plc's (NYSE: GSK) Zejula is indicated as monotherapy for the maintenance treatment of advanced ovarian cancer. AnaptysBio has received a $35 million upfront payment for selling its 1% royalty on global net sales of Zejula, which, due t;13.720000267028809;;43.63999938964844;;10.109999656677246;Pharmaceutical businesses spend billions of dollars developing medicines that they then protect with a fortress of intellectual property (IP) safeguards to make sure that competitors can't benefit from their work.  But if you're not looking for dividend payments, it's hard to see how it would outperform the market, since it isn't engaged in a high-growth niche, nor is it planning to make significant innovations that would give it an edge over the competition.;232.4600067138672;;8.640000343322754;;150.99000549316406;;103.61000061035156;- Durability of response to TransCon PTH therapy through Week 110 demonstrated by continued normalization of serum calcium and 93% achieving independence from conventional therapy - Participants with more years of disease duration had higher baseline bone mineral density (BMD) Z-scores and larger decreases in BMD Z-scores following treatment, trending toward age- and sex-matched norms through Week 110 - Replacement therapy with TransCon PTH was well tolerated through Week 110, with continued nor;11.579999923706055;;29.709999084472656;;44.380001068115234;;10.109999656677246;;14.350000381469727;;30.610000610351562;;67.2699966430664;;255.8800048828125;;5.579999923706055;;31.979999542236328;;2.2300000190734863;;5.269999980926514;;;;3.809999942779541;;5.610000133514404;;47.380001068115234;;;;25.049999237060547;;8.960000038146973;;6.0;;10.529999732971191;;2.2300000190734863;;39.84000015258789;LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoskeletal disorders with high unmet medical need, today announced that it presented preliminary clinical data from the Part 2 multiple ascending dose (“MAD”) portion of its Phase 1 clinical trial of KER-012 in;16.290000915527344;;21.170000076293945;SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 246,600 shares of its common stock to thirteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as indu;4.289999961853027;;14.149999618530273;;4.079999923706055;Data support continued advancement of LB101 toward IND submission late this yearBOSTON and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today announced non-clinical pharmacokinetic (PK) and safety data in non-human primates (NHPs) for LB101 (PD-L1xCD47), its first LockBody;7.309999942779541;;16.450000762939453;;28.200000762939453;If you want to know who really controls Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ), then you'll have to look at the...;21.530000686645508;;25.84000015258789;SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncolog;21.010000228881836;;19.200000762939453;;3.009999990463257;;13.449999809265137;
2022-09-13;161.3300018310547;;46.189998626708984;;306.4800109863281;;106.04000091552734;;138.52999877929688;"This adage is a terrific way to illustrate that buying quality stocks when demand is low will pay off when demand is up.  As Warren Buffet once said, ""Whether we're talking about socks or stocks, I like buying quality merchandise when it is marked down.""  ""Best-in-breed"" companies that have massive moats and pay impressive yields are a great place to start, and Amazon (NASDAQ: AMZN), Intuitive Surgical (NASDAQ: ISRG), and AbbVie (NYSE: ABBV) are three fantastic examples.Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX® Cosmetic 'See Yourself' campaign. After receiving nearly 20,000 submissions to its first-ever open casting call, BOTOX® Cosmetic, the #1 selling product of its kind1, is creating a content series that captures inspiring and intimate accounts of people speaking candidly about how they seWhen it comes to finding a great dividend stock to add to your investment portfolio, there's a wide variety of stocks to choose from.  David Jagielski: In June, dividend stalwart Abbott Laboratories announced it was paying a dividend for the 394th quarter in a row.  At first glance, the healthcare company's dividend yield of 1.8% may look humdrum given that the S&P 500 average yield is 1.7%.AbbVie (ABBV) closed the most recent trading day at $142.24, moving +0.58% from the previous trading session.";81.94999694824219;;86.27999877929688;;58.9900016784668;"Reuters reports that a U.S. judge dismissed a shareholder lawsuit claiming AstraZeneca Plc (NASDAQ: AZN) concealed problems in developing its COVID-19 vaccine, making it unlikely to win FDA approval. The judge said the proposed action failed to identify any misleading statements or adequately allege that AstraZeneca intended to defraud shareholders. Shareholders said AstraZeneca stock fell in late 2020 and early 2021 as it became clear that clinical trials for its vaccine had been ""hamstrung"" byAstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States.  U.S. District Judge Paul Oetken in Manhattan said AstraZeneca shareholders in the proposed class action failed to identify any misleading statements, or adequately allege that the Britain-based company intended to defraud them.  Shareholders said the price of AstraZeneca's American depositary shares fell in late 2020 and early 2021 as it became clear that clinical trials for its vaccine had been ""hamstrung"" by design and execution flaws and poor communications with regulators and the public.NEW YORK (Reuters) -AstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States.  U.S. District Judge Paul Oetken in Manhattan said AstraZeneca shareholders in the proposed class action failed to identify any misleading statements, or adequately allege that the Britain-based company intended to defraud them.  Shareholders said the price of AstraZeneca's American depositary shares fell in late 2020 and early 2021 as it became clear that clinical trials for its vaccine had been ""hamstrung"" by design and execution flaws and poor communications with regulators and the public.AstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that the company failed to disclose problems in developing its COVID-19 vaccine, making it unlikely to win regulatory approval to market the vaccine in the United States.  U.S. District Judge Paul Oetken in Manhattan said AstraZeneca shareholders in the proposed class action failed to identify any misleading statements, or adequately allege that the company intended to defraud them.  AstraZeneca and its lawyers did not immediately respond to similar requests.";71.04000091552734;Companies in The News Are: AAPL, BMY, TWTR, GILDRecently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.Finding stock picks to beat the market are rare finds nowadays. In September stock markets began on downbeat momentum following the S&P 500 rally throughout the summer. Euphoria gave way to a market slump. Markets reversed their mood when the Federal Reserve reiterated a tough stance during the annual meeting at Jackson Hole.InvestorPlace - Stock Market News, Stock Advice & Trading Tips The September slump created seven screaming picks to beat the market for investors. AAPL Apple $163.43 BMY BriCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday.  On Sunday, Clovis reported that Rubraca tested very well as a monotherapy for ovarian cancer in the initial part of a phase 3 trial.  All told, 538 women suffering from high-grade ovarian, fallopian tube, or primary peritoneal cancer took part in the trial.The stock market was in rally mode again after the Nasdaq and S&P 500 jumped above their 50-day moving averages Friday.Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.By Greg MeyersShares of drug giant Bristol-Myers Squibb  gapped higher Monday, as traders reacted to a positive update on their psoriasis medicine Sotyktu.  A decline got moving on the downside in August including a downside price gap.Energy and technology shares powered U.S. stock indexes to their highest in more than two weeks on Monday ahead of a crucial inflation reading this week that could determine the pace of interest rate hikes by the Federal Reserve.  All eyes are on consumer prices data on Tuesday for any signs that price pressures may be easing.  Headline inflation is expected to rise at an 8.1% pace over the year in August, compared with 8.5% in July.Bristol Myers Squibb received good news from the FDA, but only enough to put a key resistance level in play. Here's the level it needs to clear.;40.529998779296875;Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.Sanofi (SNY) closed at $41.49 in the latest trading session, marking a +1.69% move from the prior day.;31.6299991607666;;13.359999656677246;"OSAKA, Japan, September 13, 2022--Takeda (TSE:4502/NYSE:TAK) today announced four new partnerships to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare for people in developing and emerging countries. Even the best clinics and hospitals are unable to offer consistent, appropriate, quality care if people cannot access them; a strong health workforce, sustainable supply chains, appropriate resources, and much more are key to buildi";42.61000061035156;;9.489999771118164;Finding stock picks to beat the market are rare finds nowadays. In September stock markets began on downbeat momentum following the S&P 500 rally throughout the summer. Euphoria gave way to a market slump. Markets reversed their mood when the Federal Reserve reiterated a tough stance during the annual meeting at Jackson Hole.InvestorPlace - Stock Market News, Stock Advice & Trading Tips The September slump created seven screaming picks to beat the market for investors. AAPL Apple $163.43 BMY Bri;222.77999877929688;Repligen Corporation ( NASDAQ:RGEN ) led the NASDAQGS gainers with a relatively large price hike in the past couple of...;8.5;;150.91000366210938;;102.69999694824219;;10.789999961853027;;28.729999542236328;;43.09000015258789;;9.619999885559082;;13.34000015258789;;29.530000686645508;;65.05000305175781;WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its fireside chat at an upcoming investor conference hosted by Bank of America. Updated Conference Details Bank of America Global Healthcare Conference: Fireside chat on Friday, September 16, 2022 at 9:55 a.m. BST / 4:55 a.m. ET. The conference events will be available via a live webcast from the “Events a;238.47999572753906;;5.409999847412109;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting with the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab, a novel CD47 antibody, in combination with";29.18000030517578;;2.119999885559082;;4.909999847412109;;;;3.549999952316284;;5.639999866485596;;45.849998474121094;;;;22.8700008392334;;8.649999618530273;;5.699999809265137;;9.949999809265137;;2.2200000286102295;;39.400001525878906;;15.760000228881836;;21.1299991607666;;3.9800000190734863;;12.640000343322754;;4.260000228881836;;7.230000019073486;;15.619999885559082;;26.760000228881836;;20.440000534057617;;23.75;;21.559999465942383;;19.190000534057617;;2.7100000381469727;;13.100000381469727;
2022-09-14;164.66000366210938;Johnson & Johnson affirmed its full-year outlook and announced a new $5 billion buyback. Should you be a buyer right now?;46.150001525878906;;309.6099853515625;;105.04000091552734;Pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca got a ratings boost from Berenberg analysts from their respective returns on R&D investment, and ability to withstand pressure coming from recent U.S price reform.;139.5500030517578;AbbVie today announced the start of its two-week public voting period for the 2022 Thriving Undergraduate and Graduate Scholarships. Following this voting period, scholarships totaling $25,000 each will be awarded to two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system.There is little enthusiasm about coming study results for treatments targeting the protein amyloid beta, so there is upside for risk-seeking investors.;80.91000366210938;;86.94999694824219;;58.720001220703125;Pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca got a ratings boost from Berenberg analysts from their respective returns on R&D investment, and ability to withstand pressure coming from recent U.S price reform.;70.47000122070312;Alyssa Johnsen, vice president and head of clinical development, Immunology and Fibrosis, shares her perspective on the great strides that have been made in the science of modulating the body’s imm...Pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca got a ratings boost from Berenberg analysts from their respective returns on R&D investment, and ability to withstand pressure coming from recent U.S price reform.By Peter Nurse;40.04999923706055;Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n;31.200000762939453;Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.;13.380000114440918;When dividend stocks dip in price and go on sale, they can create buying opportunities for long-term investors.  Takeda Pharmaceuticals (NYSE: TAK) and Verizon Communications (NYSE: VZ) are both at multi-year lows, and here's why they could be attractive options for a $5,000 investment.  Takeda Pharmaceuticals is one of the largest drug companies in the world.Takeda (TSE:4502/NYSE:TAK) today announced the national launch of the CDPATH™ program, which includes an innovative, validated personalized prognostic tool that uses blood tests† to help predict the potential risk of developing serious Crohn's disease-related complications within three years.1,2 CDPATH is available for use by US-based physicians and offered at no cost to eligible patients††, providing an opportunity for patients to partner with their physicians to map out a personalized disease;42.439998626708984;;9.430000305175781;;227.02999877929688;;8.239999771118164;;151.1199951171875;;106.61000061035156;;10.680000305175781;;28.6200008392334;;43.4900016784668;;9.609999656677246;;13.229999542236328;;29.649999618530273;;66.66999816894531;;243.86000061035156;;5.320000171661377;;30.0;;2.0899999141693115;;5.380000114440918;;;;3.549999952316284;;6.409999847412109;;45.27000045776367;;;;22.719999313354492;Looking at Emergent BioSolutions Inc.'s ( NYSE:EBS ) insider transactions over the last year, we can see that insiders...;8.989999771118164;;5.610000133514404;;9.84000015258789;;2.25;;39.849998474121094;;16.209999084472656;;21.34000015258789;;4.0;;13.8100004196167;The consensus price target hints at a 262% upside potential for GH Research PLC (GHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;4.639999866485596;- Registrational studies planned to start in 4Q 2022 - - Two-year data from Phase 2a Open Label Extension study expected in 4Q 2022 - BOSTON and LONDON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan;7.300000190734863;;15.869999885559082;;28.90999984741211;;19.219999313354492;;23.31999969482422;;21.790000915527344;;19.0;Company announcement – No. 40 / 2022 Zealand Pharma grants warrants to employees in Denmark Copenhagen, DK and Boston, MA, September 13, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces granting of warrants to employees in accordance with Zealand's Remuneration policy and overall guidelines for incentive pay, as adopted at the annual genera;2.7899999618530273;;13.220000267028809;
2022-09-15;165.0800018310547;Style Box ETF report for VONVRight now, analysts up and down Wall Street are pounding the table on a little-known biotech company called MindMed (NASDAQ: MNMD).  MindMed's lead candidate is MM-120, a proprietary formulation of lysergic acid diethylamide, better known as LSD.  MindMed is developing MM-120 for the treatment of generalized anxiety disorder (GAD).Johnson & Johnson (NYSE: JNJ) has had its ups and downs this year, to put it tactfully.  Before the trading day opened, Johnson & Johnson announced that its board of directors has authorized a $5 billion share repurchase program for the company's common stock.  As is typical for such initiatives, Johnson & Johnson said it will repurchase its own stock from time to time, at its own discretion.If you’re looking for dividend stocks to buy and hold forever, a good place to start is companies that have done an excellent job increasing their dividends and are expected to keep doing so in the future. While the first place to look for such names should logically be a list of S&P 500 Dividend Aristocrats, I widened the search to the S&P 1500. That way, I had three times more stocks to choose from, giving me a much better chance of finding special dividend stocks that deliver income and capit;45.939998626708984;;309.4700012207031;Eli Lilly (LLY) closed at $309.61 in the latest trading session, marking a +1.02% move from the prior day.;103.20999908447266;;142.50999450683594;AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the 2022 International Parkinson and Movement Disorder Society's (MDS) International Congress, taking place in Madrid, Spain, from September 15-18. A total of 13 abstracts will be presented across multiple disease states, including Parkinson's disease, spasticity and cervical dystonia.;80.73999786376953;"Half Year 2022 Oxford BioMedica PLC Earnings CallThe Swiss competition commission (COMCO) has initiated an investigation against Novartis AG (NYSE: NVS) over the alleged unlawful patent use to reduce competitive pressure. COMCO conducted an early morning raid on the company; however, it did not reveal the company's name in its statement. Meanwhile, the pharma major released a press release stating it is under investigation. ""The company allegedly attempted to protect its drug for the treatment of skin diseases against competing products by usiThe probe into Novartis's assertion of a patent in the broader field of dermatology treatments doesn't imply wrongdoing or financial impact, the company said.Company confident to clarify legitimacy of its position and fully cooperating with authorities Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss Competition Commission (COMCO) which has initiated an investigation, in collaboration with the European Commission, into the assertion of a patent in the broader field of dermatology treatments. In connection with this investigation, COMCO representatives visited the company headquarters in Basel. The opening ofThe Swiss competition commission (COMCO) has opened an investigation of Novartis over possible unlawful use of a patent to reduce competitive pressure, the Swiss drugmaker confirmed on Thursday.  COMCO conducted an early morning raid on the company on Sept. 13, it said in a statement that did not name Novartis, which subsequently said in its own statement that it was the group under investigation.  ""The company allegedly attempted to protect its drug for the treatment of skin diseases against competing products by using one of its patents to initiate litigation proceedings,"" COMCO said in a statement.By Scott KanowskyEuropean stock markets edged higher Thursday, stabilizing after losses earlier in the week, but sentiment remains fragile as investors fret about the impact of tightening monetary policy as economic growth slows.  U.K. consumer confidence slipped into negative territory for the first time since the pandemic lockdown in the middle of 2020, while French consumer prices grew more than expected in August.  At the moment the inflation battle is uppermost in their minds, with the European Central Bank hiking interest rates by a hefty 75 basis points last Thursday, just weeks after a 50 basis point move, and promising several more steps over the coming months.A federal judge dismissed a whistleblower lawsuit accusing Novartis AG (NYSE: NVS) of paying doctors kickbacks at ""sham"" speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya. U.S. District Judge Kimba Wood dismissed the whistleblower lawsuit, arguing that former Novartis sales representative Steven Camburn did not provide enough detail to support his claims. Camburn's lawyer says he and his client plan to appeal the decision, adding that they're confident th";86.75;Pharmaceutical giant Merck (NYSE: MRK) delivered outstanding second-quarter results in July, largely driven by its mainstay cancer blockbuster, Keytruda.  The company reported 28% year-over-year total revenue growth and continues to develop Keytruda for new cancer indications.  Under the radar, however, Keytruda returned some bad news in three separate late-stage clinical trials this summer.The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth.  The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease.  Looking out over the long term, Merck's pipeline is just as strong as its existing products.Merck, Cisco, Morgan Stanley, CME Group and Canadian Natural Resources are included in this Analyst Blog.Merck (MRK) closed at $86.95 in the latest trading session, marking a +0.78% move from the prior day.Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Cisco Systems, Inc. (CSCO) and Morgan Stanley (MS).Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.;58.13999938964844;Q2 2022 Innate Pharma SA Earnings CallThe worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.;71.77999877929688;PRINCETON, N.J., September 15, 2022--BMS Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement....In the latest trading session, Bristol Myers Squibb (BMY) closed at $70.47, marking a -0.8% move from the previous day.Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.NEW YORK, September 14, 2022--Bristol Myers Squibb Announces DividendThe FDA approval of Sotyktu for psoriasis has ignited and dampened prospects for smaller biotech stocks.Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.;40.66999816894531;Q2 2022 Innate Pharma SA Earnings Call;31.020000457763672;GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.;13.40999984741211;Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.;42.16999816894531;;9.550000190734863;;232.22000122070312;;8.369999885559082;SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombi;151.14999389648438;;109.29000091552734;;10.479999542236328;;28.75;;43.5;SOMERSET, N.J., September 15, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5th Avenue in New York City. Please click here to register for the event.;9.640000343322754;;12.069999694824219;;29.889999389648438;;64.75;;244.05999755859375;;5.420000076293945;;30.420000076293945;;2.059999942779541;;4.965000152587891;;;;3.6600000858306885;;6.429999828338623;;44.939998626708984;;;;23.059999465942383;;8.75;;5.440000057220459;;10.319999694824219;;2.3499999046325684;;39.70000076293945;;16.3700008392334;SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of drug strategic development experience in the biopharmaceutical and biotechnology industries, and currently serves as Head of Biotech Strategy at Lumanity Inc., a global pharmaceutical and biotechnology adv;21.3700008392334;;4.139999866485596;;12.539999961853027;;4.75;;7.300000190734863;;16.3799991607666;;28.75;;18.690000534057617;;22.780000686645508;;22.219999313354492;;19.0;;2.859999895095825;;13.079999923706055;
2022-09-16;167.60000610351562;J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.Warren Buffett, Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) chief executive officer and chairman, has been investing since the age of 11.  With his net worth at nearly $100 billion, the understatement of the century would be to say that Buffett knows a thing or two about investing.  This is why it's worth paying attention to the holdings within Berkshire Hathaway's $344 billion investment portfolio.(Bloomberg) -- 3M Co., facing more than 200,000 lawsuits accusing it of harming soldiers with defective combat earplugs, opens a new round of mediation Thursday overseen by the same federal judge the industrial conglomerate has been feuding with since July.Most Read from BloombergAdobe Near Deal for Online Design Startup Figma, Sources SayRay Dalio Does the Math: Rates at 4.5% Would Sink Stocks by 20%Putin Acknowledges Xi’s ‘Concerns’ on Ukraine, Showing TensionAdobe Tumbles After Deal to Buy FiJ&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.;46.029998779296875;;308.8900146484375;In that spirit, let's examine two healthcare stocks that seem to have the tools to provide solid returns over the long term: Eli Lilly (NYSE: LLY) and Teladoc Health (NYSE: TDOC).  Eli Lilly seems to excel in both areas.  Take one of the company's most recent approvals: Mounjaro, a therapy used to control blood glucose levels in patients with type 2 diabetes.;101.41999816894531;;144.05999755859375;Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter. The new National Biotechnology and Biomanufacturing Initiative is designed to encourage biotech production in the U.S. An executive order signed by President Joe Biden on Sept. 12, was followed by a White House summit featuring Cabinet-level initiatives that will increase the nation’s biotech and biomanufacturing capabilities. This;80.6500015258789;Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.;87.72000122070312;Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.RAHWAY, N.J., September 16, 2022--Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children;58.04999923706055;J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.WILMINGTON, Del., September 16, 2022--A prespecified interim analysis of the ALPHA Phase III trial evaluating danicopan (ALXN2040), an investigational, oral factor D inhibitor, as an add-on to C5 inhibitor therapy ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) showed positive high-level results in patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH).The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has backed using AstraZeneca Plc's (NASDAQ: AZN) COVID-19 drug treatment. AstraZeneca said the EMA had backed Evusheld as a treatment for adults and adolescents with COVID who do not need supplemental oxygen and are at increased risk of worsening their disease. The antibody cocktail was previously only approved as a preventative treatment for people with compromised immune systems who see little or nAstraZeneca Plc (NASDAQ: AZN) said its Danicopan add-on anti-blood-clotting drug met a primary endpoint in the ALPHA phase 3 trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH). A prespecified interim analysis of the Phase 3 trial evaluating danicopan (ALXN2040) as an add-on to C5 inhibitor therapy Ultomiris (ravulizumab) or Soliris (eculizumab) showed positive results. Related: AstraZeneca Settles Ultomiris-RelatedEurope's medicines regulator has backed using AstraZeneca's preventative COVID-19 drug as a treatment for the disease and also endorsed its therapy against a major cause of pneumonia.  The regulator's recommendations are usually followed by the European Commission when it takes a final decision on drug approvals.  AstraZeneca said on Friday the European Medicines Agency (EMA) had backed Evusheld as a treatment for adults and adolescents with COVID who do not need supplemental oxygen and who are at increased risk of their disease worsening.WILMINGTON, Del., September 15, 2022--Today, AstraZeneca (Nasdaq: AZN) launched Up The Antibodies, an important new campaign that embraces the reality for millions of immunocompromised Americans1,2: COVID-19 isn’t over. While it feels like life has gone back to normal for many, this community still has very real cause for concern. Now, an added layer of COVID-19 protection can help people who are immunocompromised start to get back out into the world, doing what they love with whom they love.;71.5199966430664;The New York-based Initiative for Medicines, Access & Knowledge (I-MAK) said in a report that three of the top 10 selling drugs in the U.S. face no competition in the country and will cost Americans an estimated further $167 billion before they are expected to so.  I-MAK said cheaper generic and biosimilar versions of Bristol-Myers Squibb and Pfizer's  blood clot preventer Eliquis, AbbVie's Humira, and Amgen's Enbrel, both used to treat rheumatoid arthritis, will have been available in Europe for an average of 7.7 years before their expected U.S. launch.  AbbVie, Amgen, Bristol-Myers Squibb, and Pfizer, did not immediately respond to requests for comment.The latest clinical news from Bristol Myers Squibb (NYSE: BMY) was quite encouraging, sufficient to drive the pharmaceutical giant's stock higher on an otherwise uninspired day for the broader stock market.  Bristol Myers Squibb's share price experienced a nearly 2% bump, a notably better showing than the S&P 500 index's more than 1% decline.  Bristol Myers Squibb's good news from the lab was that its enduringly popular cancer drug Opdivo did quite well in its latest round of testing.Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate -76K trial evaluating Opdivo (nivolumab) in melanoma patients. Opdivo as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo. Related: Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis. No new safe;40.81999969482422;CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants Recommendation is based on the Beyfortus clinical trial program which demonstrated protection against medically attended lower respiratory tract infection caused by RSV with a single dose during the RSV seasonIf approved, Beyfortus would be the first broadly protective option for newborns and infants Paris, September 16, 2022. The European Medicines Agency’s Committee for Medicinal Products for Human UseRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published positive results from a Phase 3 Dupixent® (dupilumab) trial in children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis. These data were the basis for the U.S. Food and Drug Administration (FDA) approval of Dupixent in June 2022 and for a regulatory submission currently under review by the European Medicines Agency.;30.829999923706055;GSK (GSK) closed the most recent trading day at $31.02, moving -0.58% from the previous trading session.;13.449999809265137;OSAKA, Japan & CAMBRIDGE, Mass., September 16, 2022--Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem c;41.95000076293945;;9.300000190734863;;221.32000732421875;;8.449999809265137;;151.07000732421875;;107.33000183105469;;10.170000076293945;"Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today officially launched the construction of its J.POD ® biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France.";28.610000610351562;;42.790000915527344;;9.569999694824219;As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...;12.100000381469727;;28.360000610351562;;62.560001373291016;;239.35000610351562;Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?;5.079999923706055;;28.100000381469727;;2.049999952316284;Shareholders Approve All Measures at First Annual Meeting of StockholdersNEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (Nasdaq: TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company’s board of directors and approved all other shareholder proposals during the company’s first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Healt;4.599999904632568;;;;3.4700000286102295;;6.059999942779541;;43.84000015258789;;;;22.950000762939453;;8.119999885559082;;5.25;LAUSANNE, Switzerland, September 16, 2022--ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The positive opinion from the CHMP is now referred to the European Commission for an;9.399999618530273;;2.3399999141693115;;36.7599983215332;;15.5600004196167;;20.59000015258789;;3.859999895095825;;12.960000038146973;;4.309999942779541;;6.96999979019165;;15.569999694824219;;27.5;;17.850000381469727;;21.540000915527344;;20.850000381469727;;18.145999908447266;;2.6500000953674316;;12.520000457763672;
2022-09-19;166.27999877929688;Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.;45.439998626708984;;305.0899963378906;;101.23999786376953;;142.66000366210938;Building up a quarterly stream of passive income through shares of dividend-paying stocks is a dream for many investors, but a lot of people approach it the wrong way.  You can't expect to build up a huge amount of passive revenue overnight, and you'll need to have the right strategy to accumulate shares of dividend stocks that will be stable in the long term.  Let's work through an example with the pharmaceutical company AbbVie (NYSE: ABBV) to see how dividend reinvestment can boost your returns.The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of AbbVie Inc's (NYSE: ABBV) risankizumab regime for Crohn's disease. The recommendation comes for Skyrizi (600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) for active Crohn's disease who have had an inadequate response, lost response, or was intolerant to conventional or biologic therapy. Related: AbbVie Psoriatic Arthritis Drug Shows Long-AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CMHP) adopted a positive opinion recommending the approval of risankizumab (SKYRIZI®, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.;80.7300033569336;AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in postmenopausal women with osteoporosisOsteoporosis accounts for 8.9 million bone fractures annually, including debilitating hip fractures – a number set to increase substantially over next two decades1 Positive trial results follow filing acceptances for two other proposed Sandoz biosimilars, adalimumab HCF;86.63999938964844;AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.;57.9900016784668;CHMP recommends authorizing AstraZeneca's (AZN) Evusheld as a COVID-19 treatment and its RSV vaccine, nirsevimab in Europe.AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.;70.19000244140625;It's hard to imagine a world in which pharmaceutical spending doesn't increase year in and year out.The European Commission approved Bristol Myers Squibb & Co's (NYSE: BMY) fixed-dose combination of Opdualag (nivolumab and relatlimab) for melanoma patients aged 12 years and above. Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) in the skin. The approval covers the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents with tumor cell PD-L1 expression < 1%. Also Read: Melanoma Study AchBristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.;40.59000015258789;It's hard to imagine a world in which pharmaceutical spending doesn't increase year in and year out.;30.780000686645508;Theravance Biopharma Inc. said Monday its board has authorized a $250 million capital return program, that includes buying back its own stock from GSK Plc . The company will purchase GSK's entire holdings of about 9.6 million shares at $9.75 a share with the closing expected Tuesday. The company also plans to launch a Dutch auction tender offer in the near term to buy about $95 million of its ordinary shares. It will then enter an open market share buyback plan to use the additional roughly $60;13.399999618530273;OSAKA, Japan & CAMBRIDGE, Mass., September 19, 2022--Takeda (TSE:4502/NYSE:TAK) and Enel North America today announced the signing of a long-term virtual power purchase agreement (VPPA) for the electricity delivered to the power grid from a 79 megawatt (MW) portion of Enel’s Seven Cowboy wind project in the state of Oklahoma in the U.S. The agreement, advised by Edison Energy LLC, advances progress towards achieving Takeda’s goals of reducing 40 percent of scopes 1 and 2 greenhouse gas (GHG) emi;41.650001525878906;;9.289999961853027;;225.1999969482422;The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.;8.270000457763672;;151.2100067138672;"Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (""Biohaven"") today announced that it has set a record date of September 26, 2022 (the ""Record Date"") for the previously announced spin-off by Biohaven of its Biohaven Ltd. (""SpinCo"") subsidiary, which will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Biohaven. The completion of";105.26000213623047;;9.989999771118164;;28.299999237060547;;42.0;;9.069999694824219;;10.949999809265137;;28.049999237060547;;63.79999923706055;;234.83999633789062;;5.0;;27.520000457763672;;1.9700000286102295;;4.760000228881836;;;;3.549999952316284;;5.510000228881836;;43.54999923706055;;;;22.5;;7.300000190734863;;5.480000019073486;;9.670000076293945;;2.2699999809265137;;37.150001525878906;;14.789999961853027;;20.270000457763672;;3.700000047683716;;12.550000190734863;;4.650000095367432;;6.956999778747559;;15.34000015258789;;27.040000915527344;;18.489999771118164;;20.540000915527344;;20.5;;17.149999618530273;Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly reduced the requirement for intravenous glucose to maintain glycemia in newborns and infants with CHI (Part 1 of Phase 3 trial)Dasiglucagon reduced time in hypoglycemia and enabled discontinuation of intravenous glucose in most infants and limited the need for pancreatectomy (Part 2 of Phase 3 trial)Results support t;2.630000114440918;;12.170000076293945;
2022-09-20;164.97000122070312;"BRISBANE, Calif., September 20, 2022--Johnson & Johnson (NYSE: JNJ) (the Company) today opened its San Francisco Bay Campus, a state-of-the-art Research & Development (R&D) facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by coAn outbreak of Ebola has been declared in Uganda after health authorities confirmed a case of the relatively rare Sudan strain, the health ministry and World Health Organization (WHO) said on Tuesday.  A 24-year-old man in Uganda's central Mubende district showed symptoms and later died.  ""We want to inform the country that we have an outbreak of Ebola which we confirmed yesterday,"" Diana Atwine, the health ministry's permanent secretary, told a news conference.People suing Johnson & Johnson over the company's talc products urged an appeals court on Monday to revive their claims, saying the profitable company should not be allowed to use a bankrupt subsidiary to block lawsuits alleging the products cause cancer.  They asked a panel of the Philadelphia-based 3rd U.S. Circuit Court of Appeals to dismiss the bankruptcy of J&J's subsidiary LTL Management, saying that LTL is a ""concocted"" corporation set up solely to stop them from getting their day in court.  J&J, which maintains its talc products are safe, spun off LTL in October, assigned its talc liabilities to it and placed the newly created subsidiary into bankruptcy days later.The latest pronouncements by the president aren't exactly doing the two healthcare companies any favors.In the latest trading session, Johnson & Johnson (JNJ) closed at $166.28, marking a -0.79% move from the previous day.Due to their well-established nature and track records of success, these companies are positioned to weather a dark fiscal cloud better than most.";44.77000045776367;;301.7300109863281;While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...;99.45999908447266;SNY vs. NVO: Which Stock Is the Better Value Option?;141.77000427246094;These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.Apple, Amazon, AbbVie, Philip Morris International and BlackRock are included in this Analyst Blog.Insiders were net sellers of AbbVie Inc.'s ( NYSE:ABBV ) stock during the past year. That is, insiders sold more stock...AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session.Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Amazon.com, Inc. (AMZN) and AbbVie Inc. (ABBV).Based on Monday's view of an IBD-produced screen, they now include small-cap enterprise software firm Model N, lithium metal producer Albemarle, electrical equipment firm Hubbell and trendy footwear and apparel firm Deckers Outdoor.  In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.;79.58000183105469;Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.;86.0;Merck & Co Inc (NYSE: MRK) will initiate a new Phase 3 program with once-daily islatravir to treat people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir (DOR/ISL). One study will evaluate DOR/ISL in previously untreated adults with HIV-1 infection, and two studies will evaluate DOR/ISL as a switch in antiretroviral therapy (ART) in adults with HIV-1 infection virologically suppressed. Certain study pThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...The ‘70s are coming back in a big way, and while that’s not so bad in fashion or in music, it’s safe to say that no one really wants that ‘70s economy back. That was the decade that brought stagflation, a nasty mix of high inflation, increasing unemployment, and stagnant job growth. Economists had long thought that combo impossible, but the economic mismanagement of the Carter Administration proved them wrong. At least one top economist, Mohamed El-Erian from Allianz, sees a stagflationary perioMerck & Co Inc said on Tuesday it would start fresh late-stage studies of its HIV treatment, islatravir, months after the U.S. Food and Drug Administration put the trials on hold, citing safety concerns.  The FDA has reviewed and agreed with the plan to study lower-dose versions of the once-daily pill for treating HIV patients, the company said.  The drugmaker, however, said it was discontinuing development of a once-a-month dose of islatravir for preventing HIV infection.RAHWAY, N.J., September 20, 2022--Merck to Start New Ph 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1The EMA's CHMP recommends approving Merck's (MRK) pneumococcal 15-valent conjugate vaccine for expanded use in infants and children. The vaccine received similar approval from the FDA in June 2022.;57.400001525878906;The European Commission has approved AstraZeneca plc's (NASDAQ: AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination as COVID-19 treatment in adults and adolescents. The approval comes for COVID-19 patients who do not require supplemental oxygen and are at increased risk of progressing to severe COVID‑19. The approval was based on results from the TACKLE Phase 3 trial, which showed that one intramuscular dose of Evusheld provided clinically and statist;69.7300033569336;By Karin Shanahan, Executive Vice President, Global Product Development and SupplyOne of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Based on Monday's view of an IBD-produced screen, they now include small-cap enterprise software firm Model N, lithium metal producer Albemarle, electrical equipment firm Hubbell and trendy footwear and apparel firm Deckers Outdoor.  In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.;39.939998626708984;SNY vs. NVO: Which Stock Is the Better Value Option?Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.  More than 2,000 legal cases related to Zantac have been filed in the United States over allegations that the compound contains a probable carcinogen.  Zantac, originally marketed by a forerunner of GSK, has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi as well as a plethora of generic drugmakers.Sanofi (SNY) closed at $40.59 in the latest trading session, marking a -0.56% move from the prior day.The CHMP recommends authorizing Sanofi's (SNY) Enjaymo as a treatment for hemolytic anemia in patients with cold agglutinin disease (CAD). The CHMP endorses SNY's RSV vaccine for use in infants.;30.489999771118164;"These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.Haleon Plc (NYSE: HLN) notified GSK Plc (NYSE: GSK) and Pfizer Inc (NYSE: PFE) that it had rejected their requests for indemnification concerning U.S.-based litigation over the heartburn drug, Zantac. In a statement, Haleon said the rejection is based on the scope of the indemnities set out in the joint venture agreement, only covering their consumer healthcare businesses as conducted when the JV was formed in 2018. Over 2,000 cases related to Zantac have been filed in the U.S. over the allegedTheravance Biopharma Inc (NASDAQ: TBPH) is buying back over 9.6 million shares from GSK plc (NYSE: GSK) for roughly $94 million, according to an SEC filing. In addition, Theravance plans to buy back $95 million from its existing investors ""in the near term"" and another $60 million in its shares on the open market. In a press release, Theravance says it hopes to complete that part of its plan by the end of 2023. Related content: Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patien";13.220000267028809;"Takeda Canada Inc. (""Takeda"") is pleased to announce that Health Canada has authorized (Notice of Compliance) LIVTENCITY™ (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 Compared to conventionally used antivirals to treat post-transplant CMV, LIVTENCITY offers twice the efficacy1 and more than 10 times less toxicity.1*";41.02000045776367;;9.039999961853027;;214.8699951171875;Repligen Corporation (NASDAQ: RGEN) entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market. Through this agreement, Repligen will assume responsibility for the commercialization of Culpeo and the development of future products and technologies in partnership with DRS Daylight Solutions. Also read: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says. Both companiesSigns 15-year Strategic Collaboration and Exclusive License AgreementWALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market. Through this agreement, Repligen will assume responsibility for the c;8.449999809265137;;151.25;;107.56999969482422;;9.420000076293945;"Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) today announced that the U.S. Department of Defense (""DOD"") has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid development of monoclonal antibody (""mAb"")-based drug product prototypes targeting plague. Plague, an infectious disease caused by the bacterium Yersinia pestis ("" Y .";27.299999237060547;;41.38999938964844;;9.0;;10.9399995803833;;27.530000686645508;;63.560001373291016;;241.8800048828125;;5.0;;26.799999237060547;;1.940000057220459;;4.849999904632568;;;;3.4000000953674316;;5.440000057220459;;43.43000030517578;;;;21.790000915527344;;7.389999866485596;;5.289999961853027;;9.479999542236328;;2.2899999618530273;;36.869998931884766;;13.069999694824219;;19.920000076293945;;3.6700000762939453;;11.600000381469727;;4.579999923706055;– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) –– Company recognizes World Narcolepsy Day on September 22nd – BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been accepted for poster presentation at the 26th Conference of the European Sleep Research Society meeting (S;6.75;;15.0;;26.729999542236328;;19.229999542236328;Roflumilast cream showed higher efficacy compared to vehicle in both Phase 3 studies on the primary efficacy endpoint of Investigator Global Assessment (IGA) success, with 40% of roflumilast cream treated patients achieving IGA success at eight weeksRoflumilast cream also demonstrated statistically significant improvements over vehicle in key secondary endpoints with ~70% of patients achieving Intertriginous-IGA success and ~40% of patients achieving PASI-75 at eight weeksImprovement in itch occ;19.68000030517578;;20.959999084472656;;17.618000030517578;;2.8399999141693115;First use of Ciitizen platform as source of real-world data in regulatory filingSAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developm;12.289999961853027;
2022-09-21;163.27999877929688;Johnson & Johnson (NYSE: JNJ) and Becton, Dickinson (NYSE: BDX) are set-it-and-forget-it dividend stocks in the healthcare sector.  For example, in the second quarter, the company's pharmaceutical segment was responsible for $13.3 billion in revenue, up 6.7%, year over year, while consumer healthcare brought in $3.8 billion, down 1.3% over the same period in 2021.Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.(Bloomberg) -- Johnson & Johnson faced tough questions from federal appellate judges about whether placing a unit in bankruptcy to deal with more than 40,000 cancer lawsuits over its baby powder was legitimate.Most Read from BloombergHome-Flipper Opendoor Hit With Losses in Echo of Zillow CollapseTycoon's Wild $3 Billion Gamble on ‘China's LVMH’ CrashesFed Set to Reveal ‘Pain’ Coming in Next Stage of Inflation FightSouthwest Mexico Struck by 7.5 Magnitude Earthquake, Buildings Sway in CapitalMar;43.91999816894531;The U.S. Centers for Disease Control and Prevention expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October.  The CDC said in a document released on Tuesday that it expects to make a recommendation in early- to mid-October on the use of the new bivalent vaccines in the group, if they are authorized by the U.S. Food and Drug Administration (FDA).  The vaccines, which target both the original version and the currently circulating variants of the virus, were rolled out for people 12 years or older earlier this month.It is hard to get excited after looking at Pfizer's (NYSE:PFE) recent performance, when its stock has declined 8.9...Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.;296.4800109863281;Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.These companies are leaders in their respective industries, and their stocks can be pillars for your portfolio.Eli Lilly (LLY) closed at $301.73 in the latest trading session, marking a -1.1% move from the prior day.The idea that anyone could have a problem with Joe Biden’s cancer moonshot is unimaginable. After all, who hasn’t had a friend or relative affected by cancer? My dad died from a combination of prostate and bone cancer. Now, you could argue that, at 81, old age might have done him in, regardless of the disease eating away at his body. But, the reality is that so many die much younger than my dad from various forms of cancer. It is a scourge to longevity everywhere. Biden’s cancer moonshot aims to;99.22000122070312;;140.30999755859375;AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.;77.54000091552734;"Sesen Bio Inc (NASDAQ: SESN) and privately held Carisma Therapeutics Inc have entered into a merger agreement to combine the companies in an all-stock transaction. The combined company will operate under the Carisma Therapeutics moniker under the ""CARM symbol"" and is expected to have approximately $180 million of cash and cash equivalents, including $30 million from concurrent financing by Carisma, which is expected to fund the company through 2024. Sesen Bio suffered FDA rejection for its leadBear markets are never fun.  Keeping with this theme, the 2022 bear market has created a slew of attractive buying opportunities.  Cosmetic surgery company InMode (NASDAQ: INMD),  Swiss pharma giant Novartis (NYSE: NVS), and diabetes care behemoth DexCom (NASDAQ: DXCM) are three highly profitable companies that have been unfairly punished by this irrational market.Swiss drug major Novartis AG (NYSE: NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing regimen patent. The decision comes as the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the decision regarding the patient validity covering a dosing regimen for 0.5mg Gilenya. In August 2020, the U.S. District Court for the District of Delaware issued a favorable decision. A permanent injunction was granted against HBy Scott KanowskyNovartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals court ruling, the Swiss drugmaker said on Wednesday.  The ruling meant HEC Pharma and other drugmakers would  potentially be able to launch a generic version of 0.5mg Gilenya imminently, pending any other judicial actions, it said.Ad hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans to file a petition seeking further review of the CAFC’s decision with the US Supreme Court. In August 2020, the U.S. District Court for the District of Delaware issued a favoEuropean stock markets are expected to open lower Wednesday, as investors braced for another hefty interest rate hike by the U.S. Federal Reserve, likely curbing growth in the world’s largest economy.  At 02:00 ET (06:00 GMT), the DAX futures contract in Germany traded 0.4% lower, CAC 40 futures in France dropped 0.3%, and the FTSE 100 futures contract in the U.K. fell 0.2%.  The Fed is widely expected to hike interest rates by at least 75 basis points following last week’s hotter-than-expected U.S. inflation reading, but some are also pricing in the possibility of a 100 bps hike.The idea that anyone could have a problem with Joe Biden’s cancer moonshot is unimaginable. After all, who hasn’t had a friend or relative affected by cancer? My dad died from a combination of prostate and bone cancer. Now, you could argue that, at 81, old age might have done him in, regardless of the disease eating away at his body. But, the reality is that so many die much younger than my dad from various forms of cancer. It is a scourge to longevity everywhere. Biden’s cancer moonshot aims to";84.52999877929688;Here are the three best Dow Jones stocks of 2022 so far -- and whether or not they're good picks to buy now.  Chevron (NYSE: CVX) ranks as the clear winner among Dow stocks this year.  After the Dow Jones booted ExxonMobil in 2020, Chevron was left as the only energy stock in the prestigious index.Merck (MRK) closed at $86 in the latest trading session, marking a -0.74% move from the prior day.The idea that anyone could have a problem with Joe Biden’s cancer moonshot is unimaginable. After all, who hasn’t had a friend or relative affected by cancer? My dad died from a combination of prostate and bone cancer. Now, you could argue that, at 81, old age might have done him in, regardless of the disease eating away at his body. But, the reality is that so many die much younger than my dad from various forms of cancer. It is a scourge to longevity everywhere. Biden’s cancer moonshot aims to;56.439998626708984;Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.The European Commission approved AstraZeneca Plc's (NASDAQ: AZN) Tezspire (tezepelumab) as an add-on maintenance treatment for severe asthma. The approval covers patients 12 years and above who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product. The approval was based on results from the PATHFINDER clinical trial programme, in which Tezspire demonstrated superiority across every primary and key secondary endpoint. Also Read: AstraZeneca's Blood ClotDon't let the bear market scare you into thinking these solid companies have become bad investments.;69.45999908447266;Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.;38.7599983215332;Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.Sanofi (SNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).;29.770000457763672;Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.To avert a collision of patents and safety regulations, the Supreme Court must ensure that a damaging ruling is quickly undone.;12.989999771118164;TAK vs. ZTS: Which Stock Is the Better Value Option?Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.Puma Biotechnology Inc (NASDAQ: PBYI) announced an agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK) to license the worldwide research and development and commercial rights to alisertib for cancer indications. Alisertib has been tested in metastatic cancers, including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, and acute myeloid leukemia. Under the terms of the agreement, Puma will assume sole responsibility for the global develo;40.70000076293945;;9.039999961853027;The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 percent compared to placeboNESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot injectable products, announced today positive top-line results from the GA Depo;206.49000549316406;;8.109999656677246;;151.14999389648438;;106.01000213623047;;9.170000076293945;Adapsyn Bioscience Inc, a chemical bioinformatics company, announced a strategic collaboration with Evotec SE (OTC: EVOTF) (NASDAQ: EVO). Under the collaboration, Evotec will have the opportunity to evaluate small molecules developed by Adapsyn as potential therapeutic candidates in proprietary and partnered drug discovery projects. The Adapsyn platform uses artificial intelligence and machine learning to identify and isolate novel drug-like metabolites from microbes for downstream assay and dev;26.799999237060547;;39.939998626708984;;8.789999961853027;;9.5;;26.690000534057617;;62.900001525878906;;231.83999633789062;;4.75;;26.06999969482422;;1.899999976158142;;4.610000133514404;;;;3.2899999618530273;;4.889999866485596;;42.779998779296875;;;;21.3700008392334;;7.179999828338623;;5.070000171661377;;9.079999923706055;;2.109999895095825;;35.5099983215332;;12.90999984741211;;19.56999969482422;;3.440000057220459;;11.600000381469727;;4.519999980926514;;6.75;;14.420000076293945;;24.719999313354492;;18.75;;18.299999237060547;;20.299999237060547;;18.155000686645508;Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) BI 456906 effectively lowered HbA1c up to -1.88% at week 16 in patients with type 2 diabetes in the Phase 2 clinical trialPreclinical pharmacology of BI 456906 supports ongoing Phase 2 studies in obesity or non-alcoholic steatohepatitis Copenhagen, Denmark and Boston MA, U.S. September 21, 2022 – Zealand Phar;2.8299999237060547;BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET. The event will be available v;12.15999984741211;
2022-09-22;166.17999267578125;Investors who have a high exposure to stocks in 2022 probably wish the year would end. Unless they raised their allocation in cash, their losses in the portfolio are mounting. The war in Ukraine earlier this year increased energy costs in Europe. This raised the pace of inflation. Globally, most countries faced unprecedented inflation rates. In turn, central banks collectively raised interest rates. This dynamic is pressuring investors to seek safe havens. Central banks are fearful that their feStyle Box ETF report for IWDSector ETF report for FHLCSmart Beta ETF report for DGRWMerck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir;44.56999969482422;"Pfizer Inc (NYSE: PFE) would supply up to 6 million courses of its COVID-19 antiviral treatment to NGO Global Fund for low- and middle-income countries. The company said Paxlovid treatment courses would be available for procurement through Global Fund's COVID-19 Response Mechanism to 132 low- and middle-income countries this year, subject to local regulatory clearances. Eligible countries will be offered treatment courses according to Pfizer's tiered pricing approach, where all low- and lower-miJPMorgan analyst Eric Joseph slashed his price target on Novavax by more than $100, to $27 per share.NEW YORK, September 22, 2022--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 fourth-quarter 2022 dividend on the company’s common stock, payable December 5, 2022, to holders of the Common Stock of record at the close of business on November 4, 2022. The fourth-quarter 2022 cash dividend will be the 336th consecutive quarterly dividend paid by Pfizer.Pfizer Inc. said Thursday it has reached an agreement to supply up to six million treatment courses of its COVID antiviral Paxlovid to the Global Fund for low and middle-income countries. The company said it expects supply to be available starting in 2022, pending regulatory authorization or approval and based on demand from individual countries. ""Through Global Fund's framework and mechanism, eligible countries will be offered treatment courses according to Pfizer's tiered pricing approach, whePfizer Inc said on Thursday it would supply up to 6 million courses of its COVID-19 antiviral treatment to NGO Global Fund for low- and middle-income countries that seeks to address worldwide disparities in COVID response.  The company said Paxlovid treatment courses will be available for procurement through Global Fund's COVID-19 Response Mechanism to 132 low- and middle-income countries this year, subject to local regulatory clearances.  While Paxlovid is widely available in many rich countries, availability has been severely restricted in poorer ones.NEW YORK, September 22, 2022--Pfizer Inc. (NYSE: PFE) announced today an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to Global Fund as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary channel for providing grant support to low- and middle-income countries to purchase COVID-19 tests, treatments, personal protective equipment and critical elements of healtSector ETF report for FHLC";310.8699951171875;The company’s last attempt to target the devastating disease flopped. Results from a key trial of Biogen and Eisai’s new drug, lecanemab, are coming soon—and have huge implications.Wall Street's main indexes fell on Thursday, extending declines for a third straight session, as investors worried that the U.S. Federal Reserve's aggressive approach to rein in inflation could trigger a recession.  Weighing on the S&P 500 and the Nasdaq, shares of megacap technology and growth companies such as Apple Inc, Amazon.com Inc, Tesla Inc and Nvidia Corp fell between 1.0% and 3.6% as benchmark U.S. Treasury yields hit an 11-year high.Wall Street's main indexes were set for a muted open on Thursday as investors assessed the impact on U.S. economic growth from the Federal Reserve's unwavering focus to rein in inflation through aggressive interest rate hikes.  The Nasdaq and the S&P 500 ended at their lowest point since July 1 and June 30, respectively.  Goldman Sachs, Barclays and a bunch of investment banks have raised their estimates for U.S. policy rates following Fed's hawkish message, with Societe Generale economists also projecting a mild recession in early 2024.By Peter NurseEli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has granted approval to Retevmo® (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on ORR and duration of resp;98.30999755859375;Novo Nordisk A/S (NYSE: NVO) presented new data from the phase 3a ONWARDS 2 trial of insulin icodec in type 2 diabetes at the European Association for the Study of Diabetes Annual Meeting 2022. The data demonstrated that 37% of patients treated with once-weekly insulin icodec achieved an HbA1c <7.0% without experiencing severe or clinically significant hypoglycemia, compared with 27% of those treated with insulin deglude. Related: Novo Nordisk's Subcutaneous Semaglutide Shows Positive Action InData presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial Bagsværd, Denmark, Thursday 22 September 2022 – Novo Nordisk today presented new data from the phase 3a ONWARDS 2 trial, demonstrating that 37% of adults with type 2 diabetes treated with once-weekly insulin icodec achieved an HbA1c <7.0%, without experiencing severe or clinically significant hypoglycaemia, compared with 27% of those treated with ins;143.00999450683594;Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), and skinbetter science® announce a new report from their DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative®, along with a long-term partnership with Shutterstock Studios. The report, titled Forces of Beauty®, provides a new understanding of what inclusive and representative beauty looks like today by shedding light on how narrowly defined Eurocentric ideals continue to impact women of color. By surveying over 4,000 women agOne good way to start your search is by looking at Dividend Kings.  AbbVie (NYSE: ABBV) sells the biggest blockbuster of all time.  AbbVie's two other immunology drugs -- Skyrizi and Rinvoq -- together are set to eventually surpass peak sales of Humira.;77.13999938964844;"Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.Novartis AG (NYSE: NVS) has revealed insights into the updated company strategy. The company said that a 'US-first' mindset, increasing the share of U.S. patients in clinical trials, and building capability and talent, among other actions, will enable Novartis to achieve this objective. Novartis' aspiration is ""to improve competitive positioning and organically build its U.S. business to become a top-five player in the U.S. by 2027,"" it said in a statement. In April, Novartis announced integratiSwiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were passed to rein in drug prices in the world's largest pharmaceutical market.  As part of an investor event, the company said on Thursday it would adopt a ""U.S.-first mindset"", increase the share of U.S. patients in clinical trials, build capability there and give U.S. staff and executives more say and better career opportunities within the organisation.  Novartis' aspiration is to ""organically build its U.S. business to become a top-five player in the U.S. by 2027,"" it said in a statement.Swiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were passed to rein in drug prices in the world's largest pharmaceutical market.  As part of an investor event, the company said on Thursday it would adopt a ""U.S.-first mindset"", increase the share of U.S. patients in clinical trials, build capability there and give U.S. staff and executives more say and better career opportunities within the organisation.  Novartis' aspiration is to ""organically build its U.S. business to become a top-five player in the U.S. by 2027,"" it said in a statement.Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the US Advancing eight in-market brands with multi-billion dollar peak sales potential and prioritizing pipeline to focus on high-value NMEs Continuing to deliver growing sales, Core Op Inc, and cash flows with consistent shareholder friendly capital allocation Basel, September 22, 2022 — Novartis executives are meeting investors and industry a";87.51000213623047;Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.MADISON, N.J., September 22, 2022--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today that it has signed a definitive agreement under which Merck Animal Health will acquire Vence from its founders and shareholders. Vence is an innovator in virtual fencing for rotational grazing and livestock management. The acquisition is expected to be completed in the third quarter of 2022, subjRAHWAY, N.J., September 22, 2022--LYNPARZA® Approved in China as First-Line Maintenance Treatment With Bevacizumab for HRD-Positive Advanced Ovarian CancerRAHWAY, N.J., September 22, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent infringement suit against Viatris related to sitagliptin, an active ingredient in JANUVIA, JANUMET and JANUMET XR. The Court found that both Merck patents at issue were valid and infringed. The decision is subject to appeal.Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir;56.310001373291016;"AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.On Tuesday, the FDA released briefing documents related to Spectrum Pharmaceutical Inc's (NASDAQ: SPPI) application for poziotinib for treating patients with previously treated locally advanced or metastatic NSCLC. HC Wainwright says that though they were ready for a contentious ODAC meeting, the questions and the text in the ODAC briefing documents suggest a more argumentative meeting than expected. The analyst reiterates the Buy rating but cuts the price target from $12 to $9. ""We understood t";71.29000091552734;;39.130001068115234;Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.;30.010000228881836;AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.Shares of Spero Therapeutics Inc. soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year. If approved, it would offer patients an oral medication option instead of in-hospital intravenous therapy, the companies said. Spero is receiving $66 million upfront, with at least $GSK Plc (NASDAQ: GSK) has entered into an exclusive license agreement for Spero Therapeutics Inc's (NASDAQ: SPRO) late-stage antibiotic asset, tebipenem HBr. Tebipenem HBr is being developed as the first oral carbapenem antibiotic for complicated urinary tract infections (cUTI). Spero expects to start a new phase 3 trial in 2023, following encouraging FDA regulatory feedback on the proposed trial design. Spero received an FDA Complete Response Letter in June 2022, citing data from Spero's initiaThe exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties. GSK to purchase $9 million in shares of Spero common stock LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agreeMerck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir;13.15999984741211;;41.060001373291016;;8.9399995803833;;189.94000244140625;;7.739999771118164;;151.1999969482422;;103.87999725341797;;8.949999809265137;;26.290000915527344;;39.77000045776367;;7.550000190734863;;9.029999732971191;;26.40999984741211;;61.09000015258789;;234.99000549316406;;4.670000076293945;;26.149999618530273;;1.8899999856948853;;4.409999847412109;;;;3.2200000286102295;;4.949999809265137;;42.869998931884766;"Harmony Biosciences Holdings, Inc. (""Harmony"") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.";;;21.139999389648438;;7.420000076293945;;5.050000190734863;LAUSANNE, Switzerland, September 21, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), which will be held in Houston, Texas from September 28–October 1, 2022.;8.630000114440918;;2.049999952316284;;35.08000183105469;;12.8100004196167;;18.959999084472656;;3.3299999237060547;;11.765000343322754;;4.340000152587891;;;;14.020000457763672;;24.059999465942383;;18.459999084472656;;17.739999771118164;;19.760000228881836;;18.155000686645508;;2.5799999237060547;;11.649999618530273;
2022-09-23;166.72000122070312;The hedge fund legend has spoken. Pay attention.Medical device companies and some drugmakers with manufacturing operations in Puerto Rico said they do not expect meaningful disruption from Hurricane Fiona, which knocked out power for over 3 million people and caused flooding and landslides on the island.  The U.S. Food and Drug Administration, which worked with companies to prevent shortages of drugs and medical devices after Hurricane Maria battered the medical manufacturing hub in 2017, said it is in discussion with companies it regulates there regarding any impact on supplies.  Most companies Reuters spoke to, including Baxter International, said they had initially either temporarily halted operations or were running their plants on generators since Fiona struck on Sunday.Shares of Johnson & Johnson (NYSE: JNJ) defied the overall market downturn on Thursday, with its shares rising 1.7% higher as of the market close.  Instead, investors appeared to favor relatively stable stocks such as J&J on a day when small-cap and tech stocks took a drubbing.  After today's gain, J&J's shares are still down around 2.5% year to date.;44.08000183105469;"The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.A manufacturing-quality problem has led to some vaccine providers only offering the Pfizer-BioNTech booster shot.The U.S. Centers for Disease Control and Prevention reported on Thursday that 4.4 million people had received updated COVID-19 booster shots, a few weeks into the government's new vaccination campaign.  The United States began its rollout of the Omicron-tailored shots from Pfizer/BioNTech and Moderna earlier this month.  A federal health agency said on Tuesday that over 25 million doses of the so-called bivalent shots had been sent out.The United States is significantly cutting back the number of Pfizer/BioNTech COVID-19 vaccine doses it will buy for donation to poorer nations this year, Pfizer said on Thursday, citing diminished demand for the shots in those countries.  Pfizer said it agreed to reduce the number of doses it will deliver by year end to 600 million, down from the billion-dose commitment the U.S. government made a year ago.  The United States will have an option to buy up to an additional 400 million shots for the program after this year.Eli Lilly's blockbuster potential diabetes drug Mounjaro is ""de-risked and transformative,"" an analyst said Thursday as he updated LLY stock.";311.4599914550781;"On Friday, Eli Lilly reached a key performance benchmark, with its Relative Strength (RS) Rating climbing into the 90-plus percentile with an improvement to 92, up from 89 the day before.  Eli Lilly is trying to complete a flat base with a 335.43 entry.  Eli Lilly reported negative growth for both sales and earnings last quarter.Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.Plus, we take looks at Eli Lilly and Raytheon Technologies after positive news developments for both companies.Medical device companies and some drugmakers with manufacturing operations in Puerto Rico said they do not expect meaningful disruption from Hurricane Fiona, which knocked out power for over 3 million people and caused flooding and landslides on the island.  The U.S. Food and Drug Administration, which worked with companies to prevent shortages of drugs and medical devices after Hurricane Maria battered the medical manufacturing hub in 2017, said it is in discussion with companies it regulates there regarding any impact on supplies.  Most companies Reuters spoke to, including Baxter International, said they had initially either temporarily halted operations or were running their plants on generators since Fiona struck on Sunday.Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.Many commentators, analysts, and economists are convinced that the U.S. will enter a recession next year. Given the strength of the labor market and of corporate balance sheets, along with the onshoring phenomenon and the many jobs that the energy transition is creating, I have my doubts as to whether a recession is on the way. Still, I can certainly understand investors’ desire to find recession-proof growth stocks to buy. Such equities can come in a few different forms. Pharmaceutical stocks rThe Dow Jones fell amid recession fears after the latest Fed meeting. Tesla stock fell and Elon Musk lashed out after a mass recall. Bitcoin rallied.Eli Lilly's blockbuster potential diabetes drug Mounjaro is ""de-risked and transformative,"" an analyst said Thursday as he updated LLY stock.UBS analysts upgraded Eli Lilly stock to Buy, stating that the pharma company's Type 2 diabetes medication could become a best-selling drug. Shares of Eli Lilly & Co. Inc. gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company's newly approved Type 2 diabetes drug, could be ""the biggest drug ever."" UBS analysts predict peak sales of $25 billion if the therapy is also approved as a treatment for weight management in people with obesity. ""Tirzepatide's robust efficacy in both obesity and [Type 2 diabetes] should drive sales into a range that we believe could see thisThe major stock market indexes added to Wednesday's bad vibes and are trading lower on Thursday afternoon, close to lows for the day. The market is still reeling from Fed Chair Jerome Powell's comments, which have intensified fears of a recession. The Nasdaq fell 1.5%. The S&P 500 lost 0.8%. The Dow Jones Industrial Average dropped 0.4%. Small caps fared...The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.UBS's Colin Bristow raised his rating on the stock to Buy from Neutral, saying Well Street's expectations for sales of Mounjaro are too low.Technology and financial stocks pulled Wall Street's main indexes lower for a third straight session on Thursday, as investors worried that the Federal Reserve's aggressive approach to rein in inflation could trigger a recession.  The Fed lifted rates by an expected 75 basis points on Wednesday and signaled a longer trajectory for policy rates than markets had priced in, fuelling fears of further volatility in stock and bond trading in a year that has already seen bear markets in both asset classes.  As of Friday, the S&P 500's estimated earnings growth for the third quarter is at 5%, according to Refinitiv data.By Yasin Ebrahim";97.93000030517578;;143.05999755859375;Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie is one of the largest pharmaceutical companies around.  Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.As one of the world's largest pharmaceutical companies, it's no surprise to hear that AbbVie (NYSE: ABBV) has plenty of moving parts for investors to think about when they're wondering what to do to make the most money from their shares.  AbbVie develops new medicines as its core business, and to make money from doing so, it needs to perform clinical trials to show regulators at the Food and Drug Administration (FDA) that its drugs are both safe and effective.  For example, if you buy shares right when everyone is hyped about some recently published clinical trial results, you'll be jumping on the bandwagon right when a ticket is the most expensive.AbbVie recently submitted a regulatory application in the European Union for Rinvoq to treat patients with a form of inflammatory bowel disease.;76.01000213623047;"Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.Novartis AG on Thursday told investors that the Swiss drug maker plans to adopt a ""U.S.-first mindset"" in its bid to become a ""top-five player"" in the U.S. market by 2027. Novartis is one of the world's largest pharmaceutical companies; however in the U.S., it was the tenth largest by revenue in the U.S. in 2021,Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.";86.77999877929688;Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in the United StatesRoche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.Taiwan Semiconductor Manufacturing Company (NYSE: TSM) is one of those beneficiaries.  In simplest terms, Taiwan Semiconductor (or TSMC) is a contract chip manufacturer.  Despite a weakening economy expected to sap chip sales, analysts expect TSMC to keep growing all the same.Citius Pharmaceuticals Inc (NASDAQ: CTXR) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. (NYSE: MRK) Keytruda (pembrolizumab) for recurrent or metastatic solid tumors. The investigator-initiated trial at UPMC is an open-label, Phase 1/1b study consisting of two parts. Part I is a dose escalation study of four cohorts and is expected to enroll 18-30 patients. Part 2 is a dose expansion study of approximately 40 p;54.58000183105469;"Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced topline data from the Phase 2b SOLANO study of ION449 (AZD8233) for hypercholesterolemia (high cholesterol levels). Ionis said that although the candidate met the primary endpoint, its partners at AstraZeneca Plc (NASDAQ: AZN) have decided not to move it into Phase III studies because the ""results did not achieve pre-specified efficacy criteria."" The trial showed that 60mg of ION449 (AZD8233) administered monthly achieved a statistically signifiAstrazeneca (AZN) closed the most recent trading day at $56.31, moving -0.23% from the previous trading session.";70.70999908447266;Shares of Bristol Myers Squibb (NYSE: BMY) were bouncing 3.4% higher as of 3:31 p.m. ET on Thursday after slipping a little earlier this week.  Instead, today's move appeared to be the result of investors seeking relatively safe stocks as the Nasdaq Composite index and Russell 2000 small-cap index fell.  Bristol Myers Squibb has seemed to be sort of a safe haven for investors throughout much of 2022.Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.;38.400001525878906;The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.;29.360000610351562;The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.In the latest trading session, GSK (GSK) closed at $30.01, marking a +0.81% move from the previous day.Many commentators, analysts, and economists are convinced that the U.S. will enter a recession next year. Given the strength of the labor market and of corporate balance sheets, along with the onshoring phenomenon and the many jobs that the energy transition is creating, I have my doubts as to whether a recession is on the way. Still, I can certainly understand investors’ desire to find recession-proof growth stocks to buy. Such equities can come in a few different forms. Pharmaceutical stocks r;13.0;;40.33000183105469;;8.6899995803833;Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in the United StatesMerck stock jumped Thursday after the company won a patent battle against generic-drug maker Viatris over an ingredient used in diabetes meds.;181.24000549316406;;7.03000020980835;;151.75999450683594;;100.6500015258789;;8.579999923706055;;25.75;;38.79999923706055;;7.480000019073486;;8.869999885559082;;26.209999084472656;;58.31999969482422;;226.1199951171875;;4.590000152587891;;25.0;;1.8799999952316284;;4.519999980926514;;;;3.140000104904175;;4.829999923706055;;42.470001220703125;Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.;;;20.860000610351562;;7.579999923706055;;4.889999866485596;;8.470000267028809;;2.0999999046325684;;35.040000915527344;;12.529999732971191;;18.15999984741211;;3.2200000286102295;;11.199999809265137;;4.340000152587891;;6.795000076293945;;13.619999885559082;With several worrying developments domestically and internationally, many investors chose to rush for the exits, though a brave few may have opportunities in small-cap stocks to buy on the dip. Tethered to small-capitalization companies, these market ideas don’t always grab the spotlight. But when they do, their relatively diminutive profiles occasionally enable massive profitability. Effectively, small-cap stocks to buy are the equivalent of carrying small objects uphill rather than large ones.;22.1200008392334;;18.190000534057617;;18.290000915527344;;19.200000762939453;;16.624000549316406;;2.5;;12.0;
2022-09-26;165.6999969482422;Drug companies are facing patent expirations and price pressure, but investors won’t make them pay for those problems just yet.;43.83000183105469;"Pfizer and BioNTech asked U.S. health regulators to clear use of their updated Covid-19 booster in children 5 years to 11 years, just as retooled shots for people 12 and older roll out.Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have completed an FDA submission seeking Emergency Use Authorization (EUA) for a 10-µg booster dose for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The emergency use request of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is supported by safety and immunogenicity data from the companies' bivalent Omicron BA.1-adapted vaccine, non-clinical & manufacturing data, and pre-clPfizer Inc's (NYSE: PFE) CEO Albert Bourla said he had tested positive for COVID-19. ""I'm feeling well and symptom-free,"" 60-year-old Bourla said in a statement. In August, he contacted COVID and received one course of paxlovid, Pfizer's oral COVID-19 antiviral treatment. Bourla has received four doses of the COVID vaccine developed by Pfizer and BioNTech SE (NASDAQ: BNTX). Bourla said he has not yet taken the new bivalent booster. Developed by Moderna Inc (NASDAQ: MRNA) and Pfizer/BioNTech, thePfizer Inc and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration's authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years.  The application comes just days after Moderna also applied for FDA authorization of its own Omicron-targeting shot in adolescents aged 12 to 17 years and children aged six to 11.  The applications represent a step towards getting children vaccinated by a so-called bivalent vaccine, which targets both the original strain of the virus and the circulating BA.4 and BA.5 subvariants of Omicron.Drug companies are facing patent expirations and price pressure, but investors won’t make them pay for those problems just yet.Pfizer Inc. and German partner BioNTech SE said Monday they have submitted an application to the U.S. Food and Drug Administration seeking an emergency use authorization for their bivalent vaccine booster for use in children aged 5 to 11 years of age. The application is for a 10-ug booster dose of the vaccine targeting omicron BA.4 and BA.5 subvariants, which have become dominant in the U.S and around the world. The application ""is supported by safety and immunogenicity data from the companies'NEW YORK & MAINZ, Germany, September 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The request for Emergency Use Authorization of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is supSwitzerland would have to discard 10.3 million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine, the health ministry said Saturday. The ministry said it had no choice but to eliminate the shots after the doses expired. It told the news agency that 2.5 million doses were being stored at a Swiss army logistics base and 7.8 million were in an external storage depot in Belgium. The ministry confirmed an initial report, which estimated that the destroyed doses would be worth around CHF280 milli";307.5;Dow Jones futures fell Monday with Treasury yields jumping and the British pound hitting a new low. The bear market is eyeing a new leg down.;95.27999877929688;"Bagsværd, Denmark, 26 September 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme";141.2100067138672;When looking for the best stocks to buy and watch, focus on those with rising relative price strength.  One stock that fits that bill is AbbVie, which saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 88 to 91.  When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.;74.61000061035156;Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.;86.18000030517578;Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.Drug companies are facing patent expirations and price pressure, but investors won’t make them pay for those problems just yet.;53.02000045776367;AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.;70.1500015258789;Bristol Myers Squibb Company:Drug companies are facing patent expirations and price pressure, but investors won’t make them pay for those problems just yet.;37.25;;28.81999969482422;GSK plc (NYSE: GSK) has appointed Julie Brown as its first-ever female chief financial officer to succeed Iain Mackay. Mackay, 60, will retire next year after serving as GSK's finance chief for nearly four years. Julie will join GSK in April 2023 and will work with Iain to transition responsibilities, taking responsibility as CFO and as an Executive Director of GSK on 1 May 2023. Ms. Brown currently serves as Chief Operating and Financial Officer at the luxury fashion brand Burberry Group plc (OBritish consumer goods giant Unilever PLC (NYSE: UL) Chief Executive Officer Alan Jope intends to retire in 2023 end. The decision comes after the CEO came under severe criticism over a failed takeover bid of drugmaker GSK Plc's (NYSE: GSK) consumer health unit worth £50 billion ($53 billion), Bloomberg reported. GSK rejected Unilever's bid and ended up spinning off its consumer healthcare business into an independently-traded public company, named Haleon. The company reported an underlying EPS;12.8100004196167;;39.880001068115234;;8.529999732971191;;179.3300018310547;;6.909999847412109;;151.97000122070312;;98.6500015258789;;8.399999618530273;;25.149999618530273;On World Contraception Day (September 26), Organon (NYSE: OGN), a global women's health company, is launching Act with Her, a multi-faceted approach to help tackle the global health issue of unintended pregnancies (UIPs) and to improve access to contraception. Organon is proud to support the Society of Obstetricians and Gynaecologists of Canada (SOGC) to reinforce the importance of education and awareness in reducing unplanned pregnancies in Canada through roundtable discussions. In addition, Or;38.75;;7.710000038146973;;9.050000190734863;;26.81999969482422;;59.29999923706055;;217.02999877929688;Before jumping directly into momentum stocks worth buying now, it’s important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement of a stock or sector. A good screener from which to identify current momentum stocks can be found here. The theory then goes that momentum investors sell shares that are trending down and buy those that are trending up. While the strategy flies in the face of the age-old adage to ‘buy low, sell high’;4.550000190734863;;24.100000381469727;;1.809999942779541;Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.;4.409999847412109;;;;3.0799999237060547;;4.650000095367432;;42.060001373291016;;;;20.09000015258789;;7.610000133514404;SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities Precision Oncology Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat;4.659999847412109;;8.319999694824219;;2.1600000858306885;;34.70000076293945;;12.329999923706055;;18.110000610351562;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...;3.140000104904175;;10.930000305175781;;4.480000019073486;;7.0;;13.050000190734863;;22.969999313354492;;18.209999084472656;Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from the ARRECTOR Pivotal Phase 3 trial of roflumilast foam 0.3% for treating adults and adolescents with scalp and body psoriasis. The study met its co-primary endpoints of Scalp-Investigator Global Assessment (S-IGA) Success, Body-Investigator Global Assessment (B-IGA) Success, and all secondary endpoints. About 67.3% of individuals treated with roflumilast foam achieved S-IGA Success compared to 28.1% of individuals treatedStudy met both co-primary endpoints and all secondary endpointsAt week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1% of individuals treated with vehicleAt week eight, 46.5% of individuals treated with roflumilast foam achieved Body-Investigator Global Assessment (B-IGA) Success compared to 20.8% of individuals treated with vehicleOnce-daily roflumilast foam demonstrated a favorable safety and tolerability;18.040000915527344;;18.760000228881836;;16.649999618530273;;2.4800000190734863;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...;11.729999542236328;
2022-09-27;164.94000244140625;UnitedHealth Group, Johnson & Johnson, Chevron, The Home Depot and AT&T are part of the Zacks top Analyst Blog.In the latest trading session, Johnson & Johnson (JNJ) closed at $165.70, marking a -0.61% move from the previous day.Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Chevron Corporation (CVX).As we near the end of the third quarter, the U.S. stock market is approaching new lows. As volatility increases, investors are becoming more emotional as many portfolios continue to rack up losses. As a result, some investors are looking for safer places to put their money before the stock market rebounds. Specifically, they are seeking dividend stocks to buy before the bull market returns. Dividend stocks can often be safe havens for investors, even if short-term selling pressures knock the sha;44.09000015258789;As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections. Once infected with the less fatal strain, Omicron, people would isolate themselves for a few days and then return to work. By shifting away from its reliance on drug companies, investors must recognize there are vaccine stocks that it’s time to sell. The government cut orders for vaccines and antiviraThe following are the top stories in the Wall Street Journal.  - Pfizer Inc and BioNTech SE asked U.S. health regulators to clear use of their updated Covid-19 booster in children 5 years to 11 years.  - Ford Motor Co is asking a Georgia court for a new trial, after a jury reached a $1.7 billion verdict against the auto maker last month involving a truck rollover accident that left two people dead.Pfizer (PFE) closed the most recent trading day at $43.83, moving -0.57% from the previous trading session.Yahoo Finance reporter Anjalee Khemlani shares the latest updates on Pfizer's COVID booster, which could soon be approved for children ages 5-11.Is Pfizer stock a sell on an expected decline for Covid vaccine sales in the third quarter? Is PFE stock now a sell?Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.;311.1000061035156;"The U.S. Equal Employment Opportunity Commission (EEOC) accused Eli Lilly And Co (NYSE: LLY) of illegally refusing to hire older workers for sales representative jobs because of their age. According to the EEOC's suit, in 2017, Lilly's senior vice president for human resources and diversity recognized at a Leadership Town Hall that Lilly's workforce was composed of older workers. The senior vice president then announced goals for ""Early Career"" hiring to add more millennials to Lilly's workforceShares of Eli Lilly (NYSE: LLY) recently ticked higher in response to encouraging words from a Wall Street analyst who follows the pharmaceutical industry.  Colin Bristow at UBS, an investment bank, thinks this is the most attractive pharma stock you can buy right now.  Is Bristow right about Eli Lilly?Eli Lilly and Co was sued on Monday by the U.S. Equal Employment Opportunity Commission, which accused the drugmaker of illegally refusing to hire older workers for sales representative jobs because of their age.  The complaint said Lilly's violations began after Stephen Fry, its senior vice president for human resources and diversity, lamented during an April 2017 ""Leadership Town Hall"" that its sales force was skewed toward older workers, with 20% fewer ""millennials"" than the American workforce.  According to the EEOC, Fry suggested that the lack of millennials was a problem, and the Indianapolis-based company would target 40% ""Early Career"" hiring.Eli Lilly (LLY) closed the most recent trading day at $307.50, moving -1.27% from the previous trading session.";95.9000015258789;Shares of Eli Lilly (NYSE: LLY) recently ticked higher in response to encouraging words from a Wall Street analyst who follows the pharmaceutical industry.  Colin Bristow at UBS, an investment bank, thinks this is the most attractive pharma stock you can buy right now.  Is Bristow right about Eli Lilly?;141.72000122070312;An increase in a quarterly dividend payment is something all income investors love to hear about.  Two stocks that have been raising their payouts for decades are AbbVie (NYSE: ABBV) and ExxonMobil (NYSE: XOM).  Let's find out a bit more about these two dividend stocks.Many investors dream of building a portfolio that delivers significant passive income.  Let's delve into a few arguments in favor of loading up on passive income stocks right now and a few in favor of holding off.  One big argument in favor of buying passive income stocks right now is investors will be able to lock in more income for each invested dollar than before.AbbVie (NYSE: ABBV) announced today the availability of the XEN® 63 Gel Implant, a surgical implant designed to lower high eye pressure in open angle glaucoma sufferers, where previous medical treatment options have failed.1 The XEN 63 Gel Implant is an additional option for surgeons, clinically proven to reduce intraocular pressure (IOP) in patients with primary open angle glaucoma.3AbbVie (ABBV) closed at $141.21 in the latest trading session, marking a -1.29% move from the prior day.;74.6500015258789;;85.83999633789062;Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.The China National Medical Products Administration signed off Corvus Pharmaceuticals Inc's (NASDAQ: CRVS) IND application to initiate a Phase 1/1b trial of mupadolimab (formerly CPI-006). The study will be conducted by Angel Pharmaceuticals Ltd, Corvus' partner in China. Mupadolimab is a humanized monoclonal antibody directed against CD73 with a mechanism of activating B cells to generate immune responses to tumor antigens and viruses in patients with relapsed refractory non-small cell lung cancMADISON, N.J., September 27, 2022--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today that it has completed a minority investment in LeeO Precision Farming B.V. (LeeO). Merck Animal Health also will assume distribution of LeeO’s digital swine traceability solution in selected markets over the coming months. Merck Animal Health joins LeeO’s existing founders and shareholders, PrairRAHWAY, N.J., September 27, 2022--Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)While investors might not desire anything less than the most exciting investment opportunities following the wild ride last year, 2022 may be the moment for Dow sleeper stocks to buy. After all, the companies listed in the Dow 30 didn’t get there as part of a fly-by-night operation. Though not commanding the most heart-pounding storylines, these blue chips have the potential to help keep your portfolio afloat in times of stress. Fundamentally, the Federal Reserve changed the broader monetary and;53.2400016784668;Japan's health agency has approved AstraZeneca Plc's (NASDAQ: AZN) Koselugo (selumetinib) for pediatric patients with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms and which cannot be entirely removed by surgery without the risk of substantial morbidity. The approval is based on positive results from the SPRINT Stratum 1 Phase 2 trial that showed Koselugo reduced the size of inoperable tumors in children. The SPRINT Stratum 1 Phase 2 trial showed KoselugoAs people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections. Once infected with the less fatal strain, Omicron, people would isolate themselves for a few days and then return to work. By shifting away from its reliance on drug companies, investors must recognize there are vaccine stocks that it’s time to sell. The government cut orders for vaccines and antiviraYou don't need a mountain of cash to build wealth on Wall Street -- especially with deals like these.;70.36000061035156;Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.;37.220001220703125;;28.65999984741211;Burberry CFO Julie Brown was named the next finance chief at GSK, joining CEO Emma Walmsley.Pharmaceutical firm GSK hired the finance chief of British luxury fashion group Burberry to lead its finances after the recent spinoff of its consumer-health business.;12.800000190734863;;40.22999954223633;;8.479999542236328;Dividend stocks can be foundational to your portfolio and help you build it up year after year.  Buying stocks trading at discounts can also increase your odds of coming away with a great return on your investment years later.  A couple of incredibly cheap dividend stocks you can buy today include Viatris (NASDAQ: VTRS) and Kraft Heinz (NASDAQ: KHC).;180.9600067138672;;6.599999904632568;;152.1999969482422;;100.13999938964844;;8.430000305175781;;24.260000228881836;;38.349998474121094;SOMERSET, N.J., September 27, 2022--Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved CARVYKTI™ for the treatment of adults with relapsed or refractory MM.;7.929999828338623;;9.050000190734863;;27.719999313354492;;61.7599983215332;;222.6199951171875;;4.610000133514404;;25.459999084472656;;1.8600000143051147;;4.679999828338623;;;;3.049999952316284;;4.96999979019165;;42.650001525878906;;;;20.530000686645508;Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® (brincidofovir), the first oral antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.;8.130000114440918;;4.820000171661377;;8.0600004196167;;2.0399999618530273;;35.33000183105469;;12.989999771118164;;18.59000015258789;;3.390000104904175;- atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers - EMP-01 is a 3,4-methylenedioxy-methamphetamine (MDMA) derivative under development for the treatment of post-traumatic stress disorder (PTSD) and other indications NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) --;11.75;;4.480000019073486;;7.150000095367432;;14.15999984741211;;23.209999084472656;;18.299999237060547;;19.209999084472656;;20.149999618530273;;16.540000915527344;;2.4600000381469727;;11.899999618530273;
2022-09-28;166.36000061035156;"The goal of many stock investors is to build a portfolio to generate a passive income stream so they can live off the dividends or at least add to their retirement distributions and Social Security benefits. One possible way to accomplish this goal is to follow a dividend growth investing strategy, buying stocks that pay an ever-increasing dividend each year and reinvesting the dividends. It’s a long-term approach, but start early enough, and the passive income stream snowballs. The most promineYou might be living under a rock if you haven't heard the word ""recession"" being thrown around in the media over the past few months.  Thanks to inflation, the Federal Reserve's efforts to control inflation, and an overflow of global problems, a worldwide economic contraction is on the table (though not guaranteed) in the near future.  The first step to prepare for a recession is to think about your financial goals and clarify them.Johnson & Johnson named its consumer business Kenvue on Wednesday, moving ahead with its plans to spin-off the unit in what would be the biggest shake-up in the healthcare conglomerate's 135-year history.  Usage of the new company logo and corporate brand identity will be effective upon completion of the planned separation, which Johnson & Johnson last year said will be completed by November 2023.Johnson & Johnson's planned new consumer health company will be named Kenvue, the healthcare conglomerate said on Wednesday.  Johnson & Johnson said last year it planned to spin off its consumer business into a new publicly traded company by November 2023, in the biggest shake-up in the U.S. company's 135-year history.NEW BRUNSWICK, N.J., September 28, 2022--Johnson & Johnson (the ""Company"") (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The new corporate brand comes to life through a compelling purpose, and a timeless visual brand.We’re in the midst of a bear market. That’s something investors haven’t seen in quite some time. While many stocks are getting crushed, it does create an opportunity for patient buyers, especially with top blue-chip stocks to buy. While some may say it’s irresponsible to buy in an environment like this, I think it’s irresponsible for long-term investors not to be buying. At the very least, investors should be putting together a list of stocks they want to own and at what price they want to own tIt’s a bear market, and virtually all stocks are trending downward. But some are holding up better than others, and the Dow Jones Industrial Index stocks are one of the stronger groups. Through Sept. 26, the Dow Jones was down 20% for the year. That’s not great, of course. But it’s well ahead of the S&P 500 which is down 24% and the Nasdaq, which has sunk 31% over the same period. The Dow skews much more than other indexes towards so-called “old economy” stocks that are in more staid industries.";44.43000030517578;Data is still scarce on latest COVID-19 boostersRecently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemicPfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.;334.3800048828125;Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.AZN vs. LLY: Which Stock Is the Better Value Option?Cambridge, Massachusetts-based biotech Biogen  and Japanese drug maker Eisai  reported on Wednesday morning that their experimental Alzheimer's disease treatment had met the main goal of a late-stage clinical trial.  The candidate, Lecanemab, reduced the pace of cognitive decline in patients diagnosed with early-stage disease by 27% over 18 months compared to those treated with a placebo.  This result could be a major accomplishment for researchers who have been trying for decades to find a way to treat Alzheimer's. The medicine, before Biogen and Eisai started trying to develop it, was licensed from Sweden's BioArctic.While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Eli Lilly (NYSE: LLY) and its shareholders are sitting pretty right now.  Eli Lilly owes this performance to a combination of factors.  The drugmaker specializes in diabetes medicines, and this chronic illness won't take a break just because we are facing challenging economic conditions.Investors on Wall Street continued to have doubts about when the stock market is likely to recover, as ongoing worries about inflation, interest rates, and the global financial system have everyone on edge.  Biotech stocks have been among those hit hardest by the bear market in 2022, but Biogen (NASDAQ: BIIB) announced good news in a key clinical trial that has huge implications for those suffering from a harsh and debilitating disease.  Biogen's favorable outcome also gave industry peer Eli Lilly (NYSE: LLY) a boost, on optimism that a new way of coming up with important treatments could spur further successes.;99.36000061035156;;144.60000610351562;To get a sense of who is truly in control of AbbVie Inc. ( NYSE:ABBV ), it is important to understand the ownership...Prolonged periods of volatility along with dips near or even into bear market territory have become commonplace for investors in recent months as fears of a looming recession, geopolitical headwinds, and ongoing concerns about the global economy continue to remain front of mind.  For investors who have the capital to put to work right now, even a market like the one we're seeing presents its own share of opportunities to invest in these types of compelling companies at a bargain.  Healthcare stocks had quite the heyday in the early pandemic, when investors were rushing to put their cash into any and all companies in this space.;76.31999969482422;;86.77999877929688;"These businesses might be slightly ""boring,"" but that may just be a good thing in today's market.If you want to know who really controls Merck & Co., Inc. ( NYSE:MRK ), then you'll have to look at the makeup of its...Merck (MRK) closed the most recent trading day at $85.84, moving -0.39% from the previous trading session.";54.689998626708984;AZN vs. LLY: Which Stock Is the Better Value Option?PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition. Formerly known as PB2452, bentracimab reverses the effects of AstraZeneca Plc's (NASDAQ: AZN) blood thinner Brilinta (ticagrelor) In January 2020, PhaseBio announced a financing and co-development partnership with SFJ Pharmaceuticals. PhaseBio retains exclusive worldwide commercial rights.;72.05999755859375;"These businesses might be slightly ""boring,"" but that may just be a good thing in today's market.A look at the shareholders of Bristol-Myers Squibb Company ( NYSE:BMY ) can tell us which group is most powerful. And...";38.16999816894531;"French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since Sanofi does much of its business in the United States.  Sanofi said its preliminary estimate of currency impacts on its third-quarter 2022 sales was for a boost of approximately 10% to 11%, and for a lift of around 12% and 13% on its business earnings per share (EPS).  Sanofi will report third-quarter results on Oct. 28.PARIS (Reuters) -French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since Sanofi does much of its business in the United States.  Sanofi said its preliminary estimate of currency impacts on its third-quarter 2022 sales was for a boost of approximately 10% to 11%, and for a lift of around 12% and 13% on its business earnings per share (EPS).  Sanofi will report third-quarter results on Oct. 28.Availability of the Q3 2022 Memorandum for modelling purposes Paris, France – September 28, 2022 - Sanofi announced today that its Q3 2022 Memorandum for modelling purposes is available on the ""Investors"" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q3-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on variou";29.459999084472656;;13.069999694824219;;41.2599983215332;;8.729999542236328;;188.77000427246094;;6.489999771118164;;151.92999267578125;;103.29000091552734;;8.710000038146973;;24.510000228881836;;40.36000061035156;;8.220000267028809;New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.;9.15999984741211;;28.0;;63.0;;225.6199951171875;;4.699999809265137;;27.06999969482422;;1.9500000476837158;;5.199999809265137;;;;3.2100000381469727;;5.5;;43.91999816894531;;;;21.329999923706055;;8.350000381469727;;5.090000152587891;;10.40999984741211;;2.059999942779541;;36.650001525878906;;13.779999732971191;;19.889999389648438;;3.4000000953674316;;12.800000190734863;;4.670000076293945;;7.150000095367432;;15.069999694824219;"SAN DIEGO, September 27, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.";25.280000686645508;;18.959999084472656;;20.110000610351562;;20.979999542236328;;17.3799991607666;;2.5299999713897705;;12.34000015258789;
2022-09-29;164.52999877929688;The healthcare giant has been a fairly stable investment this year, but does it belong in your portfolio for the long term?Aligos Therapeutics Inc (NASDAQ: ALGS) has filed a response to the complaint of and counterclaims against Janssen Biopharma. In November 2014, Johnson & Johnson (NYSE: JNJ) acquired Alios BioPharma Inc, a privately held infectious disease biotech, for approximately $1.75 billion in cash. Lawrence Blatt and Leonid Beigelman co-founded Alios. Following J&J's 2014 acquisition, Blatt and Beigelman become employees at Janssen. But Blatt and Beigelman left Janssen, starting Aligos Therapeutics Inc (NAThe factors keeping ARK Invest's boss away might actually be reasons to buy, depending on your needs.;44.15999984741211;"Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.Biohaven Pharmaceutical Holding Company Ltd said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recent months.  The migraine drugmaker in May agreed to an $11.6 billion acquisition deal by Pfizer Inc, which plans to spin off its non-migraine drugs into a new publicly traded company.  On Thursday, Biohaven said its drug for ALS did not achieve statistically significant improvement in patients' performance of daily activities compared to a placebo in a mid-to-late-stage trial.Merck & Co Inc (NYSE: MRK) signed a cooperation framework agreement in China for its COVID-19 antiviral pills, which were co-developed by Ridgeback Therapeutics. The pharma giant has granted Sinopharm exclusive import and distribution rights to Lagevrio (molnupiravir). The companies will also negotiate the feasibility of a technical transfer under the framework so that the drug Molnupiravir could be produced and provided in the Chinese mainland market, Global Times reported. While Pfizer's pillsWhen close to half the companies in the United States have price-to-earnings ratios (or ""P/E's"") above 14x, you may...";330.010009765625;The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.Biogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday.  The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease.  The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.;100.38999938964844;;142.72000122070312;AbbVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI®) in Crohn's disease and upadacitinib (RINVOQ®) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online. In total, AbbVie is presenting 17 abstracts across a broad range of studies in inflammatory bowel disease (IBD).;76.56999969482422;Vas Narasimhan, CEO of Novartis, talks about the Big Pharma company's new focus on the U.S. market—and why he believes investors are undervaluing its potential.NVS vs. RHHBY: Which Stock Is the Better Value Option?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Company lays out nearly completed transformation for analysts;86.63999938964844;Merck & Co Inc (NYSE: MRK) signed a cooperation framework agreement in China for its COVID-19 antiviral pills, which were co-developed by Ridgeback Therapeutics. The pharma giant has granted Sinopharm exclusive import and distribution rights to Lagevrio (molnupiravir). The companies will also negotiate the feasibility of a technical transfer under the framework so that the drug Molnupiravir could be produced and provided in the Chinese mainland market, Global Times reported. While Pfizer's pillsRAHWAY, N.J., September 29, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, October 27. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook.Drugmaker Merck & Co said on Wednesday that it agreed to allow China's Sinopharm to distribute and import its COVID-19 antiviral molnupiravir in China if the drug is approved for use there.  The drugmaker said in a statement that it reached a cooperation framework agreement with Sinopharm that grants the Chinese company distribution and exclusive import rights of the medicine in the China mainland market.  Merck also said it will allow China National Biotec Group, an affiliate of Sinopharm, to make the drug in China and has agreed to transfer technology to help with that production.The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.;54.90999984741211;;71.70999908447266;;38.0;The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent became the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. The FDA evaluated the Dupixent application for prurigo nodularis under Priority Review. Related: RegeneronHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S. Paris and Tarrytown, N.Y. September 28, 2022Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among;29.360000610351562;;12.970000267028809;OSAKA, Japan, & GENEVA, Switzerland, September 29, 2022--As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies. The initiative will draw on UNITAR’s experti;40.33000183105469;;8.600000381469727;;191.05999755859375;;5.949999809265137;;151.52999877929688;Biohaven Pharmaceutical Holding Company Ltd said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recent months.  The migraine drugmaker in May agreed to an $11.6 billion acquisition deal by Pfizer Inc, which plans to spin off its non-migraine drugs into a new publicly traded company.  On Thursday, Biohaven said its drug for ALS did not achieve statistically significant improvement in patients' performance of daily activities compared to a placebo in a mid-to-late-stage trial.Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of treatment with verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS). The HEALEY ALS Platform Trial, the first-ever platform trial in ALS, is designed as an adaptive trial to evaluate multiple investigational treatments simultaneously, thus accelerating the development of effective and breakthrough treatments for people living with ALS.;102.62000274658203;;8.470000267028809;;23.549999237060547;;40.11000061035156;;8.039999961853027;;8.630000114440918;;27.8700008392334;;65.41000366210938;;224.5;;4.28000020980835;;27.149999618530273;STAMFORD, Conn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 2 trial evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors. Ovarian granulosa cell tumors ac;1.8700000047683716;;4.949999809265137;;;;3.0399999618530273;;4.940000057220459;;43.63999938964844;;;;20.780000686645508;;7.900000095367432;;4.889999866485596;;9.859999656677246;;2.0899999141693115;;36.310001373291016;;12.890000343322754;;19.299999237060547;;3.25;;12.220000267028809;;4.25;;6.559999942779541;;13.979999542236328;;25.030000686645508;;18.6299991607666;;19.6200008392334;;19.43000030517578;;17.59000015258789;;2.359999895095825;;12.020000457763672;
2022-09-30;163.36000061035156;"Over the past 20 years, medical device giant Intuitive Surgical (NASDAQ: ISRG) has substantially outperformed the market.  In fact, over the next couple of decades, Intuitive Surgical has a shot at becoming the largest healthcare stock.  Currently, the two largest healthcare companies are pharmaceutical giant Johnson & Johnson, with a market cap of $433 billion, and insurance specialist UnitedHealth Group, whose market cap is $475 billion.Dividends are a popular wealth-building tool, but let's face it: A dividend is only as helpful as it is reliable.  Chasing stocks because they have high dividend yields is a dangerous game; sometimes, a high yield reflects the market's concern that a company can't afford its payout.  Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) could be your stock if dependability is your goal.";43.7599983215332;The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.  The 7.6 million figure represents only 3.5% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series.  The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people.The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.;323.3500061035156;The major indexes fell, with the S&P 500 breaking below bear market lows. Biogen soared on an Alzheimer's drug while Nike dived.;99.62999725341797;Biotechnology startup Ventus Therapeutics is licensing its lead research program, a drug candidate for inflammatory disorders, to Novo Nordisk A/S (NYSE: NVO) for an upfront $70 million. The lead experimental drug, dubbed VENT-01, is a small molecule that targets inflammasomes, which are protein complexes in immune system cells that activate inflammatory responses. An inflammasome known as NLRP3 is the focus of Ventus' experimental treatment. NLRP3 is implicated in many diseases, including Alzhe;134.2100067138672;In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV).  The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year.  Its other immunology drugs and the neuroscience business also are thriving.;76.01000213623047;;86.12000274658203;RAHWAY, N.J., September 29, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. (now Viatris) related to sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin hydrochloride) and JANUMET® XR (sitagliptin and metformin hydrochloride extended-releaseA Merck Sharp & Dohme Corp patent related to its diabetes drugs Januvia and Janumet is valid, a U.S. appeals court said Thursday, rejecting a challenge to the patent by generic drugmaker Mylan Pharmaceuticals Inc.  Viatris Inc's Mylan failed to convince the U.S. Court of Appeals for the Federal Circuit that the patent was invalid based on an earlier patent and other publications.;54.84000015258789;Coca-Cola (KO), General Dynamics (GD), AstraZeneca (AZN), Boise Cascade (BCC), and Insperity (NSP) that offer dividend growth could be compelling picks amid market volatility.;71.08999633789062;In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.71, marking a -0.49% move from the previous day.;38.02000045776367;In the latest trading session, Sanofi (SNY) closed at $38, marking a -0.45% move from the previous day.Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.;29.43000030517578;GSK (GSK) closed at $29.36 in the latest trading session, marking a -0.34% move from the prior day.;12.970000267028809;;40.18000030517578;;8.520000457763672;A Merck Sharp & Dohme Corp patent related to its diabetes drugs Januvia and Janumet is valid, a U.S. appeals court said Thursday, rejecting a challenge to the patent by generic drugmaker Mylan Pharmaceuticals Inc.  Viatris Inc's Mylan failed to convince the U.S. Court of Appeals for the Federal Circuit that the patent was invalid based on an earlier patent and other publications.;187.11000061035156;;6.159999847412109;;151.1699981689453;Biohaven Pharmaceutical said Thursday its experimental ALS treatment failed in a midstage study, leading BHVN stock to dip slightly.Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS). Verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy outcome, disease progression measured by the ALS Functional Rating Scale-Revised, survival, or key secondary efficacy measures during the 24-week study period. Initial safety data analysis was consistent with th;103.26000213623047;;8.789999961853027;;23.399999618530273;;40.79999923706055;;7.880000114440918;;8.859999656677246;;28.260000228881836;;68.30000305175781;WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral presentations of data from the Phase 3 DERBY and OAKS studies evaluating pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration will be presented at the American Academy of Ophthalmology (AAO) Annual Meeting on September 30 – October 3 in Chicago, Illinois. Dat;224.92999267578125;;4.010000228881836;;28.530000686645508;;1.8899999856948853;;4.949999809265137;;;;3.200000047683716;;4.96999979019165;;44.290000915527344;;;;20.989999771118164;;7.800000190734863;;4.820000171661377;;11.020000457763672;;2.0199999809265137;;37.619998931884766;;13.029999732971191;;19.639999389648438;;3.309999942779541;;11.619999885559082;;4.019999980926514;;7.0;;14.819999694824219;;25.1299991607666;;19.110000610351562;;20.030000686645508;;22.739999771118164;;17.59000015258789;Company announcement – No. 41 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1) Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a statistically significant reduction in weekly parenteral support volume by 5.13 Liters/week from baseline at 24 weeks66% of patients in the twice weekly group had a clinically meaningful response (>20% reduction in parenteral support volume)In total 9 pa;2.2699999809265137;;12.130000114440918;
2022-10-03;163.1999969482422;;44.13999938964844;;321.54998779296875;;102.55000305175781;Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.Bagsværd, Denmark, 3 October 2022 – Novo Nordisk today announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300) in 1,085 insulin-naïve people with type 2 diabetes in a clinical practice setting including fewer trial visits comparNovo Nordisk, Suncor Energy, Nasdaq, W.W. Grainger and Textron are included in this Analyst Blog.;138.32000732421875;;76.66999816894531;On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia.  With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug.  Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.;87.55000305175781;;55.54999923706055;Shares of LogicBio Therapeutics Inc. skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company announced an agreement to be acquired by AstraZeneca PLC's Alexion, AstraZeneca Rare Disease in a deal that values LogicBio at about $68.23 million. The stock had closed Friday at a record low of 27 cents, representing a market capitalization for LogicBio of about $8.9 million. Under terms of the buyout deal, AlexiAstraZeneca Plc's (NASDAQ: AZN) subsidiary, Alexion, has agreed to acquire LogicBio Therapeutics Inc (NASDAQ: LOGC) for $2.07 per share. Both boards have unanimously approved the transaction. Alexion plans to close the deal in four to six weeks, subject to the tender of at least a majority of the outstanding shares of LogicBio common stock. It plans to retain LogicBio employees at their current location. Also Read: LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its PediatriWILMINGTON, Del., October 03, 2022--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development.Coca-Cola, General Dynamics, AstraZeneca, Boise Cascade and Insperity have been highlighted in this Screen of The Week article.;70.52999877929688;Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.;39.189998626708984;;30.25;Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.;13.050000190734863;;40.189998626708984;;8.720000267028809;The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc.  The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent in a ruling that helped clear the way for Mylan's generic version of Tecfidera.  Biogen sued Mylan, now part of Canonsburg, Pennsylvania-based Viatris, in West Virginia in 2017, saying Mylan's proposed generic version of Tecfidera would infringe Biogen patents.The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc.  The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent in a ruling that helped clear the way for Mylan's generic version of Tecfidera.;197.8699951171875;;6.440000057220459;;;;99.41999816894531;- TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical activity as monotherapy or in combination with pembrolizumab - Abstract for dose-escalation topline data accepted for an oral presentation at SITC 2022, November 8-12 in Boston - Recommended Phase 2 dose to be evaluated in four indication-specific dose-expansion cohorts COPENHAGEN, Denmark, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced completion of the dose-es;9.0;;24.06999969482422;;40.279998779296875;;7.940000057220459;;8.760000228881836;;29.059999465942383;;61.040000915527344;"Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan for geographic atrophy (GA) secondary to age-related macular degeneration. Investigator Charles Wykoff called the ""first direct evidence of function preservation by slowing GA growth"" in an investigational treatment. Apellis' drug pegcetacoplan led to less retinal sensitivity loss versus sham within 250 microns on either side of the GA lesion over 24 months. Related: Apellis's Pegc";229.60000610351562;;3.9700000286102295;;27.030000686645508;;1.909999966621399;Quite a few insiders have dramatically grown their holdings in OPKO Health, Inc. ( NASDAQ:OPK ) over the past 12...;4.579999923706055;;;;3.140000104904175;;5.179999828338623;;45.400001525878906;;;;21.06999969482422;;8.09000015258789;;4.829999923706055;;10.479999542236328;;2.0799999237060547;;39.45000076293945;;13.109999656677246;;18.889999389648438;SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a board-certified physician with more than 30 years of pharmaceutical industry experience in clinical development, pharmacovigilance, and medical and regulatory affairs. “Dr. Pizzuti’s expertise in working with global regulators to safely and effectively progress multiple programs through development and ul;3.319999933242798;;12.369999885559082;;4.059999942779541;;6.599999904632568;;14.899999618530273;;25.940000534057617;;19.200000762939453;;20.059999465942383;;21.420000076293945;;;;2.309999942779541;;12.550000190734863;
2022-10-04;165.6199951171875;;44.459999084472656;;329.8900146484375;;105.37999725341797;Novo Nordisk A/S (NYSE: NVO) has completed posting topline results across its six Phase 3a clinical trials in the ONWARDS program of once-weekly insulin icodec in people with diabetes. In ONWARDS 5 study, once-weekly insulin icodec was found to be non-inferior to once-daily basal insulin in reducing HbA1c. With that, the 52-week open-label trial met its primary endpoint at the end of the study. Novo’s icodec led to a reduction of -1.68% points on HbA1c, compared to -1.31% for the once-daily cont;141.99000549316406;;78.2300033569336;;88.38999938964844;;57.040000915527344;AstraZeneca Rare Disease, the local division formed when the British pharma giant acquired Alexion Pharmaceuticals Inc. last year, has scooped up a struggling local biotech at a significant premium.  AstraZeneca plc (Nasdaq: AZN) is buying LogicBio Therapeutics Inc. (Nasdaq: LOGC) for $2.07 per share, a 660% premium that values the total acquisition at $68 million.  Lexington-based LogicBio has been struggling since February, when the U.S. Food and Drug Administration ordered a halt to an early-stage trial testing a drug in pediatric patients with methylmalonic acidemia, a disorder in which the body cannot break down certain proteins and fats.;71.20999908447266;Autolus Therapeutics plc (NASDAQ: AUTL) has entered into an agreement with Bristol-Myers Squibb Co (NYSE: BMY). The agreement grants Bristol Myers Squibb access to incorporate Autolus' proprietary RQR8 safety switch into an initial set of selected cell therapy cancer programs. Bristol Myers has an option to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs. Safety switches are designed to allow pharmacological agents to selectively- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties - LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol MBMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.Based on Monday's view of an IBD-produced screen, they now include small-cap enterprise software firm Model N, lithium metal producer Albemarle, electrical equipment firm Hubbell and trendy footwear and apparel firm Deckers Outdoor.  In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling.  Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.;40.119998931884766;Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.Holding on to popular or trending stocks for the long-term can make your portfolio a winner.;30.709999084472656;Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.With recent stock market weakness, look for long-term dividend stocks to buy. After failing to hold a rally that began in June 2022, the S&P 500 erased more than it gained by Sept. All thanks to persistently higher inflation, and the Federal Reserve’s aggressive monetary tightening campaign. Still, investors will benefit by looking beyond weak markets. In fact, nowadays, investors can take advantage of discounted stocks, and collect a dividend along the way. After all, since interest rates may r;13.600000381469727;;41.66999816894531;;9.210000038146973;The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera. The ruling clears the way for Viatris Inc (NASDAQ: VTRS) to continue marketing its generic version of the drug, launched more than two years ago. The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent. Related: These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win. Biogen sued Mylan, n;213.5500030517578;REGN vs. RGEN: Which Stock Is the Better Value Option?;6.860000133514404;Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year.  Steven F. Mayer, an independent board member since 2011 and a former senior managing director of Cerberus Global Private Equity, will become executive chairman, effective immediately.  The company's outgoing non-executive chairman, Victor Grifols Roura, who was chief executive from 1987 to 2016, has been named honorary chairman.Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced today changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairperson while Mr. Victor Grifols Roura retired as Chairperson and was named Chairperson of Honor. Both changes are effective immediately.;;;108.58999633789062;;9.479999542236328;;25.709999084472656;;41.09000015258789;;8.380000114440918;;9.229999542236328;;30.139999389648438;;60.4900016784668;Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases.;236.25;;4.090000152587891;;28.219999313354492;;2.009999990463257;;5.079999923706055;;;;3.3499999046325684;;5.570000171661377;;47.4900016784668;;;;21.420000076293945;;8.5;;5.239999771118164;;11.460000038146973;;2.2300000190734863;"BRIDGEWATER, N.J., October 03, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.";40.599998474121094;;13.319999694824219;;19.049999237060547;;3.4600000381469727;NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in in the following investor events & host a virtual R&D Day in October: Roth Inaugural Healthcare Opportunities Conference in New York CityFormat: Company presentationDate and Time: Thursday, October 6th, 11:45 a.m. ET – 12:15 p.m. ETConference link: Roth Inaugural Healthc;13.5;;3.9800000190734863;;6.929999828338623;;16.729999542236328;;25.520000457763672;Reata Pharmaceuticals (RETA) is yet to generate product revenues due to the lack of marketed drugs in its portfolio. However, two of its pipeline candidates are close to potential FDA approval.;20.399999618530273;;20.940000534057617;;22.829999923706055;;;;2.430000066757202;;13.779999732971191;
2022-10-05;165.11000061035156;;44.119998931884766;;331.7799987792969;;106.02999877929688;;143.3300018310547;A war in Europe and the subsequent energy crisis it's causing would be enough to tank global stock markets in any given year.  On top of Russia's invasion of Ukraine, markets are also reeling from rapidly rising interest rates intended to quell runaway inflation.  Once you consider all the challenges stock markets face, it's a little surprising that the benchmark S&P 500 index has only lost around 25% of its value this year.;77.37000274658203;;88.38999938964844;;56.72999954223633;In this article, we will be taking a look at the 10 healthcare stocks to watch in light of Biden’s 60 Minutes interview. To skip our detailed analysis of these stocks and Biden’s insights, you can go directly to see the 5 Healthcare Stocks to Watch in Light of Biden’s 60 Minutes Interview. On September […]The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on.  For decades, Germany's Fresenius Medical Care (FMC) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function.  The company’s 17.6 billion euros ($17.6 billion) in annual revenue has been sustained for decades by high rates of obesity and diabetes, which contribute to kidney damage.;71.44999694824219;Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.;39.81999969482422;French pharma major Sanofi SA (NASDAQ: SNY) entered into a collaboration and licensing agreement with little-known U.S. biotech miRecule, an innovator of next-generation RNA therapeutics. Under the terms of the deal, Sanofi will develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD). Sanofi is getting exclusive worldwide rights for the program, known as MC-DX4, while miRecule gets upfront and near-term milestones of about $30 millGaithersburg's miRecule Inc. has inked its first major licensing agreement to bring one new drug to market — and kicked off a Series A funding round to accelerate development of a separate cancer treatment.  The company, which develops RNA therapies for drug-resistant cancers and other diseases, announced Tuesday a collaboration with French pharmaceutical giant Sanofi to develop and commercialize a drug for a type of muscular dystrophy with no approved treatments.  The deal, worth up to $400 million, would give the clinical-stage biotech its first revenue stream.;30.40999984741211;AnaptysBio Inc (NASDAQ: ANAB) - GSK plc (NYSE: GSK) partnered PERLA head-to-head trial of Jemperli vs. Keytruda for metastatic non-squamous non-small cell lung cancer, met its primary endpoint of objective response rate (ORR). GSK expects to present full results from the PERLA trial, including the primary endpoint of ORR and the key secondary endpoint of progression-free survival, with results by programmed death ligand-1 (PD-L1) expression subgroups, at an upcoming scientific meeting. The trialThe company has been without a product on the market since the FDA withdrew emergency use authorization in April of its Covid 19 treatment as the Covid virus mutated.GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.In this article, we will be taking a look at the 10 healthcare stocks to watch in light of Biden’s 60 Minutes interview. To skip our detailed analysis of these stocks and Biden’s insights, you can go directly to see the 5 Healthcare Stocks to Watch in Light of Biden’s 60 Minutes Interview. On September […]Vir Biotechnology inked a deal Tuesday worth up to $1 billion for its experimental flu treatment, leading Vir stock to surge.;13.449999809265137;CAMBRIDGE, Mass., October 05, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food & Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for the potential expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age. Currently, children with HAE under the age of 6 have no approved prophylaxis treatment. If approved, TAKHZYRO could potentially become;41.72999954223633;;9.180000305175781;;220.55999755859375;;6.559999942779541;;;;113.45999908447266;;8.859999656677246;;25.6299991607666;;41.0099983215332;;8.220000267028809;;9.300000190734863;;29.829999923706055;;57.689998626708984;;218.66000366210938;;3.940000057220459;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022.";28.09000015258789;;1.909999966621399;;5.059999942779541;;;;3.359999895095825;;5.400000095367432;;48.470001220703125;;;;20.84000015258789;;8.569999694824219;;5.099999904632568;;11.069999694824219;;2.2300000190734863;;40.040000915527344;;12.640000343322754;"SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced six poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting which is being held November 8 – 12th in Boston. ""Our presentations at SITC highlight the versatility of our targeted protein modulation platform and applications of our first-in-class CBL-B inhibito";18.440000534057617;;3.380000114440918;- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT) under development for treatment-resistant depression (TRD) in combination with atai’s digital therapeutic designed to provide contextual “(mind)set-and-setting” support to patients prior to dosing. - Approximately one-third of people with depression are treatment resistant, totaling over 100 million;12.979999542236328;;3.859999895095825;;6.7769999504089355;MIAMI and BARRANQUILLA, Colombia, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced it will participate in the BTG Pactual LatAm CEO Conference being held at the InterContinental NY Barclays Hotel October 11-13, 2022. Procaps Group Chief Executive Officer Rubén Minski, Chief Financial Officer Patricio Vargas, and Investor Relations Director Melissa Angelini will conduct in-person one-;16.1200008392334;;24.530000686645508;;19.940000534057617;;20.540000915527344;;22.06999969482422;;;;2.2899999618530273;;13.5;
2022-10-06;161.91000366210938;;43.09000015258789;;332.95001220703125;"The FDA has granted Fast Track designation for Eli Lilly And Co's (NYSE: LLY) tirzepatide for adults with obesity or overweight with weight-related comorbidities. Based on discussions with the FDA, Lilly plans to initiate a rolling submission of a marketing application for tirzepatide this year, which, when complete, will be based primarily on results from two Phase 3 clinical trials: SURMOUNT-1, which is complete, and SURMOUNT-2, which is expected to complete by the end of April 2023. AssumingIn this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […]Eli Lilly and Company's ( NYSE:LLY ) price-to-earnings (or ""P/E"") ratio of 55.4x might make it look like a strong sell...Eli Lilly and Co. said Thursday that its experimental obesity drug received a Fast Track designation from the Food and Drug Administration. The drug maker also said it plans to begin a rolling submission to the FDA for tirzepatide as a treatment for adults with obesity or who have overweight with related comorbidities. The submission will use data from two clinical trials, the final of which is expected to wrap up in April of next year. Tirzepatide has shown in clinical trials that it can help p";105.81999969482422;In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […]One of the largest employers in Johnston County is making a substantial real estate purchase to facilitate an expansion of hundreds of additional employees.;140.2899932861328;"The S&P 500 is down 24% this year, and the stock market hasn't been a great place to be holding your money of late.  Investors have been dumping stocks left and right, with many quality companies seeing their valuations plummet as interest rate increases and rising inflation have made people second-guess their investments.  Warren Buffett isn't a fan of economic projections, or what he refers to as ""dancing"" in and out of stocks based solely on economic outlooks.In this article, we discuss 10 best monthly dividend stocks to buy in October. You can skip our detailed analysis of dividend stocks and their returns in the past, and go directly to read 5 Best Monthly Dividend Stocks to Buy in October. Investors often advocate income-generating stocks during periods of high inflation and slow economic growth. […]Looking at AbbVie Inc.'s ( NYSE:ABBV ) insider transactions over the last year, we can see that insiders were net...Costco and Ford are among the top trending stocks in after hours trading on Wednesday, October 5, 2022.The stock market is rolling over as the third quarter comes to a close. The S&P 500 is down 21% year-to-date (YTD) as of this writing. Quality dividend stocks become even more valuable during bear markets, as their consistent earnings and high dividend yields help offset declining markets. This is why income investors should consider pharmaceutical giant AbbVie (NYSE:ABBV). Currently, ABBV stock is up 7% YTD, coming in second place in InvestorPlace’s Best Stocks for 2022 contest as of the end of";76.04000091552734;"GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.Whether you're looking for dividends or growth, Novartis and Paramount Global could be viable options for you.Biogen's patent battles over Tecfidera are over after SCOTUS decision; Ginkgo Bioworks delves into the RNA therapeutics; and Peter Thiel invests in Waltham startup creating ""humanized"" mice.";87.44000244140625;;54.90999984741211;Honeywell (Nasdaq: HON) today announced the opening of a plant in Baton Rouge, La., that is the company's first large-scale manufacturing site for Solstice® Air (HFO-1234ze(E) cGMP), a near-zero global-warming-potential (GWP) medical propellant for use in respiratory inhalers.In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […]FTSE 100 set for record cash returns to investors but dividend forecasts stall.;70.23999786376953;In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […]Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.While the SPDR S&P Healthcare ETF is down 10% year to date, the SPDR S&P Biotech ETF has plummeted 29%.  Investors should always keep the long-term potential of businesses in mind when investing in the stock market.  Sunosi, purchased from Jazz Pharmaceuticals in May, has been Axsome's blockbuster drug.The S&P 500 ETF (NYSEARCA:SPY) has not performed well in 2022. It is down 22.4% so far this year, including dividends. But the market is made up of individual stocks, and not all stocks have done so poorly. In fact, a few have even managed to generate positive returns in this difficult environment. One such stock is my pick for InvestorPlace’s Best Stocks for 2022 — Bristol-Myers Squibb (NYSE:BMY) stock. The company has generated total returns (including dividends) of 15.1% this year as of thisWhen Tamica D'Souza applied for a research and development internship at Bristol Myers Squibb, she had no idea that a few months later she would be loading up a 30-pound backpack in preparation for a once-in-a-lifetime opportunity to take a multi-day hiking trip through the wilderness of the Sierra Nevada Mountains in California.;38.900001525878906;The stock market continued to try to build a base on Thursday after a punishing first nine months of 2022.  Futures markets for the Dow Jones Industrial Average (DJINDICES: ^DJI), S&P 500 (SNPINDEX: ^GSPC), and Nasdaq Composite (NASDAQINDEX: ^IXIC) showed the likelihood of a flat start when regular trading begins this morning.  Below, you'll learn more about why Pinterest (NYSE: PINS) and Provention Bio (NASDAQ: PRVB) are on investors' radar Thursday morning and whether their latest moves could be the beginning of a broader move higher.Provention Bio Inc (NASDAQ: PRVB) has entered into a co-promotion agreement with Sanofi SA (NASDAQ: SNY) to launch Provention's lead investigational candidate, teplizumab, to delay type 1 diabetes in at-risk individuals. Teplizumab is under FDA review, with an action date of November 17. Under the terms of the agreement, Sanofi will commit commercial resources in the U.S. In exchange, Provention will reimburse field force-related expenses that Sanofi will incur in connection with commercializingSanofi US has announced it has entered into a co-promotion service agreement with Provention Bio, Inc., for the commercialization of teplizumab in the United States. Teplizumab, developed by Provention, is an investigational anti-CD3 monoclonal antibody that is being evaluated for the delay of clinical type 1 diabetes (T1D) in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies. If approved by the U.S. Food and Drug Administration (FDA), teplizumab would b;30.0;GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […]In the latest trading session, GSK (GSK) closed at $30.41, marking a -0.98% move from the previous day.;13.119999885559082;In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […]The FDA has accepted Takeda Pharmaceutical Co Ltd's (NYSE: TAK) supplemental marketing application for the potential expanded use of TAKHZYRO (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age. Children with HAE under the age of 6 have no approved prophylaxis treatment. If approved, TAKHZYRO could potentially become the first treatment of its kind for this population. Related: With Approval For Dengue Vaccine, Takeda M;41.060001373291016;;8.9399995803833;;218.39999389648438;;6.409999847412109;;;;115.9000015258789;;9.010000228881836;;24.760000228881836;;40.90999984741211;;8.039999961853027;;8.630000114440918;;29.959999084472656;;59.099998474121094;;218.00999450683594;;3.930000066757202;;28.719999313354492;;1.850000023841858;;5.119999885559082;;;;3.380000114440918;;5.440000057220459;;48.119998931884766;;;;20.68000030517578;;8.449999809265137;;5.010000228881836;;11.1899995803833;;2.2200000286102295;BRIDGEWATER, N.J., October 06, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2022 financial results on Friday November 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 4, 2022.;40.56999969482422;;11.819999694824219;;17.950000762939453;SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted CRN04777 an “Innovation Passport” for the treatment of congenital hyperinsulinism (HI), which enables Crinetics to access the Innovative Licensing and Access Pathway (ILAP). The ILAP was launched in the United Kingdom in 2021 with the goal of reducing the time to market for innovative medicines that tr;3.4100000858306885;;12.710000038146973;;3.9000000953674316;;6.89900016784668;;16.049999237060547;;24.520000457763672;;19.799999237060547;WESTLAKE VILLAGE, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 32,300 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 85,800 shares of Arcutis’ common stock to nine newly hired employees. These awards were approved by the Compensation Committee o;20.510000228881836;;22.450000762939453;;;;2.2799999713897705;;13.300000190734863;
2022-10-07;160.1999969482422;;42.31999969482422;;326.6600036621094;Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.Bank of America analysts on Friday told investors that Eli Lilly & Co. Inc.’s  (LLY)  diabetes treatment and possible weight-management drug could be a $100 billion medication.  The drug, tirzepatide, received Food and Drug Administration approval as a treatment for Type 2 diabetes earlier this year.  It has also shown in clinical trials that it can help people lose up to 20% of their body weight.Most investors would like to see their stock portfolio grow significantly, especially if they have quite a few years left until retirement.  Alphabet (NASDAQ: GOOG), Vertex Pharmaceuticals (NASDAQ: VRTX), Eli Lilly and Company (NYSE: LLY), and Meridian Bioscience (NASDAQ: VIVO) all show solid potential to grow your investments significantly.  Alphabet's stock has risen 105% over the past five years.Eli Lilly said Thursday it plans to begin the process of asking the FDA to approve its obesity treatment. LLY stock rose on the news.;104.05999755859375;Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.Eli Lilly said Thursday it plans to begin the process of asking the FDA to approve its obesity treatment. LLY stock rose on the news.;138.75999450683594;It's easy to get poor returns if you don't diversify your portfolio and carefully calibrate your expectations.In this article, we will take a look at the Top 10 Stock Picks of Frederick DiSanto’s Ancora Advisors. To skip our analysis of Frederick DiSanto’s profile, investment strategy, and 13F holdings, you can go directly to see the Top 5 Stock Picks of Frederick DiSanto’s Ancora Advisors. Frederick DiSanto is the Chairman and CEO […];75.6500015258789;Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy are part of the Zacks top Analyst Blog.Today's Research Daily features new research reports on 12 major stocks, including Novartis AG (NVS), Lowe's Companies, Inc. (LOW) and The Goldman Sachs Group, Inc. (GS).;87.5999984741211;In this article, we will look at the 11 best long-term stocks to buy now. If you want to explore similar stocks, you can also take a look at 5 Best Long-Term Stocks To Buy Now. The current market situation is not ideal for short-term investors and day traders. As of October 5, the S&P […]If you want to know who really controls Merck & Co., Inc. ( NYSE:MRK ), then you'll have to look at the makeup of its...Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics announced data from two real-world evidence studies evaluating Lagevrio (molnupiravir), an investigational oral antiviral COVID-19 medicine. According to the results of a pivotal clinical trial in the U.K., Merck’s COVID-19 antiviral pill failed to show it can lower the risks of hospitalization and death among adults at higher risk from the disease. Preliminary results from a trial of more than 25,000 people show that taking molnupiravir c;55.400001525878906;;69.69999694824219;In this article, we discuss top 13 high-dividend stocks to buy according to hedge funds. You can skip our detailed analysis of dividend stocks and their returns, and go directly to read Top 5 High Dividend Stocks to Buy According to Hedge Funds. Dividend stocks are gaining popularity among investors as these stocks can potentially […]NEW YORK, October 07, 2022--Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022MARKETWATCH OPTIONS TRADER  The stock market had two strong rally days this week.  That was mostly because of the massive oversold condition that existed, and it was aided by news from Europe that central banks were easing off on the increase in interest rates.;38.86000061035156;Although crimson seems to be the shade of the moment in the equities sector, by targeting under-$50 stocks to buy, astute and daring investors may be able to tap into a hidden bull market. How can this be? Really, it comes down to simple math. Depending on your sources, retail investors enjoy access to approximately 6,000 securities listed on the New York Stock Exchange and the Nasdaq. The harsh reality, then, is that investors can’t be everywhere all at once. Moreover, with phenomena like memeIn this article, we will discuss the 10 best European dividend stocks to buy now. If you want to see more stocks, you can also take a look at the 5 Best European Dividend Stocks to Buy Now. In late April, Guillaume Jaisson, a strategist at Goldman Sachs, highlighted that there is a significant difference […];30.110000610351562;It's easy to get poor returns if you don't diversify your portfolio and carefully calibrate your expectations.Several big pharma stocks have held up quite well as the overall stock market fell this year.  At first glance, Wall Street might not seem all that optimistic about GSK.  This multiple looks even more impressive considering that analysts project the company will deliver average annual earnings growth of more than 10% over the next five years.;13.140000343322754;;40.86000061035156;;8.739999771118164;;209.88999938964844;Jonathan Good, manager of the Baird Small/Mid Cap Growth Fund, explains his index-beating strategy in an interview.;6.230000019073486;;;;113.0;;8.6899995803833;;24.010000228881836;;40.08000183105469;;7.690000057220459;;8.279999732971191;;27.15999984741211;;58.22999954223633;;210.22999572753906;BOSTON, October 06, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia will be shared at the 35th European College of Neuropsychopharmacology (ECNP) Congress, to be held October 15-18, 2022, in Vienna, Austria. A poster presentation and symposium will incl;3.6600000858306885;;27.329999923706055;;1.75;;4.840000152587891;;;;3.5299999713897705;PureTech Health plc (NASDAQ: PRTC) has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ: NKTR). In April, Nektar Therapeutics announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team. Nektar and Bristol Myers Squibb Co (NYSE: BMY) jointly decided to end the global clinical development program for bempegaldesleukin after disappointing renal cell carcinoma an;5.119999885559082;;47.310001373291016;;;;19.510000228881836;;7.889999866485596;;4.760000228881836;;10.390000343322754;;2.130000114440918;;39.869998931884766;;10.970000267028809;Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 9.09% and 12.33%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in cash and marketable securities as of August 31, 2022 Expanded leadership team and board of directors with experienced industry leaders Announced multiple presentations at upcoming SITC 2022 annual meeting, including initial PK/PD data for NX-1607 program SAN FRANCISCO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clini;17.399999618530273;;3.369999885559082;;12.260000228881836;;3.799999952316284;;6.664999961853027;;15.390000343322754;;23.780000686645508;;19.139999389648438;;19.549999237060547;;20.65999984741211;;;;2.200000047683716;;13.069999694824219;
2022-10-10;160.41000366210938;;41.75;;323.8900146484375;Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Eli Lilly and Company...Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. This combination makes these companies attractive to value investors. In general, however, investing in biotech stocks is not for risk-averse investors. Many of these companies are smaller players. They may or may not be generating revenue, much less profit. But it’s usually at these compa;103.8499984741211;"Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark 10 October 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period begIn this article, we discuss 10 best global stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Global Stocks To Buy Now. A strong U.S jobs market may actually make a recession more likely. Wall Street is concerned that the Fed could see additional hirings as […]";138.30999755859375;"With a price-to-earnings (or ""P/E"") ratio of 19.5x AbbVie Inc. ( NYSE:ABBV ) may be sending bearish signals at the...Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. This combination makes these companies attractive to value investors. In general, however, investing in biotech stocks is not for risk-averse investors. Many of these companies are smaller players. They may or may not be generating revenue, much less profit. But it’s usually at these compa";75.55000305175781;Gilead (GILD) is having a good run despite the volatility on a string of positive updates.Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.;90.4800033569336;Merck & Co Inc (NYSE: MRK) announced topline results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin receptor type IIA-Fc fusion protein as an add-on to stable background therapy for pulmonary arterial hypertension (PAH). The drug is designed to tone down inflammation in PAH patients, a rare type of high blood pressure that affects the arteries in the lungs and the right side of the heart. Merck added sotatercept, the lead drugMerck & Co said on Monday a therapy it gained through the drugmaker's $11.5 billion acquisition of Acceleron Pharma last year met the main goal of a late-stage study in patients with a progressive blood vessel disorder.  Merck's shares rose 2.5% at $89.79 in premarket trading.  Sotatercept, when compared to placebo, significantly extended how far patients with pulmonary arterial hypertension (PAH) could walk in six minutes.RAHWAY, N.J., October 10, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein being evaluated as an add-on to stable background therapy for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1). The trial met its primary efficacy outcome measure, dem;54.209999084472656;Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.;68.4800033569336;Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.;39.099998474121094;;30.190000534057617;"Gilead (GILD) is having a good run despite the volatility on a string of positive updates.Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.The FDA has approved GSK Plc's (NYSE: GSK) Boostrix vaccine during the third trimester of pregnancy to prevent whooping cough in infants younger than two months. ""When the Boostrix vaccine is given during pregnancy, it boosts antibodies in the mother, which are transferred to the developing baby,"" the agency said. While the FDA's approval of Boostrix has always included its use during pregnancy to protect the vaccinated individual, the latest decision expands its use to help prevent pertussis, cThe vaccine is also indicated against tetanus, diphtheria and pertussis in individuals aged 10 years and older, GSK said.";13.0;;40.400001525878906;;8.75;;207.89999389648438;;6.079999923706055;;10.9399995803833;;110.41999816894531;;8.300000190734863;;23.670000076293945;;39.0;;7.510000228881836;;8.350000381469727;"HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China. wAIHA is an autoimmune disorder that can lead to anemia and has limited treatment options. The first patient received the first dose on September 30, 2022. This is a randomized, double blin";26.989999771118164;;57.90999984741211;Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.;205.8699951171875;;3.5199999809265137;;27.06999969482422;;1.7999999523162842;;4.820000171661377;;;;3.549999952316284;;5.019999980926514;;47.29999923706055;;;;19.68000030517578;;7.239999771118164;;4.289999961853027;;9.600000381469727;;2.0299999713897705;;42.290000915527344;;10.989999771118164;;16.889999389648438;;3.3299999237060547;;11.420000076293945;;3.880000114440918;;6.679999828338623;;14.649999618530273;;22.149999618530273;;19.040000915527344;;19.6200008392334;;21.34000015258789;;;;2.130000114440918;;12.5;
2022-10-11;162.72999572753906;;41.91999816894531;;327.6000061035156;In this article, we discuss 10 best immunotherapy stocks to buy now. If you want to read about some more immunotherapy stocks, go directly to 5 Best Immunotherapy Stocks To Buy Now. The global immunotherapy market is rapidly evolving as technological, regulatory, and economic trends combine to alter the growth and risk dynamics within the […]Eli Lilly (LLY) closed at $323.89 in the latest trading session, marking a -0.85% move from the prior day.;104.38999938964844;;141.50999450683594;In this article, we discuss 10 best immunotherapy stocks to buy now. If you want to read about some more immunotherapy stocks, go directly to 5 Best Immunotherapy Stocks To Buy Now. The global immunotherapy market is rapidly evolving as technological, regulatory, and economic trends combine to alter the growth and risk dynamics within the […]While the stock market may be facing a turbulent environment at the moment, it's always a good time to invest in wonderful companies with great businesses that can generate prolonged portfolio returns.  Now, with patent exclusivity on the drug set to expire in the U.S. in 2023, you'll be glad to learn that Abbvie also has other highly lucrative products on which to rely for future revenue and profits.  Taking a step back and looking at the healthcare stock's financial performance over the much longer period of five years, the company has boosted its annual revenue, net income, and cash from operations by 100%, 117%, and 129%, respectively.It's inevitable that offspring are compared with their parents. This happens with famous people and not-so-famous people alike. And it also happens with companies. For example, Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV) in 2013.The term “value stocks” refers to shares of companies that appear to be underpriced relative to their fundamentals. In the column below, I will provide you with information about seven undervalued value stocks that investors should buy now. I used multiple criteria, including financial results, price-earnings ratios, and analysts’ price targets to determine which stocks are in the latter category. Investors can contrast value stocks with growth stocks which often appear overpriced relative to th;75.86000061035156;Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.;91.05000305175781;Ginkgo Bioworks Holdings Inc (NYSE: DNA) collaborated with Merck & Co Inc (NYSE: MRK) to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. Through this collaboration, Ginkgo will leverage its experience in cell engineering and enzyme design and its capabilities in automated high throughput screening, manufacturing process development/optimization, bioinformatics, and analytics to deliver optimal strains for the expressionMerck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.Every investor in Merck & Co., Inc. ( NYSE:MRK ) should be aware of the most powerful shareholder groups. With 75...Merck & Company Inc. is hiring synthetic biology firm Ginkgo Bioworks Holdings Inc. to engineer a crucial component of some of its medicines.;55.29999923706055;(Bloomberg) -- GSK Plc is free to hire a top dealmaker from AstraZeneca Plc after reaching an agreement with its rival, which had sued to block the sharing of sensitive information.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketThis Is What 7% Mortgages Will Do to the Housing MarketIt’s Official: The Fed’s in the RedThe Most Powerful Buyers in Treasuries Are All Bailing at OnceScreening Procedure Fails to Prevent Colon Cancer Deaths in Large StudyChris Sheldon wThe nasal version of the Oxford/AstraZeneca COVID vaccine failed to elicit an antibody response in an early trial and the company is shelving its developmentAstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection. The AstraZeneca-funded phase 1 trial tested the efficacy of the Oxford vaccine when delivered through a simple device that sprays droplets up the nose. In a statement, the University of Oxford said that an antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial. While the trial raiseThe British drugmaker is reducing production of its Covid-19 vaccine and betting on new therapies for other conditions to help boost its growth.A nasal version of the Oxford/AstraZeneca Covid-19 vaccine has failed in an early-stage trial, dealing a blow to hopes for a more effective way to prevent transmission of the virus.  Oxford university said on Tuesday a nasal formulation of the vaccine elicited mucosal antibody responses in a “minority of participants” and systemic immune responses were weaker compared with intramuscular vaccination.  The setback highlights the complexity of designing a nasal formulation against coronavirus, which spreads through tiny particles in the air.Attempts by Oxford University researchers and AstraZeneca Plc  to create a nasal-spray version of their jointly developed COVID-19 shot suffered a setback on Tuesday as initial testing on humans did not yield the desired protection.  An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing, the University of Oxford said in a statement on Tuesday.  Also, the immune response measured in the blood was weaker than that from a shot-in-the-arm vaccination.;69.6500015258789;"Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.Global biopharmaceutical firm Bristol-Myers Squibb was downgraded to ""Neutral"" by a sell-side firm Tuesday. I have been an on and off fan of BMY and this may be another pivot by me after we review the charts.In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […]The term “value stocks” refers to shares of companies that appear to be underpriced relative to their fundamentals. In the column below, I will provide you with information about seven undervalued value stocks that investors should buy now. I used multiple criteria, including financial results, price-earnings ratios, and analysts’ price targets to determine which stocks are in the latter category. Investors can contrast value stocks with growth stocks which often appear overpriced relative to th";39.689998626708984;"Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) presented more positive data for their Dupixent product. The companies said new Dupixent data showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly. In May 2022, FDA approved Dupixent 300 mg weekly for EoE in people aged 12 years and older, weighing at lDupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old 68% of children on a higher dose of Dupixent achieved histological disease remission at week 16First and only Phase 3 trial to show positive results in this patient population; currently no approved treatments are specifically indicated for children under 12 years of age with EoEData reinforce well-established efficaRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE). The data will be shared at United European Gastroenterology (UEG) Week 2022 and submitted to regulatory authorities around the world, starting with the U.S. Food and Drug Administration (FDA) next year. In May 2022, Dupixent 300 mg weekly";30.43000030517578;In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […](Bloomberg) -- GSK Plc is free to hire a top dealmaker from AstraZeneca Plc after reaching an agreement with its rival, which had sued to block the sharing of sensitive information.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketThis Is What 7% Mortgages Will Do to the Housing MarketIt’s Official: The Fed’s in the RedThe Most Powerful Buyers in Treasuries Are All Bailing at OnceScreening Procedure Fails to Prevent Colon Cancer Deaths in Large StudyChris Sheldon w;12.8100004196167;;41.27000045776367;;9.390000343322754;;199.1300048828125;;6.010000228881836;;11.789999961853027;;110.0;;8.140000343322754;;23.5;;38.79999923706055;One simple way to benefit from a rising market is to buy an index fund. But in any given year a good portion of stocks...;7.510000228881836;;8.0600004196167;;27.1200008392334;;57.459999084472656;;205.02000427246094;"PARAMUS, N.J., October 11, 2022--PsychoGenics Inc. (""PsychoGenics"" or the ""Company""), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders.";3.390000104904175;;26.979999542236328;;1.75;;5.199999809265137;;;;3.559999942779541;;5.179999828338623;;47.65999984741211;;;;19.8700008392334;;7.539999961853027;;4.110000133514404;ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.;9.1899995803833;;2.059999942779541;;42.34000015258789;;11.050000190734863;;17.260000228881836;SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 237,600 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducemen;3.3299999237060547;;10.890000343322754;;4.010000228881836;;6.630000114440918;MIAMI and BARRANQUILLA, Colombia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the completion of its inaugural 2021 ESG Annual Report, a comprehensive overview of environmental, social and governance metrics and corresponding strategies and initiatives for ESG priorities. Procaps commitments and initiatives include advancing a healthy, climate-resilient future, social responsibil;15.630000114440918;;22.959999084472656;;18.530000686645508;;19.510000228881836;;21.09000015258789;;;;2.0399999618530273;;12.859999656677246;
2022-10-12;162.69000244140625;;42.029998779296875;;324.57000732421875;Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.Futures pared gains as the 10-year Treasury yield in flux with big inflation reports due. The S&P 500 is at bear market lows.The Fed as a whole needs to get their act together. Probably, it would be far better if these folks just piped the heck down.Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.A month after detailing its strategic shift toward autoimmune diseases and cancer, Nimbus Therapeutics has captured the interest of a major pharmaceutical player.An inspection in July by the FDA revealed several issues surrounding quality control at Eli Lilly And Co's (NYSE: LLY) manufacturing site in Branchburg, NJ. According to Reuters, the Form 483 inspection report stated that employees at the facility did not track contaminated drug batches and were supposed to be tracked by the facility's quality check unit. The report also found unknown debris in a production area and raw ingredients not being adequately controlled. The report did not say whether;103.9800033569336;Emergex Vaccines Holding Limited acquired the assets of Zosano Pharma Corporation. The sale was part of the customary proceedings after Zosano filed for bankruptcy in June. The assets acquired include intellectual property, license agreements, and manufacturing equipment. They also include Zosano's proprietary microneedle array patch (MAP) intradermal drug delivery system, including a reusable applicator, solid-coated microneedle array patch technology, product packaging, methods for formulationOzempic and other injections meant to treat chronic medical conditions are in high demand among elites looking to lose a little weight.In this article, we will take a look at 15 of the most valuable Danish companies in the world. If you want to see some more of the most valuable Danish companies, go directly to 5 Most Valuable Danish Companies in the World. Denmark is a country with a population of 5.8 million and a […]Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.;139.97999572753906;In this article, we discuss the 10 best cancer stocks. To skip the detailed analysis of the oncology market, go directly to 5 Best Cancer Stocks to Buy Now. Due to the COVID-19 pandemic, the oncology segment of the market saw a slight impact. The screening and oncology care services saw a decline in priority […]In this article, we discuss 10 best high-dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best High-Dividend Stocks to Buy Now. A historical analysis of high-dividend stocks shows their exceptional performance over other asset classes. According to […]The market continues its downward trend. The U.S. Federal Reserve is raising interest rates in response to high inflation. Consequently, investors are selling because they fear high interest rates will cause a recession. Adding to investors’ negative sentiment are record drought in many places in the world and Russia’s invasion of Ukraine. On the other hand, the current bear market has created some deals. Stocks overvalued for years are now undervalued or at least fairly valued. Moreover, divide;75.30999755859375;Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.;90.41999816894531;"(Bloomberg) -- Covid-19 vaccine maker Moderna Inc. rose the most in two months after Merck & Co. said it would exercise an option to maintain its partnership with the biotech company on a messenger RNA cancer vaccine.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketIntel Is Planning Thousands of Job Cuts in Face of PC SlumpPutin Says All Infrastructure at Risk After Nord Stream HitUS Core Inflation Seen Returning to 40-Year High as Rents RiseAlex Jones Must Pay $9A cancer vaccine deal with pharma heavyweight Merck is lighting a fire underneath the biotech's shares today.Yahoo Finance Live's Julie Hyman discusses the rise in shares for Merck and Moderna after Moderna announced the joint development and potential sale of an mRNA-based cancer vaccine.Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.Moderna Inc (NASDAQ: MRNA) said Merck & Co Inc (NYSE: MRK) had exercised an option to jointly develop and potentially sell personalized mRNA-based cancer vaccine. Personalized cancer vaccines prime the immune system so patients can generate a tailored antitumor response to their tumor mutation signature to treat their cancer. mRNA-4157/V940 is designed to stimulate an immune response by generating T-cell responses based on the mutational signature of a patient's tumor. Also Read: Moderna Says No""Together we have made significant progress in advancing mRNA-4157 as an investigational personalized cancer treatment used in combination with (Merck & Co.'s) Keytruda,"" Moderna said Wednesday.Merck & Co. Inc.  (MRK)  and Moderna Inc.  (MRNA)  said Wednesday that they plan to jointly develop and commercialize a personalized cancer vaccine.  The investigational vaccine is currently being tested in a Phase 2 clinical trial as a treatment for patients with high-risk melanoma in combination with Merck’s Keytrduda, an anti-PD-1 therapy that has been approved to treat several types of cancer.  It is Merck’s best-selling drug, with $5.2 billion in revenue in 2021.Moderna Inc said on Wednesday Merck & Co Inc had exercised an option to jointly develop and potentially sell an mRNA-based cancer vaccine.  The vaccine, mRNA-4157, is being tested along with Merck's blockbuster cancer immunotherapy Keytruda, in a mid-stage trial.Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. This approval is based on the results from the Phase 3 KEYNOTE-564 trial, which demonstrated a statisticalAs the largest shareholder of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), Buffett has exposure to every stock that the giant conglomerate owns.  Its equity holdings aren't limited to those that it discloses on 13-F filings to the U.S. Securities and Exchange Commission, though.  Berkshire Hathaway also fully owns New England Asset Management -- and it, too, has a portfolio that includes dozens of stocks.Shares of Moderna surged more than 11% on Wednesday after the biotech company [announced](https://investors.modernatx.com/news/news-details/2022/Merck-and-Moderna-Announce-Exercise-of-Option-by-Merck-for-Joint-Development-and-Commercialization-of-Investigational-Personalized-Cancer-Vaccine/default.aspx) it would develop and sell a personalized cancer vaccine with Merck. The stock was the biggest gainer on the S 500 around midday. Shares of Merck were little changed. Merck will pay Moderna $250 mIn the latest trading session, Merck (MRK) closed at $91.05, marking a +0.63% move from the previous day.Dow Jones leader Merck is one of the top stocks to watch, as it approaches a new buy point despite the stock market correction.Merck could be sitting on a blockbuster from a recent acquisition that would help reduce dependence on cancer drug Keytruda.";55.06999969482422;In this article, we discuss the 10 best cancer stocks. To skip the detailed analysis of the oncology market, go directly to 5 Best Cancer Stocks to Buy Now. Due to the COVID-19 pandemic, the oncology segment of the market saw a slight impact. The screening and oncology care services saw a decline in priority […]Here are two excellent companies to consider: AstraZeneca (NASDAQ: AZN) and Roku (NASDAQ: ROKU).  U.K.-based AstraZeneca has a rich and diversified lineup of drugs.  The company's best-selling therapeutic area is oncology.WILMINGTON, Del., October 12, 2022--Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, October 26 to 28, 2022.Illumina Inc (NASDAQ: ILMN) entered a strategic research collaboration with AstraZeneca plc (NASDAQ: AZN) on drug target discovery. Financial and other details of the partnership were not disclosed. Under the terms of the agreement, the firms will join forces on artificial intelligence-based genome interpretation and genomic analysis and evaluate whether a combined framework can increase the yield of and confidence in target discovery. AstraZeneca's Center for Genomics Research will use the comb;69.27999877929688;Two stocks that have been beating the bear market this year and that could be good options to consider now are Bristol Myers Squibb (NYSE: BMY) and Chevron (NYSE: CVX).  What makes Bristol Myers an attractive investment is that the healthcare business is robust and hugely profitable.Merck could be sitting on a blockbuster from a recent acquisition that would help reduce dependence on cancer drug Keytruda.;39.2400016784668;;30.3700008392334;Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.;12.819999694824219;;41.09000015258789;Novel collaboration structure supports pipeline innovationNEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia. “We are excited to collaborate with Merck,” said Pablo Legorreta, Royalty Pharma’s fo;9.390000343322754;Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced that it has been named to Forbes' list of World's Best Employers 2022. Viatris has received this recognition in each of its first two years since launching in 2020 as a new company. For 2022, Viatris is ranked in the top 10% of the 800 global employers who made the list. This recognition is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider.;199.6199951171875;Webcast and Conference Call to Be Held Tuesday, November 1, 2022 at 8:30 a.m. EDTWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2022 financial results on Tuesday, November 1, 2022. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine- month reporting periods ended S;5.960000038146973;;11.09000015258789;;110.9000015258789;The consensus price target hints at a 34.6% upside potential for Ascendis Pharma AS (ASND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.In this article, we will take a look at 15 of the most valuable Danish companies in the world. If you want to see some more of the most valuable Danish companies, go directly to 5 Most Valuable Danish Companies in the World. Denmark is a country with a population of 5.8 million and a […];8.050000190734863;;23.649999618530273;;38.5;;7.71999979019165;;8.050000190734863;;26.899999618530273;;57.689998626708984;Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.;208.47999572753906;;3.509999990463257;;27.360000610351562;;1.7400000095367432;;5.159999847412109;;;;3.5199999809265137;Nektar cut about 500 jobs and decided to sublease 200,000 square feet in San Francisco after a promising cancer drug failed clinical trials earlier this year.;4.960000038146973;;46.63999938964844;;;;19.670000076293945;;7.570000171661377;Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and tolerable profiles for combination development CNS-penetrant EGFR inhibitor ERAS-801 demonstrates superior anti-tumor activity over osimertinib in preclinical model of EGFR mutant NSCLC with CNS metastases Potent and selective KRAS G12D inhibitors identified with robust, dose-dependent anti-tumor activity SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasda;4.300000190734863;The heavy selling pressure might have exhausted for ADC Therapeutics SA (ADCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.;9.0600004196167;;2.0299999713897705;;45.029998779296875;;10.9399995803833;;17.850000381469727;;3.299999952316284;– Initial results showed that single ascending oral dosing of KUR-101 produces dose-dependent analgesia (pain relief) with effects on respiration comparable to that of placebo. – Topline results, including Part 2 comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, are expected by the end of 2022. – KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD). – Ne;11.220000267028809;;4.03000020980835;;6.610000133514404;;15.430000305175781;;24.420000076293945;;18.25;;19.780000686645508;;21.170000076293945;;;;2.0799999237060547;;12.670000076293945;Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
2022-10-13;165.14999389648438;;42.97999954223633;;332.1000061035156;;104.83000183105469;;142.9199981689453;AbbVie (NYSE: ABBV) and Fighting Blindness Canada have launched the Glaucoma in Perspective (GiP) app to help Canadians understand the impact of glaucoma and manage disease progression. The launch of GiP coincides with World Sight Day, as the vision loss community comes together to raise awareness and understanding of eye diseases like glaucoma.Despite the tough economic environment, Hormel Foods (NYSE: HRL), AbbVie (NYSE: ABBV), and Aflac (NYSE: AFL) each raised their payouts to shareholders over the last 12 months.  This activity extended the dividend growth streaks of these three companies to a range of 39 years to 56 years straight.  Let's take a look at why each company appears poised to continue growing its dividend for many more years.;76.01000213623047;Novartis said on Thursday that it would cut up to 400 jobs in Ireland, or about a quarter of its workforce there, as part of a previously announced restructuring programme that will cut 8,000 jobs globally.  The Swiss pharmaceutical giant said in June that the plan targeting savings of at least $1 billion by 2024 would reduce its total workforce of over 100,000 people by around 7.4%.  The changes could potentially impact around 400 staff at its global service centre in Dublin, Novartis said in a statement.;92.48999786376953;Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.Investors have been scared of high inflation for a long time, and traders apparently didn't want to have a lot of exposure to the stock market heading into Thursday morning's release of the September Consumer Price Index.  After having spent most of the day in positive territory, the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) once again set fresh closing lows for the year, and the Dow Jones Industrial Average (DJINDICES: ^DJI) moved modestly lower as well.  Amid the turbulent market, though, there were a couple of stocks that gave investors positive surprises.Pharmaceutical manufacturers Moderna and Merck are partnering together to develop a cancer vaccine.;55.529998779296875;Bear markets are never fun.  Good news often fails to land with investors, blue chip stocks rarely prove to be rock-solid safe havens, and important sources of passive income, such as dividends, can dry up as companies rethink their capital allocation strategies.  History has shown, however, that bear markets are some of the best times to buy equities and hold them for long periods.In the latest trading session, Astrazeneca (AZN) closed at $55.07, marking a -0.42% move from the previous day.;70.7699966430664;Bristol Myers Squibb Company:;39.91999816894531;;30.649999618530273;"FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.The British pharmaceutical giant said its experimental vaccine against respiratory syncytial virus sharply reduced the risk of disease in a key trial, paving the way for a contest with Pfizer Inc. in what the companies expect to be a lucrative market.GSK plc (NYSE: GSK) announced positive Phase 3 trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above to be presented at IDWeek 2022. The company announced the headline results in June. ""These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research,"" said Tony Wood, GSK Chief Scientific Officer, in a statement. The vaccine candidate was highly efficacGSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine candidate for adults aged over 60 years met its primary endpoint.By Scott Kanowsky";12.880000114440918;;41.650001525878906;Art McGivern joins Royalty Pharma as EVP, Investments & General CounselGeorge Lloyd promoted to EVP, Investments & Chief Legal Officer NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Art McGivern has joined Royalty Pharma as Executive Vice President, Investments & General Counsel and George Lloyd has been promoted to Executive Vice President, Investments & Chief Legal Officer. Pablo Legorreta, Royalty Pharma’s fou;9.649999618530273;;198.4600067138672;;6.059999942779541;;11.0;;112.2699966430664;;8.350000381469727;;24.030000686645508;;38.81999969482422;;7.670000076293945;;7.880000114440918;;27.40999984741211;;58.720001220703125;;209.8800048828125;;3.5299999713897705;;27.290000915527344;;1.7799999713897705;;5.199999809265137;;;;3.619999885559082;;5.179999828338623;;47.630001068115234;;;;19.959999084472656;;7.480000019073486;;4.46999979019165;;8.789999961853027;;2.0;;45.880001068115234;;11.0;;18.329999923706055;Topline results for PATHFNDR-1 study expected in Q3 2023SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating the safety and efficacy of once-daily oral paltusotine in acromegaly patients. Topline results from the PATHFNDR-1 study are expected in the third quarter of 2023. The Phase 3 PATHFNDR-2 study’s;3.200000047683716;"SAINT LAURENT, Quebec, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the ""Company"" or ""IntelGenx"") today provided an update on its collaboration with its strategic partner, atai Life Sciences (NASDAQ:ATAI) (“atai”), for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenx's polymeric film technologies. Pursuant to the first of two current feasibility agreements between the companies, IntelGenx conducted pre-development, formula";12.0;;4.190000057220459;;6.610000133514404;;15.600000381469727;;25.049999237060547;;18.219999313354492;;20.549999237060547;;21.829999923706055;;;;1.9900000095367432;;12.649999618530273;BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2022-10-14;164.4600067138672;;42.86000061035156;;331.3900146484375;While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Microsoft, Alphabet, Eli Lilly, Visa and Morgan Stanley are included in this Analyst Blog.Biogen could easily take on Roche and Eli Lilly in Alzheimer's treatment, an analyst said Thursday as he upgraded Biogen stock.Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Alphabet Inc. (GOOGL) and Eli Lilly and Company (LLY).J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, sales in the second half are expected to have been better than the first.;103.80000305175781;Bagsværd, Denmark, 14 October 2022 – Novo Nordisk today announced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Forma, Novo Nordisk has today acquired all outstanding shares of common stock of Forma at a price of USD 20 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offCowen Vice President Equity Research Michael Nedelcovych joins Yahoo Finance Live to discuss Elon Musk touting a prescription weight-loss drug, the company Novo Nordisk, and U.S. adults living with obesity.;142.94000244140625;In this article, we discuss 10 best gene editing stocks to buy. If you want to see more stocks in this selection, check out 5 Best Gene Editing Stocks To Buy. A report by The Wall Street Journal dated September 16 suggests that Intellia Therapeutics, Inc. (NASDAQ:NTLA) revealed positive early-stage trial results for its CRISPR […]One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...;75.56999969482422;"The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. Reportedly, Novartis sued HEC and several other generic drugmakers, accusing them of patent infringement, in Delaware federal court after they applied for FDA approval of Gilenya generics. According to a Reuters report, Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya. Related: Novartis DPhase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and 108,000 prostate cancer-related deaths occurred across Europe in 20202; Metastatic prostate cancer has a 5-year survival rate of approximately 30%3 Two Phase III trials are underway to evaluate Pluvicto® for treatment in earlier stages of metastatic prostate cancer Basel, October 14, 2022 — Novartis aThe U.S. Supreme Court on Thursday turned down Novartis' bid to block the launch of generic versions of the company's blockbuster multiple sclerosis drug Gilenya in a dispute with China's HEC Pharm Co Ltd and other generic drugmakers.  Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company's third highest-selling drug last year with $2.8 billion in sales.The U.S. Supreme Court on Thursday turned down Novartis Pharmaceuticals Corp's bid to block the launch of generic versions of the company's blockbuster multiple sclerosis drug Gilenya in a dispute with China's HEC Pharm Co Ltd and other generic drugmakers.  Novartis had asked the justices to stay a lower court's ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company's third highest-selling drug last year with $2.8 billion in sales.";92.18000030517578;Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.;54.970001220703125;Healthcare is a reliable sector of the economy for those looking to create wealth over the long haul.In the latest trading session, Astrazeneca (AZN) closed at $55.53, marking a +0.84% move from the previous day.;70.62000274658203;;39.58000183105469;For example, Sanofi (NASDAQ: SNY) and Intel (NASDAQ: INTC) are not only trading near multi-year lows, they're yielding more than 4%.  French pharmaceutical company Sanofi makes a variety of medicines focused on therapeutic areas such as oncology, neurology, and immunology, as well as several rare diseases and rare blood disorders.  The company's diversification is a source of strength, and could potentially make this an appealing long-term investment.Sanofi ADR is throwing its weight behind a new startup that aims to tackle diseases of the immune system with covalent drugs.Sanofi (SNY) closed at $39.92 in the latest trading session, marking a +1.73% move from the prior day.Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n;30.709999084472656;GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.GSK (GSK) closed at $30.65 in the latest trading session, marking a +0.92% move from the prior day.;12.869999885559082;European Medicines Agency's Committee for Medicinal Products for Human Use recommended approving Takeda Pharmaceutical Co Ltd's (NYSE: TAK) dengue vaccine candidate, TAK-003. In August, Indonesia approved Takeda's dengue vaccine, Qdenga, for individuals six to 45 years. The recommendation covers the dengue vaccine candidate to prevent dengue disease caused by any serotype in individuals four years of age and older in Europe and dengue-endemic countries. The Committee's positive opinion was suppoOSAKA, Japan & CAMBRIDGE, Mass., October 14, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of Takeda’s dengue vaccine candidate, TAK-003, for the prevention of dengue disease caused by any serotype in individuals four years of age and older in Europe and in dengue-endemic countries participating in the parallel EU-M4all procedure. The final step in the path to approva;41.40999984741211;;9.550000190734863;;193.5399932861328;;6.139999866485596;;10.880000114440918;;107.33000183105469;;8.3100004196167;;23.309999465942383;;39.75;;7.519999980926514;The recent 4.6% drop in CureVac N.V.'s ( NASDAQ:CVAC ) stock could come as a blow to insiders who purchased €97m worth...;7.989999771118164;;26.739999771118164;;56.939998626708984;;205.89999389648438;;3.7300000190734863;;25.200000762939453;;1.7300000190734863;;4.949999809265137;;;;3.549999952316284;;4.940000057220459;;51.06999969482422;;;;19.43000030517578;;7.150000095367432;;4.699999809265137;;8.800000190734863;;1.9600000381469727;;43.93000030517578;;10.869999885559082;;17.65999984741211;;3.009999990463257;;11.739999771118164;;4.010000228881836;;6.599999904632568;;14.300000190734863;;30.209999084472656;"PLANO, Texas, October 13, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (""FDA"") has informed the Company that it does not plan to hold an advisory committee meeting in connection with its review of the Company’s New Drug Application (""NDA"") for omaveloxolone for the treatment of patients with Friedreich’s ataxia.";18.639999389648438;;20.8799991607666;;20.68000030517578;;;;1.6699999570846558;;13.350000381469727;
2022-10-17;166.58999633789062;Moderna CEO Stephane Bancel on competing with traditional players in the drug and vaccine space.Q3 Earnings Season to Gather Pace This Week;43.650001525878906;;332.760009765625;;106.0;"Bagsværd, Denmark 17 October 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme in";144.41000366210938;"Paying attention to big price swings is useful mostly to determine those opportunistic times to ""buy low.""  The four stocks are AbbVie (NYSE: ABBV), Amazon (NASDAQ: AMZN), Texas Instruments (NASDAQ: TXN), and Intuitive Surgical (NASDAQ: ISRG).  Boring old pharmaceutical giant AbbVie is the largest holding in my portfolio.In this article, we discuss 11 best dividend aristocrats with over 3% yield. You can skip our detailed analysis of the past performance of dividend aristocrats, and go directly to read 5 Best Dividend Aristocrats With Over 3% Yield. Dividend Aristocrats are the companies in the S&P 500 that have records of raising their dividends consistently […]AbbVie (NYSE: ABBV) announced today that Laura J. Schumacher, vice chairman of external affairs and chief legal officer, will retire from the company after a period of transition, following a distinguished 32-year career at AbbVie and its predecessor company Abbott. The company also announced that Perry C. Siatis, who currently serves as senior vice president and deputy general counsel, will assume the role of executive vice president, general counsel and secretary.These ultra-reliable businesses could deliver quarterly payments that steadily grow throughout your retirement.";77.2699966430664;;94.12000274658203;An eye disease drug from NGM Biopharmaceuticals Inc. failed a mid-stage clinical trial, the company said early Monday, sending shares of the South San Francisco company falling to a new 52-week low ahead of an option decision by its Big Pharma partner.  The drug, called NGM-621, is part of a $450 million research-and-development deal with Merck & Co. Inc. (NYSE: MRK) originally signed in 2015 with a focus on NGM compounds in obesity, diabetes and the fatty liver disease called nonalcoholic steatohepatitis, or NASH.  Merck has about three months left to decide whether to exercise an option on NGM-621 and related compounds, either alone or bundled with two other pre-clinical eye drugs, NGM (NASDAQ: NGM) said.Moderna CEO Stéphane Bancel spoke with Anjalee Khemlani at Yahoo Finance's All Markets Summit about the company's deal with Merck to develop a cancer vaccine.;56.18000030517578;Moderna CEO Stephane Bancel on competing with traditional players in the drug and vaccine space.In this article, we discuss 10 best FTSE dividend stocks to buy now. If you want to see more stocks in this selection, check out 5 Best FTSE Dividend Stocks To Buy Now. The Office for National Statistics reported that the U.K. economy contracted by 0.3% in August, potentially initiating a long recession that can […]Ultomiris was just approved in the European Union to treat patients with generalized myasthenia gravis.;71.37999725341797;Sometimes, the strongest payout growth can be found among the future Dividend Aristocrats, not the current ones.;40.439998626708984;;31.299999237060547;;12.729999542236328;;41.779998779296875;NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on December 15, 2022, to shareholders of record at the close of business on November 18, 2022. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical;9.609999656677246;In this article, we discuss 10 stocks to buy according to James Morrow’s Callodine Capital Management. If you want to skip our detailed analysis of Morrow’s history, investment philosophy, and hedge fund performance, go directly to 5 Stocks to Buy According to James Morrow’s Callodine Capital Management. In 2018, James Morrow founded Callodine Capital Management, the […];204.64999389648438;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.;6.300000190734863;;10.350000381469727;;112.05999755859375;;8.770000457763672;"Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Toronto Innovation Acceleration Partners (""TIAP"") today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.TORONTO, Canada & HAMBURG, Germany, October 17, 2022--Toronto Innovation Acceleration Partners (""TIAP"") and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of US$14M to expedite LAB150 programs towards the formation of new companies.";23.809999465942383;;40.20000076293945;;7.679999828338623;;8.5600004196167;;26.68000030517578;;58.400001525878906;;208.55999755859375;;3.799999952316284;;26.665000915527344;;1.809999942779541;;5.28000020980835;;;;3.630000114440918;;5.190000057220459;;49.459999084472656;;;;20.09000015258789;;7.53000020980835;;5.03000020980835;;8.819999694824219;;2.059999942779541;;46.25;;11.319999694824219;;18.1200008392334;;2.940000057220459;;11.739999771118164;;3.819999933242798;;6.599999904632568;;16.09000015258789;;35.88999938964844;Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;19.399999618530273;;19.670000076293945;SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program (CTEP) to expa;20.649999618530273;;;;1.7100000381469727;;13.520000457763672;
2022-10-18;166.00999450683594;"The modest cuts will reflect economic pressures and the planned separation of its consumer-health business next year.J&J (JNJ) beats estimates for third-quarter earnings as well as sales. It lowers the full-year sales guidance. Stock upYahoo Finance's Anjalee Khemlani discusses Johnson & Johnson earnings as well as the outlook for COVID boosters ahead of the winter.Pre-Markets in the Green on Strong Earnings NumbersWith the Dow +640 points at this hour, the Nasdaq +280 and the S&P 500 +85 points, it's safe to say we're in the midst of a rally.A rebound in the medical device business is among the reasons for the company's strong earnings.The Dow Jones Industrial Average surged Tuesday, as Goldman Sachs and J&J reported earnings results. Netflix earnings are due out late.Yahoo Finance Live anchors discuss third-quarter earnings for Johnson & Johnson.(Bloomberg) -- Johnson & Johnson reported third-quarter earnings that beat analyst estimates as revenue grew in its drugs and medical-device businesses despite pressure from the stronger dollar.Most Read from BloombergBlinken Says China Wants to Seize Taiwan on ‘Much Faster Timeline’A Tense Pay Dispute Overshadows Nintendo’s Upcoming Bayonetta 3Putin’s War Escalation Is Hastening Demographic Crash for RussiaForecast for US Recession Within Year Hits 100% in Blow to BidenStocks Extend Rebound onBy Liz MoyerStock market investors are hoping October will prove to be a turning point for the stock market, and despite considerable volatility during the first half of the month, markets have started to cooperate more this week.  After massive gains for the Dow Jones Industrial Average (DJINDICES: ^DJI), S&P 500 (SNPINDEX: ^GSPC), and Nasdaq Composite (NASDAQINDEX: ^IXIC) on Monday, Wall Street appeared to be in a positive mood Tuesday morning as well, as futures contracts on key stock indexes had climbed another 2% by 8:45 a.m. ET.  Companies reporting their third-quarter financial results are getting a lot of attention from investors, and Johnson & Johnson (NYSE: JNJ) added its name to the list of stocks getting short-term boosts from favorable quarterly reports.Johnson & Johnson (NYSE: JNJ) has reported Q3 FY22 adjusted earnings of $2.55 per share, down 1.9% Y/Y and slightly ahead of the consensus of $2.52. Net sales increased 1.9% Y/Y (8.1% on an operational basis) to $23.8 billion, marginally beating the consensus of $23.47 billion. Pharmaceuticals contributed $13.21 billion in sales, +2.6% (9% operational), due to Darzalex, Tremfya, Stelara, Erleada, and paliperidone palmitate and COVID-19 vaccine, offset by lower sales from Remicade and Imbruvica.Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.41% and 2.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Shares of Johnson & Johnson rose 2.3% toward a two-month high in premarket trading Tuesday, after the drug and consumer products company reported third-quarter profit and sales that beat expectations, with all of its business segments topping forecasts. Net income rose to $4.46 billion, or $1.68 a share, from $3.67 billion, or $1.37 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share slipped to $2.55 from $2.60 but was above the FactSet consensus of $2.48.Johnson & Johnson on Tuesday posted better than expected third-quarter earnings on strong demand for its cancer drug Darzalex, but said it may still cut some jobs as it contends with inflationary pressure and challenges created by the strong dollar.  J&J Chief Financial Officer Joseph Wolk said the U.S. healthcare conglomerate is looking at ""right sizing"" itself, particularly as it moves from being a three-segment business to a two segment business through the spinoff of its consumer unit.  J&J said it was not immune to the affects of inflation on its business and the impact of a strong dollar, despite ""healthcare being more resilient"" than most industries.""Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,"" said CEO Joaquin Duato.The U.S. health conglomerate, which also sells medical devices and consumer health products such as Band Aid bandages and painkiller Tylenol, tightened its full-year adjusted profit forecast range.  J&J has raised prices at its consumer health unit, which it expects to spin off in mid-to-late 2023, in response to surging inflation.  On Tuesday, the company signaled that supply-chain pressures that pushed up costs at the unit were expected to ease next year.NEW BRUNSWICK, N.J., October 18, 2022--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. ""Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,"" said Joaquin Duato, Chief Executive Officer. ""Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain conStock futures extend rally as dollar eases, sentiment improves; Goldman Sachs to close out big bank earnings; Johnson & Johnson rises ahead of Q3 earnings; Nordstrom continues takeover defense with CFO departure and Netflix ad service in focus as q3 earnings loom.By Peter NurseIn this article, we will look at the 11 best nano-cap stocks to buy for 2022. If you want to explore similar stocks, you can also take a look at 5 Best Nano-Cap Stocks To Buy For 2022. Nano-cap stocks refer to companies that have a market cap of less than or around $50 million. […]In this article, we discuss 11 best dividend stocks to buy according to Warren Buffett. You can skip our detailed analysis of Buffett’s investment strategies and his fund’s recent developments, and go directly to read 5 Best Dividend Stocks to Buy According to Warren Buffett. As expected, Warren Buffett is using the current market selloff […]By Oliver GrayJohnson & Johnson  is expected to report their latest earnings on Tuesday before the market opens.  The On-Balance-Volume (OBV) line made a low in early September and another equal low in October.  The Moving Average Convergence Divergence (MACD) oscillator made a low in September and a much higher low in October for another bullish divergence.In this article, we will take a look at 12 best undervalued stocks to buy now. If you want to see some more undervalued stocks to buy, go directly to 5 Best Undervalued Stocks To Buy Now. Undervalued stocks are defined as stocks that arguably trade for below what they are worth in terms of […]By Liz Moyer";44.09000015258789;In this article, we discuss 10 best low price pharma stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Low Price Pharma Stocks To Buy Now. The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a […]Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.41% and 2.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?The European Commission today tables a number of proposals on how to curb energy price rises, increase joint purchases and fund bills for households and small businesses.  EU ambassadors in Luxembourg last night gave an overall thumbs up to what the commission described as a “heroic” package, but expect more agonising about the fine print in the coming days.Pfizer (PFE) closed the most recent trading day at $43.65, moving +1.84% from the previous trading session.Pfizer CEO Albert Bourla discusses the outlook for the mRNA platform and vaccine applications at Yahoo Finance's All Markets Summit. IBD Stock Of The Day Sarepta will lead the gene therapy market in treating a form of muscular dystrophy, an analyst said Monday.Pfizer CEO Albert Bourla joins Yahoo Finance's All Markets Summit to discuss the pharmaceutical giant's future and how it will continue to develop as current patents begin to expire.Is Pfizer stock a buy or a sell after finishing its acquisitions of GBT and Biohaven? Is PFE stock a buy or a sell right now?Pfizer CEO Albert Bourla joins Yahoo Finance's Julie Hyman at Yahoo Finance's 2022 All Markets Summit.In a historically-volatile year in the market so far in 2022, dividends have been a significant perk, helping to shield investors from drawdowns.The FDA authorized emergency use of the bivalent booster for Moderna and Pfizer for younger kids last week.Moderna CEO says not everyone will need an annual COVID booster.;335.0299987792969;When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...What happened Shares of small-cap gene therapy company Akouos (NASDAQ: AKUS) popped by as much as 87% in premarket trading Tuesday morning. The biotech's stock is racing higher this morning in response to an all-cash buyout agreement with pharma heavyweight Eli Lilly (NYSE: LLY).In this article, we discuss 10 best low price pharma stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Low Price Pharma Stocks To Buy Now. The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a […]Big Pharma Eli Lilly And Co (NYSE: LLY) has agreed to acquire Boston biotech Akouos Inc (NASDAQ: AKUS) for a 78% premium over Monday’s closing price of $7.01. Lilly is paying $12.50 per share. Lilly is also shelling out one contingent value right (CVR) for up to $3 a share. The transaction is valued at approximately $487 million plus a contingent value right for an aggregate amount of up to approximately $610 million. Akouos has integrated expertise across otology, inner ear drug delivery, and aEli Lilly and Co will acquire genetic medicine developer Akouos Inc for about $487 million in cash as the drugmaker aims to bolster its arsenal of gene therapies that target a range of disabilities.  Shares of Akouos, which is developing gene therapies for sensorineural hearing loss, soared 84% to trade 40 cents above Lilly's offer price of $12.50 before the opening bell.Shares of Akouos, which is developing gene therapies for sensorineural hearing loss, soared 84% to trade 40 cents above Lilly's offer price of $12.50 before the opening bell.  Eli Lilly has been striving to build its pipeline of gene therapies, following the acquisition of Prevail Therapeutics Inc for $1 billion last year.  It announced a $700 million investment in a new research hub in Boston, Massachusetts earlier this year that focuses on developing gene therapies.Eli Lilly and Co. said Tuesday it has entered an agreement to acquire Akouos Inc. , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610 million in cash. Under the terms of the deal, Akouos shareholders will receive $12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 in cash, for a total consideration of up to $15.50 per shEli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.By Peter NurseEli Lilly (LLY) closed at $332.76 in the latest trading session, marking a +0.41% move from the prior day.The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding common stock.;106.69999694824219;Denmark-based biotech Novo Nordisk (NYSE: NVO) is a longtime leader in the diabetes drug market.  The company's pipeline is full of exciting programs.  One in particular, icodec, looks destined to become a major growth driver for Novo Nordisk.;144.60000610351562;Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor […]Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.While AbbVie Inc. ( NYSE:ABBV ) shareholders have enjoyed a good week with stock up 4.4%, they need remain vigilant...A major pharmaceutical company like AbbVie (NYSE: ABBV) and a rising cannabis company like Tilray Brands (NASDAQ: TLRY) operate in different industries and have several other characteristics that make proper comparisons complicated.  Tilray's smaller size and strong position in a rapidly growing industry would suggest to some that its stock has great potential to 5x in value relatively quickly.  In contrast, AbbVie's got a large pipeline of potential new pharmaceuticals its developing.;77.48999786376953;Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.;94.61000061035156;"Merck & Co Inc (NYSE: MRK) and the Bill & Melinda Gates Medical Research Institute (Gates MRI) announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for tuberculosis (TB) treatment. Merck scientists discovered these candidates as part of the TB Drug Accelerator (TBDA), a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and developmeA big challenge with Moderna (NASDAQ: MRNA) right now is that many investors see it as a COVID-19 stock and not much else.  The company is developing more types of COVID vaccines, and its revenue for the foreseeable future will come primarily from Spikevax.  Although the COVID vaccine has been a huge success story for Moderna, for forward-looking investors, the business remains full of question marks and uncertainty.Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co, Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. launch of Animo® GPS, an activity and behavior monitor for dogs with GPS tracking capabilities. The product can alert pet owners within 20 seconds if their dog leaves its designated ""Safe Zone"" and offers real-time tracking with location updates from every five seconds when in ""Lost Dog Mode.""RAHWAY, N.J. & CAMBRIDGE Mass., October 18, 2022--Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates";55.970001220703125;Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor […]Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today provided a research & development update on the Company’s lead ta;71.73999786376953;Bristol Myers Squibb Company;40.04999923706055;;31.25;"SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ: CTIC) with an Outperform rating and a $13 price target. CTIC is a commercial-stage biopharmaceutical company launching Vonjo — a differentiated, next-generation JAK inhibitor for myelofibrosis. SVB thinks Vonjo will transform the treatment paradigm and offer blockbuster sales potential. ""In contrast to other targeted oncology launches, we think Vonjo will surpass expectations based on results from our proprietary MEDACorp survey of my";12.710000038146973;;42.02000045776367;NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference c;9.609999656677246;In the latest trading session, Viatris (VTRS) closed at $9.61, marking a +0.63% move from the previous day.;206.83999633789062;;6.429999828338623;In this article, we discuss 10 best low price pharma stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Low Price Pharma Stocks To Buy Now. The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a […];10.479999542236328;;112.19000244140625;;9.109999656677246;In this article, we discuss 10 best low price pharma stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Low Price Pharma Stocks To Buy Now. The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a […]Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) today announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany). PanHunter is Evotec's PanOmics data access and analytics platform and was developed and used successfully internally and in industry-shaping drug discovery partnerships over many years.;24.170000076293945;;45.90999984741211;;7.679999828338623;;9.039999961853027;;27.15999984741211;;59.0;;210.75;;3.930000066757202;;26.93000030517578;;1.7599999904632568;;5.5;;;;3.6500000953674316;;5.210000038146973;;51.209999084472656;;;;19.540000915527344;GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook for full year 2022. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, please register in advanc;7.300000190734863;;4.920000076293945;;9.119999885559082;;2.119999885559082;Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.;45.66999816894531;These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...;11.569999694824219;;18.260000228881836;;2.8299999237060547;– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal INB-01, a sol-gel based drug-delivery technology. – INB-01 may enable direct-to-brain delivery of various compounds in development across atai’s pipeline, with topline results expected in H1 2023. – Potential advantages may include ease of administration, increased patient compliance, lower dose requirements, rapid onset of action, and minimized syste;11.300000190734863;;3.75;;6.929999828338623;;15.930000305175781;With the business potentially at an important milestone, we thought we'd take a closer look at Arcturus Therapeutics...;36.5;The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.;18.979999542236328;;19.360000610351562;;19.93000030517578;;;;1.7300000190734863;;13.630000114440918;
2022-10-19;164.69000244140625;Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It outpaced revenue estimates and raised its full-year revenue guidance.In this article, we discuss 11 best high-dividend stocks under $100. You can skip our detailed discussion of dividend stocks and their returns, and go directly to read 5 Best High-Dividend Stocks Under $100. The current economic situation has completely altered investment trends this year. Investors are flocking to long-term investment strategies, with dividends gaining […]In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […]Since hitting their respective all-time highs between mid-November and the first week of January, the broad-based S&P 500, celebrated Dow Jones Industrial Average, and growth-focused Nasdaq Composite have all plunged into bear market territory (i.e., a minimum decline of 20% from a recent high).  Just ask the longtime shareholders of healthcare conglomerate Johnson & Johnson (NYSE: JNJ).  Johnson & Johnson, or J&J for short, was founded 136 years ago by three brothers (Robert Johnson, Edward Johnson, and James Johnson) who'd worked in the medical products industry.The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.Johnson & Johnson topped third-quarter expectations on Thursday despite exchange-rate challenges, but JNJ stock pared back gains.In this piece, we will take a look at the ten best recession-proof stocks to buy in October. For more stocks, head on over to 5 Best Recession-Proof Stocks to Buy in October. The aftershocks of the coronavirus pandemic are still being felt all over the globe. The virus saw industrial output collapse and led […]Please note that today's meeting may include forward-looking statements relating to, among other things, the company's future financial performance, product development, market position, and business strategy, and the anticipated separation of the company's consumer health business.  As a reminder, you can find additional materials, including today's presentation and associated schedules, on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.Given that J&J beat consensus earnings expectations by 7 cents a share, one could argue that the fourth-quarter results (and raised guidance) are already baked into the current stock price.  In this zone, we find a bevy of moving averages, including the 21-week, 50-week and 200-day.J&J’s enviable growth and focus on a consumer split means it is moving more slowly when it comes to mergers and acquisitions.In this article, we discuss 10 best S&P 500 stocks to buy according to hedge funds. If you want to read about some more S&P 500 stocks, go directly to 5 Best S&P 500 Stocks to Buy According to Hedge Funds. The Bureau of Labor Statistics in the United States recently released new inflation numbers […];43.11000061035156;"Many health-care companies talk about addressing high costs and health equity, but too many fall flat when in reaping true impact, according to at least one health-care CEO.
""We have to clean up our act. None of us is blame-free in this environment of ever-increasing health care costs,"" SCAN Group & Health Plan CEO Dr. Sachin Jain told Yahoo Finance at the 2022 All Markets Summit. Jain previously served in a number of roles spanning the industry including for federal government, academia, insurance, and Big Pharma.In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […]The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?In this article, we will take a look at 10 dividend stocks to buy amid the market decline. If you want to see some more high quality dividend stocks, go directly to 5 Dividend Stocks to Buy Amid the Market Decline. Like many other stocks in 2022, many dividend stocks have fallen substantially this year. […]Pfizer Inc. ( NYSE:PFE ) shareholders might be concerned after seeing the share price drop 13% in the last quarter. On...COVID-19 gave a shot in the arm to Pfizer's sales and culture. Now CEO Albert Bourla lays out a plan to replace vaccine revenue as the virus' impact wanes.J&J’s enviable growth and focus on a consumer split means it is moving more slowly when it comes to mergers and acquisitions.In this article, we discuss 10 best S&P 500 stocks to buy according to hedge funds. If you want to read about some more S&P 500 stocks, go directly to 5 Best S&P 500 Stocks to Buy According to Hedge Funds. The Bureau of Labor Statistics in the United States recently released new inflation numbers […]NEW YORK, October 18, 2022--IDWeek press release";329.2900085449219;Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.If you were to save $50 each week, that would result in an annual savings of $2,600.  Thanks to compounding and dividends, you can turn a $50-per-week investment into a nest egg that can help you live comfortably in your retirement years.  A couple of solid stocks that have generated consistent revenue growth over the years while also paying dividends are health insurance giant UnitedHealth Group (NYSE: UNH) and top drugmaker Eli Lilly (NYSE: LLY).Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor […]Eli Lilly & Co. is scooping up a local gene-editing startup at a 121% premium.  Lilly (NYSE: LLY) on Tuesday announced that it would acquire Boston-based Akouos Inc. (Nasdaq: AKUS) for $487 million up-front plus one non-tradeable contingent value right per share, which would put the value of the transaction at $610 million.  Lilly is valuing each Akouos share at $12.50, a 121% premium over where they had been trading over the previous 30 days on average.;104.61000061035156;In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […];143.1300048828125;In this article, we will take a look at 10 dividend stocks to buy amid the market decline. If you want to see some more high quality dividend stocks, go directly to 5 Dividend Stocks to Buy Amid the Market Decline. Like many other stocks in 2022, many dividend stocks have fallen substantially this year. […]Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;76.51000213623047;In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […];93.26000213623047;Pharmaceutical giant Merck & Co. (NYSE: MRK) spun off its women's health and biosimilars divisions, along with its portfolio of older drugs, into a separate company, Organon, last year so it could focus on its oncology therapies and vaccines.  The move has paid off handsomely both for Merck and investors.  Merck's stock is up more than 17% this year, while the Dow Jones Industrial Average has fallen more than 20% in that same period.In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […]Merck (NYSE:MRK), known as MSD outside the United States and Canada, has been named to Fortune's 2022 Change the World list. The annual list recognizes companies that have had a positive social impact through activities that are part of their core business strategy.Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;54.5099983215332;In general, the last quarter of the year is good for equity markets. However, it’s too early to assume that the markets are automatically headed higher. From the perspective of most investors, Q4 is set up to provide both opportunities and challenges. The upside is that the best time to look for stocks to buy is when there is blood in the streets. The bad news is that stocks may continue to struggle, given the current macro backdrop. So, what’s the reason for concern? Well, inflation remains hig;71.13999938964844;Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […]While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...J&J’s enviable growth and focus on a consumer split means it is moving more slowly when it comes to mergers and acquisitions.;39.63999938964844;;31.309999465942383;I know that saying “This time could be different” is dangerous. But still, when it comes to U.S. stocks, I believe that this time could be different and that the long-awaited (by me, at least) bull market may have begun. As a result, I’m more sure than I’ve ever been during the current bear market that now is the time to find high-quality, cheap stocks to buy and hold for a long time. Repeating a theme that has recurred throughout this bear market (and one that I identified early on and repeatedIn this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […];12.420000076293945;One happy consequence of a bear market is that dividend yields rise as stock prices fall.  Three beaten-up stocks trading near their 52-week lows that could be especially attractive right now include Takeda Pharmaceuticals (NYSE: TAK), Duke Energy (NYSE: DUK), and Home Depot (NYSE: HD).  Japanese drugmaker Takeda Pharmaceuticals is a leading healthcare company that makes vaccines and products addressing multiple therapeutic areas, including cancer, rare diseases, gastroenterology, and hematology.;41.040000915527344;;9.380000114440918;In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […];179.5;Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor […];6.050000190734863;;12.399999618530273;"Biohaven Ltd. (NYSE: BHVN) (""Biohaven"") announced today that it has commenced a public offering of 20,000,000 of its common shares pursuant to a registration statement on Form S-1 (the ""Registration Statement"") filed with the Securities and Exchange Commission (the ""SEC""). Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.";109.0;;8.640000343322754;;23.799999237060547;;45.0099983215332;Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.;7.329999923706055;;8.449999809265137;;25.75;CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S. financial markets open. Management will host a conference call to discuss third quarter 2022 financial results and recent business updates on Tuesday, November 8, 2022, at 8:00 a.m. ET. To access the call;57.09000015258789;;203.8800048828125;;3.680000066757202;;24.200000762939453;;1.7300000190734863;;4.300000190734863;;;;3.3499999046325684;;4.920000076293945;;50.189998626708984;;;;18.549999237060547;;7.079999923706055;;4.690000057220459;;8.75;;2.190000057220459;;43.86000061035156;;10.979999542236328;SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it will make several presentations, including a Keynote Plenary presentation by Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, at the 5th Annual TPD Summit which is being held October 25‒28, 2022, in Boston, MA. Presentation Details: Title: The First BTK Degraders in He;17.329999923706055;;2.630000114440918;;11.0600004196167;;3.569999933242798;;6.699999809265137;;14.65999984741211;;36.209999084472656;;17.75;;19.219999313354492;;19.81999969482422;;;;1.6799999475479126;;12.800000190734863;
2022-10-20;165.11000061035156;In this article, we discuss 13 best long-term dividend stocks to buy now. You can skip our detailed analysis of dividend investing in the current market environment, and go directly to read 5 Best Long-Term Dividend Stocks to Buy Now. Investor confidence has been shattered this year due to rising interest rates and an all-time […]In this piece, we will take a look at the ten Warren Buffett stocks that are too cheap to ignore. If you want to skip our introduction to the investment guru, and want to take a look at the top five stocks in this list, then head on over to 5 Warren Buffett Stocks That […]Investors are starting to clamor about whether we have seen the low for 2022 or, at the very least, whether the lows we reached last month will hold for the next several weeks. In any case, however investors really should be looking for the best blue-chip stocks to buy. In fact, no matter what the market is doing, investors really ought to be looking to buy the stocks of high-quality companies with strong businesses. Sometimes during euphoric markets, poor businesses generate robust gains. But t;42.90999984741211;ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with palbociclib in patients with KRAS- and NRAS-mutant colorectal cancer and KRAS-mutant pancreatic cancer Erasca previously signed CTCSAs with Pfizer and Lilly to evaluate ERAS-007 in combination with encorafenib and cetuximab SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializinImproving COVID booster numbers won’t be easy, according to Pfizer CEO Albert Bourla.What happened Shares of Moderna (NASDAQ: MRNA) fell 7.9% on Wednesday after health regulators authorized Novavax's (NASDAQ: NVAX) COVID-19 vaccine, Adjuvanted, as a booster for adults.  So what The Centers for Disease Control and Prevention (CDC) will allow Novavax's vaccine to be used as a first booster shot for people aged 18 and older who would rather take it than initial boosters offered by Moderna and Pfizer (NYSE: PFE).Novavax gets FDA nod for original formula as its booster differs from mRNA boosters.The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approving Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) 3-µg dose of COVID-19 vaccine for kids less than five years. The recommendation is based on data from a Phase 2/3 trial. Following the third dose in this age group, the companies' original COVID-19 vaccine was found to be 73.2% effective at preventing COVID-19, with a favorable safety profile similar to the placebo. Related:;329.07000732421875;In this article, we discuss 13 best long-term dividend stocks to buy now. You can skip our detailed analysis of dividend investing in the current market environment, and go directly to read 5 Best Long-Term Dividend Stocks to Buy Now. Investor confidence has been shattered this year due to rising interest rates and an all-time […]The company formally opened its second Gateway Labs facility in South San Francisco, in the same building as its Loxo at Lilly cancer drug unit.Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.;104.05999755859375;;142.92999267578125;"AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd (""DJS""), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS's lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the treatment of Idiopathic PulAbbVie (NYSE: ABBV) today announced Health Canada approval for SKYRIZI® (risankizumab 600 mg intravenous [IV] induction at Week 0, Week 4 and Week 8, followed by 360 mg subcutaneous [SC] injection maintenance at Week 12 and every eight weeks thereafter) for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunom";75.55000305175781;;92.94000244140625;Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.In this article, we will take a look at 15 of the biggest Dow companies by market cap. If you want to see more of the biggest Dow companies by market cap, go directly to 5 Biggest Dow Companies By Market Cap. The Dow Jones Industrial Average, or simply the Dow, is one of the […]Merck (MRK) closed the most recent trading day at $93.26, moving -1.43% from the previous trading session.;54.349998474121094;WILMINGTON, Del., October 20, 2022--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the fourth annual Cancer Community Awards (C2 Awards). A part of the AstraZeneca YOUR Cancer program, the C2 Awards celebrate and recognize inspiring work that exemplifies the full promise of community partnerships in advancing equitable access to quality cancer care.;70.3499984741211;Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?Bristol Myers Squibb Co (NYSE: BMY) announced results from the Phase 3 CheckMate -76K trial evaluating adjuvant Opdivo (nivolumab) for up to 12 months versus placebo in 790 patients with completely resected stage IIB or IIC melanoma. Opdivo as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo. Opdivo reduced the risk of recurrence or death by 58% versus placebo. Twelve-month RFS rates for Opdivo were 89PRINCETON, N.J., October 19, 2022--BMS Presents Data from CheckMate -76K Showing Opdivo Reduced the Risk of Recurrence or Death by 58% Versus Placebo.....;39.630001068115234;In the latest trading session, Sanofi (SNY) closed at $39.64, marking a -1.02% move from the previous day.;31.059999465942383;GSK (GSK) closed the most recent trading day at $31.31, moving +0.19% from the previous trading session.Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;12.5;OSAKA, Japan & FREIBURG, Germany & DARMSTADT, Germany, October 20, 2022--Takeda (TSE:4502/NYSE:TAK), Zedira and Dr. Falk Pharma GmbH today announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease. TAK-227 is a potential first-in-class therapy designed to prevent the immune response to gluten in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage to t;40.86000061035156;;9.34000015258789;;170.9499969482422;;6.0;;11.960000038146973;;106.70999908447266;;8.680000305175781;;23.559999465942383;JERSEY CITY, N.J., October 20, 2022--Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022;45.0;;7.210000038146973;;8.729999542236328;;25.610000610351562;;58.0;;203.44000244140625;;3.7899999618530273;;23.729999542236328;;1.7400000095367432;;4.510000228881836;;;;3.3499999046325684;;4.960000038146973;;48.86000061035156;;;;18.170000076293945;;7.090000152587891;ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with palbociclib in patients with KRAS- and NRAS-mutant colorectal cancer and KRAS-mutant pancreatic cancer Erasca previously signed CTCSAs with Pfizer and Lilly to evaluate ERAS-007 in combination with encorafenib and cetuximab SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializin;4.679999828338623;;8.970000267028809;;2.1600000858306885;;43.90999984741211;;10.979999542236328;(Bloomberg) -- Cathie Wood has been buying shares of Nurix Therapeutics Inc., a small and relatively little-known biopharmaceutical company, every trading day since Oct. 10.Most Read from BloombergWeed Is Coming to Circle K Gas Stations in US Next YearTrump Prosecutors See Evidence for Obstruction ChargesChina Is Debating a Reduction to Covid Quarantine for Inbound TravelersTruss’s Government on Brink as Tories Agitate for Her to GoA Tense Pay Dispute Overshadows Nintendo’s Upcoming Bayonetta 3W;16.940000534057617;;2.8299999237060547;NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day. During this event, management and scientific leaders will provide a comprehensive review of atai’s diversified mental health pipeline. The event will also provide updates on near-term catalysts, with a focus on the upcoming Phase 2a toplin;10.800000190734863;;3.9200000762939453;;7.0;;14.140000343322754;;34.65999984741211;;17.360000610351562;;19.25;;18.5;;;;1.6699999570846558;;12.869999885559082;
2022-10-21;168.7100067138672;"The Centers for Disease Control and Prevention has refuted claims that it will add COVID-19 vaccine to immunization schedules for schoolchildren, noting authority for that decision lies with states and other local entities.J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.Reddit stocks get a bad rap.  Sure, the social media platform where retail investors sometimes swap stock tips has helped spur the curious multiple rises and falls of GameStop, AMC Entertainment, and Bed, Bath and Beyond.  Sure, there are plenty of dubious names on the list, but you'll also find a few stocks that are great long-term investments, or as Reddit users and cryptotraders like to say, ""HODLS.""A 1965 Harvard alumnus has given the school $350 million to support a Harvard institute that seeks to develop technology to aid health care and the environment.Johnson & Johnson and Procter & Gamble both produced solid results";44.95000076293945;Pfizer's plan to as much as quadruple current U.S. prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said.  The drugmaker, which developed and sells the vaccine with Germany's BioNTech said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the United States moves to a commercial market next year.  Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set.Notable business headlines include Walmart agreeing to pay a $215 million fine to the state of Florida over opioid crisis claims, Deutsche Bank laying off dozens of employees, Pfizer aiming to raise the prices for its COVID vaccine, and Adidas cutting its full-year guidance.(Reuters) -Pfizer's plan to as much as quadruple U.S. prices for its COVID-19 vaccine next year is beyond Wall Street's expectations and will spur its revenue for years despite weaker than anticipated demand for the new booster shot so far, analysts said.  The drugmaker, which developed and sells the vaccine with Germany's BioNTech, said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the United States moves to a commercial market next year.  Pfizer shares were up 4.3% at $44.77 in afternoon trading.Pfizer's attempt to as much as quadruple its current U.S. prices for its COVID-19 vaccines going forward could spur revenues for years, analysts said.  The drugmaker, which developed and sells the vaccine with Germany's BioNTech said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the United States moves to a commercial market next year.  Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set.The company plans to sell the COVID-19 shot it developed with BioNTech for $110 to $130 per dose once the U.S. market for COVID-19 shots becomes commercial.With the dwindling demand for COVID-19 shots, vaccine makers such as Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), and Novavax Inc (NASDAQ: NVAX) could possibly raise prices to meet Wall Street forecasts. The hike could be as much as three times current levels. Citing a recent poll by Kaiser Family Foundation, Reuters reported that two-thirds of American adults do not plan on getting a COVID vaccine soon. Analysts expect the U.S. market to be as low as one-thirdThe following are the top stories in the Wall Street Journal.  - The Pentagon is set to expand its use of Elon Musk’s SpaceX satellite capabilities despite a recent dispute between the two sides over the funding of satellite-based internet services for an embattled Ukraine.  - Texas sued Alphabet Inc’s Google on Thursday, alleging the search giant violated state laws by collecting biometric data on face and voice features without seeking the full consent of users.The drugmaker laid out a potential price as it prepares to sell the shot commercially, perhaps early next year.Pfizer Inc expects to roughly quadruple the price of its COVID-19 vaccine to about $110 to $130 per dose after the United States government's current purchase program expires, Pfizer executive Angela Lukin said on Thursday.  Lukin said she expects the vaccine - currently provided for free to all by the government - will be made available at no cost to people who have private insurance or government paid insurance.  Reuters earlier on Thursday reported that Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant vaccine makers would need to hike prices to meet revenue forecasts for 2023 and beyond.Pfizer Inc expects to charge about $110 to $130 per dose for its COVID-19 vaccine after the United States government's current program expires, Pfizer executive Angela Lukin said on a call with analysts.  Lukin said she expects the vaccine will be made available with no co-pay to people who have private insurance or government paid insurance.  The U.S. government currently provides the vaccine for free to all but pays about $30 per dose to Pfizer and German partner BioNTech SE.If the Centers for Disease Control and Prevention follows the guidance of its advisory panel, the shots would be part of the agency’s lists of recommended inoculations for adults and children.The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.;340.7699890136719;Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.Alzheimer's therapies are big news lately.  The disease is the leading cause of dementia and memory loss.  The Alzheimer's Association estimates that 6.5 million Americans 65 and older are living with Alzheimer's dementia (AD) and by 2050, the number of people 65 and older with AD is projected to reach 12.7 million.Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.;104.22000122070312;;147.05999755859375;J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.S&P 500 members that have increased their dividends for at least 25 consecutive years -- meet that quality threshold.  Here are three Dividend Aristocrats to buy right now with no hesitation (listed in alphabetical order).  AbbVie (NYSE: ABBV) has increased its dividend for 50 years in a row.Take the case of AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA).  AbbVie spun off from Abbott Laboratories in 2013 to shield the parent company from an impending loss-of-exclusivity disaster.  International sales of AbbVie's lead drug, an anti-inflammation injection called Humira, tanked a few years ago when biosimilar competition became available in the EU.In the latest trading session, AbbVie (ABBV) closed at $142.93, marking a -0.14% move from the previous day.;77.0999984741211;Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.;95.66999816894531;AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;54.970001220703125;Alzheimer's therapies are big news lately.  The disease is the leading cause of dementia and memory loss.  The Alzheimer's Association estimates that 6.5 million Americans 65 and older are living with Alzheimer's dementia (AD) and by 2050, the number of people 65 and older with AD is projected to reach 12.7 million.Astrazeneca (AZN) closed the most recent trading day at $54.35, moving -0.29% from the previous trading session.;72.20999908447266;PRINCETON, N.J., October 21, 2022--U.S. FDA Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) .....Bristol Myers Squibb (BMY) closed the most recent trading day at $70.35, moving -1.11% from the previous trading session.Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.;40.439998626708984;;31.8700008392334;;12.680000305175781;;41.02000045776367;;9.380000114440918;;167.02999877929688;LGND vs. RGEN: Which Stock Is the Better Value Option?;6.079999923706055;Spanish pharma group Grifols said on Friday a lawsuit filed in the United States by blood donors who claim the company violated their privacy would have no material impact, after a report in newspaper El Economista sent the shares sharply lower.  The company said about 54,000 donors in Illinois had filed a lawsuit claiming Grifols breached data protection regulations, confirming the newspaper report.  Grifols shares were down 5.3% on Friday morning, briefly the worst performer on the blue-chip Ibex-35 index, which was down 2.1%.;14.079999923706055;"Biohaven Ltd. (NYSE: BHVN) (""Biohaven"") announced today the pricing of the public offering of 25,000,000 of its common shares, at a public offering price of $10.50 per common share. Biohaven has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 common shares. The offering is expected to close on October 25, 2022, subject to the satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate p";108.5;;8.8100004196167;;23.68000030517578;;47.630001068115234;;7.489999771118164;;8.930000305175781;;26.229999542236328;;59.81999969482422;;210.1699981689453;;3.880000114440918;;24.43000030517578;;1.7699999809265137;;4.809999942779541;;;;3.490000009536743;;5.309999942779541;;50.16999816894531;;;;18.65999984741211;;7.489999771118164;;4.78000020980835;;9.220000267028809;;2.119999885559082;;44.959999084472656;;11.369999885559082;;17.34000015258789;;2.859999895095825;;10.699999809265137;;3.690000057220459;;7.0;;14.710000038146973;;33.38999938964844;"PLANO, Texas, October 20, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" or ""we""), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education data on Friedreich’s ataxia will be presented at the International Congress for Ataxia Research 2022 (""ICAR"") being held in Dallas, TX from November 1 – 4, 2022.";17.479999542236328;Findings presented at the annual Fall Clinical Dermatology ConferenceSurvey found that path to diagnosis for people with seborrheic dermatitis (average of 3.6 years) substantially longer than estimated by physicians (average of 1.5 years)Prior to diagnosis, 71% of individuals with seborrheic dermatitis said they had not heard of the disease and 56% found it hard to find information onlineNearly 9 in 10 individuals with seborrheic dermatitis wished they had known that there were specific symptoms;19.540000915527344;;19.389999389648438;;;;1.600000023841858;;13.270000457763672;
2022-10-26;172.2100067138672;;46.060001373291016;;357.8599853515625;;107.80999755859375;;152.50999450683594;;79.61000061035156;In this article, we will discuss 10 best foreign stocks with dividends. You can skip our detailed discussion on foreign investments, and go directly to read 5 Best Foreign Stocks With Dividends. A Wall Street Journal report published earlier this year cited data from the United Nations and mentioned that foreign investments saw a 77% […]Novartis stock was mostly unmoved Tuesday after the company's earnings beat expectations, but third-quarter sales came up short.Thank you again for taking the time to participate in Novartis' Quarter 3 conference call.  For a description of some of these factors, please refer to the company's Form 20-F, its most recent quarterly results on Form 6-K that respectively were filed with and furnished to the U.S. Securities and Exchange Commission.Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.;98.41000366210938;;57.959999084472656;;74.44999694824219;;41.849998474121094;;32.689998626708984;Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Merck will soon share its positive phase 3 clinical trial results for a rare disease drug candidate at an upcoming event.The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.  J&J's teclistamab, branded as Tecvayli, is approved for treating adults with multiple myeloma that is hard to treat or has come back after receiving four or more prior lines of certain classes of therapies, the company said.  Tecvayli is a bispecific antibody, which is engineered to redirect body's immune system to recognize and kill cancer cells.;12.970000267028809;;42.02000045776367;;9.970000267028809;;182.1999969482422;Gritstone bio Inc. (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;6.420000076293945;;;;101.61000061035156;COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, November 2, 2022, at 4:30 p.m. Eastern Time (ET) to review its third quarter 2022 financial results and provide a business update. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Invest;9.789999961853027;;25.290000915527344;;48.83000183105469;;7.599999904632568;;8.760000228881836;;28.040000915527344;;58.40999984741211;;218.25;There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...;3.9700000286102295;;25.579999923706055;;1.8899999856948853;;5.190000057220459;;;;3.759999990463257;Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.;5.5;;51.439998626708984;Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Harmony Biosciences, Tuesday's IBD 50 Stocks to Watch pick, is a leading health stock hitting a buy point in a cup-with-handle base.  The company ranks fourth in the Medical-Biomed/Biotech industry group, which is sixth out of the 197 IBD groups, holding a solid 97 Group Relative Strength Rating.  The pharmaceutical juggernaut specializes in therapies for people with neurological conditions, focusing on narcolepsy, a rare sleep disorder.;;;21.229999542236328;;7.380000114440918;;4.769999980926514;On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.;10.850000381469727;;2.309999942779541;;46.79999923706055;;12.069999694824219;Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation and immunomodulatory activity achieved by day 8 and associated with confirmed complete response at first clinical assessment Clinical activity is consistent with potential synergy of NX-2127 dual mechanism of action Clinical update on chronic lymphocytic leukemia (CLL) patients in the NX-2127 Phase 1 trial scheduled for presentation at the American Soci;18.510000228881836;;2.984999895095825;;10.0;;3.990000009536743;;6.96999979019165;;17.030000686645508;;32.65999984741211;;16.6200008392334;WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 5:00 p.m. ET on Tuesday, November 8, 2022, to report its third quarter financial results. The schedule for the press release and conference call/webcast is as follows: Q3 2022 Press Release: Tuesday, November 8, 2022, after t;20.6200008392334;;19.649999618530273;;17.59000015258789;;1.7799999713897705;;14.8100004196167;
2022-10-27;172.30999755859375;;45.7400016784668;;356.3299865722656;;106.61000061035156;;153.5;;79.54000091552734;Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.Now is the time for investors to load up on dividend stocks.  Not only could the stocks on this list deliver profits from their share prices, but they can also provide solid dividend income for the foreseeable future.  Shares of Novartis (NYSE: NVS), Enbridge (NYSE: ENB), and Verizon Communications (NYSE: VZ) are all down this year.;99.73999786376953;;57.61000061035156;;74.5999984741211;Bristol Myers Squibb (NYSE: BMY) has been a top healthcare stock to own for decades.  It had eight blockbuster drugs last year that generated more than $1 billion in annual revenue, including top-selling cancer drug Revlimid, which brought in nearly $13 billion all on its own.  At the end of October 2017, shares of Bristol Myers closed at $61.66.Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has opted to extend the term of the parties' multi-year strategic collaboration for the discovery and development of novel, regulated cell therapies that utilize Obsidian's cytoDRiVE® technology for the controlled expression of the immune enhancer CD40L. Today's announcement builds on the existing relationship between Obsidian andTo get a sense of who is truly in control of Bristol-Myers Squibb Company ( NYSE:BMY ), it is important to understand...Bristol Myers Squibb's management team was quick to point to the strong performance of several new drugs in its portfolio.  Bristol Myers Squibb CEO Giovanni Caforio noted in the Q3 results press release that the company has launched nine new products over the last three years, with three of them coming in 2022.  Bristol Myers Squibb's share price is up around 17%, trouncing the performance of the S&P 500.;41.58000183105469;;32.720001220703125;"Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.GSK plc (NYSE: GSK) has issued an update on the ContRAst phase 3 program for otilimab, an investigational monoclonal antibody for moderate to severe rheumatoid arthritis (RA). The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to or could not tolerate available treatments. ContRAst-1 and ContRAst-2 met their primary endpoints of a statistically significant ACR20 response versus placebo at week 12 in patients with inadequate responsThe FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 13 to 3 votes in favor of GSK plc's (NYSE: GSK) daprodustat for adult dialysis patients with anemia of chronic kidney disease (CKD). In adult non-dialysis patients with anemia of CKD, the CRDAC did not support that the benefit of treatment with daprodustat outweighs the risks with a 5 to 11 vote. In April 2022, the FDA accepted the daprodustat marketing application and assigned a Prescription Drug User Fee Act date of 1 FeGSK Plc came closer to securing its first drug approval since its consumer health spin-off in July as an expert panel of the U.S. health regulator backed an approval for its drug to treat anemia in some patients with chronic kidney disease (CKD).  The advisers to the Food and Drug Administration on Wednesday voted 13-3 in favor of the oral drug for patients on dialysis, although GSK was expecting approval for a broader CKD population.  ""The statistical data (was)... more reassuring for this population than for the ND (not on dialysis) population,"" said panelist Thomas Wang from UT Southwestern Medical Center in Texas.A panel of U.S. Food and Drug Administration advisers on Wednesday recommended approval for GSK Plc's drug to treat anemia caused by chronic kidney disease (CKD) for a smaller-than-expected patient population.";13.039999961853027;"Takeda Pharmaceutical Co Ltd's (NYSE: TAK) first-half net profit declined 9.2% from the prior year to ¥166.8 billion. Earnings per share fell 8.1% to ¥108. Core net profit grew 9.2% Y/Y to ¥446.7 billion, and core earnings per share were up 34.6% to ¥288. Revenue increased by 10.1% to ¥1.97 trillion. Core revenues climbed 19%, and core revenues at constant exchange rates grew 5.5%. Related: European Regulator Backs Approval Of Takeda's Dengue Vaccine. ""Our first half results are driven by strongOSAKA, Japan, October 27, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2022 (period ended September 30, 2022), upgrading reported and core forecasts and free cash flow outlook for the fiscal year and reconfirming Management Guidance for core growth at constant exchange rate (CER).";42.040000915527344;;9.869999885559082;Viatris Inc's (NASDAQ: VTRS) Mylan is voluntarily recalling one lot of Octreotide Acetate Injection, 500 mcg/mL, packaged in a carton of ten 1mL syringes due to a product complaint of the presence of glass particles in a syringe. The lot was manufactured by Italfarmaco SpA, Italy, and was distributed by Mylan Institutional LLC in the U.S. between January 11 and June 21, 2022. Also read: Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label. Octreotide Acetate Injection is ind;180.7100067138672;;6.170000076293945;;;;103.76000213623047;;9.619999885559082;;25.950000762939453;;47.15999984741211;;7.510000228881836;;8.649999618530273;"HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China. The first patient in China received the first dose on October 27, 2022. The study is a randomized, open-label, active-controlled study to evalu";28.190000534057617;;59.2400016784668;;221.88999938964844;;3.950000047683716;;24.389999389648438;;1.7999999523162842;;5.28000020980835;;;;3.6600000858306885;Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;5.389999866485596;CULVER CITY, Calif., October 27, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be presenting at the Jefferies London Healthcare Conference, which is taking place in London from November 15-17, 2022.;51.70000076293945;;;;20.8700008392334;"SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (""SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the company has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc. (NYSE: EBS). Emergent will provide contract development an";7.25;;4.519999980926514;AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.;10.59000015258789;;2.2300000190734863;;47.95000076293945;;12.220000267028809;;18.43000030517578;;2.990000009536743;;9.850000381469727;;3.880000114440918;;6.900000095367432;;16.200000762939453;"SAN DIEGO, October 26, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2022 after the market close on Wednesday, November 9 and will also host a conference call and webcast a";30.0;;16.6299991607666;;20.81999969482422;;19.049999237060547;;;;1.9299999475479126;;14.640000343322754;
2022-10-28;174.8699951171875;;47.43000030517578;;359.8999938964844;;108.95999908447266;;147.61000061035156;;80.76000213623047;Zymergen signed a 12-year lease for the biotech landmark site — once the headquarters of Chiron Corp. — and mostly completed renovations but never moved in before completing the company's sale this month to Ginkgo.Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.;100.7699966430664;;58.709999084472656;;76.83000183105469;;43.04999923706055;Sanofi SA (NASDAQ: SNY) said it now expects 2022 adjusted earnings per share to grow by about 16%. The positive currency impact on 2022 business EPS is estimated at +9.5% to +10.5%. It had previously forecast growth of 15%. The company reported Q3 sales of €12.48 billion, +19.7% Y/Y supported by the strong performance of specialty care driven by Dupixent, Flu vaccines, and core assets from General Medicines. Dupixent sales increased 44.5% to €2.3 billion. Related: Sanofi Ends Development Of BreaFrench drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.  Sanofi said it now expects 2022 adjusted earnings per share to grow by about 16%, not taking into account an expected positive currency impact of between 9.5% and 10.5%.  It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to 4.5 billion euros ($4.5 billion), well ahead of an average analyst estimate of 4.17 billion.The French pharma major reported net profit of 2.08 billion euros ($2.07 billion) compared with EUR2.34 billion the year prior, missing analysts' expectations of EUR3.67 billion.(Reuters) -French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.  Sanofi said it now expects 2022 adjusted earnings per share to grow by about 16%, not taking into account an expected positive currency impact of between 9.5% and 10.5%.  It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to 4.5 billion euros ($4.5 billion), well ahead of an average analyst estimate of 4.17 billion.Continued strong growth in Q3 with key regulatory milestones achieved Paris, October 28, 2022 Q3 2022 sales growth of 9.0% at CER driven by Specialty Care and Vaccines Specialty Care grew 19.9% driven by Dupixent® performance (€2,314 million, +44.5%) and launch momentum in Rare DiseaseVaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchisesGeneral Medicines achieved 2.4% core assets growth despite lower Lovenox® sales due to dBioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.;33.27000045776367;;13.199999809265137;;42.7599983215332;;10.069999694824219;;181.99000549316406;;6.28000020980835;;;;110.0;;9.609999656677246;"Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO today announced the launch of ""Extend"", a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries.";26.18000030517578;;49.560001373291016;;7.599999904632568;;8.619999885559082;;28.729999542236328;;60.599998474121094;;225.07000732421875;;3.859999895095825;;25.360000610351562;;1.8600000143051147;;5.400000095367432;CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced it will host a conference call and webcast on Thursday, November 10, 2022 at 8:00 a.m. ET to report its third quarter 2022 financial results and provide a business update. A live webcast of the call will be available on the “Investor Relations” page of the Company’;;;3.759999990463257;ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;5.800000190734863;;52.380001068115234;;;;21.450000762939453;;7.989999771118164;;4.579999923706055;;11.170000076293945;;2.3399999141693115;;50.810001373291016;;12.829999923706055;;18.75;;3.0;;10.598999977111816;;4.0;;6.809999942779541;;17.360000610351562;;29.81999969482422;;17.5;;21.350000381469727;;20.459999084472656;Just because a business does not make any money, does not mean that the stock will go down. For example, although...;;;1.9800000190734863;;15.609999656677246;
2022-10-31;173.97000122070312;;46.54999923706055;;362.0899963378906;;108.83999633789062;BAYRY vs. NVO: Which Stock Is the Better Value Option?;146.39999389648438;;81.12999725341797;;101.19999694824219;;58.810001373291016;;77.47000122070312;Bristol Myers Squibb & Co (NYSE: BMY) announced topline data from COMMANDS Phase 3 study of Reblozyl (luspatercept-aamt) in adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) who require RBC transfusions. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in red blood cell transfusion independence (RBC-TI) with concurrent hemoglobin (Hb) increase. Read Next: Revlimid Generic Competition,Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...PRINCETON, N.J., October 31, 2022--Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial;43.22999954223633;Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.;33.16999816894531;;13.220000267028809;;42.31999969482422;;10.130000114440918;;182.49000549316406;;6.309999942779541;;;;115.0;- PDUFA target action date is April 30, 2023 - MAA submission to EMA on track for this quarter COPENHAGEN, Denmark, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism and has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2023. TransCon PTH is;9.729999542236328;;26.18000030517578;;49.81999969482422;;7.28000020980835;;8.84000015258789;;27.959999084472656;;60.4900016784668;;219.33999633789062;The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns.;3.7100000381469727;;24.010000228881836;;1.899999976158142;;5.139999866485596;;;;3.759999990463257;;5.5;;52.0;;;;20.860000610351562;;8.170000076293945;;4.440000057220459;LAUSANNE, Switzerland, October 31, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates.;11.069999694824219;;2.200000047683716;;50.34000015258789;;12.729999542236328;;18.459999084472656;;2.950000047683716;;10.180000305175781;;3.9700000286102295;BOSTON and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies London Healthcare ConferenceDate: Thursday, November 17, 2022Location: London, UKFireside Chat: 10:55 AM GMT Event: Evercore ISI HealthCONx Conference (V;7.369999885559082;;17.700000762939453;;32.20000076293945;The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns.;17.68000030517578;;21.139999389648438;;20.0;;;;1.9700000286102295;;15.0600004196167;
2022-11-01;173.08999633789062;;48.0099983215332;;352.5799865722656;;106.43000030517578;;146.91000366210938;;81.05999755859375;Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.Madison Funds, managed by Madison Asset Management, LLC, released its “Madison Investors Fund” third quarter 2022 investor letter – a copy of which can be downloaded here. The Madison Investors Fund (Class Y) was down -5.46% in the third quarter, compared to the -4.88% decline in the benchmark S&P 500 Index. The Fund (-21.21%) remains ahead […];99.76000213623047;;59.849998474121094;;77.69999694824219;;42.9900016784668;;33.459999084472656;"Pfizer Inc said on Tuesday its experimental respiratory syncytial virus (RSV) vaccine was found effective for preventing severe infections in infants after being given in a late-stage study to expectant mothers in the second half of pregnancy.  Pfizer's shot, if approved, could be the first maternal vaccine available to relieve the burden of the disease in young infants.  ""Maternal immunization takes advantage of the ability to protect the infant from day one... which is important because the peak of hospitalization in these infants due to RSV is around one to two months of age,"" Kena Swanson, Vice President of Viral Vaccines at Pfizer, said in an interview.The growing $7 billion market is currently dominated by Pfizer, and rivals’ interest in winning more of the business shows the pharmaceutical industry’s renewed focus on vaccines.Sales of GSK's vaccine segment, especially meningitis and influenza vaccines, are likely to have been an important contributor to third-quarter 2022 sales.";13.279999732971191;;42.220001220703125;;10.25;In this article, we will discuss 11 best dividend stocks under $20. You can skip our detailed analysis of dividend stocks and their returns in the past, and go directly to read 5 Best Dividend Stocks Under $20. Before dividend stocks, growth companies were all the rage as they reinvested capital to grow their businesses. […];185.5500030517578;Repligen (RGEN) delivered earnings and revenue surprises of 13.24% and 4.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organicDelivers base business growth of 29% for the quarterExpands Process Analytics portfolio with DRS Daylight Solutions agreement WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2022. ProvidWALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (“Purolite”), for the development and manufacturing of affinity ligands focused on monoclonal antibodies (“mAb”) and antibody fragments. Repligen entered into an exclusive agreement with Purolite in 2018 for the development and supply of NGL-Impact® Protein A ligands. This agreement extends our exclusive partnersRepligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.;6.599999904632568;;;;116.70999908447266;;9.720000267028809;;26.389999389648438;;51.0099983215332;;7.260000228881836;;8.600000381469727;;29.31999969482422;;60.65999984741211;Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its third quarter 2022 financial results on Monday, November 7, 2022 at 4:30 p.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events a;224.33999633789062;BOSTON, November 01, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Troy Ignelzi, chief financial officer of Karuna Therapeutics, will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, November 16, 2022, at 3:50 p.m. GMT (10:50 a.m. EST).Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. The fund delivered negative returns in the third quarter. The portfolio recorded impressive gains at the beginning of the quarter. In contrast, there was a disappointing selloff […];3.9000000953674316;;24.260000228881836;Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their collaboration with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, for the development of a systems pharmacology model in multip;1.899999976158142;MIAMI, Nov. 01, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2022 after the close of the U.S. financial markets on Tuesday, November 8, 2022. OPKO’s senior management will provide a business update and discuss financial results as well as provide financial guidance during a conference call and live audio webcast on November 8th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCA;5.300000190734863;;;;3.809999942779541;;5.489999771118164;;59.2599983215332;"Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,600 Prader-Willi Syndrome (PWS) Phase 2 Proof-Of-Concept Study Topline Data Showed Positive Signal in Treating Excessive Daytime Sleepiness Good Momentum in Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study Conference Call and Webcast to be Held Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- HarmonHarmony Biosciences Holdings, Inc. (""Harmony"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced initial topline results from its Phase 2 proof-of-concept study in patients with Prader-Willi syndrome (PWS), which showed a positive signal on improvement in the primary outcome related to excessive daytime sleepiness (EDS).";;;20.920000076293945;Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.;8.010000228881836;;4.420000076293945;LAUSANNE, Switzerland, November 01, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022. The Company also announced the appointment of Peter Graham as Chief Legal Officer, effective November 1, 2022. Both Ms. Harrington-Smith and Mr. Graham will serve on the Company’s leadership team.;11.180000305175781;;2.3299999237060547;"BRIDGEWATER, N.J., October 31, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced it has appointed Reem Malki as Senior Vice President, Chief Quality Officer, and Maryll W. Toufanian as Senior Vice President, Regulatory Strategy and Policy.";50.689998626708984;;13.1899995803833;;18.5;;3.380000114440918;NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its third quarter 2022 financial results and business update on Thursday, November 10, 2022. A video interview with atai management will be available at 8:30 a.m. (ET) at https://vimeo.com/atailifesciences. The archived video will be available in the “Events” section of th;10.0;;4.159999847412109;;6.918000221252441;;18.280000686645508;Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?;33.529998779296875;"PLANO, Texas, October 31, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the third quarter ended September 30, 2022, and provide an update on the Company’s business operations and clinical development programs on November 8, 2022, before the U.S. financial markets open.";18.209999084472656;;20.219999313354492;;18.899999618530273;;;;2.0299999713897705;;15.430000305175781;
2022-11-02;170.42999267578125;;47.06999969482422;;354.9599914550781;;113.2300033569336;Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.Novo Nordisk A/S (NYSE: NVO) reported that its 9-month operating profit increased by 28% Y/Y and 14% at constant exchange rates to DKK 57.7 billion. Q3 operating profit was up 33% to DKK 20.18 billion. Net profit for nine months increased to DKK 41.9 billion from DKK 36.9 billion in the prior year. Q3 net profit increased 19% to DKK 14.41 billion. Net sales increased to DKK 128.86 billion from DKK 102.47 billion, and sales were up 28% Y/Y to DKK 45.57 billion in Q3. Lars Fruergaard Jørgensen, thNovo Nordisk raised its full-year earnings outlook after better-than-expected profit on strong sales of diabetes treatment Ozempic.(Reuters) -European shares gave up early gains and closed lower on Wednesday as investors exercised some caution ahead of the U.S. Federal Reserve's interest rate hike decision later in the day.  The pan-European STOXX 600 index slipped 0.3% to snap a three-day winning run that took it to near seven-week highs.  Wall Street's main indexes also slipped after a bigger-than-expected increase in October private payrolls offered more evidence of labour market resilience, suggesting that the Fed could stick to its aggressive rate hikes for a while.Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.(Reuters) -Danish drugmaker Novo Nordisk raised its full-year earnings outlook after reporting better-than-expected profit on strong sales of diabetes treatment Ozempic, lifting its shares to a three-month high.  The company predicted 2022 operating profit growth at constant exchange rates of 13-16%, up from a previous target range of 11-15%.  Third-quarter operating profit rose by almost a third to 20.2 billion Danish crowns ($2.7 billion), above the 19.2 billion forecast by analysts, based on Refinitiv data.Financial report for the period 1 January 2022 to 30 September 2022 Operating profit increased by 28% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 57.7 billion. Sales in North America Operations increased by 37% in Danish kroner (22% at CER), and sales in International Operations increased by 16% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 29% in Danish kroner to DKK 113.2 billion (18% at CER), mainly driven by GLP-1 diabetes sales gro;144.52000427246094;;80.58999633789062;;99.4000015258789;;59.70000076293945;;77.44999694824219;The annual price of a newly-launched cancer drug in the United States averaged $283,000 last year, a 53% increase from 2017, according to a new report from U.S. Democratic Representative Katie Porter, a consumer bankruptcy law professor running for re-election in California.  Cancer is the second leading cause of death in the United States, oncology treatments are nearly four times as costly as other therapies and are largely paid for by taxpayer-funded programs like the government's Medicare plan for people over age 65, the report notes.  Reuters reported in August on the record-high launch prices of new drugs in 2022 versus 2021 – an area that has driven drugmaker profits as they limited year-over-year price increases on existing drugs due to pressure from lawmakers and the public.Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.PRINCETON, N.J., November 02, 2022--Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022Bristol Myers Squibb has a long-standing partnership with The Leukemia & Lymphoma Society (LLS) and has been the top biopharma fundraising team for Light The Night® for more than a decade. Since 1949, the LLS has invested nearly $1.5 billion in cancer research, and has provided more than $431 million in co-pay financial assistance to patients. While Light The Night® is a U.S.-based event, it supports the LLS, which is a global leader in cancer research.;42.939998626708984;Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.;33.119998931884766;GSK Plc's (NYSE: GSK) Q3 turnover reached £7.83 billion, up 18% Y/Y on the actual exchange rate (AER) and 9% on a constant exchange rate (CER) basis. Specialty Medicines turnover was £2.7 billion, up 36% AER, and 24% CER, driven by consistent growth in all therapy areas. Excluding sales of Xevudy were £2.34 billion, up 22% at AER, and 11% at CER in the quarter. Sales of Xevudy (sotrovimab) for COVID-19 treatment stood at £411 million. Recently, GSK decided not to progress with regulatory submissThe GSK group posted an 18% rise in sales to £7.8bn over the third quarter.Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?By Peter NurseBy Scott Kanowsky;13.130000114440918;;42.27000045776367;;10.069999694824219;Viatris (VTRS) closed at $10.25 in the latest trading session, marking a +1.18% move from the prior day.Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.;171.52000427246094;;6.489999771118164;;14.6899995803833;;113.94000244140625;;9.479999542236328;"Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today presents at its Capital Markets Day an update on how the Company is taking meaningful steps to transform biologics manufacturing to enable global access.";25.93000030517578;;50.529998779296875;;7.179999828338623;;8.65999984741211;;28.739999771118164;;59.25;;217.66000366210938;;3.6500000953674316;;23.239999771118164;;1.8799999952316284;;5.309999942779541;;;;3.640000104904175;;5.369999885559082;;58.4900016784668;Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) shareholders would be excited to see that the share price has had a...Harmony crushed third-quarter forecasts and unveiled promising results for its narcolepsy drug — leading the biotech stock to surge Tuesday.At this time, I would like to welcome everyone to the Harmony Biosciences third quarter 2022 financial results conference call.  Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences third quarter 2022 financial results and provide a business update.;;;20.079999923706055;GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted single dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in prior recipients of other investigational alphavirus vaccines. The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participan;7.329999923706055;;4.130000114440918;;10.25;BILLERICA, Mass., November 01, 2022--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, November 8, 2022, to discuss its third quarter 2022 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company’s President and Chief Executive Officer, and Michael Doyle, the Company’s Chief Financial Officer.;2.109999895095825;"BRIDGEWATER, N.J., November 02, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (""FDA"") for leuprolide acetate for injection.";49.619998931884766;;12.619999885559082;;18.010000228881836;;3.140000104904175;NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences: Financial Times Pharma and Biotech Summit in LondonFormat: Industry PanelDate and Time: Wednesday, November 9th, 9:55 a.m. – 10:40 a.m. ETConference link: Financial Times’ Pharma and Biotech Summit Credit Suisse Ann;10.390000343322754;;4.110000133514404;;6.920000076293945;;21.690000534057617;"Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced a strategic collaboration with CSL Seqirus, a unit of CSL Limited (OTC: CSLLY) Under the terms of the agreement, Arcturus will provide CSL Seqirus with a license to their self-amplifying mRNA technology to support the research, development, manufacture, and commercialization of vaccines for SARS-CoV-2 (COVID-19), influenza, pandemic-preparedness, as well as three other globally prevalent respiratory infectious diseases. The collaboratioSAN DIEGO, November 01, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced a strategic collaboration with CSL Seqirus, a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines. CSL Seqirus’ vaccine portfolioCSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc (""Arcturus Therapeutics"") to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.";33.369998931884766;;17.579999923706055;;19.5;;18.31999969482422;;;;2.0;;14.8100004196167;
2022-11-03;170.72000122070312;;46.56999969482422;;361.67999267578125;;113.87000274658203;"Companies In The News Are: CVS, HUM, ETR, NVO.You likely know it as a brand of paint and a chain of paint stores, but that's not all The Sherwin-Williams Company (NYSE: SHW) is.  The company also manages an industrial coatings business serving industries ranging from automotive to energy to aerospace to packaging and more.  The homebuilding boom between 2011 and early this year coincides with comparably paced revenue growth for this popular paint brand.Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.My name is Lars Fruergaard Jorgensen, and I'm the CEO of Novo Nordisk.  With me today, I have executive vice president and head of commercial strategy and corporate affairs, Camilla Sylvest; executive vice president and head of North America operations, Doug Langa; executive vice president and head of development, Martin Holst Lange; and finally, chief financial officer, Karsten Munk.";144.4199981689453;;80.37999725341797;;98.75;;59.93000030517578;;78.4800033569336;– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from BristThere's no better time to build a strong watchlist of great companies than during a serious market correction, or when the current outlook for stocks turns positive after a sharp slide in prices. Therefore, this story covers five top NYSE stocks to buy or watch closely.;42.84000015258789;Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.;32.84000015258789;GSK said its experimental treatment for uncomplicated urinary-tract infections was effective in two large clinical trials, paving the way for what could be the first new oral antibiotic for the common ailment in more than two decades.GSK stock jumped Wednesday after the company beat third-quarter forecasts due to strength from specialty medicines and Shingrix.GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment;13.109999656677246;;42.29999923706055;;9.670000076293945;;173.4600067138672;In this article we are going to estimate the intrinsic value of Repligen Corporation ( NASDAQ:RGEN ) by taking the...Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022;6.380000114440918;Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).;14.789999961853027;;119.77999877929688;"- SKYTROFA® U.S. revenue more than doubled quarter-to-quarter again, reaching €12.3 million in the third quarter - FDA accepted for Priority Review TransCon™ PTH NDA in adult patients with hypoparathyroidism; target action PDUFA date is April 30, 2023 - Announced selection of Phase 2 recommended dose of TransCon TLR7/8 Agonist; first-in-human data accepted for oral presentation at SITC 2022 - Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ascendis Phar";8.9399995803833;"Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022.Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX,)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co.";25.8799991607666;JERSEY CITY, N.J., November 03, 2022--Organon reports results for the third quarter ended September 30, 2022;51.36000061035156;;6.980000019073486;;8.529999732971191;;28.469999313354492;;60.04999923706055;Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH)WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that results from the long-term extension study of EMPAVELI® (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) will be presented at the American Society of Hematology;222.4499969482422;Karuna Therapeutics, Inc. (KRTX) delivered earnings and revenue surprises of -19.60% and 99.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?BOSTON, November 03, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the third quarter of 2022 and provided a general business update.;3.7100000381469727;"I-Mab (the ""Company"") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and translational research data of lemzoparlimab, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022, in New Orleans, Louisiana.";23.399999618530273;– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 – – Expanded Global, Non-Exclusive Collaboration with GSK to Continue Evaluating Nirogacestat in Combination with Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma – – Dosed First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors – – Strengthened Fi;1.7999999523162842;;5.329999923706055;;;;3.559999942779541;;5.269999980926514;;59.939998626708984;;;;19.530000686645508;;7.289999961853027;;4.369999885559082;LAUSANNE, Switzerland, November 03, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug conjugates (ADCs), including ZYNLONTA® (loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and ADCT-602, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, which will be held in New Orleans, Louisiana from December 10-13, 2022.– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected to be Initiated in 1Q23 – MOUNTAIN VIEW, Calif. and LAUSANNE, Switzerland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they ha;10.380000114440918;;2.0799999237060547;;50.459999084472656;LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that five abstracts will be presented from the KER-050 and KER-047 hematology programs at the 64th American Society of Hematology (“ASH”) Annual MLEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended September 30, 2022. “Keros continued to build upon the posi;12.59000015258789;Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignanciesSAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that its clinical-stage BTK degrader programs will be featured in two oral presentations and one poster presentatSAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in November: Credit Suisse 31st Annual Healthcare Conference Presentation date and time: Tuesday, November 8 at 11:25;18.200000762939453;;2.9800000190734863;;10.760000228881836;;3.9600000381469727;New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentationBOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that new data from an additional 18-months of continued treatment with SerpinPC from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC for the treatment of hemophilia, has been accepted for oral presenta;6.989999771118164;;22.010000228881836;Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) are skyrocketing today, up by 26.5% as of 11:15 a.m. ET.  The huge gain came after Arcturus announced yesterday that it has entered into a strategic collaboration with CSL Seqirus, a unit of CSL Limited (OTC: CSLL.Y).  The two companies plan to work together to develop and market messenger RNA (mRNA) vaccines targeting COVID-19, flu, pandemic preparedness, and three other respiratory infectious diseases.;32.56999969482422;;17.8799991607666;;19.3700008392334;;16.770000457763672;IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 8.97% and 15.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?– Data from T cell Engager Portfolio for Hematologic Malignancies, Including First Preclinical Data for IGM-2644 and IGM-2537, Selected for Poster Presentations at 2022 ASH Annual Meeting – – Data Update from Phase 1 Trial of Imvotamab Demonstrates Durable Benefit for R/R NHL Patients, with 7/8 Complete Response Patients Tumor Free After 1 Year – MOUNTAIN VIEW, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creati– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected to be Initiated in 1Q23 – MOUNTAIN VIEW, Calif. and LAUSANNE, Switzerland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they ha;;;2.0999999046325684;;14.619999885559082;
2022-11-04;171.47999572753906;Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Investors should focus on individual businesses -- not economic predictions -- when making investment decisions.;47.220001220703125;;357.4100036621094;;112.41000366210938;Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.The first highly effective weight-loss drug, Wegovy, has been in short supply since it was approved last year.;145.27999877929688;;81.72000122070312;Contrary to conventional wisdom, A.I. actually forges a symbiotic relationship between an organization and its talent.;99.19999694824219;;60.9900016784668;Amgen (AMGN) beats Q3 estimates for earnings and sales. It tightens previously issued revenue and adjusted earnings guidance ranges.;78.77999877929688;Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...;43.619998931884766;Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.The European Commission has approved AstraZeneca plc (NASDAQ: AZN) and Sanofi SA’s (NASDAQ: SNY) Beyfortus (nirsevimab) long-acting antibody to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions. In the pivotal MELODY efficacy trial, BEuropean Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants Beyfortus is the first and only broadly protective option against RSV for newborns and infantsResults from the clinical development program reinforce Beyfortus’ consistency in reducing RSV infections requiring medical care, including hospitalizations Paris, November 4, 2022. The European Commission has approved Beyfortus® (nirsevimab) for the prevention of respiratory syncytialThe European Commission on Friday approved Sanofi and AstraZeneca's Beyfortus for the prevention of a common and highly contagious type of respiratory infections in infants.  The long-acting therapy, also known as nirsevimab, was given EU marketing authorisation for the prevention of disease from infections caused by the respiratory syncytial virus (RSV), Sanofi said in a statement.;32.9900016784668;GSK plc (NYSE: GSK) announced that phase 3 EAGLE-2 and EAGLE-3 trials evaluating gepotidacin for uncomplicated urinary tract infection would stop enrolment early for efficacy. The move follows a recommendation by the Independent Data Monitoring Committee (IDMC). This decision was based on a pre-specified interim analysis of efficacy and safety data in over 3,000 patients across the trials. IDMC flagged that the non-inferiority trials testing GSK’s gepotidacin versus nitrofurantoin already met th;13.1899995803833;;41.939998626708984;;9.699999809265137;;174.36000061035156;;6.570000171661377;;15.470000267028809;;118.73999786376953;;9.380000114440918;;24.350000381469727;;51.369998931884766;SOMERSET, N.J., November 03, 2022--Legend Biotech announced today that seven company-sponsored studies were accepted for presentation at the 64th ASH Annual Meeting and Exposition.;7.199999809265137;;8.859999656677246;;27.989999771118164;;50.41999816894531;Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.Inclusion of the 24-month data has the potential to strengthen the product profile at launch, with minimal impact to launch timing Submission will be a Major Amendment to the New Drug Application (NDA), extending the review period by three months with an expected PDUFA target action date in February 2023 WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today provided an update on its New D;216.00999450683594;;3.819999933242798;;23.899999618530273;;1.7799999713897705;;5.489999771118164;;;;3.7699999809265137;Nektar (NKTR) delivered earnings and revenue surprises of 48.94% and 1.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?;5.03000020980835;;58.849998474121094;;;;19.959999084472656;;6.809999942779541;;4.230000019073486;Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;10.010000228881836;;2.119999885559082;"Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?BRIDGEWATER, N.J., November 04, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") announced its results today for the third quarter ended September 30, 2022.Select Medical (SEM) delivered earnings and revenue surprises of -52.27% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?";48.63999938964844;;12.960000038146973;The consensus price target hints at an 187% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;17.8799991607666;;3.009999990463257;"TORONTO, November 04, 2022--The Women in Psychedelics Network (""WIPN"" or ""Network""), a network of professionals from all corners of the psychedelic industry strengthening women’s voices and providing opportunities to move mental health solutions forward, today announced atai Life Sciences N.V. (NASDAQ: ATAI) (""atai""), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, as a platinum sponsor of the Network, through its philanthropic arm atai Im";9.760000228881836;;3.690000057220459;;7.019999980926514;;23.3799991607666;Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.;32.90999984741211;;17.979999542236328;;19.25;;16.5;;;;2.0899999141693115;;14.359999656677246;
2022-11-07;172.97999572753906;;47.09000015258789;;365.07000732421875;;115.05000305175781;;148.10000610351562;By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...;81.80999755859375;EUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins, the leading class of antibiotics worldwideNew project brings total planned investment into Sandoz antibiotics network across Europe to over EUR 250 millionTechnology upgrades at Kundl site will help to meet increasing global penicillins demand and partially offset impact of high energy costs at unit cost levelSandoz stresses importance of fundamental market reforms to ensure long-term susIf you want to know who really controls Novartis AG ( VTX:NOVN ), then you'll have to look at the makeup of its share...;100.06999969482422;;61.099998474121094;Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.(Bloomberg) -- Ryanair Holdings Plc, the first out of the gate among major European companies reporting earnings this week, shrugged off the threat of recession, lifting its passenger target and forecasting profit to exceed €1 billion ($995 million) this year.Most Read from BloombergTwitter Now Asks Some Fired Workers to Please Come BackHouston Mogul’s $75 Million Win on Astros Hits Caesars HardestElon Musk Walks Back on Twitter Job Cuts, Blue Checks in Second WeekUkraine Latest: US and Russia D;79.19000244140625;The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.  The justices turned away Juno's appeal of a lower court's ruling throwing out the award in the litigation over Kite's biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry.WASHINGTON (Reuters) -The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.  The justices turned away Juno's appeal of a lower court's ruling throwing out the award in the litigation over Kite's biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry.  Juno and Sloan Kettering Institute for Cancer Research sued Kite in 2017 in federal court in Los Angeles, accusing it of copying technology that the institute licenses to Juno.Berkshire Bristol-Myers Squibb, Verizon Communications, Canadian National Railway, Airbnb and First Republic Bank are included in this Analyst Blog.British drugmaker GSK Plc said on Monday its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show that the treatment was better than the standard of care on the market.  GSK said Blenrep did not meet the primary endpoint of progression-free survival, or the time in which a disease does not worsen or lead to death, when compared with a combination of pomalidomide and low doses of the steroid dexamethasone in patients with relapsed or refractory multiple myeloma.  Pomalidomide was developed by Celgene, now part of Bristol-Myers Squibb.;43.45000076293945;;31.940000534057617;GSK plc's (NYSE: GSK) DREAMM-3 Phase 3 head-to-head superiority trial of Blenrep (belantamab mafodotin) for relapsed or refractory multiple myeloma (RRMM) did not meet its primary endpoint of progression-free survival (PFS). The trial evaluated Blenrep monotherapy versus pomalidomide in combination with low-dose dexamethasone (PomDex). In the DREAMM-3 trial, the primary endpoint of PFS demonstrated a hazard ratio (HR) of 1.03. The median progression-free survival was longer for Blenrep vs. PomDeBy Geoffrey SmithBritish drugmaker GSK Plc said on Monday its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show that the treatment was better than the standard of care on the market.  GSK said Blenrep did not meet the primary endpoint of progression-free survival, or the time in which a disease does not worsen or lead to death, when compared with a combination of pomalidomide and low doses of the steroid dexamethasone in patients with relapsed or refractory multiple myeloma.  Pomalidomide was developed by Celgene, now part of Bristol-Myers Squibb.;13.319999694824219;;42.369998931884766;;10.970000267028809;By Liz MoyerViatris (VTRS) delivered earnings and revenue surprises of 4.88% and 1.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), today announced that it has entered into a definitive agreement under which Viatris Inc. (Nasdaq: VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovViatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences and that it will provide a strategic update on its February 2022 Investor Event in a conference call and live webcast today at 8:30 a.m. ET.Viatris Inc. (NASDAQ: VTRS) today reported strong results for the third quarter of 2022 and reaffirmed its 2022 financial guidance. The Company also announced that its Board of Directors declared a quarterly dividend of twelve cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on December 16, 2022, to shareholders of record at the close of business on November 23, 2022.;172.0500030517578;;6.989999771118164;;15.680000305175781;Coca-Cola (NYSE:KO) Director Herbert Allen bought $2 million worth of shares on Oct. 28: 33,200 shares at $60.1793 apiece. Shares slipped 1% for the week.;124.75;;9.5;;24.0;Organon (NYSE: OGN), a global women's health company, is announcing the launch and product availability of Aybintio®, a biosimilar of Avastin®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recur;50.560001373291016;;7.340000152587891;;10.260000228881836;;27.110000610351562;;47.619998931884766;;212.41000366210938;;3.869999885559082;;22.579999923706055;;1.8200000524520874;;5.429999828338623;CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST. A live and archived webcast of the fireside chat will be available by visiting the News & Events;;;3.799999952316284;;4.989999771118164;;57.11000061035156;;;;20.299999237060547;Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.;6.960000038146973;;4.260000228881836;LAUSANNE, Switzerland, November 07, 2022--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.;9.649999618530273;;2.3499999046325684;;46.349998474121094;;13.029999732971191;;17.3700008392334;;2.9000000953674316;;9.420000076293945;;3.5799999237060547;;6.929999828338623;;22.959999084472656;;34.900001525878906;;18.510000228881836;;19.479999542236328;;17.110000610351562;;;;2.109999895095825;BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences: Guggenheim’s 4th Annual Immunology and Neurology Conference Fireside chat on Monday, November 14, 2022 a;14.210000038146973;"CAMBRIDGE, Mass. & MONTREAL, November 07, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:"
2022-11-08;173.83999633789062;Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.The healthcare industry is constantly growing, changing, and evolving, which will continue in the coming years.  Among the leaders in these segments of the industry are HCA Healthcare (NYSE: HCA) and Johnson & Johnson (NYSE: JNJ).  HCA Healthcare is a leading hospital chain company with operations throughout the U.S. Although there is plenty of competition, the company has grown its market share in the past decade and again during the troubled pandemic years.In the meantime, it makes sense to be prepared for an economic downturn by buying stocks that can thrive in that environment.  Healthcare giant Johnson & Johnson (NYSE: JNJ), discount merchandiser Dollar General (NYSE: DG), and storage and moving rental company Amerco (NASDAQ: UHAL) all do well in a recession because of their business structure.  Shares of Johnson & Johnson are up more than 3% over the past year, while the S&P 500 has fallen 20% in that time.Whatever your investment style or strategy, there's no denying that tried-and true dividend stocks can be a superb addition to any portfolio.  Companies with an enviable track record of paying and increasing their dividends in all types of markets can both provide a safe haven for investors in market storms while maximizing portfolio returns over the long run.  If you're on the hunt for unstoppable dividend stocks to invest in this month, don't overlook these two powerhouses for your buy list.Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.One of the coalition's next challenges is to work with hospitals on improved pricing, during a time when fees continue to climb.In this article, we will take a look at 12 of the best blue chip stocks to buy today. If you want to see more of the best blue chip stocks to buy today, go directly to 5 Best Blue Chip Stocks To Buy Today. 2022 has been a challenging year for many stocks in […];47.349998474121094;;366.6600036621094;;114.8499984741211;;148.52999877929688;"In this article, we discuss the 10 best safe dividend stocks for retirement portfolios. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Safe Dividend Stocks For Retirement Portfolios. Retirement portfolios in the US are got hammered in 2022 amid rising inflation, Russia-Ukraine war and rising interest rates. […]AbbVie Inc.'s ( NYSE:ABBV ) dividend will be increasing from last year's payment of the same period to $1.48 on 15th of...Dividend stocks are rarely the lightning-growth companies that many investors seem to gravitate toward, but these types of investments certainly have an allure of their own.  Whether providing additional capital that you can put back into your portfolio again and again, or increasing your total returns with time, the best dividend stocks are compelling investments that you can buy and hold for decades or even a lifetime.  Here are two such winning dividend stocks to consider adding to your portfolio ASAP.AbbVie (NYSE: ABBV) today announced new results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery patients. The primary endpoint of evaluating the occurrence of continuous atrial fibrillation (AF) ≥ 30 seconds was not met for the modified intent-to-treat (mITT) population; however, the data showed relative risk reduction in spec";81.83000183105469;Results from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (LDL-C) over four years of treatment1,2At any time throughout the trial, approximately 80% of patients reached an LDL-C level of <70mg/dL2Longest Leqvio safety follow-up study to date demonstrates safety-benefit profile is consistent with findings in previous 18-month Phase III trials1-4 LDL-C is one ofImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022;101.5;;61.33000183105469;Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.;79.9800033569336;Dividend stocks are rarely the lightning-growth companies that many investors seem to gravitate toward, but these types of investments certainly have an allure of their own.  Whether providing additional capital that you can put back into your portfolio again and again, or increasing your total returns with time, the best dividend stocks are compelling investments that you can buy and hold for decades or even a lifetime.  Here are two such winning dividend stocks to consider adding to your portfolio ASAP.In this article we are going to estimate the intrinsic value of Bristol-Myers Squibb Company ( NYSE:BMY ) by taking the...The U.S. Supreme Court turned away an appeal made by rebuffed efforts made by Bristol Myers Squibb Co's (NYSE: BMY) Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc's (NASDAQ: GILD) Kite Pharma Inc over Yescarts, a lymphoma drug. Juno and Sloan Kettering Institute for Cancer Research sued Kite in 2017 in a federal court in Los Angeles, accusing it of copying technology the institute licenses to Juno. A jury awarded the plaintiffs $778 mi;43.439998626708984;;32.220001220703125;Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future milestone payments and tiered royaltiesCAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare;13.420000076293945;The Canadian Inflammatory Bowel Disease Research Consortium (CIRC) awards the inaugural $1 million PIONEER Grant from Takeda Canada Inc. (Takeda), in support of high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD).;42.689998626708984;Net cash provided by operating activities (GAAP) of $539 million and Adjusted Cash Receipts(1) (non-GAAP) of $597 million Announced transactions of up to $3.0 billion year-to-date, including $1.7 billion in upfront payments Increased 2022 guidance: Adjusted Cash Receipts(1) expected to be $2,750 to $2,800 million, which includes $458m from the acceleration of payments related to Pfizer’s acquisition of Biohaven NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today r;11.100000381469727;"Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.Viatris Inc.'s shares rose 13% after the pharmaceutical company announced it had made two acquisitions in a new therapy area and then outlined more details on its previously announced $9 billion divestiture plan.  Viatris (Nasdaq: VTRS), which is celebrating its two-year anniversary this month after the merger of Mylan NV and the Upjohn unit of Pfizer, said it was acquiring Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences for between $700 million and $750 million to build a vision medication business.  Executive Chairman Robert J. Coury also disclosed during the call with analysts more details about its divestitures, which will include its over-the-counter business and women's care portfolio.Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties Strengthened Financial Position Supports Operations and APX3330 Program into 2025 Conference Call Tomorrow November 8, 2022 at 8:30 AM ET FARMINGTON HILLS, Mich., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) today announced it has concluded an exclusive license agreement with FamyGen Life Sciences, Inc. (Famy) for the developmCoury said the divestitures would also include smaller geographical markets where Viatris has no established infrastructure.Shares of Viatris (NASDAQ: VTRS) were jumping 16.2% higher as of 11:56 a.m. ET on Monday.  The big gain came after the company announced its third-quarter results and revealed plans for two acquisitions.  Viatris reported Q3 revenue of $4.08 billion.Viatris Inc (NASDAQ: VTRS) has agreed to acquire Oyster Point Pharma Inc (NASDAQ: OYST) as the foundation of its new ophthalmology franchise. Viatris will commence a tender offer for $11.00 per share in cash at closing, plus a contingent value right (CVR) for a potential cash payment of up to $2.00 per share upon achievement of specified performance targets by Oyster Point Pharma for the full year 2022. ""Oyster Point Pharma brings to Viatris the strength of TYRVAYA Nasal Spray, the first and onlViatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.";174.75;WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences. The Stifel 2022 Healthcare Conference being held November 15-16 in New York. Jon K. Snodgres, Chief Financial Officer, will participate in an analyst-led discussion on Wednesday, November 16, at 2:25 p.m. EST.Stephens’ Annual Investment Conference being held NovemberBIIB vs. RGEN: Which Stock Is the Better Value Option?;7.320000171661377;;15.569999694824219;;123.91000366210938;;9.529999732971191;Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...;23.559999465942383;;51.02000045776367;;7.309999942779541;;9.710000038146973;;25.700000762939453;"Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclidine in Alzheimer’s disease psychosis; Phase 1 trial in healthy, elderly volunteers to be initiated by year-end Cash, cash equivalents and marketable securities of $1,030 million as of September 30, 2022, expected to support opera";47.11000061035156;"Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -18.24% and 11.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Plans to submit 24-month Phase 3 data to the FDA for intravitreal pegcetacoplan for geographic atrophy (GA); expected PDUFA target action date in February 2023EU marketing authorization application submission on track for December 2022Reported 24-month data with pegcetacoplan in GA showing increased effects over time and continued favorable safety profileAchieved $17.7 million in Q3 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesCash and investments of $708.6 million as of Sept. 30, 202";221.07000732421875;;3.740000009536743;;22.600000381469727;;1.850000023841858;;5.559999942779541;;;;3.7899999618530273;;4.869999885559082;;58.650001525878906;;;;19.729999542236328;AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the company's progress with its collaboration deals and the performance of its business units.;7.019999980926514;;4.139999866485596;ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?LAUSANNE, Switzerland, November 08, 2022--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter ended September 30, 2022 and provided business updates.;9.329999923706055;;2.3299999237060547;;45.04999923706055;"The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 96.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced results from a preclinical study of a research form of KER-012 (""RKER-012"") on cardiac and pulmonary pathology in an established rat model of pulm";12.979999542236328;;17.719999313354492;;2.799999952316284;;9.229999542236328;;3.380000114440918;;7.099999904632568;;22.81999969482422;"SAN DIEGO, November 07, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company,"" ""Arcturus,"" Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.";40.290000915527344;"Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.09% and 62.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?PLANO, Texas, November 08, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" ""our,"" ""us,"" or ""we""), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.";18.700000762939453;;19.770000457763672;Topline results for full pivotal FIREFLY-1 study population with tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG) are expected in the first quarter of 2023 Strengthened leadership team with key appointments to senior management team and board of directors SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies;17.200000762939453;MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 15 at 9:45 a.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 17 at 9:45 a.m. GMT/ 4:45 a.m. EST i;;;2.4000000953674316;;14.800000190734863;
2022-11-09;172.4499969482422;Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO servicesHalozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.These top-notch income stocks, which range in yield from 1.8% to 7.6%, are as rock solid as they come.In this article, we will take a look at 10 best blue chip stocks with strong balance sheets. If you want to see more of the best blue chip stocks with strong balance sheets, go directly to 5 Best Blue Chip Stocks With Strong Balance Sheets. Companies with strong balance sheets have more flexibility in […]With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting. Two, the best pharma stocks are still ranked as some of the safest, recession-resistant investments to own. After all, we can’t stop people from aging. Three, we can’t forget about secular tailwinds, such as population aging and growth. In fact, according to the Popul;46.720001220703125;;363.2699890136719;;114.16999816894531;Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.;147.6199951171875;The growth stock boom of 2021 left some investors wondering if dividend stocks were still prudent holdings to drive long-term returns.  Enrolling in a dividend reinvestment plan (DRIP) can be a terrific choice because it compounds earnings over time (more shares = larger dividends), and you can set it and forget it -- most reputable brokerages will do the legwork free of charge.  Using dividends to reinvest in other stocks is an excellent option for those who wish to take a more active role.AbbVie (NYSE: ABBV) will participate in the 4th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Neil Gallagher, vice president development and chief medical officer will present virtually at 10:30 a.m. Central time.AbbVie (NYSE: ABBV) shares have been one of the bright spots in the stock market this year.  All of this may sound grim, but there are positive elements to AbbVie's story that outweigh the negative news, and they're why I still view the stock as a buy.  AbbVie makes Juvederm, the dermal filler collection patients in the U.S. choose most.With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting. Two, the best pharma stocks are still ranked as some of the safest, recession-resistant investments to own. After all, we can’t stop people from aging. Three, we can’t forget about secular tailwinds, such as population aging and growth. In fact, according to the PopulAbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI® (risankizumab) for psoriasis and psoriatic arthritis at the American College of Rheumatology's annual meeting (ACR Convergence 2022) taking place November 10-14 in Philadelphia, PA, as well as virtually.In this article, we will discuss Goldman Sachs’ cheap dividend stocks. You can skip our detailed analysis of dividend investing and the firm’s outlook on dividend stocks, and go directly to read Goldman Sachs’ 5 Cheap Dividend Stocks. Growth tech stocks have dominated the market for years due to their innovative products and services. However, […];82.97000122070312;;101.58999633789062;;61.04999923706055;ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark, the Russell 1000 Value Index, in the third quarter. Sector allocation effects and overall stock selection contributed positively to the strategy’s relative performance in the […]AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.WILMINGTON, Del., November 09, 2022--The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favorable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older. In adolescents aged 12 to 17 years, the Committee voted 9 to 8 that the data do not support a favorable benefit risk assessment for the use of PT027 for the treatment of asthma. In childre;79.77999877929688;Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.NEW YORK, November 09, 2022--Bristol Myers Squibb to Participate in the Wolfe Research Healthcare ConferenceWith the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting. Two, the best pharma stocks are still ranked as some of the safest, recession-resistant investments to own. After all, we can’t stop people from aging. Three, we can’t forget about secular tailwinds, such as population aging and growth. In fact, according to the PopulBristol Myers Squibb Company;43.34000015258789;"Sanofi has signed a strategic research collaboration with Hong Kong-based biotech firm Insilico Medicine in a deal worth up to US$1.2 billion, leveraging artificial intelligence (AI) to speed up its drug-discovery process. The French healthcare company will put up as much as US$21.5 million in upfront payment and target nomination fees to Insilico, which could rise to US$1.2 billion subject to hitting certain undisclosed research, development and sales milestones, according to Insilico. ""AI is b";32.41999816894531;;13.220000267028809;;43.029998779296875;Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (NasdPASADENA, Calif. & NEW YORK, November 09, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.;10.829999923706055;"One is a footwear company and the other a drugmaker that was this writer's ""top pick"" for the balance of the year last spring.In this article, we will discuss Goldman Sachs’ cheap dividend stocks. You can skip our detailed analysis of dividend investing and the firm’s outlook on dividend stocks, and go directly to read Goldman Sachs’ 5 Cheap Dividend Stocks. Growth tech stocks have dominated the market for years due to their innovative products and services. However, […]";174.7100067138672;;7.190000057220459;;14.739999771118164;"Biohaven Ltd. (BHVN) delivered earnings and revenue surprises of 30.83% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Biohaven Ltd. (NYSE: BHVN) (""Biohaven"" or the ""Company""), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders, today reported financial results for the third quarter ended September 30, 2022, and provided a review of recent accomplishments and anticipated upcoming milestones. The reported financial results present,In this article, we discuss the top 10 stock picks of billionaire George Soros. If you want to see more stocks in this selection, check out George Soros Stock Portfolio: Top 5 Stock Picks. George Soros is a Hungarian-American billionaire and businessman who launched Soros Fund Management in 1970. Soros Fund Management, which is now […]";122.2300033569336;;8.539999961853027;"Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2022.By Geoffrey Smith";23.850000381469727;;51.5;;7.0;;9.050000190734863;;25.65999984741211;;43.9900016784668;Apellis' (APLS) earnings miss estimates in the third quarter of 2022 while revenues beat the same.;214.75;;3.609999895095825;;21.770000457763672;;1.5499999523162842;"OPKO Health's (OPK) third-quarter results reflect dismal segmental performances.Image source: The Motley Fool.  Opko Health (NASDAQ: OPK)Q3 2022 Earnings CallNov 08, 2022, 4:30 p.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood day, and welcome to the OPKO Health third quarter 2022 financial results conference call.OPKO Health (OPK) delivered earnings and revenue surprises of -10% and 4.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Nov. 08, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2022. Business highlights for the third quarter of 2022 and subsequent weeks include the following: Pfizer’s NGENLA® (somatrogon) launched in Japan, Germany and other global markets; Pfizer seeking pricing approvals in additional European countries and continuing to work with FDA t";5.449999809265137;;;;3.5799999237060547;Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model and on CD8+ T effector cell (Tcell) and natural killer (NK) cell proliferation in non-human primates.;4.349999904632568;;57.08000183105469;"Harmony Biosciences Holdings, Inc. (""Harmony"" or the ""Company"") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.";;;12.850000381469727;Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO servicesAfter the speakers' presentation, there will be a question-and-answer session [Operator instructions] Please be advised that today's conference is being recorded.  My name is Bob Burrows, VP and IRO for the company.  As is customary, today's call is open to all participants and the call is being recorded and is copyrighted by Emergent BioSolutions.Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?GAITHERSBURG, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2022. “For more than 20 years, Emergent has been a dependable partner to customers, including the U.S. and allied governments, in helping prepare for public health threats through our products, services, and development programs,” said Robert G. Kramer, president and CEO. “As we continue to strengthen our operations, be guided by f;6.679999828338623;;4.010000228881836;;9.449999809265137;Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 4.76% and 18.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?BILLERICA, Mass., November 08, 2022--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced operating results for the three months ended September 30, 2022.;2.25;Amneal Pharmaceuticals ( NYSE:AMRX ) Third Quarter 2022 Results Key Financial Results Revenue: US$545.6m (up 3.2% from...;42.470001220703125;Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.;12.0;;16.81999969482422;;2.7200000286102295;;9.8100004196167;;3.369999885559082;;7.119999885559082;MIAMI and BARRANQUILLA, Colombia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it expects to report its results for the third quarter ended September 30, 2022, after the market closes on Monday, November 14, 2022. The Company expects to host a conference call and webcast at 04 p.m. Eastern time, on November 16, 2022.To access the call, please use the following information: Date:We;21.09000015258789;;38.27000045776367;Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.Shares of Reata Pharmaceuticals (NASDAQ: RETA) had soared 11.8% higher as of 11 a.m. ET on Tuesday.  The agency confirmed that it doesn't currently plan to convene an advisory committee meeting to review Reata's New Drug Application (NDA) for omaveloxolone.  Does all of this mean that FDA approval for omaveloxolone is a slam dunk?;18.6200008392334;Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Launched ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in adolescents and adults in mid-August, achieving net revenues of $0.7 million for the third quarterZORYVE now covered by one of the top pharmacy benefit managers and a large national health planAnnounced positive topline results from pivotal Phase 3 trial of roflumilast foam in scalp and body psoriasisCompleted enrollment in INTEGUMENT-1 and INTEGUMENT-2, the two pivotal Phase 3 trials in subjects with atopic derma;18.770000457763672;;16.049999237060547;;;;2.2300000190734863;To get a sense of who is truly in control of Praxis Precision Medicines, Inc. ( NASDAQ:PRAX ), it is important to...;14.600000381469727;
2022-11-10;174.47000122070312;If you're a risk-averse investor looking for stocks to buy, it's hard to go wrong with stalwarts in the healthcare industry such as Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ).  One of the most attractive reasons to buy Johnson & Johnson right now is the company's pivot more toward growth.  On Nov. 1, Johnson & Johnson announced plans to acquire Abiomed, a business that makes heart pumps and that achieved 22% sales growth in its most recent fiscal year (which ended in March) with revenue totaling more than $1 billion.Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) recently made headlines by announcing it will acquire medical device company Abiomed for $16.6 billion in an all-cash transaction.  The buyout offer was roughly a 50% premium to where shares of Abiomed traded at the time of the announcement, signaling Johnson & Johnson's desire to make the deal happen.  Few companies have the financial firepower Johnson & Johnson has, so I'll break down the acquisition's financial impact and whether Abiomed will make its new parent company a better investment for long-term investors.This is because the essential goods and services offered by healthcare companies have generally been proven to be more recession-resistant than other sectors of the economy.  Here are two dividend-paying healthcare stocks that have outperformed this year and could do well for shareholders for many years to come.  Johnson & Johnson (NYSE: JNJ) hardly needs an introduction.Inflation ranks as one of investors' biggest enemies. These stocks offer protection against this foe.IBD Stock Of The Day Halozyme is entering a new wave of development — leading HALO stock to surge into a breakout Wednesday.The Q3 earnings picture for the healthcare sector seems solid, with results from companies that have reported so far up 2.1% on 5.8% revenue growth.;47.380001068115234;Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.;368.7200012207031;;115.54000091552734;;149.72000122070312;"Many healthcare stocks' earnings reports lately include the phrases ""inflationary pressures,"" ""labor shortages,"" ""supply chain issues,"" and ""short-term macroeconomic conditions"" to describe why earnings are flat or down.  UnitedHealth Group (NYSE: UNH), AbbVie (NYSE: ABBV), and Vertex Pharmaceuticals (NASDAQ: VRTX) are all up 8.5% or more this year despite the headwinds affecting so many companies.  It's easy to see why UnitedHealth Group's shares are up more than 8.5% so far this year.";85.12999725341797;;101.88999938964844;;65.08999633789062;"AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.Bloomberg FTX 'Urgently Needs' $8B To Avoid Bankruptcy, Bankman-Fried Reportedly Tells Investors FTX (FTT/USD) CEO Sam Bankman-Fried reportedly told investors on Wednesday that he urgently needs $8 billion in emergency funding to cover withdrawal requests and avert bankruptcy. In a call with investors, Bankman-Fried said he hoped to raise as much as $3 billion to $4 billion in equity and some debt. FTX Stares At More Trouble As Justice Department Reportedly Joins SEC Probe Into Liquidity CrisisTwo stocks that risk-averse investors should consider today are AstraZeneca (NASDAQ: AZN) and Coca-Cola (NYSE: KO).  AstraZeneca is a top healthcare company with solid financials, a bright future, and a terrific dividend.  Sales rose 43% year over year to $22.2 billion as AstraZeneca benefited from growth in multiple segments as well as the acquisition of rare disease company Alexion Pharmaceuticals, which it completed last year.AstraZeneca Plc (NASDAQ: AZN) has reported Q3 core EPS of $1.67, up 55% Y/Y (+70 constant currency), beating the consensus of $0.72. The company clocked Q3 sales of $10.98 billion, +11% (+19% CC), beating the consensus of $10.91 billion. Sales of AstraZeneca's key cancer medicines — Tagrisso and Imfinzi — helped the company's revenue beat, with sales of its broader oncology portfolio rising 24%. Tagrisso generated nearly $1.4 billion, and Imfinzi brought in $737 million in the quarter. Related:Astrazeneca's Chief Financial Officer Aradhana Sarin discusses the UK drugmaker's earnings for this quarter. Profit surged to $1.67 per share in the third quarter, beating the $1.52 analysts had estimated. The company benefited from sales of cancer drugs as diagnoses progressively return to pre-pandemic levels.AstraZeneca  PLC said it had dropped plans to submit its Covid-19 vaccine to the Food and Drug Administration for approval, ending a long-running ambition to eventually sell the shot in the U.S. despite initial setbacks.  The Cambridge, England-based pharmaceutical company said Thursday that there would likely be a lack of demand in the U.S., where it said primary vaccination needs had been met.  It would continue to focus its efforts on ensuring the availability of the vaccine, called Vaxzevria, elsewhere, including seeking its approval as a booster shot, the company said.AstraZeneca returns to profit on higher drugs revenue.European shares clocked an 11-week closing high on Thursday as a slower-than-expected rise in U.S. consumer prices strengthened hopes of less aggressive interest rate hikes from the Federal Reserve going ahead.  The pan-European STOXX 600 jumped 2.8%, notching its biggest percentage gain in five weeks.  A U.S. Labor Department report showed consumer prices rose less than expected in October, pushing the annual increase below 8% for the first time in eight months.(Bloomberg) -- AstraZeneca Plc raised its profit guidance for this year, saying drugs like Farxiga for diabetes and Tagrisso for cancer are fueling demand.Most Read from BloombergMusk’s First Email to Twitter Staff Ends Remote WorkSam Bankman-Fried’s $16 Billion Fortune Is Eviscerated in DaysUS Inflation Slows More Than Forecast, Gives Fed Downshift RoomFTX Warns of Bankruptcy Without Rescue for $8 Billion ShortfallMeta to Cut 11,000 Jobs; Zuckerberg Says ‘I Got This Wrong’Core earnings per sharAfter tax, profit was $1.64 billion compared with a loss of $1.65 billion the year prior. Analysts had expected the company to post a net profit of $629 million.(Reuters) -AstraZeneca raised its full-year earnings outlook on Thursday after strong sales of its key cancer drugs helped it beat quarterly profit and revenue forecasts, driving its shares to a 2-1/2 month high.  The Anglo-Swedish company said it managed to grow its business in China despite protracted COVID lockdowns and was no longer pursuing U.S. approval for its COVID-19 vaccine.  AstraZeneca is seen as a bellwether for the pharmaceutical sector in China, which accounted for about 16% of the company's total revenue last year.By Scott KanowskyAZN shares have been a bright spot in an otherwise dim market in 2022, up nearly 8% and widely outperforming the general market.The FDA's Pulmonary-Allergy Drugs Advisory Committee has voted 16 to 1 that the data support a favorable benefit-risk assessment for AstraZeneca Plc's (NASDAQ: AZN) PT027 (albuterol/budesonide) for asthma in people aged 18 years and older. In adolescents aged 12 to 17 years, the Committee voted 9 to 8, and for children aged 4 to 11 years, the Committee voted 16 to 1 that the data do not support a favorable benefit-risk assessment for PT027 for asthma. The FDA is slated to decide in the first hal";79.37999725341797;Today, Bristol Myers Squibb Canada (BMS) announced Health Canada's approval of CAMZYOSTM (mavacamten capsules) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.i Hypertrophic Cardiomyopathy (HCM) is a chronic disease where the heart's walls become thickened, making it harder for the heart to pump blood. CAMZYOSTM is the first Canadian-approved allosteric and selective cardiac myosin inhibitor thatBiopharma leader Bristol-Myers Squibb posted solid Q3 results, despite competition from generic-drug makers for its popular cancer pill.;44.310001373291016;Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK, after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.  The shot with the brand name VidPrevtyn Beta can be given to people who have already had a primary course of vaccination from other approved shots, the French drugmaker and the European Medicines Agency said in separate statements.  Shipments are ready to be distributed to European countries under advance purchase agreements, Sanofi said.Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission First and only next-generation protein-based adjuvanted COVID-19 booster approved in EuropeStrong immune response against all tested variants of concernReady to supply for fall-winter COVID-19 vaccination campaigns in Europe Paris, November 10, 2022. After the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® BetBiogen Inc. stock rose 1% in premarket trades on Thursday after Christopher A. Viehbacher was named president and chief executive officer and a member of the board, effective Nov. 14. Viehbacher succeeds CEO Michel Vounatsos, who has led the company since 2017. Biogen Chairman Stelios Papadopoulos said Viehbacher's innovation and understanding of the complexities of the pharma business enabled him to turn around Sanfoi when he was CEO and leave it a much better company. Vounatsos will be leaving;33.470001220703125;By Geoffrey Smith;13.84000015258789;;43.9900016784668;;11.34000015258789;Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it and Kindeva Drug Delivery L.P. have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca's Symbicort® patent, U.S. Patent No. 10,166,247, is invalid. The district court determined that the patent is invalid on two separate grounds – lack of written description and lack of enablement.Dividend stocks are a good way to supplement your income.  Three stocks that provide high yields that are more than double the S&P 500 average of 1.8% and that could, together, allow you to receive dividends every month are Paramount Global (NASDAQ: PARA), Hasbro (NASDAQ: HAS), and Viatris (NASDAQ: VTRS).  Paramount Global provides investors with the highest yield on this list at 5.9%.;189.16000366210938;;7.289999961853027;;15.760000228881836;;129.3000030517578;;9.369999885559082;;24.709999084472656;;52.0;;7.360000133514404;"/ CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (""mRNA""), will report financial results, and provide business updates for the third quarter of 2022 on Wednesday, November 16, 2022. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m.";9.520000457763672;NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 16 and Thursday, November 17, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in Australia, China, Hong Kong, Germany, and Switzerland will respond to questions during formal presentations and will;28.049999237060547;;45.09000015258789;;227.44000244140625;;3.9800000190734863;;23.780000686645508;;1.600000023841858;;3.890000104904175;"Aumolertinib: Clarity on path for potential U.S. approval; continue to pursue ex-U.S. approvals based on existing data, with MAA under review by U.K.’s MHRASugemalimab: Based on recent FDA feedback, EQRx has concluded that there is no commercially viable path for sugemalimab plus chemotherapy in Stage IV NSCLC in the U.S.; continue to pursue ex-U.S. approvals based on existing dataLate-stage pipeline: Prioritize development of aumolertinib and lerociclib, which could form the basis of future com";;;3.890000104904175;Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.Nektar Therapeutics ( NASDAQ:NKTR ) Third Quarter 2022 Results Key Financial Results Revenue: US$23.6m (down 5.2% from...;5.230000019073486;;58.709999084472656;;;;15.0;Emergent BioSolutions led a decline for biotech stocks on Wednesday as EBS stock tumbled on declining sales and a delayed contract.Emergent BioSolutions Inc's (NYSE: EBS) Q3 sales fell 27% Y/Y to $240 million, missing the consensus of $268.30 million. Revenues from CDMO services decreased $76.4 million, largely due to lower combined revenues of $59.1 million from AstraZeneca Plc (NASDAQ: AZN) and Johnson & Johnson's (NYSE: JNJ) Janssen, reflecting the impact of reduced production activities for the companies' COVID-19 vaccines. The company reported an adjusted EPS loss of $(1.27), compared to $(0.36) a year ago and missing;7.789999961853027;"Positive preliminary monotherapy data for ERAS-007 and ERAS-601 support ongoing and future combination trials Signed CTCSAs with Eli Lilly to supply cetuximab in combination with ERAS-601 and with Pfizer to supply palbociclib in combination with ERAS-007; signed strategic R&D collaboration with MD Anderson Strong balance sheet with cash, cash equivalents, and marketable securities of $365 million SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision";4.0;;11.720000267028809;Quanterix ( NASDAQ:QTRX ) Third Quarter 2022 Results Key Financial Results Revenue: US$26.6m (down 3.8% from 3Q 2021...;2.380000114440918;;47.790000915527344;;13.729999542236328;Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with potent anti-tumor activity in disease models SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presentePresentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy in DeTIL-0255 programSAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell;18.59000015258789;;2.930000066757202;Last patient dosed in the Phase 2a proof-of-concept trial of PCN-101 (R-ketamine) for treatment-resistant depression (TRD), with topline results expected around year-end 2022.Announced positive preliminary pharmacokinetics and pharmacodynamics results in a Phase 1 study of GRX-917 (deuterated etifoxine) being developed for generalized anxiety disorder (GAD), demonstrating target engagement based on qEEG. Announced positive preliminary results of the single ascending dose (SAD) portion of the Pha;10.5;DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business. Third Quarter 2022 Financial Highlights Cash position Cash was $256.9 million as of September 30, 2022, compared to $276.8 million as of December 31, 2021. We believe that our e;3.4600000381469727;"– Company highlights three significant near-term milestones – – Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study on track to begin this quarter – – Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous treatment at American Society of Hematology (ASH) Annual Meeting in December 2022 – – IND submission for LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody, on track for late 2022 – – Cash runway";6.989999771118164;;19.420000076293945;"Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, November 09, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", ""Arcturus Therapeutics"", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2022, and provided corporate updates.";37.72999954223633;;19.479999542236328;Emergent BioSolutions led a decline for biotech stocks on Wednesday as EBS stock tumbled on declining sales and a delayed contract.;20.899999618530273;;20.93000030517578;;;;2.0999999046325684;"PRAX-944 Phase 2b Essential1 study topline results for essential tremor expected in 1Q23 PRAX-222 EMBRAVE study for SCN2A-DEE to initiate in 4Q22; topline results for initial dose cohort expected in 2023 PRAX-628 Phase 1 healthy volunteer study to initiate in 4Q22; focal epilepsy study planned for 2023 Cash and investments of $123.7 million as of September 30, 2022 supports runway into 1Q24 BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stag";15.9399995803833;"Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 955% and 160.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?CAMBRIDGE, Mass. & MONTREAL, November 09, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022."
2022-11-11;169.25;In this article, we will discuss 15 best consistent dividend stocks to buy. You can skip our detailed discussion on dividend stocks and their past performance, and go directly to read 5 Best Consistent Dividend Stocks to Buy. Since the start of this year, the plunging stock prices have investors worried about the future of […]In this article, we discuss 13 best American stocks to buy heading into 2023. If you want to see more stocks in this selection, check out 5 Best American Stocks To Buy Heading Into 2023. As per Bank of America, a new bull market could emerge in 2023 after the Federal Reserve aggressively hiked interest […]Buffett loves stocks that pay dividends. Is it any wonder Berkshire Hathaway is poised to collect more than $6 billion worth of them next year?;47.599998474121094;NEW YORK, November 11, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe Research Healthcare Conference on Friday, November 18, 2022 at 8:45 a.m. EST.I believe that every investor should have a portfolio that’s divided into two segments. The core portfolio should have stocks that are worth holding for the long term. A dynamic portfolio can be focused on an event-based investment strategy. The focus of this column is on a core portfolio of stocks for investors over 30 to buy and hold. Even in the long-term portfolio, there needs to be diversification. First, in the form of exposure to different industries. Furthermore, in the form of balancedVertex Pharmaceuticals (NASDAQ: VRTX) is something of a unicorn in the world of stocks right now.  While the S&P 500 has slid by nearly 20% over the past 12 months, Vertex is up by around 60% in that same period.  While it's true that healthcare stocks tend to outperform when the market is down, this is far from the only tailwind driving Vertex's precipitous growth in such a volatile market.To say the Covid-19 vaccination wave in 2021 moved the needle for Pfizer (NYSE:PFE) stock is an understatement. Revenue nearly doubled thanks to its vaccine candidate (Comirnaty), which the pharma firm co-developed with BioNTech (NASDAQ:BNTX). PFE stock performed strongly as well during this timeframe. So far in 2022, however, Pfizer’s performance has been far less stellar. The vaccination wave peaked earlier this year, and revenue/earnings are expected to drop in 2023.InvestorPlace - Stock MarkIn this article, we will take a look at 12 of the cheapest stocks on Robinhood. If you want to see more of the cheapest stocks on Robinhood, go directly to 5 Cheapest Stocks on Robinhood. Robinhood is a trading app famous for offering free trades on stocks as a business model. Instead of making […]In this article, we will take a look at 10 cheap ESG stocks to buy now. If you want to see more cheap ESG stocks, go directly to 5 Cheap ESG Stocks to Buy Now. ESG investing is investing in a way that considers environmental, social, and governance issues. The term is often interchangeably used […];352.29998779296875;"In this article, we discuss 13 best American stocks to buy heading into 2023. If you want to see more stocks in this selection, check out 5 Best American Stocks To Buy Heading Into 2023. As per Bank of America, a new bull market could emerge in 2023 after the Federal Reserve aggressively hiked interest […]Pharmaceutical giant Eli Lilly has been on an upward path on the charts. The last time we examined the charts of LLY was back on May 2 where we wrote that ""In our April 28 review of LLY, we recommended that, 'In the short run the better-than-expected numbers from Lilly may keep the stock buoyant, but the divergences noted above tell me to at least be cautious or even defensive going forward.ClearBridge Investments, an investment management firm, published its “Global Growth Strategy” third-quarter 2022 investor letter – a copy of which can be downloaded here. During the third quarter, the ClearBridge Global Growth Strategy outperformed its MSCI ACWI benchmark. On an absolute basis, the Strategy saw losses across nine of the 10 sectors in which it […]";111.47000122070312;;150.16000366210938;In this article, we will discuss 15 best consistent dividend stocks to buy. You can skip our detailed discussion on dividend stocks and their past performance, and go directly to read 5 Best Consistent Dividend Stocks to Buy. Since the start of this year, the plunging stock prices have investors worried about the future of […]With the monetary paradigm shifting beneath our feet, investors have every reason to consider no-brainer dividend stocks to buy for 2023 and beyond. This is no marketing gimmick – folks need to avoid paralysis by analysis and direct their portfolios based on intuitive dynamics. That’s an overly complicated way of saying don’t fight the current but swim with it. Earlier for InvestorPlace’s Today’s Market segment, I discussed the conundrum that faces the technology sector. Nevertheless, the belowIn this article, we discuss the top 10 value stocks from the Goldman Sachs portfolio. If you want to see more stocks in this selection, check out Goldman Sachs Value Stocks: Top 5 Stock Picks. Jason Brady, president and CEO of Thornburg Investment Management, joined CNBC’s ‘The Exchange’ on November 8, where he noted that […];84.0199966430664;A global pharmaceutical company is shifting its gene therapy production to Durham as it closes a facility outside of North Carolina.  After completing an evaluation of its manufacturing site network, Swiss drugmaker Novartis (NYSE: NVS) has decided to shut down operations at a facility in Libertyville, Illinois, by the end of 2023.  With this closure, Novartis plans to consolidate operations to make, test and release its gene therapy products in Durham.David Epstein spent more than 25 years at the Swiss pharmaceutical giant Novartis, where he helped build its oncology business.;97.95999908447266;In this article, we will discuss 15 best consistent dividend stocks to buy. You can skip our detailed discussion on dividend stocks and their past performance, and go directly to read 5 Best Consistent Dividend Stocks to Buy. Since the start of this year, the plunging stock prices have investors worried about the future of […];62.77000045776367;Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.The FDA has approved AstraZeneca plc’s (NASDAQ: AZN) Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy for Stage IV (metastatic) non-small cell lung cancer (NSCLC). The approval was based on the results from the POSEIDON Phase 3 trial. Patients treated with a limited course of five cycles of the anti-CTLA-4 antibody Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy experienced a 23% reduction in the risk of death versus a rangeWILMINGTON, Del., November 11, 2022--AstraZeneca’s IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).Before I hand it over to AstraZeneca, I'd like to read the safe harbor statement.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.  Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.The company trounced analyst profitability estimates for its latest quarter and raised its guidance.AstraZeneca leaned on cancer drugs in the third-quarter, leading to double-digit sales growth, a strong beat and a jump for AZN stock.WILMINGTON, Del., November 10, 2022--Today, TIME named AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab) on their 2022 list of Best Inventions. Their selection of EVUSHELD reflects its impact as the first and only long-acting monoclonal antibody to receive emergency use authorization in the US for the prevention of COVID-19 in immunocompromised people.;75.95999908447266;Numerous worries about the state of the global economy and geopolitical climate have led the S&P 500 index to dip 18% so far this year.  In particular, healthcare stocks have held up quite well so far.  After such a run, is the stock a buy for dividend growth investors?In this article, we will take a look at 10 cheap ESG stocks to buy now. If you want to see more cheap ESG stocks, go directly to 5 Cheap ESG Stocks to Buy Now. ESG investing is investing in a way that considers environmental, social, and governance issues. The term is often interchangeably used […];42.79999923706055;China counted more than 10,000 fresh COVID cases on Friday sparking further restrictions on movement, but also eased some travel requirementsBayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis Recommendation is based on data from two pivotal trials showing Dupixent significantly improved itch, skin lesions and health-related quality of life in adults with prurigo nodularisIf approved, Dupixent would be the first and only targeted medicine specifically indicated for prurigo nodularis in the European Union Paris and Tarrytown, N.Y. November 11, 2022. The European Medicines Agency’s CommiRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In SeptembeHere's a few things to know about Christopher Viehbacher, the former Sanofi CEO who will soon step into the corner office at Biogen.The veteran pharmaceutical executive takes charge after the failed launch of Biogen’s once-promising Alzheimer’s disease drug Aduhelm.The European Commission has approved Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) partnered COVID-19 vaccine booster after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion. The shot with the brand name VidPrevtyn Beta can be given to people who have already had a primary vaccination course from other approved shots. It is based on lab-made viral proteins provided by Sanofi and an adjuvant ingredient from GSK that increases the imBiogen's new CEO is Christopher Viehbacher, former head of French pharma giant Sanofi. Biogen faces challenges after the commercial failure of Alzheimer’s disease therapy Aduhelm.;31.579999923706055;Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.GSK plc (NYSE: GSK) would restrict the second-line maintenance indication for Zejula to only patients with harmful, or suspected to be harmful, inherited BRCA mutations at the request of the FDA. The decision follows an FDA review of the final overall survival (OS) analysis of the ENGOT-OV16/NOVA phase 3 trial, which served as the basis for the approval of the second-line maintenance indication. Also Read: GSK's Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal OveThe European Commission has approved Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) partnered COVID-19 vaccine booster after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion. The shot with the brand name VidPrevtyn Beta can be given to people who have already had a primary vaccination course from other approved shots. It is based on lab-made viral proteins provided by Sanofi and an adjuvant ingredient from GSK that increases the imIonis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.;13.850000381469727;OSAKA, Japan & CAMBRIDGE, Mass., November 11, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) has granted Marketing Authorization for LIVTENCITYTM (maribavir) for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet, in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid org;43.91999816894531;;11.4399995803833;Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.Prosecutors and regulators say Ramkumar Rayapureddy, global chief information officer, tipped a friend about a regulatory drug approval.TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3’22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covere;199.2899932861328;;8.180000305175781;;16.270000457763672;;131.97000122070312;;9.850000381469727;Evotec ( ETR:EVT ) Third Quarter 2022 Results Key Financial Results Revenue: €173.9m (up 8.9% from 3Q 2021). Net loss...;25.309999465942383;;52.5;;7.349999904632568;"/ CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (""mRNA""), today announced data from the Phase 1 expansion study of CV8102, the company's non-coding RNA candidate in oncology.";9.899999618530273;;29.3700008392334;CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. Event: Guggenheim Healthcare Talks 4th Annual Immunology & Neurology DayDate: Tuesday, November 15, 2022Format: One-on-one meetings Event: Stifel 2022 Healthcare ConferenceDate: Wednesday, November 16, 2022Format:;45.150001525878906;;231.6699981689453;;4.230000019073486;;24.979999542236328;;1.649999976158142;;3.6700000762939453;;;;4.28000020980835;;5.840000152587891;CULVER CITY, Calif., November 10, 2022--NEJM Evidence has published results from the QUILT 3.032 trial studying N-803 plus BCG in adults with NMIBC CIS with or without Ta/T1 papillary disease. These positive data form the basis of ImmunityBio’s BLA for BCG-unresponsive NMIBC CIS, which the FDA accepted for review in July 2022.;56.880001068115234;;;;15.739999771118164;The Gaithersburg company is a longtime supplier to the federal government's Strategic National Stockpile.;8.40999984741211;;4.099999904632568;;12.680000305175781;BILLERICA, Mass., November 10, 2022--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue and Chief Financial Officer Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 17, 2022 at 4:30 p.m. EST in Boston, MA. Toloue will also host one-on-one and group meetings with institutional investors tha;2.4600000381469727;BRIDGEWATER, N.J., November 11, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for IPX203 for the treatment of Parkinson’s disease (PD). IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules.;46.08000183105469;;14.59000015258789;;18.389999389648438;SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 200,000 shares of its common stock to four new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducement;2.75;;11.149999618530273;;3.549999952316284;;7.0;;18.549999237060547;;42.04999923706055;"PLANO, Texas, November 10, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (""Reata,"" the ""Company,"" or ""we""), a clinical-stage biopharmaceutical company, today announced that management will participate in the Guggenheim 2022 Immunology & Neurology Conference on November 14 – 15, 2022 in New York, NY, and will participate in the Stifel 2022 Healthcare Conference on November 15 – 16, 2022 in New York, NY.";19.09000015258789;WESTLAKE VILLAGE, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference. Details for the company’s participation are as follows: Guggenheim 4th Annual Immunology and Neurology DayFireside Chat Date: Tuesday, November 15, 2022Fireside Chat Time: 10:45 a.m. ET The webcast f;21.290000915527344;SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced two upcoming presentations at the Society for Neuro-Oncology (SNO) annual meeting, being held from November 16-20, 2022 in Tampa, FL. Details are as follows: Title: FIREFLY-1 (PNOC026): Phase 2 Study of Pan-RAF Inhibi;25.3799991607666;;;;2.109999895095825;;16.25;
2022-11-14;171.91000366210938;In this article, we discuss top 25 Dividend Kings by yield. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read Dividend Kings List by Yield: Top 10 Stocks. Dividend Kings are the stocks that have raised their dividends for at least 50 straight years […]Smart Beta ETF report for VYM;49.2400016784668;"Fresenius Medical Care (NYSE: FMS), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) have seen their shares slide so far this year.  Fresenius, a German company that specializes in healthcare services for kidney dialysis patients, has seen its shares fall more than 54% this year.  Fresenius reported third-quarter numbers on Nov. 1, and the results were mixed.Moderna Inc said on Monday its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot.  Data shows that both of Moderna's Omicron-tailored shots, mRNA-1273.214 and mRNA-1273.222, produced a higher antibody response against BA.4/5 subvariants than its original shot in vaccinated and boosted adults, the company said.  Moderna, however, said levels of neutralizing antibody response dropped nearly 5-fold against the emerging subvariant BQ.1.1 when compared with BA.4/5, in an analysis of about 40 participants, although the virus neutralizing activity still remained ""robust"".BioNTech SE, the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc, acquired a manufacturing facility in Singapore, its first in Asia, the company said on Monday.  The facility, bought from a Novartis unit, will be its first messenger ribonucleic acid, or mRNA, facility in Singapore and support its vaccines production for the Asia Pacific region, BioNTech said in a statement, without disclosing financial details.";356.05999755859375;"""While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer's dataset to the field,"" Roche said.By Liz Moyer";114.43000030517578;;151.74000549316406;AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.;83.44999694824219;;100.3499984741211;Archer Daniels Midland, Charles River Associates, Murphy USA, Merck and New Fortress Energy are included in this Analyst Blog.RAHWAY, N.J., November 14, 2022--Merck LYNPARZA CHMP Release;63.90999984741211;The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approving AstraZeneca Plc (NASDAQ: AZN) - Merck & Co Inc (NYSE: MRK) partnered Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for prostate cancer setting. The opinion covers metastatic castration-resistant prostate cancer (mCRPC) patients for whom chemotherapy is not clinically indicated. The CHMP also backed the approval of AstraZeneca’s Imfinzi (durvalu;76.38999938964844;"The V Foundation in Cary will receive a gift of $1.5 million thanks to a cross-country ride by employees of Bristol Myers Squibb.The UK and France are poised to unveil an expanded migration deal that will seek to curb the growing number of asylum seekers coming to Britain by crossing the English Channel in small boats, according to officials.  - The head of the UK's largest business lobby group has warned chancellor Jeremy Hunt that he risks pushing corporate Britain into ""hibernation"" and curbing business investment if the Autumn Statement does not include reforms to nurture economic growth.  - The chief executive of Bristol-Myers Squibb has warned that the US pharmaceutical company could divert investment away from the UK due to the expansion of a levy designed to limit the NHS's medicines bill.The chief executive of Bristol Myers Squibb has warned that the US pharmaceutical company could divert investment away from the UK due to the expansion of a levy designed to limit the NHS’s medicines bill.  Giovanni Caforio also said low pricing for medicines purchased by the NHS from pharmaceutical companies was a major issue that threatened the UK’s ambition to become a leader in the life sciences industry.  Caforio told the Financial Times he was “very concerned” by the voluntary scheme for branded medicines pricing and access in the UK.";43.209999084472656;Amazon, Sanofi, Target, Humana and PNC Financial Services are included in this Analyst Blog.The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.;32.540000915527344;A key trend in the Raleigh and Durham real estate market is seeing old properties torn down to make flex space with specialized uses for life sciences, retail or office buildings.;13.710000038146973;;42.5;;11.5600004196167;Fresenius Medical Care (NYSE: FMS), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS) have seen their shares slide so far this year.  Fresenius, a German company that specializes in healthcare services for kidney dialysis patients, has seen its shares fall more than 54% this year.  Fresenius reported third-quarter numbers on Nov. 1, and the results were mixed.;200.72000122070312;;8.140000343322754;;15.920000076293945;;110.26000213623047;"TransCon PTH is designed to be the first parathyroid hormone replacement therapy, addressing an area of major unmet medical needCOPENHAGEN, Denmark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism. TransCon PTH is an investigational prodrug designed to restore parathyroid hormone (Ascendis Pharma A/S (NASDAQ: ASND) has announced positive topline results from the ACcomplisH Phase 2 trial of once-weekly TransCon CNP compared to a placebo in children with achondroplasia aged 2 to 10 years old. Achondroplasia is a form of short-limbed dwarfism. The ACcomplisH Trial evaluated 57 children. All 57 randomized children completed the blinded portion of ACcomplisH and are currently continuing in the open-label extension (OLE) at the 100 µg/kg/week dose. The trial met its primary obj- Data demonstrated that once-weekly TransCon CNP has the potential to meet patient and caregiver needs for a safe, effective, tolerable and convenient treatment - The primary endpoint, annualized height velocity (AHV) at Week 52, demonstrated superiority of TransCon CNP at 100 µg/kg/week compared to placebo (p=0.0218) - TransCon CNP was generally well tolerated with low frequency of injection site reactions; all 57 randomized children continued, with the longest treatment duration beyond two ye";9.680000305175781;;24.780000686645508;Organon (NYSE:OGN), a global women's healthcare company, today announced its formal commitment to FP2030 to help prevent 120 million unintended pregnancies by 2030. Recognizing the urgency of the crisis, Organon is taking action to scale access to contraceptive options for more than 100 million women in low- and middle-income countries (LMICs), in addition to strategic partnerships focused on education, training, advocacy and youth engagement.Organon (NYSE: OGN), a global women's health company, today announced the availability and distribution of Ontruzant®, a biosimilar of Herceptin®, providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC).1;52.29999923706055;;8.270000457763672;;10.979999542236328;HUTCHMED (China) Limited (NASDAQ: HCM) announced initial results from FRUTIGA Phase 3 trial of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful. The other primary endpoint of overall survival (OS) was not statistically significant per the pre-specified statistica— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant — — Safety findings consistent with fruquintinib known profile — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces initial results from FRU;29.3799991607666;;46.880001068115234;;227.05999755859375;;4.510000228881836;;26.18000030517578;;1.7000000476837158;;3.700000047683716;;;;4.079999923706055;;6.150000095367432;;58.56999969482422;;;;13.449999809265137;Indivior PLC (OTC: INVVY) has agreed to acquire Opiant Pharmaceuticals Inc (NASDAQ: OPNT) for $20.00 per share in cash, plus contingent value rights (CVRs) of up to $8.00 per share. Achievement of the CVR payments, if any, is based on attaining certain revenue thresholds for OPNT003, nasal nalmefene, and Opiant's investigational treatment for opioid overdose. Completion of rolling New Drug Application (NDA) submission for OPNT003 is on track for Q4 2022. The upfront payment of $20.00 per share rEmergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studiesGAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. Emergen;8.470000267028809;The average of price targets set by Wall Street analysts indicates a potential upside of 125.9% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.;4.159999847412109;;12.84000015258789;;2.369999885559082;;44.18000030517578;;14.239999771118164;;18.43000030517578;Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of 0% and 54.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to prior injected SRL therapy for up to 103 weeks in participants living with acromegaly participating in the ACROBAT Advance Long-term Extension Study SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2022. “Thi;2.8499999046325684;;11.010000228881836;;3.5199999809265137;;6.989999771118164;;18.229999542236328;;42.11000061035156;;18.709999084472656;;22.0;;24.959999084472656;;;;2.130000114440918;;17.399999618530273;The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 106.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2022-11-15;172.38999938964844;In this article, we discuss the top 10 small-cap stocks from Ray Dalio’s Q3 2022 portfolio. If you want to see more stocks in this selection, check out Ray Dalio Stock Portfolio Q3 2022: Top 5 Small-Cap Stocks. According to Royce Investment Partners, although equity prices declined in the volatile market environment through the first […]Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose Investments”) has filed and been receipted for a preliminary prospectus by the Canadian securities regulators in connection with the proposed launch of the first yield-focused single-stock ETFs (as outlined below) (collectively, the “ETFs” or “Purpose Yield Shares”). ETF NamesUnderlying Issuer Security Apple (AAPL) Yield SharesApple Inc.Common stockAmazon (AMZ) Yield SharesAmazon.com Inc.Common stockTesla (TSLA) YieldSector ETF report for IHE;48.56999969482422;Moderna stock popped Monday after the company said its bivalent Covid booster led to a 15-fold jump in omicron-blocking antibodies.The executive went through elaborate measures to hide his activityModerna  was rising sharply Monday after the vaccine maker said its updated Covid-19 boosters work against the BA.4 and BA.5 variants better than its previous shot.  Moderna  (ticker: MRNA) announced Monday that in a trial of more than 500 adults the company’s updated Covid-19 boosters “induced significantly higher neutralizing antibody titers” against BA.4/BA.5 compared with a booster dose of mRNA-1273, the company’s original booster.  “We are pleased to see that both of our bivalent booster vaccine candidates offer superior protection against Omicron BA.4/BA.5 variants compared to our original booster, which is encouraging given Covid-19 remains a leading cause of hospitalization and death globally,” Chief Executive Stéphane Bancel said in a news release.;349.95001220703125;Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.A swarm of impostors forced the social media company to temporarily pull back on its rollout of verified badges for anyone that pays $8 a month.Sector ETF report for PJPChevron, Eli Lilly, Charles Schwab, Salesforce and SAP are included in this Analyst Blog.It's time to be extra picky.You don't hear Elon Musk and Eli Lilly and company (NYSE: LLY) mentioned in the same sentence very often.  Musk has been in the news quite a bit lately after his acquisition of Twitter.  Among the victims was none other than Eli Lilly.Eli Lilly reportedly is pulling advertising from Twitter after a fake account promised free insulin in a fiasco that depressed LLY stock.The Fortune 500 company was one of a few brands that fell victim to Twitter's altered verification policy.Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Eli Lilly and Company (LLY) and The Charles Schwab Corporation (SCHW).Yahoo Finance Live anchors discuss the decline in stock for Eli Lilly after an unofficial verified account tweeted that insulin was now free.;113.63999938964844;Bagsværd, Denmark, 15 November 2022 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and theirThe benefits of obesity drugs such as Novo Nordisk's Wegovy on healthcare systems in countries such as the United States are so significant that the expected entry of rival drugs will not hurt its margins, CEO Lars Jorgensen told Reuters on Tuesday.  The main active ingredient in Ozempic is semaglutide, which is also the key ingredient in Novo's obesity drug Wegovy.  The drugs belong to a family of medicines known as GLP-1 analogues that are designed to regulate hunger.;153.0399932861328;;83.83000183105469;;99.5999984741211;The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.;63.95000076293945;The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.;76.27999877929688;In this article we take an in-depth look at why Michael Burry is Betting Everything on These 6 Stocks. Click to jump straight to the ‘Big Short’ icon’s top stock picks to see why Michael Burry is Betting Heavily on These 3 Stocks. The GEO Group, Inc. (NYSE:GEO), Qurate Retail, Inc. (NASDAQ:QRTEA), and CoreCivic, Inc. (NYSE:CXW) […];43.54999923706055;Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi;32.290000915527344;GSK plc (NYSE: GSK) announced positive results from a Phase 2a study demonstrating that GSK3036656, an investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment. The trial included participants with drug-susceptible pulmonary tuberculosis (TB). Earlier this year, GSK committed to investing £1 billion over the next decade to accelerate R&D on infectious diseases, including TB, that disproportionately;13.75;;42.08000183105469;;11.319999694824219;The executive went through elaborate measures to hide his activity;210.83999633789062;;7.989999771118164;;15.739999771118164;;110.1500015258789;;9.25;;24.8799991607666;JERSEY CITY, N.J., November 15, 2022--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.;52.5;;8.069999694824219;;11.539999961853027;"Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today provides a corporate and strategic update, following an in-depth evaluation of the business. In response to the challenging market conditions currently affecting the global biopharmaceutical sector, HUTCHMED has taken a numb";29.350000381469727;;46.61000061035156;;230.77000427246094;;4.860000133514404;;27.399999618530273;;1.7599999904632568;;3.6500000953674316;;;;3.9200000762939453;;6.050000190734863;;56.099998474121094;;;;13.3100004196167;;8.170000076293945;;4.409999847412109;;12.149999618530273;;2.299999952316284;Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.;44.7599983215332;;14.199999809265137;;18.239999771118164;;2.880000114440918;;11.739999771118164;;3.5299999713897705;;6.989999771118164;Constant currency Net Revenues Increased by 15% year-over-year in the 9M22 and by 11% in the 3Q22, signaling a strong demand across our businessesMIAMI and BARRANQUILLA, Colombia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the three months ended September 30, 2022 (“3Q22”) and the nine months ended September 30, 2022 (“9M22”). “Demand remains robu;18.0;;41.66999816894531;;19.440000534057617;Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis. The study met its primary endpoint with 32.0% of individuals treated with roflumilast cream 0.15% achieving IGA Success – Atopic Dermatitis score of 'clear' or 'almost clear' plus a 2-grade improvement from baseline at Week 4, compared to 15.2% of individuals treated with vehicle. About 43.2% of individuals treated witArcutis Biotherapeutics Inc said on Tuesday its skin cream met the main goal in a late-stage study for treating mild to moderate atopic dermatitis.  Atopic dermatitis is the most common type of eczema, which affects nearly 9.6 million children and 16.5 million adults in the United States, Arcutis said.Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success compared to 15.2% of individuals treated with vehicle (P<0.0001)43.2% of individuals treated with roflumilast cream 0.15% achieved a 75% reduction in Eczema Area and Severity Index (EASI-75) and 33.6% achieved a clinically meaningful reduction in itch at Week 4Roflumilast cream demonstrated a favorable;21.889999389648438;;26.020000457763672;;;;2.140000104904175;;17.110000610351562;
2022-11-16;173.4600067138672;In this article, we discuss the top 10 stock picks of billionaire Ray Dalio’s Bridgewater Associates 13F portfolio. If you want to see more stocks in this selection, check out Billionaire Ray Dalio’s Bridgewater Associates 13F Portfolio: Top 5 Stock Picks. Ray Dalio founded Bridgewater Associates from his apartment in Manhattan back in 1975 and […];48.04999923706055;Pfizer, Goldman Sachs, General Electric, Microchip Technology and Genuine Parts are included in this Analyst Blog.If you buy a high-yielding dividend stock that's trading at a low earnings multiple, it can significantly improve your odds of making a good profit on your investment.  Although the outlook for the economy may not be the greatest, if you're a long-term investor, you just need to be confident that the businesses you're investing in will be able to weather the current storm and remain good buys afterward.  Pfizer (NYSE: PFE) and Goldman Sachs (NYSE: GS) are stocks that should be fairly safe investments to hang on to here.Pfizer (NYSE:PFE) has had a great run on the share market with its stock up by a significant 13% over the last month...Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Goldman Sachs Group, Inc. (GS) and General Electric Company (GE).;352.92999267578125;Has the stock market bottomed out?  Let's look at two stocks worth owning when that happens: Eli Lilly (NYSE: LLY) and Shopify (NYSE: SHOP).  Eli Lilly is currently trouncing the market, with its shares up by 29% since the beginning of the year.Eli Lilly and Company (NYSE: LLY) will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022. Jacob Van Naarden, Lilly executive vice president and CEO of Loxo@Lilly, and David Hyman, M.D., chief medical officer, Loxo@Lilly, will participate in a fireside chat at 12:10 p.m., Eastern time.Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.It joins some big name celebrities who have already headed for the exits.Nissan, Cadbury’s, and Guinness-brewer Diageo have been told to avoid “dangerous” and “toxic” Twitter by their marketing agency, as an advertising boycott of the company under Elon Musk gathers pace.;113.37000274658203;;151.8699951171875;"Health Canada has approved AbbVie Inc's (NYSE: ABBV) Ubrelvy (ubrogepant) for the acute treatment of migraine, with or without aura, in adults. Ubrelvy is the first orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for migraine attacks once they start. Calcitonin gene-related peptide (CGRP) is a neuropeptide in the peripheral and central nervous systems. CGRP is released from sensory nerve endings during a migraine attack. Ubrogepant blocks the binding of CGWhen close to half the companies in the United States have price-to-earnings ratios (or ""P/E's"") below 14x, you may...AbbVie (NYSE: ABBV) announced today that Health Canada has approved UBRELVY® (ubrogepant tablet) for the acute treatment of migraine, with or without aura, in adults.1 UBRELVY® is the first orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start.";83.55000305175781;(Bloomberg) -- Novartis AG is weighing sales of non-core assets as it seeks to raise money to invest in cutting-edge medicines, people familiar with the matter said.Most Read from BloombergUkraine Latest: Biden Says Missile Likely Not Fired From RussiaTrump Makes His 2024 Run Official, Defies Calls to Move OnPoland Says Russian-Made Missile Hit Territory and Killed Two PeopleBiden Says Unlikely Rocket That Hit Poland Was Fired From RussiaMusk Steps Up Purge of Twitter Engineers Who Criticize HimSwiss drugmaker Novartis AG is considering selling its ophthalmology and respiratory units, a Bloomberg report said on Wednesday, citing people familiar with the matter.  The company is seeking to raise money from the possible sale of the assets to invest in cutting-edge medicines, the report said, adding that the ophthalmology unit could alone fetch about $5 billion.  Novartis in August said it was planning to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines.The company is seeking to raise money from the possible sale of the assets to invest in cutting-edge medicines, the report said, adding that the ophthalmology unit could alone fetch about $5 billion.  Novartis in August said it was planning to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines.  Sandoz sales have been hurt by pricing pressure that has affected the broader generics industry for years, particularly in the United States, although the country accounts for less than a quarter of its total sales.Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.;99.93000030517578;Climate change doesn't only affect the health of our planet - it also impacts the health of our people.Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.National Institute for Health and Care Excellence (NICE) has recommended stopping using five COVID-19 treatments, including Merck & Co Inc's (NYSE: MRK) antiviral pill for high-risk patients, citing cost-effectiveness concerns. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's (NASDAQ: GILD) hospital-administered antiviral remdesivir are effective at treating COVID-19, not found to be cost-effective. It also recommended against three other COVID treatmeMerck's (NYSE:MRK) stock is up by 9.4% over the past three months. Since the market usually pay for a company’s...Britain’s agency that determines if medicines should be used in the National Health Service (NHS), has recommended stopping the use of five COVID-19 treatments, including Merck & Co's's antiviral pill for high-risk patients, citing cost-effectiveness concerns.  The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase.  NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's hospital-administered antiviral remdesivir are effective at treating COVID-19.Despite the recent rebound of many U.S. stocks, the S&P 500 is still down 17% in 2022. It’s also 8% below its Aug. high. Yet the unweighted S&P 500 index is doing much better, down only 11% this year and just 4.5% off its Aug. high. The outperformance of the unweighted S&P 500 indicates that investors should buy names aside from the big tech stocks that get the biggest weight in the regular S&P 500 index. A good way to accomplish the latter goal is by finding some of the best value stocks to buy;63.79999923706055;WILMINGTON, Del., November 16, 2022--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.;76.1500015258789;;43.86000061035156;;32.90999984741211;;13.770000457763672;Are these a couple of rare opportunities that investors shouldn't pass up, or are the price drops valid because of significant concerns that should keep you away from these companies?  Takeda is a Japan-based healthcare company that makes vaccines and pharmaceutical products.;42.54999923706055;;11.079999923706055;;190.97000122070312;;7.900000095367432;;14.569999694824219;;114.8499984741211;;8.760000228881836;;24.389999389648438;;51.650001525878906;;8.170000076293945;;11.270000457763672;;28.43000030517578;;43.77000045776367;;230.10000610351562;;4.349999904632568;;25.510000228881836;;1.7000000476837158;Potential OPKO Health, Inc. ( NASDAQ:OPK ) shareholders may wish to note that the Chairman & CEO, Phillip Frost...;3.440000057220459;;;;3.5199999809265137;;5.679999828338623;;55.63999938964844;;;;12.1899995803833;;7.5;;4.309999942779541;As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...;11.8100004196167;;2.2300000190734863;;43.84000015258789;;13.729999542236328;;18.190000534057617;;2.869999885559082;;10.789999961853027;;3.440000057220459;;6.599999904632568;;17.459999084472656;The latest analyst coverage could presage a bad day for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ), with the...;38.08000183105469;;19.229999542236328;Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success compared to 15.2% of individuals treated with vehicle (P<0.0001)43.2% of individuals treated with roflumilast cream 0.15% achieved a 75% reduction in Eczema Area and Severity Index (EASI-75) and 33.6% achieved a clinically meaningful reduction in itch at Week 4Roflumilast cream demonstrated a favorable;21.209999084472656;;25.700000762939453;Those following along with IGM Biosciences, Inc. ( NASDAQ:IGMS ) will no doubt be intrigued by the recent purchase of...;;;2.109999895095825;;17.0;Celebrations may be in order for Repare Therapeutics Inc. ( NASDAQ:RPTX ) shareholders, with the analysts delivering a...
2022-11-17;174.86000061035156;In this article, we discuss the 14 biggest beauty companies in the world. If you want to read about some more beauty companies, go directly to 5 Biggest Beauty Companies In The World. The beauty industry has successfully navigated the multiple challenges posed by the pandemic crisis and the subsequent economic slowdown of the past […];48.33000183105469;The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have initiated a Phase 1 study to evaluate the safety, tolerability, and immunogenicity of a next-generation COVID-19 vaccine candidate. The next-gen vaccine candidate aims to enhance SARS-CoV-2 T cell responses and potentially broaden protection against COVID-19. The candidate, dubbed BNT162b4, includes T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins and will be evaluated in combination with the companies' omicron BA.4/BA.5-adCVS's launch of the initiative comes four months after the FDA first authorized state-licensed pharmacists to prescribe Pfizer's anti-viral treatment.;360.7699890136719;"Investors shouldn't be overly concerned with the stock's earnings multiple -- a premium is justifiable for this top business.We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to...Eli Lilly & Co Chief Executive Officer Dave Ricks said on Wednesday that the recent imposter Twitter account incident ""demonstrates some of the challenges"" on the social media platform.  Speaking at the STAT Summit 2022, Ricks described the incident as ""disappointing"".  The drugmaker had issued an apology from its official Twitter account, @LillyPad, after an imposter Twitter account with the handle @EliLillyandCo tweeted that insulin would be free, amid political backlash and scrutiny into high medicine costs.(Reuters) -Eli Lilly & Co Chief Executive Officer Dave Ricks said on Wednesday that the recent imposter Twitter account incident ""demonstrates some of the challenges"" on the social media platform.  Twitter recently saw a surge in fake accounts, with the blue verification check purporting to be listed companies such as Lilly, Nestle and Lockheed Martin following the launch of an $8 subscription service, which has since been halted.  Speaking at the STAT Summit 2022, Ricks described the incident as ""disappointing"".";112.91000366210938;Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works are included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Amgen Inc. (AMGN) and Automatic Data Processing, Inc. (ADP).BAYRY vs. NVO: Which Stock Is the Better Value Option?;152.16000366210938;Yesterday, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), celebrated the fourth annual – and most successful – BOTOX® Cosmetic Day yet.;83.45999908447266;Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.Novartis AG (NYSE: NVS) is reportedly weighing divesting non-core assets as it seeks to raise money to invest in cutting-edge medicines, people familiar with the matter said. The pharma giant is in the early stages of considering options for its ophthalmology and respiratory units. Some private equity firms are already studying the businesses. Bloomberg noted that the ophthalmology business could fetch about $5 billion. The people said that any sales of the ophthalmology and respiratory business;102.30999755859375;Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.One of them is Merck (NYSE: MRK).  Here's why Merck is an excellent stock for investors focused on the long game.  Like most large pharmaceutical companies, Merck has a lineup of medicines that continues to help it grow its top and bottom lines.Merck is best known for its top-selling cancer drug called Keytruda, which is on pace to exceed $20 billion in net sales in 2022.  Merck's net sales climbed 13.7% year over year to reach just shy of $15 billion in the third quarter.  This was mostly driven by double-digit percentage net sales growth from Keytruda and the company's human papillomavirus vaccine (HPV) franchise Gardasil, as well as a $436 million contribution from Lagevrio.;64.05999755859375;Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.;77.16000366210938;By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...;43.709999084472656;;32.59000015258789;In this article, we discuss the 10 new stock picks of Ken Fisher. If you want to see more stocks in this selection, check out Ken Fisher Strategy: 5 New Stock Picks. Fisher Asset Management’s investment philosophy consists of a fundamental belief in capitalism. The investment firm believes that demand and supply of stocks are […];13.930000305175781;OSAKA, Japan & CAMBRIDGE, Mass, November 17, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ICLUSIG® (ponatinib) plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-negative complete remission (CR) compared to imatinib. MRD-negativity is associated;42.33000183105469;;10.960000038146973;;174.69000244140625;;7.579999923706055;;14.300000190734863;;115.58000183105469;;8.800000190734863;;23.920000076293945;;51.099998474121094;;8.5;;11.1899995803833;;28.389999389648438;;43.2400016784668;;226.52000427246094;The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.;4.139999866485596;;24.3700008392334;;1.6299999952316284;;3.3399999141693115;;;;3.430000066757202;;5.599999904632568;CULVER CITY, Calif., November 17, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022.;56.060001373291016;;;;12.109999656677246;;7.590000152587891;;4.010000228881836;;11.180000305175781;BILLERICA, Mass., November 16, 2022--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced plans to participate in the upcoming 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force in San Francisco, California from November 29 to December 2, 2022. Quanterix CEO Masoud Toloue is scheduled to present on Tuesday, November 29 at 9:55 a.m. PST, along with a panel of assay industry leaders, on leveraging the us;2.190000057220459;;44.5;;13.0600004196167;;17.579999923706055;;2.799999952316284;NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massachusetts General Hospital (MGH). The study will utilize a neuroimaging method to identify neuroplasticity biomarkers in patients with treatment-resistant depression (TRD) undergoing intravenous (IV) ketamine treatment. The main obj;10.15999984741211;;3.5399999618530273;;6.880000114440918;;17.579999923706055;;35.400001525878906;;18.770000457763672;ZORYVE is now on formulary for one of the top pharmacy benefit managers serving commercially insured patients, effective November 18, 2022ZORYVE is a once-daily non-steroidal cream and the first and only topical PDE4 inhibitor approved for use in plaque psoriasis, including all affected areas of the body, on July 29Arcutis announced the commercial launch of ZORYVE on August 10 WESTLAKE VILLAGE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage;21.09000015258789;SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:00 a.m. EST. A live audio webcast of the discussion will be available by v;22.049999237060547;;;;2.059999942779541;;17.729999542236328;
2022-11-18;176.1999969482422;Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.It’s not just about crypto.;48.22999954223633;Pfizer Inc. and German partner BioNTech SE said Friday a new analysis of data reviewing the immune response created by the omicron BA.4/BA.5 adapted bivalent COVID vaccine showed strong results against newer omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1. The data, which has been posted on the preprint server bioRxiv, show that the booster induces a greater increase in neutralizing antibody titers than the companies' original COVID-19 vaccine against these emerging omicron suPfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.  Antibody levels against the subvariant rose nearly nine-fold in older adults, aged 55 and above, who received the Omicron shot compared to a roughly two-fold increase in participants with the original shot, according to data posted on online archive bioRxiv.Pfizer and BioNTech said Thursday they've started testing a next-generation Covid shot, and both vaccine stocks reversed early declines.;361.6700134277344;Eli Lilly have been highlighted in this Investment Ideas article.In this article, we discuss top dividend stocks to buy according to billionaire Ken Fisher. You can skip our detailed discussion on Fisher’s investment strategy and his hedge fund’s performance, and go directly to read Billionaire Ken Fisher’s Top 5 Dividend Stock Picks. Ken Fisher founded Fisher Investments in 1979 and is currently serving as […]Markets typically applaud the 'certainty' that comes with a split Congress.;113.44000244140625;;154.97999572753906;;85.69999694824219;;104.2300033569336;Raymond James maintains Outperform on Gossamer Bio Inc (NASDAQ: GOSS) with a price target down from $18 to $15. The analyst expects a somewhat smaller effect size for seralutinib vs. sotatercept's. Seralutinib Phase 2 TORREY study is on track for topline readout in the second half of November or the first half of December. Merck & Co Inc (NYSE: MRK) is developing sotatercept as an add-on to stable background therapy for pulmonary arterial hypertension (PAH). Merck recently reported topline dataStrong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.;65.06999969482422;Let's look at two pharma giants that could help investors navigate the next recession and beyond: Bristol Myers Squibb (NYSE: BMY) and AstraZeneca (NASDAQ: AZN).  Bristol Myers' top-line growth seems unimpressive right now.  During the third quarter, the company's revenue declined by 3% year over year (YoY) to $11.2 billion.Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.;77.44999694824219;Let's look at two pharma giants that could help investors navigate the next recession and beyond: Bristol Myers Squibb (NYSE: BMY) and AstraZeneca (NASDAQ: AZN).  Bristol Myers' top-line growth seems unimpressive right now.  During the third quarter, the company's revenue declined by 3% year over year (YoY) to $11.2 billion.;44.5099983215332;"Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.Provention Bio Inc said on Friday its recently approved diabetes drug, teplizumab, would cost $13,850 a vial.  The U.S. Food and Drug Administration approved use of the drug, to be sold under brand name Tzield, late on Thursday for delaying the onset of insulin-dependent type 1 diabetes, which is less common than type 2 of the disease, for people aged 8 years and above.  In October, Provention signed a co-promotion deal for the drug with Sanofi, offering the French drugmaker first negotiation for exclusive global rights to commercialize the drug in exchange for an upfront payment of $20 million.Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.Provention Bio said on Thursday the U.S. Food and Drug Administration had approved the use of its drug teplizumab in those aged eight years and older, the first treatment aimed at delaying the onset of insulin-dependent type 1 diabetes.  The U.S. health regulator has allowed teplizumab, to be sold under the brand name Tzield, for patients with stage 2 of the disease who have two or more disease autoantibodies and abnormality in blood sugar stability, Provention Bio said.  ""We expect to have drug in the channel by the end of the year,"" said Jason Hoitt, Provention's chief commercial officer, adding that preparations were underway with its partner Sanofi for a full launch in January 2023.As of Nov. 11, just 29% of Morningstar-covered stocks that reported Q3 earnings beat estimates by at least 10%.The European Commission has approved Sanofi SA (NASDAQ: SNY) Enjaymo (sutimlimab) for hemolytic anemia in adult patients with cold agglutinin disease (CAD). CAD is a rare chronic autoimmune hemolytic anemia, where the body's immune system mistakenly attacks healthy red blood cells, rupturing them (hemolysis). Related: Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster. Enjaymo is currently the only approved treatment for CAD. It is a first-in-class humanized monoclonal antiEuropean Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has granted marketing authorization for Enjaymo® (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chr";32.88999938964844;Wells Fargo, Honeywell International, Northrop Grumman, The Travelers Companies and GSK are included in this Analyst Blog.Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo & Company (WFC), Honeywell International Inc. (HON) and Northrop Grumman Corporation (NOC).;14.100000381469727;Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Phase 3 PhALLCON trial of Iclusig (ponatinib) met its primary endpoint in newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. The study demonstrated that Iclusig plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-complete negative remission (CR) compared to imatinib. In the trial, no new safety signals were observed. Related: Takeda Seeks FDA Approval For Hereditary A;42.869998931884766;;11.0;;175.92999267578125;;7.53000020980835;;14.100000381469727;;118.62999725341797;;8.449999809265137;;24.399999618530273;;52.11000061035156;;8.15999984741211;;10.770000457763672;Company Executives Shared Vision and Answered Questions Live at VirtualInvestorConferences.comNEW YORK, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the presentations from its Depositary Receipts Virtual Investor Conference (“dbVIC”) held on November 16th and 17th are now available for online viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3GjK8UZThe company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials fr;28.799999237060547;;50.45000076293945;Shares of Apellis Pharmaceuticals Inc. jumped 16.8% in premarket trading on Friday after the company said the Food and Drug Administration accepted an amendment to its drug-approval submission for a geographic atrophy therapy. The FDA is expected to make a decision on the drug by Feb. 26, and the company said the regulator does not plan to hold an advisory committee meeting to discuss the new drug application for pegcetacoplan. Apellis' stock has declined 33.9% over the last three months, whileWALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug Administration (FDA) has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The updated Prescription Drug User Fee Act (PDUFA) goal date is F;227.0;;4.070000171661377;;24.969999313354492;;1.6200000047683716;;3.319999933242798;;;;3.490000009536743;;5.269999980926514;;57.0099983215332;;;;12.319999694824219;;7.880000114440918;;3.9200000762939453;;11.729999542236328;;2.240000009536743;;46.290000915527344;;13.0;;17.829999923706055;;3.069999933242798;;10.649999618530273;;3.509999990463257;To get a sense of who is truly in control of Centessa Pharmaceuticals plc ( NASDAQ:CNTA ), it is important to...;6.869999885559082;;16.780000686645508;;37.939998626708984;;18.719999313354492;;21.34000015258789;;21.149999618530273;;;;2.0;;18.1299991607666;
2022-11-21;175.97000122070312;Safe haven investments are a great way to lower risk over the long haul. Companies with consistent revenue and earnings tend to be more stable and help significantly lower risk during volatile market conditions. They are a great way to diversify your portfolio and protect your investments during market turbulence. You can find safe havens by looking for companies with a history of consistent growth, strong financials, and a history of paying dividends. Given the current market conditions, investLarge-cap stocks are always great to have in a portfolio. These companies are some of the biggest and best-known stocks in the market. That makes finding the best large-cap stocks a worthy exercise. Of course, in this market, it can be a challenge to identify the best large-cap stocks. With the Dow Jones Industrial Average down more than 16% and other major indices down more than that, you just can’t throw darts at a board to find your winners. For this list, I use my Portfolio Grader exclusive;48.18000030517578;For anyone looking to get ahead in the investing game, following in the footsteps of stock picking legends is an obvious path to follow. Hardly any are more legendary than George Soros, forever known as the ‘man who broke the Bank of England,’ after pocketing a cool billion dollars in one day when betting against the Pound back in 1992. That single act, however, does not define Soros, who has made sound investment decisions throughout his career which bought decades-long returns of 30% to his QuPfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.;361.1700134277344;"Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually. These presentations include new results from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]), and LOXO-783 (an investigational mutant-selectiveBig Pharma has taken much of the heat for sky-high insulin prices, but scrutiny could soon shift to other companies grabbing a growing slice of spending.While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Eli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy";113.41000366210938;"Bagsværd, Denmark, 21 November 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programmEli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy";157.11000061035156;AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.Right now all three of these top dividend stocks offer yields above the 3% threshold that many investors consider acceptable.  AbbVie (NYSE: ABBV) is the biopharmaceutical company behind Humira, a top-selling drug for arthritis and psoriasis.  The stock offers an above-average yield of 3.8% right now because Humira won't be on the list of top sellers for much longer.;86.79000091552734;;105.61000061035156;"Yahoo Finance Live anchors discuss reports that Merck will acquire Imago BioSciences for $1.35 billion.Here is how Merck (MRK) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.Merck & Co Inc (NYSE: MRK) has agreed to acquire Imago BioSciences Inc (NASDAQ: IMGO) for $36.00 per share in cash for an approximate total equity value of $1.35 billion. ""This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,"" commented Merck's President & CEO, Robert Davis. Imago is a clinical-stage biopharmaceutical company developing new medicines for myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Related: CentreMerck said it will pay $36 a share cash for Imago, which is developing drugs to treat bone-marrow diseases.Merck & Co Inc said on Monday it would acquire cancer drug developer Imago BioSciences for a total equity value of $1.35 billion.  Merck's offer of $36 per share in cash for Imago represents nearly a 107% premium to the company's last closing price.  The deal for the clinical-stage biopharmaceutical company that is developing drugs for the treatment of bone marrow-related diseases is expected to close in the first quarter of 2023, Merck said.Shares of Imago BioSciences Inc. soared toward an eight-month high in premarket trading Monday, after the biopharmaceutical company developing treatments for myeloproliferative neoplasms (MPNs) and other bone marrow diseases announced an agreement to be acquired by Merck & Co. Inc. in a cash deal with a equity value of $1.35 billion. Under terms of the deal, Merck will pay $36.00 for each Imago share, which represents a 106.9% premium to Friday's closing price of $17.40. The buyout price implies(Reuters) -Merck & Co Inc said on Monday it will acquire cancer drug developer Imago BioSciences Inc for a total equity value of $1.35 billion to expand its portfolio of blood disorder treatments.  With Merck's blockbuster cancer immunotherapy Keytruda expected to lose key patents in 2028, the company has been trying to expand its drug portfolio.  Last year, it bought Acceleron Pharma for about $11.5 billion to gain access to its experimental therapy for treating a type of high blood pressure.RAHWAY, N.J., November 21, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Eliav Barr, senior vice president and head of Global Clinical Development, chief medical officer, Merck Research Laboratories, is scheduled to participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, Dec. 1, 2022 at 9:40 a.m. ET.RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif., November 21, 2022--Merck to Acquire Imago BioSciences, Inc.Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.";65.43000030517578;;78.95999908447266;Every investor in Bristol-Myers Squibb Company ( NYSE:BMY ) should be aware of the most powerful shareholder groups...PRINCETON, N.J., November 21, 2022--Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood DiseasesBig Pharma is bristling at new doctor's orders. As part of the Inflation Reduction Act passed earlier this year, the US Government now has the...;44.7400016784668;;33.439998626708984;;14.069999694824219;;42.91999816894531;;11.09000015258789;;174.00999450683594;It is hard to get excited after looking at Repligen's (NASDAQ:RGEN) recent performance, when its stock has declined 22...;7.809999942779541;;14.34000015258789;For anyone looking to get ahead in the investing game, following in the footsteps of stock picking legends is an obvious path to follow. Hardly any are more legendary than George Soros, forever known as the ‘man who broke the Bank of England,’ after pocketing a cool billion dollars in one day when betting against the Pound back in 1992. That single act, however, does not define Soros, who has made sound investment decisions throughout his career which bought decades-long returns of 30% to his Qu;117.37999725341797;;8.270000457763672;;24.719999313354492;;51.0099983215332;SOMERSET, N.J., November 21, 2022--The U.S. FDA has granted Legend Biotech's IND application for LB2102 in extensive stage small cell lung cancer.;7.949999809265137;;10.489999771118164;;27.350000381469727;;48.22999954223633;The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.;225.1199951171875;;3.7200000286102295;;24.18000030517578;;1.590000033378601;;3.309999942779541;;;;3.359999895095825;;5.159999847412109;;57.279998779296875;;;;11.84000015258789;;7.360000133514404;;3.7699999809265137;;11.90999984741211;;2.259999990463257;;46.38999938964844;;12.470000267028809;;17.6200008392334;;2.869999885559082;;9.9399995803833;;3.569999933242798;;6.559999942779541;;16.260000228881836;;36.380001068115234;;18.200000762939453;Report highlights efforts to advance diversity and inclusion, access to medicine, sustainable business practices, and governance WESTLAKE VILLAGE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced the Company’s inaugural Environmental, Social, and Governance (ESG) report including a baseline of key performance metrics. “Our first ESG report h;20.40999984741211;Just because a business does not make any money, does not mean that the stock will go down. For example, although...;20.75;;;;1.8799999952316284;;17.280000686645508;
2022-11-22;176.82000732421875;;49.08000183105469;ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant tumors support the initiation of two Phase 3 registrational trials NEW HAVEN, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced initial results from the Phase 2 cohort expansion portion (VERITAC) of a phase 1/2 study with ARV-471,The treatment, called Xocova, is made by Shionogi & Co., which plans to seek approval from the FDA for its pill in the U.S.Sector ETF report for FHLCIs Pfizer stock a buy after surging on Moderna's omicron-focused booster shot data? Is PFE stock a buy right now?;360.8800048828125;Drugs to treat obesity and promote weight loss could constitute a global market exceeding $50 billion by 2030Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.;115.37999725341797;Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.Novo Nordisk A/S (NYSE: NVO) plans to invest DKK 5.4 billion to expand its existing facilities in Bagsvaerd, Denmark. The plans also include constructing a new plant to extend the existing facilities. Novo, the world's biggest producer of diabetes drugs, said the project is expected to be finalized in 2024 and create about 160 new jobs. The investment would establish additional capacity in research and development for manufacturing of active pharmaceutical ingredients (API), the main biologicallDanish drug maker Novo Nordisk said on Tuesday it plans to invest 5.4 billion Danish crowns ($744 million) to expand its facilities in Bagsvaerd, Denmark.  The world's biggest producer of diabetes drugs, Novo said the project is expected to be finalised in 2024 and create about 160 new jobs.  The investment would add capacity in research and development for manufacturing of active pharmaceutical ingredients (API), the main biologically active components of medicines, to supply its global clinical trials.COPENHAGEN (Reuters) -Danish drug maker Novo Nordisk said on Tuesday it plans to invest 5.4 billion Danish crowns ($744 million) to expand its facilities in Bagsvaerd, Denmark.  The world's biggest producer of diabetes drugs, Novo said the project is expected to be finalised in 2024 and create about 160 new jobs.  The investment would add capacity in research and development for manufacturing of active pharmaceutical ingredients (API), the main biologically active components of medicines, to supply its global clinical trials.Bagsværd, Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply our global clinical trials. These expansions will provide capacity for developing Novo Nordisk’s future oral anDrugs to treat obesity and promote weight loss could constitute a global market exceeding $50 billion by 2030;159.7899932861328;The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem.AbbVie (NYSE: ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Tom Hudson senior vice president, R&D and chief scientific officer, will present at 8:30 a.m. Central time.AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 15th of February to...The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.Today's market is tough. And your portfolio may be suffering. But if you invest in dividend stocks, the picture may begin to look brighter. These companies pay you annually -- just for owning their shares.;87.69999694824219;First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious complement-mediated blood disorder New data evaluating the superiority of first-line (1L) Kisqali® plus endocrine therapy vs. combination chemotherapy in pre-menopausal patients with HR+/HER2- metastatic breast cancer with aggressive disease, including patients with visceral disease New analysis fr;106.9000015258789;"Merck & Co Inc (NYSE: MRK) has announced topline results from the pivotal Phase 3 KEYNOTE-859 trial of its flagship anti-PD-1 therapy, Keytruda, in gastric or Gastroesophageal Junction GEJ adenocarcinoma. The trial evaluated Keytruda in combination with chemotherapy for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. Related: Five-Year Data For Merck's Keytruda Plus Chemo Shows SustainWe have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.Merck & Co Inc said on Tuesday its therapy involving cancer drug Keytruda in combination with chemotherapy met the main goal of a late-stage study for treating a type of gastric cancer.  The combo therapy showed a ""statistically significant"" and ""clinically meaningful"" improvement in the study by helping cancer patients live longer, compared with chemotherapy as a standalone treatment, the drugmaker said.  The treatment also helped in improving progression-free survival of patients with the cancer, Merck said, citing the study.RAHWAY, N.J., November 22, 2022--Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of OS in Patients With HER2-Negative Gastric or GEJ CancersThe treatment, called Xocova, is made by Shionogi & Co., which plans to seek approval from the FDA for its pill in the U.S.The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.In this article, we will take a look at the 10 stocks skyrocketing today. If you want to check out some other stocks gaining value on Monday, go directly to These 5 Stocks are Skyrocketing Today. U.S. stocks inched lower this morning as investors feared that China might reimpose mobility restrictions following the resurgence of […]Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.Investors haven't been happy with the performance of the Nasdaq Composite (NASDAQINDEX: ^IXIC) so far in 2022, with the index firmly in bear market territory despite having seen a significant bounce in recent weeks.  One high-profile stock that has been part of the Nasdaq's most recent decline is Tesla (NASDAQ: TSLA), which fell to its lowest level in two years on Monday.  Shares of Tesla dropped almost 3% shortly after the opening bell on Monday morning.";66.0;WILMINGTON, Del., November 22, 2022--AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022.Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund delivered negative returns. The market continued its decline in the third quarter and the S&P 500 Index fell -4.9%. In addition, […];78.86000061035156;Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.;45.04999923706055;;33.849998474121094;GSK plc (NYSE: GSK) has initiated the withdrawal process of the U.S. marketing authorization for Blenrep (belantamab mafodotin-blmf) following the FDA request. This request was based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial, which did not meet the requirements of the FDA Accelerated Approval regulations. Blenrep is a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. Also seeThe pharmaceutical giant said the request comes after its Dreamm-3 Phase 3 study didn't meet its primary endpoint of progression-free survival.GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, in another setback for the British drugmaker's oncology business.  The company had said this month that Blenrep had failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the U.S. Food and Drug Administration (FDA).  On Tuesday GSK said it has begun the process to withdraw Blenrep's marketing authorisation in the country but would continue trial programmes for the drug, adding that some patients would have the option to enrol for continued access to the treatment.;14.229999542236328;The biopharmaceutical company specializes in cancer therapies.  Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia.  The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.;43.369998931884766;;11.069999694824219;;171.9199981689453;;7.980000019073486;;15.34000015258789;;120.08999633789062;COPENHAGEN, Denmark, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in the 5th Annual Evercore ISI HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore. Details: Event5th Annual Evercore ISI HealthCONx ConferenceLocationVirtualDateThursday, December 1, 2022Time1:00-1:20 p.m. Eastern Time / 10:00-10:20 a.m. Pacific Time A live webcast of the event will be availabl;8.1899995803833;;24.829999923706055;;48.77000045776367;;7.610000133514404;The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.;10.050000190734863;;29.100000381469727;;48.97999954223633;;231.85000610351562;Biotech stocks, on balance, had a year to forget in 2022.  An unsavory mix of profit-taking, clinical setbacks, a stricter Food and Drug Administration (FDA), geopolitcal unrest, rising interest rates, and good old fashioned risk aversion sent key indicators like the SPDR S&P Biotech ETF spiraling downward this year.  Hammering this point home, the SPDR S&P Biotech ETF plummeted by a staggering 53% -- from its prior three-year high -- through the first 11 months of 2022.;3.6600000858306885;;24.43000030517578;STAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference, taking place virtually on Tuesday, November 29, 2022 at 4:20 p.m. ET. To access the live webcast please visit the Events & Presentations pag;1.4700000286102295;;3.430000066757202;;;;3.430000066757202;;5.389999866485596;;57.95000076293945;;;;12.050000190734863;;7.150000095367432;SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that company management will present at the following investor conferences: 5th Annual Evercore ISI HealthCONx Conference (November 29 – December 1, Virtual) Format: Fireside Chat Date and Time: Tuesday, November 29, 8:50 – 9:10 AM EST We;3.740000009536743;;12.039999961853027;;2.359999895095825;;48.61000061035156;LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in fireside chat presentations at the Piper Sandler 34;12.520000457763672;;18.260000228881836;SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 – December 1, 2022. Details of the Crinetics fireside chat are as follows: Date & Time: November 30, 2022 at 1:00 PM (ET)Moderator: Josh Schimmer, Research Analyst, Evercore ISIWebcast Link: https://wsw.com/webcast/ever;2.9200000762939453;;12.510000228881836;Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street’s version of playing chicken. However, there’s a smart way to go about this speculative endeavor. Too many times, rookie traders focus simply on the short percentage of float. However, the best short-squeeze stocks to buy represent a multidimensional framework. Traders should also target the short interes;3.930000066757202;;6.630000114440918;;16.190000534057617;;35.650001525878906;Insiders who purchased Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) shares in the past 12 months are unlikely to be...;18.309999465942383;;21.68000030517578;;21.18000030517578;;;;1.9900000095367432;;17.15999984741211;
2022-11-23;177.00999450683594;The stock market has been fairly volatile over the past three years, which isn't surprising given the worldwide crises we have experienced.  Let's look at two that fit the bill: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).  Johnson & Johnson is one of the largest healthcare companies in the world, and typically generates higher sales than most other pharmaceutical peers.David Jiménez, a multidecade veteran of Johnson & Johnson who was most recently president of the Janssen immunology division, has joined Moderna to oversee U.S. commercial operations.;48.849998474121094;Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.;361.7200012207031;Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.;117.83000183105469;In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […];159.38999938964844;AbbVie, PepsiCo, The Walt Disney, Caterpillar and PBF Energy are part of The Zacks top Analyst Blog.The stock market has been fairly volatile over the past three years, which isn't surprising given the worldwide crises we have experienced.  Let's look at two that fit the bill: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).  Johnson & Johnson is one of the largest healthcare companies in the world, and typically generates higher sales than most other pharmaceutical peers.AbbVie (NYSE: ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Tom Hudson senior vice president, R&D and chief scientific officer, will present at 9:55 a.m. Central time.Share prices of the pharmaceutical Dividend King AbbVie (NYSE: ABBV) are actually 16% higher in 2022.  Hot off the 5% hike in its quarterly dividend per share to $1.48, this raises the following question: Is AbbVie still a buy for dividend growth investors after its sizable rally?  Let's dig into the company's fundamentals and valuation and see if we can answer the question.AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.1,2,3AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American Society of Hematology (ASH) annual meeting (December 10-13) in New Orleans, Louisiana.Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and AbbVie Inc (NYSE: ABBV) have finalized the settlement's terms worth over $6.6 billion to resolve several lawsuits by U.S. state and local governments over the marketing of opioid painkillers. Under the deals, first announced in July, Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone. AbbVie will pay up to $2.37 billion. Reuters reported that the final amounts of settlements would depend on how many state and loToday's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and The Walt Disney Company (DIS).Teva Pharmaceutical Industries Ltd and AbbVie Inc have finalized the terms of settlements worth more than $6.6 billion to resolve thousands of lawsuits by U.S. state and local governments over the marketing of opioid painkillers, the companies and lawyers for the governments said Tuesday.  Under the deals, first announced in July, Israel-based Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone.  AbbVie will pay up to $2.37 billion.;87.29000091552734;Novartis AG (NYSE: NVS) and Medicines for Malaria Venture (MMV) have decided to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment of patients with acute uncomplicated malaria. Ganaplacide is a novel agent with a new mechanism of action combined with a new formulation of lumefantrine optimized for once-daily dosing. This combination has the potential not only to clear malaria infection, including artemisinin-resistant strains, but als;106.81999969482422;Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.Encompass Health (EHC) intends to build a 50-bed inpatient rehabilitation hospital in the Daytona Beach area to further amplify its presence in Florida.Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.;66.12000274658203;"In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […]A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in ""the best of both worlds"" as the official rare disease unit of the U.K. pharma giant.";79.13999938964844;;45.040000915527344;;33.689998626708984;In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […]The following are the top stories on the business pages of British newspapers.  A potential blockbuster blood cancer treatment Blenrep being developed by GSK Plc is to be removed from the American market after a request from regulators.  Cristiano Ronaldo has left Manchester United Plc without receiving any compensation after the two parties agreed to rip up his contract.;14.359999656677246;The FDA has accepted and granted priority review to Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Biologics License Application (BLA) for TAK-003, the company's investigational dengue vaccine candidate. In the U.S., TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals four years through 60 years of age. Dengue is a mosquito-borne virus endemic in more than 125 countries. The TAK-003 application is supported by safety and efficacy data frOSAKA, Japan and CAMBRIDGE, Massachusetts, November 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of the Biologics License Application (BLA) for TAK-003, the company’s investigational dengue vaccine candidate. In the U.S., TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age.;42.93000030517578;;11.020000457763672;;172.5800018310547;;8.229999542236328;;15.40999984741211;;118.83999633789062;;8.569999694824219;;24.809999465942383;;48.650001525878906;;7.630000114440918;;10.449999809265137;;29.1299991607666;;49.4900016784668;WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences: 5th Annual Evercore ISI HealthCONx Conference: Fireside chat on Tuesday, November 29, 2022, at 8:25 a.m. ET.Bank of America 2022 Virtual Biotech SMID Cap Conference: Fireside chat on Wednesday, December 7, 2022, at 9:40 a.m. ET. Each conference event wil;229.02000427246094;;3.700000047683716;;24.479999542236328;;1.5;;3.490000009536743;;;;3.2799999713897705;;5.340000152587891;;57.5;Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.;;;11.829999923706055;;7.010000228881836;;3.6700000762939453;;11.789999961853027;;2.4200000762939453;"BRIDGEWATER, N.J., November 23, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ""Company"") today announced that the management team will attend the following investor conferences:BRIDGEWATER, N.J., November 22, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing Neupogen®. RELEUKO® is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois.";48.7400016784668;;11.890000343322754;;18.5;;3.1700000762939453;;11.949999809265137;;3.990000009536743;;6.599999904632568;;16.43000030517578;;36.709999084472656;;17.729999542236328;;21.139999389648438;;22.100000381469727;;;;1.9500000476837158;;15.859999656677246;
2022-11-25;177.24000549316406;;49.209999084472656;An experimental vaccine provided broad protection against all 20 known influenza A and B virus subtypes in initial tests in mice and ferrets, potentially opening a pathway to a universal flu shot that might help prevent future pandemics, according to a U.S. study published on Thursday.  The two-dose vaccine employs the same messenger RNA (mRNA)technology used in the COVID-19 shots developed by Pfizer with BioNTech, and by Moderna.  It delivers tiny lipid particles containing mRNA instructions for cells to create replicas of so-called hemagglutinin proteins that appear on influenza virus surfaces.;365.25;For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...;118.79000091552734;;159.6199951171875;AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.TORONTO, November 25, 2022--NEO is proud to welcome CIBC back to the NEO Exchange with a suite of five new CDRs™ to expand their existing lineup to 35 global companies.;87.70999908447266;;107.5;;66.16999816894531;AstraZeneca (Thailand) Co., Ltd., was recently honoured with two accolades in the categories of Industry Champions of the Year and Community Initiative at the Asia Corporate Excellence & Sustainability Awards 2022 (ACES Awards 2022).;79.23999786376953;One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Bristol Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;45.38999938964844;;33.9900016784668;;14.579999923706055;;42.97999954223633;;11.140000343322754;;171.5800018310547;;8.170000076293945;;15.850000381469727;;115.94000244140625;;8.880000114440918;;25.110000610351562;;48.11000061035156;;7.46999979019165;;10.710000038146973;;28.510000228881836;;50.959999084472656;;230.9499969482422;;3.5999999046325684;;23.829999923706055;;1.4700000286102295;;3.509999990463257;;;;3.240000009536743;;5.340000152587891;;58.09000015258789;;;;11.899999618530273;;7.010000228881836;;3.5899999141693115;;11.75;;2.390000104904175;;48.709999084472656;;11.859999656677246;;18.09000015258789;;3.0899999141693115;;12.170000076293945;;4.050000190734863;;6.610000133514404;;16.479999542236328;;36.029998779296875;;17.969999313354492;;21.40999984741211;;21.290000915527344;;;;1.9299999475479126;;16.059999465942383;
2022-11-28;177.3300018310547;;49.56999969482422;;365.7699890136719;;121.2300033569336;In this article, we discuss 11 best diabetes stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Diabetes Stocks To Buy Now. The global diabetes market is segmented based on the type, drug class, and devices used to treat the condition. Based on the type, the […];158.42999267578125;;87.68000030517578;;108.44999694824219;;66.20999908447266;The global licensing deal also includes exclusive rights for other undisclosed inflammatory and respiratory diseases.Drug Discovery company C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca plc (NASDAQ: AZN) worth up to $402 million for its NRF2 Activator program. C4X Discovery is listed on the London Stock exchange, and the deal is the third significant deal with a major pharmaceutical company. AstraZeneca will develop and commercialize an oral therapy for inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). ReC4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, United Kingdom, Nov. 28, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement withIn this article, we discuss 11 best diabetes stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Diabetes Stocks To Buy Now. The global diabetes market is segmented based on the type, drug class, and devices used to treat the condition. Based on the type, the […];79.13999938964844;According to a U.K. trial, Eliquis (apixaban), widely prescribed for COVID-19, did not help patients recovering from moderate and severe COVID. The drug used after discharge from the hospital does not lessen the chances for COVID-19 patients of readmission or improve survival. The results were shared with the Financial Times. Eliquis is indicated to reduce the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat. Related: National Institute;45.540000915527344;;33.7599983215332;;14.550000190734863;;42.869998931884766;;11.0600004196167;;171.63999938964844;;7.909999847412109;;14.40999984741211;The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.;119.5;;8.680000305175781;;24.65999984741211;;48.150001525878906;;7.019999980926514;;11.890000343322754;;27.799999237060547;;50.63999938964844;;223.6300048828125;;3.4700000286102295;;23.270000457763672;;1.399999976158142;;3.490000009536743;;;;3.0999999046325684;;5.03000020980835;;57.88999938964844;;;;11.609999656677246;;6.739999771118164;;3.4000000953674316;"BEIJING, November 28, 2022--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (""Biocytogen"", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodie";11.90999984741211;;2.4200000762939453;;47.81999969482422;;11.350000381469727;;17.030000686645508;SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). On October 24, 2022, Crinetics submitted an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA) to initiate the first U.S. clinical study of CRN04777, which i;3.009999990463257;;11.975000381469727;;3.9800000190734863;;6.619999885559082;;16.09000015258789;;38.20000076293945;;17.260000228881836;Newly published phase 2b trial data show those treated with roflumilast cream had significantly greater improvements in itch compared to those treated with vehicle by Week 2 as assessed by the Worst Itch Numeric Rating Scale (WI-NRS) and Psoriasis Symptom Diary (PSD)Among a subset of participants with a baseline WI-NRS ≥6, significantly more individuals treated with roflumilast cream 0.3% than with vehicle achieved a ≥4-point improvement as early as Week 2 Roflumilast-treated patients also exper;20.1200008392334;;19.75;;;;1.9600000381469727;BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced plans to initiate the PRAX-562 Phase 2 EMBOLD study for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEEs), following U.S. Food and Drug Admini;15.319999694824219;
2022-11-29;176.08999633789062;;49.4900016784668;;363.95001220703125;;121.3499984741211;;158.1999969482422;;87.36000061035156;;108.83999633789062;;66.08000183105469;"AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments.  Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead.  ""Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years,"" said Susan Galbraith, AstraZeneca's executive vice president of oncology research.By Scott Kanowsky";79.02999877929688;"Envisagenics, an Artificial Intelligence (""AI"")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY). The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone paymentsToday we will run through one way of estimating the intrinsic value of Bristol-Myers Squibb Company ( NYSE:BMY ) by...";45.869998931884766;;34.36000061035156;;14.5;;43.06999969482422;NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022 at 10:30 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma;11.180000305175781;"Viatris Inc.'s divestiture of its biosimilars business to Biocon was completed Tuesday with a $2 billion cash payment to the Canonsburg pharmaceutical company, the first of an expected $9 billion in divestitures.  The terms of the agreement with Biocon Biologics Ltd. also include $1 billion in convertible preferred equity in Biocon Biologics that the companies said amounted to a 12.9% stake in the company plus $335 million in cash in 2024.  Viatris (Nasdaq: VTRS) will also provide commercialization and regulatory-related services to Biocon for two years.Viatris Inc. (NASDAQ: VTRS) today announced that it has closed its transaction with Biocon Biologics Limited (""Biocon Biologics""), creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader. Viatris and Biocon Biologics have entered a Transition Services Agreement (TSA) pursuant to which Viatris will provide commercialization and certain other transition services for an expected two-year period intended to ensure business continuity for patients, customers";167.49000549316406;;7.78000020980835;;15.399999618530273;Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.;118.41999816894531;;8.399999618530273;;24.940000534057617;;48.5099983215332;;6.980000019073486;;12.970000267028809;;27.5;;50.119998931884766;;223.27000427246094;;3.5299999713897705;;23.510000228881836;;1.409999966621399;OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.;3.509999990463257;;;;2.9100000858306885;;5.230000019073486;;57.439998626708984;;;;11.770000457763672;;7.099999904632568;;3.380000114440918;;12.699999809265137;;2.609999895095825;;47.56999969482422;;11.710000038146973;;17.399999618530273;;3.1600000858306885;- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee - - He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries - - His deal sheet includes transactions totaling more than USD 2.7 billion in CNS and beyond - NEW YORK and BERLIN, Nov. 29, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (NASDAQ: ATAI) (“atai” or the “Company”;11.229999542236328;;3.890000104904175;;6.489999771118164;;17.270000457763672;;39.209999084472656;;17.059999465942383;;20.350000381469727;;20.59000015258789;;;;2.140000104904175;BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee. “It’s an incredi;15.270000457763672;
2022-11-30;178.0;;50.130001068115234;;371.0799865722656;;124.5999984741211;Novo Nordisk ADR had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against the rest of the market.;161.17999267578125;;89.55999755859375;In this article, we discuss the 11 safe healthcare stocks for a retirement stock portfolio. If you want to read about some more healthcare stocks, go directly to Retirement Stock Portfolio: 5 Safe Healthcare Stocks to Consider. The healthcare sector is being forced to deal with new challenges related to valuation and access to capital […];110.12000274658203;;67.97000122070312;The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.WILMINGTON, Del., November 30, 2022--AstraZeneca will present 47 abstracts showcasing new data from across its hematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10 to 13, 2022.;80.27999877929688;Two examples of massive companies that are worth more than $100 billion and that have still managed to double their sales over the past five years are Bristol Myers Squibb (NYSE: BMY) and Amazon (NASDAQ: AMZN).  Pharmaceutical giant Bristol Myers Squibb has a market cap of more than $160 billion and a portfolio of blockbuster drugs that generate more than $1 billion in annual revenue.  Bristol Myers also has a strong pipeline of potential treatments for more than 35 diseases.In this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now. Biotechnology is a sector that has long been contributing to the improvement of […];45.349998474121094;;34.59000015258789;;14.729999542236328;(Bloomberg) -- Japan stayed out of the foreign exchange market in November, after the yen made gains amid growing expectations that the Federal Reserve will moderate its pace of interest rate hikes.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceNYC Becomes One Billionaire Family’s Haven From China Property CrashThese Are the Best and Worst Cities for Expats to Live and Work InBanks Stuck With $42 Billion Debt Seize Chance to Offload ItThe finance ministry dArrowhead provided a bullish update for its midstage liver disease treatment on Monday, pushing ARWR stock to rocket Tuesday.;43.970001220703125;;11.029999732971191;;178.83999633789062;;8.149999618530273;;15.819999694824219;;123.05999755859375;;8.739999771118164;;26.020000457763672;;51.5099983215332;;7.25;;12.130000114440918;;28.959999084472656;;49.93000030517578;;235.30999755859375;;3.700000047683716;;24.18000030517578;;1.5;;3.759999990463257;;;;2.799999952316284;;5.510000228881836;;59.77000045776367;;;;12.300000190734863;Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a few such toxic stocks.;7.550000190734863;ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed CTCSAs with Pfizer and Eli Lilly to evaluate encorafenib and cetuximab in combination with ERAS-007 SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patient;3.6600000858306885;;13.300000190734863;;2.559999942779541;;49.84000015258789;;12.390000343322754;;17.8700008392334;;3.5299999713897705;;10.9399995803833;;4.0;BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer. In this newly created position, Karen will lead the Company’s human resources function and help define Centessa’s people and culture strategy. Karen joins Centessa with over 25 years of experience in human reso;6.46999979019165;;18.440000534057617;;39.58000183105469;;17.229999542236328;;21.229999542236328;;22.010000228881836;;;;2.2100000381469727;;16.030000686645508;
2022-12-01;178.74000549316406;;51.08000183105469;;370.3299865722656;;126.12999725341797;Novo Nordisk ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.;161.6300048828125;;89.81999969482422;;109.80000305175781;;68.33999633789062;The healthcare industry can make for a safe place to invest regardless of the macroeconomic conditions.  A couple of healthcare stocks that are diversified and that could be good buys heading into the new year are AstraZeneca (NASDAQ: AZN) and PetMed Express (NASDAQ: PETS).  AstraZeneca's business performed well in 2022, but its stock isn't doing as well as perhaps it should be.Shares of Compugen (NASDAQ: CGEN), a clinical-stage biotech company that specializes in immunology therapies to treat cancer, saw its shares rise 16.5% on Wednesday.  The stock closed on Tuesday at $1.03, then opened on Wednesday at $1.01, before jumping to $1.23 in the late afternoon and closing at $1.20.  The stock has been volatile, with a 52-week low of $0.51 and a 52-week high of $4.88.;80.87999725341797;bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.Although hard, it's not impossible, there are healthcare companies with solid earnings and dividend growth that can be had for less than a bill with Ben Franklin's picture on it.  Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) have posted triple-digit percentage gains over the past 10 years in revenue, earnings per share (EPS), and total return price.  On top of that, shares of Gilead and Bristol can both be bought for less than $90 a share, at least for the time being.;45.869998931884766;;35.029998779296875;;14.869999885559082;;44.040000915527344;;11.239999771118164;;188.1699981689453;;8.3100004196167;;16.530000686645508;;121.75;;9.1899995803833;;26.420000076293945;;49.77000045776367;;7.670000076293945;;12.949999809265137;;28.3700008392334;;49.790000915527344;;229.97999572753906;;3.690000057220459;;23.670000076293945;;1.4600000381469727;;3.509999990463257;;;;2.880000114440918;;5.610000133514404;;60.0;;;;11.8100004196167;Emergent Biosolutions, Western Digital, Thoughtworks Holding and DASAN Zhone Solutions are part of the Zacks Screen of the Week article.;7.340000152587891;;3.4800000190734863;;13.460000038146973;;2.569999933242798;;50.09000015258789;;12.180000305175781;;17.56999969482422;;3.3399999141693115;;10.65999984741211;;4.010000228881836;;6.5;;18.389999389648438;Whilst it may not be a huge deal, we thought it was good to see that the Arcturus Therapeutics Holdings Inc...;38.689998626708984;;17.079999923706055;;21.219999313354492;;21.0;MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” sectio;;;2.180000066757202;;16.209999084472656;The consensus price target hints at a 95.5% upside potential for Repare Therapeutics Inc. (RPTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2022-12-02;178.8800048828125;;50.90999984741211;;374.760009765625;;126.9000015258789;Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.;163.66000366210938;;89.98999786376953;;110.04000091552734;Merck & Co., Inc.We have narrowed our search to four Dow stocks. These are: CAT, WMT, MRK, UNH.Most readers would already be aware that Merck's (NYSE:MRK) stock increased significantly by 27% over the past three...;68.47000122070312;Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.;81.12999725341797;Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;45.0099983215332;;35.349998474121094;Aristotle Capital Management, LLC, an investment management company, released its “International Equity Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund returned ‐7.90% gross of fees, compared to a ‐9.36% return for the MSCI EAFE Index and ‐9.91% return for the MSCI ACWI ex USA […];14.819999694824219;;43.849998474121094;;11.170000076293945;;186.0500030517578;Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;8.40999984741211;;16.739999771118164;;125.38999938964844;;9.140000343322754;;26.719999313354492;;50.91999816894531;;7.699999809265137;;13.5;;29.639999389648438;;50.630001068115234;;236.82000732421875;;3.819999933242798;;25.09000015258789;;1.4700000286102295;;3.7799999713897705;Submission is EQRx’s first to European Medicines AgencyApplication is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory c;;;3.049999952316284;;6.230000019073486;;60.47999954223633;;;;12.0;;7.610000133514404;;3.619999885559082;;13.380000114440918;;2.430000066757202;;51.189998626708984;;12.609999656677246;;18.420000076293945;;3.549999952316284;"Key Takeaways; Cannabis Sector Cannabis technology company BYND Cannasoft, is aiming for the $10.97 billion global condom market. Hempacco and Sonora Paper announced a new joint venture to manufacture and market Hemp paper smoking products. Key Takeaways; Psychedelic Sector atai recorded gains as the company strengthened leadership team. Clearmind is preparing for clinical trial to […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.";12.300000190734863;;3.859999895095825;;6.460000038146973;;19.100000381469727;;38.97999954223633;;17.510000228881836;MyHealthTeam, creator of the largest and fastest-growing social networks for people living with chronic health conditions, today launched MySebDermTeam, an online community for those living with seborrheic dermatitis to find the people, support, and medically-reviewed information they need to better manage their condition. Created by MyHealthTeam, with sponsorship by Arcutis Biotherapeutics, an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, MyS;21.739999771118164;;20.920000076293945;;;;2.190000057220459;;17.31999969482422;Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
2022-12-05;178.77999877929688;;50.72999954223633;;369.2900085449219;;127.08000183105469;Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.;163.94000244140625;;90.95999908447266;Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been treated with androgen-receptor pathway inhibitor (ARPI) therapy1 Pluvicto becomes the first PSMA-targeted radioligand therapy to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy1, addressing a significant unmet need2Findings to be presented at an upcoming medicalAd hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been treated with androgen-receptor pathway inhibitor (ARPI) therapy1 Pluvicto becomes the first PSMA-targeted radioligand therapy to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy1, addressing a significant unmet need2Findings to be presented at an upcoming medical;110.01000213623047;Caterpillar, Merck, UnitedHealth Group and Walmart are included in this Analyst Blog.;68.41999816894531;;80.69999694824219;;44.93000030517578;;35.15999984741211;GSK and Roche have pulled drugs approved on an accelerated basis, while other drugmakers win speedy approvals only after starting confirmatory studies.;14.5600004196167;;43.0099983215332;;10.920000076293945;GSK and Roche have pulled drugs approved on an accelerated basis, while other drugmakers win speedy approvals only after starting confirmatory studies.;178.61000061035156;;8.470000267028809;;16.31999969482422;;119.41999816894531;- The program will allow physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United States - TransCon PTH is under Priority Review by the FDA, with a target PDUFA date of April 30, 2023 COPENHAGEN, Denmark, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has allowed the Company to initiate an expanded access program (EAP;8.760000228881836;;26.350000381469727;;50.9900016784668;;7.599999904632568;;13.710000038146973;;28.309999465942383;;49.380001068115234;;226.9499969482422;;3.7100000381469727;;24.25;;1.4199999570846558;;3.4600000381469727;;;;2.9700000286102295;Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST. Nektar management will be joined by Dr. Cameron Turtle, Professor and Chair of Cancer Immunotherapy at the University of Sydney, Australia and Fred Hutchinson Cancer Center affiliate, to discuss the NKTR-255 program and the potential role of IL-15 within the cell therapy landscape.;5.889999866485596;;60.90999984741211;;;;11.789999961853027;;7.28000020980835;;3.509999990463257;GSK and Roche have pulled drugs approved on an accelerated basis, while other drugmakers win speedy approvals only after starting confirmatory studies.;13.0;;2.369999885559082;;50.0;;12.380000114440918;;18.31999969482422;;3.4800000190734863;;11.399999618530273;;3.930000066757202;;6.039999961853027;;17.670000076293945;;39.619998931884766;;17.350000381469727;ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver drug deep into the skin to the base of the hair follicle where key alopecia areata inflammation occurs WESTLAKE VILLAGE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovat;21.450000762939453;A major sell-side firm rated Day One Biopharmaceuticals  a new fundamental buy with a $45 price target Monday.  In the daily bar chart of DAWN, below, we have a mixed picture.  The price gap and huge volume surge in June distorts the volume histogram and makes it look like there is hardly any trading volume at all.;20.049999237060547;;;;2.140000104904175;;16.489999771118164;
2022-12-06;176.10000610351562;In this article, we discuss the 10 best undervalued UK stocks to buy now. If you want to read about some more undervalued UK stocks, go directly to 5 Best Undervalued UK Stocks to Buy Now. The United Kingdom economy has been in turmoil as a result of the separation from the European Union, political […]In this article, we will take a look at the 11 best quality stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best Quality Stocks to Buy Now. During these uncertain times, when the Federal Reserve is on a mission to fight inflation by increasing benchmark […]Johnson & Johnson dropped out of the bidding process for Horizon Therapeutics, pushing HZNP stock into the red on Monday.The concept of targeting iron-clad stocks to buy for volatility might seem overkill. After all, the Labor Department just revealed that the U.S. economy added 263,000 jobs, above analysts’ expectations. However, it also means that the Federal Reserve’s efforts to tackle the money supply’s expansion took a massive hit. Let’s just get down to the brass tacks. With more people gainfully employed, this equates to more dollars chasing after fewer goods. Add in the impact of global supply chain disrup;49.709999084472656;;368.5400085449219;These stocks make sense, given the relatively flat forecast for stocks over the next six months by Goldman strategists.The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.Covid-19 cases are surging, few people are getting updated boosters, and there's even talk of mask mandates in California.;125.79000091552734;;163.72000122070312;AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.;90.73999786376953;;108.93000030517578;Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.  The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, and plans to launch a Phase 3 trial enrolling only those patients by the end of this year, Mirati Chief Executive Officer David Meek told Reuters.  The trial will compare the adagrasib combination with the current standard of care, which is chemotherapy plus Keytruda, also known as pembrolizumab.;68.55999755859375;In this article, we will take a look at 10 best foreign stocks to buy now. If you want to see more best foreign stocks to buy, go directly to 5 Best Foreign Stocks to Buy Now. Although it has the largest economy in the world, the United States doesn’t have a monopoly on good companies. […];79.91999816894531;Bristol Myers Squibb Company:;48.54999923706055;Johnson & Johnson dropped out of the bidding process for Horizon Therapeutics, pushing HZNP stock into the red on Monday.Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence.  The pharmaceutical company closed out October at $6.94 and opened November at $7.  The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.;37.91999816894531;Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined -10.05%, underperforming the MSCI ACWI Index and the MSCI ACWI Value Index, which returned -6.82% and -7.66%, respectively. Multiple headwinds from all over the world affected […];14.5600004196167;;41.93000030517578;;10.930000305175781;NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety Profile in Pediatric and Adult SubjectsFARMINGTON HILLS, Mich., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Admin;169.1300048828125;;8.050000190734863;;15.970000267028809;;120.66000366210938;;8.319999694824219;;26.149999618530273;;53.959999084472656;;7.460000038146973;;13.279999732971191;;27.209999084472656;;46.880001068115234;;200.7899932861328;BOSTON, December 06, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Bill Meury as president and chief executive officer (CEO) and a member of the Company’s board, effective January 3, 2023. Mr. Meury will succeed Steve Paul, M.D., the current president, chief executive officer and chairman, who will tr;3.700000047683716;;24.049999237060547;;1.3799999952316284;;3.200000047683716;;;;2.9100000858306885;;5.679999828338623;;59.650001525878906;;;;12.1899995803833;Shares of Emergent BioSolutions Inc. were up 1.7% in premarket trading on Tuesday after the company said the Food and Drug Administration is reviewing its application for over-the-counter Narcan. The spray is used to treat known or suspected opioid overdoses. The regulator is set to make its decision whether to approve the application by March 29. The FDA indicated in November that it would consider approving OTC use of Narcan for the first time. Emergent's stock has tumbled 73.9% this year, whiThe FDA’s priority review gives opioid-overdose reversal drug an expected approval date of March 2023, company says.Emergent’s supplemental new drug application is the first prescription-to-over-the-counter switch application in history to be granted Priority Review by the FDA.NARCAN® (naloxone HCI) Nasal Spray 4 mg, the first intranasal form of naloxone approved by the FDA in 2015, is designed for community use for the treatment of known or suspected opioid overdose. GAITHERSBURG, Md., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE:EBS) announced that the U.S. Food and Drug Adminis;7.139999866485596;;3.4100000858306885;;13.0;BILLERICA, Mass., December 05, 2022--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from November 29 to December 2, 2022.;2.4100000858306885;;49.43000030517578;;12.460000038146973;;18.139999389648438;;3.1600000858306885;;10.949999809265137;;3.759999990463257;;6.199999809265137;;17.329999923706055;;37.65999984741211;;17.239999771118164;WESTLAKE VILLAGE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 8,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to two newly hired employees. These awards were approved by the Compensation Committee of;21.059999465942383;;19.59000015258789;;;;2.069999933242798;;16.270000457763672;
2022-12-07;177.1699981689453;Johnson & Johnson (JNJ) closed the most recent trading day at $176.10, moving -1.5% from the previous trading session.In this article, we discuss 12 very high-yield dividend stocks to buy now. You can skip our detailed analysis of high-dividend stocks and their performance, and go directly to read 5 Very High-Yield Dividend Stocks To Buy Now. The soaring inflation and consistent interest rates hike have analysts worried about a full-blown recession in the […];50.2400016784668;;371.9700012207031;"Eli Lilly And Co (NYSE: LLY) announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for HR-positive, HER2-negative high-risk early breast cancer. The new data showed Verzenio’s benefits held up across patient subgroups after longer follow-up. Also read: Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage. In 2020, The monarchE trial hit statistical significance after a median oThe DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with Jardiance® (empagliflozin) compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes. When Jardiance was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012). The results were presEli Lilly and Company (NYSE: LLY) today announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio® (abemaciclib) in combination with standard endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC). These data, which include results for investigational uses in the intent-to-treat (ITT) and Cohort 1 populations, were presented today as an";125.23999786376953;;165.39999389648438;The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.48 on the 15th of...;91.7300033569336;"MorphoSys AG's (NASDAQ: MOR) subsidiary Constellation Pharmaceuticals Inc has entered into a global licensing agreement with Novartis AG (NYSE: NVS) to research, develop and commercialize its pre-clinical inhibitors of a novel cancer target. This program was added to MorphoSys' research portfolio following its acquisition of Constellation Pharmaceuticals in 2021 for $1.7 billion. ""At MorphoSys, we will continue to focus our resources on driving our late- and mid-stage oncology pipeline forward,Novartis AG (NYSE: NVS) announced results from the RIGHT Choice Phase 2 trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2−) metastatic breast cancer. Kisqali demonstrated a nearly one-year progression-free survival (PFS) benefit, supporting the superiority of Kisqali pluRIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) versus combination chemotherapy (CT)1Kisqali plus ET demonstrated a statistically significant progression-free survival (PFS) benefit of one year compared to combination CT; data to be presented at SABCS 20221Kisqali is a unique CDK4/6i that has consistently shown statistically";110.08999633789062;Amid the rising possibility of a recession, defensive stocks with solid prospects will cushion investors from market jitters while their robust fundamentals ensure higher returns. ADM, HSY, UNH and MRK are some such stocks.If you want to know who really controls Merck & Co., Inc. ( NYSE:MRK ), then you'll have to look at the makeup of its...;68.8499984741211;WILMINGTON, Del., December 07, 2022--Updated results from the DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. These results and primary results from the DESTINY-Breast02 Phase III trial wi;79.93000030517578;In this piece, we will take a look at the fifteen most creative companies in the world. For more companies, head on over to 5 Most Creative Companies In The World. While creativity is generally thought to lie in the domain of the arts, it plays a central role in the business world as well. […]This top health stock stands out with its proven year-over-year earnings growth record, increased earnings estimates and hefty 2.7% dividend.While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...;47.939998626708984;"U.S. District Judge Robin Rosenberg in Florida has dismissed about 50,000 claims associated with GSK Plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), Sanofi SA (NASDAQ: SNY), and Boehringer Ingelheim, claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by solid science. The move does not directly affect tens of thousands of similar cases pending in state courts around the country. The litigation initially included claims of over ten types of cancer allegedlAfter a Florida judge threw out thousands of lawsuits involving heartburn drug Zantac on Tuesday, causing a number of pharmaceutical stocks to soar, analysts are bullish about forthcoming state cases.Tens of thousands of lawsuits alleged that the heartburn treatment could cause cancer. Complaints are still active in state courts.Shares of GSK and Sanofi surged on Wednesday, adding more than $20 billion in combined value in early trade following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.  The ruling on Tuesday by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocked out about 50,000 claims in federal court on the basis that they were not backed by sound science.  The drugmakers, citing scientific consensus, have repeatedly asserted that Zantac does not cause cancer.By Scott KanowskyEven a dour outlook for the broader stock market couldn't outweigh good news for these companies.Thousands of lawsuits over the heartburn drug Zantac were thrown out Tuesday, essentially removing an overhang from a number of drug stocks.Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday were spared  thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.  The ruling by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court, though it does not directly affect tens of thousands of similar cases pending in state courts around the country.Drugmakers GSK Plc, Pfizer Inc, Sanofi SA and Boehringer Ingelheim on Tuesday were spared  thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.  The ruling by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court, though it does not directly affect tens of thousands of similar cases pending in state courts around the country.  ""We are extremely surprised by this miscarriage of justice,"" and ""fully expect"" the ruling will be reversed on appeal, lawyers for the plaintiffs said in a joint statement.";36.880001068115234;"U.S. District Judge Robin Rosenberg in Florida has dismissed about 50,000 claims associated with GSK Plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), Sanofi SA (NASDAQ: SNY), and Boehringer Ingelheim, claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by solid science. The move does not directly affect tens of thousands of similar cases pending in state courts around the country. The litigation initially included claims of over ten types of cancer allegedlTens of thousands of lawsuits alleged that the heartburn treatment could cause cancer. Complaints are still active in state courts.Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday were spared  thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.  The ruling by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court, though it does not directly affect tens of thousands of similar cases pending in state courts around the country.Drugmakers GSK Plc, Pfizer Inc, Sanofi SA and Boehringer Ingelheim on Tuesday were spared  thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.  The ruling by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court, though it does not directly affect tens of thousands of similar cases pending in state courts around the country.  ""We are extremely surprised by this miscarriage of justice,"" and ""fully expect"" the ruling will be reversed on appeal, lawyers for the plaintiffs said in a joint statement.";14.6899995803833;;42.130001068115234;;10.899999618530273;Investors looking to boost their income often turn to high-yielding dividend stocks.  If they invest in quality stocks, they can generate recurring revenue.  If they invest in quality stocks that are currently trading at depressed valuations related to the bear market, they can also benefit from the stock price appreciation that is likely to occur going forward.;170.3300018310547;;7.949999809265137;;16.40999984741211;;119.9800033569336;;8.3100004196167;;26.079999923706055;;54.900001525878906;;7.579999923706055;;12.399999618530273;;27.139999389648438;;47.52000045776367;;200.00999450683594;;3.6700000762939453;;24.059999465942383;;1.3600000143051147;;3.180000066757202;;;;2.9100000858306885;;6.210000038146973;;60.02000045776367;;;;12.380000114440918;Emergent BioSolutions Inc. (NYSE: EBS) has cleared an important hurdle in a bid to make its opioid overdose antidote available to the public without a doctor’s order.  The Gaithersburg company said Tuesday that the Food and Drug Administration has accepted its supplemental new drug application for Narcan Nasal Spray, currently available with a prescription, as an emergency over-the-counter treatment for opioid overdose.  The FDA expects to issue its decision of approval or denial March 29, 2023.Emergent is seeking the U.S. Food and Drug Administration's approval for a prescription-free sale of its nasal spray, Narcan, which is already cleared for the treatment of opioid overdose in the country.  The agency will make its decision by March 29 and its priority review status puts Narcan on track to become the first naloxone-based drug to be sold over the counter, Benchmark analyst Robert Wasserman said.;7.0;;2.869999885559082;;13.029999732971191;;2.319999933242798;;49.060001373291016;;12.350000381469727;;17.739999771118164;;3.180000066757202;;11.199999809265137;;3.5799999237060547;;6.260000228881836;;17.829999923706055;;37.7599983215332;;16.959999084472656;;22.0;;19.780000686645508;;;;2.059999942779541;;16.530000686645508;
2022-12-08;177.1999969482422;"Eli Lilly (NYSE: LLY), CRISPR Therapeutics (NASDAQ: CRSP), and Johnson & Johnson (NYSE: JNJ) have all been doing so.  Eli Lilly and CRISPR are developing radical new therapies, while Johnson & Johnson is going all-in on using artificial intelligence to bring new therapies to market more quickly.  It's hard to see Eli Lilly as a revolutionary stock.Johnson & Johnson (NYSE: JNJ) is in the midst of a transition.  One way the business can accelerate its plans for growth is via acquisitions, and Johnson & Johnson has been busy on that front of late.  Horizon Therapeutics Public (NASDAQ: HZNP), a healthcare business that makes medicines to treat autoimmune and inflammatory diseases, issued a press release on Nov. 29 stating that it is in ""preliminary discussions"" regarding a potential acquisition of its business.NEW BRUNSWICK, N.J., December 07, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time).";51.779998779296875;;371.7900085449219;Eli Lilly (NYSE: LLY), CRISPR Therapeutics (NASDAQ: CRSP), and Johnson & Johnson (NYSE: JNJ) have all been doing so.  Eli Lilly and CRISPR are developing radical new therapies, while Johnson & Johnson is going all-in on using artificial intelligence to bring new therapies to market more quickly.  It's hard to see Eli Lilly as a revolutionary stock.Eli Lilly And Co's (NYSE: LLY) DINAMO Phase 3 trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with Jardiance (empagliflozin) compared with placebo for children and adolescents with type 2 diabetes. When Jardiance was added to other baseline treatments (diet, exercise, metformin and/or insulin), HbA1c was reduced by 0.84% compared with the placebo at week 26. Related: Eli Lilly Is Best-In-Class Growth, Says Analyst W;127.79000091552734;;165.99000549316406;A couple of potential stocks that you can confidently hold forever are AbbVie (NYSE: ABBV) and Coca-Cola (NYSE: KO).  What makes AbbVie a solid buy-and-hold investment is that the company is diverse, has excellent margins, and generates plenty of free cash flow.  AbbVie has dozens of trials ongoing, many of which are in phase 3 and near the finish line.In this article, we discuss 10 best halal dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read 5 Best Halal Dividend Stocks To Buy. Halal companies are those that employ halal (permissible according to religion) practices in their operations and comply with Shariah […];91.58000183105469;"Novartis AG's (NYSE: NVS) Phase 3 APPOINT-PNH study of iptacopan in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH) met its primary endpoint. Topline results showed that a significant proportion of patients treated with iptacopan (200 mg twice daily) achieved clinically meaningful hemoglobin-level increases of 2 g/dL or more from baseline without blood transfusions at 24 weeks. In the study, the safety profile of iptacopan monotherapy was consistent with previousPhase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH)1Topline APPOINT-PNH data were consistent with APPLY-PNH readout and showed a significant proportion of complement-inhibitor-naïve patients treated with iptacopan achieved clinically meaningful increases in hemoglobin levels vs. baseline without the need for blood transfusions1PNH has a significantThe FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.";110.8499984741211;This year has been one in which many investors have been flocking to safe stocks, including ones that pay dividends.  As a result, many normally safe stocks that generate only modest gains have been producing oversized returns for investors.  Three stocks that have dwarfed the S&P 500 this year and that are up over 20% and also pay a high rate of dividends include Merck (NYSE: MRK), General Mills (NYSE: GIS), and Chevron (NYSE: CVX).;69.16999816894531;WILMINGTON, Del., December 08, 2022--Detailed results from the SERENA-2 Phase II trial showed AstraZeneca’s next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at both 75mg and 150mg dose levels versus FASLODEX® (fulvestrant) 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer, previously treaWILMINGTON, Del., December 08, 2022--Detailed results from the CAPItello-291 Phase III trial showed AstraZeneca’s capivasertib in combination with FASLODEX® (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus FASLODEX in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative, locally advanced or metastatic breast cancer, following recurrence or prAstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) (OTC: DSKYF) shared updated data from the DESTINY-Breast03 Phase 3 trial evaluating Enhertu versus trastuzumab emtansine (T-DM1) in previously treated patients with HER2-positive unresectable and/or metastatic breast cancer. Enhertu demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to T-DM1. In the key secondary endpoint analysis of overall survival for DESTINY-Breast03, E;79.87999725341797;;46.91999816894531;A dengue vaccine developed by Japanese drugmaker Takeda Pharmaceutical Co was authorised for use in the European Union on Thursday, making it the second approved inoculation against the mosquito-borne disease that causes millions of infections annually.  The vaccine, branded QDENGA, is authorized for use in those aged 4 and older to prevent any of the four so-called serotypes of dengue.  Between 20,000 and 25,000 people, mostly children, die each year from the virus, according to the World Health Organization.The vaccine from Japanese drugmaker Takeda will provide an alternative to a Sanofi vaccine that has been dogged by safety issues.Revolution Medicines Inc (NASDAQ: RVMD) announced that Sanofi SA (NASDAQ: SNY) has terminated global SHP2 development and commercialization collaboration. Following termination, Revolution Medicines will regain all global rights granted to Sanofi under the agreement, including decision-making regarding R&D and rights to all commercial proceeds from RMC-4630, an SHP2 inhibitor drug candidate in development for certain RAS-addicted cancers. The companies plan to collaborate to transition Sanofi's;36.599998474121094;Bluebell Capital Partners' attempt to oust BlackRock Inc CEO Larry Fink represents the small activist hedge fund's boldest bet that its punch-above-weight strategy could deliver a financial win, even if its push for changes faces long odds.  In the three years since its launch, Bluebell has challenged the policies and executives of some of the world's biggest companies, including GSK Plc, Glencore Plc, Vivendi SE and Danone SA, while owning very small stakes.  The major prize Bluebell has so far scored was at Danone, where it helped oust a chief executive.There are currently higher-than-normal levels of RSV and the flu in the U.S. At the same time, the number of new COVID-19 infections is rising.GSK plc (NYSE: GSK) announced results from the PERLA phase 2 trial investigating Jemperli (dostarlimab) + chemotherapy versus Merck & Co Inc's (NYSE: MRK) Keytruda pembrolizumab + chemo as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). Dostarlimab plus chemotherapy achieved promising results for the primary endpoint of confirmed objective response rate (ORR) and the key secondary endpoint of median progression-free survival (mPFS). The ORR was 46% (n=56/12;14.84000015258789;A dengue vaccine developed by Japanese drugmaker Takeda Pharmaceutical Co was authorised for use in the European Union on Thursday, making it the second approved inoculation against the mosquito-borne disease that causes millions of infections annually.  The vaccine, branded QDENGA, is authorized for use in those aged 4 and older to prevent any of the four so-called serotypes of dengue.  Between 20,000 and 25,000 people, mostly children, die each year from the virus, according to the World Health Organization.OSAKA, Japan & CAMBRIDGE, Mass., December 08, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) for the prevention of dengue disease in individuals from four years of age in the European Union (EU).i QDENGA should be used in accordance with official recommendations. The approval follows the positive recommendation from the European MeThe vaccine from Japanese drugmaker Takeda will provide an alternative to a Sanofi vaccine that has been dogged by safety issues.;42.33000183105469;Does the December share price for Royalty Pharma plc ( NASDAQ:RPRX ) reflect what it's really worth? Today, we will...;10.960000038146973;Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;173.8699951171875;RBC Capital Markets has initiated coverage on Repligen Corporation (NASDAQ: RGEN) with a Sector Perform rating and a price target of $190. The analyst likes the company due to product differentiation in some of the fastest-growing areas of biopharma. But RBC is hesitant towards the stock due to the 12.7x sales multiple, lack of operational earnings beats, declining gross margins, and low absolute R&D investment relative to larger companies in the space. Related: Repligen Beefs Up Process Analyti;7.769999980926514;;15.029999732971191;;119.44999694824219;;8.380000114440918;;26.860000610351562;;55.459999084472656;;8.100000381469727;;14.0;;27.3799991607666;;50.36000061035156;WALTHAM, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to two new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the compApellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;202.10000610351562;;4.070000171661377;;24.280000686645508;;1.350000023841858;;3.0999999046325684;;;;2.9000000953674316;;6.210000038146973;;59.84000015258789;;;;12.460000038146973;The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.;7.309999942779541;;3.069999933242798;;13.109999656677246;;2.3399999141693115;;50.400001525878906;;12.649999618530273;Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET)SAN FRANCISCO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trial of its leading BTK degrader program, NX-2127, at 8:30 pm CT (9:30 p.;17.59000015258789;;3.2899999618530273;;11.170000076293945;;3.6500000953674316;;6.400000095367432;;18.040000915527344;;37.189998626708984;;16.959999084472656;;21.959999084472656;;20.280000686645508;;;;2.059999942779541;;16.5;
2022-12-09;175.74000549316406;Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.While healthcare stocks may not elicit the same excitement from investors that other higher-growth sectors do, this space features a significant collection of companies with attractive track records of driving returns in many different types of markets.  In general, healthcare-centric businesses tend to be more resilient in recessions and bear markets because consumers still need the products these businesses sell, regardless of the economic environment of the moment.  On that note, here are two top healthcare stocks that could make investors richer in 2022 -- and well beyond.We discuss the market outlook and investing strategies for 2023.;51.720001220703125;;360.989990234375;The best mutual funds scooped up shares of MRK, LLY, ABBV and AMGN, while also adding retailers like WING to their holiday listsLLY, PFE, JPM, ULTA, QQQ have been highlighted in this Market Edge article.Tracey Ryniec and John Blank are back with their annual look at the economy and how to invest in the new year.Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.;128.91000366210938;Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.;163.05999755859375;A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.If you're looking to add more dividend stocks to your portfolio this month, it's important to focus on companies that not only regularly increase their payout to investors but have a long track record of maintaining their dividends even in difficult environments.  Here are two such top dividend stocks to consider adding to your portfolio ASAP.  AbbVie (NYSE: ABBV) originated as a spin-off of Abbott Laboratories nearly a decade ago, and in doing so, inherited its predecessor's dividend history.AbbVie (ABBV) closed at $165.99 in the latest trading session, marking a +0.36% move from the prior day.The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe.;90.94999694824219;Erasca Inc (NASDAQ: ERAS) has entered into an exclusive worldwide license agreement with Novartis AG (NYSE: NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor for NRAS mutant (NRASm) melanoma and other RAS/MAPK pathway-driven tumors. To date, naporafenib has been dosed in over 500 patients across multiple trials and has demonstrated preliminary clinical proof-of-concept and favorable safety and tolerability, Erasca says. Erasca will pay Novartis a one-time upfront cash payment of $2A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca’s addressable population Erasca to host conference call and webcast today at 8:30 am ET SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerciNovartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.;108.77999877929688;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Merck & Co...;69.55000305175781;The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.  Enhertu, which won U.S. approval in late 2019, is used in patients with advanced breast, gastric and lung cancers whose tumor cells carry a protein called HER2.  Early this year, researchers found that Enhertu could also benefit certain breast cancer patients whose HER2 levels were previously thought to be too low for the drug to have a meaningful effect.AstraZeneca Plc (NASDAQ: AZN) reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd). The data showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR)-positive, HER2-low, or HER2-negative (IHC 0) unresectable or metastatic breast cancer. Safety results were consistent with previous trials of datopotamab deruxtecan. Also see: AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials. In this cohort ofAstraZeneca Plc (NASDAQ: AZN) announced detailed results from the SERENA-2 Phase 2 trial of camizestrant in pretreated post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer. The data showed that camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at 75mg and 150mg dose levels versus Faslodex (fulvestrant) 500mg in patients previously treated with endocrine therapy. In t;78.83000183105469;Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.NEW YORK, December 08, 2022--Bristol Myers Squibb Announces Dividend Increase;46.2599983215332;Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.;35.970001220703125;;14.979999542236328;OSAKA, Japan & CAMBRIDGE, Mass., December 09, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Orleans. Takeda’s latest research focuses on improving long-term outcomes for patients with hematologic diseases.;41.75;;10.779999732971191;;163.32000732421875;;7.860000133514404;;15.430000305175781;;117.06999969482422;;8.420000076293945;;27.049999237060547;;53.54999923706055;;7.980000019073486;;13.59000015258789;;26.100000381469727;;49.130001068115234;;197.27999877929688;;4.090000152587891;;23.989999771118164;;1.3300000429153442;;2.859999895095825;;;;2.799999952316284;;6.150000095367432;;59.029998779296875;;;;12.109999656677246;Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;5.679999828338623;Erasca Inc (NASDAQ: ERAS) has entered into an exclusive worldwide license agreement with Novartis AG (NYSE: NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor for NRAS mutant (NRASm) melanoma and other RAS/MAPK pathway-driven tumors. To date, naporafenib has been dosed in over 500 patients across multiple trials and has demonstrated preliminary clinical proof-of-concept and favorable safety and tolerability, Erasca says. Erasca will pay Novartis a one-time upfront cash payment of $2Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca’s addressable population Erasca to host conference call and webcast today at 8:30 am ET SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerciSAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 15,384,616 shares of its common stock at a price of $6.50 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before;3.0999999046325684;;13.0;;2.299999952316284;;49.709999084472656;;11.930000305175781;;16.260000228881836;;3.200000047683716;;10.850000381469727;;3.880000114440918;;6.25;;16.920000076293945;;35.619998931884766;Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.;17.0;;20.5;;18.850000381469727;;;;2.0799999237060547;;15.720000267028809;
2022-12-12;177.83999633789062;While many provide an excellent way to earn a passive regular income in retirement, some dividend stocks are also great options for a diversified portfolio being built to fund a future retirement.  Today, we are going to take a look at two strong dividend stocks that could make great buy-and-hold options until you retire.  Healthcare giant Johnson & Johnson (NYSE: JNJ) has a sizable presence in the global market with its popular and innovative products under its consumer and health segments.;52.15999984741211;;367.25;So far this month, Eli Lilly (NYSE:LLY) stock has continued to rally. Hitting yet another new all-time high just a few days ago before backing down, LLY stock is up a total of 24% so far this year. That’s an impressive move for this mega-cap pharma stock, especially during this down year for the overall stock market. Yet far from the product of speculative frenzy, the market is rightfully bullish about LLY. In recent months, prospects for one of Lilly’s key drug candidates, tirzepatide (marketedYou don't have to be in a hurry when it comes to buying stocks.  Here are three top stocks to buy hand over fist before the end of 2022 (listed in alphabetical order).  Eli Lilly (NYSE: LLY) should have plenty of good news on the way next year.;129.80999755859375;;165.32000732421875;In this article, we discuss the 11 best sectors to invest in heading into 2023. If you want to see more of the top sectors to consider, check out 5 Best Sectors To Invest In Heading Into 2023. With a recession on the horizon, many investors are cautious when it comes to putting their money […]In this article, we discuss 10 best medical stocks under $20. If you want to see more stocks in this selection, check out 5 Best Medical Stocks Under $20. The healthcare industry has undergone a significant restructuring in the wake of the COVID-19 pandemic. There were multiple new healthcare trends in 2022 that have a […]AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in combination for the treatment of patients with relapsed/refractory (R/R) follicular lymphoma (FL), previously untreated FL, R/R diffuse large B-cell lymphoma (DLBCL), as well as Richter's syndrome at the 64th American Society of Hematology (ASH) Annual Meeting.;90.87999725341797;Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.(Bloomberg) -- Clovis Oncology Inc. filed for bankruptcy and plans to sell its experimental cancer drug at an auction with Novartis Innovative Therapies making a binding, opening bid worth as much as $681 million.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyElon Musk Is Ruining Trump’s Presidential CampaignUS Stocks Start Fed Week Higher as CPI Data Loom: Markets WrapFed’s Message That Rates Will S;108.97000122070312;RAHWAY, N.J., December 12, 2022--Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.Merck, Bristol-Myers Squibb and Deere are included in this Analyst Blog.;69.27999877929688;;78.88999938964844;PRINCETON, N.J., December 12, 2022--Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in TreatmentMerck, Bristol-Myers Squibb and Deere are included in this Analyst Blog.;46.65999984741211;"Amgen Inc (NASDAQ: AMGN) has agreed to buy Horizon Therapeutics plc (NASDAQ: HZNP), implying an enterprise value of approximately $28.3 billion, marking the largest healthcare merger of the year. The Wall Street Journal was the first to report on Sunday that Amgen is in advanced talks to buy Horizon. Horizon confirmed its takeover talks with three large pharma companies in late November. Last week, Johnson & Johnson's (NYSE: JNJ) unit, Janssen, pulled out of the talks. Sunday, Sanofi SA (NASDAQ:Amgen Inc said on Monday it would buy rare disease drugmaker Horizon Therapeutics Plc for $26.40 billion in its biggest deal yet, giving the biotech company access to blockbuster thyroid eye disease treatment Tepezza.  Amgen will pay $116.50 in cash for each Horizon share held, or a premium of nearly 20% to the stock's last close.  A deal will add several approved drugs to the company's portfolio including Krystexxa used for the treatment of gout that is not controlled by other medicines.Amgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.  The U.S. biotechnology company has offered about $116.5 for each Horizon share, according to the report, citing a person familiar with the matter.  The offer is at about a 20% premium to Horizon's closing price of $97.29 on Friday.By Scott KanowskyJust as China faces a testing time over its dramatic COVID-19 policy pivot, financial markets are on full alert ahead of interest rate decisions coming out this week from the world's top central banks.  Initial market enthusiasm over China's easing of its stringent ""zero-COVID"" measures has now switched to worries over a wave of infections likely disrupting the economy.  European stock markets are set for a weaker start on Monday, dragged by declines in Asian stocks, with the spotlight on a series of central bank meetings even as expectations rise that euro zone inflation is peaking.By Scott KanowskyAmgen Inc is in advanced talks to buy biotech company Horizon Therapeutics Plc, the Wall Street Journal reported on Sunday, while rival bidder French health group Sanofi announced it had dropped its bid.  A deal for Amgen to buy the company could be finalised by Monday assuming the talks don’t fall apart, the Journal report added.  Amgen and Horizon did not immediately respond to Reuters requests for comments.A deal for Amgen to buy the company could be finalised by Monday assuming the talks don’t fall apart, the Journal report added.  Amgen and Horizon did not immediately respond to Reuters requests for comments.  Last month, Horizon Therapeutics - which has a market capitalization of about $22 billion - had said it was in talks with Amgen Inc, Sanofi and Johnson & Johnson's Janssen Global Services unit, all three of which have been active in deal-making this year.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “TAKEOVER RULES”). THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”) Paris, December 11, 2022. Sanofi S.A. (“Sanofi”) regu";35.709999084472656;PHILADELPHIA, December 11, 2022--GSK plc (LSE/NYSE:GSK) today announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR) in myelofibrosis patients previously treated with an approved Janus kinase (JAK) inhibitor. Additionally, new analyses from MOMENTUM showed;14.920000076293945;;42.18000030517578;;11.140000343322754;;166.8800048828125;;7.820000171661377;;16.239999771118164;;122.52999877929688;;8.5;;27.579999923706055;"DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-LBT); License Agreement with Organon to Commercialize XACIATO™; Ovaprene® IDE Approval for Pivotal Contraceptive Efficacy Study; Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1 2023 Anticipated Milestones Include: XACIATO FirstJERSEY CITY, N.J., December 12, 2022--Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary";52.04999923706055;;7.739999771118164;;13.75;;27.030000686645508;;51.709999084472656;Needless to say, every investor is looking for big returns and while there are many routes to follow in trying to achieve that goal, tracking the moves made by Wall Street’s most successful investors is surely a good place to start. One investor sitting pretty near the top of the pile is Izzy Englander. Interested in the stock market from an early age, Englander was already trading stocks in high school. By 1989, he established the Millennium Management hedge fund with $35 million in seed money,;210.47999572753906;;3.759999990463257;;23.959999084472656;;1.309999942779541;;2.8499999046325684;;;;2.7100000381469727;Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual Meeting.;6.769999980926514;CULVER CITY, Calif., December 12, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.;60.029998779296875;;;;11.90999984741211;;4.929999828338623;;3.0999999046325684;Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans.;13.3100004196167;;2.440000057220459;;47.31999969482422;Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET.LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from;12.350000381469727;The nature of investing is that you win some, and you lose some. And there's no doubt that Nurix Therapeutics, Inc...;16.15999984741211;;3.0799999237060547;;11.600000381469727;;3.8299999237060547;;6.369999885559082;;17.690000534057617;"CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc (""Arcturus Therapeutics""; NASDAQ: ARCT). The agreement grants access to Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of inf";35.79999923706055;;16.579999923706055;Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from the INTEGUMENT-1 trial released in NovemberFor the primary endpoint, 28.9% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success compared to 12.0% of individuals treated with vehicle (P<0.0001)42.0% of individuals treated with roflumilast cream 0.15% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) and 30.2% achieved a;19.969999313354492;;19.1200008392334;;;;2.0999999046325684;;15.609999656677246;
2022-12-13;179.2100067138672;A Dividend King is any stock that has increased its dividend for 50+ cosecutive years, doubling that of a Dividend Aristocrat.Racking up a five-bagger investment -- when one of your holdings grows by 5x -- is quite the accomplishment, and finding potential five-baggers is a great way to set your portfolio up for success.  On that note, powerful pharmaceutical businesses like Johnson & Johnson (NYSE: JNJ) and Vertex Pharmaceuticals (NASDAQ: VRTX) are stable enough and profitable enough to 5x, and they've both done it before.  Johnson & Johnson's market capitalization is around $461 billion, making it one of the largest businesses in the world.Dividend stocks can be a safe place to park your money amid a downturn in the markets.  Three stocks that not only provide better yields than the S&P 500 average (1.7%), but that could rise in value next year and continue to outperform are Johnson & Johnson (NYSE: JNJ), PepsiCo (NASDAQ: PEP), and Village Super Market (NASDAQ: VLGEA).  Let's find out a bit more about these three high-yielding dividend stocks that could beat the market in 2023.Over the course of two days on 29-30 November, Johnson & Johnson was proud to partner with the Global Fund and Asian Venture Philanthropy Network (AVPN) to host the 2nd annual Asia Pacific Tuberculosis Forum – a platform for youth leaders, policymakers, NGOs and academics to collaborate on tuberculosis (TB) elimination efforts in the Asia Pacific, home to more than half of all TB cases. The Forum's agenda, which was designed with the support of the Global TB Caucus, was focused on understandingJohnson & Johnson (JNJ) closed the most recent trading day at $177.84, moving +1.19% from the previous trading session.In this article, we will discuss the 10 best performing healthcare ETFs in 2022. If you want to explore similar ETFs, you can take a look at 5 Best Performing Healthcare ETFs in 2022. 2022 has been riddled with volatility, inflation, interest rates, and panicky investors. Investors’ focus has shifted from cyclical and growth sectors […];53.06999969482422;"Two examples are Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  Pfizer has been one of the most successful companies in the coronavirus vaccine market with Comirnaty.  Pfizer has beefed up its pipeline recently, partly thanks to acquisitions.By Yasin EbrahimIn this article, we discuss the 10 best immunology stocks to invest in. If you want to read about some more immunology stocks, go directly to 5 Best Immunology Stocks to Invest In. Immunology is the study of the immune system of higher organisms in relation to disease. To be more precise, immunology is the […]Benzinga Sam Bankman-Fried Arrested In The Bahamas Disgraced crypto mogul Sam Bankman-Fried was arrested in the Bahamas on Monday following the receipt of formal notification from the U.S. Bahamian authorities said that the U.S. is likely to request his extradition. ""The Bahamas and the United States have a shared interest in holding accountable all individuals with FTX who may have betrayed the public trust and broken the law,"" Phillip Davis, Prime Minister of The Bahamas, said in a statement.";358.6600036621094;In this article, we discuss the 10 best immunology stocks to invest in. If you want to read about some more immunology stocks, go directly to 5 Best Immunology Stocks to Invest In. Immunology is the study of the immune system of higher organisms in relation to disease. To be more precise, immunology is the […]Eli Lilly and Co said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade as it bets on multi-billion dollar markets for treating obesity and Alzheimer's disease.  The drugmaker is spending heavily on marketing and research and development as it prepares for data release and potential approvals for two keenly watched drugs next year, donanemab for Alzheimer's and tirzepatide for obesity.  The higher spending led Lilly to forecast 2023 profit below analysts' estimates and its shares fell about 1% to $363.59.(Reuters) -Eli Lilly and Co said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade as it bets on multi-billion dollar markets for treating obesity and Alzheimer's disease.  The drugmaker is spending heavily on marketing and research and development as it prepares for data release and potential approvals for two keenly watched drugs next year, donanemab for Alzheimer's and tirzepatide for obesity.  The higher spending led Lilly to forecast 2023 profit below analysts' estimates and its shares fell about 1% to $363.59.Eli Lilly & Co. announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide. The company said it expects per-share earnings to range from $7.65 to $7.85, and adjusted EPS of $8.10 to $8.30. It expects revenue to range from $30.3 billion to $30.8 billion. The FactSet consensus is for EPS of $9.16 and revenue of $30.2 billion. Shares fell 3% in premarket tradEli Lilly and Company (NYSE: LLY) today announced its 2023 financial guidance, highlighted by expected volume-based revenue growth and increased investments to maximize future value. The company will review potential key events for the upcoming year, including important data readouts for several investigational medicines in its clinical pipeline and the possibility of multiple regulatory submissions and approvals, in a call with investors today.Citigroup CEO Jane Fraser expects a recession in 2023.  Here are three high-flying stocks to buy and hold if a recession is on the way.  Biotech stocks often soar, regardless of what's going on with the economy.In the latest trading session, Eli Lilly (LLY) closed at $367.25, marking a +1.73% move from the previous day.Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN trial in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Richter transformation (RT), and Waldenström macroglobulinemia (WM). Pirtobrutinib is an investigational, highly selective, reversible (non-covalent) inhibitor of Bruton's tyrosine kinase (BTK). These data are featured in oralEli Lilly & Co. said Monday that its board has authorized a 15% increase in the pharma company's quarterly dividend to $1.13 a share. The dividend is payable on March 10 to shareholders of record on Feb. 15, the company said. Lilly stock rose more than 1% on Monday, tracking the broader market, and has gained 33% this year, contrasting with losses of around 16% for the S&P 500 index.The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2023 of $1.13 per share on outstanding common stock.In this article, we will discuss the 10 best performing healthcare ETFs in 2022. If you want to explore similar ETFs, you can take a look at 5 Best Performing Healthcare ETFs in 2022. 2022 has been riddled with volatility, inflation, interest rates, and panicky investors. Investors’ focus has shifted from cyclical and growth sectors […]In this article, we discuss 12 defensive healthcare dividend stocks to buy now. You can skip our detailed analysis of the healthcare sector and its performance over the years, and go directly to read 5 Defensive Healthcare Dividend Stocks to Buy. People invest in dividend stocks for several reasons. One reason is that these stocks […];132.83999633789062;"Novo Nordisk A/S (NYSE: NVO) will roll out its obesity treatment, Wegovy (semaglutide), in Europe in 2023 to ensure it has enough supply. Following the launch in the U.S. in mid-2021, Wegovy faced a significant bottleneck. Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, ""allegedly"" the culprit behind the supply shortage for Wegovy. Bloomberg reported that the pharma company had plans to launch Wegovy in the summer of this year in the U.K., with the";164.7899932861328;This is especially true for growth, tech, and consumer discretionary stocks, which are incredibly popular among individual investors.  Many investors are looking again at dividend growth as a tool to grow wealth after the recent growth stock bubble and crash.  AbbVie (NYSE: ABBV) and Vici Properties (NYSE: VICI) have yields over 3%, excellent dividend growth histories, and have dominated the market this year, as shown below.In this article, we discuss the 10 best immunology stocks to invest in. If you want to read about some more immunology stocks, go directly to 5 Best Immunology Stocks to Invest In. Immunology is the study of the immune system of higher organisms in relation to disease. To be more precise, immunology is the […]In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. […]AbbVie (NYSE: ABBV) today announced that for the tenth consecutive year, it has been named to the Dow Jones Sustainability World Index (DJSI World) and Dow Jones Sustainability North America Index (DJSI North America). Additionally, AbbVie achieved the highest score in the biotech sector on the 2022 S&P Global Corporate Sustainability Assessment (CSA). Since AbbVie's founding in 2013, the company has been listed on the DJSI World and DJSI North America every year.;91.20999908447266;Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH) patients with residual anemia despite prior anti-C5 therapy1 Iptacopan demonstrated an 80% difference to anti-C5 in the estimated proportion of patients* achieving 2 g/dL or more hemoglobin-level increases from baseline without the need for red blood cell transfusions1 Iptacopan demonstrated a 67% differencFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.;110.91000366210938;"Here we have shortlisted five stocks - CVX, MRK, AMGN, TRV and IBM- that have fared better than the Dow Jones Index this year and have more upside potential for investment consideration.Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss initial cancer vaccine trial results for Moderna and Merck.Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 combined with Keytruda met its primary endpoint. Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial. In October, Merck exercised its option to develop and commercialize mRNA-4157/V940 jointly with Moderna and share costs and profits equally under the worldwide collaboration. The investigationalBy Liz MoyerMerck & Co. Inc. and Moderna Inc. said Tuesday that their experimental mRNA-based cancer vaccine reduced the risk of recurrence or death when used with Merck's Keytruda in patients with late-stage melanoma. Merck's stock was up 1.9% in premarket trading, while Moderna shares rallied 5.6%. The Phase 2b study compared the combination treatment with Keytruda. The companies said they now plan to move forward with a Phase 3 clinical trial testing the combination treatment in 2023, and they also planWith a price-to-earnings (or ""P/E"") ratio of 18x Merck & Co., Inc. ( NYSE:MRK ) may be sending bearish signals at the...Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningfulAn experimental personalized melanoma vaccine developed by Moderna Inc given with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of the skin cancer's recurrence or death by 44% compared with Keytruda alone in a midstage trial.  The study is the first randomized trial to show that combining mRNA vaccine technology - which has been behind the development of successful COVID-19 vaccines - with a drug that revs up the immune response would offer a better result for patients with the most deadly type of skin cancer.  Paul Burton, Moderna's chief medical officer, said in a separate interview the combination ""has the capacity to be a new paradigm in the treatment of cancer.""Indonesia will produce drugmaker Merck & Co's vaccines for human papillomavirus (HPV), the chief of its state-owned pharmaceutical company Bio Farma said on Tuesday, in a bid to combat HPV-linked cervical cancer in the country.  Cervical cancer is the fourth-most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020, according to the World Health Organization (WHO).  In Indonesia, the disease killed more than 36,000 people in 2021, the health ministry said, adding that the Bio Farma-Merck deal was meant to stem the number of cervical cancer cases in the country.In this article, we will discuss the 10 best performing healthcare ETFs in 2022. If you want to explore similar ETFs, you can take a look at 5 Best Performing Healthcare ETFs in 2022. 2022 has been riddled with volatility, inflation, interest rates, and panicky investors. Investors’ focus has shifted from cyclical and growth sectors […]";69.58000183105469;WILMINGTON, Del., December 13, 2022--AstraZeneca is proud to announce $4 million in financial contributions to 52 nonprofit organizations through its second-annual Accelerate Change Together (ACT) on Health Equity: Community Solutions Challenge and National Strategic Collaborations. Building on the learnings and impact from its inaugural year, the 2022 contributions will support community-based, regional and national nonprofit programs working to advance health equity and enhance STEM (Science,;77.3499984741211;In this article we are going to share 11 best low beta stocks to buy according to 900+ hedge funds tracked by Insider Monkey. You can also check out our recently published article – 12 Safest Stocks to Invest In – on a related topic. Geopolitical tensions, concerns about inflation, and a hawkish Federal Reserve […]Bristol Myers Squibb (BMY) closed the most recent trading day at $78.89, moving +0.08% from the previous trading session.In this article, we will discuss the 10 best performing healthcare ETFs in 2022. If you want to explore similar ETFs, you can take a look at 5 Best Performing Healthcare ETFs in 2022. 2022 has been riddled with volatility, inflation, interest rates, and panicky investors. Investors’ focus has shifted from cyclical and growth sectors […];47.040000915527344;;36.150001525878906;Wave Life Sciences Ltd (NASDAQ: WVE) and GSK plc (NYSE: GSK) have announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program targeting alpha-1 antitrypsin deficiency, WVE-006. The discovery collaboration has an initial four-year research term. The collaboration includes two main components. The first is a discovery collaboration that enables GSK to advance up to eight programs and Wave to advance up to three programs. In additionSix floor office building on New Oxford Street will be workplace for 3,000 staff including CEOWave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and GSK’s expertise in genetics and genomics GSK to advance up to eight preclinical programs Additionally, GSK receives exclusive global license to Wave’s preclinical, potential first-in-class RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency, a disease that impacts the lungs and liver;15.239999771118164;"In this article, we discuss the 10 best immunology stocks to invest in. If you want to read about some more immunology stocks, go directly to 5 Best Immunology Stocks to Invest In. Immunology is the study of the immune system of higher organisms in relation to disease. To be more precise, immunology is the […]Takeda Pharmaceutical Co Ltd (NYSE: TAK) will acquire NDI-034858 from Nimbus Therapeutics, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor for multiple autoimmune diseases. It is in an ongoing Phase 2b study in active psoriatic arthritis, and Takeda plans to investigate it for inflammatory bowel disease (IBD) and other autoimmune diseases. Nimbus recently disclosed topline results from a Phase 2b study evaluating NDI-034858 in patients with moderate-to-severe plaque psoriasis. TIn one of the largest acquisitions of a drug this year, Takeda has agreed to buy a drug in mid-stage development for autoimmune diseases for $4 billion upfront plus $2 billion in milestone payments from Cambridge-based Nimbus Therapeutics.Takeda Pharmaceutical will buy U.S.-based Nimbus Therapeutics' experimental psoriasis drug for up to $6 billion, the Japanese drugmaker said on Tuesday, as it looks to cut reliance on treatments facing loss of patents.  The drug, codenamed ""NDI-034858"", last week showed statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year.  The company is also studying the drug to treat inflammatory bowel disease and psoriatic arthritis.OSAKA, Japan & CAMBRIDGE, Mass., December 13, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. When the transaction is complete, NDI-034858 will be known as TAK-279.";41.81999969482422;;11.34000015258789;;177.99000549316406;;8.029999732971191;;15.4399995803833;;122.80999755859375;;8.489999771118164;;28.200000762939453;;50.130001068115234;;8.079999923706055;;14.270000457763672;;27.729999542236328;;53.31999969482422;;210.9199981689453;;3.799999952316284;;23.829999923706055;;1.309999942779541;;2.700000047683716;;;;2.7699999809265137;;6.659999847412109;;59.290000915527344;;;;12.0600004196167;A Durham biopharmaceutical company is cutting a quarter of its workforce even as it initiates a phase 3 trial for its lead clinical program.  Chimerix (Nasdaq: CMRX) announced Thursday plans to cut its staff by about 25 percent.  The decision follows the sale of the company's sole commercial product, a smallpox antiviral called Tembexa.;4.929999828338623;ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application;3.2100000381469727;;13.6899995803833;;2.490000009536743;;51.77000045776367;;12.140000343322754;Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK mutations conferring resistance to both covalent and non-covalent BTK inhibitors remain susceptible to degradation by NX-2127 Nurix will host a Key Opinion Leader (KOL) webcast event at 9:30 pm ET today to review data presented at ASH and progress in its degrader portfolio SAN FRANCISCO, Dec. 12, 2022;16.25;SAN DIEGO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 356,300 shares of its common stock to twelve new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as induceme;3.0999999046325684;;10.869999885559082;;3.75;;6.449999809265137;;18.979999542236328;"SAN DIEGO, December 13, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Ma";35.9900016784668;;17.059999465942383;;20.100000381469727;;20.190000534057617;;;;2.200000047683716;;15.449999809265137;
2022-12-14;179.75999450683594;"Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.For example, consider Dividend Kings.  The two healthcare companies below are not only Dividend Kings with proven track records, but their strong fundamentals make them stocks that long-term investors can rely on moving forward.  You'll find healthcare conglomerate Johnson & Johnson (NYSE: JNJ) all over the industry; it sells consumer health products, prescription drugs, and medical devices worldwide.NEW BRUNSWICK, N.J., December 14, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. (""Offeror""), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the ""Offer"") to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ: ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitlinIn this article, we will discuss the 10 best performing leveraged ETFs in 2022. If you want to explore similar ETFs, you can also take a look at 5 Best Performing Leveraged ETFs in 2022. What Are Leveraged ETFs? Leveraged ETFs are exchange–traded funds that use financial derivatives and debt to amplify the returns of […]In this article, we discuss 10 best performing dividend ETFs in 2022. If you want to see more ETFs in this selection, check out 5 Best Performing Dividend ETFs in 2022. Investing in dividends, especially those that increase on a year-over-year basis, can contribute meaningfully to long-term portfolio returns in a volatile market. Market uncertainty, […]NEW BRUNSWICK, N.J., December 13, 2022--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 24th to review fourth-quarter results. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer, and Jessica Moore, Vice President, Investor Relations will host the call.Johnson & Johnson  is a household name to millions.  In this daily bar chart of JNJ, below, we can see that prices are pointed upwards for a possible retest of the highs of June and maybe April.  A move of the 50-day line above the 200-day line could happen in the days ahead to give us a bullish golden cross buy signal (obviously a lagging indicator).";54.47999954223633;"China Meheco Group Co Ltd said on Wednesday it had signed an agreement with Pfizer to import and distribute the pharmaceutical firm's oral COVID-19 treatment Paxlovid in mainland China.  The agreement is valid until Nov. 30, 2023, China Meheco said in a filing to the Shanghai stock exchange.  Pfizer shares rose 2.4%, or $1.25, to $54.32 in morning trade.The U.S. government announced a new purchase agreement for Pfizer Inc's (NYSE: PFE) COVID-19 antiviral treatment Paxlovid. This purchase supplements the 20 million treatment courses previously contracted by and already delivered to the U.S. Government. The additional 3.7 million treatment courses are planned for delivery by early 2023. Related: Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry. The Biden administration previously agreed to payPfizer's (NYSE:PFE) stock is up by a considerable 16% over the past three months. As most would know, fundamentals are...The U.S. government agreed to pay Pfizer Inc nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral treatment Paxlovid, the company said on Tuesday.  The new purchase supplements the 20 million courses previously bought by the United States and delivery is planned by early 2023, Pfizer said in a statement.  The Biden administration previously agreed to pay around $10.6 billion - roughly $530 per treatment course - for the first 20 million courses ordered.The U.S. government agreed to pay drugmaker Pfizer Inc nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral drug Paxlovid, the company said on Tuesday.  The new courses of the drug supplement the 20 million courses previously contracted by Pfizer and are planned for delivery by early 2023, Pfizer said in a statement.Drug giant Pfizer released its most detailed plan yet to make up for patent expirations that will mean a $17 billion hit by 2030.Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results sent Moderna shares soaring.In this article, we discuss the 10 biotech stocks with the biggest upside. If you want to read about some more biotech stocks with the biggest upside, go directly to 5 Biotech Stocks With The Biggest Upside. The biotechnology sector has been one of the most profitable growth spaces in the stock market over the […]Drugmaker Pfizer Inc said on Tuesday it is working to improve supply of its COVID-19 antiviral drug Paxlovid in China in order to ensure adequate access to the drug as cases rise in the country.  ""Pfizer is actively collaborating with all stakeholders to secure an adequate supply of Paxlovid in China and remains committed to fulfilling the COVID-19 treatment needs of patients in China,"" the company said in an emailed statement.  The drug received conditional approval in China in February.By Yasin Ebrahim";363.5;In this article, we will be taking a look at the 15 biggest diet/weight loss companies in the world. To skip our detailed analysis of these companies, you can go directly to see the 5 Biggest Diet/Weight Loss Companies in the World. Over the years, there has been a growth in popularity when it comes to […]Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.Drug giant Pfizer released its most detailed plan yet to make up for patent expirations that will mean a $17 billion hit by 2030.Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance.In this article, we discuss the 10 biotech stocks with the biggest upside. If you want to read about some more biotech stocks with the biggest upside, go directly to 5 Biotech Stocks With The Biggest Upside. The biotechnology sector has been one of the most profitable growth spaces in the stock market over the […]Before we discuss the top 10 stock picks for 2023, we can all agree that the economy has two pathways from here. One, the real impact of the rate hikes sits in front of us and will trigger a deep recession in 2023. Two, the rate hikes in 2022 were appropriate for the level of inflation, and the market will steadily recover in 2023 as rates stabilize. To figure out which path is more likely, let’s take a look at this chart: Source: Charts by TradingView Effective Fed Funds Rate vs the S&P500 We cEli Lilly expects 2023 adjusted earnings in the range of $8.10 to $8.30 a share, below analysts' expectations.;134.72000122070312;Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.Two of them are Novo Nordisk (NYSE: NVO) and Southwest Airlines (NYSE: LUV).  It hasn't been a bad year for Danish pharmaceutical giant Novo Nordisk, and its shares have risen 15% in 2022.  Through the first nine months of 2022, Wegovy's sales have totaled 3.7 billion Danish Krone ($524 million), which is more than six times what it generated a year ago.Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance.In this article, we discuss the 22 most charitable companies in 2022. If you want to skip the details about corporate and individual charitable practices and global charity statistics, go directly to the 5 Most Charitable Companies in 2022. According to the Charities Aid Foundation World Giving Index 2022, 40% of the global population took […];164.86000061035156;In this article, we discuss 10 biggest dividend cuts and suspensions in 2022. You can skip our detailed analysis of dividend investment and its benefits, and go directly to read 5 Biggest Dividend Cuts and Suspensions of 2022. Dividend companies are stealing the limelight this year as investors turn to these income-generating stocks to fight […]Exicure Inc (NASDAQ: XCUR) announced the termination of its collaboration agreements with AbbVie Inc (NYSE: ABBV) and Ipsen BioPharm Limited (OTC: IPSEY). Through separate agreements with AbbVie and Ipsen, Exicure was collaboratively advancing specified discovery programs in hair loss disorders and rare neurodegenerative disorders, respectively. As a result of this termination, Exicure can develop medicines targeting hair loss disorders, Angelman syndrome independently, and Huntington's diseaseIn this article, we will discuss the 10 best performing leveraged ETFs in 2022. If you want to explore similar ETFs, you can also take a look at 5 Best Performing Leveraged ETFs in 2022. What Are Leveraged ETFs? Leveraged ETFs are exchange–traded funds that use financial derivatives and debt to amplify the returns of […]In this article, we discuss 10 best performing dividend ETFs in 2022. If you want to see more ETFs in this selection, check out 5 Best Performing Dividend ETFs in 2022. Investing in dividends, especially those that increase on a year-over-year basis, can contribute meaningfully to long-term portfolio returns in a volatile market. Market uncertainty, […]In this article, we discuss the 10 biotech stocks with the biggest upside. If you want to read about some more biotech stocks with the biggest upside, go directly to 5 Biotech Stocks With The Biggest Upside. The biotechnology sector has been one of the most profitable growth spaces in the stock market over the […]In this article, we discuss 16 best dividend stocks of 2022. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Best Dividend Stocks of 2022. This year’s inflation and continued interest rates hike were heavy on the markets. Analysts recommended investing in income-generating […];92.52999877929688;Harrow Health Inc (NASDAQ: HROW) entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis AG (NYSE: NVS). This acquisition will further expand and diversify Harrow's portfolio of branded pharmaceutical products and its ability to serve the U.S. ophthalmic surgical and acute care markets. Assuming this transaction closes during Q1 of 2023, Harrow expects 2023 net revenues of $135-$143 million and adjusted EBITDA of $44-$50Novartis AG (NYSE: NVS) announced detailed results from the pivotal Phase 3 APPLY-PNH trial. The results showed that most of the paroxysmal nocturnal hemoglobinuria (PNH) patients receiving the investigational iptacopan achieved clinically meaningful increases in hemoglobin levels compared to anti-C5 therapy. The study met both primary endpoints and most secondary endpoints. The study met both primary endpoints, showing superiority for iptacopan vs. anti-C51. For the first, an estimated 82.3% of;111.55000305175781;Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.The shot combined with a Merck immunotherapy reduced the risk of relapse in people with skin cancer in a study, Moderna said.Yahoo Finance health correspondent Anjalee Khemlani joins the Live show to review Moderna and Merck shares following positive results seen in their joint cancer vaccine trial.In this article, we discuss 16 best dividend stocks of 2022. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Best Dividend Stocks of 2022. This year’s inflation and continued interest rates hike were heavy on the markets. Analysts recommended investing in income-generating […]Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc's (NYSE: MRK) investigational personalized mRNA cancer vaccine + Keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival versus Keytruda. SVB Leerink has raised the price target on Moderna from $101 to $102. The analyst says it has fielded a steady stream of inbounds from investors nervous about elevated expectations for personalized cancer vaccine (PCV) data and expects shares to trade up oModerna and Merck released preliminary results of a personalized cancer vaccine for late-stage melanoma patients.;70.44000244140625;Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.AstraZeneca is breaking out on the strength of its relative strength highs and as profits continue to grow.;77.13999938964844;Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.;47.95000076293945;;35.91999816894531;Shares of Wave Life Sciences Ltd. jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline to develop oligonucleotide therapeutics. Wave is already testing WVE-006, an experimental oligonucleotide treatment, for alpha-1 antitrypsin deficiency, a genetic disease that causes liver and lung disease, in preclinical research. GSK will make a $170 million upfront payment to Wave in cash and equity, with up to $525 million in;15.40999984741211;;41.459999084472656;;11.319999694824219;Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced it is donating a total of $1 million to aid in supporting access to healthcare, food security and water stewardship in communities around the world, through four organizations: Direct Relief, World Central Kitchen (WCK), WaterAid and World Food Program USA, the U.S. partner of the United Nations World Food Programme.Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that its near-term science-based emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). SBTi is a global body enabling businesses to set ambitious emissions reduction targets in line with the latest climate science.;177.4199981689453;;8.260000228881836;Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citing unidentified financial sources.  The company may sell its Chinese business and its diagnoses unit, Cinco Dias reported.  A spokesperson for the company declined to comment though in November Grifols said it was committed to reducing its 9.4 billion net debt.;15.710000038146973;;121.47000122070312;;8.449999809265137;;28.6200008392334;;51.880001068115234;Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Legend Biotech...;7.170000076293945;;14.359999656677246;;26.8799991607666;;52.68000030517578;;204.57000732421875;;3.8399999141693115;;23.43000030517578;;1.2899999618530273;;2.440000057220459;;;;2.740000009536743;;6.739999771118164;;58.650001525878906;;;;11.90999984741211;;4.840000152587891;;3.4800000190734863;;13.899999618530273;;2.3299999237060547;;50.2400016784668;;12.359999656677246;;16.290000915527344;;3.0999999046325684;;10.180000305175781;;3.549999952316284;;6.199999809265137;;18.850000381469727;;35.2400016784668;;16.6299991607666;;21.610000610351562;;19.790000915527344;;;;2.490000009536743;BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. “We are excited to partner with UCB, a global leader in epilepsy drug development, as we work together toward a n;14.859999656677246;
2022-12-15;177.49000549316406;Ebola vaccines developed by Johnson & Johnson (NYSE: JNJ) and Merck & Co Inc (NYSE: MRK) produced virus-fighting antibodies and appeared to be safe in children and adults, two studies conducted in West Africa show. Both companies’ vaccines produced antibodies 14 days after the first of two shots and were detectable at varying levels in both children and adults for one year. The results were published in The New England Journal of Medicine. The vaccines target the Zaire strain of the virus, not tJohnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.Ebola vaccines developed by Johnson & Johnson and Merck & Co produced virus-fighting antibodies and appear to be  safe in children and adults, according to data from two studies published on Wednesday.  Both companies' vaccines produced antibodies 14 days after the first of two shots and were detectable at varying levels in both children and adults for one year, data from the studies conducted in Western Africa showed.  The vaccines are designed to target the Zaire strain of the virus, not the Sudan strain of Ebola that recently caused an outbreak and at least 56 deaths in Uganda.In this article, we discuss the 12 best FMCG stocks to buy now. If you want to skip our industry analysis you can see the 5 Best FMCG Stocks To Buy Now. Fast-moving consumer goods (FMCG), also known as consumer packaged goods (CPG), refer to highly in-demand products that are affordable and thus, sold quickly. Such […];53.61000061035156;"The latest Covid-19 surge comes as newer Omicron subvariants nudge out BA.5 as the dominant variant in the U.S.(Bloomberg) -- Pfizer Inc. cemented a deal first announced in March to sell its antiviral medication Paxlovid in China through a state-owned company, adding to supply of Covid treatments in the country that’s now facing a massive infection surge. Most Read from BloombergIs Putin Finally Getting Smart About His Ukraine Disaster?Powell Says Fed Still Has a ‘Ways to Go’ After Half-Point HikeElon Musk’s Tesla Share Sales Approach the $40 Billion MarkApple to Allow Outside App Stores in Overhaul SpurWith mandatory testing dropped, it can no longer accurately gauge the number of people who have COVID but don’t have symptoms, its National Health Commission said.China Meheco Group Co Ltd said on Wednesday it  signed an agreement with Pfizer Inc to import and distribute the U.S. drugmaker's oral COVID-19 treatment Paxlovid in mainland China, as the country braces for a surge in COVID patients after scaling back its ""zero COVID"" policy.  The agreement is valid between Dec. 14 and Nov. 30, 2023, China Meheco said in a filing to the Shanghai stock exchange.  Pfizer shares were up 3% at $54.72.Wall Street's main indexes rose on Wednesday ahead of the Federal Reserve's monetary policy decision and economic projections for clues on the path of interest rates.  The U.S. central bank is expected to raise its key rate by 50 basis points to 4.25-4.50% at its last meeting of 2022 after four straight 75 bps increases following a surprise drop in inflation.  Fed officials will also issue new projections showing just how close that endpoint of rates may be, with Tuesday's data showing cooling inflation data for November triggering bets across stock and bond markets it may be closer than expected.Icosavax Inc (NASDAQ: ICVX) provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV), demonstrating a sustained neutralizing antibody (nAb) response against RSV, lasting at least six months after a single administration of IVX-121. William Blair analyst thinks the best comparison for IVX-121 is Pfizer Inc’s (NYSE: PFE) RSVpreF vaccine. The estimated percentage of retained titers for RSV-A from 28 days to 180 days post-immunization";360.010009765625;Both of these businesses are in good financial shape and can afford to boost their payouts significantly.When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...SNY vs. LLY: Which Stock Is the Better Value Option?Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.;133.67999267578125;Novo Nordisk has been highlighted in this Investment Ideas article.Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.Letting the market guide us rather than trying to predict what will happen is the most prudent course of action.;163.10000610351562;One simple way to benefit from the stock market is to buy an index fund. But if you buy good businesses at attractive...In this article, we discuss 10 best Dogs of the Dow stocks ranked by hedge fund sentiment. You can skip our detailed analysis of the Dogs’ performance over the years, and go directly to read 5 Best Dogs of the Dow Stocks Ranked By Hedge Fund Sentiment. ‘Dogs of the Dow’ is an investment strategy […]AbbVie (ABBV) closed the most recent trading day at $164.86, moving +0.04% from the previous trading session.With all the commercials on TV it is hard not to remember that AbbVie ABBV is the manufacturer of Humira to treat rheumatoid arthritis and Crohn's disease.  In this updated daily bar chart of ABBV, below, we can see a bullish golden cross of the 50-day and 200-day moving average lines in December.  The Moving Average Convergence Divergence (MACD) oscillator is in a bullish alignment above the zero line but the two moving averages are poised for a downward crossover and take profit sell signal.Humira, a monoclonal antibody used to treat arthritis among other conditions, is the most lucrative drug in history. Since entering the market in 2003, it has made its manufacturer an estimated $200 billion in revenue. Its sales of about $21 billion globally in 2021 are second only to Pfizer and Moderna’s covid vaccines.;90.88999938964844;In this article, we will take a look at 12 best dividend stocks that outperformed in 2022. If you want to see more best dividend stocks that outperformed in 2022, go directly to 5 Best Dividend Stocks That Outperformed in 2022. Dividend stocks are stocks of companies that pay dividends. Although not always the case, […];109.62999725341797;Companies in The News Are:BRZE,DAL,MRNA,MRK,SOFIEbola vaccines developed by Johnson & Johnson (NYSE: JNJ) and Merck & Co Inc (NYSE: MRK) produced virus-fighting antibodies and appeared to be safe in children and adults, two studies conducted in West Africa show. Both companies’ vaccines produced antibodies 14 days after the first of two shots and were detectable at varying levels in both children and adults for one year. The results were published in The New England Journal of Medicine. The vaccines target the Zaire strain of the virus, not tRAHWAY, N.J., December 15, 2022--AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone in mCRPCThe FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) supplemental marketing application for Lynparza (olaparib) by three months. The application seeks approval for Lynparza in combination with abiraterone & prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC). Related: AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer. The supplemental application isEbola vaccines developed by Johnson & Johnson and Merck & Co produced virus-fighting antibodies and appear to be  safe in children and adults, according to data from two studies published on Wednesday.  Both companies' vaccines produced antibodies 14 days after the first of two shots and were detectable at varying levels in both children and adults for one year, data from the studies conducted in Western Africa showed.  The vaccines are designed to target the Zaire strain of the virus, not the Sudan strain of Ebola that recently caused an outbreak and at least 56 deaths in Uganda.;69.73999786376953;The Commerce Department also removed nine Russian entities from the unverified list and addded them to the entity list because the United States has been unable to conduct site visits.  Companies are added to the unverified list if the United States cannot complete on-site visits to determine if they can be trusted to receive sensitive U.S. technology exports, inspections which in China require approval from the commerce ministry.Investors need to pay close attention to AstraZeneca (AZN) stock based on the movements in the options market lately.The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) supplemental marketing application for Lynparza (olaparib) by three months. The application seeks approval for Lynparza in combination with abiraterone & prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC). Related: AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer. The supplemental application isJohnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.;75.0;In today's volatile market and challenging economy, dividend stocks may be just what many investors need.  Dividends can be a source of passive income -- something that could come in handy with nearly 40-year-high inflation -- and help smooth out market losses.  Let's look at two excellent dividend stocks that fit the bill: Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY).NEW YORK, December 15, 2022--Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023How far off is Bristol-Myers Squibb Company ( NYSE:BMY ) from its intrinsic value? Using the most recent financial...;47.15999984741211;Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.The European Commission (EC) has expanded the marketing authorization of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for moderate-to-severe prurigo nodularis. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat prurigo nodularis in Europe and the U.S. Related: UK Drug Regulator Warns Of Severe Eye ReactDupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis Approval based on direct-to-Phase 3 program showing more than three times as many Dupixent patients experienced a clinically meaningful reduction in itch at 24 weeksDupixent also significantly reduced skin lesions and improved health-related quality of life compared to placebo In Europe, about 70,000 adults living with prurigo nodularis are most in need of new treatment oRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among inflammatory skin diseases. With this approval,Kymera unveiled promising results for its skin-disease treatment on Wednesday, snagging interest from Sanofi and sending KYMR stock flying.Sanofi (SNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.SNY vs. LLY: Which Stock Is the Better Value Option?;35.630001068115234;;15.140000343322754;;40.790000915527344;Promotions of Sara Klymkowsky, Brienne Kugler and Alessandra Sassun NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team. This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced leadership team responsible for formulating and executing on its mission to accelerate innovation and transform patient lives. The following promotions are effective January 1, 2023, and each;11.140000343322754;;168.25;;8.109999656677246;;14.819999694824219;;119.01000213623047;;8.0600004196167;;28.280000686645508;JERSEY CITY, N.J., December 15, 2022--Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference;51.84000015258789;;6.769999980926514;"CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (""mRNA""), today announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares.";13.829999923706055;;25.514999389648438;;52.40999984741211;;200.0;;3.740000009536743;;22.56999969482422;;1.25;;2.049999952316284;;;;2.700000047683716;;6.710000038146973;;56.130001068115234;;;;11.140000343322754;;4.769999980926514;;3.319999933242798;;13.270000457763672;;2.2699999809265137;;49.68000030517578;;11.90999984741211;;16.239999771118164;;3.059999942779541;;9.800000190734863;;3.5199999809265137;;6.300000190734863;;18.239999771118164;;34.7400016784668;;16.489999771118164;;21.420000076293945;Needham has initiated coverage on Day One Biopharmaceuticals Inc (NASDAQ: DAWN) with a Buy rating and a price target of $40. Day One's lead product candidate, tovorafenib, is under development for relapsed or progressive pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children. Initial data demonstrated an overall response rate (ORR) of 64% and a clinical benefit rate (CBR) of 91%. The analyst writes that Tovorafenib could become a best-in-class RAF inhibitor for pLGG;18.5;;;;2.450000047683716;;14.930000305175781;
2022-12-16;175.6699981689453;It's no surprise why investors love Dividend Kings -- they're stocks that have grown their dividends for at least 50 years on end without fail.  With such reliable track records, it's an easy affair to invest a relatively small amount of money up front and then watch the payout grow year after year -- and that's why they're excellent options for generating passive income from your portfolio.  Let's take a look at a pair of those Dividend Kings that shouldn't take too long to ramp up to providing you with an annual passive income of $250 after making an initial investment that's likely within your reach today.In this article, we take a look at 12 cheap stocks to buy that outperformed in 2022. If you want to see more cheap stocks to buy that outperformed in 2022, go directly to 5 Cheap Stocks to Buy That Outperformed in 2022. A cheap stock is a stock of a company that’s trading for […]There's a lot to love about Coca-Cola (NYSE: KO) and Johnson & Johnson (NYSE: JNJ). At least that's what billionaire investor Warren Buffett thinks. He holds shares of both of these market giants. Buffett originally bought Coca-Cola back in the late 1980s.The Oracle of Omaha's $5.9 billion hidden portfolio is home to five amazing companies that are ripe for the picking.;51.400001525878906;Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss China’s reopening challenges as COVID cases rise as well as the latest surrounding Pfizer and BioNTech’s combined COVID and flu vaccine.AbbVie's (NYSE: ABBV) share price has soared more than 20% in 2022.  Meanwhile, Pfizer (NYSE: PFE) stock is down year to date, even though the drugmaker is on track to generate close to $100 billion in revenue this year -- more than any other biopharmaceutical company has ever made.  Here's why Pfizer stock is riskier than AbbVie.Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have produced strong total returns over the past decade, and both pharmaceutical companies have what it takes to keep up the pace going forward, despite looming patent cliffs for both.  Over the past five years, AbbVie's total return is 249%, and Pfizer's is 167%, and given their strong cash flow and ability to purchase assets and develop their own therapies with large pipelines, there are plenty of reasons to see the two dividend stocks doubling your return over the next decade.  Pfizer is off to a record year, with management saying in its third-quarter earnings report that it expects annual revenue between $99.5 billion to $102 billion, which at the midpoint represents a rise of 23.9% over 2021.Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.Pfizer and Moderna stocks are breaking out to the upside. Here's how to trade both names now, even as the market swoons.;359.8699951171875;Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.Eli Lilly and Company ( NYSE:LLY ) will increase its dividend on the 10th of March to $1.13, which is 15% higher than...Eli Lilly & Co. Inc. and Sosei Group Corp. said Friday they plan to develop and commercialize therapies for diabetes and metabolic diseases. Lilly is paying the Japanese drug maker an upfront payment of $37 million, with potential milestone payments up to $694 million in addition to tiered royalties on sales. Lilly's stock is up 30.3% year-to-date, while Sosei's shares, listed in Japan, have gained 16.7%. The S&P 500 has declined 18.2% so far this year.;133.17999267578125;;160.47999572753906;AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.The market has dished plenty of ups and downs to investors over the past year, and there's no telling exactly when the volatility will end.  The good news is, as a long-term investor, you don't need to make your investment decisions around the whims of the market.  Rather, as you focus your capital on quality companies with strong track records of growth and abundant pathways to future growth, you can continue to invest in all market environments to supercharge your portfolio gains over the long haul.AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food and Drug Administration (FDA) for the treatment of children and adolescents 6 to 17 years of age with functional constipation (FC). The sNDA submission is based on results from a Phase 3 clinical trial, which met the primary and secondary endpoints, evaluating linaclotide (72 mcg) for increased frequency of spontaneous bowel movements (SBM) and improvemAbbVie's (NYSE: ABBV) share price has soared more than 20% in 2022.  Meanwhile, Pfizer (NYSE: PFE) stock is down year to date, even though the drugmaker is on track to generate close to $100 billion in revenue this year -- more than any other biopharmaceutical company has ever made.  Here's why Pfizer stock is riskier than AbbVie.Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have produced strong total returns over the past decade, and both pharmaceutical companies have what it takes to keep up the pace going forward, despite looming patent cliffs for both.  Over the past five years, AbbVie's total return is 249%, and Pfizer's is 167%, and given their strong cash flow and ability to purchase assets and develop their own therapies with large pipelines, there are plenty of reasons to see the two dividend stocks doubling your return over the next decade.  Pfizer is off to a record year, with management saying in its third-quarter earnings report that it expects annual revenue between $99.5 billion to $102 billion, which at the midpoint represents a rise of 23.9% over 2021.In this article, we discuss 10 best BDC stocks to buy now. You can skip our detailed analysis of business development companies and their returns in the past, and go directly to read 5 Best BDC Stocks To Buy. A Business Development Company, or BDC, is a unique investment option that combines features of both […]Politico, which first reported on AbbVie's exit, said the drugmaker was also leaving the industry group Biotechnology Innovation Organization as well as Business Roundtable, citing a person with knowledge of the matter.  Reuters reported in August the pharmaceutical industry spent at least $142.6 million on lobbying Congress and federal agencies in the first half of 2022, more than any industry.  President Joe Biden's signature Inflation Reduction Act will allow the government to choose 10 drugs to negotiate from among the 50 costliest ones for Medicare, the government healthcare program for people aged 65 and older or disabled, starting in 2026.;90.4800033569336;Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.;109.19999694824219;WomenInc., a media platform that showcases and drives positive dialogue about women, recognized three Merck leaders in its just-released list: 2022 Most Influential Women Executives in Corporate America.;67.94000244140625;Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platformCancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and moreExpects ACT to contribute US$25-30 million in revenues in 2023Positions Prenetics solidly within the US$80+ billion global precision oncology ma;73.48999786376953;;46.97999954223633;The global population is growing with each passing year.  The pharmaceutical industry has been at the forefront, with the launch of game-changing medicines and vaccines in recent decades.  With the global population expected to rise from around 8 billion now to 9.7 billion by 2050, rising demand for medical treatments is practically built into the business model of big pharma.Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis If approved, Dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with eosinophilic esophagitis in the European UnionIn the U.S., Dupixent is currently the only medicine indicated to treat eosinophilic esophagitisApproval recommendation based on pivotal trial data demonstrating patients on Dupixent 300 mg weekly experienced signifRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE). This positive opinion covers those who are 12 years and older, weighing at least 40 kg, and inadequately controlled by, are intolerant to or who are not can;34.95000076293945;;15.050000190734863;(Bloomberg) -- Japan’s economic clout calculated per person is seen slipping behind neighbors such as Taiwan and South Korea, a likely development accelerated by the yen’s slide that raises concerns about the country’s long-term growth prospects.Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesCovid Unleashed in Beijing Shows Rest of China What’s NextWorld’s Largest Hotel Aquarium Bursts Spilling 1,500 FishAccountant That Vetted Binance Reserves Halts Cr;40.209999084472656;;10.960000038146973;;164.83999633789062;;7.78000020980835;;15.09000015258789;;118.5999984741211;;8.109999656677246;"Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY).";27.440000534057617;;50.95000076293945;;6.809999942779541;;13.770000457763672;Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platformCancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and moreExpects ACT to contribute US$25-30 million in revenues in 2023Positions Prenetics solidly within the US$80+ billion global precision oncology ma;25.350000381469727;Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful and statistically significant improvement with emraclidine in PANSS total score at six weeks and was overall well-tolerated compared with placebo Results demonstrate selective targeting of the M4 muscarinic receptor subtype as a potential novel treatment approach for schizophrenia Comprehensive Phase 2 development program in schizophrenia currently u;53.0;WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GA is a leading cause of blindness that impacts;199.35000610351562;;3.619999885559082;;22.969999313354492;;1.25;;2.180000066757202;;;;2.6600000858306885;;6.440000057220459;;55.68000030517578;;;;11.300000190734863;;4.550000190734863;If you want to know who really controls Erasca, Inc. ( NASDAQ:ERAS ), then you'll have to look at the makeup of its...;3.25;;13.430000305175781;;2.2300000190734863;;49.04999923706055;;12.170000076293945;NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies Phase 1 clinical trial now enrolling patients in the United Kingdom with plans to expand to clinical sites in the United States SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it has rec;16.850000381469727;;3.0899999141693115;NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The $2 million Fellowship Fund was announced in December 2021 to facilitate research into the potential of psychedelics to address unmet patient needs in ment;9.699999809265137;;3.259999990463257;;6.28000020980835;;18.030000686645508;;37.52000045776367;;15.960000038146973;;21.420000076293945;;19.709999084472656;;;;2.2799999713897705;;15.34000015258789;
2022-12-19;175.47999572753906;Cash flow remains king.;51.36000061035156;The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.Pfizer Inc. said Monday that it will help develop and commercialize sisunatovir, LianBio's experimental respiratory syncytial virus (RSV) treatment candidate, in mainland China, Hong Kong, Macau and Singapore. Sisunatovir is being tested as a treatment for pediatric and adult patients. The agreement follows Pfizer's acquisition earlier this year of ReViral Ltd., which had licensed development and commercialization rights to sisunatovir to LianBio in the four regions. Pfizer will pay LianBio $20Pfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive a $20 million upfront payment, to be released from previously restricted cash paid by Pfizer to LianBio in 2020 under the companies’ existing strategic collaborationLianBio is eligible to receive up to $135 million in potential development and commercial milestone payments and tiered low single digit percent of net sales in the territories SHANGHAI, China;357.7799987792969;;130.61000061035156;Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.;161.49000549316406;Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD.The FDA approved AbbVie Inc's (NYSE: ABBV) Vraylar (cariprazine) as an adjunctive therapy to antidepressants for major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant. In addition to being approved as an adjunctive therapy to antidepressants for MDD in adults, it is FDA-approved to treat adults withDoes the December share price for AbbVie Inc. ( NYSE:ABBV ) reflect what it's really worth? Today, we will estimate the...Some of the hottest biotech stocks are safe and recession-proof. After all, we can’t stop people from aging – at least, not yet. We can’t stop people from seeking treatments for a myriad of issues. Plus, there’s growing demand for innovation in gene therapies, immune-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs. Plus, according to Grand View Research, the global biotech industry could be worth up to $2.44 trillion by 2028. “The factors dri;90.19000244140625;Amazon.com, Novartis, Philip Morris International, Automatic Data Processing and Live Nation Entertainment are part of the Zacks top Analyst Blog.;109.44000244140625;;67.47000122070312;The European Commission has approved AstraZeneca Plc (NASDAQ: AZN) - Daiichi Sankyo’s (OTC: DSKYF) (OTC: DSNKY) Enhertu (trastuzumab deruxtecan) for advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The approval covers patients who have received a prior trastuzumab-based regimen. Concurrently, the Committee for Medicinal Products (CHMP) for Human Use (CHMP) of the European Medicines Agency has backed the approval for Enhertu for unresectable or metastatic HER2-lowAstraZeneca Plc (NASDAQ: AZN) announced topline data from the PEARL Phase 3 trial of Imfinzi (durvalumab) monotherapy versus platinum-based chemotherapy (investigator's choice) as a 1st-line treatment in patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). The study did not achieve statistical significance for the primary endpoints of improving overall survival (OS) versus platinum-based chemotherapy as a monotherapy treatment for metastatic NSCLC whose tumor cells express higThe recommendation covers heart failure with reduced ejection fraction--a measure of the amount of blood the heart's left ventricle pumps with each heartbeat.The Anglo-Swedish pharma giant said the Committee for Medicinal Products for Human Use of the European Medicines Agency based its opinion on results from the Himalaya Phase 3 trial, and results from the Poseidon Phase 3 trial.By Geoffrey Smith;73.16000366210938;While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...;46.97999954223633;"Roche (RHHBY) receives a positive CHMP recommendation for label expansion of the hemophilia A drug Hemlibra in the European Union (EU).Shares of Innate Pharma SA ADR [S: ipha] rallied 35.2% in premarket trading on Monday after the company said Sanofi licensed its natural killer (NK) cell engager program as part of an already established collaboration between the two companies. ""We are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy,"" Valeria Fantin, Sanofi's global head of oncology research, said in a news release. Sanofi will pay Innate about $26.5 million upfront, with reguInnate Pharma SA (NASDAQ: IPHA) and Sanofi SA (NASDAQ: SNY) have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate's ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing, and commercialization. Under the terms of the new license agreement, Innate will recFDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD.Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology Sanofi gains exclusive license to Innate’s B7H3 ANKETTM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization Paris, December 19, 2022 Sanofi (NASDAQ: SNY) and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today an expansion of their collaboration, with Sanofi licensing a natural kilInformation concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies RegiMARSEILLE, France, December 19, 2022--Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology";34.869998931884766;;14.960000038146973;;39.56999969482422;;10.90999984741211;Viatris Inc. (NASDAQ: VTRS): The 'NCDs in Focus Act Now' Summit was recently organised by global healthcare company, Viatris, in collaboration with the Thai Hypertension Society and the Thai NCD Alliance. The objective of the summit was to address the clinical practice challenges in the management of NCDs and understand patient journey gaps. Themed, 'NCDs in Even More Focus Forum 2022', the event was chaired by Prof. Apichard Sukonthasarn, President Thai hypertension Society and Director Bangkok;162.4199981689453;Conestoga Capital Advisors, an asset management company, released its “Conestoga Mid Cap Growth Fund” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the Mid Cap composite returned -4.84% net of fees compared to a -0.65% return for the Russell Mid Cap Growth Index. Negative stock selection and allocation effects […];7.619999885559082;;14.039999961853027;;116.26000213623047;;8.15999984741211;;27.43000030517578;;49.25;;6.599999904632568;;13.109999656677246;— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and Australia — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKE;31.010000228881836;Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia Emraclidine demonstrated a mean change from baseline in 24-hour ambulatory systolic blood pressure at week eight of -2.7 mmHg for 10 mg QD and -0.4 mmHg for 30 mg QD Trial ruled out a 3 mmHg or greater increase in 24-hour mean systolic blood pressure for both doses of emraclidine based on the upper bound of the 95% confidence interval, per FDA guidanc;52.060001373291016;;194.3300018310547;;3.619999885559082;;21.760000228881836;;1.149999976158142;;2.130000114440918;Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancerAcceptance of the marketing authorization application (MAA) is EQRx’s second from the United Kingdom’s Medicines and Healthcare products Regulatory Agency after acceptance of aumolertinib MAA earlier this year CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharm;;;2.440000057220459;;5.71999979019165;;55.27000045776367;;;;11.15999984741211;;4.449999809265137;;3.0399999618530273;"LAUSANNE, Switzerland, December 19, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose ""Pepe"" Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve on the Company’s executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities.";12.739999771118164;;2.1600000858306885;;46.939998626708984;;10.649999618530273;;15.489999771118164;;2.950000047683716;The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS).The trial was initiated and has begun patient screening this month with first-patient-in anticipated by end-of-year.There are currently no FDA-approved medications for CIAS, a major cause of disability in 80% of patients with schizophrenia1.Topline results are expected in the first half of 2024. NEW YORK and BERLIN, Dec;9.460000038146973;;3.2699999809265137;;6.199999809265137;;16.760000228881836;"SAN DIEGO, December 19, 2022--Arcturus Therapeutics Holdings Inc. (the ""Company"", ""Arcturus"", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.";36.43000030517578;;14.729999542236328;Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque psoriasisIf approved, ZORYVE would be the first steroid-free topical phosphodiesterase-4 (PDE4) inhibitor for children with plaque psoriasisZORYVE has been shown to be safe and very well tolerated, with minimal local site reactions WESTLAKE VILLAGE, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Arcutis Biot;19.799999237060547;;18.950000762939453;;;;2.109999895095825;;14.800000190734863;"CAMBRIDGE, Mass. & MONTREAL,, December 19, 2022--Repare Therapeutics Inc. (""Repare"" or the ""Company"") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer, Lloyd M. Segal, Executive Vice President and Chief Financial Officer, Steve Forte, Executive Vice President and Chief Medical Officer, Maria Koehl"
2022-12-20;175.6699981689453;Investors will be thankful to have 2022 behind us, as the markets endured a rough year. 2023 is expected to be much of the same, at least in the first half, which is why it is important to align your portfolio with high-quality blue-chip dividend stocks.Smart Beta ETF report for OUSALet's check out two big pharmaceutical companies that offer exciting prospects in the months and years to come.  Pfizer (NYSE: PFE) has become a household name thanks to its development of Comirnaty, its coronavirus vaccine, and Paxlovid, a coronavirus treatment.  Both products are bringing in billions of dollars in annual revenue.Caring for sick children has become extra stressful recently for many U.S. parents due to shortages of Children’s Tylenol and other medicines.S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.In the latest trading session, Johnson & Johnson (JNJ) closed at $175.48, marking a -0.11% move from the previous day.;51.31999969482422;As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.NEW YORK, December 20, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2022 Performance Report, to be issued that morning.Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.Berkshire Hathaway, Exxon Mobil, Pfizer, Charles Schwab and ABB are part of the Zacks top Analyst Blog.Let's check out two big pharmaceutical companies that offer exciting prospects in the months and years to come.  Pfizer (NYSE: PFE) has become a household name thanks to its development of Comirnaty, its coronavirus vaccine, and Paxlovid, a coronavirus treatment.  Both products are bringing in billions of dollars in annual revenue.Officials and global health experts outside China are anxiously watching a COVID-19 surge there, worried a nation of 1.4 billion people is inadequately vaccinated and may not have the healthcare tools to treat a wave of illness expected to kill more than one million people through 2023.  Advance preparation of the healthcare system, accurate and shared data collection, and open communication are all important to battling mass coronavirus infections, say health experts from countries outside China who struggled through their own COVID waves.  Many of those elements appear to be lacking in China, they say.Pfizer Inc (NYSE: PFE) has opted into the right to develop and commercialize LianBio's (NASDAQ: LIAN) sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in Mainland China, Hong Kong, Macau, and Singapore under the companies' existing strategic collaboration to expand patient access in Greater China. In June 2022, Pfizer acquired ReViral Ltd. and its portfolio of RSV therapeutic candidates, except development and commercialization rights for sisunatovir in Mainland China, HonToday's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BR.B), Exxon Mobil Corporation (XOM) and Pfizer Inc. (PFE).;359.6400146484375;Based on the average brokerage recommendation (ABR), Lilly (LLY) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...In the latest trading session, Eli Lilly (LLY) closed at $357.78, marking a -0.58% move from the previous day.;132.19000244140625;"Bagsværd, Denmark, 19 December 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the ""Safe Harbour Rules""). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programm";160.5800018310547;This is kind of a strange time to be a passive income investor.  If you want a portfolio that generates enough dividend income to fuel your dream retirement, it's a good idea to fill it with companies that have the capacity to raise their payouts at a rapid pace.  AbbVie (NYSE: ABBV) is a leading pharmaceutical company that offers investors a 3.7% yield at its current share price.;90.37000274658203;;109.70999908447266;"BOTHELL, Wash. & TOKYO & RAHWAY, N.J., December 20, 2022--Seagen Inc. (Nasdaq: SGEN), Astellas Pharma Inc. (TSE:4503) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review supplemental Biologics License Applications (sBLAs) for PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) for use of these two agents in combination for the treatment of patients with locally advancAstellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., ""Astellas""), Seagen Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review supplemental Biologics License Applications (sBLAs) for PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) for use of these two agents in combination for the treatment of patients with locally advanced o";67.72000122070312;AstraZeneca's new asthma rescue treatment could soon be approved in the United States for adults.The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.Astrazeneca (AZN) closed the most recent trading day at $67.47, moving -0.69% from the previous trading session.;72.6500015258789;Bristol Myers Squibb (BMY) closed the most recent trading day at $73.16, moving -0.45% from the previous trading session.St. Mary Medical Center's heart program received a big boost in the form of a $1 million gift from the Bristol Myers Squibb Foundation, the independent charitable arm of the Big Pharma company.  The Bucks County hospital plans to use the donation to support major equipment and software upgrades for its cardiac catheterization labs in the St. Mary Heart and Vascular Center.  The Business Journal reported in August how Trinity Health Mid-Atlantic, the Langhorne hospital's parent company, is working to make St. Mary be the health system's hub for advanced heart surgery procedures.;47.15999984741211;The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.;34.9900016784668;;15.329999923706055;;39.689998626708984;;10.739999771118164;In this article, we will discuss the 13 Best Undervalued Stocks To Buy Now. You can skip our market analysis and go directly to the 5 Best Undervalued Stocks To Buy Now. Global equities this year have declined due to a shift in the macro environment and various geopolitical risks emanating from the Russia-Ukraine war and […];163.97999572753906;;7.679999828338623;;14.109999656677246;;119.01000213623047;;8.130000114440918;;27.450000762939453;;50.459999084472656;;6.449999809265137;;13.25;;31.959999084472656;;52.79999923706055;Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.;195.00999450683594;;3.4700000286102295;;22.420000076293945;;1.1799999475479126;;2.1700000762939453;;;;2.440000057220459;;5.789999961853027;;56.130001068115234;;;;11.430000305175781;;4.340000152587891;Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support combination development BRAF Class 2 and 3 alterations have no approved targeted therapies and represent up to 25% of all BRAF-driven tumors SAN DIEGO, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, develo;3.180000066757202;;12.069999694824219;;2.0999999046325684;"If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Amneal...BRIDGEWATER, N.J., December 20, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (""Amneal"" or the ""Company"") today announced that the Company has successfully launched 26 new generic products in 2022. In the fourth quarter of 2022, the Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays, and prednisolone sodium phosphate oral solution.";48.29999923706055;;11.180000305175781;;15.899999618530273;;2.9800000190734863;;9.65999984741211;;3.049999952316284;;6.210000038146973;;18.559999465942383;;36.54999923706055;;14.199999809265137;;20.399999618530273;SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. A live audio webcast of t;19.90999984741211;;;;2.069999933242798;;14.779999732971191;
2022-12-21;177.67999267578125;Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.The Federal Reserve announced another rate increase last week.  If a business has tons of cash on its books and is generating lots of money, an increase in interest rates won't make the company a risky buy.  Amazon is a growth beast, and it may stand to benefit from interest rate increases and declining valuations in the markets.If you have $20,000 to invest in the stock market right now, you're likely searching for durable businesses with a strong track record of growth that can generate consistent returns in a wide variety of markets.  Despite increased competition through the years, Johnson & Johnson (NYSE: JNJ) remains a giant in each of the three key markets in which it operates: consumer health, pharmaceuticals, and medical devices.  The company's consumer health business, which it is about to spin off into a stand-alone company called Kenvue, sells some of the world's most well-known daily use brands like Band-Aid, Tylenol, and Listerine.There has been a lot of talk about a possible recession next year, when it might come, about how hard it might be, etc. Two healthcare stocks that are likely to thrive in such an environment include Cigna (NYSE: CI) and Johnson & Johnson (NYSE: JNJ).  The two companies have a big international reach and varied revenue streams that will likely benefit from the expected growth in healthcare spending as our population ages.  Cigna's stock is up more than 53% over the past 52 weeks, while the S&P 500 is down more than 15% over that same period.Despite the uptick in COVID cases, one NYC-based physician is optimistic about how the U.S. will fare throughout the winter, thanks to the development of boosters.Children's fever and pain reductio medications are in short supply, forcing major retail pharmacies to limit purchases.Tesla keeps sliding down the rankings of the most valuable U.S. companies. The automaker is on pace to close as the eighth-largest company in the U.S. by market cap. Its value has fallen below that of healthcare giant Johnson Johnson for the first time since Nov. 16, 2020, according to Dow Jones Market Data. Here is how the rankings of top companies by market cap have changed since then. **Nov. 16, 2020:** 1\. Apple 2\. Microsoft 3\. Amazon.com 4\. Alphabet 5\. Facebook 6\. Berkshire Hathaway 7\;51.65999984741211;The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be increasing its dividend by 2.5% on the 3rd of March...Pfizer Inc. said Wednesday that the Food and Drug Administration and the European Medicines Agency accepted the new drug application for its ulcerative colitis treatment candidate. The FDA is expected to make a decision whether to approve etrasimod in the second half of next year. Pfizer recently told investors it expects the drug to generate up to $2 billion in peak sales. The company's stock is down 13.1% this year, while the broader S&P 500 had declined 19.8%. . e.onventional, biologic, or JaNEW YORK, December 21, 2022--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC). The FDA’s decision is expected in the second half of 2023. The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for etrasimod in the same patient population with the decision anticipateDespite the uptick in COVID cases, one NYC-based physician is optimistic about how the U.S. will fare throughout the winter, thanks to the development of boosters.Is Pfizer stock a buy after the FDA gives it a speedy review for an older adult RSV vaccine? Is PFE stock a buy right now?An influential drug pricing research group has cut its suggested price range for Pfizer Inc's COVID-19 antiviral treatment Paxlovid by more than 80%, partly to reflect the decreased disease burden as the Omicron variant of the coronavirus tends to cause less severe illness.  The Institute for Clinical and Economic Review (ICER) said on Tuesday that its new suggested U.S. price based on the benefits and value to patients was in the range of $563 to $906 per treatment course.  ICER is not a government agency and has no authority to set prices.;368.010009765625;;132.49000549316406;;162.2100067138672;The risk of a stalled top line in 2023 means the potential for reward for those who can see beyond it.AbbVie (ABBV) closed the most recent trading day at $160.58, moving -0.56% from the previous trading session.;90.9000015258789;;111.11000061035156;Merck & Co Inc (NYSE: MRK) has notified NGM Biopharmaceuticals Inc (NASDAQ: NGM) that it will not exercise its option to license NGM621 and its related compounds. Merck will also not exercise the related ophthalmology bundle option. NGM estimated in its latest quarterly report that it could also have received $20.7 million in reimbursable expenses if Merck went ahead with NGM621. In June 2021, NGM Biopharma and Merck extended their ongoing collaboration through March 2024 with a narrower scope.The global workforce is going through a significant transformation. In 2021, an unprecedented number of workers quit their jobs.The European Commission has approved AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) Lynparza (olaparib) plus abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC) for patients for whom chemotherapy is not clinically indicated. The approval was based on results from the PROpel Phase III trial. In the trial, Lynparza combo therapy reduced the risk of disease progression or death by 34% versus abiraterone and prednisone or prednisolonRAHWAY, N.J., December 21, 2022--LYNPARZA PROpel EU Approval News ReleaseIn the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may have...Moderna Inc. has added a new senior vice president to its upper ranks: Chantal Friebertshäuser, who will oversee commercial operations in Europe, the Middle East and Canada starting next month.Fundamental analysts appear to be positive about a number of Merck & Co.'s  cancer treatments and that seems to be translating into a strong looking charts and indicators.  In this daily bar chart of MRK, below, I see a chart that has ignored the weakness in the broad market.  The On-Balance-Volume (OBV) line shows us a bullish rise the past year.;67.9000015258789;The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.The European Commission has approved AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) Lynparza (olaparib) plus abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC) for patients for whom chemotherapy is not clinically indicated. The approval was based on results from the PROpel Phase III trial. In the trial, Lynparza combo therapy reduced the risk of disease progression or death by 34% versus abiraterone and prednisone or prednisolon;73.33000183105469;Bristol Myers Squibb Company;48.27000045776367;Merck (MRK) and Seagen's (SGEN) sBLAs seek approval of Padcev plus Keytruda for locally advanced or metastatic urothelial cancer in patients who are not eligible for cisplatin-containing chemotherapy.The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.;35.29999923706055;Children's fever and pain reductio medications are in short supply, forcing major retail pharmacies to limit purchases.;15.399999618530273;;39.599998474121094;;10.850000381469727;;169.25;It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...;7.960000038146973;;13.529999732971191;;120.70999908447266;;8.130000114440918;;27.790000915527344;;50.52000045776367;;6.679999828338623;;14.699999809265137;;31.690000534057617;;52.15999984741211;;202.4600067138672;;3.609999895095825;;23.68000030517578;;1.1699999570846558;;2.2200000286102295;;;;2.4800000190734863;;5.849999904632568;;57.189998626708984;;;;11.510000228881836;;4.199999809265137;;3.0399999618530273;LAUSANNE, Switzerland, December 21, 2022--ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval follows a positive opinion issued in September by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA);12.720000267028809;;2.2100000381469727;;49.119998931884766;;11.260000228881836;;16.110000610351562;;3.1600000858306885;;9.199999809265137;;3.25;;6.058000087738037;;18.770000457763672;;35.41999816894531;;13.960000038146973;;20.59000015258789;;18.65999984741211;;;;2.059999942779541;;14.949999809265137;
